<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35419092</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1844-3117</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of medicine and life</Title><ISOAbbreviation>J Med Life</ISOAbbreviation></Journal><ArticleTitle>Diet, fibers, and probiotics for irritable bowel syndrome.</ArticleTitle><Pagination><StartPage>174</StartPage><EndPage>179</EndPage><MedlinePgn>174-179</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.25122/jml-2022-0028</ELocationID><Abstract><AbstractText>Many aspects make irritable bowel syndrome (IBS) challenging for both patients and physicians. The unclear pathogenesis with many pathways to be explored, bothering symptoms that affect the quality of life, and many subtypes of the condition are only a few reasons that make IBS difficult to control and obtain satisfactory results. Treatment options start with general advice for lifestyle, continue with non-pharmaceutical treatments, and finally touch classic treatments. In this review, pharmaceutical treatment options are not accounted for. Consensus groups and meta-analyses have concluded guidelines that overall are the same, with variations in the strength of recommendations and some cultural and geographical particularities. Dietary interventions, probiotics, and fibers can be seen as non-pharmaceutical treatments that coexist in various protocols because of the relevant evidence regarding their efficacy in treating IBS symptoms.</AbstractText><CopyrightInformation>&#xa9;2022 JOURNAL of MEDICINE and LIFE.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Galica</LastName><ForeName>Adelina Nicoleta</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>2 Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nursing, Faculty of Natural and Human Sciences, Fan S. Noli University, Kor&#xe7;e, Albania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galica</LastName><ForeName>Reitano</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Regional Hospital Kor&#xe7;e, Kor&#xe7;e, Albania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dumitra&#x219;cu</LastName><ForeName>Dan Lucian</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>2 Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Romania</Country><MedlineTA>J Med Life</MedlineTA><NlmUniqueID>101477617</NlmUniqueID><ISSNLinking>1844-122X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004187">Disaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009005">Monosaccharides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004032" MajorTopicYN="N">Diet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004187" MajorTopicYN="N">Disaccharides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005285" MajorTopicYN="N">Fermentation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009005" MajorTopicYN="N">Monosaccharides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FGID &#x2013; functional gastrointestinal disorders</Keyword><Keyword MajorTopicYN="N">FODMAP</Keyword><Keyword MajorTopicYN="N">FODMAP &#x2013; fermentable oligosaccharides, disaccharides, monosaccharides, and polyols</Keyword><Keyword MajorTopicYN="N">IBS &#x2013; C irritable bowel syndrome subtype with constipation</Keyword><Keyword MajorTopicYN="N">IBS &#x2013; D irritable bowel syndrome subtype with diarrhea</Keyword><Keyword MajorTopicYN="N">IBS &#x2013; irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">LFD &#x2013; low FODMAP diet</Keyword><Keyword MajorTopicYN="N">NICE/mNICE &#x2013; National Institute for Health and Care Excellence/modified diet</Keyword><Keyword MajorTopicYN="N">gut microbiota</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">non-pharmacological therapy</Keyword><Keyword MajorTopicYN="N">probiotics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>14</Day><Hour>5</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35419092</ArticleId><ArticleId IdType="pmc">PMC8999090</ArticleId><ArticleId IdType="doi">10.25122/jml-2022-0028</ArticleId><ArticleId IdType="pii">JMedLife-15-174</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Drossman DA. Functional gastrointestinal disorder and the Rome IV process. Functional gastrointestinal disorders. In: Drossman DA, Chang L, Chey WD, et al., editors. Disorders of brain-gut interaction. 4th. Vol. 1. Raleigh, NC: Rome Foundation; 2016. pp. 1&#x2013;32.</Citation></Reference><Reference><Citation>Enck P, Aziz Q, Barbara G, Farmer AD, et al. Irritable bowel syndrome. Nat Rev Dis Primers 2016;2:16014. doi: 10.1038/nrdp.2016.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.14</ArticleId><ArticleId IdType="pmc">PMC5001845</ArticleId><ArticleId IdType="pubmed">27159638</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperber AD, Dumitrascu DL, Fukudo S, Gerson C, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: A Rome Foundation working team literature review. Gut. 2017;66(6):1075&#x2013;1082. doi: 10.1136/gutjnl-2015-311240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-311240</ArticleId><ArticleId IdType="pubmed">26818616</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712&#x2013;721.e4. doi: 10.1016/j.cgh.2012.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2012.02.029</ArticleId><ArticleId IdType="pubmed">22426087</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99&#x2013;114.e3. doi: 10.1053/j.gastro.2020.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.04.014</ArticleId><ArticleId IdType="pubmed">32294476</ArticleId></ArticleIdList></Reference><Reference><Citation>Palsson OS, Whitehead W, T&#xf6;rnblom H, Sperber AD, Simren M. Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom. Gastroenterology. 2020;158(5):1262&#x2013;1273.e3. doi: 10.1053/j.gastro.2019.12.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2019.12.021</ArticleId><ArticleId IdType="pubmed">31917991</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh P, Staller K, Barshop K, Dai E, et al. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation. World J Gastroenterol. 2015;21(26):8103&#x2013;8109. doi: 10.3748/wjg.v21.i26.8103.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v21.i26.8103</ArticleId><ArticleId IdType="pmc">PMC4499353</ArticleId><ArticleId IdType="pubmed">26185382</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman DA, Chang L, Schneck S, Blackman C, et al. A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity. Dig Dis Sci. 2009;54(7):1532&#x2013;1541. doi: 10.1007/s10620-009-0792-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-009-0792-6</ArticleId><ArticleId IdType="pubmed">19337833</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol. 2020;17(8):473&#x2013;486. doi: 10.1038/s41575-020-0286-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-020-0286-8</ArticleId><ArticleId IdType="pubmed">32296140</ArticleId></ArticleIdList></Reference><Reference><Citation>Surdea-Blaga T, Cozma-Petrut A, Dumitra&#x15f;cu DL. Dietary interventions and irritable bowel syndrome &#x2013; what really works?. Curr Opin Gastroenterol. 2021;37(2):152&#x2013;157. doi: 10.1097/MOG.0000000000000706.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOG.0000000000000706</ArticleId><ArticleId IdType="pubmed">33332914</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozma-Petru&#x163; A, Loghin F, Miere D, Dumitra&#x15f;cu DL. Diet in irritable bowel syndrome: What to recommend, not what to forbid to patients!. World J Gastroenterol. 2017;23(21):3771&#x2013;3783. doi: 10.3748/wjg.v23.i21.3771.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v23.i21.3771</ArticleId><ArticleId IdType="pmc">PMC5467063</ArticleId><ArticleId IdType="pubmed">28638217</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannesson E, Jakobsson Ung E, Sadik R, Ringstr&#xf6;m G. Experiences of the effects of physical activity in persons with irritable bowel syndrome (IBS): a qualitative content analysis. Scand J Gastroenterol. 2018 Oct-Nov;53(10-11):1194&#x2013;1200. doi: 10.1080/00365521.2018.1519596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365521.2018.1519596</ArticleId><ArticleId IdType="pubmed">30472905</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannesson E, Ringstr&#xf6;m G, Abrahamsson H, Sadik R. Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects. World J Gastroenterol. 2015 Jan 14;21(2):600&#x2013;8. doi: 10.3748/wjg.v21.i2.600.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v21.i2.600</ArticleId><ArticleId IdType="pmc">PMC4294172</ArticleId><ArticleId IdType="pubmed">25593485</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M, Hatlebakk JG, Hausken T. Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones. Nutrients. 2019;11(8):1824. doi: 10.3390/nu11081824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11081824</ArticleId><ArticleId IdType="pmc">PMC6723613</ArticleId><ArticleId IdType="pubmed">31394793</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntosh K, Reed DE, Schneider T, Dang F, et al. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut. 2017 Jul;66(7):1241&#x2013;1251. doi: 10.1136/gutjnl-2015-311339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-311339</ArticleId><ArticleId IdType="pubmed">26976734</ArticleId></ArticleIdList></Reference><Reference><Citation>Eswaran SL, Chey WD, Han-Markey T, Ball S, Jackson K. A Randomized Controlled Trial Comparing the Low FODMAP Diet vs. Modified NICE Guidelines in US Adults with IBS-D. Am J Gastroenterol. 2016;111(12):1824&#x2013;1832. doi: 10.1038/ajg.2016.434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2016.434</ArticleId><ArticleId IdType="pubmed">27725652</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson PR, Halmos EP, Muir JG. Review article: FODMAPS, prebiotics and gut health-the FODMAP hypothesis revisited. Aliment Pharmacol Ther. 2020;52:233&#x2013;246. doi: 10.1111/apt.15818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15818</ArticleId><ArticleId IdType="pubmed">32562590</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;hn L, St&#xf6;rsrud S, Liljebo T, Collin L, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015;149(6):1399&#x2013;1407.e2. doi: 10.1053/j.gastro.2015.07.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2015.07.054</ArticleId><ArticleId IdType="pubmed">26255043</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher HM, Lomer MC, Anderson JL, Barrett JS, et al. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr. 2012;142(8):1510&#x2013;1518. doi: 10.3945/jn.112.159285.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/jn.112.159285</ArticleId><ArticleId IdType="pubmed">22739368</ArticleId></ArticleIdList></Reference><Reference><Citation>Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67&#x2013;75.e5. doi: 10.1053/j.gastro.2013.09.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2013.09.046</ArticleId><ArticleId IdType="pubmed">24076059</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumitrascu DL, Baban A, Bancila I, Barboi O, et al. Romanian Guidelines for Nonpharmacological Therapy of IBS. J Gastrointestin Liver Dis. 2021;30(2):291&#x2013;306. doi: 10.15403/jgld-3581.</Citation><ArticleIdList><ArticleId IdType="doi">10.15403/jgld-3581</ArticleId><ArticleId IdType="pubmed">33951120</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira AI, Garrido M, Castro-Po&#xe7;as F. Irritable Bowel Syndrome: News from an Old Disorder. GE Port J Gastroenterol. 2020;27(4):255&#x2013;268. doi: 10.1159/000503757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000503757</ArticleId><ArticleId IdType="pmc">PMC7383263</ArticleId><ArticleId IdType="pubmed">32775547</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravina AG, Dallio M, Romeo M, Di Somm A, et al. Adherence and Effects Derived from FODMAP Diet on Irritable Bowel Syndrome: A Real Life Evaluation of a Large Follow-Up Observation. Nutrients. 2020;12(4):928. doi: 10.3390/nu12040928.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12040928</ArticleId><ArticleId IdType="pmc">PMC7231245</ArticleId><ArticleId IdType="pubmed">32230832</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Keeffe M, Jansen C, Martin L, Williams M, et al. Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome. Neurogastroenterol Motil. 2018;30(1) doi: 10.1111/nmo.13154. doi: 10.1111/nmo.13154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13154</ArticleId><ArticleId IdType="doi">10.1111/nmo.13154</ArticleId><ArticleId IdType="pubmed">28707437</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarpato E, Auricchio R, Penagini F, Campanozzi A, et al. Efficacy of the gluten free diet in the management of functional gastrointestinal disorders: a systematic review on behalf of the Italian Society of Paediatrics. Ital J Pediatr. 2019;45(1):9. doi: 10.1186/s13052-019-0606-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13052-019-0606-1</ArticleId><ArticleId IdType="pmc">PMC6329096</ArticleId><ArticleId IdType="pubmed">30635010</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Deng Y, Chu H, Cong Y, et al. Prevalence and presentation of lactose intolerance and effects on dairy product intake in healthy subjects and patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2013;11:262&#x2013;268.e1. doi: 10.1016/j.cgh.2012.11.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2012.11.034</ArticleId><ArticleId IdType="pubmed">23246646</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta D, Ghoshal UC, Misra A, Misra A, et al. Lactose intolerance in patients with irritable bowel syndrome from northern India: a case-control study. J Gastroenterol Hepatol. 2007;22:2261&#x2013;2265. doi: 10.1111/j.1440-1746.2007.04986.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1746.2007.04986.x</ArticleId><ArticleId IdType="pubmed">17559357</ArticleId></ArticleIdList></Reference><Reference><Citation>Varju P, Gede N, Szakacs Z, Hegyi P, et al. Lactose intolerance but not lactose maldigestion is more frequent in patients with irritable bowel syndrome than in healthy controls: A meta-analysis. Neurogastroenterol Motil. 2019;31:e13527. doi: 10.1111/nmo.13527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13527</ArticleId><ArticleId IdType="pmc">PMC7379306</ArticleId><ArticleId IdType="pubmed">30560578</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Lacy BE, Talley NJ. Irritable Bowel Syndrome. N Engl J Med. 2017;376:2566&#x2013;2578. doi: 10.1056/NEJMra1607547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1607547</ArticleId><ArticleId IdType="pubmed">28657875</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagarajan N, Morden A, Bischof D, King EA, et al. The role of fiber supplementation in the treatment of irritable bowel syndrome: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2015;27:1002&#x2013;1010. doi: 10.1097/MEG.0000000000000425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000000425</ArticleId><ArticleId IdType="pubmed">26148247</ArticleId></ArticleIdList></Reference><Reference><Citation>Moayyedi P, Quigley EM, Lacy BE, Lembo AJ, et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(9):1367&#x2013;1374. doi: 10.1038/ajg.2014.195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2014.195</ArticleId><ArticleId IdType="pubmed">25070054</ArticleId></ArticleIdList></Reference><Reference><Citation>McRorie JW. Evidence-Based Approach to Fiber Supplementsand Clinically Meaningful Health Benefits, Part 1: What to Look for and How to Recommend an Effective Fiber Therapy. Nutr Today. 2015;50:82&#x2013;89. doi: 10.1097/NT.0000000000000082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NT.0000000000000082</ArticleId><ArticleId IdType="pmc">PMC4415962</ArticleId><ArticleId IdType="pubmed">25972618</ArticleId></ArticleIdList></Reference><Reference><Citation>Moayyedi P, Andrews CN, MacQueen G, Korownyk C, et al. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). J Can Assoc Gastroenterol. 2019 Apr;2(1):6&#x2013;29. doi: 10.1093/jcag/gwy071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jcag/gwy071</ArticleId><ArticleId IdType="pmc">PMC6507291</ArticleId><ArticleId IdType="pubmed">31294724</ArticleId></ArticleIdList></Reference><Reference><Citation>Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, et al. Soluble or insoluble fibre in irritable bowel syndrome in primary care?Randomised placebo controlled trial. BMJ. 2009;339:b3154. doi: 10.1136/bmj.b3154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b3154</ArticleId><ArticleId IdType="pmc">PMC3272664</ArticleId><ArticleId IdType="pubmed">19713235</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh B. Psyllium as therapeutic and drug delivery agent. Int J Pharm. 2007;334(1-2):1&#x2013;14. doi: 10.1016/j.ijpharm.2007.01.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2007.01.028</ArticleId><ArticleId IdType="pubmed">17329047</ArticleId></ArticleIdList></Reference><Reference><Citation>Muir J. An Overview of Fiber and Fiber Supplements for Irritable Bowel Syndrome. Gastroenterol Hepatol (N Y) 2019;15:387&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6676347</ArticleId><ArticleId IdType="pubmed">31391809</ArticleId></ArticleIdList></Reference><Reference><Citation>Toskes PP, Connery KL, Ritchey TW. Calcium polycarbophil compared with placebo in irritable bowel syndrome. Aliment Pharmacol Ther. 1993;7(1):87&#x2013;92. doi: 10.1111/j.1365-2036.1993.tb00074.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.1993.tb00074.x</ArticleId><ArticleId IdType="pubmed">8439642</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenzie YA, Bowyer RK, Leach H, Gulia P, et al. British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet. 2016 Oct;29(5):549&#x2013;75. doi: 10.1111/jhn.12385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jhn.12385</ArticleId><ArticleId IdType="pubmed">27272325</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson GR, Hutkins R, Sanders ME, Prescott SL, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017 Aug;14(8):491&#x2013;502. doi: 10.1038/nrgastro.2017.75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2017.75</ArticleId><ArticleId IdType="pubmed">28611480</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill C, Guarner F, Reid G, Gibson GR, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506&#x2013;14. doi: 10.1038/nrgastro.2014.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2014.66</ArticleId><ArticleId IdType="pubmed">24912386</ArticleId></ArticleIdList></Reference><Reference><Citation>Distrutti E, Monaldi L, Ricci P, Fiorucci S. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World J Gastroenterol. 2016;22(7):2219&#x2013;2241. doi: 10.3748/wjg.v22.i7.2219.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i7.2219</ArticleId><ArticleId IdType="pmc">PMC4734998</ArticleId><ArticleId IdType="pubmed">26900286</ArticleId></ArticleIdList></Reference><Reference><Citation>Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017 May 16;474(11):1823&#x2013;1836. doi: 10.1042/BCJ20160510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20160510</ArticleId><ArticleId IdType="pmc">PMC5433529</ArticleId><ArticleId IdType="pubmed">28512250</ArticleId></ArticleIdList></Reference><Reference><Citation>Mari A, Abu Bake F, Mahamid M, Sbeit W, Khoury T. The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge. J Clin Med. 2020;9(3):685. doi: 10.3390/jcm9030685.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9030685</ArticleId><ArticleId IdType="pmc">PMC7141230</ArticleId><ArticleId IdType="pubmed">32143424</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodi&#xf1;o-Janeiro BK, Vicario M, Alonso-Cotoner C, Pascua-Garc&#xed;a R, Santos J. A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies. Adv Ther. 2018;35(3):289&#x2013;310. doi: 10.1007/s12325-018-0673-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-018-0673-5</ArticleId><ArticleId IdType="pmc">PMC5859043</ArticleId><ArticleId IdType="pubmed">29498019</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenzie YA, Thompson J, Gulia P, Lomer MC, (IBS Dietetic Guideline Review Group on behalf of Gastroenterology Specialist Group of the British Dietetic Association) British Dietetic Association systematic review of systematic reviews and evidence-based practice guidelines for the use of probiotics in the management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet. 2016;29(5):576&#x2013;592. doi: 10.1111/jhn.12386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jhn.12386</ArticleId><ArticleId IdType="pubmed">27265510</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018 Nov;48(10):1044&#x2013;1060. doi: 10.1111/apt.15001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15001</ArticleId><ArticleId IdType="pubmed">30294792</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukudo S, Okumura T, Inamori M, Okuyama Y, et al. Evidence-based clinical practice guidelines for irritable bowel syndrome 2020. J Gastroenterol. 2021;56(3):193&#x2013;217. doi: 10.1007/s00535-020-01746-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00535-020-01746-z</ArticleId><ArticleId IdType="pmc">PMC7932982</ArticleId><ArticleId IdType="pubmed">33538894</ArticleId></ArticleIdList></Reference><Reference><Citation>Herndon CC, Wang YP, Lu CL. Targeting the gut microbiota for the treatment of irritable bowel syndrome. Kaohsiung J Med Sci. 2020;36(3):160&#x2013;170. doi: 10.1002/kjm2.12154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/kjm2.12154</ArticleId><ArticleId IdType="pmc">PMC11896346</ArticleId><ArticleId IdType="pubmed">31782606</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan F, Ni H, Asche CV, Kim M, et al. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Curr Med Res Opin. 2017;33(7):1191&#x2013;1197. doi: 10.1080/03007995.2017.1292230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03007995.2017.1292230</ArticleId><ArticleId IdType="pubmed">28166427</ArticleId></ArticleIdList></Reference><Reference><Citation>Cayzeele-Decherf A, Pelerin F, Leuillet S, Douillard B, et al. Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis. World J Gastroenterol. 2017;23(2):336&#x2013;344. doi: 10.3748/wjg.v23.i2.336.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v23.i2.336</ArticleId><ArticleId IdType="pmc">PMC5236513</ArticleId><ArticleId IdType="pubmed">28127207</ArticleId></ArticleIdList></Reference><Reference><Citation>Fikree A, Byrne P. Management of functional gastrointestinal disorders. Clin Med (Lond). 2021;21(1):44&#x2013;52. doi: 10.7861/clinmed.2020-0980.</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2020-0980</ArticleId><ArticleId IdType="pmc">PMC7850201</ArticleId><ArticleId IdType="pubmed">33479067</ArticleId></ArticleIdList></Reference><Reference><Citation>Doron S, Snydman DR. Risk and safety of probiotics. Clin Infect Dis. 2015;60(Suppl 2(Suppl 2)):S129&#x2013;S134. doi: 10.1093/cid/civ085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/civ085</ArticleId><ArticleId IdType="pmc">PMC4490230</ArticleId><ArticleId IdType="pubmed">25922398</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee BJ, Bak YT. Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil. 2011;17(3):252&#x2013;266. doi: 10.5056/jnm.2011.17.3.252.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm.2011.17.3.252</ArticleId><ArticleId IdType="pmc">PMC3155061</ArticleId><ArticleId IdType="pubmed">21860817</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22314561</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1899-1505</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of physiology and pharmacology : an official journal of the Polish Physiological Society</Title><ISOAbbreviation>J Physiol Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options.</ArticleTitle><Pagination><StartPage>591</StartPage><EndPage>599</EndPage><MedlinePgn>591-9</MedlinePgn></Pagination><Abstract><AbstractText>Stress, which is defined as an acute threat to homeostasis, shows both short- and long-term effects on the functions of the gastrointestinal tract. Exposure to stress results in alterations of the brain-gut interactions ("brain-gut axis") ultimately leading to the development of a broad array of gastrointestinal disorders including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and other functional gastrointestinal diseases, food antigen-related adverse responses, peptic ulcer and gastroesophageal reflux disease (GERD). The major effects of stress on gut physiology include: 1) alterations in gastrointestinal motility; 2) increase in visceral perception; 3) changes in gastrointestinal secretion; 4) increase in intestinal permeability; 5) negative effects on regenerative capacity of gastrointestinal mucosa and mucosal blood flow; and 6) negative effects on intestinal microbiota. Mast cells (MC) are important effectors of brain-gut axis that translate the stress signals into the release of a wide range of neurotransmitters and proinflammatory cytokines, which may profoundly affect the gastrointestinal physiology. IBS represents the most important gastrointestinal disorder in humans, and is characterized by chronic or recurrent pain associated with altered bowel motility. The diagnostic testing for IBS patients include routine blood tests, stool tests, celiac disease serology, abdominal sonography, breath testing to rule out carbohydrate (lactose, fructose, etc.) intolerance and small intestinal bacterial overgrowth. Colonoscopy is recommended if alarming symptoms are present or to obtain colonic biopsies especially in patients with diarrhoea predominant IBS. The management of IBS is based on a multifactorial approach and includes pharmacotherapy targeted against the predominant symptom, behavioural and psychological treatment, dietary alterations, education, reassurance and effective patient-physician relationship. When evaluating for the stress-induced condition in the upper GI tract, the diagnostic testing includes mainly blood tests and gastroscopy to rule out GERD and peptic ulcer disease. The therapy for these conditions is mainly based on the inhibition of gastric acid by proton pump inhibitors and eradication of Helicobacter pylori-infection. Additionally, melatonin an important mediator of brain gut axis has been shown to exhibit important protective effects against stress-induced lesions in the gastrointestinal tract. Finally, probiotics may profoundly affect the brain-gut interactions ("microbiome-gut-brain axis") and attenuate the development of stress-induced disorders in both the upper and lower gastrointestinal tract. Further studies on the brain-gut axis are needed to open new therapeutic avenues in the future.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Konturek</LastName><ForeName>Peter C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Department of Medicine, Thuringia Clinic Saalfeld, Teaching Hospital of the University Jena, Germany. pkonturek@thueringen-kliniken.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brzozowski</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Konturek</LastName><ForeName>S J</ForeName><Initials>SJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>J Physiol Pharmacol</MedlineTA><NlmUniqueID>9114501</NlmUniqueID><ISSNLinking>0867-5910</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000930">Antidiarrheals</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000930" MajorTopicYN="N">Antidiarrheals</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017615" MajorTopicYN="N">Enteric Nervous System</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005767" MajorTopicYN="N">Gastrointestinal Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D041981" MajorTopicYN="N">Gastrointestinal Tract</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22314561</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37541528</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1528-0012</ISSN><JournalIssue CitedMedium="Internet"><Volume>165</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Gastroenterology</Title><ISOAbbreviation>Gastroenterology</ISOAbbreviation></Journal><ArticleTitle>Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis.</ArticleTitle><Pagination><StartPage>1206</StartPage><EndPage>1218</EndPage><MedlinePgn>1206-1218</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1053/j.gastro.2023.07.018</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0016-5085(23)04838-2</ELocationID><Abstract><AbstractText Label="BACKGROUND &amp; AIMS">Some probiotics may be beneficial in irritable bowel syndrome (IBS), but differences in species and strains used, as well as endpoints reported, have hampered attempts to make specific recommendations as to which should be preferred. We updated our previous meta-analysis examining this issue.</AbstractText><AbstractText Label="METHODS">MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched (up to March 2023). Randomized controlled trials (RCTs) recruiting adults with IBS, comparing probiotics with placebo were eligible. Dichotomous symptom data were pooled to obtain a relative risk of global symptoms, abdominal pain, or abdominal bloating or distension persisting after therapy, with a 95% confidence interval (CI). Continuous data were pooled using a standardized mean difference with a 95% CI. Adverse events data were also pooled.</AbstractText><AbstractText Label="RESULTS">We identified 82 eligible trials, containing 10,332 patients. Only 24 RCTs were at low risk of bias across all domains. For global symptoms, there was moderate certainty in the evidence for a benefit of Escherichia strains, low certainty for Lactobacillus strains and Lactobacillus plantarum 299V, and very low certainty for combination probiotics, LacClean Gold S, Duolac 7s, and Bacillus strains. For abdominal pain, there was low certainty in the evidence for a benefit of Saccharomyces cerevisae I-3856 and Bifidobacterium strains, and very low certainty for combination probiotics, Lactobacillus, Saccharomyces, and Bacillus strains. For abdominal bloating or distension there was very low certainty in the evidence for a benefit of combination probiotics and Bacillus strains. The relative risk of experiencing any adverse event, in 55 trials, including more than 7000 patients, was not significantly higher with probiotics.</AbstractText><AbstractText Label="CONCLUSIONS">Some combinations of probiotics or strains may be beneficial in IBS. However, certainty in the evidence for efficacy by GRADE criteria was low to very low across almost all of our analyses.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goodoory</LastName><ForeName>Vivek C</ForeName><Initials>VC</Initials><AffiliationInfo><Affiliation>Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, United Kingdom; Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khasawneh</LastName><ForeName>Mais</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, United Kingdom; Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, United Kingdom; Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quigley</LastName><ForeName>Eamonn M M</ForeName><Initials>EMM</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Lynda K. and David M. Underwood Center for Digestive Disorders, Houston Methodist Hospital and Weill Cornell Medical College, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moayyedi</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Gastroenterology Division, McMaster University, Health Sciences Center, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ford</LastName><ForeName>Alexander C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, United Kingdom; Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom. Electronic address: alexf12399@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Gastroenterology</MedlineTA><NlmUniqueID>0374630</NlmUniqueID><ISSNLinking>0016-5085</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Gastroenterology. 2024 Mar;166(3):545-546. doi: 10.1053/j.gastro.2023.11.019.</RefSource><PMID Version="1">37979710</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Gastroenterology. 2024 Nov;167(6):1248. doi: 10.1053/j.gastro.2024.08.017.</RefSource><PMID Version="1">39207347</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="Y">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015746" MajorTopicYN="N">Abdominal Pain</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abdominal Bloating</Keyword><Keyword MajorTopicYN="N">Abdominal Pain</Keyword><Keyword MajorTopicYN="N">Irritable Bowel Syndrome</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Probiotics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>31</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>5</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>4</Day><Hour>19</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37541528</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2023.07.018</ArticleId><ArticleId IdType="pii">S0016-5085(23)04838-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35433498</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2235-2988</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in cellular and infection microbiology</Title><ISOAbbreviation>Front Cell Infect Microbiol</ISOAbbreviation></Journal><ArticleTitle>Efficacy of Probiotics for Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis.</ArticleTitle><Pagination><StartPage>859967</StartPage><MedlinePgn>859967</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">859967</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcimb.2022.859967</ELocationID><Abstract><AbstractText Label="BACKGROUND">Irritable bowel syndrome (IBS) is a common gastrointestinal condition. Studies regarding the treatment of IBS with probiotics have not yielded consistent results, and the best probiotics has not yet been confirmed. Therefore, we performed a network meta-analysis (NMA) to assess the relative rank order of different probiotics for IBS.</AbstractText><AbstractText Label="METHOD">We searched for RCTs on the efficacy of probiotics for IBS until August 25, 2021. The primary outcome was the symptom relief rate, as well as global symptoms, abdominal pain, bloating, and straining scores. The NMA was conducted using Stata 15.0. We also used meta-regression to explore whether the treatment length and dose influenced the efficacy.</AbstractText><AbstractText Label="RESULTS">Forty-three RCTs, with 5,531 IBS patients, were included in this analysis. Firstly, we compared the efficacy of different probiotic species. <i>B.coagulans</i> exhibited the highest probability to be the optimal probiotic specie in improving IBS symptom relief rate, as well as global symptom, abdominal pain, bloating, and straining scores. In regard to the secondary outcomes, <i>L.plantarum</i> ranked first in ameliorating the QOL of IBS patients, but without any significant differences compared with other probiotic species in standardized mean differences (SMD) estimates. Moreover, patients received <i>L.acidophilus</i> had lowest incidence of adverse events. The meta-regression revealed that no significant differences were found between participants using different doses of probiotics in all outcomes, while the treatment length, as a confounder, can significantly influence the efficacy of probiotics in ameliorating abdominal pain (Coef = -2.30; p = 0.035) and straining (Coef = -3.15; p = 0.020) in IBS patients. Thus, we performed the subgroup analysis on treatment length subsequently in these two outcomes, which showed that efficacy of <i>B.coagulans</i> using 8 weeks ranked first both in improving the abdominal pain and straining scores. Additionally, <i>B. coagulans</i> still had significant efficacy compared to different types of probiotic combinations in present study.</AbstractText><AbstractText Label="CONCLUSIONS">The findings of this NMA suggested that <i>B.coagulans</i> had prominent efficacy in treating IBS patients, and incorporating <i>B.coagulans</i> into a probiotic combination, or genetically engineering it to amplify its biological function may be a future research target to treat IBS patients. With few direct comparisons available between individual therapies today, this NMA may have utility in forming treatment guideline for IBS with probiotics.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Zhang, Zhang, Zhang, Sun and Duan.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Cunzheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jindong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>China Center for Evidence Based Medical and Clinical Research, Peking University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Public Health, Peking University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Liping</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000099094">Network Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cell Infect Microbiol</MedlineTA><NlmUniqueID>101585359</NlmUniqueID><ISSNLinking>2235-2988</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015746" MajorTopicYN="N">Abdominal Pain</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adverse events</Keyword><Keyword MajorTopicYN="N">efficacy</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">network meta-analysis</Keyword><Keyword MajorTopicYN="N">probiotics</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35433498</ArticleId><ArticleId IdType="pmc">PMC9010660</ArticleId><ArticleId IdType="doi">10.3389/fcimb.2022.859967</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abbas Z., Yakoob J., Jafri W., Ahmad Z., Azam Z., Usman M. W., et al. . (2014). Cytokine and Clinical Response to Saccharomyces Boulardii Therapy in Diarrhea-Dominant Irritable Bowel Syndrome: A Randomized Trial. Eur. J. Gastroenterol. Hepatol. 26, 630&#x2013;639. doi:&#xa0;10.1097/MEG.0000000000000094</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000000094</ArticleId><ArticleId IdType="pubmed">24722560</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal A., Houghton L. A., Morris J., Reilly B., Guyonnet D., Feuillerat. N., et al. . (2009). Clinical Trial: The Effects of a Fermented Milk Product Containing Bifidobacterium Lactis DN-173 010 on Abdominal Distension and Gastrointestinal Transit in Irritable Bowel Syndrome With Constipation. Aliment. Pharmacol. Ther. 29, 104&#x2013;114. doi:&#xa0;10.1111/j.1365-2036.2008.03853.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2008.03853.x</ArticleId><ArticleId IdType="pubmed">18801055</ArticleId></ArticleIdList></Reference><Reference><Citation>Andresen V., Gschossmann J., Layer P. (2020). Heat-Inactivated Bifidobacterium Bifidum MIMBb75 (SYN-HI-001) in the Treatment of Irritable Bowel Syndrome: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Clinical Trial. Lancet Gastroenterol. Hepatol. 5, 658&#x2013;666. doi:&#xa0;10.1016/S2468-1253(20)30056-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30056-X</ArticleId><ArticleId IdType="pubmed">32277872</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauserman M., Michail S. (2005). The Use of Lactobacillus GG in Irritable Bowel Syndrome in Children: A Double-Blind Randomized Control Trial. J. Pediatr. 147, 197&#x2013;201. doi:&#xa0;10.1016/j.jpeds.2005.05.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2005.05.015</ArticleId><ArticleId IdType="pubmed">16126049</ArticleId></ArticleIdList></Reference><Reference><Citation>Begtrup L. M., de Muckadell O. B., Kjeldsen J., Christensen R. D., Jarb&#xf8;l D. E.. (2013). Long-Term Treatment With Probiotics in Primary Care Patients With Irritable Bowel Syndrome&#x2013;a Randomised, Double-Blind, Placebo Controlled Trial. Scand. J. Gastroenterol. 48, 1127&#x2013;1135. doi:&#xa0;10.3109/00365521.2013.825314</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365521.2013.825314</ArticleId><ArticleId IdType="pubmed">23957590</ArticleId></ArticleIdList></Reference><Reference><Citation>Black C. J., Ford A. C. (2020). Global Burden of Irritable Bowel Syndrome: Trends, Predictions and Risk Factors. Nat. Rev. Gastroenterol. Hepatol. 17, 473&#x2013;486. doi:&#xa0;10.1038/s41575-020-0286-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-020-0286-8</ArticleId><ArticleId IdType="pubmed">32296140</ArticleId></ArticleIdList></Reference><Reference><Citation>Camilleri M. (2021). Diagnosis and Treatment of Irritable Bowel Syndrome: A Review. JAMA 325, 865&#x2013;877. doi:&#xa0;10.1001/jama.2020.22532</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.22532</ArticleId><ArticleId IdType="pubmed">33651094</ArticleId></ArticleIdList></Reference><Reference><Citation>Carabotti M., Scirocco A., Maselli M. A., Severi C.. (2015). The Gut-Brain Axis: Interactions Between Enteric Microbiota, Central and Enteric Nervous Systems. Ann. Gastroenterol. 28, 203&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4367209</ArticleId><ArticleId IdType="pubmed">25830558</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi C. H., Jo S. Y., Park H. J., Chang S. K., Byeon J. S., Myung S. J.. (2011). A Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Saccharomyces Boulardii in Irritable Bowel Syndrome: Effect on Quality of Life. J. Clin. Gastroenterol. 45, 679&#x2013;683. doi:&#xa0;10.1097/MCG.0b013e318204593e</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0b013e318204593e</ArticleId><ArticleId IdType="pubmed">21301358</ArticleId></ArticleIdList></Reference><Reference><Citation>Creed F., Ratcliffe J., Fernandez L., Tomenson B., Palmer S., Rigby C., et al. . (2001). Health-Related Quality of Life and Health Care Costs in Severe, Refractory Irritable Bowel Syndrome. Ann. Intern. Med. 134, 860&#x2013;868. doi:&#xa0;10.7326/0003-4819-134-9_part_2-200105011-00010</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-134-9_part_2-200105011-00010</ArticleId><ArticleId IdType="pubmed">11346322</ArticleId></ArticleIdList></Reference><Reference><Citation>Dapoigny M., Piche T., Ducrotte P., Lunaud B., Cardot J. M., Bernalier-Donadille A.. (2012). Efficacy and Safety Profile of LCR35 Complete Freeze-Dried Culture in Irritable Bowel Syndrome: A Randomized, Double-Blind Study. World J. Gastroenterol. 18, 2067&#x2013;2075. doi:&#xa0;10.3748/wjg.v18.i17.2067</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v18.i17.2067</ArticleId><ArticleId IdType="pmc">PMC3342605</ArticleId><ArticleId IdType="pubmed">22563194</ArticleId></ArticleIdList></Reference><Reference><Citation>Drouault-Holowacz S., Bieuvelet S., Burckel A., Cazaubiel M., Dray X., Marteau P.. (2008). A Double Blind Randomized Controlled Trial of a Probiotic Combination in 100 Patients With Irritable Bowel Syndrome. Gastroenterol. Clin. Biol. 32, 147&#x2013;152. doi:&#xa0;10.1016/j.gcb.2007.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gcb.2007.06.001</ArticleId><ArticleId IdType="pubmed">18387426</ArticleId></ArticleIdList></Reference><Reference><Citation>Ducrott&#xe9; P., Sawant P., Jayanthi V. (2012). Clinical Trial: Lactobacillus Plantarum 299v (DSM 9843) Improves Symptoms of Irritable Bowel Syndrome. World J. Gastroenterol. 18, 4012&#x2013;4018. doi:&#xa0;10.3748/wjg.v18.i30.4012</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v18.i30.4012</ArticleId><ArticleId IdType="pmc">PMC3419998</ArticleId><ArticleId IdType="pubmed">22912552</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Serag H. B., Olden K. (2002). Health-Related Quality of Life Among Persons With Irritable Bowel Syndrome: A Systematic Review. Aliment. Pharmacol. Ther. 16, 1171&#x2013;1185. doi:&#xa0;10.1046/j.1365-2036.2002.01290.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.2002.01290.x</ArticleId><ArticleId IdType="pubmed">12030961</ArticleId></ArticleIdList></Reference><Reference><Citation>Elshaghabee F., Rokana N., Gulhane R. D., Sharma C., Panwar H.. (2017). Bacillus As Potential Probiotics: Status, Concerns, and Future Perspectives. Front. Microbiol. 8. doi:&#xa0;10.3389/fmicb.2017.01490</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2017.01490</ArticleId><ArticleId IdType="pmc">PMC5554123</ArticleId><ArticleId IdType="pubmed">28848511</ArticleId></ArticleIdList></Reference><Reference><Citation>Enck P., Zimmermann K., Menke G., Klosterhalfen S.. (2009). Randomized Controlled Treatment Trial of Irritable Bowel Syndrome With a Probiotic E.-Coli Preparation (DSM17252) Compared to Placebo. Z Gastroenterol. 47, 209&#x2013;214. doi:&#xa0;10.1055/s-2008-1027702</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2008-1027702</ArticleId><ArticleId IdType="pubmed">19197823</ArticleId></ArticleIdList></Reference><Reference><Citation>Fond G., Loundou A., Hamdani N., Boukouaci W., Dargel A., Oliveira J., et al. . (2014). Anxiety and Depression Comorbidities in Irritable Bowel Syndrome (IBS): A Systematic Review and Meta-Analysis. Eur. Arch. Psychiatry Clin. Neurosci. 264, 651&#x2013;660. doi:&#xa0;10.1007/s00406-014-0502-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00406-014-0502-z</ArticleId><ArticleId IdType="pubmed">24705634</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A. C., Harris L. A., Lacy B. E., Quigley E. M. M., Moayyedi P.. (2018). Systematic Review With Meta-Analysis: The Efficacy of Prebiotics, Probiotics, Synbiotics and Antibiotics in Irritable Bowel Syndrome. Aliment. Pharmacol. Ther. 48, 1044&#x2013;1060. doi:&#xa0;10.1111/apt.15001</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15001</ArticleId><ArticleId IdType="pubmed">30294792</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukudo S., Okumura T., Inamori M., Okuyama Y., Kanazawa M., Kamiya T., et al. . (2021). Evidence-Based Clinical Practice Guidelines for Irritable Bowel Syndrome 2020. J. Gastroenterol. 56 (3), 193&#x2013;217. doi: 10.1007/s00535-020-01746-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00535-020-01746-z</ArticleId><ArticleId IdType="pmc">PMC7932982</ArticleId><ArticleId IdType="pubmed">33538894</ArticleId></ArticleIdList></Reference><Reference><Citation>Gayathri R., Aruna T., Malar S., Shilpa B., Dhanasekar K. R.. (2020). Efficacy of Saccharomyces Cerevisiae CNCM I-3856 as an Add-on Therapy for Irritable Bowel Syndrome. Int. J. Colorectal Dis. 35, 139&#x2013;145. doi:&#xa0;10.1007/s00384-019-03462-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-019-03462-4</ArticleId><ArticleId IdType="pubmed">31807856</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglielmetti S., Mora D., Gschwender M., Popp K.. (2011). Randomised Clinical Trial: Bifidobacterium Bifidum MIMBb75 Significantly Alleviates Irritable Bowel Syndrome and Improves Quality of Life&#x2013;A Double-Blind, Placebo-Controlled Study. Aliment. Pharmacol. Ther. 33, 1123&#x2013;1132. doi:&#xa0;10.1111/j.1365-2036.2011.04633.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2011.04633.x</ArticleId><ArticleId IdType="pubmed">21418261</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A. K., Maity C. (2021). Efficacy and Safety of Bacillus Coagulans LBSC in Irritable Bowel Syndrome: A Prospective, Interventional, Randomized, Double-Blind, Placebo-Controlled Clinical Study [CONSORT Compliant]. Med. (Baltimore) 100, e23641. doi:&#xa0;10.1097/MD.0000000000023641</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000023641</ArticleId><ArticleId IdType="pmc">PMC7837859</ArticleId><ArticleId IdType="pubmed">33545934</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyonnet D., Chassany O., Ducrotte P., Picard C., Mouret M., Mercier C. H., et al. . (2007). Effect of a Fermented Milk Containing Bifidobacterium Animalis DN-173 010 on the Health-Related Quality of Life and Symptoms in Irritable Bowel Syndrome in Adults in Primary Care: A Multicentre, Randomized, Double-Blind, Controlled Trial. Aliment. Pharmacol. Ther. 26, 475&#x2013;486. doi:&#xa0;10.1111/j.1365-2036.2007.03362.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2007.03362.x</ArticleId><ArticleId IdType="pubmed">17635382</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwee K. A., Gonlachanvit S., Ghoshal U. C., Chua A. S. B., Miwa H., Wu J., et al. . (2019). Second Asian Consensus on Irritable Bowel Syndrome. J. Neurogastroenterol. Motil. 25, 343&#x2013;362. doi:&#xa0;10.5056/jnm19041</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm19041</ArticleId><ArticleId IdType="pmc">PMC6657923</ArticleId><ArticleId IdType="pubmed">31327218</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafari E., Vahedi H., Merat S., Momtahen S., Riahi A.. (2014). Therapeutic Effects, Tolerability and Safety of a Multi-Strain Probiotic in Iranian Adults With Irritable Bowel Syndrome and Bloating. Arch. Iran Med. 17, 466&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">24979556</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabir M. A., Ishaque S. M., Ali M. S., Mahmuduzzaman M., Hasan M.. (2011). Role of Saccharomyces Boulardii in Diarrhea Predominant Irritable Bowel Syndrome. Mymensingh Med. J. 20, 397&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">21804501</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajander K., Camilleri M., McKinzie S., Lempke M. B., Burton D. D., Thomforde G. M., et al. . (2005). A Probiotic Mixture Alleviates Symptoms in Irritable Bowel Syndrome Patients: A Controlled 6-Month Intervention. Aliment. Pharmacol. Ther. 22, 387&#x2013;394. doi:&#xa0;10.1111/j.1365-2036.2005.02579.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2005.02579.x</ArticleId><ArticleId IdType="pubmed">16128676</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajander K., Myllyluoma E., Rajili&#x107;-Stojanovi&#x107; M., Kyr&#xf6;npalo S., Rasmussen M., J&#xe4;rvenp&#xe4;&#xe4; S., et al. . (2008). Clinical Trial: Multispecies Probiotic Supplementation Alleviates the Symptoms of Irritable Bowel Syndrome and Stabilizes Intestinal Microbiota. Aliment. Pharmacol. Ther. 27, 48&#x2013;57. doi:&#xa0;10.1111/j.1365-2036.2007.03542.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2007.03542.x</ArticleId><ArticleId IdType="pubmed">17919270</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H. J., Camilleri M., McKinzie S., Lempke M. B., Burton D. D., Thomforde G. M., et al. . (2003). A Randomized Controlled Trial of a Probiotic, VSL#3, on Gut Transit and Symptoms in Diarrhoea-Predominant Irritable Bowel Syndrome. Aliment Pharmacol. Ther. 17, 895&#x2013;904. doi:&#xa0;10.1046/j.1365-2036.2003.01543.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.2003.01543.x</ArticleId><ArticleId IdType="pubmed">12656692</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H. J., Roque M. I. V., Camilleri M., Stephens D., Burton D. D., Baxter K., et al. . (2005). A Randomized Controlled Trial of a Probiotic Combination VSL# 3 and Placebo in Irritable Bowel Syndrome With Bloating. Neurogastroenterol. Motil. 17, 687&#x2013;696. doi:&#xa0;10.1111/j.1365-2982.2005.00695.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2005.00695.x</ArticleId><ArticleId IdType="pubmed">16185307</ArticleId></ArticleIdList></Reference><Reference><Citation>King T. S., Elia M., Hunter J. O. (1998). Abnormal Colonic Fermentation in Irritable Bowel Syndrome. Lancet 352, 1187&#x2013;1189. doi:&#xa0;10.1016/s0140-6736(98)02146-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(98)02146-1</ArticleId><ArticleId IdType="pubmed">9777836</ArticleId></ArticleIdList></Reference><Reference><Citation>Kligler B., Cohrssen A. (2008). Probiotics. Am. Fam Physician. 78, 1073&#x2013;1078. doi:&#xa0;10.1007/s00384-011-1363-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-011-1363-9</ArticleId><ArticleId IdType="pubmed">19007054</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruis W., et al. . (2012). A Double-Blind Placebo-Controlled Trial to Study Therapeutic Effects of Probiotic Escherichia Coli Nissle 1917 in Subgroups of Patients With Irritable Bowel Syndrome. Int. J. Colorectal Dis. 27, 467&#x2013;474. doi:&#xa0;10.1007/s00384-011-1363-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-011-1363-9</ArticleId><ArticleId IdType="pmc">PMC3307993</ArticleId><ArticleId IdType="pubmed">22130826</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy B. E., Pimentel M., Brenner D. M., Chey W. D., Keefer L. A., Long M. D., et al. . (2021). ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am. J. Gastroenterol. 116, 17&#x2013;44. doi:&#xa0;10.14309/ajg.0000000000001036</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000001036</ArticleId><ArticleId IdType="pubmed">33315591</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy B. E., Patel N. K. (2017). Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J. Clin. Med. 6, 99. doi:&#xa0;10.3390/jcm6110099</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm6110099</ArticleId><ArticleId IdType="pmc">PMC5704116</ArticleId><ArticleId IdType="pubmed">29072609</ArticleId></ArticleIdList></Reference><Reference><Citation>Ligaarden S. C., Axelsson L., Naterstad K., Lydersen S., Farup P. G.. (2010). A Candidate Probiotic With Unfavourable Effects in Subjects With Irritable Bowel Syndrome: A Randomised Controlled Trial. BMC Gastroenterol. 10, 16. doi:&#xa0;10.1186/1471-230X-10-16</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-230X-10-16</ArticleId><ArticleId IdType="pmc">PMC2831047</ArticleId><ArticleId IdType="pubmed">20144246</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Zhang L., Wang X., Wang Z., Zhang J., Jiang R., et al. . (2016). Similar Fecal Microbiota Signatures in Patients With Diarrhea-Predominant Irritable Bowel Syndrome and Patients With Depression. Clin. Gastroenterol. Hepatol. 14, 1602&#x2013;1611.e5. doi:&#xa0;10.1016/j.cgh.2016.05.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2016.05.033</ArticleId><ArticleId IdType="pubmed">27266978</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyra A., Hillil&#xe4; M., Huttunen T., M&#xe4;nnikk&#xf6; S., Taalikka M., Tennil&#xe4; J., et al. . (2016). Irritable Bowel Syndrome Symptom Severity Improves Equally With Probiotic and Placebo. World J. Gastroenterol. 22, 10631&#x2013;10642. doi:&#xa0;10.3748/wjg.v22.i48.10631</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i48.10631</ArticleId><ArticleId IdType="pmc">PMC5192275</ArticleId><ArticleId IdType="pubmed">28082816</ArticleId></ArticleIdList></Reference><Reference><Citation>Madempudi R. S., Ahire J. J., Neelamraju J., Tripathi A., Nanal S.. (2019). Randomized Clinical Trial: The Effect of Probiotic Bacillus Coagulans Unique IS2 vs. Placebo on the Symptoms Management of Irritable Bowel Syndrome in Adults. Sci. Rep. 9, 12210. doi:&#xa0;10.1038/s41598-019-48554-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-48554-x</ArticleId><ArticleId IdType="pmc">PMC6704184</ArticleId><ArticleId IdType="pubmed">31434935</ArticleId></ArticleIdList></Reference><Reference><Citation>Maity C., Gupta A. K., Saroj D. B., Biyani A., Bagkar P., Kulkarni J., et al. . (2020). Impact of a Gastrointestinal Stable Probiotic Supplement Bacillus Coagulans LBSC on Human Gut Microbiome Modulation. J. Diet Suppl.18, 577&#x2013;596. doi:&#xa0;10.1080/19390211.2020.1814931</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19390211.2020.1814931</ArticleId><ArticleId IdType="pubmed">32896190</ArticleId></ArticleIdList></Reference><Reference><Citation>Majeed M., Nagabhushanam K., Natarajan S., Sivakumar A., Ali F., Pande A., et al. . (2016). Bacillus Coagulans MTCC 5856 Supplementation in the Management of Diarrhea Predominant Irritable Bowel Syndrome: A Double Blind Randomized Placebo Controlled Pilot Clinical Study. Nutr. J. 15, 21. doi:&#xa0;10.1186/s12937-016-0140-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12937-016-0140-6</ArticleId><ArticleId IdType="pmc">PMC4769834</ArticleId><ArticleId IdType="pubmed">26922379</ArticleId></ArticleIdList></Reference><Reference><Citation>Martoni C. J., Srivastava S., Leyer G. J. (2020). Lactobacillus Acidophilus DDS-1 and Bifidobacterium Lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial. Nutrients 12, 363. doi:&#xa0;10.3390/nu12020363</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12020363</ArticleId><ArticleId IdType="pmc">PMC7071206</ArticleId><ArticleId IdType="pubmed">32019158</ArticleId></ArticleIdList></Reference><Reference><Citation>Mearin F., Lacy B. E., Chang L., Chey W. D., Lembo A. J., Simren M., et al. . (2016). Bowel Disorders. Gastroenterology S0016&#x2013;5085(16)00222-5. doi:&#xa0;10.1053/j.gastro.2016.02.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.031</ArticleId><ArticleId IdType="pubmed">27144627</ArticleId></ArticleIdList></Reference><Reference><Citation>Moayyedi P., Andrews C. N., MacQueen G., Korownyk C., Marsiglio M., Graff L., et al. . (2019). Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). J. Can. Assoc. Gastroenterol. 2, 6&#x2013;29. doi:&#xa0;10.1093/jcag/gwy071</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jcag/gwy071</ArticleId><ArticleId IdType="pmc">PMC6507291</ArticleId><ArticleId IdType="pubmed">31294724</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu Y., Cong Y. (2019). Bacillus Coagulans and its Applications in Medicine. Benef. Microbes 10, 679&#x2013;688. doi:&#xa0;10.3920/BM2019.0016</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2019.0016</ArticleId><ArticleId IdType="pubmed">31203635</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng Q. X., et al. . (2018). A Meta-Analysis of the Use of Probiotics to Alleviate Depressive Symptoms. J. Affect. Disord. 228, 13&#x2013;19. doi:&#xa0;10.1016/j.jad.2017.11.063</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2017.11.063</ArticleId><ArticleId IdType="pubmed">29197739</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedzielin K., Kordecki H., Birkenfeld B. (2001). A Controlled, Double-Blind, Randomized Study on the Efficacy of Lactobacillus Plantarum 299V in Patients With Irritable Bowel Syndrome. Eur. J. Gastroenterol. Hepatol. 13, 1143&#x2013;1147. doi:&#xa0;10.1097/00042737-200110000-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00042737-200110000-00004</ArticleId><ArticleId IdType="pubmed">11711768</ArticleId></ArticleIdList></Reference><Reference><Citation>Niv E., Naftali T., Hallak R., Vaisman N.. (2005). The Efficacy of Lactobacillus Reuteri ATCC 55730 in the Treatment of Patients With Irritable Bowel Syndrome&#x2013;A Double Blind, Placebo-Controlled, Randomized Study. Clin. Nutr. 24, 925&#x2013;931. doi:&#xa0;10.1016/j.clnu.2005.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2005.06.001</ArticleId><ArticleId IdType="pubmed">16051399</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka P., Parr H., Barberio B., Black C. J., Savarino E. V., Ford A. C.. (2020). Global Prevalence of Irritable Bowel Syndrome According to Rome III or IV Criteria: A Systematic Review and Meta-Analysis. Lancet Gastroenterol. Hepatol. 5, 908&#x2013;917. doi:&#xa0;10.1016/S2468-1253(20)30217-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30217-X</ArticleId><ArticleId IdType="pubmed">32702295</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahony L., McCarthy J., Kelly P., Hurley G., Luo F., Chen K., et al. . (2005). Lactobacillus and Bifidobacterium in Irritable Bowel Syndrome: Symptom Responses and Relationship to Cytokine Profiles. Gastroenterology 128, 541&#x2013;551. doi:&#xa0;10.1053/j.gastro.2004.11.050</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2004.11.050</ArticleId><ArticleId IdType="pubmed">15765388</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Sullivan M. A., O&#x2019;Morain C. A. (2000). Bacterial Supplementation in the Irritable Bowel Syndrome. A Randomised Double-Blind Placebo-Controlled Crossover Study. Dig. Liver Dis. 32, 294&#x2013;301. doi:&#xa0;10.1016/s1590-8658(00)80021-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1590-8658(00)80021-3</ArticleId><ArticleId IdType="pubmed">11515626</ArticleId></ArticleIdList></Reference><Reference><Citation>Page M. J., McKenzie J. E., Bossuyt P. M., Boutron I., Hoffmann T. C., Mulrow C. D., et al. . (2021). The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. PloS Med. 18, e1003583. doi:&#xa0;10.1371/journal.pmed.1003583</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003583</ArticleId><ArticleId IdType="pmc">PMC8007028</ArticleId><ArticleId IdType="pubmed">33780438</ArticleId></ArticleIdList></Reference><Reference><Citation>Pineton D. C. G., Neut C., Chau A., Cazaubiel M., Pelerin F., Justen P., et al. . (2015). A Randomized Clinical Trial of Saccharomyces Cerevisiae Versus Placebo in the Irritable Bowel Syndrome. Dig. Liver Dis. 47, 119&#x2013;124. doi:&#xa0;10.1016/j.dld.2014.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2014.11.007</ArticleId><ArticleId IdType="pubmed">25488056</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto-Sanchez M. I., Hall G. B., Ghajar K., Nardelli A., Bolino C., Lau J. T., et al. . (2017). Probiotic Bifidobacterium Longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. Gastroenterology 153, 448&#x2013;459.e8. doi:&#xa0;10.1053/j.gastro.2017.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2017.05.003</ArticleId><ArticleId IdType="pubmed">28483500</ArticleId></ArticleIdList></Reference><Reference><Citation>Plaza-Diaz J., Gomez-Llorente C., Fontana L., Gil A. (2014). Modulation of Immunity and Inflammatory Gene Expression in the Gut, in Inflammatory Diseases of the Gut and in the Liver by Probiotics. World J. Gastroenterol. 20, 15632&#x2013;15649. doi:&#xa0;10.3748/wjg.v20.i42.15632</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i42.15632</ArticleId><ArticleId IdType="pmc">PMC4229528</ArticleId><ArticleId IdType="pubmed">25400447</ArticleId></ArticleIdList></Reference><Reference><Citation>Preston K., Krumian R., Hattner J., de Montigny D., Stewart M., Gaddam S. (2018). Lactobacillus Acidophilus CL1285, Lactobacillus Casei LBC80R and Lactobacillus Rhamnosus CLR2 Improve Quality-of-Life and IBS Symptoms: A Double-Blind, Randomised, Placebo-Controlled Study. Benef. Microbes 9, 697&#x2013;706. doi:&#xa0;10.3920/BM2017.0105</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2017.0105</ArticleId><ArticleId IdType="pubmed">29888656</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin J., Li R., Raes J., Arumugam M., Burgdorf K. S., Manichanh C., et al. . (2010). A Human Gut Microbial Gene Catalogue Established by Metagenomic Sequencing. Nature 464, 59&#x2013;65. doi:&#xa0;10.1038/nature08821</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08821</ArticleId><ArticleId IdType="pmc">PMC3779803</ArticleId><ArticleId IdType="pubmed">20203603</ArticleId></ArticleIdList></Reference><Reference><Citation>Raskov H., Burcharth J., Pommergaard H. C., Rosenberg J. (2016). Irritable Bowel Syndrome, the Microbiota and the Gut-Brain Axis. Gut Microbes 7, 365&#x2013;383. doi:&#xa0;10.1080/19490976.2016.1218585</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2016.1218585</ArticleId><ArticleId IdType="pmc">PMC5046167</ArticleId><ArticleId IdType="pubmed">27472486</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringel-Kulka T., Goldsmith J. R., Carroll I. M., Barros S. P., Palsson O., Jobin C., et al. . (2014). Lactobacillus Acidophilus NCFM Affects Colonic Mucosal Opioid Receptor Expression in Patients With Functional Abdominal Pain - a Randomised Clinical Study. Aliment. Pharmacol. Ther. 40, 200&#x2013;207. doi:&#xa0;10.1111/apt.12800</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.12800</ArticleId><ArticleId IdType="pmc">PMC4613798</ArticleId><ArticleId IdType="pubmed">24853043</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringel Y., Ringel-Kulka T. (2015). The Intestinal Microbiota and Irritable Bowel Syndrome. J. Clin. Gastroenterol. 49 Suppl 1, S56&#x2013;S59. doi:&#xa0;10.1097/MCG.0000000000000418</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0000000000000418</ArticleId><ArticleId IdType="pubmed">26447966</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts L. M., McCahon D., Holder R., Wilson S., Hobbs F. D. (2013). A Randomised Controlled Trial of a Probiotic &#x2018;Functional Food&#x2019; in the Management of Irritable Bowel Syndrome. BMC Gastroenterol. 13, 45. doi:&#xa0;10.1186/1471-230X-13-45</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-230X-13-45</ArticleId><ArticleId IdType="pmc">PMC3605320</ArticleId><ArticleId IdType="pubmed">23496803</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseaux C., Thuru X., Gelot A., Barnich N., Neut C., Dubuquoy L., et al. . (2007). Lactobacillus Acidophilus Modulates Intestinal Pain and Induces Opioid and Cannabinoid Receptors. Nat. Med. 13, 35&#x2013;37. doi:&#xa0;10.1038/nm1521</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1521</ArticleId><ArticleId IdType="pubmed">17159985</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;ndergaard B., Olsson J., Ohlson K., Svensson U., Bytzer P., Ekesbo R. (2011). Effects of Probiotic Fermented Milk on Symptoms and Intestinal Flora in Patients With Irritable Bowel Syndrome: A Randomized, Placebo-Controlled Trial. Scand. J. Gastroenterol. 46, 663&#x2013;672. doi:&#xa0;10.3109/00365521.2011.565066</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365521.2011.565066</ArticleId><ArticleId IdType="pubmed">21443416</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadrin S., Sennoune S., Gout B., Marque S., Moreau J., Zinoune K., et al. . (2020). A 2-Strain Mixture of Lactobacillus Acidophilus in the Treatment of Irritable Bowel Syndrome: A Placebo-Controlled Randomized Clinical Trial. Dig. Liver Dis. 52, 534&#x2013;540. doi:&#xa0;10.1016/j.dld.2019.12.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2019.12.009</ArticleId><ArticleId IdType="pubmed">31952938</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt C. (2015). Mental Health: Thinking From the Gut. Nature 518, S12&#x2013;S15. doi:&#xa0;10.1038/518S13a</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/518S13a</ArticleId><ArticleId IdType="pubmed">25715275</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinn D. H., Song J. H., Kim H. J., Lee J. H., Son H. J., Chang D. K., et al. . (2008). Therapeutic Effect of Lactobacillus Acidophilus-SDC 2012, 2013 in Patients With Irritable Bowel Syndrome. Dig. Dis. Sci. 53, 2714&#x2013;2718. doi:&#xa0;10.1007/s10620-007-0196-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-007-0196-4</ArticleId><ArticleId IdType="pubmed">18274900</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel B. M., Gralnek I. M., Bolus R., Chang L., Dulai G. S., Mayer E. A., et al. . (2004). Clinical Determinants of Health-Related Quality of Life in Patients With Irritable Bowel Syndrome. Arch. Intern. Med. 164, 1773&#x2013;1780. doi:&#xa0;10.1001/archinte.164.16.1773</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.164.16.1773</ArticleId><ArticleId IdType="pubmed">15364671</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller R., Pelerin F., Cayzeele D. A., Maudet C., Housez B., Cazaubiel M., et al. . (2016). Randomized Double Blind Placebo-Controlled Trial of Saccharomyces Cerevisiae CNCM I-3856 in Irritable Bowel Syndrome: Improvement in Abdominal Pain and Bloating in Those With Predominant Constipation. U. Eur. Gastroenterol. J. 4, 353&#x2013;362. doi:&#xa0;10.1177/2050640615602571</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2050640615602571</ArticleId><ArticleId IdType="pmc">PMC4924426</ArticleId><ArticleId IdType="pubmed">27403301</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevenson C., Blaauw R., Fredericks E., Visser J., Roux S.. (2014). Randomized Clinical Trial: Effect of Lactobacillus Plantarum 299 V on Symptoms of Irritable Bowel Syndrome. Nutrition 30, 1151&#x2013;1157. doi:&#xa0;10.1016/j.nut.2014.02.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nut.2014.02.010</ArticleId><ArticleId IdType="pubmed">25194614</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudha M. R., Jayanthi N., Aasin M., Dhanashri R. D., Anirudh T. (2018). Efficacy of Bacillus Coagulans Unique IS2 in Treatment of Irritable Bowel Syndrome in Children: A Double Blind, Randomised Placebo Controlled Study. Benef. Microbes 9, 563&#x2013;572. doi:&#xa0;10.3920/BM2017.0129</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2017.0129</ArticleId><ArticleId IdType="pubmed">29695183</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y. Y., Li M., Li Y. Y., Li L. X., Zhai W. Z., Wang P. (2018). The Effect of Clostridium Butyricum on Symptoms and Fecal Microbiota in Diarrhea-Dominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Sci. Rep. 8, 2964. doi:&#xa0;10.1038/s41598-018-21241-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-21241-z</ArticleId><ArticleId IdType="pmc">PMC5813237</ArticleId><ArticleId IdType="pubmed">29445178</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen A. Y., Li M., Li Y. Y., Li L. X., Zhai W. Z., Wang P. (2016). Efficacy of Lactobacillus Casei Shirota for Patients With Irritable Bowel Syndrome. Eur. J. Gastroenterol. Hepatol. 28, 8&#x2013;14. doi:&#xa0;10.1097/MEG.0000000000000484</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000000484</ArticleId><ArticleId IdType="pubmed">26469356</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasant D. H., Paine P. A., Black C. J., Houghton L. A., Everitt H. A., Corsetti M., et al. . (2021). British Society of Gastroenterology Guidelines on the Management of Irritable Bowel Syndrome. Gut 70, 1214&#x2013;1240. doi:&#xa0;10.1136/gutjnl-2021-324598</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324598</ArticleId><ArticleId IdType="pubmed">33903147</ArticleId></ArticleIdList></Reference><Reference><Citation>Whorwell P. J., Altringer L., Morel J., Bond Y., Charbonneau D., O'Mahony L., et al. . (2006). Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Women With Irritable Bowel Syndrome. Am. J. Gastroenterol. 101, 1581&#x2013;1590. doi:&#xa0;10.1111/j.1572-0241.2006.00734.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2006.00734.x</ArticleId><ArticleId IdType="pubmed">16863564</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins T., Sequoia J. (2017). Probiotics for Gastrointestinal Conditions: A Summary of the Evidence. Am. Fam Physician. 96, 170&#x2013;178. doi:&#xa0;10.1007/s10620-014-3299-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-014-3299-8</ArticleId><ArticleId IdType="pubmed">28762696</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong R. K., Yang C., Song G. H., Wong J., Ho K. Y. (2015). Melatonin Regulation as a Possible Mechanism for Probiotic (VSL#3) in Irritable Bowel Syndrome: A Randomized Double-Blinded Placebo Study. Dig. Dis. Sci. 60, 186&#x2013;194. doi:&#xa0;10.1007/s10620-014-3299-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-014-3299-8</ArticleId><ArticleId IdType="pubmed">25092036</ArticleId></ArticleIdList></Reference><Reference><Citation>Yano J. M., Yu K., Donaldson G. P., Shastri G. G., Ann P., Ma L., et al. . (2015). Indigenous Bacteria From the Gut Microbiota Regulate Host Serotonin Biosynthesis. Cell 161, 264&#x2013;276. doi:&#xa0;10.1016/j.cell.2015.02.047</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.02.047</ArticleId><ArticleId IdType="pmc">PMC4393509</ArticleId><ArticleId IdType="pubmed">25860609</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng J., Li Y. Q., Zuo X. L., Zhen Y. B., Yang J., Liu C. H. (2008). Clinical Trial: Effect of Active Lactic Acid Bacteria on Mucosal Barrier Function in Patients With Diarrhoea-Predominant Irritable Bowel Syndrome. Aliment. Pharmacol. Ther. 28, 994&#x2013;1002. doi:&#xa0;10.1111/j.1365-2036.2008.03818.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2008.03818.x</ArticleId><ArticleId IdType="pubmed">18671775</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37184752</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-1950</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Drugs</Title><ISOAbbreviation>Drugs</ISOAbbreviation></Journal><ArticleTitle>Antibiotics and Probiotics for Irritable Bowel Syndrome.</ArticleTitle><Pagination><StartPage>687</StartPage><EndPage>699</EndPage><MedlinePgn>687-699</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40265-023-01871-y</ELocationID><Abstract><AbstractText>Irritable bowel syndrome (IBS) is a disorder of a gut-brain interaction characterised by abdominal pain and a change in stool form or frequency. Current symptom-based definitions and the classification of IBS promote heterogeneity amongst patients, meaning that there may be several different pathophysiological abnormalities leading to similar symptoms. Although our understanding of IBS is incomplete, there are several indicators that the microbiome may be involved in a subset of patients. Techniques including a faecal sample analysis, colonic biopsies, duodenal aspirates or surrogate markers, such as breath testing, have been used to examine the gut microbiota in individuals with IBS. Because of a lack of a clear definition of what constitutes a healthy gut microbiota, and the fact that alterations in gut microbiota have only been shown to be associated with IBS, a causal relationship is yet to be established. We discuss several hypotheses as to how dysbiosis may be responsible for IBS symptoms, as well as potential treatment strategies. We review the current evidence for the use of antibiotics and probiotics to alter the microbiome in an attempt to improve IBS symptoms. Rifaximin, a non-absorbable antibiotic, is the most studied antibiotic and has now been licensed for use in IBS with diarrhoea in the USA, but the drug remains unavailable in many countries for this indication. Current evidence also suggests that certain probiotics, including Lactobacillus plantarum DSM 9843 and Bifidobacterium bifidum MIMBb75, may be efficacious in some patients with IBS. Finally, we describe the future challenges facing us in our attempt to modulate the microbiome to treat IBS.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goodoory</LastName><ForeName>Vivek C</ForeName><Initials>VC</Initials><AffiliationInfo><Affiliation>Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leeds Gastroenterology Institute, St. James's University Hospital, Room 125, 4th Floor, Bexley Wing, Beckett Street, Leeds, LS9 7TF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ford</LastName><ForeName>Alexander C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK. alexf12399@yahoo.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leeds Gastroenterology Institute, St. James's University Hospital, Room 125, 4th Floor, Bexley Wing, Beckett Street, Leeds, LS9 7TF, UK. alexf12399@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drugs</MedlineTA><NlmUniqueID>7600076</NlmUniqueID><ISSNLinking>0012-6667</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L36O5T016N</RegistryNumber><NameOfSubstance UI="D000078262">Rifaximin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078262" MajorTopicYN="N">Rifaximin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>15</Day><Hour>13</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>15</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37184752</ArticleId><ArticleId IdType="doi">10.1007/s40265-023-01871-y</ArticleId><ArticleId IdType="pii">10.1007/s40265-023-01871-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99-114.e3.</Citation><ArticleIdList><ArticleId IdType="pubmed">32294476</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2020.04.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(10):908&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">32702295</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(20)30217-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. Lancet. 2020;396(10263):1675&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">33049223</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)31548-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016;1(2):133&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">28404070</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(16)30023-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Drossman DA, Talley NJ, Ruddy J, Ford AC. Functional gastrointestinal disorders: advances in understanding and management. Lancet. 2020;396(10263):1664&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">33049221</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)32115-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Craig O, Gracie DJ, Ford AC. Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gut. 2021;70(6):1110&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">32973070</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2020-322519</ArticleId></ArticleIdList></Reference><Reference><Citation>Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.031</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Forman D, Bailey AG, Axon AT, Moayyedi P. Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol. 2008;103(5):1229&#x2013;39 (quiz 40).</Citation><ArticleIdList><ArticleId IdType="pubmed">18371141</ArticleId><ArticleId IdType="doi">10.1111/j.1572-0241.2007.01740.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Staller K, Olen O, Soderling J, Roelstraete B, Tornblom H, Khalili H, et al. Mortality risk in irritable bowel syndrome: results from a nationwide prospective cohort study. Am J Gastroenterol. 2020;115(5):746&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">32108661</ArticleId><ArticleId IdType="pmc">7196022</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000000573</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang JY, Locke GR 3rd, McNally MA, Halder SL, Schleck CD, Zinsmeister AR, et al. Impact of functional gastrointestinal disorders on survival in the community. Am J Gastroenterol. 2010;105(4):822&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">20160713</ArticleId><ArticleId IdType="pmc">2887253</ArticleId><ArticleId IdType="doi">10.1038/ajg.2010.40</ArticleId></ArticleIdList></Reference><Reference><Citation>Pace F, Molteni P, Bollani S, Sarzi-Puttini P, Stockbrugger R, Bianchi Porro G, et al. Inflammatory bowel disease versus irritable bowel syndrome: a hospital-based, case-control study of disease impact on quality of life. Scand J Gastroenterol. 2003;38(10):1031&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">14621276</ArticleId><ArticleId IdType="doi">10.1080/00365520310004524</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodoory VC, Guthrie EA, Ng CE, Black CJ, Ford AC. Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome. Aliment Pharmacol Ther. 2023;57:323&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">36544055</ArticleId><ArticleId IdType="doi">10.1111/apt.17356</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodoory VC, Ng CE, Black CJ, Ford AC. Impact of Rome IV irritable bowel syndrome on work and activities of daily living. Aliment Pharmacol Ther. 2022;56(5):844&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">35794733</ArticleId><ArticleId IdType="pmc">9543519</ArticleId><ArticleId IdType="doi">10.1111/apt.17132</ArticleId></ArticleIdList></Reference><Reference><Citation>Buono JL, Carson RT, Flores NM. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual Life Outcomes. 2017;15(1):35.</Citation><ArticleIdList><ArticleId IdType="pubmed">28196491</ArticleId><ArticleId IdType="pmc">5310011</ArticleId><ArticleId IdType="doi">10.1186/s12955-017-0611-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Frandemark A, Tornblom H, Jakobsson S, Simren M. Work productivity and activity impairment in irritable bowel syndrome (IBS): a multifaceted problem. Am J Gastroenterol. 2018;113(10):1540&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">30254230</ArticleId><ArticleId IdType="doi">10.1038/s41395-018-0262-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Frandemark A, Tornblom H, Simren M, Jakobsson S. Maintaining work life under threat of symptoms: a grounded theory study of work life experiences in persons with irritable bowel syndrome. BMC Gastroenterol. 2022;22(1):73.</Citation><ArticleIdList><ArticleId IdType="pubmed">35183112</ArticleId><ArticleId IdType="pmc">8858507</ArticleId><ArticleId IdType="doi">10.1186/s12876-022-02158-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Corney RH, Stanton R. Physical symptom severity, psychological and social dysfunction in a series of outpatients with irritable bowel syndrome. J Psychosom Res. 1990;34(5):483&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">2231481</ArticleId><ArticleId IdType="doi">10.1016/0022-3999(90)90022-V</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballou S, McMahon C, Lee HN, Katon J, Shin A, Rangan V, et al. Effects of irritable bowel syndrome on daily activities vary among subtypes based on results from the IBS in America Survey. Clin Gastroenterol Hepatol. 2019;17(12):2471-8.e3.</Citation><ArticleIdList><ArticleId IdType="pubmed">31419572</ArticleId><ArticleId IdType="pmc">7675784</ArticleId><ArticleId IdType="doi">10.1016/j.cgh.2019.08.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Yiannakou Y, Houghton LA, Ford AC. Epidemiological, CLINICAL, and psychological characteristics of individuals with self-reported irritable bowel syndrome based on the Rome IV vs Rome III criteria. Clin Gastroenterol Hepatol. 2020;18(2):392-8.e2.</Citation><ArticleIdList><ArticleId IdType="pubmed">31154027</ArticleId><ArticleId IdType="doi">10.1016/j.cgh.2019.05.037</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel P, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P, et al. Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating. Aliment Pharmacol Ther. 2015;41(5):449&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">25586008</ArticleId><ArticleId IdType="doi">10.1111/apt.13074</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodoory VC, Mikocka-Walus A, Yiannakou Y, Houghton LA, Black CJ, Ford AC. Impact of psychological comorbidity on the prognosis of irritable bowel syndrome. Am J Gastroenterol. 2021;116(7):1485&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">33840729</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000001247</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodoory VC, Ng CE, Black CJ, Ford AC. Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom. Aliment Pharmacol Ther. 2022;56(1):110&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">35491477</ArticleId><ArticleId IdType="pmc">9325446</ArticleId><ArticleId IdType="doi">10.1111/apt.16939</ArticleId></ArticleIdList></Reference><Reference><Citation>Flacco ME, Manzoli L, De Giorgio R, Gasbarrini A, Cicchetti A, Bravi F, et al. Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a meta-analysis. Eur Rev Med Pharmacol Sci. 2019;23(7):2986&#x2013;3000.</Citation><ArticleIdList><ArticleId IdType="pubmed">31002149</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Xiang W, Li CY, Li SC. Economic burden of irritable bowel syndrome in China. World J Gastroenterol. 2016;22(47):10450&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">28058026</ArticleId><ArticleId IdType="pmc">5175258</ArticleId><ArticleId IdType="doi">10.3748/wjg.v22.i47.10450</ArticleId></ArticleIdList></Reference><Reference><Citation>Peery AF, Crockett SD, Murphy CC, Lund JL, Dellon ES, Williams JL, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology. 2019;156(1):254-72.e11.</Citation><ArticleIdList><ArticleId IdType="pubmed">30315778</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2018.08.063</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah ED, Salwen-Deremer JK, Gibson PR, Muir JG, Eswaran S, Chey WD. Comparing costs and outcomes of treatments for irritable bowel syndrome with diarrhea: cost-benefit analysis. Clin Gastroenterol Hepatol. 2022;20(1):136-44.e31.</Citation><ArticleIdList><ArticleId IdType="pubmed">33010413</ArticleId><ArticleId IdType="doi">10.1016/j.cgh.2020.09.043</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah ED, Chang L, Salwen-Deremer JK, Gibson PR, Keefer L, Muir JG, et al. Contrasting clinician and insurer perspectives to managing irritable bowel syndrome: multilevel modeling analysis. Am J Gastroenterol. 2021;116(4):748&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">33982945</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000000989</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodoory VC, Ng CE, Black CJ, Ford AC. Willingness to pay for medications among patients with Rome IV irritable bowel syndrome. Neurogastroenterol Motil. 2023;35(2): e14483.</Citation><ArticleIdList><ArticleId IdType="pubmed">36178331</ArticleId><ArticleId IdType="doi">10.1111/nmo.14483</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpert A. Irritable bowel syndrome: patient-provider interaction and patient education. J Clin Med. 2018;7(1):3.</Citation><ArticleIdList><ArticleId IdType="pubmed">29301273</ArticleId><ArticleId IdType="pmc">5791011</ArticleId><ArticleId IdType="doi">10.3390/jcm7010003</ArticleId></ArticleIdList></Reference><Reference><Citation>Hearn M, Whorwell PJ, Vasant DH. Stigma and irritable bowel syndrome: a taboo subject? Lancet Gastroenterol Hepatol. 2020;5(6):607&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">31924568</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(19)30348-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasant DH, Paine PA, Black CJ, Houghton LA, Everitt HA, Corsetti M, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70(7):1214&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">33903147</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2021-324598</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021;116(1):17&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">33315591</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000001036</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Burr NE, Camilleri M, Earnest DL, Quigley EM, Moayyedi P, et al. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. Gut. 2020;69(1):74&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">30996042</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2018-318160</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Burr NE, Quigley EMM, Moayyedi P, Houghton LA, Ford AC. Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: systematic review and network meta-analysis. Gastroenterology. 2018;155(6):1753&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">30144426</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2018.08.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Staudacher HM, Ford AC. Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2022;71:1117&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">34376515</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2021-325214</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Thakur ER, Houghton LA, Quigley EMM, Moayyedi P, Ford AC. Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2020;69(8):1441&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">32276950</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2020-321191</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Yuan Y, Selinger CP, Camilleri M, Quigley EMM, Moayyedi P, et al. Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(2):117&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">31859183</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(19)30324-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Barberio B, Savarino EV, Black CJ, Ford AC. Placebo response rates in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: meta-analysis. Clin Gastroenterol Hepatol. 2021. https://doi.org/10.1016/j.cgh.2021.08.025 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2021.08.025</ArticleId><ArticleId IdType="pubmed">34425274</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM, et al. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut. 2010;59(5):605&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">20427395</ArticleId><ArticleId IdType="doi">10.1136/gut.2009.202234</ArticleId></ArticleIdList></Reference><Reference><Citation>Klem F, Wadhwa A, Prokop LJ, Sundt WJ, Farrugia G, Camilleri M, et al. Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis. Gastroenterology. 2017;152(5):1042-54.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">28069350</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2016.12.039</ArticleId></ArticleIdList></Reference><Reference><Citation>Jalanka-Tuovinen J, Salojarvi J, Salonen A, Immonen O, Garsed K, Kelly FM, et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut. 2014;63(11):1737&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">24310267</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2013-305994</ArticleId></ArticleIdList></Reference><Reference><Citation>David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">24336217</ArticleId><ArticleId IdType="doi">10.1038/nature12820</ArticleId></ArticleIdList></Reference><Reference><Citation>Villarreal AA, Aberger FJ, Benrud R, Gundrum JD. Use of broad-spectrum antibiotics and the development of irritable bowel syndrome. WMJ. 2012;111(1):17&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">22533211</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">21208106</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1004409</ArticleId></ArticleIdList></Reference><Reference><Citation>Lembo A, Pimentel M, Rao SS, Schoenfeld P, Cash B, Weinstock LB, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2016;151(6):1113&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">27528177</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2016.08.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7(12):1279&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">19602448</ArticleId><ArticleId IdType="doi">10.1016/j.cgh.2009.06.031</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah ED, Basseri RJ, Chong K, Pimentel M. Abnormal breath testing in IBS: a meta-analysis. Dig Dis Sci. 2010;55(9):2441&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20467896</ArticleId><ArticleId IdType="doi">10.1007/s10620-010-1276-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah A, Talley NJ, Jones M, Kendall BJ, Koloski N, Walker MM, et al. Small intestinal bacterial overgrowth in irritable bowel wyndrome: a systematic review and meta-analysis of case-control studies. Am J Gastroenterol. 2020;115(2):190&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">31913194</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000000504</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95(12):3503&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11151884</ArticleId><ArticleId IdType="doi">10.1111/j.1572-0241.2000.03368.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianiro G, Eusebi LH, Black CJ, Gasbarrini A, Cammarota G, Ford AC. Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2019;50(3):240&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">31136009</ArticleId><ArticleId IdType="doi">10.1111/apt.15330</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M, Winkel R, Casen C, Hausken T, Gilja OH, Hatlebakk JG. Efficacy of fecal microbiota transplantation for patients with irritable bowel syndrome at 3 years after transplantation. Gastroenterology. 2022;163(4):982-94.e14.</Citation><ArticleIdList><ArticleId IdType="pubmed">35709830</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2022.06.020</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Toole PW, Flemer B. From culture to high-throughput sequencing and beyond: a layperson&#x2019;s guide to the &#x201c;omics&#x201d; and diagnostic potential of the microbiome. Gastroenterol Clin North Am. 2017;46(1):9&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28164855</ArticleId><ArticleId IdType="doi">10.1016/j.gtc.2016.09.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Hugerth LW, Andreasson A, Talley NJ, Forsberg AM, Kjellstrom L, Schmidt PT, et al. No distinct microbiome signature of irritable bowel syndrome found in a Swedish random population. Gut. 2020;69(6):1076&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">31601615</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2019-318717</ArticleId></ArticleIdList></Reference><Reference><Citation>Tap J, Derrien M, Tornblom H, Brazeilles R, Cools-Portier S, Dore J, et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology. 2017;152(1):111-23.e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27725146</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2016.09.049</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg G, Rybakova D, Fischer D, Cernava T, Verges MC, Charles T, et al. Microbiome definition re-visited: old concepts and new challenges. Microbiome. 2020;8(1):103.</Citation><ArticleIdList><ArticleId IdType="pubmed">32605663</ArticleId><ArticleId IdType="pmc">7329523</ArticleId><ArticleId IdType="doi">10.1186/s40168-020-00875-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">20203603</ArticleId><ArticleId IdType="pmc">3779803</ArticleId><ArticleId IdType="doi">10.1038/nature08821</ArticleId></ArticleIdList></Reference><Reference><Citation>Sender R, Fuchs S, Milo R. Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell. 2016;164(3):337&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">26824647</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2016.01.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. BMJ. 2018;361: k2179.</Citation><ArticleIdList><ArticleId IdType="pubmed">29899036</ArticleId><ArticleId IdType="pmc">6000740</ArticleId><ArticleId IdType="doi">10.1136/bmj.k2179</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90(3):859&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">20664075</ArticleId><ArticleId IdType="doi">10.1152/physrev.00045.2009</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittayanon R, Lau JT, Yuan Y, Leontiadis GI, Tse F, Surette M, et al. Gut microbiota in patients with irritable bowel syndrome: a systematic review. Gastroenterology. 2019;157(1):97&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">30940523</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2019.03.049</ArticleId></ArticleIdList></Reference><Reference><Citation>Willing BP, Dicksved J, Halfvarson J, Andersson AF, Lucio M, Zheng Z, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology. 2010;139(6):1844-54.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">20816835</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2010.08.049</ArticleId></ArticleIdList></Reference><Reference><Citation>Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, et al. Reduced diversity of faecal microbiota in Crohn&#x2019;s disease revealed by a metagenomic approach. Gut. 2006;55(2):205&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">16188921</ArticleId><ArticleId IdType="pmc">1856500</ArticleId><ArticleId IdType="doi">10.1136/gut.2005.073817</ArticleId></ArticleIdList></Reference><Reference><Citation>Avuthu N, Guda C. Meta-analysis of altered gut microbiota reveals microbial and metabolic biomarkers for colorectal cancer. Microbiol Spectr. 2022;10(4): e0001322.</Citation><ArticleIdList><ArticleId IdType="pubmed">35766483</ArticleId><ArticleId IdType="doi">10.1128/spectrum.00013-22</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Lau HC, Liu Y, Kang X, Wang Y, Ting NL, et al. Altered mycobiota signatures and enriched pathogenic Aspergillus rambellii are associated with colorectal cancer based on multicohort fecal metagenomic analyses. Gastroenterology. 2022;163(4):908&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">35724733</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2022.06.038</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam MZ, Tran M, Xu T, Tierney BT, Patel C, Kostic AD. Reproducible and opposing gut microbiome signatures distinguish autoimmune diseases and cancers: a systematic review and meta-analysis. Microbiome. 2022;10(1):218.</Citation><ArticleIdList><ArticleId IdType="pubmed">36482486</ArticleId><ArticleId IdType="pmc">9733034</ArticleId><ArticleId IdType="doi">10.1186/s40168-022-01373-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Noce A, Marrone G, Di Daniele F, Ottaviani E, Wilson Jones G, Bernini R, et al. Impact of gut microbiota composition on onset and progression of chronic non-communicable diseases. Nutrients. 2019;11(5):1073.</Citation><ArticleIdList><ArticleId IdType="pubmed">31091761</ArticleId><ArticleId IdType="pmc">6567014</ArticleId><ArticleId IdType="doi">10.3390/nu11051073</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457(7228):480&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">19043404</ArticleId><ArticleId IdType="doi">10.1038/nature07540</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambeth SM, Carson T, Lowe J, Ramaraj T, Leff JW, Luo L, et al. Composition, diversity and abundance of gut microbiome in prediabetes and type 2 diabetes. J Diabetes Obes. 2015;2(3):1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">26756039</ArticleId><ArticleId IdType="pmc">4705851</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano S, Savva GM, Bedarf JR, Charles IG, Hildebrand F, Narbad A. Meta-analysis of the Parkinson&#x2019;s disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ Parkinsons Dis. 2021;7(1):27.</Citation><ArticleIdList><ArticleId IdType="pubmed">33692356</ArticleId><ArticleId IdType="pmc">7946946</ArticleId><ArticleId IdType="doi">10.1038/s41531-021-00156-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Hugon P, Dufour JC, Colson P, Fournier PE, Sallah K, Raoult D. A comprehensive repertoire of prokaryotic species identified in human beings. Lancet Infect Dis. 2015;15(10):1211&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26311042</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(15)00293-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder BO, Backhed F. Signals from the gut microbiota to distant organs in physiology and disease. Nat Med. 2016;22(10):1079&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">27711063</ArticleId><ArticleId IdType="doi">10.1038/nm.4185</ArticleId></ArticleIdList></Reference><Reference><Citation>Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">22699611</ArticleId><ArticleId IdType="pmc">3376388</ArticleId><ArticleId IdType="doi">10.1038/nature11053</ArticleId></ArticleIdList></Reference><Reference><Citation>Deschasaux M, Bouter KE, Prodan A, Levin E, Groen AK, Herrema H, et al. Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography. Nat Med. 2018;24(10):1526&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">30150717</ArticleId><ArticleId IdType="doi">10.1038/s41591-018-0160-1</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Wu W, Zheng HM, Li P, McDonald D, Sheng HF, et al. Regional variation limits applications of healthy gut microbiome reference ranges and disease models. Nat Med. 2018;24(10):1532&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">30150716</ArticleId><ArticleId IdType="doi">10.1038/s41591-018-0164-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanahan F, van Sinderen D, O&#x2019;Toole PW, Stanton C. Feeding the microbiota: transducer of nutrient signals for the host. Gut. 2017;66(9):1709&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28663354</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2017-313872</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh TS, Rampelli S, Jeffery IB, Santoro A, Neto M, Capri M, et al. Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: the NU-AGE 1-year dietary intervention across five European countries. Gut. 2020;69(7):1218&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">32066625</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2019-319654</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques TM, Wall R, Ross RP, Fitzgerald GF, Ryan CA, Stanton C. Programming infant gut microbiota: influence of dietary and environmental factors. Curr Opin Biotechnol. 2010;21(2):149&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">20434324</ArticleId><ArticleId IdType="doi">10.1016/j.copbio.2010.03.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A. 2010;107(26):11971&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">20566857</ArticleId><ArticleId IdType="pmc">2900693</ArticleId><ArticleId IdType="doi">10.1073/pnas.1002601107</ArticleId></ArticleIdList></Reference><Reference><Citation>McGuire MK, McGuire MA. Human milk: mother nature&#x2019;s prototypical probiotic food? Adv Nutr. 2015;6(1):112&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">25593150</ArticleId><ArticleId IdType="pmc">4288270</ArticleId><ArticleId IdType="doi">10.3945/an.114.007435</ArticleId></ArticleIdList></Reference><Reference><Citation>Vangay P, Ward T, Gerber JS, Knights D. Antibiotics, pediatric dysbiosis, and disease. Cell Host Microbe. 2015;17(5):553&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">25974298</ArticleId><ArticleId IdType="pmc">5555213</ArticleId><ArticleId IdType="doi">10.1016/j.chom.2015.04.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothschild D, Weissbrod O, Barkan E, Kurilshikov A, Korem T, Zeevi D, et al. Environment dominates over host genetics in shaping human gut microbiota. Nature. 2018;555(7695):210&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">29489753</ArticleId><ArticleId IdType="doi">10.1038/nature25973</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke SF, Murphy EF, O&#x2019;Sullivan O, Lucey AJ, Humphreys M, Hogan A, et al. Exercise and associated dietary extremes impact on gut microbial diversity. Gut. 2014;63(12):1913&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">25021423</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2013-306541</ArticleId></ArticleIdList></Reference><Reference><Citation>Engen PA, Green SJ, Voigt RM, Forsyth CB, Keshavarzian A. The gastrointestinal microbiome: alcohol effects on the composition of intestinal microbiota. Alcohol Res. 2015;37(2):223&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">26695747</ArticleId><ArticleId IdType="pmc">4590619</ArticleId></ArticleIdList></Reference><Reference><Citation>Antinozzi M, Giffi M, Sini N, Galle F, Valeriani F, De Vito C, et al. Cigarette smoking and human gut microbiota in healthy adults: a systematic review. Biomedicines. 2022;10(2):510.</Citation><ArticleIdList><ArticleId IdType="pubmed">35203720</ArticleId><ArticleId IdType="pmc">8962244</ArticleId><ArticleId IdType="doi">10.3390/biomedicines10020510</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee S, Schlaeppi K, van der Heijden MGA. Keystone taxa as drivers of microbiome structure and functioning. Nat Rev Microbiol. 2018;16(9):567&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">29789680</ArticleId><ArticleId IdType="doi">10.1038/s41579-018-0024-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost G, Sleeth ML, Sahuri-Arisoylu M, Lizarbe B, Cerdan S, Brody L, et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun. 2014;5:3611.</Citation><ArticleIdList><ArticleId IdType="pubmed">24781306</ArticleId><ArticleId IdType="doi">10.1038/ncomms4611</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vadder F, Kovatcheva-Datchary P, Goncalves D, Vinera J, Zitoun C, Duchampt A, et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell. 2014;156(1&#x2013;2):84&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">24412651</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2013.12.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin HV, Frassetto A, Kowalik EJ Jr, Nawrocki AR, Lu MM, Kosinski JR, et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS ONE. 2012;7(4): e35240.</Citation><ArticleIdList><ArticleId IdType="pubmed">22506074</ArticleId><ArticleId IdType="pmc">3323649</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0035240</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Zhang F, Ding X, Wu G, Lam YY, Wang X, et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science. 2018;359(6380):1151&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">29590046</ArticleId><ArticleId IdType="doi">10.1126/science.aao5774</ArticleId></ArticleIdList></Reference><Reference><Citation>Long SL, Gahan CGM, Joyce SA. Interactions between gut bacteria and bile in health and disease. Mol Aspects Med. 2017;56:54&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602676</ArticleId><ArticleId IdType="doi">10.1016/j.mam.2017.06.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Yang W, Chen Y, Huang F, Lu L, Lin C, et al. A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome. J Clin Invest. 2020;130(1):438&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">31815740</ArticleId><ArticleId IdType="doi">10.1172/JCI130976</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">23614584</ArticleId><ArticleId IdType="pmc">3701945</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1109400</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanahan F, Hill C. Language, numeracy and logic in microbiome science. Nat Rev Gastroenterol Hepatol. 2019;16(7):387&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">31168062</ArticleId><ArticleId IdType="doi">10.1038/s41575-019-0163-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei S, Bahl MI, Baunwall SMD, Hvas CL, Licht TR. Determining gut microbial dysbiosis: a review of applied indexes for assessment of intestinal microbiota imbalances. Appl Environ Microbiol. 2021;87(11):e00395-e421.</Citation><ArticleIdList><ArticleId IdType="pubmed">33741632</ArticleId><ArticleId IdType="pmc">8208139</ArticleId><ArticleId IdType="doi">10.1128/AEM.00395-21</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Alammar N, Singh R, Nanavati J, Song Y, Chaudhary R, et al. Gut microbial dysbiosis in the irritable bowel syndrome: a systematic review and meta-analysis of case-control studies. J Acad Nutr Diet. 2020;120(4):565&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">31473156</ArticleId><ArticleId IdType="doi">10.1016/j.jand.2019.05.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al. Diversity of the human intestinal microbial flora. Science. 2005;308(5728):1635&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831718</ArticleId><ArticleId IdType="pmc">1395357</ArticleId><ArticleId IdType="doi">10.1126/science.1110591</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoetendal EG, von Wright A, Vilpponen-Salmela T, Ben-Amor K, Akkermans AD, de Vos WM. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl Environ Microbiol. 2002;68(7):3401&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12089021</ArticleId><ArticleId IdType="pmc">126800</ArticleId><ArticleId IdType="doi">10.1128/AEM.68.7.3401-3407.2002</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll IM, Ringel-Kulka T, Keku TO, Chang YH, Packey CD, Sartor RB, et al. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2011;301(5):G799-807.</Citation><ArticleIdList><ArticleId IdType="pubmed">21737778</ArticleId><ArticleId IdType="pmc">3220325</ArticleId><ArticleId IdType="doi">10.1152/ajpgi.00154.2011</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangel I, Sundin J, Fuentes S, Repsilber D, de Vos WM, Brummer RJ. The relationship between faecal-associated and mucosal-associated microbiota in irritable bowel syndrome patients and healthy subjects. Aliment Pharmacol Ther. 2015;42(10):1211&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">26376728</ArticleId><ArticleId IdType="doi">10.1111/apt.13399</ArticleId></ArticleIdList></Reference><Reference><Citation>Posserud I, Stotzer PO, Bj&#xf6;rnsson ES, Abrahamsson H, Simr&#xe9;n M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56(6):802&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17148502</ArticleId><ArticleId IdType="doi">10.1136/gut.2006.108712</ArticleId></ArticleIdList></Reference><Reference><Citation>Giamarellos-Bourboulis E, Tang J, Pyleris E, Pistiki A, Barbatzas C, Brown J, et al. Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome. Scand J Gastroenterol. 2015;50(9):1076&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">25865706</ArticleId><ArticleId IdType="doi">10.3109/00365521.2015.1027261</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, Koussoulas V, Barbatzas C, Pimentel M. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci. 2012;57(5):1321&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22262197</ArticleId><ArticleId IdType="doi">10.1007/s10620-012-2033-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Villanueva-Millan MJ, Leite G, Wang J, Morales W, Parodi G, Pimentel ML, et al. Methanogens and hydrogen sulfide producing bacteria guide distinct gut microbe profiles and irritable bowel syndrome subtypes. Am J Gastroenterol. 2022;117(12):2055&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">36114762</ArticleId><ArticleId IdType="pmc">9722381</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000001997</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahakian AB, Jee SR, Pimentel M. Methane and the gastrointestinal tract. Dig Dis Sci. 2010;55(8):2135&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">19830557</ArticleId><ArticleId IdType="doi">10.1007/s10620-009-1012-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M, Chang C, Chua KS, Mirocha J, DiBaise J, Rao S, et al. Antibiotic treatment of constipation-predominant irritable bowel syndrome. Dig Dis Sci. 2014;59(6):1278&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">24788320</ArticleId><ArticleId IdType="doi">10.1007/s10620-014-3157-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegazi FZ, Abo-Elnaga IG. Degradation of organic acids by dairy lactic acid bacteria. Zentralbl Bakteriol Naturwiss. 1980;135(3):212&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">6775434</ArticleId></ArticleIdList></Reference><Reference><Citation>Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2010;22(5):512&#x2013;9 (e114&#x2013;5).</Citation><ArticleIdList><ArticleId IdType="pubmed">19903265</ArticleId></ArticleIdList></Reference><Reference><Citation>Beatty JK, Bhargava A, Buret AG. Post-infectious irritable bowel syndrome: mechanistic insights into chronic disturbances following enteric infection. World J Gastroenterol. 2014;20(14):3976&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">24744587</ArticleId><ArticleId IdType="pmc">3983453</ArticleId><ArticleId IdType="doi">10.3748/wjg.v20.i14.3976</ArticleId></ArticleIdList></Reference><Reference><Citation>Quigley EMM, Murray JA, Pimentel M. AGA clinical practice update on small intestinal bacterial overgrowth: expert review. Gastroenterology. 2020;159(4):1526&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">32679220</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2020.06.090</ArticleId></ArticleIdList></Reference><Reference><Citation>Vervier K, Moss S, Kumar N, Adoum A, Barne M, Browne H, et al. Two microbiota subtypes identified in irritable bowel syndrome with distinct responses to the low FODMAP diet. Gut. 2022;71(9):1821&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">34810234</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2021-325177</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M, Hatlebakk JG, Gilja OH, Brathen Kristoffersen A, Hausken T. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2020;69(5):859&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">31852769</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2019-319630</ArticleId></ArticleIdList></Reference><Reference><Citation>Halkjaer SI, Christensen AH, Lo BZS, Browne PD, Gunther S, Hansen LH, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut. 2018;67(12):2107&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">29980607</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2018-316434</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann P, Curtis N. The effect of antibiotics on the composition of the intestinal microbiota: a systematic review. J Infect. 2019;79(6):471&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">31629863</ArticleId><ArticleId IdType="doi">10.1016/j.jinf.2019.10.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogsgaard LR, Engsbro AL, Bytzer P. Antibiotics: a risk factor for irritable bowel syndrome in a population-based cohort. Scand J Gastroenterol. 2018;53(9):1027&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">30189148</ArticleId><ArticleId IdType="doi">10.1080/00365521.2018.1500638</ArticleId></ArticleIdList></Reference><Reference><Citation>Paula H, Grover M, Halder SL, Locke GR 3rd, Schleck CD, Zinsmeister AR, et al. Non-enteric infections, antibiotic use, and risk of development of functional gastrointestinal disorders. Neurogastroenterol Motil. 2015;27(11):1580&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">26303310</ArticleId><ArticleId IdType="pmc">4624515</ArticleId><ArticleId IdType="doi">10.1111/nmo.12655</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98(2):412&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12591062</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal UC, Srivastava D, Misra A, Ghoshal U. A proof-of-concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small-intestinal bacterial overgrowth: a randomized, double-blind, placebo-controlled trial. Eur J Gastroenterol Hepatol. 2016;28(3):281&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26731696</ArticleId><ArticleId IdType="doi">10.1097/MEG.0000000000000557</ArticleId></ArticleIdList></Reference><Reference><Citation>Lembo A, Zakko S, Ferreira N, Ringel Y, Bortey E, Courtney K, et al. Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response. Gastroenterology. 2008;134(Suppl. 1):A545.</Citation></Reference><Reference><Citation>Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101(2):326&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">16454838</ArticleId><ArticleId IdType="doi">10.1111/j.1572-0241.2006.00458.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006;145(8):557&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">17043337</ArticleId><ArticleId IdType="doi">10.7326/0003-4819-145-8-200610170-00004</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48(10):1044&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">30294792</ArticleId><ArticleId IdType="doi">10.1111/apt.15001</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah E, Kim S, Chong K, Lembo A, Pimentel M. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. Am J Med. 2012;125(4):381&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">22444104</ArticleId><ArticleId IdType="doi">10.1016/j.amjmed.2011.08.026</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaie A, Heimanson Z, McCallum R, Pimentel M. Lactulose breath testing as a predictor of response to rifaximin in patients with irritable bowel syndrome with diarrhea. Am J Gastroenterol. 2019;114(12):1886&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">31688023</ArticleId><ArticleId IdType="pmc">6903366</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000000444</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2016;43(Suppl 1):37&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">26618924</ArticleId><ArticleId IdType="doi">10.1111/apt.13437</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Agricultural Organisation of the United Nations (FAO) and World Health Organization (WHO). Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. 2001. https://www.fao.org/3/y6398e/y6398e.pdf . Accessed 23 Feb 2023.</Citation></Reference><Reference><Citation>Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">24912386</ArticleId><ArticleId IdType="doi">10.1038/nrgastro.2014.66</ArticleId></ArticleIdList></Reference><Reference><Citation>Quigley EM. Probiotics in irritable bowel syndrome: the science and the evidence. J Clin Gastroenterol. 2015;49(Suppl. 1):S60&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">26447967</ArticleId><ArticleId IdType="doi">10.1097/MCG.0000000000000348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringel-Kulka T, Goldsmith JR, Carroll IM, Barros SP, Palsson O, Jobin C, et al. Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain: a randomised clinical study. Aliment Pharmacol Ther. 2014;40(2):200&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24853043</ArticleId><ArticleId IdType="pmc">4613798</ArticleId><ArticleId IdType="doi">10.1111/apt.12800</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007;13(1):35&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17159985</ArticleId><ArticleId IdType="doi">10.1038/nm1521</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128(3):541&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">15765388</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2004.11.050</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto-Sanchez MI, Hall GB, Ghajar K, Nardelli A, Bolino C, Lau JT, et al. Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome. Gastroenterology. 2017;153(2):448-59.e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28483500</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2017.05.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Andresen V, Gschossmann J, Layer P. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial. Lancet Gastroenterol Hepatol. 2020;5(7):658&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">32277872</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(20)30056-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai T, Xu Z, Xia P, Feng Y, Liu B, Liu H, et al. The short-term efficacy of Bifidobacterium quadruple viable tablet in patients with diarrhea-predominant irritable bowel syndrome: potentially mediated by metabolism rather than diversity regulation. Am J Gastroenterol. 2022.</Citation></Reference><Reference><Citation>Quigley EMM, Markinson L, Stevenson A, Treasure FP, Lacy BE. Randomised clinical trial: efficacy and safety of the live biotherapeutic product MRx1234 in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2023;57(1):81&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">36369645</ArticleId><ArticleId IdType="doi">10.1111/apt.17310</ArticleId></ArticleIdList></Reference><Reference><Citation>Irvine EJ, Tack J, Crowell MD, Gwee KA, Ke M, Schmulson MJ, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology. 2016;150(6):1469-80.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">27147123</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2016.02.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Quigley EMM. Clinical trials of probiotics in patients with irritable bowel syndrome: some points to consider. J Neurogastroenterol Motil. 2022;28(2):204&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">35189598</ArticleId><ArticleId IdType="pmc">8978119</ArticleId><ArticleId IdType="doi">10.5056/jnm22012</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1(8390):1311&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">6145023</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(84)91816-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfil Koch&#x2019;s postulates for pyloric Campylobacter. Med J Aust. 1985;142(8):436&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">3982345</ArticleId><ArticleId IdType="doi">10.5694/j.1326-5377.1985.tb113443.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Falony G, Joossens M, Vieira-Silva S, Wang J, Darzi Y, Faust K, et al. Population-level analysis of gut microbiome variation. Science. 2016;352(6285):560&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">27126039</ArticleId><ArticleId IdType="doi">10.1126/science.aad3503</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhernakova A, Kurilshikov A, Bonder MJ, Tigchelaar EF, Schirmer M, Vatanen T, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science. 2016;352(6285):565&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">27126040</ArticleId><ArticleId IdType="pmc">5240844</ArticleId><ArticleId IdType="doi">10.1126/science.aad3369</ArticleId></ArticleIdList></Reference><Reference><Citation>Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">21508958</ArticleId><ArticleId IdType="pmc">3728647</ArticleId><ArticleId IdType="doi">10.1038/nature09944</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34203002</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6643</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Jun</Month><Day>20</Day></PubDate></JournalIssue><Title>Nutrients</Title><ISOAbbreviation>Nutrients</ISOAbbreviation></Journal><ArticleTitle>Probiotics, Prebiotics, and Synbiotics: Implications and Beneficial Effects against Irritable Bowel Syndrome.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2112</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nu13062112</ELocationID><Abstract><AbstractText>Irritable bowel syndrome (IBS) is still a common functional gastrointestinal disease that presents chronic abdominal symptoms but with a pathophysiology that is not yet fully elucidated. Moreover, the use of the synergistic combination of prebiotics and probiotics, known as synbiotics, for IBS therapy is still in the early stages. Advancements in technology led to determining the important role played by probiotics in IBS, whereas the present paper focuses on the detailed review of the various pathophysiologic mechanisms of action of probiotics, prebiotics, and synbiotics via multidisciplinary domains involving the gastroenterology (microbiota modulation, alteration of gut barrier function, visceral hypersensitivity, and gastrointestinal dysmotility) immunology (intestinal immunological modulation), and neurology (microbiota-gut-brain axis communication and co-morbidities) in mitigating the symptoms of IBS. In addition, this review synthesizes literature about the mechanisms involved in the beneficial effects of prebiotics and synbiotics for patients with IBS, discussing clinical studies testing the efficiency and outcomes of synbiotics used as therapy for IBS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Elemer</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-7050-5686</Identifier><AffiliationInfo><Affiliation>Faculty of Food Science and Technology, University of Agricultural Sciences and Veterinary Medicine, Calea M&#x103;n&#x103;&#x15f;tur 3-5, 400372 Cluj-Napoca, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>C&#x103;linoiu</LastName><ForeName>Lavinia Florina</ForeName><Initials>LF</Initials><Identifier Source="ORCID">0000-0002-0198-0472</Identifier><AffiliationInfo><Affiliation>Faculty of Food Science and Technology, University of Agricultural Sciences and Veterinary Medicine, Calea M&#x103;n&#x103;&#x15f;tur 3-5, 400372 Cluj-Napoca, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Life Sciences, University of Agricultural Sciences and Veterinary Medicine, Calea M&#x103;n&#x103;&#x15f;tur 3-5, 400372 Cluj-Napoca, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitrea</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-5232-7978</Identifier><AffiliationInfo><Affiliation>Institute of Life Sciences, University of Agricultural Sciences and Veterinary Medicine, Calea M&#x103;n&#x103;&#x15f;tur 3-5, 400372 Cluj-Napoca, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vodnar</LastName><ForeName>Dan Cristian</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Faculty of Food Science and Technology, University of Agricultural Sciences and Veterinary Medicine, Calea M&#x103;n&#x103;&#x15f;tur 3-5, 400372 Cluj-Napoca, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Life Sciences, University of Agricultural Sciences and Veterinary Medicine, Calea M&#x103;n&#x103;&#x15f;tur 3-5, 400372 Cluj-Napoca, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PN-III-P1-1.2-PCCDI-2017-0056</GrantID><Agency>Unitatea Executiva pentru Finantarea Invatamantului Superior, a Cercetarii, Dezvoltarii si Inovarii</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nutrients</MedlineTA><NlmUniqueID>101521595</NlmUniqueID><ISSNLinking>2072-6643</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D056692">Prebiotics</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005769" MajorTopicYN="N">Gastrointestinal Motility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007413" MajorTopicYN="N">Intestinal Mucosa</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007422" MajorTopicYN="N">Intestines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="Y">diet therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056692" MajorTopicYN="N">Prebiotics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058616" MajorTopicYN="N">Synbiotics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">alternative therapy</Keyword><Keyword MajorTopicYN="N">functional disease</Keyword><Keyword MajorTopicYN="N">gut microbiota</Keyword><Keyword MajorTopicYN="N">gut&#x2013;brain axis</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>2</Day><Hour>1</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34203002</ArticleId><ArticleId IdType="pmc">PMC8233736</ArticleId><ArticleId IdType="doi">10.3390/nu13062112</ArticleId><ArticleId IdType="pii">nu13062112</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jayaraman T., Wong R., Drossman D.A., Lee Y.Y. Communication breakdown between physicians and IBS sufferers: What is the conundrum and how to overcome it? J. R. Coll. Physicians Edinb. 2017;47:138&#x2013;141. doi: 10.4997/JRCPE.2017.206.</Citation><ArticleIdList><ArticleId IdType="doi">10.4997/JRCPE.2017.206</ArticleId><ArticleId IdType="pubmed">28675183</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell R.M., Ford A. Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis. Clin. Gastroenterol. Hepatol. 2012;10:712&#x2013;721.e4. doi: 10.1016/j.cgh.2012.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2012.02.029</ArticleId><ArticleId IdType="pubmed">22426087</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperber A.D., Dumitrascu D., Fukudo S., Gerson C., Ghoshal U.C., Gwee K.A., Hungin A.P.S., Kang J.-Y., Minhu C., Schmulson M., et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: A Rome Foundation working team literature review. Gut. 2017;66:1075&#x2013;1082. doi: 10.1136/gutjnl-2015-311240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-311240</ArticleId><ArticleId IdType="pubmed">26818616</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballou S., Keefer L. The impact of irritable bowel syndrome on daily functioning: Characterizing and understanding daily consequences of IBS. Neurogastroenterol. Motil. 2016;29:e12982. doi: 10.1111/nmo.12982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12982</ArticleId><ArticleId IdType="pmc">PMC5367953</ArticleId><ArticleId IdType="pubmed">27781332</ArticleId></ArticleIdList></Reference><Reference><Citation>Buono J.L., Carson R.T., Flores N.M. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual. Life Outcomes. 2017;15:1&#x2013;8. doi: 10.1186/s12955-017-0611-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-017-0611-2</ArticleId><ArticleId IdType="pmc">PMC5310011</ArticleId><ArticleId IdType="pubmed">28196491</ArticleId></ArticleIdList></Reference><Reference><Citation>Gralnek I.M., Hays R.D., Kilbourne A., Naliboff B., Mayer E.A. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;119:654&#x2013;660. doi: 10.1053/gast.2000.16484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/gast.2000.16484</ArticleId><ArticleId IdType="pubmed">10982758</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal N., Spiegel B.M. The Effect of Irritable Bowel Syndrome on Health-Related Quality of Life and Health Care Expenditures. Gastroenterol. Clin. N. Am. 2011;40:11&#x2013;19. doi: 10.1016/j.gtc.2010.12.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gtc.2010.12.013</ArticleId><ArticleId IdType="pubmed">21333898</ArticleId></ArticleIdList></Reference><Reference><Citation>Flacco M.E., Manzoli L., de Giorgio R., Gasbarrini A., Cicchetti A., Bravi F., Altini M., Caio G.P., Ursini F. Costs of irritable bowel syndrome in European countries with universal healthcare coverage: A meta-analysis. Eur. Rev. Med. Pharmacol. Sci. 2019;23:2986&#x2013;3000.</Citation><ArticleIdList><ArticleId IdType="pubmed">31002149</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy B.E. Review article: An analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 2018;48:817&#x2013;830. doi: 10.1111/apt.14948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.14948</ArticleId><ArticleId IdType="pmc">PMC6667996</ArticleId><ArticleId IdType="pubmed">30194692</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R. Bowel Disorders. Gastroenterology. 2016;150:1393&#x2013;1407.e5. doi: 10.1053/j.gastro.2016.02.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.031</ArticleId><ArticleId IdType="pubmed">27144627</ArticleId></ArticleIdList></Reference><Reference><Citation>Quigley E.M. The Gut-Brain Axis and the Microbiome: Clues to Pathophysiology and Opportunities for Novel Management Strategies in Irritable Bowel Syndrome (IBS) J. Clin. Med. 2018;7:6. doi: 10.3390/jcm7010006.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm7010006</ArticleId><ArticleId IdType="pmc">PMC5791014</ArticleId><ArticleId IdType="pubmed">29301380</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma G., Collins S.M., Bercik P. The microbiota-gut-brain axis in functional gastrointestinal disorders. Gut Microbes. 2014;5:419&#x2013;429. doi: 10.4161/gmic.29417.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/gmic.29417</ArticleId><ArticleId IdType="pmc">PMC4153782</ArticleId><ArticleId IdType="pubmed">24921926</ArticleId></ArticleIdList></Reference><Reference><Citation>Labus J.S., Hollister E.B., Jacobs J., Kirbach K., Oezguen N., Gupta A., Acosta J., Luna R.A., Aagaard K., Versalovic J., et al. Differences in gut microbial composition correlate with regional brain volumes in irritable bowel syndrome. Microbiome. 2017;5:1&#x2013;17. doi: 10.1186/s40168-017-0260-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40168-017-0260-z</ArticleId><ArticleId IdType="pmc">PMC5410709</ArticleId><ArticleId IdType="pubmed">28457228</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazaridis N. Current insights into the innate immune system dysfunction in irritable bowel syndrome. Ann. Gastroenterol. 2018;31:171&#x2013;187. doi: 10.20524/aog.2018.0229.</Citation><ArticleIdList><ArticleId IdType="doi">10.20524/aog.2018.0229</ArticleId><ArticleId IdType="pmc">PMC5825947</ArticleId><ArticleId IdType="pubmed">29507464</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng Q.X., Soh A.Y.S., Loke W., Lim D.Y., Yeo W.-S. The role of inflammation in irritable bowel syndrome (IBS) J. Inflamm. Res. 2018;11:345&#x2013;349. doi: 10.2147/JIR.S174982.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S174982</ArticleId><ArticleId IdType="pmc">PMC6159811</ArticleId><ArticleId IdType="pubmed">30288077</ArticleId></ArticleIdList></Reference><Reference><Citation>Enck P., Aziz Q., Barbara G., Farmer A.D., Fukudo S., Mayer E.A., Niesler B., Quigley E.M.M., Rajili&#x107;-Stojanovi&#x107; M., Schemann M., et al. Irritable bowel syndrome. Nat. Rev. Dis. Prim. 2016;2:1&#x2013;24. doi: 10.1038/nrdp.2016.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.14</ArticleId><ArticleId IdType="pmc">PMC5001845</ArticleId><ArticleId IdType="pubmed">27159638</ArticleId></ArticleIdList></Reference><Reference><Citation>Camilleri M. Management Options for Irritable Bowel Syndrome. Mayo Clin. Proc. 2018;93:1858&#x2013;1872. doi: 10.1016/j.mayocp.2018.04.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2018.04.032</ArticleId><ArticleId IdType="pmc">PMC6314474</ArticleId><ArticleId IdType="pubmed">30522596</ArticleId></ArticleIdList></Reference><Reference><Citation>Enck P., Junne F., Klosterhalfen S., Zipfel S., Martens U. Therapy options in irritable bowel syndrome. Eur. J. Gastroenterol. Hepatol. 2010;22:1402&#x2013;1411. doi: 10.1097/MEG.0b013e3283405a17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0b013e3283405a17</ArticleId><ArticleId IdType="pubmed">21389791</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi C.H., Kwon J.G., Kim S.K., Myung S.-J., Park K.S., Sohn C.-I., Rhee P.-L., Lee K.J., Lee O.Y., Jung H.-K., et al. Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: A randomized, double-blind, placebo-controlled, multicenter, phase II trial. Neurogastroenterol. Motil. 2015;27:705&#x2013;716. doi: 10.1111/nmo.12544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12544</ArticleId><ArticleId IdType="pubmed">25809913</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M., Mazzawi T. Fecal microbiota transplantation for managing irritable bowel syndrome. Expert Rev. Gastroenterol. Hepatol. 2018;12:439&#x2013;445. doi: 10.1080/17474124.2018.1447380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17474124.2018.1447380</ArticleId><ArticleId IdType="pubmed">29493330</ArticleId></ArticleIdList></Reference><Reference><Citation>Quigley E.M. Probiotics, Prebiotics, and Synbiotics. Elsevier; Amsterdam, The Netherlands: 2016. Probiotics, Prebiotics, Synbiotics, and Other Strategies to Modulate the Gut Microbiota in Irritable Bowel Syndrome (IBS) pp. 549&#x2013;556.</Citation></Reference><Reference><Citation>Yu T., Zheng Y.-P., Tan J.-C., Xiong W.-J., Wang Y., Lin L. Effects of Prebiotics and Synbiotics on Functional Constipation. Am. J. Med. Sci. 2017;353:282&#x2013;292. doi: 10.1016/j.amjms.2016.09.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjms.2016.09.014</ArticleId><ArticleId IdType="pubmed">28262216</ArticleId></ArticleIdList></Reference><Reference><Citation>Butel M.-J. Probiotics, gut microbiota and health. M&#xe9;d. Mal. Infect. 2014;44:1&#x2013;8. doi: 10.1016/j.medmal.2013.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medmal.2013.10.002</ArticleId><ArticleId IdType="pubmed">24290962</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbara G., Cremon C., Azpiroz F. Probiotics in irritable bowel syndrome: Where are we? Neurogastroenterol. Motil. 2018;30:e13513. doi: 10.1111/nmo.13513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13513</ArticleId><ArticleId IdType="pubmed">30460770</ArticleId></ArticleIdList></Reference><Reference><Citation>FAO/WHO . Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria. Amerian C&#xf3;rdoba Park Hotel; C&#xf3;rdoba, Argentina: 2001.</Citation></Reference><Reference><Citation>Collado M.C., Gueimonde M., Sanz Y., Salminen S. Adhesion Properties and Competitive Pathogen Exclusion Ability of Bifidobacteria with Acquired Acid Resistance. J. Food Prot. 2006;69:1675&#x2013;1679. doi: 10.4315/0362-028X-69.7.1675.</Citation><ArticleIdList><ArticleId IdType="doi">10.4315/0362-028X-69.7.1675</ArticleId><ArticleId IdType="pubmed">16865903</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira A.T., Teixeira M.M., Martins F.D.S. The Role of Probiotics and Prebiotics in Inducing Gut Immunity. Front. Immunol. 2013;4:445. doi: 10.3389/fimmu.2013.00445.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2013.00445</ArticleId><ArticleId IdType="pmc">PMC3859913</ArticleId><ArticleId IdType="pubmed">24376446</ArticleId></ArticleIdList></Reference><Reference><Citation>Doron S., Gorbach S.L. Probiotics: Their role in the treatment and prevention of disease. Expert Rev. Anti-Infect. Ther. 2006;4:261&#x2013;275. doi: 10.1586/14787210.4.2.261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14787210.4.2.261</ArticleId><ArticleId IdType="pubmed">16597207</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y.-J., Yu W.-K., Heo T.-R. Identification and screening for antimicrobial activity against Clostridium difficile of Bifidobacterium and Lactobacillus species isolated from healthy infant faeces. Int. J. Antimicrob. Agents. 2003;21:340&#x2013;346. doi: 10.1016/S0924-8579(02)00389-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0924-8579(02)00389-8</ArticleId><ArticleId IdType="pubmed">12672580</ArticleId></ArticleIdList></Reference><Reference><Citation>Collado M.C., Grze&#x15b;kowiak &#x141;., Salminen S. Probiotic Strains and Their Combination Inhibit In Vitro Adhesion of Pathogens to Pig Intestinal Mucosa. Curr. Microbiol. 2007;55:260&#x2013;265. doi: 10.1007/s00284-007-0144-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00284-007-0144-8</ArticleId><ArticleId IdType="pubmed">17657533</ArticleId></ArticleIdList></Reference><Reference><Citation>Gueimonde M., Noriega L., Margolles A., Reyes-Gavil&#xe1;n C.G.D.L., Salminen S. Ability of Bifidobacterium strains with acquired resistance to bile to adhere to human intestinal mucus. Int. J. Food Microbiol. 2005;101:341&#x2013;346. doi: 10.1016/j.ijfoodmicro.2004.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijfoodmicro.2004.11.013</ArticleId><ArticleId IdType="pubmed">15925715</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara S., Hashiba H., Hirota T., Forstner J.F. Inhibition of the binding of enterotoxigenic Escherichia coli Pb176 to human intestinal epithelial cell line HCT-8 by an extracellular protein fraction containing BIF of Bifidobacterium longum SBT2928: Suggestive evidence of blocking of the binding receptor gangliotetraosylceramide on the cell surface. Int. J. Food Microbiol. 2001;67:97&#x2013;106. doi: 10.1016/s0168-1605(01)00432-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0168-1605(01)00432-9</ArticleId><ArticleId IdType="pubmed">11482574</ArticleId></ArticleIdList></Reference><Reference><Citation>Gueimonde M., Jalonen L., He F., Hiramatsu M., Salminen S. Adhesion and competitive inhibition and displacement of human enteropathogens by selected lactobacilli. Food Res. Int. 2006;39:467&#x2013;471. doi: 10.1016/j.foodres.2005.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.foodres.2005.10.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito M.B., Diaz J.P., Mu&#xf1;oz-Quezada S., Llorente C.G., Gil A. Probiotic Mechanisms of Action. Ann. Nutr. Metab. 2012;61:160&#x2013;174. doi: 10.1159/000342079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000342079</ArticleId><ArticleId IdType="pubmed">23037511</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Rodr&#xed;guez I., S&#xe1;nchez B., Ruiz L., Turroni F., Ventura M., Ruas-Madiedo P., Gueimonde M., Margolles A. Role of Extracellular Transaldolase from Bifidobacterium bifidum in Mucin Adhesion and Aggregation. Appl. Environ. Microbiol. 2012;78:3992&#x2013;3998. doi: 10.1128/AEM.08024-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.08024-11</ArticleId><ArticleId IdType="pmc">PMC3346390</ArticleId><ArticleId IdType="pubmed">22447584</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson G.R., Hutkins R., Sanders M.E., Prescott S.L., Reimer R.A., Salminen S.J., Scott K., Stanton C., Swanson K.S., Cani P.D., et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat. Rev. Gastroenterol. Hepatol. 2017;14:491&#x2013;502. doi: 10.1038/nrgastro.2017.75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2017.75</ArticleId><ArticleId IdType="pubmed">28611480</ArticleId></ArticleIdList></Reference><Reference><Citation>Alakomi H.-L., Skytta E., Saarela M., Mattila-Sandholm T., Latva-Kala K., Helander I.M. Lactic Acid Permeabilizes Gram-Negative Bacteria by Disrupting the Outer Membrane. Appl. Environ. Microbiol. 2000;66:2001&#x2013;2005. doi: 10.1128/AEM.66.5.2001-2005.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.66.5.2001-2005.2000</ArticleId><ArticleId IdType="pmc">PMC101446</ArticleId><ArticleId IdType="pubmed">10788373</ArticleId></ArticleIdList></Reference><Reference><Citation>De Keersmaecker S.C., Verhoeven T.L., Desair J., Marchal K., Vanderleyden J., Nagy I. Strong antimicrobial activity ofLactobacillus rhamnosusGG againstSalmonella typhimuriumis due to accumulation of lactic acid. FEMS Microbiol. Lett. 2006;259:89&#x2013;96. doi: 10.1111/j.1574-6968.2006.00250.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6968.2006.00250.x</ArticleId><ArticleId IdType="pubmed">16684107</ArticleId></ArticleIdList></Reference><Reference><Citation>Makras L., Triantafyllou V., Fayol-Messaoudi D., Adriany T., Zoumpopoulou G., Tsakalidou E., Servin A., De Vuyst L. Kinetic analysis of the antibacterial activity of probiotic lactobacilli towards Salmonella enterica serovar Typhimurium reveals a role for lactic acid and other inhibitory compounds. Res. Microbiol. 2006;157:241&#x2013;247. doi: 10.1016/j.resmic.2005.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resmic.2005.09.002</ArticleId><ArticleId IdType="pubmed">16266797</ArticleId></ArticleIdList></Reference><Reference><Citation>Sj&#xf6;gren J., Magnusson J., Broberg A., Schn&#xfc;rer J., Kenne L. Antifungal 3-Hydroxy Fatty Acids from Lactobacillus plantarum MiLAB. Appl. Environ. Microbiol. 2003;69:7554&#x2013;7557. doi: 10.1128/AEM.69.12.7554-7557.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.69.12.7554-7557.2003</ArticleId><ArticleId IdType="pmc">PMC309954</ArticleId><ArticleId IdType="pubmed">14660414</ArticleId></ArticleIdList></Reference><Reference><Citation>Umu &#xd6;.C.O., Rudi K., Diep D.B. Modulation of the gut microbiota by prebiotic fibres and bacteriocins. Microb. Ecol. Health Dis. 2017;28:1348886. doi: 10.1080/16512235.2017.1348886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/16512235.2017.1348886</ArticleId><ArticleId IdType="pmc">PMC5614387</ArticleId><ArticleId IdType="pubmed">28959178</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassan M., Kjos M., Nes I., Diep D., Lotfipour F. Natural antimicrobial peptides from bacteria: Characteristics and potential applications to fight against antibiotic resistance. J. Appl. Microbiol. 2012;113:723&#x2013;736. doi: 10.1111/j.1365-2672.2012.05338.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2672.2012.05338.x</ArticleId><ArticleId IdType="pubmed">22583565</ArticleId></ArticleIdList></Reference><Reference><Citation>Yildirim Z., Winters D.K., Johnson M.G. Purification, amino acid sequence and mode of action of bifidocin B produced by Bifidobacterium bifidum NCFB. J. Appl. Microbiol. 1999;86:45&#x2013;54. doi: 10.1046/j.1365-2672.1999.00629.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2672.1999.00629.x</ArticleId><ArticleId IdType="pubmed">10030011</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen D.S., Cho G.-S., Hanak A., Huch M., Franz C.M., Arneborg N. The effect of bacteriocin-producing Lactobacillus plantarum strains on the intracellular pH of sessile and planktonic Listeria monocytogenes single cells. Int. J. Food Microbiol. 2010;141:S53&#x2013;S59. doi: 10.1016/j.ijfoodmicro.2010.03.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijfoodmicro.2010.03.040</ArticleId><ArticleId IdType="pubmed">20447709</ArticleId></ArticleIdList></Reference><Reference><Citation>Mokoena M.P. Lactic Acid Bacteria and Their Bacteriocins: Classification, Biosynthesis and Applications against Uropathogens: A Mini-Review. Molecules. 2017;22:1255. doi: 10.3390/molecules22081255.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules22081255</ArticleId><ArticleId IdType="pmc">PMC6152299</ArticleId><ArticleId IdType="pubmed">28933759</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar M., Dhaka P., Vijay D., Vergis J., Mohan V., Kumar A., Kurkure N.V., Barbuddhe S.B., Malik S., Rawool D.B. Antimicrobial effects of Lactobacillus plantarum and Lactobacillus acidophilus against multidrug-resistant enteroaggregative Escherichia coli. Int. J. Antimicrob. Agents. 2016;48:265&#x2013;270. doi: 10.1016/j.ijantimicag.2016.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2016.05.014</ArticleId><ArticleId IdType="pubmed">27451088</ArticleId></ArticleIdList></Reference><Reference><Citation>Oelschlaeger T.A. Mechanisms of probiotic actions&#x2014;A review. Int. J. Med. Microbiol. 2010;300:57&#x2013;62. doi: 10.1016/j.ijmm.2009.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmm.2009.08.005</ArticleId><ArticleId IdType="pubmed">19783474</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohland C.L., Macnaughton W.K. Probiotic bacteria and intestinal epithelial barrier function. Am. J. Physiol. Liver Physiol. 2010;298:G807&#x2013;G819. doi: 10.1152/ajpgi.00243.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00243.2009</ArticleId><ArticleId IdType="pubmed">20299599</ArticleId></ArticleIdList></Reference><Reference><Citation>Madsen K., Cornish A., Soper P., McKaigney C., Jijon H., Yachimec C., Doyle J., Jewell L., De Simone C. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001;121:580&#x2013;591. doi: 10.1053/gast.2001.27224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/gast.2001.27224</ArticleId><ArticleId IdType="pubmed">11522742</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewaschuk J.B., Diaz H., Meddings L., Diederichs B., Dmytrash A., Backer J., Langen M.L.-V., Madsen K.L. Secreted bioactive factors fromBifidobacterium infantisenhance epithelial cell barrier function. Am. J. Physiol. Liver Physiol. 2008;295:G1025&#x2013;G1034. doi: 10.1152/ajpgi.90227.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.90227.2008</ArticleId><ArticleId IdType="pubmed">18787064</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Henry K.C., Donato K.A., Shen-Tu G., Gordanpour M., Sherman P.M. Lactobacillus rhamnosus Strain GG Prevents Enterohemorrhagic Escherichia coli O157:H7-Induced Changes in Epithelial Barrier Function. Infect. Immun. 2008;76:1340&#x2013;1348. doi: 10.1128/IAI.00778-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.00778-07</ArticleId><ArticleId IdType="pmc">PMC2292865</ArticleId><ArticleId IdType="pubmed">18227169</ArticleId></ArticleIdList></Reference><Reference><Citation>Masselot C.R., Herrmann A., Carlstedt I., Michalski J.-C., Capon C. Glycosylation of the two O-glycosylated domains of human MUC2 mucin in patients transposed with artificial urinary bladders constructed from proximal colonic tissue. Glycoconj. J. 2008;25:213&#x2013;224. doi: 10.1007/s10719-007-9079-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10719-007-9079-3</ArticleId><ArticleId IdType="pubmed">18004654</ArticleId></ArticleIdList></Reference><Reference><Citation>Moal V.L.-L., Amsellem R., Servin A.L., Coconnier M.-H. Lactobacillus acidophilus (strain LB) from the resident adult human gastrointestinal microflora exerts activity against brush border damage promoted by a diarrhoeagenic Escherichia coli in human enterocyte-like cells. Gut. 2002;50:803&#x2013;811. doi: 10.1136/gut.50.6.803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.50.6.803</ArticleId><ArticleId IdType="pmc">PMC1773224</ArticleId><ArticleId IdType="pubmed">12010882</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillipson M., Johansson M.E.V., Henriksn&#xe4;s J., Petersson J., Gendler S.J., Sandler S., Persson A.E.G., Hansson G.C., Holm L. The gastric mucus layers: Constituents and regulation of accumulation. Am. J. Physiol. Liver Physiol. 2008;295:G806&#x2013;G812. doi: 10.1152/ajpgi.90252.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.90252.2008</ArticleId><ArticleId IdType="pubmed">18719000</ArticleId></ArticleIdList></Reference><Reference><Citation>Windle H.J., Fox &#xc1;., N&#xed;Eidhin D., Kelleher D. The Thioredoxin System of Helicobacter pylori. J. Biol. Chem. 2000;275:5081&#x2013;5089. doi: 10.1074/jbc.275.7.5081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.275.7.5081</ArticleId><ArticleId IdType="pubmed">10671551</ArticleId></ArticleIdList></Reference><Reference><Citation>Aristoteli L.P., Willcox M.D.P. Mucin Degradation Mechanisms by Distinct Pseudomonas aeruginosa Isolates In Vitro. Infect. Immun. 2003;71:5565&#x2013;5575. doi: 10.1128/IAI.71.10.5565-5575.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.71.10.5565-5575.2003</ArticleId><ArticleId IdType="pmc">PMC201046</ArticleId><ArticleId IdType="pubmed">14500475</ArticleId></ArticleIdList></Reference><Reference><Citation>Macfarlane S., Woodmansey E.J., Macfarlane G.T. Colonization of Mucin by Human Intestinal Bacteria and Establishment of Biofilm Communities in a Two-Stage Continuous Culture System. Appl. Environ. Microbiol. 2005;71:7483&#x2013;7492. doi: 10.1128/AEM.71.11.7483-7492.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.71.11.7483-7492.2005</ArticleId><ArticleId IdType="pmc">PMC1287682</ArticleId><ArticleId IdType="pubmed">16269790</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack D.R., Ahrne S., Hyde L., Wei S., A Hollingsworth M. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut. 2003;52:827&#x2013;833. doi: 10.1136/gut.52.6.827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.52.6.827</ArticleId><ArticleId IdType="pmc">PMC1773687</ArticleId><ArticleId IdType="pubmed">12740338</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattar A.F., Teitelbaum D.H., Drongowski R.A., Yongyi F., Harmon C.M., Coran A.G. Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model. Pediatr. Surg. Int. 2002;18:586&#x2013;590. doi: 10.1007/s00383-002-0855-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00383-002-0855-7</ArticleId><ArticleId IdType="pubmed">12471471</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y., Kim S.-H., Whang K.-Y., Kim Y.-J., Oh S. Inhibition of Escherichia coli O157:H7 attachment by interactions between lactic acid bacteria and intestinal epithelial cells. J. Microbiol. Biotechnol. 2008;18:1278&#x2013;1285.</Citation><ArticleIdList><ArticleId IdType="pubmed">18667857</ArticleId></ArticleIdList></Reference><Reference><Citation>Otte J.-M., Podolsky D.K. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am. J. Physiol. Liver Physiol. 2004;286:G613&#x2013;G626. doi: 10.1152/ajpgi.00341.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00341.2003</ArticleId><ArticleId IdType="pubmed">15010363</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelsall B.L. Innate and adaptive mechanisms to control of pathological intestinal inflammation. J. Pathol. 2008;214:242&#x2013;259. doi: 10.1002/path.2286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.2286</ArticleId><ArticleId IdType="pubmed">18161750</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf6;ndel M., Schroeder B., Zimmermann K., Huber H., Nuding S., Beisner J., Fellermann K., Stange E.F., Wehkamp J. Probiotic E. coli treatment mediates antimicrobial human &#x3b2;-defensin synthesis and fecal excretion in humans. Mucosal Immunol. 2008;2:166&#x2013;172. doi: 10.1038/mi.2008.77.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mi.2008.77</ArticleId><ArticleId IdType="pmc">PMC10026704</ArticleId><ArticleId IdType="pubmed">19129752</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlee M., E Harder J., K&#xf6;ten B., Stange E.F., Wehkamp J., Fellermann K. Probiotic lactobacilli and VSL#3 induce enterocyte &#x3b2;-defensin. Clin. Exp. Immunol. 2008;151:528&#x2013;535. doi: 10.1111/j.1365-2249.2007.03587.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2007.03587.x</ArticleId><ArticleId IdType="pmc">PMC2276967</ArticleId><ArticleId IdType="pubmed">18190603</ArticleId></ArticleIdList></Reference><Reference><Citation>Wehkamp J., Harder J., Wehkamp K., Meissner B.W.-V., Schlee M., Enders C., Sonnenborn U., Nuding S., Bengmark S., Fellermann K., et al. NF-&#x3ba;B- and AP-1-Mediated Induction of Human Beta Defensin-2 in Intestinal Epithelial Cells by Escherichia coli Nissle 1917: A Novel Effect of a Probiotic Bacterium. Infect. Immun. 2004;72:5750&#x2013;5758. doi: 10.1128/IAI.72.10.5750-5758.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.72.10.5750-5758.2004</ArticleId><ArticleId IdType="pmc">PMC517557</ArticleId><ArticleId IdType="pubmed">15385474</ArticleId></ArticleIdList></Reference><Reference><Citation>Menendez A., Finlay B.B. Defensins in the immunology of bacterial infections. Curr. Opin. Immunol. 2007;19:385&#x2013;391. doi: 10.1016/j.coi.2007.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2007.06.008</ArticleId><ArticleId IdType="pubmed">17702560</ArticleId></ArticleIdList></Reference><Reference><Citation>Farquhar M.G., Palade G.E. Junctional Complexes in Various Epithelia. J. Cell Biol. 1963;17:375&#x2013;412. doi: 10.1083/jcb.17.2.375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.17.2.375</ArticleId><ArticleId IdType="pmc">PMC2106201</ArticleId><ArticleId IdType="pubmed">13944428</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas C.M., Versalovic J. Probiotics-host communication. Gut Microbes. 2010;1:148&#x2013;163. doi: 10.4161/gmic.1.3.11712.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/gmic.1.3.11712</ArticleId><ArticleId IdType="pmc">PMC2909492</ArticleId><ArticleId IdType="pubmed">20672012</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman P.M., Johnson-Henry K.C., Yeung H.P., Ngo P.S.C., Goulet J., Tompkins T.A. Probiotics Reduce Enterohemorrhagic Escherichia coli O157:H7- and Enteropathogenic E. coli O127:H6-Induced Changes in Polarized T84 Epithelial Cell Monolayers by Reducing Bacterial Adhesion and Cytoskeletal Rearrangements. Infect. Immun. 2005;73:5183&#x2013;5188. doi: 10.1128/IAI.73.8.5183-5188.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.73.8.5183-5188.2005</ArticleId><ArticleId IdType="pmc">PMC1201237</ArticleId><ArticleId IdType="pubmed">16041036</ArticleId></ArticleIdList></Reference><Reference><Citation>Putaala H., Salusj&#xe4;rvi T., Nordstr&#xf6;m M., Saarinen M., Ouwehand A.C., Hansen E.B., Rautonen N. Effect of four probiotic strains and Escherichia coli O157:H7 on tight junction integrity and cyclo-oxygenase expression. Res. Microbiol. 2008;159:692&#x2013;698. doi: 10.1016/j.resmic.2008.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resmic.2008.08.002</ArticleId><ArticleId IdType="pubmed">18783733</ArticleId></ArticleIdList></Reference><Reference><Citation>Dykstra N.S., Hyde L., Adawi D., Kulik D., Ahrn&#xe9; S., Molin G., Jeppsson B., MacKenzie A., Mack D.R. Pulse Probiotic Administration Induces Repeated Small Intestinal Muc3 Expression in Rats. Pediatr. Res. 2011;69:206&#x2013;211. doi: 10.1203/PDR.0b013e3182096ff0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/PDR.0b013e3182096ff0</ArticleId><ArticleId IdType="pubmed">21135754</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingberg T.D., Pedersen M.H., Cencic A., Budde B.B. Application of Measurements of Transepithelial Electrical Resistance of Intestinal Epithelial Cell Monolayers To Evaluate Probiotic Activity. Appl. Environ. Microbiol. 2005;71:7528&#x2013;7530. doi: 10.1128/AEM.71.11.7528-7530.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.71.11.7528-7530.2005</ArticleId><ArticleId IdType="pmc">PMC1287686</ArticleId><ArticleId IdType="pubmed">16269795</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahan S., Dalmasso G., Imbert V., Peyron J.-F., Rampal P., Czerucka D. Saccharomyces boulardii Interferes with Enterohemorrhagic Escherichia coli-Induced Signaling Pathways in T84 Cells. Infect. Immun. 2003;71:766&#x2013;773. doi: 10.1128/IAI.71.2.766-773.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.71.2.766-773.2003</ArticleId><ArticleId IdType="pmc">PMC145355</ArticleId><ArticleId IdType="pubmed">12540556</ArticleId></ArticleIdList></Reference><Reference><Citation>Resta&#x2013;Lenert S., Barrett K.E. Probiotics and Commensals Reverse TNF-&#x3b1;&#x2013; and IFN-&#x3b3;&#x2013;Induced Dysfunction in Human Intestinal Epithelial Cells. Gastroenterology. 2006;130:731&#x2013;746. doi: 10.1053/j.gastro.2005.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2005.12.015</ArticleId><ArticleId IdType="pubmed">16530515</ArticleId></ArticleIdList></Reference><Reference><Citation>Resta-Lenert S. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC) Gut. 2003;52:988&#x2013;997. doi: 10.1136/gut.52.7.988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.52.7.988</ArticleId><ArticleId IdType="pmc">PMC1773702</ArticleId><ArticleId IdType="pubmed">12801956</ArticleId></ArticleIdList></Reference><Reference><Citation>Llorente C.G., Mu&#xf1;oz S., Gil A. Proceedings of the Nutrition Society. Volume 69. Cambridge University Press (CUP); Cambridge, UK: 2010. Role of Toll-like receptors in the development of immunotolerance mediated by probiotics; pp. 381&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">20416121</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothhammer V., Quintana F.J. The aryl hydrocarbon receptor: An environmental sensor integrating immune responses in health and disease. Nat. Rev. Immunol. 2019;19:184&#x2013;197. doi: 10.1038/s41577-019-0125-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0125-8</ArticleId><ArticleId IdType="pubmed">30718831</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto S., Toshimitsu T., Matsuoka S., Maruyama A., Oh-Oka K., Takamura T., Nakamura Y., Ishimaru K., Fujii-Kuriyama Y., Ikegami S., et al. Identification of a probiotic bacteria-derived activator of the aryl hydrocarbon receptor that inhibits colitis. Immunol. Cell Biol. 2014;92:460&#x2013;465. doi: 10.1038/icb.2014.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/icb.2014.2</ArticleId><ArticleId IdType="pubmed">24518984</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonowal R., Swimm A., Sahoo A., Luo L., Matsunaga Y., Wu Z., Bhingarde J., Ejzak E.A., Ranawade A., Qadota H., et al. Indoles from commensal bacteria extend healthspan. Proc. Natl. Acad. Sci. USA. 2017;114:E7506&#x2013;E7515. doi: 10.1073/pnas.1706464114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1706464114</ArticleId><ArticleId IdType="pmc">PMC5594673</ArticleId><ArticleId IdType="pubmed">28827345</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones R., Desai C., Darby T.M., Luo L., Wolfarth A.A., Scharer C.D., Ardita C.S., Reedy A.R., Keebaugh E.S., Neish A.S. Lactobacilli Modulate Epithelial Cytoprotection through the Nrf2 Pathway. Cell Rep. 2015;12:1217&#x2013;1225. doi: 10.1016/j.celrep.2015.07.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.07.042</ArticleId><ArticleId IdType="pmc">PMC4640184</ArticleId><ArticleId IdType="pubmed">26279578</ArticleId></ArticleIdList></Reference><Reference><Citation>Alc&#xe1;ntara C., Coll-Marqu&#xe9;s J.M., Jad&#xe1;n-Piedra C., V&#xe9;lez D., Devesa V., Z&#xfa;&#xf1;iga M., Monedero V. Polyphosphate in Lactobacillus and Its Link to Stress Tolerance and Probiotic Properties. Front. Microbiol. 2018;9:1944. doi: 10.3389/fmicb.2018.01944.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.01944</ArticleId><ArticleId IdType="pmc">PMC6137179</ArticleId><ArticleId IdType="pubmed">30245671</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyte M. Probiotics function mechanistically as delivery vehicles for neuroactive compounds: Microbial endocrinology in the design and use of probiotics. BioEssays. 2011;33:574&#x2013;581. doi: 10.1002/bies.201100024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bies.201100024</ArticleId><ArticleId IdType="pubmed">21732396</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Yu M., Ochani M., Amella C.A., Tanovic M., Susarla S., Li J.H., Wang H., Yang H., Ulloa L., et al. Nicotinic acetylcholine receptor &#x3b1;7 subunit is an essential regulator of inflammation. Nature. 2003;421:384&#x2013;388. doi: 10.1038/nature01339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature01339</ArticleId><ArticleId IdType="pubmed">12508119</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahony C., Scully P., O&#x2019;Mahony D., Murphy S., O&#x2019;Brien F., Lyons A., Sherlock G., Mac Sharry J., Kiely B., Shanahan F., et al. Commensal-Induced Regulatory T Cells Mediate Protection against Pathogen-Stimulated NF-&#x3ba;B Activation. PLoS Pathog. 2008;4:e1000112. doi: 10.1371/journal.ppat.1000112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000112</ArticleId><ArticleId IdType="pmc">PMC2474968</ArticleId><ArticleId IdType="pubmed">18670628</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas L., Suzuki K., Zhao J. Probiotics: A proactive approach to health. A symposium report. Br. J. Nutr. 2015;114:S1&#x2013;S15. doi: 10.1017/S0007114515004043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0007114515004043</ArticleId><ArticleId IdType="pubmed">26548336</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakoff-Nahoum S., Paglino J., Eslami-Varzaneh F., Edberg S., Medzhitov R. Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis. Cell. 2004;118:229&#x2013;241. doi: 10.1016/j.cell.2004.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2004.07.002</ArticleId><ArticleId IdType="pubmed">15260992</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan F., Polk D.B. Probiotic Bacterium Prevents Cytokine-induced Apoptosis in Intestinal Epithelial Cells. J. Biol. Chem. 2002;277:50959&#x2013;50965. doi: 10.1074/jbc.M207050200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M207050200</ArticleId><ArticleId IdType="pmc">PMC4006994</ArticleId><ArticleId IdType="pubmed">12393915</ArticleId></ArticleIdList></Reference><Reference><Citation>Neish A.S. Prokaryotic Regulation of Epithelial Responses by Inhibition of Ikappa B-alpha Ubiquitination. Science. 2000;289:1560&#x2013;1563. doi: 10.1126/science.289.5484.1560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.289.5484.1560</ArticleId><ArticleId IdType="pubmed">10968793</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart A.L., Lammers K., Brigidi P., Vitali B., Rizzello F., Gionchetti P., Campieri M., A Kamm M., Knight S.C., Stagg A.J. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut. 2004;53:1602&#x2013;1609. doi: 10.1136/gut.2003.037325.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2003.037325</ArticleId><ArticleId IdType="pmc">PMC1774301</ArticleId><ArticleId IdType="pubmed">15479680</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng S.C., Hart A.L., Kamm M.A., Stagg A.J., Knight S.C. Mechanisms of action of probiotics: Recent advances. Inflamm. Bowel Dis. 2009;15:300&#x2013;310. doi: 10.1002/ibd.20602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ibd.20602</ArticleId><ArticleId IdType="pubmed">18626975</ArticleId></ArticleIdList></Reference><Reference><Citation>Drakes M., Blanchard T., Czinn S. Bacterial Probiotic Modulation of Dendritic Cells. Infect. Immun. 2004;72:3299&#x2013;3309. doi: 10.1128/IAI.72.6.3299-3309.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.72.6.3299-3309.2004</ArticleId><ArticleId IdType="pmc">PMC415669</ArticleId><ArticleId IdType="pubmed">15155633</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlsson H., Larsson P., Wold A., Rudin A. Pattern of Cytokine Responses to Gram-Positive and Gram-Negative Commensal Bacteria Is Profoundly Changed when Monocytes Differentiate into Dendritic Cells. Infect. Immun. 2004;72:2671&#x2013;2678. doi: 10.1128/IAI.72.5.2671-2678.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.72.5.2671-2678.2004</ArticleId><ArticleId IdType="pmc">PMC387913</ArticleId><ArticleId IdType="pubmed">15102775</ArticleId></ArticleIdList></Reference><Reference><Citation>Braat H., Brande J.V.D., Van Tol E., Hommes D., Peppelenbosch M., Van Deventer S. Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function. Am. J. Clin. Nutr. 2004;80:1618&#x2013;1625. doi: 10.1093/ajcn/80.6.1618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/80.6.1618</ArticleId><ArticleId IdType="pubmed">15585777</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathmakanthan S., Li C.K.F., Cowie J., Hawkey C.J. Lactobacillus plantarum 299: Beneficial in vitro immunomodulation in cells extracted from inflamed human colon. J. Gastroenterol. Hepatol. 2004;19:166&#x2013;173. doi: 10.1111/j.1440-1746.2004.03181.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1746.2004.03181.x</ArticleId><ArticleId IdType="pubmed">14731126</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha-Ram&#xed;rez L.M., P&#xe9;rez-Solano R.A., Casta&#xf1;&#xf3;n-Alonso S.L., Guerrero S.S.M., Pacheco A.R., Garibay M.G., Eslava C. Probiotic Lactobacillus Strains Stimulate the Inflammatory Response and Activate Human Macrophages. J. Immunol. Res. 2017;2017:1&#x2013;14. doi: 10.1155/2017/4607491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/4607491</ArticleId><ArticleId IdType="pmc">PMC5516745</ArticleId><ArticleId IdType="pubmed">28758133</ArticleId></ArticleIdList></Reference><Reference><Citation>Shida K., Kiyoshima-Shibata J., Kaji R., Nagaoka M., Nanno M. Peptidoglycan from lactobacilli inhibits interleukin-12 production by macrophages induced byLactobacillus caseithrough Toll-like receptor 2-dependent and independent mechanisms. Immunology. 2009;128:e858&#x2013;e869. doi: 10.1111/j.1365-2567.2009.03095.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2009.03095.x</ArticleId><ArticleId IdType="pmc">PMC2753894</ArticleId><ArticleId IdType="pubmed">19740347</ArticleId></ArticleIdList></Reference><Reference><Citation>He F., Morita H., Ouwehand A.C., Hosoda M., Hiramatsu M., Kurisaki J.-I., Isolauri E., Benno Y., Salminen S. Stimulation of the Secretion of Pro-Inflammatory Cytokines byBifidobacteriumStrains. Microbiol. Immunol. 2002;46:781&#x2013;785. doi: 10.1111/j.1348-0421.2002.tb02765.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1348-0421.2002.tb02765.x</ArticleId><ArticleId IdType="pubmed">12516776</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hemert S., Meijerink M., Molenaar D., A Bron P., De Vos P., Kleerebezem M., Wells J.M., Marco M.L. Identification of Lactobacillus plantarum genes modulating the cytokine response of human peripheral blood mononuclear cells. BMC Microbiol. 2010;10:293. doi: 10.1186/1471-2180-10-293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2180-10-293</ArticleId><ArticleId IdType="pmc">PMC3000848</ArticleId><ArticleId IdType="pubmed">21080958</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijerink M., van Hemert S., Taverne N., Wels M., De Vos P., Bron P.A., Savelkoul H.F., van Bilsen J., Kleerebezem M., Wells J.M. Identification of Genetic Loci in Lactobacillus plantarum That Modulate the Immune Response of Dendritic Cells Using Comparative Genome Hybridization. PLoS ONE. 2010;5:e10632. doi: 10.1371/journal.pone.0010632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0010632</ArticleId><ArticleId IdType="pmc">PMC2869364</ArticleId><ArticleId IdType="pubmed">20498715</ArticleId></ArticleIdList></Reference><Reference><Citation>Galdeano C.M., Cazorla S.I., Dumit J.M.L., V&#xe9;lez E., Perdig&#xf3;n G. Beneficial Effects of Probiotic Consumption on the Immune System. Ann. Nutr. Metab. 2019;74:115&#x2013;124. doi: 10.1159/000496426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000496426</ArticleId><ArticleId IdType="pubmed">30673668</ArticleId></ArticleIdList></Reference><Reference><Citation>Galdeano C.M., Perdig&#xf3;n G. The Probiotic Bacterium Lactobacillus casei Induces Activation of the Gut Mucosal Immune System through Innate Immunity. Clin. Vaccine Immunol. 2006;13:219&#x2013;226. doi: 10.1128/CVI.13.2.219-226.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.13.2.219-226.2006</ArticleId><ArticleId IdType="pmc">PMC1391937</ArticleId><ArticleId IdType="pubmed">16467329</ArticleId></ArticleIdList></Reference><Reference><Citation>Link-Amster H., Rochat F., Saudan K., Mignot O., Aeschlimann J. Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intake. FEMS Immunol. Med. Microbiol. 1994;10:55&#x2013;63. doi: 10.1111/j.1574-695X.1994.tb00011.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-695X.1994.tb00011.x</ArticleId><ArticleId IdType="pubmed">7874079</ArticleId></ArticleIdList></Reference><Reference><Citation>Isolauri E., Joensuu J., Suomalainen H., Luomala M., Vesikari T. Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine. 1995;13:310&#x2013;312. doi: 10.1016/0264-410X(95)93319-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0264-410X(95)93319-5</ArticleId><ArticleId IdType="pubmed">7631519</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaila M., Isolauri E., Saxelin M., Arvilommi H., Vesikari T. Viable versus inactivated lactobacillus strain GG in acute rotavirus diarrhoea. Arch. Dis. Child. 1995;72:51&#x2013;53. doi: 10.1136/adc.72.1.51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/adc.72.1.51</ArticleId><ArticleId IdType="pmc">PMC1510973</ArticleId><ArticleId IdType="pubmed">7717739</ArticleId></ArticleIdList></Reference><Reference><Citation>Majamaa H., Isolauri E., Saxelin M., Vesikari T. Lactic Acid Bacteria in the Treatment of Acute Rotavirus Gastroenteritis. J. Pediatr. Gastroenterol. Nutr. 1995;20:333&#x2013;338. doi: 10.1097/00005176-199504000-00012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005176-199504000-00012</ArticleId><ArticleId IdType="pubmed">7608829</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J.-H., Um J.-I., Lee B.-J., Goh J.-S., Park S.-Y., Kim W.-S., Kim P.-H. Encapsulated Bifidobacterium bifidum potentiates intestinal IgA production. Cell. Immunol. 2002;219:22&#x2013;27. doi: 10.1016/S0008-8749(02)00579-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0008-8749(02)00579-8</ArticleId><ArticleId IdType="pubmed">12473264</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinderola G., Matar C., Perdigon G. Role of Intestinal Epithelial Cells in Immune Effects Mediated by Gram-Positive Probiotic Bacteria: Involvement of Toll-Like Receptors. Clin. Vaccine Immunol. 2005;12:1075&#x2013;1084. doi: 10.1128/CDLI.12.9.1075-1084.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CDLI.12.9.1075-1084.2005</ArticleId><ArticleId IdType="pmc">PMC1235795</ArticleId><ArticleId IdType="pubmed">16148174</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoarau C., Lagaraine C., Martin L., Velge-Roussel F., Lebranchu Y. Supernatant of Bifidobacterium breve induces dendritic cell maturation, activation, and survival through a Toll-like receptor 2 pathway. J. Allergy Clin. Immunol. 2006;117:696&#x2013;702. doi: 10.1016/j.jaci.2005.10.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2005.10.043</ArticleId><ArticleId IdType="pubmed">16522473</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeuthen L.H., Fink L., Fr&#xf8;kiaer H. Toll-like receptor 2 and nucleotide-binding oligomerization domain-2 play divergent roles in the recognition of gut-derived lactobacilli and bifidobacteria in dendritic cells. Immunology. 2008;124:489&#x2013;502. doi: 10.1111/j.1365-2567.2007.02800.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2007.02800.x</ArticleId><ArticleId IdType="pmc">PMC2492941</ArticleId><ArticleId IdType="pubmed">18217947</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo N.A., Perdigon G., Leblanc A.D.M.D. Oral administration of a probiotic Lactobacillus modulates cytokine production and TLR expression improving the immune response against Salmonella enterica serovar Typhimurium infection in mice. BMC Microbiol. 2011;11:177. doi: 10.1186/1471-2180-11-177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2180-11-177</ArticleId><ArticleId IdType="pmc">PMC3173335</ArticleId><ArticleId IdType="pubmed">21813005</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740&#x2013;745. doi: 10.1038/35047123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35047123</ArticleId><ArticleId IdType="pubmed">11130078</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouladoux N., A Hall J., Grainger J.R., Dos Santos L.M., Kann M.G., Nagarajan V., Verthelyi D., Belkaid Y. Regulatory role of suppressive motifs from commensal DNA. Mucosal Immunol. 2012;5:623&#x2013;634. doi: 10.1038/mi.2012.36.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mi.2012.36</ArticleId><ArticleId IdType="pmc">PMC3427718</ArticleId><ArticleId IdType="pubmed">22617839</ArticleId></ArticleIdList></Reference><Reference><Citation>Rachmilewitz D., Katakura K., Karmeli F., Hayashi T., Reinus C., Rudensky B., Akira S., Takeda K., Lee J., Takabayashi K., et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology. 2004;126:520&#x2013;528. doi: 10.1053/j.gastro.2003.11.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2003.11.019</ArticleId><ArticleId IdType="pubmed">14762789</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss D.S., Raupach B., Takeda K., Akira S., Zychlinsky A. Toll-Like Receptors Are Temporally Involved in Host Defense. J. Immunol. 2004;172:4463&#x2013;4469. doi: 10.4049/jimmunol.172.7.4463.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.172.7.4463</ArticleId><ArticleId IdType="pubmed">15034062</ArticleId></ArticleIdList></Reference><Reference><Citation>Gourbeyre P., Denery S., Bodinier M. Probiotics, prebiotics, and synbiotics: Impact on the gut immune system and allergic reactions. J. Leukoc. Biol. 2011;89:685&#x2013;695. doi: 10.1189/jlb.1109753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.1109753</ArticleId><ArticleId IdType="pubmed">21233408</ArticleId></ArticleIdList></Reference><Reference><Citation>Shida K., Takahashi R., Iwadate E., Takamizawa K., Yasui H., Sato T., Habu S., Hachimura S., Kaminogawa S. Lactobacillus casei strain Shirota suppresses serum immunoglobulin E and immunoglobulin G1 responses and systemic anaphylaxis in a food allergy model. Clin. Exp. Allergy. 2002;32:563&#x2013;570. doi: 10.1046/j.0954-7894.2002.01354.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0954-7894.2002.01354.x</ArticleId><ArticleId IdType="pubmed">11972603</ArticleId></ArticleIdList></Reference><Reference><Citation>Shihab U.S., Mahfuza R., Mollika P., Masud R., Ranjan Kumar B., Mir Imam I.W., Rafiqul I.K. Ameliorative Effect of Probiotic Strains, Lactobacillus acidophilus and Lactobacillus bulgaricus against Acetic Acid-Induced Inflammation in the Mouse Colon. Am. J. Life Sci. 2020;8:183&#x2013;188. doi: 10.11648/j.ajls.20200806.11.</Citation><ArticleIdList><ArticleId IdType="doi">10.11648/j.ajls.20200806.11</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S., Bhatia R., Khare P., Sharma S., Rajarammohan S., Bishnoi M., Bhadada S.K., Sharma S.S., Kaur J., Kondepudi K.K. Anti-inflammatory Bifidobacterium strains prevent dextran sodium sulfate induced colitis and associated gut microbial dysbiosis in mice. Sci. Rep. 2020;10:1&#x2013;14. doi: 10.1038/s41598-020-75702-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-75702-5</ArticleId><ArticleId IdType="pmc">PMC7596498</ArticleId><ArticleId IdType="pubmed">33122795</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore K.W., Malefyt R.D.W., Coffman R.L., O&#x2019;Garra A. Interleukin-10 and Theinterleukin-10 receptor. Annu. Rev. Immunol. 2001;19:683&#x2013;765. doi: 10.1146/annurev.immunol.19.1.683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.19.1.683</ArticleId><ArticleId IdType="pubmed">11244051</ArticleId></ArticleIdList></Reference><Reference><Citation>Pessi T., S&#xfc;tas Y., Hurme M., Isolauri E. Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. Clin. Exp. Allergy. 2000;30:1804&#x2013;1808. doi: 10.1046/j.1365-2222.2000.00948.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2222.2000.00948.x</ArticleId><ArticleId IdType="pubmed">11122221</ArticleId></ArticleIdList></Reference><Reference><Citation>Haller D., Bode C., Hammes W.P., Pfeifer A.M., Schiffrin E.J., Blum S. Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut. 2000;47:79&#x2013;87. doi: 10.1136/gut.47.1.79.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.47.1.79</ArticleId><ArticleId IdType="pmc">PMC1727962</ArticleId><ArticleId IdType="pubmed">10861268</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchiya J., Barreto R., Okura R., Kawakita S., Fesce E., Marotta F. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin. J. Dig. Dis. 2004;5:169&#x2013;174. doi: 10.1111/j.1443-9573.2004.00176.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1443-9573.2004.00176.x</ArticleId><ArticleId IdType="pubmed">15612887</ArticleId></ArticleIdList></Reference><Reference><Citation>Colecchia A., Vestito A., La Rocca A., Pasqui F., Nikiforaki A., Festi D. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study. Minerva Gastroenterol. Dietol. 2006;52:349&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">17108864</ArticleId></ArticleIdList></Reference><Reference><Citation>Dughera L., Elia C., Navino M., Cisar&#xf2; F. Effects of symbiotic preparations on constipated irritable bowel syndrome symptoms. Acta Bio-Med. Atenei Parm. 2007;78:111&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">17933278</ArticleId></ArticleIdList></Reference><Reference><Citation>Andriulli A., Neri M., Loguercio C., Terreni N., Merla A., Cardarella M.P., Federico A., Chilovi F., Milandri G.L., De Bona M., et al. Clinical Trial on the Efficacy of a New Symbiotic Formulation, Flortec, in Patients With Irritable Bowel Syndrome. J. Clin. Gastroenterol. 2008;42:S218&#x2013;S223. doi: 10.1097/MCG.0b013e31817fadd6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0b013e31817fadd6</ArticleId><ArticleId IdType="pubmed">18685503</ArticleId></ArticleIdList></Reference><Reference><Citation>Min Y.W., Park S.U., Jang Y.S., Kim Y.-H., Rhee P.-L., Ko S.H., Joo N., Kim S.I., Kim C.-H., Chang D.K. Effect of composite yogurt enriched with acacia fiber and Bifidobacterium lactis. World J. Gastroenterol. 2012;18:4563&#x2013;4569. doi: 10.3748/wjg.v18.i33.4563.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v18.i33.4563</ArticleId><ArticleId IdType="pmc">PMC3435782</ArticleId><ArticleId IdType="pubmed">22969230</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogha M., Esfahani M.Z., Zargarzadeh A.H. The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: A randomized placebo-controlled trial. Gastroenterol. Hepatol. Bed Bench. 2014;7:156&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4129566</ArticleId><ArticleId IdType="pubmed">25120896</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x160;mid A., Strni&#x161;a L., Bajc K., Vuji&#x107;-Podlipec D., Matija&#x161;i&#x107; B.B., Rogelj I. Randomized clinical trial: The effect of fermented milk with the probiotic cultures Lactobacillus acidophilus La-5&#xae; and Bifidobacterium BB-12&#xae; and Beneo dietary fibres on health-related quality of life and the symptoms of irritable bowel syndrome in adults. J. Funct. Foods. 2016;24:549&#x2013;557. doi: 10.1016/j.jff.2016.04.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jff.2016.04.031</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S.-H., Cho D.-Y., Lee S.-H., Han K.-S., Yang S.-W., Kim J.-H., Lee S.-H., Kim S.-M., Kim K.-N. A Randomized Clinical Trial of Synbiotics in Irritable Bowel Syndrome: Dose-Dependent Effects on Gastrointestinal Symptoms and Fatigue. Korean J. Fam. Med. 2019;40:2&#x2013;8. doi: 10.4082/kjfm.17.0064.</Citation><ArticleIdList><ArticleId IdType="doi">10.4082/kjfm.17.0064</ArticleId><ArticleId IdType="pmc">PMC6351792</ArticleId><ArticleId IdType="pubmed">30360032</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittner A.C., Croffut R.M., Stranahan M.C. Prescript-assist&#x2122; probiotic-prebiotic treatment for irritable bowel syndrome: A methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study. Clin. Ther. 2005;27:755&#x2013;761. doi: 10.1016/j.clinthera.2005.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2005.06.005</ArticleId><ArticleId IdType="pubmed">16117982</ArticleId></ArticleIdList></Reference><Reference><Citation>Moser A.M., Spindelboeck W., Halwachs B., Strohmaier H., Kump P., Gorkiewicz G., H&#xf6;genauer C. Effects of an oral synbiotic on the gastrointestinal immune system and microbiota in patients with diarrhea-predominant irritable bowel syndrome. Eur. J. Nutr. 2018;58:2767&#x2013;2778. doi: 10.1007/s00394-018-1826-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00394-018-1826-7</ArticleId><ArticleId IdType="pmc">PMC6768888</ArticleId><ArticleId IdType="pubmed">30251020</ArticleId></ArticleIdList></Reference><Reference><Citation>Luczynski P., Tramullas M., Viola M., Shanahan F., Clarke G., O&#x2019;Mahony S., Dinan T.G., Cryan J.F. Microbiota regulates visceral pain in the mouse. eLife. 2017;6 doi: 10.7554/eLife.25887.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.25887</ArticleId><ArticleId IdType="pmc">PMC5478269</ArticleId><ArticleId IdType="pubmed">28629511</ArticleId></ArticleIdList></Reference><Reference><Citation>Wouters M.M., Vicario M., Santos J. The role of mast cells in functional GI disorders. Gut. 2016;65:155&#x2013;168. doi: 10.1136/gutjnl-2015-309151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-309151</ArticleId><ArticleId IdType="pubmed">26194403</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbara G., Cremon C., Carini G., Bellacosa L., Zecchi L., de Giorgio R., Corinaldesi R., Stanghellini V. The Immune System in Irritable Bowel Syndrome. J. Neurogastroenterol. Motil. 2011;17:349&#x2013;359. doi: 10.5056/jnm.2011.17.4.349.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm.2011.17.4.349</ArticleId><ArticleId IdType="pmc">PMC3228974</ArticleId><ArticleId IdType="pubmed">22148103</ArticleId></ArticleIdList></Reference><Reference><Citation>Farzaei M.H., Bahramsoltani R., Abdollahi M., Rahimi R. The Role of Visceral Hypersensitivity in Irritable Bowel Syndrome: Pharmacological Targets and Novel Treatments. J. Neurogastroenterol. Motil. 2016;22:558&#x2013;574. doi: 10.5056/jnm16001.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm16001</ArticleId><ArticleId IdType="pmc">PMC5056566</ArticleId><ArticleId IdType="pubmed">27431236</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy P.J., Cryan J.F., Dinan T., Clarke G. Irritable bowel syndrome: A microbiome-gut-brain axis disorder? World J. Gastroenterol. 2014;20:14105&#x2013;14125. doi: 10.3748/wjg.v20.i39.14105.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i39.14105</ArticleId><ArticleId IdType="pmc">PMC4202342</ArticleId><ArticleId IdType="pubmed">25339800</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q., Zhang B., Verne N.G. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain. 2009;146:41&#x2013;46. doi: 10.1016/j.pain.2009.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pain.2009.06.017</ArticleId><ArticleId IdType="pmc">PMC2763174</ArticleId><ArticleId IdType="pubmed">19595511</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyland N.P., Quigley E.M.M., Brint E. Microbiota-host interactions in irritable bowel syndrome: Epithelial barrier, immune regulation and brain-gut interactions. World J. Gastroenterol. 2014;20:8859&#x2013;8866. doi: 10.3748/wjg.v20.i27.8859.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i27.8859</ArticleId><ArticleId IdType="pmc">PMC4112904</ArticleId><ArticleId IdType="pubmed">25083059</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng J., Li Y.-Q., Zuo X.-L., Zhen Y.-B., Yang J., Liu C.-H. Clinical trial: Effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 2008;28:994&#x2013;1002. doi: 10.1111/j.1365-2036.2008.03818.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2008.03818.x</ArticleId><ArticleId IdType="pubmed">18671775</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahony L., McCarthy J., Kelly P., Hurley G., Luo F., Chen K., O&#x2019;Sullivan G.C., Kiely B., Collins J.K., Shanahan F., et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541&#x2013;551. doi: 10.1053/j.gastro.2004.11.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2004.11.050</ArticleId><ArticleId IdType="pubmed">15765388</ArticleId></ArticleIdList></Reference><Reference><Citation>Verd&#xfa; E.F., Berc&#xed;k P., Bergonzelli G.E., Huang X.-X., Blennerhasset P., Rochat F., Fiaux M., Mansourian R., Corth&#xe9;sy-Theulaz I., Collins S.M. Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction. Gastroenterology. 2004;127:826&#x2013;837. doi: 10.1053/j.gastro.2004.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2004.06.007</ArticleId><ArticleId IdType="pubmed">15362038</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B., Mao Y., Diorio C., Wang L., Huizinga J.D., Bienenstock J., Kunze W. Lactobacillus reuteriingestion and IKCachannel blockade have similar effects on rat colon motility and myenteric neurones. Neurogastroenterol. Motil. 2009;22:98-e33. doi: 10.1111/j.1365-2982.2009.01384.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2009.01384.x</ArticleId><ArticleId IdType="pubmed">19788711</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdu E.F., Bercik P., Verma-Gandhu M., Huang X.-X., Blennerhassett P., Jackson W., Mao Y., Wang L., Rochat F., Collins S.M. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut. 2006;55:182&#x2013;190. doi: 10.1136/gut.2005.066100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2005.066100</ArticleId><ArticleId IdType="pmc">PMC1856497</ArticleId><ArticleId IdType="pubmed">16105890</ArticleId></ArticleIdList></Reference><Reference><Citation>Anitha M., Vijay&#x2013;Kumar M., Sitaraman S.V., Gewirtz A.T., Srinivasan S. Gut Microbial Products Regulate Murine Gastrointestinal Motility via Toll-Like Receptor 4 Signaling. Gastroenterology. 2012;143:1006&#x2013;1016.e4. doi: 10.1053/j.gastro.2012.06.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2012.06.034</ArticleId><ArticleId IdType="pmc">PMC3458182</ArticleId><ArticleId IdType="pubmed">22732731</ArticleId></ArticleIdList></Reference><Reference><Citation>Brint E.K., Mac Sharry J., Fanning A., Shanahan F., Quigley E.M.M. Differential Expression of Toll-Like Receptors in Patients With Irritable Bowel Syndrome. Am. J. Gastroenterol. 2011;106:329&#x2013;336. doi: 10.1038/ajg.2010.438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2010.438</ArticleId><ArticleId IdType="pubmed">21102570</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper A., Naghibi M.M., Garcha D. The Role of Bacteria, Probiotics and Diet in Irritable Bowel Syndrome. Foods. 2018;7:13. doi: 10.3390/foods7020013.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/foods7020013</ArticleId><ArticleId IdType="pmc">PMC5848117</ArticleId><ArticleId IdType="pubmed">29373532</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee B.J., Bak Y.-T. Irritable Bowel Syndrome, Gut Microbiota and Probiotics. J. Neurogastroenterol. Motil. 2011;17:252&#x2013;266. doi: 10.5056/jnm.2011.17.3.252.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm.2011.17.3.252</ArticleId><ArticleId IdType="pmc">PMC3155061</ArticleId><ArticleId IdType="pubmed">21860817</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X., Mao Y.-K., Wang B., Huizinga J.D., Bienenstock J., Kunze W. Lactobacillus reuteri ingestion prevents hyperexcitability of colonic DRG neurons induced by noxious stimuli. Am. J. Physiol. Liver Physiol. 2009;296:G868&#x2013;G875. doi: 10.1152/ajpgi.90511.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.90511.2008</ArticleId><ArticleId IdType="pubmed">19179624</ArticleId></ArticleIdList></Reference><Reference><Citation>McKernan D.P., Fitzgerald P., Dinan T.G., Cryan J.F. The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat. Neurogastroenterol. Motil. 2010;22:1029-e268. doi: 10.1111/j.1365-2982.2010.01520.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2010.01520.x</ArticleId><ArticleId IdType="pubmed">20518856</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarino M.P.L., Altomare A., Stasi E., Marignani M., Severi C., Alloni R., Dicuonzo G., Morelli L., Coppola R., Cicala M. Effect of Acute Mucosal Exposure to Lactobacillus rhamnosus GG on Human Colonic Smooth Muscle Cells. J. Clin. Gastroenterol. 2008;42:S185&#x2013;S190. doi: 10.1097/MCG.0b013e31817e1cac.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0b013e31817e1cac</ArticleId><ArticleId IdType="pubmed">18685510</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe4;r F., Von Koschitzky H., Roblick U., Bruch H.P., Schulze L., Sonnenborn U., B&#xf6;ttner M., Wedel T., Bottner M. Cell-free supernatants of Escherichia coli Nissle 1917 modulate human colonic motility: Evidence from anin vitroorgan bath study. Neurogastroenterol. Motil. 2009;21:559-e17. doi: 10.1111/j.1365-2982.2008.01258.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2008.01258.x</ArticleId><ArticleId IdType="pubmed">19220758</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Y., Han Y., Wang Z., Qin Z., Yang C., Cao J., Chen Y. Role of serotonin on the intestinal mucosal immune response to stress-induced diarrhea in weaning mice. BMC Gastroenterol. 2017;17:82. doi: 10.1186/s12876-017-0634-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-017-0634-5</ArticleId><ArticleId IdType="pmc">PMC5479009</ArticleId><ArticleId IdType="pubmed">28633646</ArticleId></ArticleIdList></Reference><Reference><Citation>Casado-Bedmar M., Keita &#xc5;.V. Potential neuro-immune therapeutic targets in irritable bowel syndrome. Ther. Adv. Gastroenterol. 2020;13 doi: 10.1177/1756284820910630.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756284820910630</ArticleId><ArticleId IdType="pmc">PMC7153177</ArticleId><ArticleId IdType="pubmed">32313554</ArticleId></ArticleIdList></Reference><Reference><Citation>Holzer P., Farzi A. Neuropeptides and the Microbiota-Gut-Brain Axis. Adv. Exp. Med. Biol. 2014;817:195&#x2013;219. doi: 10.1007/978-1-4939-0897-4_9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-0897-4_9</ArticleId><ArticleId IdType="pmc">PMC4359909</ArticleId><ArticleId IdType="pubmed">24997035</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee S.H., Pothoulakis C., Mayer E.A. Principles and clinical implications of the brain&#x2013;gut&#x2013;enteric microbiota axis. Nat. Rev. Gastroenterol. Hepatol. 2009;6:306&#x2013;314. doi: 10.1038/nrgastro.2009.35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2009.35</ArticleId><ArticleId IdType="pmc">PMC3817714</ArticleId><ArticleId IdType="pubmed">19404271</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S., da Cunha A.P., Rezende R.M., Cialic R., Wei Z., Bry L., Comstock L.E., Gandhi R., Weiner H.L. The Host Shapes the Gut Microbiota via Fecal MicroRNA. Cell Host Microbe. 2016;19:32&#x2013;43. doi: 10.1016/j.chom.2015.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2015.12.005</ArticleId><ArticleId IdType="pmc">PMC4847146</ArticleId><ArticleId IdType="pubmed">26764595</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbara G., Feinle-Bisset C., Ghoshal U.C., Santos J., Vanner S.J., Vergnolle N., Zoetendal E.G., Quigley E.M. The Intestinal Microenvironment and Functional Gastrointestinal Disorders. Gastroenterology. 2016;150:1305&#x2013;1318.e8. doi: 10.1053/j.gastro.2016.02.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.028</ArticleId><ArticleId IdType="pubmed">27144620</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer E.A., Savidge T., Shulman R.J. Brain&#x2013;Gut Microbiome Interactions and Functional Bowel Disorders. Gastroenterology. 2014;146:1500&#x2013;1512. doi: 10.1053/j.gastro.2014.02.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2014.02.037</ArticleId><ArticleId IdType="pmc">PMC4114504</ArticleId><ArticleId IdType="pubmed">24583088</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal U.C., Shukla R., Ghoshal U. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy. Gut Liver. 2017;11:196&#x2013;208. doi: 10.5009/gnl16126.</Citation><ArticleIdList><ArticleId IdType="doi">10.5009/gnl16126</ArticleId><ArticleId IdType="pmc">PMC5347643</ArticleId><ArticleId IdType="pubmed">28274108</ArticleId></ArticleIdList></Reference><Reference><Citation>Bercik P., Denou E., Collins J., Jackson W., Lu J., Jury J., Deng Y., Blennerhassett P., Macri J., McCoy K.D., et al. The Intestinal Microbiota Affect Central Levels of Brain-Derived Neurotropic Factor and Behavior in Mice. Gastroenterology. 2011;141:599&#x2013;609.e3. doi: 10.1053/j.gastro.2011.04.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2011.04.052</ArticleId><ArticleId IdType="pubmed">21683077</ArticleId></ArticleIdList></Reference><Reference><Citation>Bravo J.A., Forsythe P., Chew M.V., Escaravage E., Savignac H.M., Dinan T.G., Bienenstock J., Cryan J.F. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc. Natl. Acad. Sci. USA. 2011;108:16050&#x2013;16055. doi: 10.1073/pnas.1102999108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1102999108</ArticleId><ArticleId IdType="pmc">PMC3179073</ArticleId><ArticleId IdType="pubmed">21876150</ArticleId></ArticleIdList></Reference><Reference><Citation>Luczynski P., Whelan S.O., O&#x2019;Sullivan C., Clarke G., Shanahan F., Dinan T., Cryan J.F. Adult microbiota-deficient mice have distinct dendritic morphological changes: Differential effects in the amygdala and hippocampus. Eur. J. Neurosci. 2016;44:2654&#x2013;2666. doi: 10.1111/ejn.13291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejn.13291</ArticleId><ArticleId IdType="pmc">PMC5113767</ArticleId><ArticleId IdType="pubmed">27256072</ArticleId></ArticleIdList></Reference><Reference><Citation>Roohi E., Jaafari N., Hashemian F. On inflammatory hypothesis of depression: What is the role of IL-6 in the middle of the chaos? J. Neuroinflamm. 2021;18:1&#x2013;15. doi: 10.1186/s12974-021-02100-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-021-02100-7</ArticleId><ArticleId IdType="pmc">PMC7884972</ArticleId><ArticleId IdType="pubmed">33593388</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma G., Blennerhassett P., Lu J., Deng Y., Park A.J., Green W., Denou E., Silva M.A., Santacruz A., Sanz Y., et al. Microbiota and host determinants of behavioural phenotype in maternally separated mice. Nat. Commun. 2015;6:7735. doi: 10.1038/ncomms8735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms8735</ArticleId><ArticleId IdType="pubmed">26218677</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H., Ling Z., Zhang Y., Mao H., Ma Z., Yin Y., Wang W., Tang W., Tan Z., Shi J., et al. Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav. Immun. 2015;48:186&#x2013;194. doi: 10.1016/j.bbi.2015.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2015.03.016</ArticleId><ArticleId IdType="pubmed">25882912</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudo N., Chida Y., Aiba Y., Sonoda J., Oyama N., Yu X.-N., Kubo C., Koga Y. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J. Physiol. 2004;558:263&#x2013;275. doi: 10.1113/jphysiol.2004.063388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2004.063388</ArticleId><ArticleId IdType="pmc">PMC1664925</ArticleId><ArticleId IdType="pubmed">15133062</ArticleId></ArticleIdList></Reference><Reference><Citation>Heijtz R.D., Wang S., Anuar F., Qian Y., Bj&#xf6;rkholm B., Samuelsson A., Hibberd M.L., Forssberg H., Pettersson S. Normal gut microbiota modulates brain development and behavior. Proc. Natl. Acad. Sci. USA. 2011;108:3047&#x2013;3052. doi: 10.1073/pnas.1010529108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1010529108</ArticleId><ArticleId IdType="pmc">PMC3041077</ArticleId><ArticleId IdType="pubmed">21282636</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey M.T., Dowd S., Galley J.D., Hufnagle A.R., Allen R.G., Lyte M. Exposure to a social stressor alters the structure of the intestinal microbiota: Implications for stressor-induced immunomodulation. Brain Behav. Immun. 2011;25:397&#x2013;407. doi: 10.1016/j.bbi.2010.10.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2010.10.023</ArticleId><ArticleId IdType="pmc">PMC3039072</ArticleId><ArticleId IdType="pubmed">21040780</ArticleId></ArticleIdList></Reference><Reference><Citation>Ja&#x161;arevi&#x107; E., Howerton C.L., Howard C.D., Bale T.L. Alterations in the Vaginal Microbiome by Maternal Stress Are Associated With Metabolic Reprogramming of the Offspring Gut and Brain. Endocrinology. 2015;156:3265&#x2013;3276. doi: 10.1210/en.2015-1177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2015-1177</ArticleId><ArticleId IdType="pmc">PMC4541625</ArticleId><ArticleId IdType="pubmed">26079804</ArticleId></ArticleIdList></Reference><Reference><Citation>Golubeva A.V., Crampton S., Desbonnet L., Edge D., O&#x2019;Sullivan O., Lomasney K.W., Zhdanov A., Crispie F., Moloney R.D., Borre Y.E., et al. Prenatal stress-induced alterations in major physiological systems correlate with gut microbiota composition in adulthood. Psychoneuroendocrinology. 2015;60:58&#x2013;74. doi: 10.1016/j.psyneuen.2015.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2015.06.002</ArticleId><ArticleId IdType="pubmed">26135201</ArticleId></ArticleIdList></Reference><Reference><Citation>Bharwani A., Mian M.F., Foster J.A., Surette M.G., Bienenstock J., Forsythe P. Structural &amp; functional consequences of chronic psychosocial stress on the microbiome &amp; host. Psychoneuroendocrinology. 2016;63:217&#x2013;227. doi: 10.1016/j.psyneuen.2015.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2015.10.001</ArticleId><ArticleId IdType="pubmed">26479188</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson G.R., Roberfroid M.B. Dietary Modulation of the Human Colonic Microbiota: Introducing the Concept of Prebiotics. J. Nutr. 1995;125:1401&#x2013;1412. doi: 10.1093/jn/125.6.1401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jn/125.6.1401</ArticleId><ArticleId IdType="pubmed">7782892</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson G.R., Probert H.M., Van Loo J., Rastall R.A., Roberfroid M.B. Dietary modulation of the human colonic microbiota: Updating the concept of prebiotics. Nutr. Res. Rev. 2004;17:259&#x2013;275. doi: 10.1079/NRR200479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1079/NRR200479</ArticleId><ArticleId IdType="pubmed">19079930</ArticleId></ArticleIdList></Reference><Reference><Citation>Huda-Faujan N., Abdulamir A., Fatimah A., Anas O.M., Shuhaimi M., Yazid A., Loong Y. The Impact of the Level of the Intestinal Short Chain Fatty Acids in Inflammatory Bowel Disease Patients Versus Healthy Subjects. Open Biochem. J. 2010;4:53&#x2013;58. doi: 10.2174/1874091X01004010053.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1874091X01004010053</ArticleId><ArticleId IdType="pmc">PMC2887640</ArticleId><ArticleId IdType="pubmed">20563285</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamer H.M., Jonkers D.M.A.E., Vanhoutvin S.A.L.W., Troost F.J., Rijkers G., De Bru&#xef;ne A., Bast A., Venema K., Brummer R.-J.M. Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission. Clin. Nutr. 2010;29:738&#x2013;744. doi: 10.1016/j.clnu.2010.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2010.04.002</ArticleId><ArticleId IdType="pubmed">20471725</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantu-Jungles T.M., Hamaker B.R. New View on Dietary Fiber Selection for Predictable Shifts in Gut Microbiota. mBio. 2020;11:02179-19. doi: 10.1128/mBio.02179-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.02179-19</ArticleId><ArticleId IdType="pmc">PMC7029134</ArticleId><ArticleId IdType="pubmed">32071263</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung W.S.F., Meijerink M., Zeuner B., Holck J., Louis P., Meyer A.S., Wells J.M., Flint H.J., Duncan S.H. Prebiotic potential of pectin and pectic oligosaccharides to promote anti-inflammatory commensal bacteria in the human colon. FEMS Microbiol. Ecol. 2017;93 doi: 10.1093/femsec/fix127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/femsec/fix127</ArticleId><ArticleId IdType="pubmed">29029078</ArticleId></ArticleIdList></Reference><Reference><Citation>Quigley E.M. Prebiotics and Probiotics in Digestive Health. Clin. Gastroenterol. Hepatol. 2019;17:333&#x2013;344. doi: 10.1016/j.cgh.2018.09.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2018.09.028</ArticleId><ArticleId IdType="pubmed">30267869</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson K.S., Gibson G.R., Hutkins R., Reimer R.A., Reid G., Verbeke K., Scott K.P., Holscher H.D., Azad M.B., Delzenne N.M., et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nat. Rev. Gastroenterol. Hepatol. 2020;17:687&#x2013;701. doi: 10.1038/s41575-020-0344-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-020-0344-2</ArticleId><ArticleId IdType="pmc">PMC7581511</ArticleId><ArticleId IdType="pubmed">32826966</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearney S.M., Gibbons S.M. Designing synbiotics for improved human health. Microb. Biotechnol. 2017;11:141&#x2013;144. doi: 10.1111/1751-7915.12885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1751-7915.12885</ArticleId><ArticleId IdType="pmc">PMC5743828</ArticleId><ArticleId IdType="pubmed">29205932</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson B., Rossi M., Dimidi E., Whelan K. Prebiotics in irritable bowel syndrome and other functional bowel disorders in adults: A systematic review and meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 2019;109:1098&#x2013;1111. doi: 10.1093/ajcn/nqy376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/nqy376</ArticleId><ArticleId IdType="pubmed">30949662</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter J.O., Tuffnell Q., Lee A.J. Controlled Trial of Oligofructose in the Management of Irritable Bowel Syndrome. J. Nutr. 1999;129:1451S&#x2013;1453S. doi: 10.1093/jn/129.7.1451S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jn/129.7.1451S</ArticleId><ArticleId IdType="pubmed">10395619</ArticleId></ArticleIdList></Reference><Reference><Citation>Olesen M., Gudmand-H&#xf8;yer E. Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome. Am. J. Clin. Nutr. 2000;72:1570&#x2013;1575. doi: 10.1093/ajcn/72.6.1570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/72.6.1570</ArticleId><ArticleId IdType="pubmed">11101487</ArticleId></ArticleIdList></Reference><Reference><Citation>Silk D.B.A., Davis A., Vulevic J., Tzortzis G., Gibson G.R. Clinical trial: The effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2009;29:508&#x2013;518. doi: 10.1111/j.1365-2036.2008.03911.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2008.03911.x</ArticleId><ArticleId IdType="pubmed">19053980</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarino M.P.L., Altomare A., Emerenziani S., Di Rosa C., Ribolsi M., Balestrieri P., Iovino P., Rocchi G., Cicala M. Mechanisms of Action of Prebiotics and Their Effects on Gastro-Intestinal Disorders in Adults. Nutrients. 2020;12:1037. doi: 10.3390/nu12041037.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12041037</ArticleId><ArticleId IdType="pmc">PMC7231265</ArticleId><ArticleId IdType="pubmed">32283802</ArticleId></ArticleIdList></Reference><Reference><Citation>Halmos E.P., Power V.A., Shepherd S.J., Gibson P.R., Muir J.G. A Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome. Gastroenterology. 2014;146:67&#x2013;75.e5. doi: 10.1053/j.gastro.2013.09.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2013.09.046</ArticleId><ArticleId IdType="pubmed">24076059</ArticleId></ArticleIdList></Reference><Reference><Citation>Simr&#xe9;n M., Barbara G., Flint H.J., Spiegel B.M.R., Spiller R.C., Vanner S., Verdu E.F., Whorwell P., Zoetendal E.G. Intestinal microbiota in functional bowel disorders: A Rome foundation report. Gut. 2012;62:159&#x2013;176. doi: 10.1136/gutjnl-2012-302167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2012-302167</ArticleId><ArticleId IdType="pmc">PMC3551212</ArticleId><ArticleId IdType="pubmed">22730468</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi S.L., Correa D., Pak S.C. Probiotics, prebiotics, and low FODMAP diet for irritable bowel syndrome&#x2014;What is the current evidence? Complement. Ther. Med. 2019;43:73&#x2013;80. doi: 10.1016/j.ctim.2019.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctim.2019.01.010</ArticleId><ArticleId IdType="pubmed">30935559</ArticleId></ArticleIdList></Reference><Reference><Citation>Mego M., Accarino A., Tzortzis G., Vulevic J., Gibson G., Guarner F., Azpiroz F. Colonic gas homeostasis: Mechanisms of adaptation following HOST-G904 galactooligosaccharide use in humans. Neurogastroenterol. Motil. 2017;92:e13080. doi: 10.1111/nmo.13080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13080</ArticleId><ArticleId IdType="pubmed">28418214</ArticleId></ArticleIdList></Reference><Reference><Citation>Huaman J.-W., Mego M., Manichanh C., Ca&#xf1;ellas N., Ca&#xf1;ueto D., Segurola H., Jansana M., Malagelada C., Accarino A., Vulevic J., et al. Effects of Prebiotics vs a Diet Low in FODMAPs in Patients With Functional Gut Disorders. Gastroenterology. 2018;155:1004&#x2013;1007. doi: 10.1053/j.gastro.2018.06.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2018.06.045</ArticleId><ArticleId IdType="pubmed">29964041</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolida S., Gibson G.R. Synbiotics in Health and Disease. Annu. Rev. Food Sci. Technol. 2011;2:373&#x2013;393. doi: 10.1146/annurev-food-022510-133739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-food-022510-133739</ArticleId><ArticleId IdType="pubmed">22129388</ArticleId></ArticleIdList></Reference><Reference><Citation>Markowiak-Kope&#x107; P., &#x15a;li&#x17c;ewska K. Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. Nutrients. 2017;9:1021. doi: 10.3390/nu9091021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu9091021</ArticleId><ArticleId IdType="pmc">PMC5622781</ArticleId><ArticleId IdType="pubmed">28914794</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey K.R., Naik S.R., Vakil B.V. Probiotics, prebiotics and synbiotics&#x2014;A review. J. Food Sci. Technol. 2015;52:7577&#x2013;7587. doi: 10.1007/s13197-015-1921-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13197-015-1921-1</ArticleId><ArticleId IdType="pmc">PMC4648921</ArticleId><ArticleId IdType="pubmed">26604335</ArticleId></ArticleIdList></Reference><Reference><Citation>Topping D.L., Fukushima M., Bird A.R. Proceedings of the Nutrition Society. Volume 62. CABI Publishing; Wallingford, UK: 2003. Resistant starch as a prebiotic and synbiotic: State of the art; pp. 171&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">12749342</ArticleId></ArticleIdList></Reference><Reference><Citation>Manning A.P., Thompson W.G., Heaton K.W., Morris A.F. Towards positive diagnosis of the irritable bowel. BMJ. 1978;2:653&#x2013;654. doi: 10.1136/bmj.2.6138.653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.2.6138.653</ArticleId><ArticleId IdType="pmc">PMC1607467</ArticleId><ArticleId IdType="pubmed">698649</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito Y.A., Locke R.G., Talley N.J., Zinsmeister A.R., Fett S.L., Melton J.L. A Comparison of The Rome and Manning Criteria for Case Identification in Epidemiological Investigations of Irritable Bowel Syndrome. Am. J. Gastroenterol. 2000;95:2816&#x2013;2824. doi: 10.1111/j.1572-0241.2000.03192.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2000.03192.x</ArticleId><ArticleId IdType="pubmed">11051354</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy B.E., Patel N.K. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J. Clin. Med. 2017;6:99. doi: 10.3390/jcm6110099.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm6110099</ArticleId><ArticleId IdType="pmc">PMC5704116</ArticleId><ArticleId IdType="pubmed">29072609</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Harris L.A., Lacy B.E., Quigley E.M.M., Moayyedi P. Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2018;48:1044&#x2013;1060. doi: 10.1111/apt.15001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15001</ArticleId><ArticleId IdType="pubmed">30294792</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Y., Guo L.-M., Yang S.-Y., Wu Q., Meng F.-J. Effectiveness of probiotics in irritable bowel syndrome: Methodological quality of meta-analyses and systematic reviews. Front. Nurs. 2019;6:115&#x2013;121. doi: 10.2478/FON-2019-0018.</Citation><ArticleIdList><ArticleId IdType="doi">10.2478/FON-2019-0018</ArticleId></ArticleIdList></Reference><Reference><Citation>Cremon C., Guglielmetti S., Gargari G., Taverniti V., Castellazzi A.M., Valsecchi C., Tagliacarne C., Fiore W., Bellini M., Bertani L., et al. Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. United Eur. Gastroenterol. J. 2018;6:604&#x2013;613. doi: 10.1177/2050640617736478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2050640617736478</ArticleId><ArticleId IdType="pmc">PMC5987284</ArticleId><ArticleId IdType="pubmed">29881616</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepherd E.S., DeLoache W.C., Pruss K.M., Whitaker W.R., Sonnenburg J.L. An exclusive metabolic niche enables strain engraftment in the gut microbiota. Nature. 2018;557:434&#x2013;438. doi: 10.1038/s41586-018-0092-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0092-4</ArticleId><ArticleId IdType="pmc">PMC6126907</ArticleId><ArticleId IdType="pubmed">29743671</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A., Moayyedi P., Chey W.D., Harris L.A., Lacy B.E., Saito Y.A., Quigley E.M.M. American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. Am. J. Gastroenterol. 2018;113:1&#x2013;18. doi: 10.1038/s41395-018-0084-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41395-018-0084-x</ArticleId><ArticleId IdType="pubmed">29950604</ArticleId></ArticleIdList></Reference><Reference><Citation>Su G.L., Ko C.W., Bercik P., Falck-Ytter Y., Sultan S., Weizman A.V., Morgan R.L. AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology. 2020;159:697&#x2013;705. doi: 10.1053/j.gastro.2020.05.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.05.059</ArticleId><ArticleId IdType="pubmed">32531291</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32054443</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1129-2377</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Feb</Month><Day>13</Day></PubDate></JournalIssue><Title>The journal of headache and pain</Title><ISOAbbreviation>J Headache Pain</ISOAbbreviation></Journal><ArticleTitle>Gut-brain Axis and migraine headache: a comprehensive review.</ArticleTitle><Pagination><StartPage>15</StartPage><MedlinePgn>15</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">15</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s10194-020-1078-9</ELocationID><Abstract><AbstractText>The terminology "gut-brain axis "points out a bidirectional relationship between the GI system and the central nervous system (CNS). To date, several researches have shown that migraine is associated with some gastrointestinal (GI) disorders such as Helicobacter pylori (HP) infection, irritable bowel syndrome (IBS), and celiac disease (CD). The present review article aims to discuss the direct and indirect evidence suggesting relationships between migraine and the gut-brain axis. However, the mechanisms explaining how the gut and the brain may interact in patients with migraine are not entirely clear. Studies suggest that this interaction seems to be influenced by multiple factors such as inflammatory mediators (IL-1&#x3b2;, IL-6, IL-8, and TNF-&#x3b1;), gut microbiota profile, neuropeptides and serotonin pathway, stress hormones and nutritional substances. Neuropeptides including CGRP, SP, VIP, NPY are thought to have antimicrobial impact on a variety of the gut bacterial strains and thus speculated to be involved in the bidirectional relationship between the gut and the brain. According to the current knowledge, migraine headache in patients harboring HP might be improved following the bacteria eradication. Migraineurs with long headache history and high headache frequency have a higher chance of being diagnosed with IBS. IBS and migraine share some similarities and can alter gut microflora composition and thereby may affect the gut-brain axis and inflammatory status. Migraine has been also associated with CD and the condition should be searched particularly in patients with migraine with occipital and parieto-occipital calcification at brain neuroimaging. In those patients, gluten-free diet can also be effective in reducing migraine frequency. It has also been proposed that migraine may be improved by dietary approaches with beneficial effects on gut microbiota and gut-brain axis including appropriate consumption of fiber per day, adhering to a low glycemic index diet, supplementation with vitamin D, omega-3 and probiotics as well as weight loss dietary plans for overweight and obese patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arzani</LastName><ForeName>Mahsa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Headache Department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jahromi</LastName><ForeName>Soodeh Razeghi</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghorbani</LastName><ForeName>Zeinab</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Cardiovascular Diseases Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vahabizad</LastName><ForeName>Fahimeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Headache Department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Headache Department, Neurology Ward, Sina University Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martelletti</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghaemi</LastName><ForeName>Amir</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Virology, Pasteur Institute of Iran, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sacco</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neuroscience section - Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy. simona.sacco@univaq.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Togha</LastName><ForeName>Mansoureh</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9368-6835</Identifier><AffiliationInfo><Affiliation>Headache Department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. togha1961@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Headache Department, Neurology Ward, Sina University Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. togha1961@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>School of Advanced Studies of the European Headache Federation (EHF-SAS)</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Headache Pain</MedlineTA><NlmUniqueID>100940562</NlmUniqueID><ISSNLinking>1129-2369</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009479">Neuropeptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005767" MajorTopicYN="N">Gastrointestinal Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D041981" MajorTopicYN="N">Gastrointestinal Tract</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008881" MajorTopicYN="N">Migraine Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009479" MajorTopicYN="N">Neuropeptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>There is no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32054443</ArticleId><ArticleId IdType="pmc">PMC7020496</ArticleId><ArticleId IdType="doi">10.1186/s10194-020-1078-9</ArticleId><ArticleId IdType="pii">10.1186/s10194-020-1078-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, Al-Raddadi RM, et al. Global, regional, and national burden of migraine and tension-type headache, 1990&#x2013;2016: a systematic analysis for the global burden of disease study 2016. The Lancet Neurology. 2018;17(11):954&#x2013;976. doi: 10.1016/S1474-4422(18)30322-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30322-3</ArticleId><ArticleId IdType="pmc">PMC6191530</ArticleId><ArticleId IdType="pubmed">30353868</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner TJ, Stovner LJ, Vos T. GBD 2015: migraine is the third cause of disability in under 50s. J Headache Pain. 2016;17(1):104. doi: 10.1186/s10194-016-0699-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10194-016-0699-5</ArticleId><ArticleId IdType="pmc">PMC5108738</ArticleId><ArticleId IdType="pubmed">27844455</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19(1):17. doi: 10.1186/s10194-018-0846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10194-018-0846-2</ArticleId><ArticleId IdType="pmc">PMC5821623</ArticleId><ArticleId IdType="pubmed">29468450</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodick DW. A phase-by-phase review of migraine pathophysiology. Headache. 2018;58(Suppl 1):4&#x2013;16. doi: 10.1111/head.13300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/head.13300</ArticleId><ArticleId IdType="pubmed">29697154</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer EA, Tillisch K, Gupta A. Gut/brain axis and the microbiota. J Clin Invest. 2015;125(3):926&#x2013;938. doi: 10.1172/JCI76304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI76304</ArticleId><ArticleId IdType="pmc">PMC4362231</ArticleId><ArticleId IdType="pubmed">25689247</ArticleId></ArticleIdList></Reference><Reference><Citation>Hindiyeh N, Aurora SK. What the gut can teach us about migraine. Curr Pain Headache Rep. 2015;19(7):33. doi: 10.1007/s11916-015-0501-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11916-015-0501-4</ArticleId><ArticleId IdType="pubmed">26049770</ArticleId></ArticleIdList></Reference><Reference><Citation>Asano Y, Hiramoto T, Nishino R, Aiba Y, Kimura T, Yoshihara K, et al. Critical role of gut microbiota in the production of biologically active, free catecholamines in the gut lumen of mice. Am J Physiol Gastrointest Liver Physiol. 2012;303(11):G1288&#x2013;G1295. doi: 10.1152/ajpgi.00341.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00341.2012</ArticleId><ArticleId IdType="pubmed">23064760</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett E, Ross RP, O'Toole PW, Fitzgerald GF, Stanton C. Gamma-Aminobutyric acid production by culturable bacteria from the human intestine. J Appl Microbiol. 2012;113(2):411&#x2013;417. doi: 10.1111/j.1365-2672.2012.05344.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2672.2012.05344.x</ArticleId><ArticleId IdType="pubmed">22612585</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavaillon JM. Pro- versus anti-inflammatory cytokines: myth or reality. Cellular and molecular biology (Noisy-le-Grand, France). 2001;47(4):695&#x2013;702</Citation><ArticleIdList><ArticleId IdType="pubmed">11502077</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SF, Schaeffer AJ, Thumbikat P. Immune mediators of chronic pelvic pain syndrome. Nature reviews Urology. 2014;11(5):259&#x2013;269. doi: 10.1038/nrurol.2014.63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrurol.2014.63</ArticleId><ArticleId IdType="pmc">PMC4986688</ArticleId><ArticleId IdType="pubmed">24686526</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Donelan J, Kandere-Grzybowska K, Konstantinidou A. The role of mast cells in migraine pathophysiology. Brain Res Brain Res Rev. 2005;49(1):65&#x2013;76. doi: 10.1016/j.brainresrev.2004.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresrev.2004.11.006</ArticleId><ArticleId IdType="pubmed">15960987</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran R. Neurogenic inflammation and its role in migraine. Semin Immunopathol. 2018;40(3):301&#x2013;314. doi: 10.1007/s00281-018-0676-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-018-0676-y</ArticleId><ArticleId IdType="pubmed">29568973</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Mahony SM, Clarke G, Borre YE, Dinan TG, Cryan JF. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav Brain Res. 2015;277:32&#x2013;48. doi: 10.1016/j.bbr.2014.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2014.07.027</ArticleId><ArticleId IdType="pubmed">25078296</ArticleId></ArticleIdList></Reference><Reference><Citation>Amaral FA, Sachs D, Costa VV, Fagundes CT, Cisalpino D, Cunha TM, et al. Commensal microbiota is fundamental for the development of inflammatory pain. Proc Natl Acad Sci U S A. 2008;105(6):2193&#x2013;2197. doi: 10.1073/pnas.0711891105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0711891105</ArticleId><ArticleId IdType="pmc">PMC2538897</ArticleId><ArticleId IdType="pubmed">18268332</ArticleId></ArticleIdList></Reference><Reference><Citation>Holzer P, Farzi A. Neuropeptides and the microbiota-gut-brain axis. Microbial endocrinology: The microbiota-gut-brain axis in health and disease: Springer; 2014. p. 195&#x2013;219</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4359909</ArticleId><ArticleId IdType="pubmed">24997035</ArticleId></ArticleIdList></Reference><Reference><Citation>Maqsood R, Stone TW. The gut-brain Axis, BDNF. NMDA and CNS Disorders Neurochem Res. 2016;41(11):2819&#x2013;2835. doi: 10.1007/s11064-016-2039-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-016-2039-1</ArticleId><ArticleId IdType="pubmed">27553784</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HX, Wang YP. Gut microbiota-brain Axis. Chin Med J. 2016;129(19):2373&#x2013;2380. doi: 10.4103/0366-6999.190667.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0366-6999.190667</ArticleId><ArticleId IdType="pmc">PMC5040025</ArticleId><ArticleId IdType="pubmed">27647198</ArticleId></ArticleIdList></Reference><Reference><Citation>Camara-Lemarroy CR, Rodriguez-Gutierrez R, Monreal-Robles R, Marfil-Rivera A. Gastrointestinal disorders associated with migraine: a comprehensive review. World J Gastroenterol. 2016;22(36):8149&#x2013;8160. doi: 10.3748/wjg.v22.i36.8149.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i36.8149</ArticleId><ArticleId IdType="pmc">PMC5037083</ArticleId><ArticleId IdType="pubmed">27688656</ArticleId></ArticleIdList></Reference><Reference><Citation>van Hemert S, Breedveld AC, Rovers JM, Vermeiden JP, Witteman BJ, Smits MG, et al. Migraine associated with gastrointestinal disorders: review of the literature and clinical implications. Front Neurol. 2014;5:241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4240046</ArticleId><ArticleId IdType="pubmed">25484876</ArticleId></ArticleIdList></Reference><Reference><Citation>Galland L. The gut microbiome and the brain. J Med Food. 2014;17(12):1261&#x2013;1272. doi: 10.1089/jmf.2014.7000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jmf.2014.7000</ArticleId><ArticleId IdType="pmc">PMC4259177</ArticleId><ArticleId IdType="pubmed">25402818</ArticleId></ArticleIdList></Reference><Reference><Citation>Farzi A, Frohlich EE, Holzer P. Gut microbiota and the neuroendocrine system. Neurotherapeutics. 2018;15(1):5&#x2013;22. doi: 10.1007/s13311-017-0600-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-017-0600-5</ArticleId><ArticleId IdType="pmc">PMC5794709</ArticleId><ArticleId IdType="pubmed">29380303</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrella C, Giuli C, Agostini S, Bacquie V, Zinni M, Theodorou V, et al. Maternal exposure to low levels of corticosterone during lactation protects against experimental inflammatory colitis-induced damage in adult rat offspring. PLoS One. 2014;9(11):e113389. doi: 10.1371/journal.pone.0113389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0113389</ArticleId><ArticleId IdType="pmc">PMC4236199</ArticleId><ArticleId IdType="pubmed">25405993</ArticleId></ArticleIdList></Reference><Reference><Citation>Amini-Khoei H, Haghani-Samani E, Beigi M, Soltani A, Mobini GR, Balali-Dehkordi S, et al. On the role of corticosterone in behavioral disorders, microbiota composition alteration and neuroimmune response in adult male mice subjected to maternal separation stress. Int Immunopharmacol. 2019;66:242&#x2013;250. doi: 10.1016/j.intimp.2018.11.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2018.11.037</ArticleId><ArticleId IdType="pubmed">30500621</ArticleId></ArticleIdList></Reference><Reference><Citation>Verd&#xfa; EF, Bercik P, Verma-Gandhu M, Huang XX, Blennerhassett P, Jackson W, et al. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut. 2006;55(2):182&#x2013;190. doi: 10.1136/gut.2005.066100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2005.066100</ArticleId><ArticleId IdType="pmc">PMC1856497</ArticleId><ArticleId IdType="pubmed">16105890</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz HJ, Mortrud MT, Rivier JE, Brown MR. Calcitonin gene related peptide inhibits basal, pentagastrin, histamine, and bethanecol stimulated gastric acid secretion. Gut. 1985;26(6):550&#x2013;555. doi: 10.1136/gut.26.6.550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.26.6.550</ArticleId><ArticleId IdType="pmc">PMC1432758</ArticleId><ArticleId IdType="pubmed">2861147</ArticleId></ArticleIdList></Reference><Reference><Citation>Tache Y, Pappas T, Lauffenburger M, Goto Y, Walsh JH, Debas H. Calcitonin gene-related peptide: potent peripheral inhibitor of gastric acid secretion in rats and dogs. Gastroenterology. 1984;87(2):344&#x2013;349. doi: 10.1016/0016-5085(84)90711-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0016-5085(84)90711-X</ArticleId><ArticleId IdType="pubmed">6145652</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Jiang YC, Owyang C. Central CGRP inhibits pancreatic enzyme secretion by modulation of vagal parasympathetic outflow. Am J Phys. 1998;275(5):G957&#x2013;G963.</Citation><ArticleIdList><ArticleId IdType="pubmed">9815024</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandhu KV, Sherwin E, Schellekens H, Stanton C, Dinan TG, Cryan JF. Feeding the microbiota-gut-brain axis: diet, microbiome, and neuropsychiatry. Transl Res. 2017;179:223&#x2013;244. doi: 10.1016/j.trsl.2016.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2016.10.002</ArticleId><ArticleId IdType="pubmed">27832936</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng L, He Z, Chen W, Holzman IR, Lin J. Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr Res. 2007;61(1):37&#x2013;41. doi: 10.1203/01.pdr.0000250014.92242.f3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/01.pdr.0000250014.92242.f3</ArticleId><ArticleId IdType="pubmed">17211138</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Christophersen CT, Sorich MJ, Gerber JP, Angley MT, Conlon MA. Elevated fecal short chain fatty acid and ammonia concentrations in children with autism spectrum disorder. Dig Dis Sci. 2012;57(8):2096&#x2013;2102. doi: 10.1007/s10620-012-2167-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-012-2167-7</ArticleId><ArticleId IdType="pubmed">22535281</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Floch MH. Prebiotics, probiotics, and dietary Fiber in gastrointestinal disease. Gastroenterol Clin N Am. 2007;36(1):47&#x2013;63. doi: 10.1016/j.gtc.2007.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gtc.2007.03.001</ArticleId><ArticleId IdType="pubmed">17472874</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble EE, Hsu TM, Kanoski SE. Gut to brain Dysbiosis: mechanisms linking Western diet consumption, the microbiome, and cognitive impairment. Front Behav Neurosci. 2017;11:9. doi: 10.3389/fnbeh.2017.00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnbeh.2017.00009</ArticleId><ArticleId IdType="pmc">PMC5277010</ArticleId><ArticleId IdType="pubmed">28194099</ArticleId></ArticleIdList></Reference><Reference><Citation>Albenberg LG, Wu GD. Diet and the intestinal microbiome: associations, functions, and implications for health and disease. Gastroenterology. 2014;146(6):1564&#x2013;1572. doi: 10.1053/j.gastro.2014.01.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2014.01.058</ArticleId><ArticleId IdType="pmc">PMC4216184</ArticleId><ArticleId IdType="pubmed">24503132</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Li T, Beasley DE, Hed&#x11b;nec P, Xiao Z, Zhang S, et al. Diet diversity is associated with beta but not alpha diversity of pika gut microbiota. Front Microbiol. 2016;7:1169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4961685</ArticleId><ArticleId IdType="pubmed">27512391</ArticleId></ArticleIdList></Reference><Reference><Citation>Parnell JA, Reimer RA. Prebiotic fiber modulation of the gut microbiota improves risk factors for obesity and the metabolic syndrome. Gut Microbes. 2012;3(1):29&#x2013;34. doi: 10.4161/gmic.19246.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/gmic.19246</ArticleId><ArticleId IdType="pmc">PMC3827018</ArticleId><ArticleId IdType="pubmed">22555633</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchiando AM, Graham WV, Turner JR. Epithelial barriers in homeostasis and disease. Annu Rev Pathol. 2010;5:119&#x2013;144. doi: 10.1146/annurev.pathol.4.110807.092135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.pathol.4.110807.092135</ArticleId><ArticleId IdType="pubmed">20078218</ArticleId></ArticleIdList></Reference><Reference><Citation>Mennigen R, Bruewer M. Effect of probiotics on intestinal barrier function. Ann N Y Acad Sci. 2009;1165(1):183&#x2013;189. doi: 10.1111/j.1749-6632.2009.04059.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2009.04059.x</ArticleId><ArticleId IdType="pubmed">19538305</ArticleId></ArticleIdList></Reference><Reference><Citation>Y&#xfc;cel M, Kotan D, &#xc7;ift&#xe7;i GG, &#xc7;ift&#xe7;i I, Cikriklar H. Serum levels of endocan, claudin-5 and cytokines in migraine. Eur Rev Med Pharmacol Sci. 2016;20(5):930&#x2013;936.</Citation><ArticleIdList><ArticleId IdType="pubmed">27010153</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung L, Cahill CM. TNF-alpha and neuropathic pain--a review. J Neuroinflammation. 2010;7(1):27. doi: 10.1186/1742-2094-7-27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-7-27</ArticleId><ArticleId IdType="pmc">PMC2861665</ArticleId><ArticleId IdType="pubmed">20398373</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruno PP, Carpino F, Carpino G, Zicari A. An overview on immune system and migraine. Eur Rev Med Pharmacol Sci. 2007;11(4):245&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">17876959</ArticleId></ArticleIdList></Reference><Reference><Citation>Perini F, D'Andrea G, Galloni E, Pignatelli F, Billo G, Alba S, et al. Plasma cytokine levels in migraineurs and controls. Headache. 2005;45(7):926&#x2013;931. doi: 10.1111/j.1526-4610.2005.05135.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1526-4610.2005.05135.x</ArticleId><ArticleId IdType="pubmed">15985111</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez C, Vieites-Prado A, Perez-Mato M, Sobrino T, Rodriguez-Osorio X, Lopez A, et al. Role of adipocytokines in the pathophysiology of migraine: a cross-sectional study. Cephalalgia. 2018;38(5):904&#x2013;911. doi: 10.1177/0333102417720213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0333102417720213</ArticleId><ArticleId IdType="pubmed">28677995</ArticleId></ArticleIdList></Reference><Reference><Citation>Martami F, Razeghi Jahromi S, Togha M, Ghorbani Z, Seifishahpar M, Saidpour A. The serum level of inflammatory markers in chronic and episodic migraine: a case-control study. Neurol Sci. 2018;39(10):1741&#x2013;1749. doi: 10.1007/s10072-018-3493-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-018-3493-0</ArticleId><ArticleId IdType="pubmed">30009333</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathophysiology of Headaches From Molecule to Man. Paolo Martelletti RJ, editor: Springer, Cham; 2015</Citation></Reference><Reference><Citation>Noseda R, Borsook D, Burstein R. Neuropeptides and neurotransmitters that modulate Thalamo-cortical pathways relevant to migraine headache. Headache. 2017;57(Suppl 2):97&#x2013;111. doi: 10.1111/head.13083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/head.13083</ArticleId><ArticleId IdType="pmc">PMC5424619</ArticleId><ArticleId IdType="pubmed">28485844</ArticleId></ArticleIdList></Reference><Reference><Citation>Filpa V, Moro E, Protasoni M, Crema F, Frigo G, Giaroni C. Role of glutamatergic neurotransmission in the enteric nervous system and brain-gut axis in health and disease. Neuropharmacology. 2016;111:14&#x2013;33. doi: 10.1016/j.neuropharm.2016.08.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2016.08.024</ArticleId><ArticleId IdType="pubmed">27561972</ArticleId></ArticleIdList></Reference><Reference><Citation>Holzer P, Reichmann F. Farzi AJN. Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut&#x2013;brain axis. 2012;46(6):261&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3516703</ArticleId><ArticleId IdType="pubmed">22979996</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer JA, Born W. Novel peptides from the calcitonin gene: expression, receptors and biological function. Peptides. 1985;6(Suppl 3):265&#x2013;271. doi: 10.1016/0196-9781(85)90384-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0196-9781(85)90384-5</ArticleId><ArticleId IdType="pubmed">3008119</ArticleId></ArticleIdList></Reference><Reference><Citation>Raybould HE. Mechanisms of CCK signaling from gut to brain. Curr Opin Pharmacol. 2007;7(6):570&#x2013;574. doi: 10.1016/j.coph.2007.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2007.09.006</ArticleId><ArticleId IdType="pmc">PMC2692370</ArticleId><ArticleId IdType="pubmed">17954038</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballaz S. The unappreciated roles of the cholecystokinin receptor CCK (1) in brain functioning. Rev Neurosci. 2017;28(6):573&#x2013;585. doi: 10.1515/revneuro-2016-0088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/revneuro-2016-0088</ArticleId><ArticleId IdType="pubmed">28343167</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao G, Han X, Hao T, Huang Q, Yu T. Effects of rizatriptan on the expression of calcitonin gene-related peptide and cholecystokinin in the periaqueductal gray of a rat migraine model. Neurosci Lett. 2015;587:29&#x2013;34. doi: 10.1016/j.neulet.2014.12.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2014.12.021</ArticleId><ArticleId IdType="pubmed">25524408</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Connor TP, van der Kooy D. Enrichment of a vasoactive neuropeptide (calcitonin gene related peptide) in the trigeminal sensory projection to the intracranial arteries. J Neurosci. 1988;8(7):2468&#x2013;2476. doi: 10.1523/JNEUROSCI.08-07-02468.1988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.08-07-02468.1988</ArticleId><ArticleId IdType="pmc">PMC6569540</ArticleId><ArticleId IdType="pubmed">2470872</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrara LA, Pacioni D, Di Fronzo V, Russo BF, Speranza E, Carlino V, et al. Low-lipid diet reduces frequency and severity of acute migraine attacks. Nutr Metab Cardiovasc Dis. 2015;25(4):370&#x2013;375. doi: 10.1016/j.numecd.2014.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.numecd.2014.12.006</ArticleId><ArticleId IdType="pubmed">25698152</ArticleId></ArticleIdList></Reference><Reference><Citation>Ornello R, Ripa P, Pistoia F, Degan D, Tiseo C, Carolei A, et al. Migraine and body mass index categories: a systematic review and meta-analysis of observational studies. J Headache Pain. 2015;16(1):27. doi: 10.1186/s10194-015-0510-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10194-015-0510-z</ArticleId><ArticleId IdType="pmc">PMC4385329</ArticleId><ArticleId IdType="pubmed">25903159</ArticleId></ArticleIdList></Reference><Reference><Citation>Liou AP, Lu X, Sei Y, Zhao X, Pechhold S, Carrero RJ, et al. The G-protein-coupled receptor GPR40 directly mediates long-chain fatty acid-induced secretion of cholecystokinin. Gastroenterology. 2011;140(3):903&#x2013;912. doi: 10.1053/j.gastro.2010.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2010.10.012</ArticleId><ArticleId IdType="pmc">PMC4717904</ArticleId><ArticleId IdType="pubmed">20955703</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke G, Grenham S, Scully P, Fitzgerald P, Moloney RD, Shanahan F, et al. The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol Psychiatry. 2013;18(6):666&#x2013;673. doi: 10.1038/mp.2012.77.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2012.77</ArticleId><ArticleId IdType="pubmed">22688187</ArticleId></ArticleIdList></Reference><Reference><Citation>Saulnier DM, Ringel Y, Heyman MB, Foster JA, Bercik P, Shulman RJ, et al. The intestinal microbiome, probiotics and prebiotics in neurogastroenterology. Gut Microbes. 2013;4(1):17&#x2013;27. doi: 10.4161/gmic.22973.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/gmic.22973</ArticleId><ArticleId IdType="pmc">PMC3555881</ArticleId><ArticleId IdType="pubmed">23202796</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster JA, Neufeld K-AM. Gut&#x2013;brain axis: how the microbiome influences anxiety and depression. Trends Neurosci. 2013;36(5):305&#x2013;312. doi: 10.1016/j.tins.2013.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2013.01.005</ArticleId><ArticleId IdType="pubmed">23384445</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghorbani Z, Nazari S, Etesam F, Nourimajd S, Ahmadpanah M, Razeghi JS. The effect of Synbiotic as an adjuvant therapy to fluoxetine in moderate depression: a randomized multicenter trial. Arch Neurosci. 2018;5(2):e60507. doi: 10.5812/archneurosci.60507.</Citation><ArticleIdList><ArticleId IdType="doi">10.5812/archneurosci.60507</ArticleId></ArticleIdList></Reference><Reference><Citation>Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A. 2009;106(10):3698&#x2013;3703. doi: 10.1073/pnas.0812874106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0812874106</ArticleId><ArticleId IdType="pmc">PMC2656143</ArticleId><ArticleId IdType="pubmed">19234110</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittal R, Debs LH, Patel AP, Nguyen D, Patel K, O'Connor G, et al. Neurotransmitters: the critical modulators regulating gut-brain Axis. J Cell Physiol. 2017;232(9):2359&#x2013;2372. doi: 10.1002/jcp.25518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.25518</ArticleId><ArticleId IdType="pmc">PMC5772764</ArticleId><ArticleId IdType="pubmed">27512962</ArticleId></ArticleIdList></Reference><Reference><Citation>Aamodt AH, Stovner LJ, Hagen K, Zwart JA. Comorbidity of headache and gastrointestinal complaints. The Head-HUNT Study Cephalalgia. 2008;28(2):144&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">18197884</ArticleId></ArticleIdList></Reference><Reference><Citation>Inaloo S, Dehghani SM, Hashemi SM, Heydari M, Heydari ST. Comorbidity of headache and functional constipation in children: a cross-sectional survey. Turk J Gastroenterol. 2014;25(5):508&#x2013;511. doi: 10.5152/tjg.2014.6183.</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/tjg.2014.6183</ArticleId><ArticleId IdType="pubmed">25417610</ArticleId></ArticleIdList></Reference><Reference><Citation>Meucci G, Radaelli F, Prada A, Bortoli A, Crotta S, Cerrato C, et al. Increased prevalence of migraine in patients with uninvestigated dyspepsia referred for open-access upper gastrointestinal endoscopy. Endoscopy. 2005;37(7):622&#x2013;625. doi: 10.1055/s-2005-870251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2005-870251</ArticleId><ArticleId IdType="pubmed">16010605</ArticleId></ArticleIdList></Reference><Reference><Citation>Pe&#x15f;kersoy C, Peker &#x15e;, Kaya A, &#xdc;nalp A, G&#xf6;kay N. Evaluation of the relationship between migraine disorder andoral comorbidities: multicenter randomized clinical trial. Turkish journal of medical sciences. 2016;46(3):712&#x2013;718. doi: 10.3906/sag-1412-71.</Citation><ArticleIdList><ArticleId IdType="doi">10.3906/sag-1412-71</ArticleId><ArticleId IdType="pubmed">27513246</ArticleId></ArticleIdList></Reference><Reference><Citation>Su J, Zhou XY, Zhang GX. Association between helicobacter pylori infection and migraine: a meta-analysis. World J Gastroenterol. 2014;20(40):14965&#x2013;14972. doi: 10.3748/wjg.v20.i40.14965.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i40.14965</ArticleId><ArticleId IdType="pmc">PMC4209561</ArticleId><ArticleId IdType="pubmed">25356058</ArticleId></ArticleIdList></Reference><Reference><Citation>Savi L, Ribaldone DG, Fagoonee S, Pellicano R. Is helicobacter pylori the infectious trigger for headache?: a review. Infectious disorders drug targets. 2013;13(5):313&#x2013;317. doi: 10.2174/1871526513666131201125021.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871526513666131201125021</ArticleId><ArticleId IdType="pubmed">24304354</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole JA, Rothman KJ, Cabral HJ, Zhang Y, Farraye FA. Migraine, fibromyalgia, and depression among people with IBS: a prevalence study. BMC Gastroenterol. 2006;6(1):26. doi: 10.1186/1471-230X-6-26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-230X-6-26</ArticleId><ArticleId IdType="pmc">PMC1592499</ArticleId><ArticleId IdType="pubmed">17007634</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang FY, Lu CL. Irritable bowel syndrome and migraine: bystanders or partners? Journal of neurogastroenterology and motility. 2013;19(3):301&#x2013;311. doi: 10.5056/jnm.2013.19.3.301.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm.2013.19.3.301</ArticleId><ArticleId IdType="pmc">PMC3714407</ArticleId><ArticleId IdType="pubmed">23875096</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabrielli M, Cremonini F, Fiore G, Addolorato G, Padalino C, Candelli M, et al. Association between migraine and celiac disease: results from a preliminary case-control and therapeutic study. Am J Gastroenterol. 2003;98(3):625&#x2013;629. doi: 10.1111/j.1572-0241.2003.07300.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2003.07300.x</ArticleId><ArticleId IdType="pubmed">12650798</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Or O, Zelnik N, Shaoul R, Pacht A, Lerner A. The neurologic profile of children and adolescents with inflammatory bowel disease. J Child Neurol. 2015;30(5):551&#x2013;557. doi: 10.1177/0883073814521296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0883073814521296</ArticleId><ArticleId IdType="pubmed">24700662</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira GR, Teles BC, Brasil EF, Souza MH, Furtado LE, de Castro-Costa CM, et al. Peripheral neuropathy and neurological disorders in an unselected Brazilian population-based cohort of IBD patients. Inflamm Bowel Dis. 2008;14(3):389&#x2013;395. doi: 10.1002/ibd.20304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ibd.20304</ArticleId><ArticleId IdType="pubmed">17924556</ArticleId></ArticleIdList></Reference><Reference><Citation>Moisset X, Bommelaer G, Boube M, Ouchchane L, Goutte M, Dapoigny M, et al. Migraine prevalence in inflammatory bowel disease patients: a tertiary-care Centre cross-sectional study. Eur J Pain. 2017;21(9):1550&#x2013;1560. doi: 10.1002/ejp.1056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejp.1056</ArticleId><ArticleId IdType="pubmed">28508514</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraji F, Zarinfar N, Zanjani AT, Morteza A. The effect of helicobacter pylori eradication on migraine: a randomized, double blind, controlled trial. Pain physician. 2012;15(6):495&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">23159967</ArticleId></ArticleIdList></Reference><Reference><Citation>Waeber C, Moskowitz MA. Migraine as an inflammatory disorder. Neurology. 2005;64(10 suppl 2):S9&#x2013;S15. doi: 10.1212/WNL.64.10_suppl_2.S9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.64.10_suppl_2.S9</ArticleId><ArticleId IdType="pubmed">15911785</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Zou Y, Zhang X. [Determination of serum calicotonin gene-related peptide in patients with duodenal ulcer infected with Helicobacter pylori]. Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University. 1999;24(3):273&#x2013;4</Citation><ArticleIdList><ArticleId IdType="pubmed">12016804</ArticleId></ArticleIdList></Reference><Reference><Citation>Munno I, Marinaro M, Bassi A, Cassiano MA, Causarano V, Centonze V. Immunological aspects in migraine: increase of IL-10 plasma levels during attack. Headache. 2001;41(8):764&#x2013;767. doi: 10.1046/j.1526-4610.2001.01140.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1526-4610.2001.01140.x</ArticleId><ArticleId IdType="pubmed">11576199</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeberle HA, Kubin M, Bamford KB, Garofalo R, Graham DY, El-Zaatari F, et al. Differential stimulation of interleukin-12 (IL-12) and IL-10 by live and killed helicobacter pylori in vitro and association of IL-12 production with gamma interferon-producing T cells in the human gastric mucosa. Infect Immun. 1997;65(10):4229&#x2013;4235. doi: 10.1128/IAI.65.10.4229-4235.1997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.65.10.4229-4235.1997</ArticleId><ArticleId IdType="pmc">PMC175607</ArticleId><ArticleId IdType="pubmed">9317031</ArticleId></ArticleIdList></Reference><Reference><Citation>Windle HJ, Ang YS, Athie-Morales V, McManus R, Kelleher D. Human peripheral and gastric lymphocyte responses to helicobacter pylori NapA and AphC differ in infected and uninfected individuals. Gut. 2005;54(1):25&#x2013;32. doi: 10.1136/gut.2003.025494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2003.025494</ArticleId><ArticleId IdType="pmc">PMC1774350</ArticleId><ArticleId IdType="pubmed">15591500</ArticleId></ArticleIdList></Reference><Reference><Citation>Hida N, Shimoyama T, Jr, Neville P, Dixon MF, Axon AT, Shimoyama T, Sr, et al. Increased expression of IL-10 and IL-12 (p40) mRNA in helicobacter pylori infected gastric mucosa: relation to bacterial cag status and peptic ulceration. J Clin Pathol. 1999;52(9):658&#x2013;664. doi: 10.1136/jcp.52.9.658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jcp.52.9.658</ArticleId><ArticleId IdType="pmc">PMC501540</ArticleId><ArticleId IdType="pubmed">10655986</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JW, Cho YS, Lee SY, Kim ES, Cho H, Shin HE, et al. Concomitant functional gastrointestinal symptoms influence psychological status in Korean migraine patients. Gut and liver. 2013;7(6):668&#x2013;674. doi: 10.5009/gnl.2013.7.6.668.</Citation><ArticleIdList><ArticleId IdType="doi">10.5009/gnl.2013.7.6.668</ArticleId><ArticleId IdType="pmc">PMC3848535</ArticleId><ArticleId IdType="pubmed">24312707</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson WC, Sullivan SN, Corke M, Rush D. Globus and headache: common symptoms of the irritable bowel syndrome. Can Med Assoc J. 1978;118(4):387&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1817959</ArticleId><ArticleId IdType="pubmed">630498</ArticleId></ArticleIdList></Reference><Reference><Citation>Lankarani KB, Akbari M, Tabrizi R. Association of Gastrointestinal Functional Disorders and Migraine Headache: a Population Base study. Middle East journal of digestive diseases. 2017;9(3):139&#x2013;145. doi: 10.15171/mejdd.2017.64.</Citation><ArticleIdList><ArticleId IdType="doi">10.15171/mejdd.2017.64</ArticleId><ArticleId IdType="pmc">PMC5585926</ArticleId><ArticleId IdType="pubmed">28894515</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau CI, Lin CC, Chen WH, Wang HC, Kao CH. Association between migraine and irritable bowel syndrome: a population-based retrospective cohort study. Eur J Neurol. 2014;21(9):1198&#x2013;1204. doi: 10.1111/ene.12468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12468</ArticleId><ArticleId IdType="pubmed">24838228</ArticleId></ArticleIdList></Reference><Reference><Citation>Martami F, Ghorbani Z, Abolhasani M, Togha M, Meysamie A, Sharifi A, et al. Comorbidity of gastrointestinal disorders, migraine, and tension-type headache: a cross-sectional study in Iran. Neurol Sci. 2018;39(1):63&#x2013;70. doi: 10.1007/s10072-017-3141-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-017-3141-0</ArticleId><ArticleId IdType="pubmed">29022143</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, Price DD, Callam CS, Woodruff MA, Verne GN. Effects of the N-methyl-D-aspartate receptor on temporal summation of second pain (wind-up) in irritable bowel syndrome. J Pain. 2011;12(2):297&#x2013;303. doi: 10.1016/j.jpain.2010.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpain.2010.09.002</ArticleId><ArticleId IdType="pmc">PMC3058359</ArticleId><ArticleId IdType="pubmed">21146468</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandvik PO, Wilhelmsen I, Ihlebaek C, Farup PG. Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical implications. Aliment Pharmacol Ther. 2004;20(10):1195&#x2013;1203. doi: 10.1111/j.1365-2036.2004.02250.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2004.02250.x</ArticleId><ArticleId IdType="pubmed">15569123</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Yu S, Li H, Zhou J, Liu J, Tang W, et al. Clinical features and risk factors for irritable bowel syndrome in migraine patients. Pak J Med Sci. 2017;33(3):720&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5510134</ArticleId><ArticleId IdType="pubmed">28811802</ArticleId></ArticleIdList></Reference><Reference><Citation>De Roos N, Giezenaar C, Rovers J, Witteman B, Smits M, Van Hemert S. The effects of the multispecies probiotic mixture ecologic&#xae; barrier on migraine: results of an open-label pilot study. Benef Microbes. 2015;6(5):641&#x2013;646. doi: 10.3920/BM2015.0003.</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2015.0003</ArticleId><ArticleId IdType="pubmed">25869282</ArticleId></ArticleIdList></Reference><Reference><Citation>van Hemert S, Breedveld AC, Rovers JM, Vermeiden JP, Witteman BJ, Smits MG et al (2014) Migraine associated with gastrointestinal disorders: review of the literature and clinical implications. Front Neurol 5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4240046</ArticleId><ArticleId IdType="pubmed">25484876</ArticleId></ArticleIdList></Reference><Reference><Citation>Aurora SK, Papapetropoulos S, Kori SH, Kedar A, Abell TL. Gastric stasis in migraineurs: etiology, characteristics, and clinical and therapeutic implications. Cephalalgia. 2013;33(6):408&#x2013;415. doi: 10.1177/0333102412473371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0333102412473371</ArticleId><ArticleId IdType="pmc">PMC5098810</ArticleId><ArticleId IdType="pubmed">23463252</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgescu D, Reisz D, Gurban CV, Georgescu LA, Ionita I, Ancusa OE, et al. Migraine in young females with irritable bowel syndrome: still a challenge. Neuropsychiatr Dis Treat. 2018;14:21&#x2013;28. doi: 10.2147/NDT.S144955.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/NDT.S144955</ArticleId><ArticleId IdType="pmc">PMC5741982</ArticleId><ArticleId IdType="pubmed">29302188</ArticleId></ArticleIdList></Reference><Reference><Citation>de Roos NM, van Hemert S, Rovers JMP, Smits MG, Witteman BJM. The effects of a multispecies probiotic on migraine and markers of intestinal permeability-results of a randomized placebo-controlled study. Eur J Clin Nutr. 2017;71(12):1455&#x2013;1462. doi: 10.1038/ejcn.2017.57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejcn.2017.57</ArticleId><ArticleId IdType="pubmed">28537581</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydinlar EI, Dikmen PY, Tiftikci A, Saruc M, Aksu M, Gunsoy HG, et al. IgG-based elimination diet in migraine plus irritable bowel syndrome. Headache. 2013;53(3):514&#x2013;525. doi: 10.1111/j.1526-4610.2012.02296.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1526-4610.2012.02296.x</ArticleId><ArticleId IdType="pubmed">23216231</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowell MD. Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br J Pharmacol. 2004;141(8):1285&#x2013;1293. doi: 10.1038/sj.bjp.0705762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0705762</ArticleId><ArticleId IdType="pmc">PMC1574906</ArticleId><ArticleId IdType="pubmed">15100164</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulak A, Paradowski L. Migraine and irritable bowel syndrome. Neurol Neurochir Pol. 2005;39(4 Suppl 1):S55&#x2013;S60.</Citation><ArticleIdList><ArticleId IdType="pubmed">16419571</ArticleId></ArticleIdList></Reference><Reference><Citation>Camilleri M. Review article: new receptor targets for medical therapy in irritable bowel syndrome. Aliment Pharmacol Ther. 2010;31(1):35&#x2013;46. doi: 10.1111/j.1365-2036.2009.04153.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2009.04153.x</ArticleId><ArticleId IdType="pmc">PMC2896496</ArticleId><ArticleId IdType="pubmed">19785622</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, McCarson KE, Welch KM, Berman NE. Mechanisms of pain modulation by sex hormones in migraine. Headache. 2011;51(6):905&#x2013;922. doi: 10.1111/j.1526-4610.2011.01908.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1526-4610.2011.01908.x</ArticleId><ArticleId IdType="pubmed">21631476</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannahan S, Leffler DA. Diagnosis and updates in celiac disease. Gastrointest Endosc Clin N Am. 2017;27(1):79&#x2013;92. doi: 10.1016/j.giec.2016.08.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.giec.2016.08.011</ArticleId><ArticleId IdType="pubmed">27908520</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh P, Arora A, Strand TA, Leffler DA, Catassi C, Green PH, et al. Global prevalence of celiac disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(6):823&#x2013;836. doi: 10.1016/j.cgh.2017.06.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2017.06.037</ArticleId><ArticleId IdType="pubmed">29551598</ArticleId></ArticleIdList></Reference><Reference><Citation>Rani U, Imdad A, Beg M. Rare neurological manifestation of celiac disease. Case Rep Gastroenterol. 2015;9(2):200&#x2013;205. doi: 10.1159/000431170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000431170</ArticleId><ArticleId IdType="pmc">PMC4478317</ArticleId><ArticleId IdType="pubmed">26120302</ArticleId></ArticleIdList></Reference><Reference><Citation>Aaron L, Torsten M, Patricia W. Autoimmunity in celiac disease: Extra-intestinal manifestations. Autoimmun Rev. 2019;18(3):241&#x2013;246. doi: 10.1016/j.autrev.2018.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2018.09.010</ArticleId><ArticleId IdType="pubmed">30639642</ArticleId></ArticleIdList></Reference><Reference><Citation>Zis P, Julian T, Hadjivassiliou M. Headache associated with coeliac disease: a systematic review and meta-analysis. Nutrients. 2018;10(10):1445. doi: 10.3390/nu10101445.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu10101445</ArticleId><ArticleId IdType="pmc">PMC6213149</ArticleId><ArticleId IdType="pubmed">30301194</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimitrova AK, Ungaro RC, Lebwohl B, Lewis SK, Tennyson CA, Green MW, et al. Prevalence of migraine in patients with celiac disease and inflammatory bowel disease. Headache. 2013;53(2):344&#x2013;355. doi: 10.1111/j.1526-4610.2012.02260.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1526-4610.2012.02260.x</ArticleId><ArticleId IdType="pubmed">23126519</ArticleId></ArticleIdList></Reference><Reference><Citation>Burk K, Farecki ML, Lamprecht G, Roth G, Decker P, Weller M, et al. Neurological symptoms in patients with biopsy proven celiac disease. Movement disorders : official journal of the Movement Disorder Society. 2009;24(16):2358&#x2013;2362.</Citation><ArticleIdList><ArticleId IdType="pubmed">19845007</ArticleId></ArticleIdList></Reference><Reference><Citation>Lionetti E, Francavilla R, Maiuri L, Ruggieri M, Spina M, Pavone P, et al. Headache in pediatric patients with celiac disease and its prevalence as a diagnostic clue. J Pediatr Gastroenterol Nutr. 2009;49(2):202&#x2013;207. doi: 10.1097/MPG.0b013e31818f6389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0b013e31818f6389</ArticleId><ArticleId IdType="pubmed">19543115</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaconu G, Burlea M, Grigore I, Anton DT, Trandafir LM. Celiac disease with neurologic manifestations in children. Rev Med Chir Soc Med Nat Iasi. 2013;117(1):88&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">24505898</ArticleId></ArticleIdList></Reference><Reference><Citation>Battistella PA, Mattesi P, Casara GL, Carollo C, Condini A, Allegri F, et al. Bilateral cerebral occipital calcifications and migraine-like headache. Cephalalgia. 1987;7(2):125&#x2013;129. doi: 10.1046/j.1468-2982.1987.0702125.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1468-2982.1987.0702125.x</ArticleId><ArticleId IdType="pubmed">3111714</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopishinskaya SV, Gustov AV. Gluten migraine. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(8):13&#x2013;17. doi: 10.17116/jnevro20151158113-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.17116/jnevro20151158113-17</ArticleId><ArticleId IdType="pubmed">26356609</ArticleId></ArticleIdList></Reference><Reference><Citation>Currie S, Hadjivassiliou M, Clark MJ, Sanders DS, Wilkinson ID, Griffiths PD, et al. Should we be &#x2018;nervous&#x2019; about coeliac disease? Brain abnormalities in patients with coeliac disease referred for neurological opinion. J Neurol Neurosurg Psychiatry. 2012;83(12):1216&#x2013;1221. doi: 10.1136/jnnp-2012-303281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-303281</ArticleId><ArticleId IdType="pubmed">22906616</ArticleId></ArticleIdList></Reference><Reference><Citation>La Mantia L, Pollo B, Savoiardo M, Costa A, Eoli M, Allegranza A, et al. Meningo-cortical calcifying angiomatosis and celiac disease. Clin Neurol Neurosurg. 1998;100(3):209&#x2013;215. doi: 10.1016/S0303-8467(98)00029-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0303-8467(98)00029-8</ArticleId><ArticleId IdType="pubmed">9822844</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Amico D, Rigamonti A, Spina L, Bianchi-Marzoli S, Vecchi M, Bussone G. Migraine, celiac disease, and cerebral calcifications: a new case. Headache. 2005;45(9):1263&#x2013;1267. doi: 10.1111/j.1526-4610.2005.00253_2.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1526-4610.2005.00253_2.x</ArticleId><ArticleId IdType="pubmed">16178961</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormile R. Celiac disease and migraine: is there a common backstage? Int J Color Dis. 2014;29(12):1571. doi: 10.1007/s00384-014-1923-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-014-1923-x</ArticleId><ArticleId IdType="pubmed">24965856</ArticleId></ArticleIdList></Reference><Reference><Citation>Cady RK, Farmer K, Dexter JK, Hall J. The bowel and migraine: update on celiac disease and irritable bowel syndrome. Curr Pain Headache Rep. 2012;16(3):278&#x2013;286. doi: 10.1007/s11916-012-0258-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11916-012-0258-y</ArticleId><ArticleId IdType="pubmed">22447132</ArticleId></ArticleIdList></Reference><Reference><Citation>Nenna R, Petrarca L, Verdecchia P, Florio M, Pietropaoli N, Mastrogiorgio G, et al. Celiac disease in a large cohort of children and adolescents with recurrent headache: a retrospective study. Dig Liver Dis. 2016;48(5):495&#x2013;498. doi: 10.1016/j.dld.2015.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2015.12.015</ArticleId><ArticleId IdType="pubmed">26826905</ArticleId></ArticleIdList></Reference><Reference><Citation>Lionetto L, Negro A, Palmisani S, Gentile G, Del Fiore MR, Mercieri M, et al. Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs. 2012;17(3):393&#x2013;406. doi: 10.1517/14728214.2012.709846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14728214.2012.709846</ArticleId><ArticleId IdType="pubmed">22862686</ArticleId></ArticleIdList></Reference><Reference><Citation>Razeghi Jahromi S, Ghorbani Z, Martelletti P, Lampl C, Togha M. Association of diet and headache. J Headache Pain. 2019;20(1):106. doi: 10.1186/s10194-019-1057-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10194-019-1057-1</ArticleId><ArticleId IdType="pmc">PMC6854770</ArticleId><ArticleId IdType="pubmed">31726975</ArticleId></ArticleIdList></Reference><Reference><Citation>Serratrice J, Disdier P, de Roux C, Christides C, Weiller PJ. Migraine and coeliac disease. Headache. 1998;38(8):627&#x2013;628. doi: 10.1046/j.1526-4610.1998.3808627.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1526-4610.1998.3808627.x</ArticleId><ArticleId IdType="pubmed">11398309</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjivassiliou M, Grunewald RA, Lawden M, Davies-Jones GA, Powell T, Smith CM. Headache and CNS white matter abnormalities associated with gluten sensitivity. Neurology. 2001;56(3):385&#x2013;388. doi: 10.1212/WNL.56.3.385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.56.3.385</ArticleId><ArticleId IdType="pubmed">11171906</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang S, Shen B. Classification and Reclassification of Inflammatory Bowel Diseases: From Clinical Perspective. Interventional Inflammatory Bowel Disease: Endoscopic Management and Treatment of Complications: Elsevier; 2018. p. 17&#x2013;34</Citation></Reference><Reference><Citation>Chehel Cheraghi S, Ebrahimi Daryani N, Ghabaee M. A survey on migraine prevalence in patients with inflammatory bowel disease - a single Centre experience. Middle East journal of digestive diseases. 2016;8(4):282&#x2013;288. doi: 10.15171/mejdd.2016.37.</Citation><ArticleIdList><ArticleId IdType="doi">10.15171/mejdd.2016.37</ArticleId><ArticleId IdType="pmc">PMC5145295</ArticleId><ArticleId IdType="pubmed">27957291</ArticleId></ArticleIdList></Reference><Reference><Citation>Doulberis M, Saleh C, Beyenburg S. Is there an association between migraine and gastrointestinal disorders? Journal of Clinical Neurology. 2017;13(3):215&#x2013;226. doi: 10.3988/jcn.2017.13.3.215.</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2017.13.3.215</ArticleId><ArticleId IdType="pmc">PMC5532317</ArticleId><ArticleId IdType="pubmed">28748672</ArticleId></ArticleIdList></Reference><Reference><Citation>Fellermann K, Steffen M, Stein J, Raedler A, Hamling J, Ludwig D, et al. Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther. 2000;14(2):171&#x2013;176. doi: 10.1046/j.1365-2036.2000.00695.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.2000.00695.x</ArticleId><ArticleId IdType="pubmed">10651657</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai YJ, Wang HY, Wang XJ, Kaye AD, Sun YH. Potential beneficial effects of probiotics on human migraine headache: a literature review. Pain physician. 2017;20(2):E251&#x2013;E2E5.</Citation><ArticleIdList><ArticleId IdType="pubmed">28158162</ArticleId></ArticleIdList></Reference><Reference><Citation>Plaza-D&#xed;az Julio, Ruiz-Ojeda Francisco, Vilchez-Padial Laura, Gil Angel. Evidence of the Anti-Inflammatory Effects of Probiotics and Synbiotics in Intestinal Chronic Diseases. Nutrients. 2017;9(6):555. doi: 10.3390/nu9060555.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu9060555</ArticleId><ArticleId IdType="pmc">PMC5490534</ArticleId><ArticleId IdType="pubmed">28555037</ArticleId></ArticleIdList></Reference><Reference><Citation>James Sensenig N, Jeffrey Marrongelle D, CCN MJS. T. Treatment of migraine with targeted nutrition focused on improved assimilation and elimination. Altern Med Rev. 2001;6(5):488&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">11703169</ArticleId></ArticleIdList></Reference><Reference><Citation>Martami F, Togha M, Seifishahpar M, Ghorbani Z, Ansari H, Karimi T, et al. The effects of a multispecies probiotic supplement on inflammatory markers and episodic and chronic migraine characteristics: a randomized double-blind controlled trial. Cephalalgia. 2019;39(7):841&#x2013;853. doi: 10.1177/0333102418820102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0333102418820102</ArticleId><ArticleId IdType="pubmed">30621517</ArticleId></ArticleIdList></Reference><Reference><Citation>Romeo MG, Romeo DM, Trovato L, Oliveri S, Palermo F, Cota F, et al. Role of probiotics in the prevention of the enteric colonization by Candida in preterm newborns: incidence of late-onset sepsis and neurological outcome. J Perinatol. 2011;31(1):63&#x2013;69. doi: 10.1038/jp.2010.57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jp.2010.57</ArticleId><ArticleId IdType="pmc">PMC3016918</ArticleId><ArticleId IdType="pubmed">20410904</ArticleId></ArticleIdList></Reference><Reference><Citation>Indrio F, Riezzo G, Raimondi F, Bisceglia M, Filannino A, Cavallo L, et al. Lactobacillus reuteri accelerates gastric emptying and improves regurgitation in infants. Eur J Clin Investig. 2011;41(4):417&#x2013;422. doi: 10.1111/j.1365-2362.2010.02425.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2362.2010.02425.x</ArticleId><ArticleId IdType="pubmed">21114493</ArticleId></ArticleIdList></Reference><Reference><Citation>de Roos N, van Hemert S, Rovers J, Smits M, Witteman B (2017) The effects of a multispecies probiotic on migraine and markers of intestinal permeability&#x2013;results of a randomized placebo-controlled study. Eur J Clin Nutr</Citation><ArticleIdList><ArticleId IdType="pubmed">28537581</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins SM. A role for the gut microbiota in IBS. Nat Rev Gastroenterol Hepatol. 2014;11(8):497&#x2013;505. doi: 10.1038/nrgastro.2014.40.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2014.40</ArticleId><ArticleId IdType="pubmed">24751910</ArticleId></ArticleIdList></Reference><Reference><Citation>Evcili G, Utku U, Ogun MN, Ozdemir G. Early and long period follow-up results of low glycemic index diet for migraine prophylaxis. Agri. 2018;30(1):8&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">29450870</ArticleId></ArticleIdList></Reference><Reference><Citation>Hildebrandt Marie A., Hoffmann Christian, Sherrill&#x2013;Mix Scott A., Keilbaugh Sue A., Hamady Micah, Chen Ying&#x2013;Yu, Knight Rob, Ahima Rexford S., Bushman Frederic, Wu Gary D. High-Fat Diet Determines the Composition of the Murine Gut Microbiome Independently of Obesity. Gastroenterology. 2009;137(5):1716-1724.e2. doi: 10.1053/j.gastro.2009.08.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2009.08.042</ArticleId><ArticleId IdType="pmc">PMC2770164</ArticleId><ArticleId IdType="pubmed">19706296</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsden CE, Zamora D, Makriyannis A, Wood JT, Mann JD, Faurot KR, et al. Diet-induced changes in n-3-and n-6-derived endocannabinoids and reductions in headache pain and psychological distress. J Pain. 2015;16(8):707&#x2013;716. doi: 10.1016/j.jpain.2015.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpain.2015.04.007</ArticleId><ArticleId IdType="pmc">PMC4522350</ArticleId><ArticleId IdType="pubmed">25958314</ArticleId></ArticleIdList></Reference><Reference><Citation>Bic Z, Blix GG, Hopp HP, Leslie FM, Schell MJ. The influence of a low-fat diet on incidence and severity of migraine headaches. J Womens Health Gend Based Med. 1999;8(5):623&#x2013;630. doi: 10.1089/jwh.1.1999.8.623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jwh.1.1999.8.623</ArticleId><ArticleId IdType="pubmed">10839648</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunner AE, Agarwal U, Gonzales JF, Valente F, Barnard ND. Nutrition intervention for migraine: a randomized crossover trial. J Headache Pain. 2014;15(1):69. doi: 10.1186/1129-2377-15-69.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1129-2377-15-69</ArticleId><ArticleId IdType="pmc">PMC4227630</ArticleId><ArticleId IdType="pubmed">25339342</ArticleId></ArticleIdList></Reference><Reference><Citation>Bashir M, Prietl B, Tauschmann M, Mautner SI, Kump PK, Treiber G, et al. Effects of high doses of vitamin D3 on mucosa-associated gut microbiome vary between regions of the human gastrointestinal tract. Eur J Nutr. 2016;55(4):1479&#x2013;1489. doi: 10.1007/s00394-015-0966-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00394-015-0966-2</ArticleId><ArticleId IdType="pmc">PMC4875045</ArticleId><ArticleId IdType="pubmed">26130323</ArticleId></ArticleIdList></Reference><Reference><Citation>Togha M, Razeghi Jahromi S, Ghorbani Z, Martami F, Seifishahpar M. Serum vitamin D status in a Group of Migraine Patients Compared with Healthy Controls: a case-control study. Headache. 2018;58(10):1530&#x2013;1540. doi: 10.1111/head.13423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/head.13423</ArticleId><ArticleId IdType="pubmed">30341768</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghorbani Z, Togha M, Rafiee P, Ahmadi ZS, Rasekh Magham R, Haghighi S, et al. Vitamin D in migraine headache: a comprehensive review on literature. Neurol Sci. 2019;40(12):2459&#x2013;2477. doi: 10.1007/s10072-019-04021-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-04021-z</ArticleId><ArticleId IdType="pubmed">31377873</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagpal R, Newman TM, Wang S, Jain S, Lovato JF, Yadav H. Obesity-linked gut microbiome Dysbiosis associated with derangements in gut permeability and intestinal cellular homeostasis independent of diet. J Diabetes Res. 2018;2018:3462092. doi: 10.1155/2018/3462092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/3462092</ArticleId><ArticleId IdType="pmc">PMC6140100</ArticleId><ArticleId IdType="pubmed">30250849</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelaye B, Sacco S, Brown WJ, Nitchie HL, Ornello R, Peterlin BL. Body composition status and the risk of migraine: a meta-analysis. Neurology. 2017;88(19):1795&#x2013;1804. doi: 10.1212/WNL.0000000000003919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003919</ArticleId><ArticleId IdType="pmc">PMC5419981</ArticleId><ArticleId IdType="pubmed">28404807</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond DS, Vithiananthan S, Nash JM, Thomas JG, Wing RR. Improvement of migraine headaches in severely obese patients after bariatric surgery. Neurology. 2011;76(13):1135&#x2013;1138. doi: 10.1212/WNL.0b013e318212ab1e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318212ab1e</ArticleId><ArticleId IdType="pmc">PMC3068014</ArticleId><ArticleId IdType="pubmed">21444898</ArticleId></ArticleIdList></Reference><Reference><Citation>Novack V, Fuchs L, Lantsberg L, Kama S, Lahoud U, Horev A, et al. Changes in headache frequency in premenopausal obese women with migraine after bariatric surgery: a case series. Cephalalgia. 2011;31(13):1336&#x2013;1342. doi: 10.1177/0333102411413162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0333102411413162</ArticleId><ArticleId IdType="pubmed">21700645</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahromi SR, Abolhasani M, Ghorbani Z, Sadre-Jahani S, Alizadeh Z, Talebpour M, et al. Bariatric surgery promising in migraine control: a controlled trial on weight loss and its effect on migraine headache. Obes Surg. 2018;28(1):87&#x2013;96. doi: 10.1007/s11695-017-2793-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11695-017-2793-4</ArticleId><ArticleId IdType="pubmed">28685361</ArticleId></ArticleIdList></Reference><Reference><Citation>Verrotti A, Agostinelli S, D'Egidio C, Di Fonzo A, Carotenuto M, Parisi P, et al. Impact of a weight loss program on migraine in obese adolescents. Eur J Neurol. 2013;20(2):394&#x2013;397. doi: 10.1111/j.1468-1331.2012.03771.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2012.03771.x</ArticleId><ArticleId IdType="pubmed">22642299</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond DS, Roth J, Nash JM, Wing RR. Migraine and obesity: epidemiology, possible mechanisms and the potential role of weight loss treatment. Obes Rev. 2011;12(5):e362&#x2013;e371. doi: 10.1111/j.1467-789X.2010.00791.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1467-789X.2010.00791.x</ArticleId><ArticleId IdType="pmc">PMC2974024</ArticleId><ArticleId IdType="pubmed">20673279</ArticleId></ArticleIdList></Reference><Reference><Citation>Laino D, Vitaliti G, Parisi P, Pavone P, Verrotti A, Lubrano R, et al. Headache, migraine and obesity: an overview on plausible links. J Biol Regul Homeost Agents. 2016;30(2):333&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">27358118</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36014888</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6643</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>16</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>17</Day></PubDate></JournalIssue><Title>Nutrients</Title><ISOAbbreviation>Nutrients</ISOAbbreviation></Journal><ArticleTitle>Efficacy of an Irritable Bowel Syndrome Diet in the Treatment of Small Intestinal Bacterial Overgrowth: A Narrative Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3382</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nu14163382</ELocationID><Abstract><AbstractText>Small intestinal bacterial overgrowth (SIBO) is highly prevalent in irritable bowel syndrome (IBS). The eradication of bacterial overgrowth with antibiotics is the first-line treatment. However, focusing only on the antimicrobial effects without taking care to improve lifestyle factors, especially dietary patterns, may predispose patients to intestinal microbiota dysfunction. The objective of this study is to determine whether the current recommendations regarding nutrition in IBS are suitable for patients with SIBO. A narrative literature review was carried out using databases, including PubMed, ScienceDirect and Google Scholar. Recent studies indicate that dietary manipulation may have a role in alleviating SIBO gastrointestinal symptoms. A low FODMAP diet proposed for IBS may promote a negative shift in the gut microbiota and deepen the existing state of dysbiosis in SIBO patients. Supplementation with soluble fiber can lessen the symptoms in IBS and SIBO. Targeted probiotic therapy may also increase the effectiveness of antibiotic treatment and regulate bowel movements. Therefore, optimal dietary patterns play a key role in the treatment of SIBO. Based on currently available literature, the potential efficacy of the IBS diet in SIBO is largely hypothetical. Future research is needed to characterize a specific diet for the treatment of SIBO.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wielgosz-Grochowska</LastName><ForeName>Justyna Paulina</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0003-2500-9653</Identifier><AffiliationInfo><Affiliation>Department of Human Nutrition, Institute of Human Nutrition Sciences, Warsaw University of Life Sciences, 02-776 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domanski</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drywie&#x144;</LastName><ForeName>Ma&#x142;gorzata Ewa</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0001-8582-8306</Identifier><AffiliationInfo><Affiliation>Department of Human Nutrition, Institute of Human Nutrition Sciences, Warsaw University of Life Sciences, 02-776 Warsaw, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nutrients</MedlineTA><NlmUniqueID>101521595</NlmUniqueID><ISSNLinking>2072-6643</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001944" MajorTopicYN="N">Breath Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004032" MajorTopicYN="N">Diet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064806" MajorTopicYN="N">Dysbiosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007421" MajorTopicYN="N">Intestine, Small</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FODMAP</Keyword><Keyword MajorTopicYN="N">IBS</Keyword><Keyword MajorTopicYN="N">SIBO</Keyword><Keyword MajorTopicYN="N">dysbiosis</Keyword><Keyword MajorTopicYN="N">fiber</Keyword><Keyword MajorTopicYN="N">microbiota</Keyword><Keyword MajorTopicYN="N">prebiotics</Keyword><Keyword MajorTopicYN="N">probiotics</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>26</Day><Hour>1</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36014888</ArticleId><ArticleId IdType="pmc">PMC9412469</ArticleId><ArticleId IdType="doi">10.3390/nu14163382</ArticleId><ArticleId IdType="pii">nu14163382</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Singh R.K., Chang H.W., Yan D., Lee K.M., Ucmak D., Wong K., Abrouk M., Farahnik B., Nakamura M., Zhu T.H., et al. Influence of Diet on the Gut Microbiome and Implications for Human Health. J. Transl. Med. 2017;15:73. doi: 10.1186/s12967-017-1175-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-017-1175-y</ArticleId><ArticleId IdType="pmc">PMC5385025</ArticleId><ArticleId IdType="pubmed">28388917</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal U.C., Shukla R., Ghoshal U. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy. Gut Liver. 2017;11:196&#x2013;208. doi: 10.5009/gnl16126.</Citation><ArticleIdList><ArticleId IdType="doi">10.5009/gnl16126</ArticleId><ArticleId IdType="pmc">PMC5347643</ArticleId><ArticleId IdType="pubmed">28274108</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong F., Deng F., Li Y., Zhao J. Identification of Gut Microbiome Signatures Associated with Longevity Provides a Promising Modulation Target for Healthy Aging. Gut Microbes. 2019;10:210&#x2013;215. doi: 10.1080/19490976.2018.1494102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2018.1494102</ArticleId><ArticleId IdType="pmc">PMC6546316</ArticleId><ArticleId IdType="pubmed">30142010</ArticleId></ArticleIdList></Reference><Reference><Citation>Minhoo Kim B.A.B. The Microbiome: An Emerging Key Player in Aging and Longevity. Transl. Med. Aging. 2020;4:103&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7437988</ArticleId><ArticleId IdType="pubmed">32832742</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh R., Zogg H., Wei L., Bartlett A., Ghoshal U.C., Rajender S., Ro S. Gut Microbial Dysbiosis in the Pathogenesis of Gastrointestinal Dysmotility and Metabolic Disorders. J. Neurogastroenterol. Motil. 2021;27:19&#x2013;34. doi: 10.5056/jnm20149.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm20149</ArticleId><ArticleId IdType="pmc">PMC7786094</ArticleId><ArticleId IdType="pubmed">33166939</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins L.J., Monga M., Miller A.W. Defining Dysbiosis for a Cluster of Chronic Diseases. Sci. Rep. 2019;9:12918. doi: 10.1038/s41598-019-49452-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-49452-y</ArticleId><ArticleId IdType="pmc">PMC6733864</ArticleId><ArticleId IdType="pubmed">31501492</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaie A., Buresi M., Lembo A., Lin H., McCallum R., Rao S., Schmulson M., Valdovinos M., Zakko S., Pimentel M. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. Am. J. Gastroenterol. 2017;112:775&#x2013;784. doi: 10.1038/ajg.2017.46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2017.46</ArticleId><ArticleId IdType="pmc">PMC5418558</ArticleId><ArticleId IdType="pubmed">28323273</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M., Saad R.J., Long M.D., Rao S.S.C. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am. J. Gastroenterol. 2020;115:165&#x2013;178. doi: 10.14309/ajg.0000000000000501.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000000501</ArticleId><ArticleId IdType="pubmed">32023228</ArticleId></ArticleIdList></Reference><Reference><Citation>Takakura W., Pimentel M. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome&#x2014;An Update. Front. Psychiatry. 2020;11:664. doi: 10.3389/fpsyt.2020.00664.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2020.00664</ArticleId><ArticleId IdType="pmc">PMC7366247</ArticleId><ArticleId IdType="pubmed">32754068</ArticleId></ArticleIdList></Reference><Reference><Citation>Chassard C., Dapoigny M., Scott K.P., Crouzet L., Del&#x2019;Homme C., Marquet P., Martin J.C., Pickering G., Ardid D., Eschalier A., et al. Functional Dysbiosis within the Gut Microbiota of Patients with Constipated-Irritable Bowel Syndrome. Aliment. Pharmacol. Ther. 2012;35:828&#x2013;838. doi: 10.1111/j.1365-2036.2012.05007.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2012.05007.x</ArticleId><ArticleId IdType="pubmed">22315951</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohm M., Siwiec R.M., Wo J.M. Diagnosis and Management of Small Intestinal Bacterial Overgrowth. Nutr. Clin. Pract. 2013;28:289&#x2013;299. doi: 10.1177/0884533613485882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0884533613485882</ArticleId><ArticleId IdType="pubmed">23614961</ArticleId></ArticleIdList></Reference><Reference><Citation>Avelar Rodriguez D., Ryan P.M.D., Toro Monjaraz E.M., Ramirez Mayans J.A., Quigley E.M. Small Intestinal Bacterial Overgrowth in Children: A State-Of-The-Art Review. Front. Pediatr. 2019;7:363. doi: 10.3389/fped.2019.00363.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2019.00363</ArticleId><ArticleId IdType="pmc">PMC6737284</ArticleId><ArticleId IdType="pubmed">31552207</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauritano E.C., Gabrielli M., Scarpellini E., Lupascu A., Novi M., Sottili S., Vitale G., Cesario V., Serricchio M., Cammarota G., et al. Small Intestinal Bacterial Overgrowth Recurrence after Antibiotic Therapy. Am. J. Gastroenterol. 2008;103:2031&#x2013;2035. doi: 10.1111/j.1572-0241.2008.02030.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2008.02030.x</ArticleId><ArticleId IdType="pubmed">18802998</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasant D.H., Paine P.A., Black C.J., Houghton L.A., Everitt H.A., Corsetti M., Agrawal A., Aziz I., Farmer A.D., Eugenicos M.P., et al. British Society of Gastroenterology Guidelines on the Management of Irritable Bowel Syndrome. Gut. 2021;70:1214&#x2013;1240. doi: 10.1136/gutjnl-2021-324598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324598</ArticleId><ArticleId IdType="pubmed">33903147</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonetto S., Fagoonee S., Battaglia E., Grassini M., Saracco G.M., Pellicano R. Recent Advances in the Treatment of Irritable Bowel Syndrome. Pol. Arch. Intern. Med. 2021;131:709&#x2013;715. doi: 10.20452/pamw.16067.</Citation><ArticleIdList><ArticleId IdType="doi">10.20452/pamw.16067</ArticleId><ArticleId IdType="pubmed">34463082</ArticleId></ArticleIdList></Reference><Reference><Citation>Algera J., Colomier E., Simr&#xe9;n M. The Dietary Management of Patients with Irritable Bowel Syndrome: A Narrative Review of the Existing and Emerging Evidence. Nutrients. 2019;11:2162. doi: 10.3390/nu11092162.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11092162</ArticleId><ArticleId IdType="pmc">PMC6770052</ArticleId><ArticleId IdType="pubmed">31505870</ArticleId></ArticleIdList></Reference><Reference><Citation>Patcharatrakul T., Juntrapirat A., Lakananurak N., Gonlachanvit S. Effect of Structural Individual Low-FODMAP Dietary Advice vs. Brief Advice on a Commonly Recommended Diet on IBS Symptoms and Intestinal Gas Production. Nutrients. 2019;11:2856. doi: 10.3390/nu11122856.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11122856</ArticleId><ArticleId IdType="pmc">PMC6950148</ArticleId><ArticleId IdType="pubmed">31766497</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanayakkara W.S., Skidmore P.M., O&#x2019;Brien L., Wilkinson T.J., Gearry R.B. Efficacy of the Low FODMAP Diet for Treating Irritable Bowel Syndrome: The Evidence to Date. Clin. Exp. Gastroenterol. 2016;9:131&#x2013;142. doi: 10.2147/CEG.S86798.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CEG.S86798</ArticleId><ArticleId IdType="pmc">PMC4918736</ArticleId><ArticleId IdType="pubmed">27382323</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey K.R., Naik S.R., Vakil B.V. Probiotics, Prebiotics and Synbiotics&#x2014;A Review. J. Food Sci. Technol. 2015;52:7577&#x2013;7587. doi: 10.1007/s13197-015-1921-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13197-015-1921-1</ArticleId><ArticleId IdType="pmc">PMC4648921</ArticleId><ArticleId IdType="pubmed">26604335</ArticleId></ArticleIdList></Reference><Reference><Citation>Jalanka J., Major G., Murray K., Singh G., Nowak A., Kurtz C., Silos-Santiago I., Johnston J.M., de Vos W.M., Spiller R. The Effect of Psyllium Husk on Intestinal Microbiota in Constipated Patients and Healthy Controls. Int. J. Mol. Sci. 2019;20:433. doi: 10.3390/ijms20020433.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20020433</ArticleId><ArticleId IdType="pmc">PMC6358997</ArticleId><ArticleId IdType="pubmed">30669509</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher H.M., Scholz M., Lomer M.C., Ralph F.S., Irving P.M., Lindsay J.O., Fava F., Tuohy K., Whelan K. Gut Microbiota Associations with Diet in Irritable Bowel Syndrome and the Effect of Low FODMAP Diet and Probiotics. Clin. Nutr. 2021;40:1861&#x2013;1870. doi: 10.1016/j.clnu.2020.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2020.10.013</ArticleId><ArticleId IdType="pubmed">33183883</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher H.M., Lomer M.C.E., Anderson J.L., Barrett J.S., Muir J.G., Irving P.M., Whelan K. Fermentable Carbohydrate Restriction Reduces Luminal Bifidobacteria and Gastrointestinal Symptoms in Patients with Irritable Bowel Syndrome. J. Nutr. 2012;142:1510&#x2013;1518. doi: 10.3945/jn.112.159285.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/jn.112.159285</ArticleId><ArticleId IdType="pubmed">22739368</ArticleId></ArticleIdList></Reference><Reference><Citation>Huaman J.W., Mego M., Manichanh C., Ca&#xf1;ellas N., Ca&#xf1;ueto D., Segurola H., Jansana M., Malagelada C., Accarino A., Vulevic J., et al. Effects of Prebiotics vs a Diet Low in FODMAPs in Patients With Functional Gut Disorders. Gastroenterology. 2018;155:1004&#x2013;1007. doi: 10.1053/j.gastro.2018.06.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2018.06.045</ArticleId><ArticleId IdType="pubmed">29964041</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Feng L., Wang X., Fox M., Luo L., Du L., Chen B., Chen X., He H., Zhu S., et al. Low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet Compared with Traditional Dietary Advice for Diarrhea-Predominant Irritable Bowel Syndrome: A Parallel-Group, Randomized Controlled Trial with Analysis of Clinical and Micr. Am. J. Clin. Nutr. 2021;113:1531&#x2013;1545. doi: 10.1093/ajcn/nqab005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/nqab005</ArticleId><ArticleId IdType="pubmed">33740048</ArticleId></ArticleIdList></Reference><Reference><Citation>Hustoft T.N., Hausken T., Ystad S.O., Valeur J., Brokstad K., Hatlebakk J.G., Lied G.A. Effects of Varying Dietary Content of Fermentable Short-Chain Carbohydrates on Symptoms, Fecal Microenvironment, and Cytokine Profiles in Patients with Irritable Bowel Syndrome. Neurogastroenterol. Motil. 2017;29:e12969. doi: 10.1111/nmo.12969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12969</ArticleId><ArticleId IdType="pubmed">27747984</ArticleId></ArticleIdList></Reference><Reference><Citation>Halmos E.P., Christophersen C.T., Bird A.R., Shepherd S.J., Gibson P.R., Muir J.G. Diets That Differ in Their FODMAP Content Alter the Colonic Luminal Microenvironment. Gut. 2015;64:93&#x2013;100. doi: 10.1136/gutjnl-2014-307264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2014-307264</ArticleId><ArticleId IdType="pubmed">25016597</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennet S.M.P., B&#xf6;hn L., St&#xf6;rsrud S., Liljebo T., Collin L., Lindfors P., T&#xf6;rnblom H., &#xd6;hman L., Simr&#xe9;n M. Multivariate Modelling of Faecal Bacterial Profiles of Patients with IBS Predicts Responsiveness to a Diet Low in FODMAPs. Gut. 2018;67:872&#x2013;881. doi: 10.1136/gutjnl-2016-313128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2016-313128</ArticleId><ArticleId IdType="pubmed">28416515</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntosh K., Reed D.E., Schneider T., Dang F., Keshteli A.H., De Palma G., Madsen K., Bercik P., Vanner S. FODMAPs Alter Symptoms and the Metabolome of Patients with IBS: A Randomised Controlled Trial. Gut. 2017;66:1241&#x2013;1251. doi: 10.1136/gutjnl-2015-311339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-311339</ArticleId><ArticleId IdType="pubmed">26976734</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson B., Rossi M., Kanno T., Parkes G.C., Anderson S., Mason A.J., Irving P.M., Lomer M.C., Whelan K. &#x3b2;-Galactooligosaccharide in Conjunction with Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal Bifidobacteria. Am. J. Gastroenterol. 2020;115:906&#x2013;915. doi: 10.14309/ajg.0000000000000641.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000000641</ArticleId><ArticleId IdType="pubmed">32433273</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvie R.M., Chisholm A.W., Bisanz J.E., Burton J.P., Herbison P., Schultz K., Schultz M. Long-Term Irritable Bowel Syndrome Symptom Control with Reintroduction of Selected FODMAPs. World J. Gastroenterol. 2017;23:4632&#x2013;4643. doi: 10.3748/wjg.v23.i25.4632.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v23.i25.4632</ArticleId><ArticleId IdType="pmc">PMC5504379</ArticleId><ArticleId IdType="pubmed">28740352</ArticleId></ArticleIdList></Reference><Reference><Citation>Naseri K., Dabiri H., Rostami-Nejad M., Yadegar A., Houri H., Olfatifar M., Sadeghi A., Saadati S., Ciacci C., Iovino P., et al. Influence of Low FODMAP-Gluten Free Diet on Gut Microbiota Alterations and Symptom Severity in Iranian Patients with Irritable Bowel Syndrome. BMC Gastroenterol. 2021;21:292. doi: 10.1186/s12876-021-01868-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-021-01868-5</ArticleId><ArticleId IdType="pmc">PMC8278734</ArticleId><ArticleId IdType="pubmed">34261437</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellini M., Tonarelli S., Nagy A.G., Pancetti A., Costa F., Ricchiuti A., de Bortoli N., Mosca M., Marchi S., Rossi A. Low FODMAP Diet: Evidence, Doubts, and Hopes. Nutrients. 2020;12:148. doi: 10.3390/nu12010148.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12010148</ArticleId><ArticleId IdType="pmc">PMC7019579</ArticleId><ArticleId IdType="pubmed">31947991</ArticleId></ArticleIdList></Reference><Reference><Citation>Hills R.D., Pontefract B.A., Mishcon H.R., Black C.A., Sutton S.C., Theberge C.R. Gut Microbiome: Profound Implications for Diet and Disease. Nutrients. 2019;11:1613. doi: 10.3390/nu11071613.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11071613</ArticleId><ArticleId IdType="pmc">PMC6682904</ArticleId><ArticleId IdType="pubmed">31315227</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumann D., Klose P., Lauche R., Dobos G., Langhorst J., Cramer H. Low Fermentable, Oligo-, Di-, Mono-Saccharides and Polyol Diet in the Treatment of Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Nutrition. 2018;45:24&#x2013;31. doi: 10.1016/j.nut.2017.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nut.2017.07.004</ArticleId><ArticleId IdType="pubmed">29129233</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson P.R., Halmos E.P., Muir J.G. Review Article: FODMAPS, Prebiotics and Gut Health-the FODMAP Hypothesis Revisited. Aliment. Pharmacol. Ther. 2020;52:233&#x2013;246. doi: 10.1111/apt.15818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15818</ArticleId><ArticleId IdType="pubmed">32562590</ArticleId></ArticleIdList></Reference><Reference><Citation>Madempudi R.S., Neelamraju J., Ahire J.J., Gupta S.K., Shukla V.K. Bacillus Coagulans Unique IS2 in Constipation: A Double-Blind, Placebo-Controlled Study. Probiotics Antimicrob. Proteins. 2020;12:335&#x2013;342. doi: 10.1007/s12602-019-09542-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12602-019-09542-9</ArticleId><ArticleId IdType="pubmed">30911991</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A.K., Maity C. Efficacy and Safety of Bacillus Coagulans LBSC in Irritable Bowel Syndrome: A Prospective, Interventional, Randomized, Double-Blind, Placebo-Controlled Clinical Study [CONSORT Compliant] Medicine (Baltimore) 2021;100:e23641. doi: 10.1097/MD.0000000000023641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000023641</ArticleId><ArticleId IdType="pmc">PMC7837859</ArticleId><ArticleId IdType="pubmed">33545934</ArticleId></ArticleIdList></Reference><Reference><Citation>Eskesen D., Jespersen L., Michelsen B., Whorwell P.J., M&#xfc;ller-Lissner S., Morberg C.M. Effect of the Probiotic Strain Bifidobacterium Animalis Subsp. Lactis, BB-12&#xae;, on Defecation Frequency in Healthy Subjects with Low Defecation Frequency and Abdominal Discomfort: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Trial. Br. J. Nutr. 2015;114:1638&#x2013;1646. doi: 10.1017/S0007114515003347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0007114515003347</ArticleId><ArticleId IdType="pmc">PMC4657032</ArticleId><ArticleId IdType="pubmed">26382580</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Collinot G., Madrigal-Santill&#xe1;n E.O., Mart&#xed;nez-Bencomo M.A., Carranza-Muleiro R.A., Jara L.J., Vera-Lastra O., Montes-Cortes D.H., Medina G., Cruz-Dom&#xed;nguez M.P. Effectiveness of Saccharomyces Boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis. Dig. Dis. Sci. 2020;65:1134&#x2013;1143. doi: 10.1007/s10620-019-05830-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-019-05830-0</ArticleId><ArticleId IdType="pubmed">31549334</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar K., Saadi M., Ramsey F.V., Schey R., Parkman H.P. Effect of Bifidobacterium Infantis 35624 (Align) on the Lactulose Breath Test for Small Intestinal Bacterial Overgrowth. Dig. Dis. Sci. 2018;63:989&#x2013;995. doi: 10.1007/s10620-018-4945-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-018-4945-3</ArticleId><ArticleId IdType="pubmed">29397491</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojetti V., Petruzziello C., Migneco A., Gnarra M., Gasbarrini A., Franceschi F. Effect of Lactobacillus Reuteri (DSM 17938) on Methane Production in Patients Affected by Functional Constipation: A Retrospective Study. Eur. Rev. Med. Pharmacol. Sci. 2017;21:1702&#x2013;1708. doi: 10.1016/s0016-5085(17)33419-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0016-5085(17)33419-4</ArticleId><ArticleId IdType="pubmed">28429333</ArticleId></ArticleIdList></Reference><Reference><Citation>Majeed M., Nagabhushanam K., Natarajan S., Sivakumar A., Ali F., Pande A., Majeed S., Karri S.K. Bacillus Coagulans MTCC 5856 Supplementation in the Management of Diarrhea Predominant Irritable Bowel Syndrome: A Double Blind Randomized Placebo Controlled Pilot Clinical Study. Nutr. J. 2016;15:21. doi: 10.1186/s12937-016-0140-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12937-016-0140-6</ArticleId><ArticleId IdType="pmc">PMC4769834</ArticleId><ArticleId IdType="pubmed">26922379</ArticleId></ArticleIdList></Reference><Reference><Citation>Ducrott&#xe9; P., Sawant P., Jayanthi V. Clinical Trial: Lactobacillus Plantarum 299v (DSM 9843) Improves Symptoms of Irritable Bowel Syndrome. World J. Gastroenterol. 2012;18:4012&#x2013;4018. doi: 10.3748/wjg.v18.i30.4012.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v18.i30.4012</ArticleId><ArticleId IdType="pmc">PMC3419998</ArticleId><ArticleId IdType="pubmed">22912552</ArticleId></ArticleIdList></Reference><Reference><Citation>Gayathri R., Aruna T., Malar S., Shilpa B., Dhanasekar K.R. Efficacy of Saccharomyces Cerevisiae CNCM I-3856 as an Add-on Therapy for Irritable Bowel Syndrome. Int. J. Colorectal Dis. 2020;35:139&#x2013;145. doi: 10.1007/s00384-019-03462-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-019-03462-4</ArticleId><ArticleId IdType="pubmed">31807856</ArticleId></ArticleIdList></Reference><Reference><Citation>Akhondi-Meybodi M., Rahimian M., Salmanroghani H., Amirbeigy M., Baghbanian M., Ghelmani S. Study of the Effect of Probiotic Saccharomyces Boulardii on the Treatment of Irritable Bowel Syndrome. J. Biol. Today&#x2019;s World. 2014;3:152&#x2013;156. doi: 10.15412/J.JBTW.01030703.</Citation><ArticleIdList><ArticleId IdType="doi">10.15412/J.JBTW.01030703</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis E.D., Antony J.M., Crowley D.C., Piano A., Bhardwaj R., Tompkins T.A., Evans M. Efficacy of Lactobacillus Paracasei HA-196 and Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study. Nutrients. 2020;12:1159. doi: 10.3390/nu12041159.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12041159</ArticleId><ArticleId IdType="pmc">PMC7230591</ArticleId><ArticleId IdType="pubmed">32326347</ArticleId></ArticleIdList></Reference><Reference><Citation>Attar A., Flourie B., Rambaud J.C., Franchisseur C., Ruszniewski P., Bouhnik Y. Antibiotic Efficacy in Small Intestinal Bacterial Overgrowth-Related Chronic Diarrhea: A Crossover, Randomized Trial. Gastroenterology. 1999;117:794&#x2013;797. doi: 10.1016/S0016-5085(99)70336-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0016-5085(99)70336-7</ArticleId><ArticleId IdType="pubmed">10500060</ArticleId></ArticleIdList></Reference><Reference><Citation>Bubnov R.V., Babenko L.P., Lazarenko L.M., Mokrozub V.V., Spivak M.Y. Specific Properties of Probiotic Strains: Relevance and Benefits for the Host. EPMA J. 2018;9:205&#x2013;223. doi: 10.1007/s13167-018-0132-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13167-018-0132-z</ArticleId><ArticleId IdType="pmc">PMC5972142</ArticleId><ArticleId IdType="pubmed">29896319</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong C., Qu C., Wang B., Liang S., Zeng B. Probiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth. J. Clin. Gastroenterol. 2017;51:300&#x2013;311. doi: 10.1097/MCG.0000000000000814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0000000000000814</ArticleId><ArticleId IdType="pubmed">28267052</ArticleId></ArticleIdList></Reference><Reference><Citation>Saffouri G.B., Shields-Cutler R.R., Chen J., Yang Y., Lekatz H.R., Hale V.L., Cho J.M., Battaglioli E.J., Bhattarai Y., Thompson K.J., et al. Small Intestinal Microbial Dysbiosis Underlies Symptoms Associated with Functional Gastrointestinal Disorders. Nat. Commun. 2019;10:2012. doi: 10.1038/s41467-019-09964-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-09964-7</ArticleId><ArticleId IdType="pmc">PMC6494866</ArticleId><ArticleId IdType="pubmed">31043597</ArticleId></ArticleIdList></Reference><Reference><Citation>Niv E., Halak A., Tiommny E., Yanai H., Strul H., Naftali T., Vaisman N. Randomized Clinical Study: Partially Hydrolyzed Guar Gum (PHGG) versus Placebo in the Treatment of Patients with Irritable Bowel Syndrome. Nutr. Metab. 2016;13:10. doi: 10.1186/s12986-016-0070-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12986-016-0070-5</ArticleId><ArticleId IdType="pmc">PMC4744437</ArticleId><ArticleId IdType="pubmed">26855665</ArticleId></ArticleIdList></Reference><Reference><Citation>Reider S.J., Moosmang S., Tragust J., Trgovec-Greif L., Tragust S., Perschy L., Przysiecki N., Sturm S., Tilg H., Stuppner H., et al. Prebiotic Effects of Partially Hydrolyzed Guar Gum on the Composition and Function of the Human Microbiota&#x2014;Results from the PAGODA Trial. Nutrients. 2020;12:1257. doi: 10.3390/nu12051257.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12051257</ArticleId><ArticleId IdType="pmc">PMC7281958</ArticleId><ArticleId IdType="pubmed">32354152</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeros D., Beintaris I., Gaglia A., Karamanolis G., Papanikolaou I.S., Dimitriadis G., Triantafyllou K. Partially Hydrolyzed Guar Gum Accelerates Colonic Transit Time and Improves Symptoms in Adults with Chronic Constipation. Dig. Dis. Sci. 2014;59:2207&#x2013;2214. doi: 10.1007/s10620-014-3135-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-014-3135-1</ArticleId><ArticleId IdType="pubmed">24711073</ArticleId></ArticleIdList></Reference><Reference><Citation>Holscher H.D., Bauer L.L., Gourineni V., Pelkman C.L., Fahey G.C., Swanson K.S. Agave Inulin Supplementation Affects the Fecal Microbiota of Healthy Adults Participating in a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. J. Nutr. 2015;145:2025&#x2013;2032. doi: 10.3945/jn.115.217331.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/jn.115.217331</ArticleId><ArticleId IdType="pubmed">26203099</ArticleId></ArticleIdList></Reference><Reference><Citation>Linetzky Waitzberg D., Alves Pereira C.C., Logullo L., Manzoni Jacintho T., Almeida D., Teixeira da Silva M.d.L., Matos de Miranda Torrinha R.S. Microbiota Benefits after Inulin and Partially Hydrolized Guar Gum Supplementation: A Randomized Clinical Trial in Constipated Women. Nutr. Hosp. 2012;27:123&#x2013;129. doi: 10.1590/S0212-16112012000100014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S0212-16112012000100014</ArticleId><ArticleId IdType="pubmed">22566311</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskouie F.H., Vahedi H., Shahrbaf M.A., Sadeghi A., Rashidkhani B., Hekmatdoost A. Gastroenterology and Hepatology from Bed to Bench. Dietary Fiber and Risk of Irritable Bowel Syndrome: A Case-Control Study. Gastroenterol. Hepatol. Bed Bench. 2018;11:20&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6347982</ArticleId><ArticleId IdType="pubmed">30774803</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg P. Inflammation in Irritable Bowel Syndrome (IBS): Role of Psyllium Fiber Supplementation in Decreasing Inflammation and Physiological Management of IBS. Turk. J. Gastroenterol. 2021;32:108&#x2013;110. doi: 10.5152/tjg.2020.20229.</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/tjg.2020.20229</ArticleId><ArticleId IdType="pmc">PMC8975494</ArticleId><ArticleId IdType="pubmed">33893774</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginnebaugh B., Chey W.D., Saad R. Small Intestinal Bacterial Overgrowth: How to Diagnose and Treat (and Then Treat Again) Gastroenterol. Clin. N. Am. 2020;49:571&#x2013;587. doi: 10.1016/j.gtc.2020.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gtc.2020.04.010</ArticleId><ArticleId IdType="pubmed">32718571</ArticleId></ArticleIdList></Reference><Reference><Citation>Khayyatzadeh S.S., Kazemi-Bajestani S.M.R., Mirmousavi S.J., Heshmati M., Khoshmohabbat S., Ferns G.A., Ghayour-Mobarhan M. Dietary Behaviors in Relation to Prevalence of Irritable Bowel Syndrome in Adolescent Girls. J. Gastroenterol. Hepatol. 2018;33:404&#x2013;410. doi: 10.1111/jgh.13908.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.13908</ArticleId><ArticleId IdType="pubmed">28770579</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;hn L., St&#xf6;rsrud S., Liljebo T., Collin L., Lindfors P., T&#xf6;rnblom H., Simr&#xe9;n M. Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome as Well as Traditional Dietary Advice: A Randomized Controlled Trial. Gastroenterology. 2015;149:1399&#x2013;1407.e2. doi: 10.1053/j.gastro.2015.07.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2015.07.054</ArticleId><ArticleId IdType="pubmed">26255043</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaribaf F., Keshteli A.H., Esmaillzadeh A., Saneei P., Feizi A., Daghaghzadeh H., Feinle-Bisset C., Adibi P. Empirically Derived Dietary Habits Are Associated with Irritable Bowel Syndrome. Eur. J. Clin. Nutr. 2018;72:1537&#x2013;1547. doi: 10.1038/s41430-018-0109-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41430-018-0109-y</ArticleId><ArticleId IdType="pubmed">29535405</ArticleId></ArticleIdList></Reference><Reference><Citation>Vakhshuury M., Khoshdel A. The Relation between Dietary Patterns and Functional Gastrointestinal Disorders among Iranian Military Men. Adv. Biomed. Res. 2019;8:2. doi: 10.4103/abr.abr_180_18.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/abr.abr_180_18</ArticleId><ArticleId IdType="pmc">PMC6357671</ArticleId><ArticleId IdType="pubmed">30775344</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37686889</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6643</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>17</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>04</Day></PubDate></JournalIssue><Title>Nutrients</Title><ISOAbbreviation>Nutrients</ISOAbbreviation></Journal><ArticleTitle>Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3856</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nu15173856</ELocationID><Abstract><AbstractText>Irritable bowel syndrome (IBS) is a common gastrointestinal disease. The efficacy of different probiotics in treating IBS remains controversial. This network meta-analysis aimed to compare and rank the outcome-specific efficacy of different probiotic strains or combinations in adults with IBS. We searched the literature up to June 2023. Randomized controlled trials (RCTs) that evaluated the efficacy of probiotics in IBS were included. A frequentist framework was used to perform this study. In total, 9253 participants from 81 RCTs were included in the study. Four probiotic strains and five mixtures were significantly superior to placebo in improving IBS Symptom Severity Scale, among which <i>Lactobacillus acidophilus</i> DDS-1 ranked first (surface under the cumulative ranking, SUCRA, 92.9%). A mixture containing five probiotics (SUCRA, 100%) ranked first in improving the IBS-Quality of life. <i>Bacillus coagulans</i> MTCC 5856 (SUCRA, 96.9%) and <i>Bacillus coagulans</i> Unique IS2 (SUCRA, 92.6%) were among the most effective probiotics for improving abdominal pain. Three probiotic strains and two mixtures were effective in alleviating abdominal bloating. Four probiotic strains and a mixture were significantly superior to placebo in reducing the bowel movement frequency in diarrhea-predominant IBS (IBS-D). <i>Bacillus coagulans</i> MTCC 5856 (SUCRA, 99.6%) and <i>Saccharomyces cerevisiae</i> CNCM I-3856 (SUCRA, 89.7%) were among the most effective probiotics for improving the Bristol stool form scale of IBS-D. Only some probiotics are effective for particular outcomes in IBS patients. This study provided the first ranking of outcome-specific efficacy of different probiotic strains and combinations in IBS. Further studies are needed to confirm these results.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Peiwei</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Mei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Xuehong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Jiahui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Lishou</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>81970471</GrantID><Agency>the National Natural Science Foundation of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000099094">Network Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nutrients</MedlineTA><NlmUniqueID>101521595</NlmUniqueID><ISSNLinking>2072-6643</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015746" MajorTopicYN="N">Abdominal Pain</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000070000" MajorTopicYN="Y">Bacillus coagulans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012441" MajorTopicYN="N">Saccharomyces cerevisiae</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">efficacy</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">network meta-analysis</Keyword><Keyword MajorTopicYN="N">outcome</Keyword><Keyword MajorTopicYN="N">probiotic</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>9</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>9</Day><Hour>1</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37686889</ArticleId><ArticleId IdType="pmc">PMC10490209</ArticleId><ArticleId IdType="doi">10.3390/nu15173856</ArticleId><ArticleId IdType="pii">nu15173856</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ford A.C., Sperber A.D., Corsetti M., Camilleri M. Functional Gastrointestinal Disorders 2 Irritable bowel syndrome. Lancet. 2020;396:1675&#x2013;1688. doi: 10.1016/S0140-6736(20)31548-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31548-8</ArticleId><ArticleId IdType="pubmed">33049223</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka P., Parr H., Barberio B., Black C.J., Savarino E.V., Ford A.C. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2020;5:908&#x2013;917. doi: 10.1016/S2468-1253(20)30217-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30217-X</ArticleId><ArticleId IdType="pubmed">32702295</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperber A.D., Dumitrascu D., Fukudo S., Gerson C., Ghoshal U.C., Gwee K.A., Hungin A.P.S., Kang J.-Y., Minhu C., Schmulson M., et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: A Rome Foundation working team literature review. Gut. 2017;66:1075&#x2013;1082. doi: 10.1136/gutjnl-2015-311240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-311240</ArticleId><ArticleId IdType="pubmed">26818616</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodoory V.C., Ng C.E., Black C.J., Ford A.C. Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom. Aliment. Pharmacol. Ther. 2022;56:110&#x2013;120. doi: 10.1111/apt.16939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.16939</ArticleId><ArticleId IdType="pmc">PMC9325446</ArticleId><ArticleId IdType="pubmed">35491477</ArticleId></ArticleIdList></Reference><Reference><Citation>Peery A.F., Crockett S.D., Murphy C.C., Lund J.L., Dellon E.S., Williams J.L., Jensen E.T., Shaheen N.J., Barritt A.S., Lieber S.R., et al. Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018. Gastroenterology. 2019;156:254&#x2013;272. doi: 10.1053/j.gastro.2018.08.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2018.08.063</ArticleId><ArticleId IdType="pmc">PMC6689327</ArticleId><ArticleId IdType="pubmed">30315778</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F., Xiang W., Li C.Y., Li S.C. Economic burden of irritable bowel syndrome in China. World J. Gastroenterol. 2016;22:10450&#x2013;10460. doi: 10.3748/wjg.v22.i47.10450.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i47.10450</ArticleId><ArticleId IdType="pmc">PMC5175258</ArticleId><ArticleId IdType="pubmed">28058026</ArticleId></ArticleIdList></Reference><Reference><Citation>Canavan C., West J., Card T. Review article: The economic impact of the irritable bowel syndrome. Aliment. Pharmacol. Ther. 2014;40:1023&#x2013;1034. doi: 10.1111/apt.12938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.12938</ArticleId><ArticleId IdType="pubmed">25199904</ArticleId></ArticleIdList></Reference><Reference><Citation>Black C.J., Ford A.C. Global burden of irritable bowel syndrome: Trends, predictions and risk factors. Nat. Rev. Gastroenterol. Hepatol. 2020;17:473&#x2013;486. doi: 10.1038/s41575-020-0286-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-020-0286-8</ArticleId><ArticleId IdType="pubmed">32296140</ArticleId></ArticleIdList></Reference><Reference><Citation>Frandemark A., Tornblom H., Jakobsson S., Simren M. Work Productivity and Activity Impairment in Irritable Bowel Syndrome (IBS): A Multifaceted Problem. Am. J. Gastroenterol. 2018;113:1540&#x2013;1549. doi: 10.1038/s41395-018-0262-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41395-018-0262-x</ArticleId><ArticleId IdType="pubmed">30254230</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman D.A., Chang L., Schneck S., Blackman C., Norton W.F., Norton N.J. A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity. Dig. Dis. Sci. 2009;54:1532&#x2013;1541. doi: 10.1007/s10620-009-0792-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-009-0792-6</ArticleId><ArticleId IdType="pubmed">19337833</ArticleId></ArticleIdList></Reference><Reference><Citation>Raskov H., Burcharth J., Pommergaard H.-C., Rosenberg J. Irritable bowel syndrome, the microbiota and the gut-brain axis. Gut Microbes. 2016;7:365&#x2013;383. doi: 10.1080/19490976.2016.1218585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2016.1218585</ArticleId><ArticleId IdType="pmc">PMC5046167</ArticleId><ArticleId IdType="pubmed">27472486</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasant D.H., Paine P.A., Black C.J., Houghton L.A., Everitt H.A., Corsetti M., Agrawal A., Aziz I., Farmer A.D., Eugenicos M.P., et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70:1214&#x2013;1240. doi: 10.1136/gutjnl-2021-324598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324598</ArticleId><ArticleId IdType="pubmed">33903147</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson G.R., Roberfroid M.B. Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics. J. Nutr. 1995;125:1401&#x2013;1412. doi: 10.1093/jn/125.6.1401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jn/125.6.1401</ArticleId><ArticleId IdType="pubmed">7782892</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill C., Guarner F., Reid G., Gibson G.R., Merenstein D.J., Pot B., Morelli L., Canani R.B., Flint H.J., Salminen S., et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014;11:506&#x2013;514. doi: 10.1038/nrgastro.2014.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2014.66</ArticleId><ArticleId IdType="pubmed">24912386</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai T., Xu Z., Xia P., Feng Y., Liu B., Liu H., Chen Y., Yan G., Lv B., Yan Z., et al. The Short-Term Efficacy of Bifidobacterium Quadruple Viable Tablet in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: Potentially Mediated by Metabolism Rather Than Diversity Regulation. Am. J. Gastroenterol. 2022;118:1256&#x2013;1267. doi: 10.14309/ajg.0000000000002147.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000002147</ArticleId><ArticleId IdType="pubmed">36717369</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantis G., Efstathiou S., Pourzitaki C., Kitsikidou E., Germanidis G., Chourdakis M. Efficacy and safety of probiotics in the treatment of irritable bowel syndrome: A systematic review and meta-analysis of randomised clinical trials using ROME IV criteria. Clin. Nutr. 2023;42:800&#x2013;809. doi: 10.1016/j.clnu.2023.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2023.03.019</ArticleId><ArticleId IdType="pubmed">37031468</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Quigley E.M.M., Lacy B.E., Lembo A.J., Saito Y.A., Schiller L.R., Soffer E.E., Spiegel B.M.R., Moayyedi P. Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-analysis. Am. J. Gastroenterol. 2014;109:1547&#x2013;1561. doi: 10.1038/ajg.2014.202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2014.202</ArticleId><ArticleId IdType="pubmed">25070051</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy B.E., Pimentel M., Brenner D.M., Chey W.D., Keefer L.A., Long M.D., Moshiree B. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am. J. Gastroenterol. 2021;116:17&#x2013;44. doi: 10.14309/ajg.0000000000001036.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000001036</ArticleId><ArticleId IdType="pubmed">33315591</ArticleId></ArticleIdList></Reference><Reference><Citation>Su G.L., Ko C.W., Bercik P., Falck-Ytter Y., Sultan S., Weizman A.V., Morgan R.L. AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology. 2020;159:697&#x2013;705. doi: 10.1053/j.gastro.2020.05.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.05.059</ArticleId><ArticleId IdType="pubmed">32531291</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Harris L.A., Lacy B.E., Quigley E.M.M., Moayyedi P. Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2018;48:1044&#x2013;1060. doi: 10.1111/apt.15001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15001</ArticleId><ArticleId IdType="pubmed">30294792</ArticleId></ArticleIdList></Reference><Reference><Citation>Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton B., Salanti G., Caldwell D.M., Chaimani A., Schmid C.H., Cameron C., Ioannidis J.P.A., Straus S., Thorlund K., Jansen J.P., et al. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann. Intern. Med. 2015;162:777&#x2013;784. doi: 10.7326/M14-2385.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M14-2385</ArticleId><ArticleId IdType="pubmed">26030634</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis C.Y., Morris J., Whorwell P.J. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment. Pharmacol. Ther. 1997;11:395&#x2013;402. doi: 10.1046/j.1365-2036.1997.142318000.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.1997.142318000.x</ArticleId><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick D.L., Drossman D.A., Frederick I.O., Dicesare J., Puder K.L. Quality of life in persons with irritable bowel syndrome: Development and validation of a new measure. Dig. Dis. Sci. 1998;43:400&#x2013;411. doi: 10.1023/A:1018831127942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1018831127942</ArticleId><ArticleId IdType="pubmed">9512138</ArticleId></ArticleIdList></Reference><Reference><Citation>Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 1983;67:361&#x2013;370. doi: 10.1111/j.1600-0447.1983.tb09716.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0447.1983.tb09716.x</ArticleId><ArticleId IdType="pubmed">6880820</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne J.A.C., Savovi&#x107; J., Page M.J., Elbers R.G., Blencowe N.S., Boutron I., Cates C.J., Cheng H.Y., Corbett M.S., Eldridge S.M., et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l4898</ArticleId><ArticleId IdType="pubmed">31462531</ArticleId></ArticleIdList></Reference><Reference><Citation>Salanti G., Del Giovane C., Chaimani A., Caldwell D.M., Higgins J.P.T. Evaluating the Quality of Evidence from a Network Meta-Analysis. PLoS ONE. 2014;9:e99682. doi: 10.1371/journal.pone.0099682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0099682</ArticleId><ArticleId IdType="pmc">PMC4084629</ArticleId><ArticleId IdType="pubmed">24992266</ArticleId></ArticleIdList></Reference><Reference><Citation>Borenstein M., Hedges L.V., Higgins J.P.T., Rothstein H.R. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res. Synth. Methods. 2010;1:97&#x2013;111. doi: 10.1002/jrsm.12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jrsm.12</ArticleId><ArticleId IdType="pubmed">26061376</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J.P.T., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002;21:1539&#x2013;1558. doi: 10.1002/sim.1186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.1186</ArticleId><ArticleId IdType="pubmed">12111919</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaimani A., Higgins J.P.T., Mavridis D., Spyridonos P., Salanti G. Graphical Tools for Network Meta-Analysis in STATA. PLoS ONE. 2013;8:e76654. doi: 10.1371/journal.pone.0076654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0076654</ArticleId><ArticleId IdType="pmc">PMC3789683</ArticleId><ArticleId IdType="pubmed">24098547</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley R.D., Higgins J.P.T., Deeks J.J. Interpretation of random effects meta-analyses. BMJ. 2011;342:d549. doi: 10.1136/bmj.d549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d549</ArticleId><ArticleId IdType="pubmed">21310794</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias S., Welton N.J., Caldwell D.M., Ades A.E. Checking consistency in mixed treatment comparison meta-analysis. Stat. Med. 2010;29:932&#x2013;944. doi: 10.1002/sim.3767.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.3767</ArticleId><ArticleId IdType="pubmed">20213715</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J.P.T., Jackson D., Barrett J.K., Lu G., Ades A.E., White I.R. Consistency and inconsistency in network meta-analysis: Concepts and models for multi-arm studies. Res. Synth. Methods. 2012;3:98&#x2013;110. doi: 10.1002/jrsm.1044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jrsm.1044</ArticleId><ArticleId IdType="pmc">PMC4433772</ArticleId><ArticleId IdType="pubmed">26062084</ArticleId></ArticleIdList></Reference><Reference><Citation>White I.R. Network meta-analysis. Stata J. 2015;15:951&#x2013;985. doi: 10.1177/1536867X1501500403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1536867X1501500403</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaimani A., Salanti G. Visualizing assumptions and results in network meta-analysis: The network graphs package. Stata J. 2015;15:905&#x2013;950. doi: 10.1177/1536867X1501500402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1536867X1501500402</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan R.L., Preidis G.A., Kashyap P.C., Weizman A.V., Sadeghirad B., McMaster Probiotic Prebiotic S. Probiotics Reduce Mortality and Morbidity in Preterm, Low-Birth-Weight Infants: A Systematic Review and Network Meta-analysis of Randomized Trials. Gastroenterology. 2020;159:467&#x2013;480. doi: 10.1053/j.gastro.2020.05.096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.05.096</ArticleId><ArticleId IdType="pmc">PMC8014956</ArticleId><ArticleId IdType="pubmed">32592699</ArticleId></ArticleIdList></Reference><Reference><Citation>Mourey F., Decherf A., Jeanne J.-F., Clement-Ziza M., Grisoni M.-L., Machuron F., Legrain-Raspaud S., Bourreille A., Desreumaux P. Saccharomyces cerevisiae I-3856 in irritable bowel syndrome with predominant constipation. World J. Gastroenterol. 2022;28:2509&#x2013;2522. doi: 10.3748/wjg.v28.i22.2509.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v28.i22.2509</ArticleId><ArticleId IdType="pmc">PMC9258277</ArticleId><ArticleId IdType="pubmed">35979259</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung K., Kim A., Lee J.-H., Cho D., Seo J., Jung E.S., Kang H.-j., Roh J., Kim W. Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1 (TM)) on Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study. Nutrients. 2022;14:2015. doi: 10.3390/nu14102015.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14102015</ArticleId><ArticleId IdType="pmc">PMC9144213</ArticleId><ArticleId IdType="pubmed">35631156</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H., Ma C., Zhao F., Chen P., Liu Y., Sun Z., Cui L., Kwok L.-Y., Zhang H. Adjunctive treatment with probiotics partially alleviates symptoms and reduces inflammation in patients with irritable bowel syndrome. Eur. J. Nutr. 2021;60:2553&#x2013;2565. doi: 10.1007/s00394-020-02437-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00394-020-02437-4</ArticleId><ArticleId IdType="pubmed">33225399</ArticleId></ArticleIdList></Reference><Reference><Citation>Skrzydlo-Radomanska B., Prozorow-Krol B., Cichoz-Lach H., Majsiak E., Bierla J.B., Kanarek E., Sowniska A., Cukrowska B. The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study. Nutrients. 2021;13:756. doi: 10.3390/nu13030756.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13030756</ArticleId><ArticleId IdType="pmc">PMC7996889</ArticleId><ArticleId IdType="pubmed">33652763</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Yu X., Yu L., Tian F., Zhao J., Zhang H., Qian L., Wang Q., Xue Z., Zhai Q., et al. Lactobacillus plantarum CCFM8610 Alleviates Irritable Bowel Syndrome and Prevents Gut Microbiota Dysbiosis: A Randomized, Double-Blind, Placebo-Controlled, Pilot Clinical Trial. Engineering. 2021;7:376&#x2013;385. doi: 10.1016/j.eng.2020.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eng.2020.06.026</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A.K., Maity C. Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome A prospective, interventional, randomized, double-blind, placebo-controlled clinical study CONSORT Compliant. Medicine. 2021;100:e23641. doi: 10.1097/MD.0000000000023641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000023641</ArticleId><ArticleId IdType="pmc">PMC7837859</ArticleId><ArticleId IdType="pubmed">33545934</ArticleId></ArticleIdList></Reference><Reference><Citation>Barraza-Ortiz D.A., Perez-Lopez N., Medina-Lopez V.M., Minero-Alfaro J.I., Zamarripa-Dorsey F., Fernandez-Martinez N.d.C., Llorente-Ramon A., Ramos-Aguilar G.A. Combination of a Probiotic and an Antispasmodic Increases Quality of Life and Reduces Symptoms in Patients with Irritable Bowel Syndrome: A Pilot Study. Dig. Dis. 2021;39:294&#x2013;300. doi: 10.1159/000510950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000510950</ArticleId><ArticleId IdType="pubmed">32810850</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadrin S., Sennoune S., Gout B., Marque S., Moreau J., Zinoune K., Grillasca J.-P., Pons O., Maixent J.-M. A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial. Dig. Liver Dis. 2020;52:534&#x2013;540. doi: 10.1016/j.dld.2019.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2019.12.009</ArticleId><ArticleId IdType="pubmed">31952938</ArticleId></ArticleIdList></Reference><Reference><Citation>Martoni C.J., Srivastava S., Leyer G.J. Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial. Nutrients. 2020;12:363. doi: 10.3390/nu12020363.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12020363</ArticleId><ArticleId IdType="pmc">PMC7071206</ArticleId><ArticleId IdType="pubmed">32019158</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis E.D., Antony J.M., Crowley D.C., Piano A., Bhardwaj R., Tompkins T.A., Evans M. Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study. Nutrients. 2020;12:1159. doi: 10.3390/nu12041159.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12041159</ArticleId><ArticleId IdType="pmc">PMC7230591</ArticleId><ArticleId IdType="pubmed">32326347</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Cho K., Kim J.S., Jung H.C., Kim B., Park M.S., Ji G.E., Cho J.-Y., Hong K.S. Probiotic treatment induced change of inflammation related metabolites in IBS-D patients/double-blind, randomized, placebo-controlled trial. Food Sci. Biotechnol. 2020;29:837&#x2013;844. doi: 10.1007/s10068-019-00717-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10068-019-00717-2</ArticleId><ArticleId IdType="pmc">PMC7256134</ArticleId><ArticleId IdType="pubmed">32523793</ArticleId></ArticleIdList></Reference><Reference><Citation>Gayathri R., Aruna T., Malar S., Shilpa B., Dhanasekar K.R. Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndrome. Int. J. Color. Dis. 2020;35:139&#x2013;145. doi: 10.1007/s00384-019-03462-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-019-03462-4</ArticleId><ArticleId IdType="pubmed">31807856</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonfrate L., Di Palo D.M., Celano G., Albert A., Vitellio P., De Angelis M., Gobbetti M., Portincasa P. Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients. Eur. J. Clin. Investig. 2020;50:e13201. doi: 10.1111/eci.13201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13201</ArticleId><ArticleId IdType="pubmed">31960952</ArticleId></ArticleIdList></Reference><Reference><Citation>Andresen V., Gschossmann J., Layer P. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: A multicentre, randomised, double-blind, placebo-controlled clinical trial. Lancet Gastroenterol. Hepatol. 2020;5:658&#x2013;666. doi: 10.1016/S2468-1253(20)30056-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30056-X</ArticleId><ArticleId IdType="pubmed">32277872</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh J.H., Jang Y.S., Kang D., Chang D.K., Min Y.W. Efficacy and Safety of New Lactobacilli Probiotics for Unconstipated Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients. 2019;11:2887. doi: 10.3390/nu11122887.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11122887</ArticleId><ArticleId IdType="pmc">PMC6950464</ArticleId><ArticleId IdType="pubmed">31783597</ArticleId></ArticleIdList></Reference><Reference><Citation>Madempudi R.S., Ahire J.J., Neelamraju J., Tripathi A., Nanal S. Randomized clinical trial: The effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults. Sci. Rep. 2019;9:12210. doi: 10.1038/s41598-019-48554-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-48554-x</ArticleId><ArticleId IdType="pmc">PMC6704184</ArticleId><ArticleId IdType="pubmed">31434935</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashtiani S.Y., Amery M. Effect of Multispecies Probiotic Supplementation on Irritable Bowel Syndrome. J. Pharm. Res. Int. 2019;28:1&#x2013;9. doi: 10.9734/jpri/2019/v28i630221.</Citation><ArticleIdList><ArticleId IdType="doi">10.9734/jpri/2019/v28i630221</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y.-Y., Li M., Li Y.-Y., Li L.-X., Zhai W.-Z., Wang P., Yang X.-X., Gu X., Song L.-J., Li Z., et al. The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. Sci. Rep. 2018;8:2964. doi: 10.1038/s41598-018-21241-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-21241-z</ArticleId><ArticleId IdType="pmc">PMC5813237</ArticleId><ArticleId IdType="pubmed">29445178</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin S.P., Choi Y.M., Kim W.H., Hong S.P., Park J.-M., Kim J., Kwon O., Lee E.H., Hahm K.B. A double blind, placebo-controlled, randomized clinical trial that breast milk derived Lactobacillus gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome. J. Clin. Biochem. Nutr. 2018;62:179&#x2013;186. doi: 10.3164/jcbn.17-73.</Citation><ArticleIdList><ArticleId IdType="doi">10.3164/jcbn.17-73</ArticleId><ArticleId IdType="pmc">PMC5874236</ArticleId><ArticleId IdType="pubmed">29610559</ArticleId></ArticleIdList></Reference><Reference><Citation>Preston K., Krumian R., Hattner J., de Montigny D., Stewart M., Gaddam S. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: A double-blind, randomised, placebo-controlled study. Benef. Microbes. 2018;9:697&#x2013;706. doi: 10.3920/BM2017.0105.</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2017.0105</ArticleId><ArticleId IdType="pubmed">29888656</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.Y., Park Y.J., Lee H.J., Park M.Y., Kwon O. Effect of Lactobacillus gasseri BNR17 on irritable bowel syndrome: A randomized, double-blind, placebo-controlled, dose-finding trial. Food Sci. Biotechnol. 2018;27:853&#x2013;857. doi: 10.1007/s10068-017-0296-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10068-017-0296-7</ArticleId><ArticleId IdType="pmc">PMC6049675</ArticleId><ArticleId IdType="pubmed">30263811</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishaque S.M., Khosruzzaman S.M., Ahmed D.S., Sah M.P. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult (R)) in the management of diarrhea- predominant irritable bowel syndrome. BMC Gastroenterol. 2018;18:71. doi: 10.1186/s12876-018-0788-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-018-0788-9</ArticleId><ArticleId IdType="pmc">PMC5970461</ArticleId><ArticleId IdType="pubmed">29801486</ArticleId></ArticleIdList></Reference><Reference><Citation>Cremon C., Guglielmetti S., Gargari G., Taverniti V., Castellazzi A.M., Valsecchi C., Tagliacarne C., Fiore W., Bellini M., Bertani L., et al. Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. United Eur. Gastroenterol. J. 2018;6:604&#x2013;613. doi: 10.1177/2050640617736478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2050640617736478</ArticleId><ArticleId IdType="pmc">PMC5987284</ArticleId><ArticleId IdType="pubmed">29881616</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto-Sanchez M.I., Hall G.B., Ghajar K., Nardelli A., Bolino C., Lau J.T., Martin F.-P., Cominetti O., Welsh C., Rieder A., et al. Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. Gastroenterology. 2017;153:448&#x2013;459. doi: 10.1053/j.gastro.2017.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2017.05.003</ArticleId><ArticleId IdType="pubmed">28483500</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobutani K., Sawada D., Fujiwara S., Kuwano Y., Nishida K., Nakayama J., Kutsumi H., Azuma T., Rokutan K. The effects of administration of the Lactobacillus gasseri strain CP2305 on quality of life, clinical symptoms and changes in gene expression in patients with irritable bowel syndrome. J. Appl. Microbiol. 2017;122:212&#x2013;224. doi: 10.1111/jam.13329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jam.13329</ArticleId><ArticleId IdType="pubmed">27761980</ArticleId></ArticleIdList></Reference><Reference><Citation>Hod K., Sperber A.D., Ron Y., Boaz M., Dickman R., Berliner S., Halpern Z., Maharshak N., Dekel R. A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS. Neurogastroenterol. Motil. 2017;29:e13037. doi: 10.1111/nmo.13037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13037</ArticleId><ArticleId IdType="pubmed">28271623</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen A.Y., Clemens C.H.M., Vankerckhoven V., Goossens H., Jonkers D.M.A.E., Masclee A.A.M. Efficacy of Lactobacillus casei Shirota for patients with irritable bowel syndrome. Eur. J. Gastroenterol. Hepatol. 2016;28:8&#x2013;14. doi: 10.1097/MEG.0000000000000484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000000484</ArticleId><ArticleId IdType="pubmed">26469356</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller R., Pelerin F., Decherf A.C., Maudet C., Housez B., Cazaubiel M., Justen P. Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: Improvement in abdominal pain and bloating in those with predominant constipation. United Eur. Gastroenterol. J. 2016;4:353&#x2013;362. doi: 10.1177/2050640615602571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2050640615602571</ArticleId><ArticleId IdType="pmc">PMC4924426</ArticleId><ArticleId IdType="pubmed">27403301</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezzasalma V., Manfrini E., Ferri E., Sandionigi A., La Ferla B., Schiano I., Michelotti A., Nobile V., Labra M., Di Gennaro P. A Randomized, Double-Blind, Placebo-Controlled Trial: The Efficacy of Multispecies Probiotic Supplementation in Alleviating Symptoms of Irritable Bowel Syndrome Associated with Constipation. BioMed Res. Int. 2016;2016:4740907. doi: 10.1155/2016/4740907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/4740907</ArticleId><ArticleId IdType="pmc">PMC4993960</ArticleId><ArticleId IdType="pubmed">27595104</ArticleId></ArticleIdList></Reference><Reference><Citation>Majeed M., Nagabhushanam K., Natarajan S., Sivakumar A., Ali F., Pande A., Majeed S., Karri S.K. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: A double blind randomized placebo controlled pilot clinical study. Nutr. J. 2016;21:15&#x2013;25. doi: 10.1186/s12937-016-0140-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12937-016-0140-6</ArticleId><ArticleId IdType="pmc">PMC4769834</ArticleId><ArticleId IdType="pubmed">26922379</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyra A., Hillila M., Huttunen T., Mannikko S., Taalikka M., Tennila J., Tarpila A., Lahtinen S., Ouwehand A.C., Veijola L. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. World J. Gastroenterol. 2016;22:10631&#x2013;10642. doi: 10.3748/wjg.v22.i48.10631.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i48.10631</ArticleId><ArticleId IdType="pmc">PMC5192275</ArticleId><ArticleId IdType="pubmed">28082816</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon H., Park Y.S., Lee D.H., Seo J.-G., Shin C.M., Kim N. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. J. Clin. Biochem. Nutr. 2015;57:129&#x2013;134. doi: 10.3164/jcbn.15-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.3164/jcbn.15-14</ArticleId><ArticleId IdType="pmc">PMC4566021</ArticleId><ArticleId IdType="pubmed">26388670</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong R.K., Yang C., Song G.-H., Wong J., Ho K.-Y. Melatonin Regulation as a Possible Mechanism for Probiotic (VSL#3) in Irritable Bowel Syndrome: A Randomized Double-Blinded Placebo Study. Dig. Dis. Sci. 2015;60:186&#x2013;194. doi: 10.1007/s10620-014-3299-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-014-3299-8</ArticleId><ArticleId IdType="pubmed">25092036</ArticleId></ArticleIdList></Reference><Reference><Citation>de Chambrun G.P., Neut C., Chau A., Cazaubiel M., Pelerin F., Justen P., Desreumaux P. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Dig. Liver Dis. 2015;47:119&#x2013;124. doi: 10.1016/j.dld.2014.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2014.11.007</ArticleId><ArticleId IdType="pubmed">25488056</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon J.S., Sohn W., Lee O.Y., Lee S.P., Lee K.N., Jun D.W., Lee H.L., Yoon B.C., Choi H.S., Chung W.-S., et al. Effect of multispecies probiotics on irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. J. Gastroenterol. Hepatol. 2014;29:52&#x2013;59. doi: 10.1111/jgh.12322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.12322</ArticleId><ArticleId IdType="pubmed">23829297</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevenson C., Blaauw R., Fredericks E., Visser J., Roux S. Randomized clinical trial: Effect of Lactobacillus plantarum 299 v on symptoms of irritable bowel syndrome. Nutrition. 2014;30:1151&#x2013;1157. doi: 10.1016/j.nut.2014.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nut.2014.02.010</ArticleId><ArticleId IdType="pubmed">25194614</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisson G., Ayis S., Sherwood R.A., Bjarnason I. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome&#x2014;A 12 week double-blind study. Aliment. Pharmacol. Ther. 2014;40:51&#x2013;62. doi: 10.1111/apt.12787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.12787</ArticleId><ArticleId IdType="pubmed">24815298</ArticleId></ArticleIdList></Reference><Reference><Citation>Shavakhi A., Minakari M., Farzamnia S., Peykar M.S., Taghipour G., Tayebi A., Hashemi H., Shavakhi S. The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial. Adv. Biomed. Res. 2014;3:140. doi: 10.4103/2277-9175.135157.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2277-9175.135157</ArticleId><ArticleId IdType="pmc">PMC4139977</ArticleId><ArticleId IdType="pubmed">25161987</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludidi S., Jonkers D.M., Koning C.J., Kruimel J.W., Mulder L., Van der Vaart I.B., Conchillo J.M., Masclee A.A.M. Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients. Neurogastroenterol. Motil. 2014;26:705&#x2013;714. doi: 10.1111/nmo.12320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12320</ArticleId><ArticleId IdType="pubmed">24588932</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzo-Zuniga V., Llop E., Suarez C., Alvarez B., Abreu L., Espadaler J., Serra J.I. 31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J. Gastroenterol. 2014;20:8709&#x2013;8716. doi: 10.3748/wjg.v20.i26.8709.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i26.8709</ArticleId><ArticleId IdType="pmc">PMC4093724</ArticleId><ArticleId IdType="pubmed">25024629</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafari E., Vahedi H., Merat S., Momtahen S., Riahi A. Therapeutic Effects, Tolerability and Safety of a Multi-strain Probiotic in Iranian Adults with Irritable Bowel Syndrome and Bloating. Arch. Iran. Med. 2014;17:466&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">24979556</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbas Z., Yakoob J., Jafri W., Ahmad Z., Azam Z., Usman M.W., Shamim S., Islam M. Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: A randomized trial. Eur. J. Gastroenterol. Hepatol. 2014;26:630&#x2013;639. doi: 10.1097/MEG.0000000000000094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000000094</ArticleId><ArticleId IdType="pubmed">24722560</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts L.M., McCahon D., Holder R., Wilson S., Hobbs F.D.R. A randomised controlled trial of a probiotic &#x2018;functional food&#x2019; in the management of irritable bowel syndrome. BMC Gastroenterol. 2013;13:45. doi: 10.1186/1471-230X-13-45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-230X-13-45</ArticleId><ArticleId IdType="pmc">PMC3605320</ArticleId><ArticleId IdType="pubmed">23496803</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J., Rheem S., Yun B., Ahn Y., Joung J., Lee S.J., Oh S., Chun T., Rheem I., Yea H.S., et al. Effects of probiotic yoghurt on symptoms and intestinal microbiota in patients with irritable bowel syndrome. Int. J. Dairy Technol. 2013;66:243&#x2013;255. doi: 10.1111/1471-0307.12028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1471-0307.12028</ArticleId></ArticleIdList></Reference><Reference><Citation>Charbonneau D., Gibb R.D., Quigley E.M.M. Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes. 2013;4:201&#x2013;211. doi: 10.4161/gmic.24196.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/gmic.24196</ArticleId><ArticleId IdType="pmc">PMC3669165</ArticleId><ArticleId IdType="pubmed">23549409</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappello C., Tremolaterra F., Pascariello A., Ciacci C., Iovino P. A randomised clinical trial (RCT) of a symbiotic mixture in patients with irritable bowel syndrome (IBS): Effects on symptoms, colonic transit and quality of life. Int. J. Color. Dis. 2013;28:349&#x2013;358. doi: 10.1007/s00384-012-1552-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-012-1552-1</ArticleId><ArticleId IdType="pmc">PMC3587687</ArticleId><ArticleId IdType="pubmed">22885882</ArticleId></ArticleIdList></Reference><Reference><Citation>Begtrup L.M., de Muckadell O.B.S., Kjeldsen J., Christensen R.d., Jarbol D.E. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome&#x2014;A randomised, double-blind, placebo controlled trial. Scand. J. Gastroenterol. 2013;48:1127&#x2013;1135. doi: 10.3109/00365521.2013.825314.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365521.2013.825314</ArticleId><ArticleId IdType="pubmed">23957590</ArticleId></ArticleIdList></Reference><Reference><Citation>Amirimani B., Nikfam S., Albaji M., Vahedi S., Nasseri-Moghaddam S., Sharafkhah M., Ansari R., Vahedi H. Probiotic vs. Placebo in Irritable Bowel Syndrome:A Randomized Controlled Trial. Middle East J. Dig. Dis. 2013;5:98&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3990144</ArticleId><ArticleId IdType="pubmed">24829677</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruis W., Chrubasik S., Boehm S., Stange C., Schulze J. A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. Int. J. Color. Dis. 2012;27:467&#x2013;474. doi: 10.1007/s00384-011-1363-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-011-1363-9</ArticleId><ArticleId IdType="pmc">PMC3307993</ArticleId><ArticleId IdType="pubmed">22130826</ArticleId></ArticleIdList></Reference><Reference><Citation>Ducrotte P., Sawant P., Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J. Gastroenterol. 2012;18:4012&#x2013;4018. doi: 10.3748/wjg.v18.i30.4012.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v18.i30.4012</ArticleId><ArticleId IdType="pmc">PMC3419998</ArticleId><ArticleId IdType="pubmed">22912552</ArticleId></ArticleIdList></Reference><Reference><Citation>Dapoigny M., Piche T., Ducrotte P., Lunaud B., Cardot J.-M., Bernalier-Donadille A. Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: A randomized, double-blind study. World J. Gastroenterol. 2012;18:2067&#x2013;2075. doi: 10.3748/wjg.v18.i17.2067.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v18.i17.2067</ArticleId><ArticleId IdType="pmc">PMC3342605</ArticleId><ArticleId IdType="pubmed">22563194</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui S., Hu Y. Multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Int. J. Clin. Exp. Med. 2012;5:238&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3403550</ArticleId><ArticleId IdType="pubmed">22837798</ArticleId></ArticleIdList></Reference><Reference><Citation>Cha B.K., Jung S.M., Choi C.H., Song I.-D., Lee H.W., Kim H.J., Do J.H., Chang S.K., Kim K., Chung W.-S., et al. The Effect of a Multispecies Probiotic Mixture on the Symptoms and Fecal Microbiota in Diarrhea-dominant Irritable Bowel Syndrome A Randomized, Double-blind, Placebo-controlled Trial. J. Clin. Gastroenterol. 2012;46:220&#x2013;227. doi: 10.1097/MCG.0b013e31823712b1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0b013e31823712b1</ArticleId><ArticleId IdType="pubmed">22157240</ArticleId></ArticleIdList></Reference><Reference><Citation>Sondergaard B., Olsson J., Ohlson K., Svensson U., Bytzer P., Ekesbo R. Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: A randomized, placebo-controlled trial. Scand. J. Gastroenterol. 2011;46:663&#x2013;672. doi: 10.3109/00365521.2011.565066.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365521.2011.565066</ArticleId><ArticleId IdType="pubmed">21443416</ArticleId></ArticleIdList></Reference><Reference><Citation>Michail S., Kenche H. Gut Microbiota is Not Modified by Randomized, Double-Blind, Placebo-Controlled Trial of VSL#3 in Diarrhea-Predominant Irritable Bowel Syndrome. Probiotics Antimicrob. Proteins. 2011;3:1&#x2013;7. doi: 10.1007/s12602-010-9059-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12602-010-9059-y</ArticleId><ArticleId IdType="pmc">PMC3255476</ArticleId><ArticleId IdType="pubmed">22247743</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglielmetti S., Mora D., Gschwender M., Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life&#x2014;A double-blind, placebo-controlled study. Aliment. Pharmacol. Ther. 2011;33:1123&#x2013;1132. doi: 10.1111/j.1365-2036.2011.04633.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2011.04633.x</ArticleId><ArticleId IdType="pubmed">21418261</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi C.H., Jo S.Y., Park H.J., Chang S.K., Byeon J.-S., Myung S.-J. A Randomized, Double-blind, Placebo-controlled Multicenter Trial of Saccharomyces boulardii in Irritable Bowel Syndrome Effect on Quality of Life. J. Clin. Gastroenterol. 2011;45:679&#x2013;683. doi: 10.1097/MCG.0b013e318204593e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0b013e318204593e</ArticleId><ArticleId IdType="pubmed">21301358</ArticleId></ArticleIdList></Reference><Reference><Citation>Simren M., Ohman L., Olsson J., Svensson U., Ohlson K., Posserud I., Strid H. Clinical trial: The effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome&#x2014;A randomized, double-blind, controlled study. Aliment. Pharmacol. Ther. 2010;31:218&#x2013;227. doi: 10.1111/j.1365-2036.2009.04183.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2009.04183.x</ArticleId><ArticleId IdType="pubmed">19863495</ArticleId></ArticleIdList></Reference><Reference><Citation>Ligaarden S.C., Axelsson L., Naterstad K., Lydersen S., Farup P.G. A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: A randomised controlled trial. BMC Gastroenterol. 2010;10:16. doi: 10.1186/1471-230X-10-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-230X-10-16</ArticleId><ArticleId IdType="pmc">PMC2831047</ArticleId><ArticleId IdType="pubmed">20144246</ArticleId></ArticleIdList></Reference><Reference><Citation>Hun L. Original Research: Bacillus coagulans Significantly Improved Abdominal Pain and Bloating in Patients with IBS. Postgrad. Med. 2009;121:119&#x2013;124. doi: 10.3810/pgm.2009.03.1984.</Citation><ArticleIdList><ArticleId IdType="doi">10.3810/pgm.2009.03.1984</ArticleId><ArticleId IdType="pubmed">19332970</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong K.S., Kang H.W., Im J.P., Ji G.E., Kim S.G., Jung H.C., Song I.S., Kim J.S. Effect of Probiotics on Symptoms in Korean Adults with Irritable Bowel Syndrome. Gut Liver. 2009;3:101&#x2013;107. doi: 10.5009/gnl.2009.3.2.101.</Citation><ArticleIdList><ArticleId IdType="doi">10.5009/gnl.2009.3.2.101</ArticleId><ArticleId IdType="pmc">PMC2852694</ArticleId><ArticleId IdType="pubmed">20431731</ArticleId></ArticleIdList></Reference><Reference><Citation>Enck P., Zimmermann K., Menke G., Klosterhalfen S. Randomized Controlled Treatment Trial of Irritable Bowel Syndrome with a Probiotic E.-coli Preparation (DSM17252) Compared to Placebo. Z. F&#xfc;r Gastroenterol. 2009;47:209&#x2013;214. doi: 10.1055/s-2008-1027702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2008-1027702</ArticleId><ArticleId IdType="pubmed">19197823</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolin B.J. Effects of a proprietary bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find. Exp. Clin. Pharmacol. 2009;31:655&#x2013;659. doi: 10.1358/mf.2009.31.10.1441078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1358/mf.2009.31.10.1441078</ArticleId><ArticleId IdType="pubmed">20140275</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng J., Li Y.Q., Zuo X.L., Zhen Y.B., Yang J., Liu C.H. Clinical trial: Effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 2008;28:994&#x2013;1002. doi: 10.1111/j.1365-2036.2008.03818.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2008.03818.x</ArticleId><ArticleId IdType="pubmed">18671775</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams E.A., Stimpson J., Wang D., Plummer S., Garaiova I., Barker M.E., Corfe B.M. Clinical trial: A multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment. Pharmacol. Ther. 2008;29:97&#x2013;103. doi: 10.1111/j.1365-2036.2008.03848.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2008.03848.x</ArticleId><ArticleId IdType="pubmed">18785988</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinn D.H., Song J.H., Kim H.J., Lee J.H., Son H.J., Chang D.K., Kim Y.-H., Kim J.J., Rhee J.C., Rhee P.-L. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig. Dis. Sci. 2008;53:2714&#x2013;2718. doi: 10.1007/s10620-007-0196-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-007-0196-4</ArticleId><ArticleId IdType="pubmed">18274900</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajander K., Myllyluoma E., Rajilic-Stojanovic M., Kyronpalo S., Rasmussen M., Jarvenpaa S., Zoetendal E.G., De Vos W.M., Vapaatalo H., Korpela R. Clinical trial: Multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment. Pharmacol. Ther. 2008;27:48&#x2013;57. doi: 10.1111/j.1365-2036.2007.03542.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2007.03542.x</ArticleId><ArticleId IdType="pubmed">17919270</ArticleId></ArticleIdList></Reference><Reference><Citation>Enck P., Zimmermann K., Menke G., Mueller-Lissner S., Martens U., Klosterhalfen S. A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome&#x2014;A randomized controlled trial with primary care physicians. Neurogastroenterol. Motil. 2008;20:1103&#x2013;1109. doi: 10.1111/j.1365-2982.2008.01156.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2008.01156.x</ArticleId><ArticleId IdType="pubmed">18565142</ArticleId></ArticleIdList></Reference><Reference><Citation>Drouault-Holowacz S., Bieuvelet S., Burckel A., Cazaubiel M., Dray X., Marteau P. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol. Clin. Et Biol. 2008;32:147&#x2013;152. doi: 10.1016/j.gcb.2007.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gcb.2007.06.001</ArticleId><ArticleId IdType="pubmed">18387426</ArticleId></ArticleIdList></Reference><Reference><Citation>Andriulli A., Neri M., Loguercio C., Terreni N., Merla A., Cardarella M.P., Federico A., Chilovi F., Milandri G.L., De Bona M., et al. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome&#x2014;A multicenter, randomized study. J. Clin. Gastroenterol. 2008;42:S218&#x2013;S223. doi: 10.1097/MCG.0b013e31817fadd6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0b013e31817fadd6</ArticleId><ArticleId IdType="pubmed">18685503</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal A., Houghton L.A., Morris J., Reilly B., Guyonnet D., Feuillerat N.G., Schlumberger A., Jakob S., Whorwell P.J. Clinical trial: The effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther. 2008;29:104&#x2013;114. doi: 10.1111/j.1365-2036.2008.03853.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2008.03853.x</ArticleId><ArticleId IdType="pubmed">18801055</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyonnet D., Chassany O., Ducrotte P., Picard C., Mouret M., Mercier C.H., Matuchansky C. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: A multicentre, randomized, double-blind, controlled trial. Aliment. Pharmacol. Ther. 2007;26:475&#x2013;486. doi: 10.1111/j.1365-2036.2007.03362.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2007.03362.x</ArticleId><ArticleId IdType="pubmed">17635382</ArticleId></ArticleIdList></Reference><Reference><Citation>Whorwell P.J., Altringer L., Morel J., Bond Y., Charbonneau D., O&#x2019;Mahony L., Kiely B., Shanahan F., Quigley E.M.M. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am. J. Gastroenterol. 2006;101:1581&#x2013;1590. doi: 10.1111/j.1572-0241.2006.00734.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2006.00734.x</ArticleId><ArticleId IdType="pubmed">16863564</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahony L., McCarthy J., Kelly P., Hurley G., Luo F.Y., Chen K.S., O&#x2019;Sullivan G.C., Kiely B., Collins J.K., Shanahan F., et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541&#x2013;551. doi: 10.1053/j.gastro.2004.11.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2004.11.050</ArticleId><ArticleId IdType="pubmed">15765388</ArticleId></ArticleIdList></Reference><Reference><Citation>Niv E., Naftali T., Hallak R., Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome&#x2014;A double blind, placebo-controlled, randomized study. Clin. Nutr. 2005;24:925&#x2013;931. doi: 10.1016/j.clnu.2005.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2005.06.001</ArticleId><ArticleId IdType="pubmed">16051399</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.J., Roque M.I.V., Camilleri M., Stephens D., Burton D.D., Baxter K., Thomforde G., Zinsmeister A.R. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol. Motil. 2005;17:687&#x2013;696. doi: 10.1111/j.1365-2982.2005.00695.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2005.00695.x</ArticleId><ArticleId IdType="pubmed">16185307</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajander K., Hatakka K., Poussa T., Markkila M., Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: A controlled 6-month intervention. Aliment. Pharmacol. Ther. 2005;22:387&#x2013;394. doi: 10.1111/j.1365-2036.2005.02579.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2005.02579.x</ArticleId><ArticleId IdType="pubmed">16128676</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.J., Camilleri M., McKinzie S., Lempke M.B., Burton D.D., Thomforde G.M., Zinsmeister A.R. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 2003;17:895&#x2013;904. doi: 10.1046/j.1365-2036.2003.01543.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.2003.01543.x</ArticleId><ArticleId IdType="pubmed">12656692</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedzielin K., Kordecki H., Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur. J. Gastroenterol. Hepatol. 2001;13:1143&#x2013;1147. doi: 10.1097/00042737-200110000-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00042737-200110000-00004</ArticleId><ArticleId IdType="pubmed">11711768</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobaek S., Johansson M.L., Molin G., Ahrne S., Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am. J. Gastroenterol. 2000;95:1231&#x2013;1238. doi: 10.1111/j.1572-0241.2000.02015.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2000.02015.x</ArticleId><ArticleId IdType="pubmed">10811333</ArticleId></ArticleIdList></Reference><Reference><Citation>Suez J., Zmora N., Segal E., Elinav E. The pros, cons, and many unknowns of probiotics. Nat. Med. 2019;25:716&#x2013;729. doi: 10.1038/s41591-019-0439-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0439-x</ArticleId><ArticleId IdType="pubmed">31061539</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland L.V., Karakan T., Karatas A. Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. Eclinicalmedicine. 2021;41:101154. doi: 10.1016/j.eclinm.2021.101154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101154</ArticleId><ArticleId IdType="pmc">PMC8529205</ArticleId><ArticleId IdType="pubmed">34712929</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman D.A. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features, and Rome IV. Gastroenterology. 2016;150:1262&#x2013;1279. doi: 10.1053/j.gastro.2016.02.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.032</ArticleId><ArticleId IdType="pubmed">27144617</ArticleId></ArticleIdList></Reference><Reference><Citation>US Department of Health and Human Services Food and Drug Administration Center for Drug Evalution and Research (CDER)  Guidance for industry: Irritable Bowel Syndrome&#x2014;Clinical Evaluation of Drugs for Treatment.  [(accessed on 15 August 2023)];2012  Available online:  https://www.fda.gov/media/78622/download.</Citation></Reference><Reference><Citation>Bijkerk C.J., de Wit N.J., Muris J.W.M., Jones R.H., Knottnerus J.A., Hoes A.W. Outcome measures in irritable bowel syndrome: Comparison of psychometric and methodological characteristics. Am. J. Gastroenterol. 2003;98:122&#x2013;127. doi: 10.1111/j.1572-0241.2003.07158.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2003.07158.x</ArticleId><ArticleId IdType="pubmed">12526947</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrae D.A., Patrick D.L., Drossman D.A., Covington P.S. Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients. Health Qual. Life Outcomes. 2013;11:208. doi: 10.1186/1477-7525-11-208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7525-11-208</ArticleId><ArticleId IdType="pmc">PMC3895767</ArticleId><ArticleId IdType="pubmed">24330412</ArticleId></ArticleIdList></Reference><Reference><Citation>Midenfjord I., Borg A., Tornblom H., Simren M. Cumulative Effect of Psychological Alterations on Gastrointestinal Symptom Severity in Irritable Bowel Syndrome. Am. J. Gastroenterol. 2021;116:769&#x2013;779. doi: 10.14309/ajg.0000000000001038.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000001038</ArticleId><ArticleId IdType="pubmed">33982947</ArticleId></ArticleIdList></Reference><Reference><Citation>Lembo A., Sultan S., Chang L., Heidelbaugh J.J., Smalley W., Verne G.N. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome with Diarrhea. Gastroenterology. 2022;163:137&#x2013;153. doi: 10.1053/j.gastro.2022.04.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.04.017</ArticleId><ArticleId IdType="pubmed">35738725</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L., Sultan S., Lembo A., Verne G.N., Smalley W., Heidelbaugh J.J. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome with Constipation. Gastroenterology. 2022;163:118&#x2013;136. doi: 10.1053/j.gastro.2022.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.04.016</ArticleId><ArticleId IdType="pubmed">35738724</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T., Zhang C.Z., Zhang J.D., Sun F., Duan L.P. Efficacy of Probiotics for Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis. Front. Cell. Infect. Microbiol. 2022;12:349. doi: 10.3389/fcimb.2022.859967.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.859967</ArticleId><ArticleId IdType="pmc">PMC9010660</ArticleId><ArticleId IdType="pubmed">35433498</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39060737</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0065-2598</ISSN><JournalIssue CitedMedium="Print"><Volume>1449</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Advances in experimental medicine and biology</Title><ISOAbbreviation>Adv Exp Med Biol</ISOAbbreviation></Journal><ArticleTitle>Probiotics in Functional Gastrointestinal Disorders.</ArticleTitle><Pagination><StartPage>157</StartPage><EndPage>174</EndPage><MedlinePgn>157-174</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/978-3-031-58572-2_10</ELocationID><Abstract><AbstractText>The most frequent functional gastrointestinal disorders (FGID) in children include infantile colic, constipation, functional abdominal pain (FAP), and irritable bowel syndrome (IBS). Unfortunately, treatment options for FGID in children are limited, therefore many dietary interventions have been evaluated, including probiotics. This chapter summarizes currently available evidence and recommendations for probiotic use in the treatment of frequent FGIDs in children. The strongest evidence exists for the use of Limosilactobacillus (L.) reuteri DSM 17938 and Bifidobacterium animalis subsp. lactis BB-12 for the treatment of infantile colic in breastfed infants. Limited but yet encouraging evidence exists for Lacticaseibacillus rhamnosus GG (LGG) for the treatment of IBS and L. reuteri DSM 17938 for FAP.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s), under exclusive license to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hojsak</LastName><ForeName>Iva</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Referral Centre for Pediatric Gastroenterology and Nutrition, Children's Hospital Zagreb, Zagreb, Croatia. iva.hojsak@kdb.hr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Zagreb, School of Medicine, Zagreb, Croatia. iva.hojsak@kdb.hr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University J.J. Strossmayer, School of Medicine Osijek, Osijek, Croatia. iva.hojsak@kdb.hr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Adv Exp Med Biol</MedlineTA><NlmUniqueID>0121103</NlmUniqueID><ISSNLinking>0065-2598</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005767" MajorTopicYN="Y">Gastrointestinal Diseases</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052200" MajorTopicYN="N">Limosilactobacillus reuteri</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Functional abdominal pain</Keyword><Keyword MajorTopicYN="N">Infantile colic</Keyword><Keyword MajorTopicYN="N">Irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">Lactobacillus</Keyword><Keyword MajorTopicYN="N">Probiotics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>28</Day><Hour>14</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>27</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>26</Day><Hour>23</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39060737</ArticleId><ArticleId IdType="doi">10.1007/978-3-031-58572-2_10</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abbott RA, Martin AE, Newlove-Delgado TV, Bethel A, Whear RS, Coon JT, Logan S (2018) Recurrent abdominal pain in children: summary evidence from 3 systematic reviews of treatment effectiveness. J Pediatr Gastroenterol Nutr 67:23&#x2013;33. https://doi.org/10.1097/MPG.0000000000001922</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000001922</ArticleId><ArticleId IdType="pubmed">29470291</ArticleId></ArticleIdList></Reference><Reference><Citation>Anabrees J, Indrio F, Paes B, AlFaleh K (2013) Probiotics for infantile colic: a systematic review. BMC Pediatr 13:186. https://doi.org/10.1186/1471-2431-13-186</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2431-13-186</ArticleId><ArticleId IdType="pubmed">24238101</ArticleId><ArticleId IdType="pmc">4225660</ArticleId></ArticleIdList></Reference><Reference><Citation>Asburce OB, Sezer OB, Ozcay F (2013) Comparison of probiotic and lactulose treatments in children with functional constipation and determination of the effects of constipation treatment on quality of life [Turkish]. Cocuk Sagligi ve Hastaliklari Dergisi 56(1):1&#x2013;7</Citation></Reference><Reference><Citation>Assa A, Ish-Tov A, Rinawi F, Shamir R (2015) School attendance in children with functional abdominal pain and inflammatory bowel diseases. J Pediatr Gastroenterol Nutr 61(5):553&#x2013;557. https://doi.org/10.1097/MPG.0000000000000850</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000000850</ArticleId><ArticleId IdType="pubmed">25950089</ArticleId></ArticleIdList></Reference><Reference><Citation>Attaluri A, Jackson M, Valestin J, Rao SS (2010) Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS. Am J Gastroenterol 105(6):1407&#x2013;1411. https://doi.org/10.1038/ajg.2009.655</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2009.655</ArticleId><ArticleId IdType="pubmed">19953090</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldassarre ME, Di Mauro A, Tafuri S, Rizzo V, Gallone MS, Mastromarino P, Capobianco D, Laghi L, Zhu C, Capozza M, Laforgia N (2018) Effectiveness and safety of a probiotic-mixture for the treatment of infantile colic: a double-blind, randomized, placebo-controlled clinical trial with fecal real-time PCR and NMR-based metabolomics analysis. Nutrients 10(2):195. https://doi.org/10.3390/nu10020195</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu10020195</ArticleId><ArticleId IdType="pubmed">29439395</ArticleId><ArticleId IdType="pmc">5852771</ArticleId></ArticleIdList></Reference><Reference><Citation>Banaszkiewicz A, Szajewska H (2005) Ineffectiveness of Lactobacillus GG as an adjunct to lactulose for the treatment of constipation in children: a double-blind, placebo-controlled randomized trial. J Pediatr 146(3):364&#x2013;369. https://doi.org/10.1016/j.jpeds.2004.10.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2004.10.022</ArticleId><ArticleId IdType="pubmed">15756221</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar F, Von Koschitzky H, Roblick U, Bruch HP, Schulze L, Sonnenborn U, Bottner M, Wedel T (2009) Cell-free supernatants of Escherichia coli Nissle 1917 modulate human colonic motility: evidence from an in vitro organ bath study. Neurogastroenterol Motil 21(5):559&#x2013;566., e516-557. https://doi.org/10.1111/j.1365-2982.2008.01258.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2008.01258.x</ArticleId><ArticleId IdType="pubmed">19220758</ArticleId></ArticleIdList></Reference><Reference><Citation>Basturk A, Artan R, Yilmaz A (2016) Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: a randomized controlled trial. Turk J Gastroenterol 27(5):439&#x2013;443. https://doi.org/10.5152/tjg.2016.16301</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/tjg.2016.16301</ArticleId><ArticleId IdType="pubmed">27782892</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauserman M, Michail S (2005) The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr 147(2):197&#x2013;201. https://doi.org/10.1016/j.jpeds.2005.05.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2005.05.015</ArticleId><ArticleId IdType="pubmed">16126049</ArticleId></ArticleIdList></Reference><Reference><Citation>Benninga MA, Voskuijl WP, Taminiau JA (2004) Childhood constipation: is there new light in the tunnel? J Pediatr Gastroenterol Nutr 39(5):448&#x2013;464</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1536-4801.2004.tb00890.x</ArticleId><ArticleId IdType="pubmed">15572881</ArticleId></ArticleIdList></Reference><Reference><Citation>Benninga MA, Faure C, Hyman PE, St James Roberts I, Schechter NL, Nurko S (2016) Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology 150(6):1443&#x2013;1455. https://doi.org/10.1053/j.gastro.2016.02.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Biagioli E, Tarasco V, Lingua C, Moja L, Savino F (2016) Pain-relieving agents for infantile colic. Cochrane Database Syst Rev 9:CD009999. https://doi.org/10.1002/14651858.CD009999.pub2</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD009999.pub2</ArticleId><ArticleId IdType="pubmed">27631535</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonilla S, Saps M (2013) Early life events predispose the onset of childhood functional gastrointestinal disorders. Rev Gastroenterol Mex 78(2):82&#x2013;91. https://doi.org/10.1016/j.rgmx.2013.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rgmx.2013.02.001</ArticleId><ArticleId IdType="pubmed">23578567</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouhnik Y, Neut C, Raskine L, Michel C, Riottot M, Andrieux C, Guillemot F, Dyard F, Flourie B (2004) Prospective, randomized, parallel-group trial to evaluate the effects of lactulose and polyethylene glycol-4000 on colonic flora in chronic idiopathic constipation. Aliment Pharmacol Ther 19(8):889&#x2013;899. https://doi.org/10.1111/j.1365-2036.2004.01918.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2004.01918.x</ArticleId><ArticleId IdType="pubmed">15080850</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu LN, Chang MH, Ni YH, Chen HL, Cheng CC (2007) Lactobacillus casei rhamnosus Lcr35 in children with chronic constipation. Pediatr Int 49(4):485&#x2013;490. https://doi.org/10.1111/j.1442-200X.2007.02397.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1442-200X.2007.02397.x</ArticleId><ArticleId IdType="pubmed">17587273</ArticleId></ArticleIdList></Reference><Reference><Citation>Chau K, Lau E, Greenberg S, Jacobson S, Yazdani-Brojeni P, Verma N, Koren G (2015) Probiotics for infantile colic: a randomized, double-blind, placebo-controlled trial investigating Lactobacillus reuteri DSM 17938. J Pediatr 166(1):74&#x2013;78. https://doi.org/10.1016/j.jpeds.2014.09.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2014.09.020</ArticleId><ArticleId IdType="pubmed">25444531</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K, Zhang G, Xie H, You L, Li H, Zhang Y, Du C, Xu S, Melsaether C, Yuan S (2021) Efficacy of Bifidobacterium animalis subsp. lactis, BB-12((R)) on infant colic - a randomised, double-blinded, placebo-controlled study. Benef Microbes 12(6):531&#x2013;540. https://doi.org/10.3920/BM2020.0233</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2020.0233</ArticleId><ArticleId IdType="pubmed">34550055</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumpitazi BP, Cope JL, Hollister EB, Tsai CM, McMeans AR, Luna RA, Versalovic J, Shulman RJ (2015) Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Aliment Pharmacol Ther 42(4):418&#x2013;427. https://doi.org/10.1111/apt.13286</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.13286</ArticleId><ArticleId IdType="pubmed">26104013</ArticleId><ArticleId IdType="pmc">4514898</ArticleId></ArticleIdList></Reference><Reference><Citation>Coccorullo P, Strisciuglio C, Martinelli M, Miele E, Greco L, Staiano A (2010) Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study. J Pediatr 157(4):598&#x2013;602. https://doi.org/10.1016/j.jpeds.2010.04.066</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2010.04.066</ArticleId><ArticleId IdType="pubmed">20542295</ArticleId></ArticleIdList></Reference><Reference><Citation>de Meij TG, de Groot EF, Eck A, Budding AE, Kneepkens CM, Benninga MA, van Bodegraven AA, Savelkoul PH (2016) Characterization of microbiota in children with chronic functional constipation. PLoS One 11(10):e0164731. https://doi.org/10.1371/journal.pone.0164731</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0164731</ArticleId><ArticleId IdType="pubmed">27760208</ArticleId><ArticleId IdType="pmc">5070844</ArticleId></ArticleIdList></Reference><Reference><Citation>de Weerth C, Fuentes S, Puylaert P, de Vos WM (2013) Intestinal microbiota of infants with colic: development and specific signatures. Pediatrics 131(2):e550&#x2013;e558. https://doi.org/10.1542/peds.2012-1449</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2012-1449</ArticleId><ArticleId IdType="pubmed">23319531</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimidi E, Christodoulides S, Scott SM, Whelan K (2017) Mechanisms of action of probiotics and the gastrointestinal microbiota on gut motility and constipation. Adv Nutr 8(3):484&#x2013;494. https://doi.org/10.3945/an.116.014407</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/an.116.014407</ArticleId><ArticleId IdType="pubmed">28507013</ArticleId><ArticleId IdType="pmc">5421123</ArticleId></ArticleIdList></Reference><Reference><Citation>Dryl R, Szajewska H (2018) Probiotics for management of infantile colic: a systematic review of randomized controlled trials. Arch Med Sci 14(5):1137&#x2013;1143. https://doi.org/10.5114/aoms.2017.66055</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/aoms.2017.66055</ArticleId><ArticleId IdType="pubmed">30154898</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois NE, Gregory KE (2016) Characterizing the intestinal microbiome in infantile colic: findings based on an integrative review of the literature. Biol Res Nurs 18(3):307&#x2013;315. https://doi.org/10.1177/1099800415620840</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1099800415620840</ArticleId><ArticleId IdType="pubmed">26721871</ArticleId></ArticleIdList></Reference><Reference><Citation>Eftekhari K, Vahedi Z, Kamali Aghdam M, Noemi Diaz D (2015) A randomized double-blind placebo-controlled trial of lactobacillus reuteri for chronic functional abdominal pain in children. Iran J Pediatr 25(6):e2616. https://doi.org/10.5812/ijp.2616</Citation><ArticleIdList><ArticleId IdType="doi">10.5812/ijp.2616</ArticleId><ArticleId IdType="pubmed">26635937</ArticleId><ArticleId IdType="pmc">4662837</ArticleId></ArticleIdList></Reference><Reference><Citation>Faure C, Wieckowska A (2007) Somatic referral of visceral sensations and rectal sensory threshold for pain in children with functional gastrointestinal disorders. J Pediatr 150(1):66&#x2013;71. https://doi.org/10.1016/j.jpeds.2006.08.072</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2006.08.072</ArticleId><ArticleId IdType="pubmed">17188617</ArticleId></ArticleIdList></Reference><Reference><Citation>Francavilla R, Miniello V, Magista AM, De Canio A, Bucci N, Gagliardi F, Lionetti E, Castellaneta S, Polimeno L, Peccarisi L, Indrio F, Cavallo L (2010) A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics 126(6):e1445&#x2013;e1452. https://doi.org/10.1542/peds.2010-0467</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2010-0467</ArticleId><ArticleId IdType="pubmed">21078735</ArticleId></ArticleIdList></Reference><Reference><Citation>Gawronska A, Dziechciarz P, Horvath A, Szajewska H (2007) A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther 25(2):177&#x2013;184. https://doi.org/10.1111/j.1365-2036.2006.03175.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2006.03175.x</ArticleId><ArticleId IdType="pubmed">17229242</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannetti E, Staiano A (2016) Probiotics for irritable bowel syndrome: clinical data in children. J Pediatr Gastroenterol Nutr 63(Suppl 1):S25&#x2013;S26. https://doi.org/10.1097/MPG.0000000000001220</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000001220</ArticleId><ArticleId IdType="pubmed">27380595</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannetti E, Maglione M, Alessandrella A, Strisciuglio C, De Giovanni D, Campanozzi A, Miele E, Staiano A (2017) A mixture of 3 bifidobacteria decreases abdominal pain and improves the quality of life in children with irritable bowel syndrome: a multicenter, randomized, double-blind, placebo-controlled, crossover trial. J Clin Gastroenterol 51(1):e5&#x2013;e10. https://doi.org/10.1097/MCG.0000000000000528</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0000000000000528</ArticleId><ArticleId IdType="pubmed">27306945</ArticleId></ArticleIdList></Reference><Reference><Citation>Guandalini S, Magazzu G, Chiaro A, La Balestra V, Di Nardo G, Gopalan S, Sibal A, Romano C, Canani RB, Lionetti P, Setty M (2010) VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr 51(1):24&#x2013;30. https://doi.org/10.1097/MPG.0b013e3181ca4d95</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0b013e3181ca4d95</ArticleId><ArticleId IdType="pubmed">20453678</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerra PV, Lima LN, Souza TC, Mazochi V, Penna FJ, Silva AM, Nicoli JR, Guimaraes EV (2011) Pediatric functional constipation treatment with Bifidobacterium-containing yogurt: a crossover, double-blind, controlled trial. World J Gastroenterol 17(34):3916&#x2013;3921. https://doi.org/10.3748/wjg.v17.i34.3916</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v17.i34.3916</ArticleId><ArticleId IdType="pubmed">22025880</ArticleId><ArticleId IdType="pmc">3198021</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez-Castrellon P, Indrio F, Bolio-Galvis A, Jimenez-Gutierrez C, Jimenez-Escobar I, Lopez-Velazquez G (2017) Efficacy of Lactobacillus reuteri DSM 17938 for infantile colic: systematic review with network meta-analysis. Medicine 96(51):e9375. https://doi.org/10.1097/MD.0000000000009375</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000009375</ArticleId><ArticleId IdType="pubmed">29390535</ArticleId><ArticleId IdType="pmc">5758237</ArticleId></ArticleIdList></Reference><Reference><Citation>Hojsak I (2019) Probiotics in functional gastrointestinal disorders. Adv Exp Med Biol 1125:121&#x2013;137. https://doi.org/10.1007/5584_2018_321</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/5584_2018_321</ArticleId><ArticleId IdType="pubmed">30578460</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI (2001) Molecular analysis of commensal host-microbial relationships in the intestine. Science 291(5505):881&#x2013;884. https://doi.org/10.1126/science.291.5505.881</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.291.5505.881</ArticleId><ArticleId IdType="pubmed">11157169</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath A, Dziechciarz P, Szajewska H (2011) Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment Pharmacol Ther 33(12):1302&#x2013;1310. https://doi.org/10.1111/j.1365-2036.2011.04665.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2011.04665.x</ArticleId><ArticleId IdType="pubmed">21507030</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyams JS, Di Lorenzo C, Saps M, Shulman RJ, Staiano A, van Tilburg M (2016) Functional disorders: children and adolescents. Gastroenterology 150(6):1456&#x2013;1468. https://doi.org/10.1053/j.gastro.2016.02.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Indrio F, Dargenio VN, Francavilla R, Szajewska H, Vandenplas Y (2023) Infantile colic and long-term outcomes in childhood: a narrative synthesis of the evidence. Nutrients 15(3):615. https://doi.org/10.3390/nu15030615</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu15030615</ArticleId><ArticleId IdType="pubmed">36771322</ArticleId><ArticleId IdType="pmc">9921915</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadresin O, Hojsak I, Misak Z, Kekez AJ, Trbojevic T, Ivkovic L, Kolacek S (2017) Lactobacillus reuteri DSM 17938 in the treatment of functional abdominal pain in children: RCT study. J Pediatr Gastroenterol Nutr 64(6):925&#x2013;929. https://doi.org/10.1097/MPG.0000000000001478</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000001478</ArticleId><ArticleId IdType="pubmed">27906800</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadresin O, Sila S, Trivic I, Misak Z, Hojsak I, Kolacek S (2018) Lack of benefit of Lactobacillus reuteri DSM 17938 as an addition to the treatment of functional constipation. J Pediatr Gastroenterol Nutr 67(6):763&#x2013;766. https://doi.org/10.1097/MPG.0000000000002134</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000002134</ArticleId><ArticleId IdType="pubmed">30134331</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadresin O, Sila S, Trivic I, Misak Z, Kolacek S, Hojsak I (2020) Lactobacillus reuteri DSM 17938 is effective in the treatment of functional abdominal pain in children: results of the double-blind randomized study. Clin Nutr 39(12):3645&#x2013;3651. https://doi.org/10.1016/j.clnu.2020.04.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2020.04.019</ArticleId><ArticleId IdType="pubmed">32362486</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadre&#x161;in O, Sila S, Trivi&#x107; I, Mi&#x161;ak Z, Kola&#x10d;ek S, Hojsak I (2020) Lactobacillus reuteri DSM 17938 is effective in the treatment of functional abdominal pain in children: results of the double-blind randomized study. Clin Nutr S0261-5614(20):30190&#x2013;30194</Citation></Reference><Reference><Citation>Kianifar H, Jafari SA, Kiani M, Ahanchian H, Ghasemi SV, Grover Z, Mahmoodi LZ, Bagherian R, Khalesi M (2015) Probiotic for irritable bowel syndrome in pediatric patients: a randomized controlled clinical trial. Electron Physician 7(5):1255&#x2013;1260. https://doi.org/10.14661/1255</Citation><ArticleIdList><ArticleId IdType="doi">10.14661/1255</ArticleId><ArticleId IdType="pubmed">26435825</ArticleId><ArticleId IdType="pmc">4590561</ArticleId></ArticleIdList></Reference><Reference><Citation>Koppen IJN, Vriesman MH, Saps M, Rajindrajith S, Shi X, van Etten-Jamaludin FS, Di Lorenzo C, Benninga MA, Tabbers MM (2018) Prevalence of functional defecation disorders in children: a systematic review and meta-analysis. J Pediatr 198:121&#x2013;130. https://doi.org/10.1016/j.jpeds.2018.02.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2018.02.029</ArticleId><ArticleId IdType="pubmed">29656863</ArticleId></ArticleIdList></Reference><Reference><Citation>Korterink J, Devanarayana NM, Rajindrajith S, Vlieger A, Benninga MA (2015) Childhood functional abdominal pain: mechanisms and management. Nat Rev Gastroenterol Hepatol 12(3):159&#x2013;171. https://doi.org/10.1038/nrgastro.2015.21</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2015.21</ArticleId><ArticleId IdType="pubmed">25666642</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubota M, Ito K, Tomimoto K, Kanazaki M, Tsukiyama K, Kubota A, Kuroki H, Fujita M, Vandenplas Y (2020) Lactobacillus reuteri DSM 17938 and magnesium oxide in children with functional chronic constipation: a double-blind and randomized clinical trial. Nutrients 12(1):225. https://doi.org/10.3390/nu12010225</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12010225</ArticleId><ArticleId IdType="pubmed">31952280</ArticleId><ArticleId IdType="pmc">7019518</ArticleId></ArticleIdList></Reference><Reference><Citation>Landgren K, Hallstrom I (2011) Parents&#x2019; experience of living with a baby with infantile colic--a phenomenological hermeneutic study. Scand J Caring Sci 25(2):317&#x2013;324. https://doi.org/10.1111/j.1471-6712.2010.00829.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-6712.2010.00829.x</ArticleId><ArticleId IdType="pubmed">20723153</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Hagiwara SI, Bhargava A (2017) Early-life adversity, epigenetics, and visceral hypersensitivity. Neurogastroenterol Motil 29(9):13170. https://doi.org/10.1111/nmo.13170</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13170</ArticleId></ArticleIdList></Reference><Reference><Citation>Loughman A, Quinn T, Nation ML, Reichelt A, Moore RJ, Van TTH, Sung V, Tang MLK (2021) Infant microbiota in colic: predictive associations with problem crying and subsequent child behavior. J Dev Orig Health Dis 12(2):260&#x2013;270. https://doi.org/10.1017/S2040174420000227</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S2040174420000227</ArticleId><ArticleId IdType="pubmed">32279681</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucassen P (2015) Colic in infants. BMJ Clin Evid 2015:0309</Citation><ArticleIdList><ArticleId IdType="pubmed">26581647</ArticleId><ArticleId IdType="pmc">4531337</ArticleId></ArticleIdList></Reference><Reference><Citation>Maragkoudaki M, Chouliaras G, Orel R, Horvath A, Szajewska H, Papadopoulou A (2017) Lactobacillus reuteri DSM 17938 and a placebo both significantly reduced symptoms in children with functional abdominal pain. Acta Paediatr 106(11):1857&#x2013;1862. https://doi.org/10.1111/apa.13992</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.13992</ArticleId><ArticleId IdType="pubmed">28712129</ArticleId></ArticleIdList></Reference><Reference><Citation>McHarg AS, Leach S (2022) The role of the gut microbiome in paediatric irritable bowel syndrome. AIMS Microbiol 8(4):454&#x2013;469. https://doi.org/10.3934/microbiol.2022030</Citation><ArticleIdList><ArticleId IdType="doi">10.3934/microbiol.2022030</ArticleId><ArticleId IdType="pubmed">36694592</ArticleId><ArticleId IdType="pmc">9834077</ArticleId></ArticleIdList></Reference><Reference><Citation>Mi GL, Zhao L, Qiao DD, Kang WQ, Tang MQ, Xu JK (2015) Effectiveness of Lactobacillus reuteri in infantile colic and colicky induced maternal depression: a prospective single blind randomized trial. Antonie Van Leeuwenhoek 107(6):1547&#x2013;1553. https://doi.org/10.1007/s10482-015-0448-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10482-015-0448-9</ArticleId><ArticleId IdType="pubmed">25876529</ArticleId></ArticleIdList></Reference><Reference><Citation>Nocerino R, De Filippis F, Cecere G, Marino A, Micillo M, Di Scala C, de Caro C, Calignano A, Bruno C, Paparo L, Iannicelli AM, Cosenza L, Maddalena Y, Della Gatta G, Coppola S, Carucci L, Ercolini D, Berni Canani R (2020) The therapeutic efficacy of Bifidobacterium animalis subsp. lactis BB-12((R)) in infant colic: a randomised, double blind, placebo-controlled trial. Aliment Pharmacol Ther 51(1):110&#x2013;120. https://doi.org/10.1111/apt.15561</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15561</ArticleId><ArticleId IdType="pubmed">31797399</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohman L, Simren M (2013) Intestinal microbiota and its role in irritable bowel syndrome (IBS). Curr Gastroenterol Rep 15(5):323. https://doi.org/10.1007/s11894-013-0323-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11894-013-0323-7</ArticleId><ArticleId IdType="pubmed">23580243</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong TG, Gordon M, Banks SS, Thomas MR, Akobeng AK (2019) Probiotics to prevent infantile colic. Cochrane Database Syst Rev 3(3):Cd012473. https://doi.org/10.1002/14651858.CD012473.pub2</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD012473.pub2</ArticleId><ArticleId IdType="pubmed">30865287</ArticleId></ArticleIdList></Reference><Reference><Citation>Partty A, Kalliomaki M (2017) Infant colic is still a mysterious disorder of the microbiota-gut-brain axis. Acta Paediatr 106(4):528&#x2013;529. https://doi.org/10.1111/apa.13754</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.13754</ArticleId><ArticleId IdType="pubmed">28318126</ArticleId></ArticleIdList></Reference><Reference><Citation>Partty A, Kalliomaki M, Endo A, Salminen S, Isolauri E (2012) Compositional development of Bifidobacterium and Lactobacillus microbiota is linked with crying and fussing in early infancy. PLoS One 7(3):e32495. https://doi.org/10.1371/journal.pone.0032495</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0032495</ArticleId><ArticleId IdType="pubmed">22403665</ArticleId><ArticleId IdType="pmc">3293811</ArticleId></ArticleIdList></Reference><Reference><Citation>Partty A, Lehtonen L, Kalliomaki M, Salminen S, Isolauri E (2015) Probiotic Lactobacillus rhamnosus GG therapy and microbiological programming in infantile colic: a randomized, controlled trial. Pediatr Res 78(4):470&#x2013;475. https://doi.org/10.1038/pr.2015.127</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/pr.2015.127</ArticleId><ArticleId IdType="pubmed">26151493</ArticleId></ArticleIdList></Reference><Reference><Citation>Partty A, Kalliomaki M, Salminen S, Isolauri E (2017) Infantile colic is associated with low-grade systemic inflammation. J Pediatr Gastroenterol Nutr 64(5):691&#x2013;695. https://doi.org/10.1097/MPG.0000000000001340</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000001340</ArticleId><ArticleId IdType="pubmed">27478897</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Burgos A, Wang L, McVey Neufeld KA, Mao YK, Ahmadzai M, Janssen LJ, Stanisz AM, Bienenstock J, Kunze WA (2015) The TRPV1 channel in rodents is a major target for antinociceptive effect of the probiotic Lactobacillus reuteri DSM 17938. J Physiol 593(17):3943&#x2013;3957. https://doi.org/10.1113/JP270229</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP270229</ArticleId><ArticleId IdType="pubmed">26084409</ArticleId><ArticleId IdType="pmc">4575579</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmani P, Ghouran-Orimi A, Motamed F, Moradzadeh A (2020) Evaluating the effects of probiotics in pediatrics with recurrent abdominal pain. Clin Exp Pediatr 63(12):485&#x2013;490. https://doi.org/10.3345/cep.2019.01613</Citation><ArticleIdList><ArticleId IdType="doi">10.3345/cep.2019.01613</ArticleId><ArticleId IdType="pubmed">32718147</ArticleId><ArticleId IdType="pmc">7738771</ArticleId></ArticleIdList></Reference><Reference><Citation>Rej A, Shaw CC, Buckle RL, Trott N, Agrawal A, Mosey K, Sanders K, Allen R, Martin S, Newton A, Robinson K, Elphick D, Chey WD, Aziz I, Sanders DS (2021) The low FODMAP diet for IBS; A multicentre UK study assessing long term follow up. Dig Liver Dis 53(11):1404&#x2013;1411. https://doi.org/10.1016/j.dld.2021.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2021.05.004</ArticleId><ArticleId IdType="pubmed">34083153</ArticleId></ArticleIdList></Reference><Reference><Citation>Rexwinkel R, Vlieger AM, Saps M, Tabbers MM, Benninga MA (2022) A therapeutic guide on pediatric irritable bowel syndrome and functional abdominal pain-not otherwise specified. Eur J Pediatr 181(7):2603&#x2013;2617. https://doi.org/10.1007/s00431-022-04459-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-022-04459-y</ArticleId><ArticleId IdType="pubmed">35460383</ArticleId><ArticleId IdType="pmc">9192445</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano C, Ferrau V, Cavataio F, Iacono G, Spina M, Lionetti E, Comisi F, Famiani A, Comito D (2014) Lactobacillus reuteri in children with functional abdominal pain (FAP). J Paediatr Child Health 50(10):E68&#x2013;E71. https://doi.org/10.1111/j.1440-1754.2010.01797.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1754.2010.01797.x</ArticleId><ArticleId IdType="pubmed">20626584</ArticleId></ArticleIdList></Reference><Reference><Citation>Roos S, Dicksved J, Tarasco V, Locatelli E, Ricceri F, Grandin U, Savino F (2013) 454 pyrosequencing analysis on faecal samples from a randomized DBPC trial of colicky infants treated with Lactobacillus reuteri DSM 17938. PLoS One 8(2):e56710. https://doi.org/10.1371/journal.pone.0056710</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0056710</ArticleId><ArticleId IdType="pubmed">23468874</ArticleId><ArticleId IdType="pmc">3585302</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo M, Giugliano FP, Quitadamo P, Mancusi V, Miele E, Staiano A (2017) Efficacy of a mixture of probiotic agents as complementary therapy for chronic functional constipation in childhood. Ital J Pediatr 43(1):24. https://doi.org/10.1186/s13052-017-0334-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13052-017-0334-3</ArticleId><ArticleId IdType="pubmed">28270173</ArticleId><ArticleId IdType="pmc">5341202</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbi T (2011) The use of lactobacillus GG in children with functional abdominal pain: a double-blind randomized control trial. Clin Nutr Suppl 6:198</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1744-1161(11)70513-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghzadeh M, Rabieefar A, Khoshnevisasl P, Mousavinasab N, Eftekhari K (2014) The effect of probiotics on childhood constipation: a randomized controlled double blind clinical trial. Int J Pediatr 2014:937212. https://doi.org/10.1155/2014/937212</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/937212</ArticleId><ArticleId IdType="pubmed">24812563</ArticleId><ArticleId IdType="pmc">4000641</ArticleId></ArticleIdList></Reference><Reference><Citation>Savino F, Cordisco L, Tarasco V, Palumeri E, Calabrese R, Oggero R, Roos S, Matteuzzi D (2010) Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics 126(3):e526&#x2013;e533. https://doi.org/10.1542/peds.2010-0433</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2010-0433</ArticleId><ArticleId IdType="pubmed">20713478</ArticleId></ArticleIdList></Reference><Reference><Citation>Savino F, Ceratto S, De Marco A, Cordero di Montezemolo L (2014) Looking for new treatments of Infantile Colic. Ital J Pediatr 40:53. https://doi.org/10.1186/1824-7288-40-53</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1824-7288-40-53</ArticleId><ArticleId IdType="pubmed">24898541</ArticleId><ArticleId IdType="pmc">4050441</ArticleId></ArticleIdList></Reference><Reference><Citation>Savino F, Garro M, Montanari P, Galliano I, Bergallo M (2018) Crying time and RORgamma/FOXP3 expression in Lactobacillus reuteri DSM17938-treated infants with colic: a randomized trial. J Pediatr 192:171&#x2013;177 e171. https://doi.org/10.1016/j.jpeds.2017.08.062</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2017.08.062</ArticleId><ArticleId IdType="pubmed">28969887</ArticleId></ArticleIdList></Reference><Reference><Citation>Savino F, Galliano I, Savino A, Dapra V, Montanari P, Calvi C, Bergallo M (2019) Lactobacillus reuteri DSM 17938 probiotics may increase CC-chemokine receptor 7 expression in infants treated with for colic. Front Pediatr 7:292. https://doi.org/10.3389/fped.2019.00292</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2019.00292</ArticleId><ArticleId IdType="pubmed">31380326</ArticleId><ArticleId IdType="pmc">6646728</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreck Bird A, Gregory PJ, Jalloh MA, Risoldi Cochrane Z, Hein DJ (2017) Probiotics for the treatment of infantile colic: a systematic review. J Pharm Pract 30(3):366&#x2013;374. https://doi.org/10.1177/0897190016634516</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0897190016634516</ArticleId><ArticleId IdType="pubmed">26940647</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonson J, Haglund K, Weber E, Fial A, Hanson L (2021) Probiotics for the management of infantile colic: a systematic review. MCN Am J Matern Child Nurs 46(2):88&#x2013;96. https://doi.org/10.1097/nmc.0000000000000691</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/nmc.0000000000000691</ArticleId><ArticleId IdType="pubmed">33315632</ArticleId></ArticleIdList></Reference><Reference><Citation>Skonieczna-&#x17b;ydecka K, Janda K, Kaczmarczyk M, Marlicz W, &#x141;oniewski I, &#x141;oniewska B (2020) The effect of probiotics on symptoms, gut microbiota and inflammatory markers in infantile colic: a systematic review, meta-analysis and meta-regression of randomized controlled trials. J Clin Med 9(4):999. https://doi.org/10.3390/jcm9040999</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9040999</ArticleId><ArticleId IdType="pubmed">32252419</ArticleId><ArticleId IdType="pmc">7231167</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith C, Nordstrom E, Sengupta JN, Miranda A (2007) Neonatal gastric suctioning results in chronic visceral and somatic hyperalgesia: role of corticotropin releasing factor. Neurogastroenterol Motil 19(8):692&#x2013;699. https://doi.org/10.1111/j.1365-2982.2007.00949.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2007.00949.x</ArticleId><ArticleId IdType="pubmed">17640185</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares AC, Lederman HM, Fagundes-Neto U, de Morais MB (2005) Breath methane associated with slow colonic transit time in children with chronic constipation. J Clin Gastroenterol 39(6):512&#x2013;515</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.mcg.0000165665.94777.bd</ArticleId><ArticleId IdType="pubmed">15942438</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudha MR, Jayanthi N, Aasin M, Dhanashri RD, Anirudh T (2018) Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled study. Benef Microbes 9(4):563&#x2013;572. https://doi.org/10.3920/BM2017.0129</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2017.0129</ArticleId><ArticleId IdType="pubmed">29695183</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung V, Hiscock H, Tang M, Mensah FK, Heine RG, Stock A, York E, Barr RG, Wake M (2012) Probiotics to improve outcomes of colic in the community: protocol for the Baby Biotics randomised controlled trial. BMC Pediatr 12:135. https://doi.org/10.1186/1471-2431-12-135</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2431-12-135</ArticleId><ArticleId IdType="pubmed">22928654</ArticleId><ArticleId IdType="pmc">3508922</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung V, Hiscock H, Tang ML, Mensah FK, Nation ML, Satzke C, Heine RG, Stock A, Barr RG, Wake M (2014) Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial. BMJ 348:g2107. https://doi.org/10.1136/bmj.g2107</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.g2107</ArticleId><ArticleId IdType="pubmed">24690625</ArticleId><ArticleId IdType="pmc">3972414</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung V, D&#x2019;Amico F, Cabana MD, Chau K, Koren G, Savino F, Szajewska H, Deshpande G, Dupont C, Indrio F, Mentula S, Partty A, Tancredi D (2018) Lactobacillus reuteri to Treat Infant Colic: A meta-analysis. Pediatrics 141(1):e20171811. https://doi.org/10.1542/peds.2017-1811</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2017-1811</ArticleId><ArticleId IdType="pubmed">29279326</ArticleId></ArticleIdList></Reference><Reference><Citation>Szajewska H, Gyrczuk E, Horvath A (2013) Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind, placebo-controlled trial. J Pediatr 162(2):257&#x2013;262. https://doi.org/10.1016/j.jpeds.2012.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2012.08.004</ArticleId><ArticleId IdType="pubmed">22981952</ArticleId></ArticleIdList></Reference><Reference><Citation>Szajewska H, Berni Canani R, Domellof M, Guarino A, Hojsak I, Indrio F, Lo Vecchio A, Mihatsch WA, Mosca A, Orel R, Salvatore S, Shamir R, van den Akker CHP, van Goudoever JB, Vandenplas Y, Weizman Z, Microbiota ESIGoG, Modifications (2023) Probiotics for the management of pediatric gastrointestinal disorders: position paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications. J Pediatr Gastroenterol Nutr 76(2):232&#x2013;247. https://doi.org/10.1097/MPG.0000000000003633</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000003633</ArticleId><ArticleId IdType="pubmed">36219218</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabbers MM, Chmielewska A, Roseboom MG, Crastes N, Perrin C, Reitsma JB, Norbruis O, Szajewska H, Benninga MA (2011) Fermented milk containing Bifidobacterium lactis DN-173 010 in childhood constipation: a randomized, double-blind, controlled trial. Pediatrics 127(6):e1392&#x2013;e1399. https://doi.org/10.1542/peds.2010-2590</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2010-2590</ArticleId><ArticleId IdType="pubmed">21606153</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabbers MM, DiLorenzo C, Berger MY, Faure C, Langendam MW, Nurko S, Staiano A, Vandenplas Y, Benninga MA, European Society for Pediatric Gastroenterology H, Nutrition, North American Society for Pediatric G (2014) Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr 58(2):258&#x2013;274. https://doi.org/10.1097/MPG.0000000000000266</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000000266</ArticleId><ArticleId IdType="pubmed">24345831</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivic I, Hojsak I (2018) Initial diagnosis of functional gastrointestinal disorders in children increases a chance for resolution of symptoms. Pediatr Gastroenterol Hepatol Nutr 21:264</Citation><ArticleIdList><ArticleId IdType="doi">10.5223/pghn.2018.21.4.264</ArticleId><ArticleId IdType="pubmed">30345239</ArticleId><ArticleId IdType="pmc">6182488</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivic I, Niseteo T, Jadresin O, Hojsak I (2021) Use of probiotics in the treatment of functional abdominal pain in children-systematic review and meta-analysis. Eur J Pediatr 180(2):339&#x2013;351. https://doi.org/10.1007/s00431-020-03809-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-020-03809-y</ArticleId><ArticleId IdType="pubmed">32940743</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Schoot A, Helander C, Whelan K, Dimidi E (2022) Probiotics and synbiotics in chronic constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Clin Nutr 41(12):2759&#x2013;2777. https://doi.org/10.1016/j.clnu.2022.10.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2022.10.015</ArticleId><ArticleId IdType="pubmed">36372047</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenplas Y, Gutierrez-Castrellon P, Velasco-Benitez C, Palacios J, Jaen D, Ribeiro H, Shek LP, Lee BW, Alarcon P (2013) Practical algorithms for managing common gastrointestinal symptoms in infants. Nutrition 29(1):184&#x2013;194. https://doi.org/10.1016/j.nut.2012.08.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nut.2012.08.008</ArticleId><ArticleId IdType="pubmed">23137717</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanuytsel T, Bercik P, Boeckxstaens G (2023) Understanding neuroimmune interactions in disorders of gut-brain interaction: from functional to immune-mediated disorders. Gut 72(4):787&#x2013;798. https://doi.org/10.1136/gutjnl-2020-320633</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-320633</ArticleId><ArticleId IdType="pubmed">36657961</ArticleId></ArticleIdList></Reference><Reference><Citation>Vulin K, Hojsak I (2015) Infantile colic - newer approach to an old problem. Lijec Vjesn 137(11&#x2013;12):367&#x2013;372</Citation><ArticleIdList><ArticleId IdType="pubmed">26975067</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsham AD, MacKenzie DA, Cook V, Wemyss-Holden S, Hews CL, Juge N, Schuller S (2016) Lactobacillus reuteri inhibition of enteropathogenic Escherichia coli adherence to human intestinal epithelium. Front Microbiol 7:244. https://doi.org/10.3389/fmicb.2016.00244</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2016.00244</ArticleId><ArticleId IdType="pubmed">26973622</ArticleId><ArticleId IdType="pmc">4771767</ArticleId></ArticleIdList></Reference><Reference><Citation>Warschburger P, Hanig J, Friedt M, Posovszky C, Schier M, Calvano C (2014) Health-related quality of life in children with abdominal pain due to functional or organic gastrointestinal disorders. J Pediatr Psychol 39(1):45&#x2013;54. https://doi.org/10.1093/jpepsy/jst070</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpepsy/jst070</ArticleId><ArticleId IdType="pubmed">24055816</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegh CAM, Baaleman DF, Tabbers MM, Smidt H, Benninga MA (2022) Nonpharmacologic treatment for children with functional constipation: a systematic review and meta-analysis. J Pediatr 240(136&#x2013;149):e135. https://doi.org/10.1016/j.jpeds.2021.09.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2021.09.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegner A, Banaszkiewicz A, Kierkus J, Landowski P, Korlatowicz-Bilar A, Wiecek S, Kwiecien J, Gawronska A, Dembinski L, Czaja-Bulsa G, Socha P (2018) The effectiveness of Lactobacillus reuteri DSM 17938 as an adjunct to macrogol in the treatment of functional constipation in children. A randomized, double-blind, placebo-controlled, multicentre trial. Clin Res Hepatol Gastroenterol 42(5):494&#x2013;500. https://doi.org/10.1016/j.clinre.2018.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinre.2018.03.008</ArticleId><ArticleId IdType="pubmed">29650440</ArticleId></ArticleIdList></Reference><Reference><Citation>Weizman Z, Abu-Abed J, Binsztok M (2016) Lactobacillus reuteri DSM 17938 for the management of functional abdominal pain in childhood: a randomized, double-blind, placebo-controlled trial. J Pediatr 174:160&#x2013;164 e161. https://doi.org/10.1016/j.jpeds.2016.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2016.04.003</ArticleId><ArticleId IdType="pubmed">27156182</ArticleId></ArticleIdList></Reference><Reference><Citation>Wojtyniak K, Horvath A, Dziechciarz P, Szajewska H (2017) Lactobacillus casei rhamnosus Lcr35 in the management of functional constipation in children: a randomized trial. J Pediatr 184:101&#x2013;105 e101. https://doi.org/10.1016/j.jpeds.2017.01.068</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2017.01.068</ArticleId><ArticleId IdType="pubmed">28284477</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu HL, Zou LL, Chen MB, Wang H, Shen WM, Zheng QH, Cui WY (2021) Efficacy of probiotic adjuvant therapy for irritable bowel syndrome in children: a systematic review and meta-analysis. PLoS One 16(8):e0255160. https://doi.org/10.1371/journal.pone.0255160</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0255160</ArticleId><ArticleId IdType="pubmed">34358238</ArticleId><ArticleId IdType="pmc">8345868</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeevenhooven J, Koppen IJ, Benninga MA (2017) The new Rome IV criteria for functional gastrointestinal disorders in infants and toddlers. Pediatr Gastroenterol Hepatol Nutr 20(1):1&#x2013;13. https://doi.org/10.5223/pghn.2017.20.1.1</Citation><ArticleIdList><ArticleId IdType="doi">10.5223/pghn.2017.20.1.1</ArticleId><ArticleId IdType="pubmed">28401050</ArticleId><ArticleId IdType="pmc">5385301</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35951774</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1949-0984</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Gut microbes</Title><ISOAbbreviation>Gut Microbes</ISOAbbreviation></Journal><ArticleTitle>The double-edged sword of probiotic supplementation on gut microbiota structure in <i>Helicobacter pylori</i> management.</ArticleTitle><Pagination><StartPage>2108655</StartPage><MedlinePgn>2108655</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2108655</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/19490976.2022.2108655</ELocationID><Abstract><AbstractText>As <i>Helicobacter pylori</i> management has become more challenging and less efficient over the last decade, the interest in innovative interventions is growing by the day. Probiotic co-supplementation to antibiotic therapies is reported in several studies, presenting a moderate reduction in drug-related side effects and a promotion in positive treatment outcomes. However, the significance of gut microbiota involvement in the competence of probiotic co-supplementation is emphasized by a few researchers, indicating the alteration in the host gastrointestinal microbiota following probiotic and drug uptake. Due to the lack of long-term follow-up studies to determine the efficiency of probiotic intervention in <i>H. pylori</i> eradication, and the delicate interaction of the gut microbiota with the host wellness, this review aims to discuss the gut microbiota alteration by probiotic co-supplementation in <i>H. pylori</i> management to predict the comprehensive effectiveness of probiotic oral administration.<b>Abbreviations</b>: acyl-CoA- acyl-coenzyme A; AMP- antimicrobial peptide; AMPK- AMP-activated protein kinase; AP-1- activator protein 1; BA- bile acid; BAR- bile acid receptor; BCAA- branched-chain amino acid; C2- acetate; C3- propionate; C4- butyrate; C5- valeric acid; CagA- Cytotoxin-associated gene A; cAMP- cyclic adenosine monophosphate; CD- Crohn's disease; CDI- C. difficile infection; COX-2- cyclooxygenase-2; DC- dendritic cell; EMT- epithelial-mesenchymal transition; FMO- flavin monooxygenases; FXR- farnesoid X receptor; GPBAR1- G-protein-coupled bile acid receptor 1; GPR4- G protein-coupled receptor 4; H2O2- hydrogen peroxide; HCC- hepatocellular carcinoma; HSC- hepatic stellate cell; IBD- inflammatory bowel disease; IBS- irritable bowel syndrome; IFN-&#x3b3;- interferon-gamma; IgA immunoglobulin A; IL- interleukin; iNOS- induced nitric oxide synthase; JAK1- janus kinase 1; JAM-A- junctional adhesion molecule A; LAB- lactic acid bacteria; LPS- lipopolysaccharide; MALT- mucosa-associated lymphoid tissue; MAMP- microbe-associated molecular pattern; MCP-1- monocyte chemoattractant protein-1; MDR- multiple drug resistance; mTOR- mammalian target of rapamycin; MUC- mucin; NAFLD- nonalcoholic fatty liver disease; NF-&#x3ba;B- nuclear factor kappa B; NK- natural killer; NLRP3- NLR family pyrin domain containing 3; NOC- N-nitroso compounds; NOD- nucleotide-binding oligomerization domain; PICRUSt- phylogenetic investigation of communities by reconstruction of unobserved states; PRR- pattern recognition receptor; RA- retinoic acid; RNS- reactive nitrogen species; ROS- reactive oxygen species; rRNA- ribosomal RNA; SCFA- short-chain fatty acids; SDR- single drug resistance; SIgA- secretory immunoglobulin A; STAT3- signal transducer and activator of transcription 3; T1D- type 1 diabetes; T2D- type 2 diabetes; Th17- T helper 17; TLR- toll-like receptor; TMAO- trimethylamine N-oxide; TML- trimethyllysine; TNF-&#x3b1;- tumor necrosis factor-alpha; Tr1- type 1 regulatory T cell; Treg- regulatory T cell; UC- ulcerative colitis; VacA- Vacuolating toxin A.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nabavi-Rad</LastName><ForeName>Ali</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7799-9404</Identifier><AffiliationInfo><Affiliation>Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadeghi</LastName><ForeName>Amir</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asadzadeh Aghdaei</LastName><ForeName>Hamid</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yadegar</LastName><ForeName>Abbas</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2135-7581</Identifier><AffiliationInfo><Affiliation>Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Sin&#xe9;ad Marian</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0003-3460-3590</Identifier><AffiliationInfo><Affiliation>Department of Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zali</LastName><ForeName>Mohammad Reza</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Gut Microbes</MedlineTA><NlmUniqueID>101495343</NlmUniqueID><ISSNLinking>1949-0976</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001647">Bile Acids and Salts</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C473772">GPBAR1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043562">Receptors, G-Protein-Coupled</NameOfSubstance></Chemical><Chemical><RegistryNumber>BBX060AN9V</RegistryNumber><NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001647" MajorTopicYN="N">Bile Acids and Salts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006528" MajorTopicYN="Y">Carcinoma, Hepatocellular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016360" MajorTopicYN="Y">Clostridioides difficile</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016480" MajorTopicYN="Y">Helicobacter pylori</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015212" MajorTopicYN="Y">Inflammatory Bowel Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008113" MajorTopicYN="Y">Liver Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043562" MajorTopicYN="N">Receptors, G-Protein-Coupled</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Helicobacter pylori</Keyword><Keyword MajorTopicYN="N">gastric cancer</Keyword><Keyword MajorTopicYN="N">gastrointestinal microbiota</Keyword><Keyword MajorTopicYN="N">gut metabolome</Keyword><Keyword MajorTopicYN="N">intestinal homeostasis</Keyword><Keyword MajorTopicYN="N">metabolic disorder</Keyword><Keyword MajorTopicYN="N">probiotic supplementation</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>11</Day><Hour>15</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35951774</ArticleId><ArticleId IdType="pmc">PMC9373750</ArticleId><ArticleId IdType="doi">10.1080/19490976.2022.2108655</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Miller AK, Williams SM.. Helicobacter pylori infection causes both protective and deleterious effects in human health and disease. Genes Immun. 2021;22(4):218&#x2013;34. doi:10.1038/s41435-021-00146-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41435-021-00146-4</ArticleId><ArticleId IdType="pmc">PMC8390445</ArticleId><ArticleId IdType="pubmed">34244666</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabavi-Rad A, Azizi M, Jamshidizadeh S, Sadeghi A, Aghdaei HA, Yadegar A, Zali MR. The effects of vitamins and micronutrients on helicobacter pylori pathogenicity, survival, and eradication: a crosstalk between micronutrients and immune system. J Immunol Res. 2022;2022:4713684. doi:10.1155/2022/4713684.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/4713684</ArticleId><ArticleId IdType="pmc">PMC8942682</ArticleId><ArticleId IdType="pubmed">35340586</ArticleId></ArticleIdList></Reference><Reference><Citation>Senchukova MA, Tomchuk O, Shurygina EI. Helicobacter pylori in gastric cancer: features of infection and their correlations with long-term results of treatment. World J Gastroenterol. 2021;27(37):6290&#x2013;6305. doi:10.3748/wjg.v27.i37.6290.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v27.i37.6290</ArticleId><ArticleId IdType="pmc">PMC8515796</ArticleId><ArticleId IdType="pubmed">34712033</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, Ito H, Kawamura M, Ogata Y, Ohtaka M, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69(6):1019. doi:10.1136/gutjnl-2019-319954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2019-319954</ArticleId><ArticleId IdType="pmc">PMC7282559</ArticleId><ArticleId IdType="pubmed">31915235</ArticleId></ArticleIdList></Reference><Reference><Citation>Malfertheiner P, Megraud F, O&#x2019;Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6&#x2013;30. doi:10.1136/gutjnl-2016-312288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2016-312288</ArticleId><ArticleId IdType="pubmed">27707777</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu WZ, Xie Y, Lu H, Cheng H, Zeng ZR, Zhou LY, Chen Y, Wang JB, Du YQ, Lu NH, et al. Fifth Chinese national consensus report on the management of Helicobacter pylori infection. Helicobacter. 2018;23(2):e12475. doi:10.1111/hel.12475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hel.12475</ArticleId><ArticleId IdType="pubmed">29512258</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyssen OP, Bordin D, Tepes B, P&#xe9;rez-Aisa &#xc1;, Vaira D, Caldas M, Bujanda L, Castro-Fernandez M, Lerang F, Leja M, et al. European registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21&#x2009;533 patients. Gut. 2021;70(1):40. doi:10.1136/gutjnl-2020-321372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-321372</ArticleId><ArticleId IdType="pubmed">32958544</ArticleId></ArticleIdList></Reference><Reference><Citation>McNicholl AG, Molina-Infante J, Lucendo AJ, Calleja JL, P&#xe9;rez&#x2010;Aisa &#xc1;, Modolell I, Aldeguer X, Calafat M, Comino L, Ramas M, et al. Probiotic supplementation with lactobacillus plantarum and pediococcus acidilactici for Helicobacter pylori therapy: a randomized, double-blind, placebo-controlled trial. Helicobacter. 2018;23(5):e12529. doi:10.1111/hel.12529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hel.12529</ArticleId><ArticleId IdType="pubmed">30141228</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham M, Azcarate-Peril MA, Barnard A. Shaping the Future of Probiotics and Prebiotics. Trends Microbiol. 2021;29(8):667&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">33551269</ArticleId></ArticleIdList></Reference><Reference><Citation>Goderska K, Agudo Pena S, Alarcon T. Helicobacter pylori treatment: antibiotics or probiotics. Appl Microbiol Biotechnol. 2018;102(1):1&#x2013;7. doi:10.1007/s00253-017-8535-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00253-017-8535-7</ArticleId><ArticleId IdType="pmc">PMC5748437</ArticleId><ArticleId IdType="pubmed">29075827</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraris C, Elli M, Tagliabue A. Gut microbiota for health: how can diet maintain a healthy gut microbiota? Nutrients. 2020;12(11):3596. doi:10.3390/nu12113596.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12113596</ArticleId><ArticleId IdType="pmc">PMC7700621</ArticleId><ArticleId IdType="pubmed">33238627</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vos WM, Tilg H, Van Hul M, Cani PD. Gut microbiome and health: mechanistic insights. Gut. 2022;71(5):1020&#x2013;1032. doi:10.1136/gutjnl-2021-326789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-326789</ArticleId><ArticleId IdType="pmc">PMC8995832</ArticleId><ArticleId IdType="pubmed">35105664</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillman ET, Lu H, Yao T, Nakatsu CH. Microbial ecology along the gastrointestinal tract. Microbes Environ. 2017;32(4):300&#x2013;313. doi:10.1264/jsme2.ME17017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1264/jsme2.ME17017</ArticleId><ArticleId IdType="pmc">PMC5745014</ArticleId><ArticleId IdType="pubmed">29129876</ArticleId></ArticleIdList></Reference><Reference><Citation>Shkoporov AN, Hill C. Bacteriophages of the human gut: the &#x201c;known unknown&#x201d; of the microbiome. Cell Host Microbe. 2019;25(2):195&#x2013;209. doi:10.1016/j.chom.2019.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2019.01.017</ArticleId><ArticleId IdType="pubmed">30763534</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Riordan KJ, Collins MK, Moloney GM, Knox EG, Aburto MR, F&#xfc;lling C, Morley SJ, Clarke G, Schellekens H, Cryan JF, et al. Short chain fatty acids: microbial metabolites for gut-brain axis signalling. Mol Cell Endocrinol. 2022;546:111572. doi:10.1016/j.mce.2022.111572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mce.2022.111572</ArticleId><ArticleId IdType="pubmed">35066114</ArticleId></ArticleIdList></Reference><Reference><Citation>Engevik M, Versalovic J. Taking a closer look at the biogeography of the human gastrointestinal microbiome. Gastroenterology. 2019;157(4):927&#x2013;929. doi:10.1053/j.gastro.2019.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2019.08.006</ArticleId><ArticleId IdType="pubmed">31400370</ArticleId></ArticleIdList></Reference><Reference><Citation>Herath M, Hosie S, Bornstein JC, Franks AE, Hill-Yardin EL. The role of the gastrointestinal mucus system in intestinal homeostasis: implications for neurological disorders. Front Cell Infect Microbiol. 2020;10:248. doi:10.3389/fcimb.2020.00248.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.00248</ArticleId><ArticleId IdType="pmc">PMC7270209</ArticleId><ArticleId IdType="pubmed">32547962</ArticleId></ArticleIdList></Reference><Reference><Citation>Martens EC, Neumann M, Desai MS. Interactions of commensal and pathogenic microorganisms with the intestinal mucosal barrier. Nat Rev Microbiol. 2018;16(8):457&#x2013;470. doi:10.1038/s41579-018-0036-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0036-x</ArticleId><ArticleId IdType="pubmed">29904082</ArticleId></ArticleIdList></Reference><Reference><Citation>Mowat AM. To respond or not to respond - a personal perspective of intestinal tolerance. Nat Rev Immunol. 2018;18(6):405&#x2013;415. doi:10.1038/s41577-018-0002-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-018-0002-x</ArticleId><ArticleId IdType="pubmed">29491358</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo JY, Groer M, Dutra SVO, Sarkar A, McSkimming DI. Gut microbiota and immune system interactions. Microorganisms. 2020;8(10):1587. doi:10.3390/microorganisms8101587.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms8101587</ArticleId><ArticleId IdType="pmc">PMC7602490</ArticleId><ArticleId IdType="pubmed">33076307</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Noci V, Bernardo G, Bianchi F, Tagliabue E, Sommariva M, Sfondrini L. Toll like receptors as sensors of the tumor microbial dysbiosis: implications in cancer progression. Front Cell Dev Biol. 2021;9:732192. doi:10.3389/fcell.2021.732192.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.732192</ArticleId><ArticleId IdType="pmc">PMC8485072</ArticleId><ArticleId IdType="pubmed">34604233</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrand A, Al Nabhani Z, Tapias NS, Mas E, Hugot JP, Barreau F. NOD2 expression in intestinal epithelial cells protects toward the development of inflammation and associated carcinogenesis. Cell Mol Gastroenterol Hepatol. 2019;7(2):357&#x2013;369. doi:10.1016/j.jcmgh.2018.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmgh.2018.10.009</ArticleId><ArticleId IdType="pmc">PMC6357788</ArticleId><ArticleId IdType="pubmed">30704984</ArticleId></ArticleIdList></Reference><Reference><Citation>Moltzau Anderson J, Lipinski S, Sommer F, Pan W-H, Boulard O, Rehman A, Falk-Paulsen M, Stengel ST, Aden K, H&#xe4;sler R, et al. NOD2 influences trajectories of intestinal microbiota recovery after antibiotic perturbation. Cell Mol Gastroenterol Hepatol. 2020;10(2):365&#x2013;389. doi:10.1016/j.jcmgh.2020.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmgh.2020.03.008</ArticleId><ArticleId IdType="pmc">PMC7327897</ArticleId><ArticleId IdType="pubmed">32289499</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Garc&#xed;a V, Gonz&#xe1;lez-Ramos S, Mart&#xed;n-Sanz P, Portillo FG-D, Laparra JM, Bosc&#xe1; L. NOD1 in the interplay between microbiota and gastrointestinal immune adaptations. Pharmacological Research. 2021;171:105775. doi:10.1016/j.phrs.2021.105775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2021.105775</ArticleId><ArticleId IdType="pubmed">34273489</ArticleId></ArticleIdList></Reference><Reference><Citation>Irving AT, Mimuro H, Kufer TA, Lo C, Wheeler R, Turner L, Thomas B, Malosse C, Gantier M, Casillas L, et al. The immune receptor NOD1 and kinase RIP2 interact with bacterial peptidoglycan on early endosomes to promote autophagy and inflammatory signaling. Cell Host Microbe. 2014;15(5):623&#x2013;635. doi:10.1016/j.chom.2014.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2014.04.001</ArticleId><ArticleId IdType="pubmed">24746552</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30(6):492&#x2013;506. doi:10.1038/s41422-020-0332-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0332-7</ArticleId><ArticleId IdType="pmc">PMC7264227</ArticleId><ArticleId IdType="pubmed">32433595</ArticleId></ArticleIdList></Reference><Reference><Citation>Zong X, Fu J, Xu B, Wang Y, Jin M. Interplay between gut microbiota and antimicrobial peptides. Animal Nutrition. 2020;6(4):389&#x2013;396. doi:10.1016/j.aninu.2020.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aninu.2020.09.002</ArticleId><ArticleId IdType="pmc">PMC7750803</ArticleId><ArticleId IdType="pubmed">33364454</ArticleId></ArticleIdList></Reference><Reference><Citation>Lueschow SR, McElroy SJ. The paneth cell: the curator and defender of the immature small intestine. Front Immunol. 2020;11:587. doi:10.3389/fimmu.2020.00587.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00587</ArticleId><ArticleId IdType="pmc">PMC7145889</ArticleId><ArticleId IdType="pubmed">32308658</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang W, Enee E, Andre-Vallee C, Falcone M, Sun J, Diana J. Intestinal cathelicidin antimicrobial peptide shapes a protective neonatal gut microbiota against pancreatic autoimmunity. Gastroenterology. 2021;162(4):1288&#x2013;1302.e16. doi:10.1053/j.gastro.2021.12.272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2021.12.272</ArticleId><ArticleId IdType="pubmed">34973295</ArticleId></ArticleIdList></Reference><Reference><Citation>Healy DB, Ryan CA, Ross RP, Stanton C, Dempsey EM. Clinical implications of preterm infant gut microbiome development. Nat Microbiol. 2022;7(1):22&#x2013;33. doi:10.1038/s41564-021-01025-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-021-01025-4</ArticleId><ArticleId IdType="pubmed">34949830</ArticleId></ArticleIdList></Reference><Reference><Citation>Lycke NY, Bemark M. The regulation of gut mucosal IgA B-cell responses: recent developments. Mucosal Immunol. 2017;10(6):1361&#x2013;1374. doi:10.1038/mi.2017.62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mi.2017.62</ArticleId><ArticleId IdType="pubmed">28745325</ArticleId></ArticleIdList></Reference><Reference><Citation>Pabst O, Slack E. IgA and the intestinal microbiota: the importance of being specific. Mucosal Immunol. 2020;13(1):12&#x2013;21. doi:10.1038/s41385-019-0227-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41385-019-0227-4</ArticleId><ArticleId IdType="pmc">PMC6914667</ArticleId><ArticleId IdType="pubmed">31740744</ArticleId></ArticleIdList></Reference><Reference><Citation>Abokor AA, McDaniel GH, Golonka RM, Campbell C, Brahmandam S, Yeoh BS, Joe B, Vijay-Kumar M, Saha P. Immunoglobulin A, an active liaison for host-microbiota homeostasis. Microorganisms. 2021;9(10):2117. doi:10.3390/microorganisms9102117.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9102117</ArticleId><ArticleId IdType="pmc">PMC8539215</ArticleId><ArticleId IdType="pubmed">34683438</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnaswamy JK, Alsen S, Yrlid U, Eisenbarth SC, Williams A. Determination of t follicular helper cell fate by dendritic cells. Front Immunol. 2018;9:2169. doi:10.3389/fimmu.2018.02169.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02169</ArticleId><ArticleId IdType="pmc">PMC6170619</ArticleId><ArticleId IdType="pubmed">30319629</ArticleId></ArticleIdList></Reference><Reference><Citation>Agus A, Cl&#xe9;ment K, Sokol H. Gut microbiota-derived metabolites as central regulators in metabolic disorders. Gut. 2021;70(6):1174&#x2013;1182. doi:10.1136/gutjnl-2020-323071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-323071</ArticleId><ArticleId IdType="pmc">PMC8108286</ArticleId><ArticleId IdType="pubmed">33272977</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaudel C, Sokol H. The gut microbiota at the service of immunometabolism. Cell Metab. 2020;32(4):514&#x2013;523. doi:10.1016/j.cmet.2020.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2020.09.004</ArticleId><ArticleId IdType="pubmed">32946809</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu KH, Owens JA, Saeedi B, Cohen CE, Bellissimo MP, Naudin C, Darby T, Druzak S, Maner-Smith K, Orr M, et al. Microbial metabolite delta-valerobetaine is a diet-dependent obesogen. Nature Metabolism. 2021;3(12):1694&#x2013;1705. doi:10.1038/s42255-021-00502-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42255-021-00502-8</ArticleId><ArticleId IdType="pmc">PMC8711632</ArticleId><ArticleId IdType="pubmed">34931082</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(4):223&#x2013;237. doi:10.1038/s41575-019-0258-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-019-0258-z</ArticleId><ArticleId IdType="pubmed">32076145</ArticleId></ArticleIdList></Reference><Reference><Citation>Portincasa P, Bonfrate L, Vacca M, De Angelis M, Farella I, Lanza E, Khalil M, Wang DQH, Sperandio M, Di Ciaula A, et al. Gut microbiota and short chain fatty acids: implications in glucose homeostasis. Int J Mol Sci. 2022;23(3):1105. doi:10.3390/ijms23031105.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23031105</ArticleId><ArticleId IdType="pmc">PMC8835596</ArticleId><ArticleId IdType="pubmed">35163038</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalile B, Van Oudenhove L, Vervliet B, Verbeke K. The role of short-chain fatty acids in microbiota-gut-brain communication. Nat Rev Gastroenterol Hepatol. 2019;16(8):461&#x2013;478. doi:10.1038/s41575-019-0157-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-019-0157-3</ArticleId><ArticleId IdType="pubmed">31123355</ArticleId></ArticleIdList></Reference><Reference><Citation>Nugent SG, Kumar D, Rampton DS, Evans DF. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut. 2001;48(4):571&#x2013;577. doi:10.1136/gut.48.4.571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.48.4.571</ArticleId><ArticleId IdType="pmc">PMC1728243</ArticleId><ArticleId IdType="pubmed">11247905</ArticleId></ArticleIdList></Reference><Reference><Citation>Traxinger BR, Richert-Spuhler LE, Lund JM. Mucosal tissue regulatory T cells are integral in balancing immunity and tolerance at portals of antigen entry. Mucosal Immunol. 2021;15(3):398&#x2013;407]. doi:10.1038/s41385-021-00471-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41385-021-00471-x</ArticleId><ArticleId IdType="pmc">PMC8628059</ArticleId><ArticleId IdType="pubmed">34845322</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim CH. Control of lymphocyte functions by gut microbiota-derived short-chain fatty acids. Cell Mol Immunol. 2021;18(5):1161&#x2013;1171. doi:10.1038/s41423-020-00625-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-00625-0</ArticleId><ArticleId IdType="pmc">PMC8093302</ArticleId><ArticleId IdType="pubmed">33850311</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu P, Wang Y, Yang G, Zhang Q, Meng L, Xin Y, Jiang X. The role of short-chain fatty acids in intestinal barrier function, inflammation, oxidative stress, and colonic carcinogenesis. Pharmacol Res. 2021;165:105420. doi:10.1016/j.phrs.2021.105420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2021.105420</ArticleId><ArticleId IdType="pubmed">33434620</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Zhang P, Shen L, Niu L, Tan Y, Chen L, Zhao Y, Bai L, Hao X, Li X, et al. Short-chain fatty acids and their association with signalling pathways in inflammation, glucose and lipid metabolism. Int J Mol Sci. 2020;21(17):6356. doi:10.3390/ijms21176356.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21176356</ArticleId><ArticleId IdType="pmc">PMC7503625</ArticleId><ArticleId IdType="pubmed">32887215</ArticleId></ArticleIdList></Reference><Reference><Citation>de Aguiar Vallim TQ, Tarling EJ, Edwards PA. Pleiotropic roles of bile acids in metabolism. Cell Metab. 2013;17(5):657&#x2013;669. doi:10.1016/j.cmet.2013.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2013.03.013</ArticleId><ArticleId IdType="pmc">PMC3654004</ArticleId><ArticleId IdType="pubmed">23602448</ArticleId></ArticleIdList></Reference><Reference><Citation>Funabashi M, Grove TL, Wang M, Varma Y, McFadden ME, Brown LC, Guo C, Higginbottom S, Almo SC, Fischbach MA, et al. A metabolic pathway for bile acid dehydroxylation by the gut microbiome. Nature. 2020;582(7813):566&#x2013;570. doi:10.1038/s41586-020-2396-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2396-4</ArticleId><ArticleId IdType="pmc">PMC7319900</ArticleId><ArticleId IdType="pubmed">32555455</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzior DV, Quinn RA. Review: microbial transformations of human bile acids. Microbiome. 2021;9(1):140. doi:10.1186/s40168-021-01101-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40168-021-01101-1</ArticleId><ArticleId IdType="pmc">PMC8204491</ArticleId><ArticleId IdType="pubmed">34127070</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia X, Lu S, Zeng Z, Liu Q, Dong Z, Chen Y, Zhu Z, Hong Z, Zhang T, Du G, et al. Characterization of gut microbiota, bile acid metabolism, and cytokines in intrahepatic cholangiocarcinoma. Hepatology. 2020;71(3):893&#x2013;906. doi:10.1002/hep.30852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.30852</ArticleId><ArticleId IdType="pubmed">31298745</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Serna-Salas S, Damba T, Borghesan M, Demaria M, Moshage H. Hepatic stellate cell senescence in liver fibrosis: characteristics, mechanisms and perspectives. Mech Ageing Dev. 2021;199:111572. doi:10.1016/j.mad.2021.111572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mad.2021.111572</ArticleId><ArticleId IdType="pubmed">34536446</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol. 2018;15(2):111&#x2013;128. doi:10.1038/nrgastro.2017.119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2017.119</ArticleId><ArticleId IdType="pmc">PMC5899973</ArticleId><ArticleId IdType="pubmed">29018272</ArticleId></ArticleIdList></Reference><Reference><Citation>Roager HM, Licht TR. Microbial tryptophan catabolites in health and disease. Nat Commun. 2018;9(1):3294. doi:10.1038/s41467-018-05470-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-05470-4</ArticleId><ArticleId IdType="pmc">PMC6098093</ArticleId><ArticleId IdType="pubmed">30120222</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng H, Wang Y, Luo W. Multifaceted role of branched-chain amino acid metabolism in cancer. Oncogene. 2020;39(44):6747&#x2013;6756. doi:10.1038/s41388-020-01480-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41388-020-01480-z</ArticleId><ArticleId IdType="pmc">PMC7606751</ArticleId><ArticleId IdType="pubmed">32978521</ArticleId></ArticleIdList></Reference><Reference><Citation>Krautkramer KA, Fan J, B&#xe4;ckhed F. Gut microbial metabolites as multi-kingdom intermediates. Nat Rev Microbiol. 2021;19(2):77&#x2013;94. doi:10.1038/s41579-020-0438-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-0438-4</ArticleId><ArticleId IdType="pubmed">32968241</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Hong J, Wang Y, Pei M, Wang L, Gong Z. Trimethylamine-N-Oxide Pathway: a Potential Target for the Treatment of MAFLD. Front Mol Biosci. 2021;8:733507. doi:10.3389/fmolb.2021.733507.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2021.733507</ArticleId><ArticleId IdType="pmc">PMC8517136</ArticleId><ArticleId IdType="pubmed">34660695</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JM, Hazen SL. Microbial modulation of cardiovascular disease. Nat Rev Microbiol. 2018;16(3):171&#x2013;181. doi:10.1038/nrmicro.2017.149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro.2017.149</ArticleId><ArticleId IdType="pmc">PMC5885760</ArticleId><ArticleId IdType="pubmed">29307889</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalal N, Jalandra R, Bayal N. Gut microbiota-derived metabolites in CRC progression and causation. J Cancer Res Clin Oncol. 2021;147(11):3141&#x2013;3155. doi:10.1007/s00432-021-03729-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00432-021-03729-w</ArticleId><ArticleId IdType="pmc">PMC11801839</ArticleId><ArticleId IdType="pubmed">34273006</ArticleId></ArticleIdList></Reference><Reference><Citation>Li XS, Obeid S, Wang Z, Hazen BJ, Li L, Wu Y, Hurd AG, Gu X, Pratt A, Levison BS, et al. Trimethyllysine, a trimethylamine N-oxide precursor, provides near- and long-term prognostic value in patients presenting with acute coronary syndromes. Eur Heart J. 2019;40(32):2700&#x2013;2709. doi:10.1093/eurheartj/ehz259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz259</ArticleId><ArticleId IdType="pmc">PMC7963132</ArticleId><ArticleId IdType="pubmed">31049589</ArticleId></ArticleIdList></Reference><Reference><Citation>McBurney MI, Davis C, Fraser CM, Schneeman BO, Huttenhower C, Verbeke K, Walter J, Latulippe ME. Establishing what constitutes a healthy human gut microbiome: state of the science, regulatory considerations, and future directions. J Nutr. 2019;149(11):1882&#x2013;1895. doi:10.1093/jn/nxz154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jn/nxz154</ArticleId><ArticleId IdType="pmc">PMC6825832</ArticleId><ArticleId IdType="pubmed">31373365</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy M, Kolodziejczyk AA, Thaiss CA, Elinav E. Dysbiosis and the immune system. Nat Rev Immunol. 2017;17(4):219&#x2013;232. doi:10.1038/nri.2017.7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2017.7</ArticleId><ArticleId IdType="pubmed">28260787</ArticleId></ArticleIdList></Reference><Reference><Citation>Jochum L, Stecher B. Label or concept - what is a pathobiont? Trends Microbiol. 2020;28(10):789&#x2013;792. doi:10.1016/j.tim.2020.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2020.04.011</ArticleId><ArticleId IdType="pubmed">32376073</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng MY, Inohara N, Nunez G. Mechanisms of inflammation-driven bacterial dysbiosis in the gut. Mucosal Immunol. 2017;10(1):18&#x2013;26. doi:10.1038/mi.2016.75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mi.2016.75</ArticleId><ArticleId IdType="pmc">PMC5788567</ArticleId><ArticleId IdType="pubmed">27554295</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiippala K, Jouhten H, Ronkainen A, Hartikainen A, Kainulainen V, Jalanka J, Satokari R. The potential of gut commensals in reinforcing intestinal barrier function and alleviating inflammation. Nutrients. 2018;10(8):988. doi:10.3390/nu10080988.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu10080988</ArticleId><ArticleId IdType="pmc">PMC6116138</ArticleId><ArticleId IdType="pubmed">30060606</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan R, Petersen FC, Shekhar S. Commensal bacteria: an emerging player in defense against respiratory pathogens. Front Immunol. 2019;10:1203. doi:10.3389/fimmu.2019.01203.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01203</ArticleId><ArticleId IdType="pmc">PMC6554327</ArticleId><ArticleId IdType="pubmed">31214175</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho AL, Fonseca S, Miquel-Clopes A, Cross K, Kok K-S, Wegmann U, Gil-Cardoso K, Bentley EG, Al Katy SHM, Coombes JL, et al. Bioengineering commensal bacteria-derived outer membrane vesicles for delivery of biologics to the gastrointestinal and respiratory tract. J Extracell Vesicles. 2019;8(1):1632100. doi:10.1080/20013078.2019.1632100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/20013078.2019.1632100</ArticleId><ArticleId IdType="pmc">PMC6598475</ArticleId><ArticleId IdType="pubmed">31275534</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosca A, Leclerc M, Hugot JP. Gut microbiota diversity and human diseases: should we reintroduce key predators in our ecosystem? Front Microbiol. 2016;7:455. doi:10.3389/fmicb.2016.00455.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2016.00455</ArticleId><ArticleId IdType="pmc">PMC4815357</ArticleId><ArticleId IdType="pubmed">27065999</ArticleId></ArticleIdList></Reference><Reference><Citation>Roswall J, Olsson LM, Kovatcheva-Datchary P, Nilsson S, Tremaroli V, Simon M-C, Kiilerich P, Akrami R, Kr&#xe4;mer M, Uhl&#xe9;n M, et al. Developmental trajectory of the healthy human gut microbiota during the first 5 years of life. Cell Host Microbe. 2021;29(5):765&#x2013;776 e763. doi:10.1016/j.chom.2021.02.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.02.021</ArticleId><ArticleId IdType="pubmed">33794185</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellicano R, Ianiro G, Fagoonee S, Settanni CR, Gasbarrini A. Review: extragastric diseases and Helicobacter pylori. Helicobacter. 2020;25(Suppl 1):e12741. doi:10.1111/hel.12741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hel.12741</ArticleId><ArticleId IdType="pubmed">32918343</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno H, Satoh-Takayama N. Stomach microbiota, Helicobacter pylori, and group 2 innate lymphoid cells. Exp Mol Med. 2020;52(9):1377&#x2013;1382. doi:10.1038/s12276-020-00485-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-020-00485-8</ArticleId><ArticleId IdType="pmc">PMC8080604</ArticleId><ArticleId IdType="pubmed">32908209</ArticleId></ArticleIdList></Reference><Reference><Citation>Iino C, Shimoyama T. Impact of Helicobacter pylori infection on gut microbiota. World J Gastroenterol. 2021;27(37):6224&#x2013;6230. doi:10.3748/wjg.v27.i37.6224.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v27.i37.6224</ArticleId><ArticleId IdType="pmc">PMC8515792</ArticleId><ArticleId IdType="pubmed">34712028</ArticleId></ArticleIdList></Reference><Reference><Citation>Engstrand L, Graham DY. Microbiome and Gastric Cancer. Dig Dis Sci. 2020;65(3):865&#x2013;873. doi:10.1007/s10620-020-06101-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-020-06101-z</ArticleId><ArticleId IdType="pmc">PMC8697197</ArticleId><ArticleId IdType="pubmed">32040665</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CC, Liou JM, Lee YC, Hong TC, El-Omar EM, Wu MS. The interplay between Helicobacter pylori and gastrointestinal microbiota. Gut Microbes. 2021;13(1):1&#x2013;22. doi:10.1080/19490976.2021.1909459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2021.1909459</ArticleId><ArticleId IdType="pmc">PMC8096336</ArticleId><ArticleId IdType="pubmed">33938378</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013;10(11):643&#x2013;655. doi:10.1038/nrclinonc.2013.170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrclinonc.2013.170</ArticleId><ArticleId IdType="pmc">PMC3927982</ArticleId><ArticleId IdType="pubmed">24061039</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Nu&#xf1;ez GM, Cornejo-Pareja I, Clemente-Postigo M, Tinahones FJ. Gut microbiota: the missing link between helicobacter pylori infection and metabolic disorders? Front Endocrinol (Lausanne). 2021;12(657). doi:10.3389/fendo.2021.639856.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2021.639856</ArticleId><ArticleId IdType="pmc">PMC8247771</ArticleId><ArticleId IdType="pubmed">34220702</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez JE, Kahana DD, Ghuman S, Wilson HP, Wilson J, Kim SCJ, Lagishetty V, Jacobs JP, Sinha-Hikim AP, Friedman TC, et al. unhealthy lifestyle and gut dysbiosis: a better understanding of the effects of poor diet and nicotine on the intestinal microbiome. Front Endocrinol (Lausanne). 2021;12:667066. doi:10.3389/fendo.2021.667066.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2021.667066</ArticleId><ArticleId IdType="pmc">PMC8218903</ArticleId><ArticleId IdType="pubmed">34168615</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaulke CA, Sharpton TJ. The influence of ethnicity and geography on human gut microbiome composition. Nat Med. 2018;24(10):1495&#x2013;1496. doi:10.1038/s41591-018-0210-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0210-8</ArticleId><ArticleId IdType="pubmed">30275567</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasapolli R, Schutte K, Schulz C, Vital M, Schomburg D, Pieper DH, Vilchez-Vargas R, Malfertheiner P. Analysis of transcriptionally active bacteria throughout the gastrointestinal tract of healthy individuals. Gastroenterology. 2019;157(4):1081&#x2013;1092 e1083. doi:10.1053/j.gastro.2019.05.068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2019.05.068</ArticleId><ArticleId IdType="pubmed">31175864</ArticleId></ArticleIdList></Reference><Reference><Citation>Bik EM, Eckburg PB, Gill SR. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci U S A. 2006;103(3):732&#x2013;737. doi:10.1073/pnas.0506655103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506655103</ArticleId><ArticleId IdType="pmc">PMC1334644</ArticleId><ArticleId IdType="pubmed">16407106</ArticleId></ArticleIdList></Reference><Reference><Citation>Li XX, Wong GL, To KF, Wong VWS, Lai LH, Chow DKL, Lau JYW, Sung JJY, Ding C. Bacterial microbiota profiling in gastritis without Helicobacter pylori infection or non-steroidal anti-inflammatory drug use. PLoS One. 2009;4(11):e7985. doi:10.1371/journal.pone.0007985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0007985</ArticleId><ArticleId IdType="pmc">PMC2776972</ArticleId><ArticleId IdType="pubmed">19956741</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Zhou X, Liao B, Zhou Y, Cheng L, Ren B. The cross-kingdom interaction between Helicobacter pylori and Candida albicans. PLoS Pathog. 2021;17(5):e1009515&#x2013;e1009515. doi:10.1371/journal.ppat.1009515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009515</ArticleId><ArticleId IdType="pmc">PMC8101746</ArticleId><ArticleId IdType="pubmed">33956895</ArticleId></ArticleIdList></Reference><Reference><Citation>Noto JM, Zackular JP, Varga MG, Delgado A, Romero-Gallo J, Scholz MB, Piazuelo MB, Skaar EP, Peek RM. Modification of the gastric mucosal microbiota by a strain-specific helicobacter pylori oncoprotein and carcinogenic histologic phenotype. mBio. 2019;10(3). doi:10.1128/mBio.00955-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00955-19</ArticleId><ArticleId IdType="pmc">PMC6538789</ArticleId><ArticleId IdType="pubmed">31138752</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Xin Y, Zhou J. Gastric mucosa-associated microbial signatures of early gastric cancer. Front Microbiol. 2020;11:1548. doi:10.3389/fmicb.2020.01548.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.01548</ArticleId><ArticleId IdType="pmc">PMC7358557</ArticleId><ArticleId IdType="pubmed">32733423</ArticleId></ArticleIdList></Reference><Reference><Citation>Coker OO, Dai Z, Nie Y, Zhao G, Cao L, Nakatsu G, Wu WK, Wong SH, Chen Z, Sung JJY, et al. Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut. 2018;67(6):1024&#x2013;1032. doi:10.1136/gutjnl-2017-314281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2017-314281</ArticleId><ArticleId IdType="pmc">PMC5969346</ArticleId><ArticleId IdType="pubmed">28765474</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Zhou J, Xin Y. Bacterial overgrowth and diversification of microbiota in gastric cancer. Eur J Gastroenterol Hepatol. 2016;28(3):261&#x2013;266. doi:10.1097/MEG.0000000000000542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000000542</ArticleId><ArticleId IdType="pmc">PMC4739309</ArticleId><ArticleId IdType="pubmed">26657453</ArticleId></ArticleIdList></Reference><Reference><Citation>Eun CS, Kim BK, Han DS, Kim SY, Kim KM, Choi BY, Song KS, Kim YS, Kim JF. Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods. Helicobacter. 2014;19(6):407&#x2013;416. doi:10.1111/hel.12145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hel.12145</ArticleId><ArticleId IdType="pubmed">25052961</ArticleId></ArticleIdList></Reference><Reference><Citation>Aviles-Jimenez F, Vazquez-Jimenez F, Medrano-Guzman R, Mantilla A, Torres J. Stomach microbiota composition varies between patients with non-atrophic gastritis and patients with intestinal type of gastric cancer. Sci Rep. 2014;4(1):4202. doi:10.1038/srep04202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep04202</ArticleId><ArticleId IdType="pmc">PMC3935187</ArticleId><ArticleId IdType="pubmed">24569566</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, Costa JL, Carneiro F, Machado JC, Figueiredo C. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut. 2018;67(2):226&#x2013;236. doi:10.1136/gutjnl-2017-314205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2017-314205</ArticleId><ArticleId IdType="pmc">PMC5868293</ArticleId><ArticleId IdType="pubmed">29102920</ArticleId></ArticleIdList></Reference><Reference><Citation>Dicksved J, Lindberg M, Rosenquist M, Enroth H, Jansson JK, Engstrand L. Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls. J Med Microbiol. 2009;58(Pt 4):509&#x2013;516. doi:10.1099/jmm.0.007302-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jmm.0.007302-0</ArticleId><ArticleId IdType="pubmed">19273648</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, Zhang Y, Gerhard M, Gao -J-J, Mejias-Luque R, Zhang L, Vieth M, Ma J-L, Bajbouj M, Suchanek S, et al. Effect of Helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer. Gut. 2020;69(9):1598&#x2013;1607. doi:10.1136/gutjnl-2019-319696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2019-319696</ArticleId><ArticleId IdType="pmc">PMC7456744</ArticleId><ArticleId IdType="pubmed">31857433</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Zhou X, Liu X, Ling Z, Ji F. Role of the gastric microbiome in gastric cancer: from carcinogenesis to treatment. Front Microbiol. 2021;12:641322. doi:10.3389/fmicb.2021.641322.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.641322</ArticleId><ArticleId IdType="pmc">PMC8005548</ArticleId><ArticleId IdType="pubmed">33790881</ArticleId></ArticleIdList></Reference><Reference><Citation>Navashenaq JG, Shabgah AG, Banach M, Jamialahmadi T, Penson PE, Johnston TP, Sahebkar A. The interaction of Helicobacter pylori with cancer immunomodulatory stromal cells: new insight into gastric cancer pathogenesis. Semin Cancer Biol. 2021. doi:10.1016/j.semcancer.2021.09.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcancer.2021.09.014</ArticleId><ArticleId IdType="pubmed">34600095</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakhti SZ, Latifi-Navid S. Interplay and cooperation of Helicobacter pylori and gut microbiota in gastric carcinogenesis. BMC Microbiol. 2021;21(1):258. doi:10.1186/s12866-021-02315-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12866-021-02315-x</ArticleId><ArticleId IdType="pmc">PMC8461988</ArticleId><ArticleId IdType="pubmed">34556055</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao JJ, Zhang Y, Gerhard M, Mejias-Luque R, Zhang L, Vieth M, Ma J-L, Bajbouj M, Suchanek S, Liu W-D, et al. Association between gut microbiota and helicobacter pylori-related gastric lesions in a high-risk population of gastric cancer. Front Cell Infect Microbiol. 2018;8:202. doi:10.3389/fcimb.2018.00202.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2018.00202</ArticleId><ArticleId IdType="pmc">PMC6018392</ArticleId><ArticleId IdType="pubmed">29971220</ArticleId></ArticleIdList></Reference><Reference><Citation>He C, Peng C, Wang H, Ouyang Y, Zhu Z, Shu X, Zhu Y, Lu N. The eradication of Helicobacter pylori restores rather than disturbs the gastrointestinal microbiota in asymptomatic young adults. Helicobacter. 2019;24(4):e12590. doi:10.1111/hel.12590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hel.12590</ArticleId><ArticleId IdType="pubmed">31124220</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost F, Kacprowski T, Ruhlemann M, Bang C, Franke A, Zimmermann K, Nauck M, V&#xf6;lker U, V&#xf6;lzke H, Biffar R, et al. Helicobacter pylori infection associates with fecal microbiota composition and diversity. Sci Rep. 2019;9(1):20100. doi:10.1038/s41598-019-56631-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-56631-4</ArticleId><ArticleId IdType="pmc">PMC6934578</ArticleId><ArticleId IdType="pubmed">31882864</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapidot Y, Reshef L, Cohen D, Muhsen K. Helicobacter pylori and the intestinal microbiome among healthy school-age children. Helicobacter. 2021;26(6):e12854. doi:10.1111/hel.12854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hel.12854</ArticleId><ArticleId IdType="pubmed">34617641</ArticleId></ArticleIdList></Reference><Reference><Citation>Heimesaat MM, Fischer A, Plickert R, Wiedemann T, Loddenkemper C, G&#xf6;bel UB, Bereswill S, Rieder G. Helicobacter pylori induced gastric immunopathology is associated with distinct microbiota changes in the large intestines of long-term infected mongolian gerbils. PLOS ONE. 2014;9(6):e100362. doi:10.1371/journal.pone.0100362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0100362</ArticleId><ArticleId IdType="pmc">PMC4062524</ArticleId><ArticleId IdType="pubmed">24941045</ArticleId></ArticleIdList></Reference><Reference><Citation>Dash NR, Khoder G, Nada AM, Al Bataineh MT. Exploring the impact of Helicobacter pylori on gut microbiome composition. PLoS One. 2019;14(6):e0218274. doi:10.1371/journal.pone.0218274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0218274</ArticleId><ArticleId IdType="pmc">PMC6581275</ArticleId><ArticleId IdType="pubmed">31211818</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Xu W, Lee A, He J, Huang B, Zheng W, Su T, Lai S, Long Y, Chu H, et al. The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: an open-label, randomized clinical trial. EBioMedicine. 2018;35:87&#x2013;96. doi:10.1016/j.ebiom.2018.08.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2018.08.028</ArticleId><ArticleId IdType="pmc">PMC6161473</ArticleId><ArticleId IdType="pubmed">30145102</ArticleId></ArticleIdList></Reference><Reference><Citation>Iino C, Shimoyama T, Chinda D, Sakuraba H, Fukuda S, Nakaji S. Influence of helicobacter pylori infection and atrophic gastritis on the gut microbiota in a Japanese population. Digestion. 2020;101:422&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">31394526</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornejo-Pareja I, Martin-Nunez GM, Roca-Rodriguez MM. H. pylori eradication treatment alters gut microbiota and GLP-1 secretion in humans. J Clin Med. 2019;8(4). doi:10.3390/jcm8040451.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm8040451</ArticleId><ArticleId IdType="pmc">PMC6517938</ArticleId><ArticleId IdType="pubmed">30987326</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Li Y, Zhong H, Ding Q, Lin Y, Tang S, Zong Y, Wang Q, Zhang X, Yang H, et al. Alterations in the human gut microbiome associated with helicobacter&#xa0;pylori infection. FEBS Open Bio. 2019;9(9):1552&#x2013;1560. doi:10.1002/2211-5463.12694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/2211-5463.12694</ArticleId><ArticleId IdType="pmc">PMC6724102</ArticleId><ArticleId IdType="pubmed">31250988</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Zhang J, Xu J, Wei X, Yang J, Liu Y, Li H, Zhao C, Wang Y, Zhang L, et al. Helicobacter pylori infection aggravates dysbiosis of gut microbiome in children with gastritis. Front Cell Infect Microbiol. 2019;9:375. doi:10.3389/fcimb.2019.00375.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2019.00375</ArticleId><ArticleId IdType="pmc">PMC6859803</ArticleId><ArticleId IdType="pubmed">31781514</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Ye Z, Lu J, Miao S, Lu X, Sun H, Wu J, Wang Y, Huang Y. Long-term changes in the gut microbiota after 14-day bismuth quadruple therapy in penicillin-allergic children. Helicobacter. 2020;25(5):e12721. doi:10.1111/hel.12721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hel.12721</ArticleId><ArticleId IdType="pubmed">32656891</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz-Ramirez ZY, Pascoe B, Mendez-Tenorio A, Mourkas E, Sandoval-Motta S, Perez-Perez G, Morgan DR, Dominguez RL, Ortiz-Princz D, Cavazza ME, et al. A 500-year tale of co-evolution, adaptation, and virulence: helicobacter pylori in the Americas. ISME J. 2021;15(1):78&#x2013;92. doi:10.1038/s41396-020-00758-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41396-020-00758-0</ArticleId><ArticleId IdType="pmc">PMC7853065</ArticleId><ArticleId IdType="pubmed">32879462</ArticleId></ArticleIdList></Reference><Reference><Citation>Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, Magris M, Hidalgo G, Baldassano RN, Anokhin AP, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222&#x2013;227. doi:10.1038/nature11053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11053</ArticleId><ArticleId IdType="pmc">PMC3376388</ArticleId><ArticleId IdType="pubmed">22699611</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopetuso LR, Scaldaferri F, Franceschi F, Gasbarrini A. The gastrointestinal microbiome &#x2013; functional interference between stomach and intestine. Best Pract Res Clin Gastroenterol. 2014;28(6):995&#x2013;1002. doi:10.1016/j.bpg.2014.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpg.2014.10.004</ArticleId><ArticleId IdType="pubmed">25439066</ArticleId></ArticleIdList></Reference><Reference><Citation>Kienesberger S, Cox LM, Livanos A, Zhang X-S, Chung J, Perez-Perez G, Gorkiewicz G, Zechner E, Blaser M. Gastric Helicobacter pylori infection affects local and distant microbial populations and host responses. Cell Rep. 2016;14(6):1395&#x2013;1407. doi:10.1016/j.celrep.2016.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.01.017</ArticleId><ArticleId IdType="pmc">PMC4758874</ArticleId><ArticleId IdType="pubmed">26854236</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi-Kanemitsu A, Knight CT, Hatakeyama M. Molecular anatomy and pathogenic actions of Helicobacter pylori CagA that underpin gastric carcinogenesis. Cell Mol Immunol. 2020;17(1):50&#x2013;63. doi:10.1038/s41423-019-0339-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-019-0339-5</ArticleId><ArticleId IdType="pmc">PMC6952403</ArticleId><ArticleId IdType="pubmed">31804619</ArticleId></ArticleIdList></Reference><Reference><Citation>Baj J, Forma A, Sitarz M, Portincasa P, Garruti G, Krasowska D, Maciejewski R. Helicobacter pylori virulence factors-mechanisms of bacterial pathogenicity in the gastric microenvironment. Cells. 2020;10(1):27. doi:10.3390/cells10010027.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10010027</ArticleId><ArticleId IdType="pmc">PMC7824444</ArticleId><ArticleId IdType="pubmed">33375694</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Ding Y, Xu H, Shen C, Chen X, Li C. Effects of sodium butyrate supplementation on inflammation, gut microbiota, and short-chain fatty acids in Helicobacter pylori-infected mice. Helicobacter. 2021;26(2):e12785. doi:10.1111/hel.12785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hel.12785</ArticleId><ArticleId IdType="pubmed">33609322</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Tang H, Chen P, Xie H, Tao Y. Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome. Signal Transduct Target Ther. 2019;4:41. doi:10.1038/s41392-019-0074-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-019-0074-5</ArticleId><ArticleId IdType="pmc">PMC6799818</ArticleId><ArticleId IdType="pubmed">31637019</ArticleId></ArticleIdList></Reference><Reference><Citation>Wibowo H, Harbuwono DS, Tahapary DL, Kartika R, Pradipta S, Larasati RA. Impact of sodium butyrate treatment in LPS-stimulated peripheral blood mononuclear cells of poorly controlled type 2 DM. Front Endocrinol (Lausanne). 2021;12:652942. doi:10.3389/fendo.2021.652942.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2021.652942</ArticleId><ArticleId IdType="pmc">PMC8358792</ArticleId><ArticleId IdType="pubmed">34393993</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos-Perez W, Martinez-Lopez E. Effects of short chain fatty acids on metabolic and inflammatory processes in human health. Biochimica Et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 2021;1866(5):158900. doi:10.1016/j.bbalip.2021.158900.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2021.158900</ArticleId><ArticleId IdType="pubmed">33571672</ArticleId></ArticleIdList></Reference><Reference><Citation>Postler TS, Ghosh S. Understanding the Holobiont: how Microbial Metabolites Affect Human Health and Shape the Immune System. Cell Metab. 2017;26(1):110&#x2013;130. doi:10.1016/j.cmet.2017.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2017.05.008</ArticleId><ArticleId IdType="pmc">PMC5535818</ArticleId><ArticleId IdType="pubmed">28625867</ArticleId></ArticleIdList></Reference><Reference><Citation>Sit WY, Chen YA, Chen YL, Lai CH, Wang WC. Cellular evasion strategies of Helicobacter pylori in regulating its intracellular fate. Semin Cell Dev Biol. 2020;101:59&#x2013;67. doi:10.1016/j.semcdb.2020.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2020.01.007</ArticleId><ArticleId IdType="pmc">PMC7102552</ArticleId><ArticleId IdType="pubmed">32033828</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuomo P, Papaianni M, Sansone C, Iannelli A, Iannelli D, Medaglia C, Paris D, Motta A, Capparelli R. an in vitro model to investigate the role of helicobacter pylori in type 2 diabetes, obesity, alzheimer&#x2019;s disease and cardiometabolic disease. Int J Mol Sci. 2020;21(21):8369. doi:10.3390/ijms21218369.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21218369</ArticleId><ArticleId IdType="pmc">PMC7664682</ArticleId><ArticleId IdType="pubmed">33171588</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhangi MA, Vajdi M. Novel findings of the association between gut microbiota-derived metabolite trimethylamine N-oxide and inflammation: results from a systematic review and dose-response meta-analysis. Crit Rev Food Sci Nutr. 2020;60(16):2801&#x2013;2823. doi:10.1080/10408398.2020.1770199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10408398.2020.1770199</ArticleId><ArticleId IdType="pubmed">32462890</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D, Cao M, Peng J, Li N, Yi S, Song L, Wang X, Zhang M, Zhao J. The effect of trimethylamine N-oxide on Helicobacter pylori-induced changes of immunoinflammatory genes expression in gastric epithelial cells. Int Immunopharmacol. 2017;43:172&#x2013;178. doi:10.1016/j.intimp.2016.11.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2016.11.032</ArticleId><ArticleId IdType="pubmed">28012316</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med. 2016;375(24):2369&#x2013;2379. doi:10.1056/NEJMra1600266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1600266</ArticleId><ArticleId IdType="pubmed">27974040</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021;19(1):55&#x2013;71. doi:10.1038/s41579-020-0433-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-0433-9</ArticleId><ArticleId IdType="pubmed">32887946</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez J, Guarner F, Bustos Fernandez L, Maruy A, Sdepanian VL, Cohen H. Antibiotics as major disruptors of gut microbiota. Front Cell Infect Microbiol. 2020;10(731). doi:10.3389/fcimb.2020.572912.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.572912</ArticleId><ArticleId IdType="pmc">PMC7732679</ArticleId><ArticleId IdType="pubmed">33330122</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaser MJ. Antibiotic use and its consequences for the normal microbiome. Science. 2016;352(6285):544&#x2013;545. doi:10.1126/science.aad9358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad9358</ArticleId><ArticleId IdType="pmc">PMC4939477</ArticleId><ArticleId IdType="pubmed">27126037</ArticleId></ArticleIdList></Reference><Reference><Citation>Palleja A, Mikkelsen KH, Forslund SK, Kashani A, Allin KH, Nielsen T, Hansen TH, Liang S, Feng Q, Zhang C, et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat Microbiol. 2018;3(11):1255&#x2013;1265. doi:10.1038/s41564-018-0257-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-018-0257-9</ArticleId><ArticleId IdType="pubmed">30349083</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarrinpar A, Chaix A, Xu ZZ, Chang MW, Marotz CA, Saghatelian A, Knight R, Panda S. Antibiotic-induced microbiome depletion alters metabolic homeostasis by affecting gut signaling and colonic metabolism. Nat Commun. 2018;9(1):2872. doi:10.1038/s41467-018-05336-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-05336-9</ArticleId><ArticleId IdType="pmc">PMC6054678</ArticleId><ArticleId IdType="pubmed">30030441</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018;555(7698):623&#x2013;628. doi:10.1038/nature25979.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25979</ArticleId><ArticleId IdType="pmc">PMC6108420</ArticleId><ArticleId IdType="pubmed">29555994</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashidi A, Ebadi M, Rehman TU, Elhusseini H, Nalluri H, Kaiser T, Holtan SG, Khoruts A, Weisdorf DJ, Staley C, et al. Gut microbiota response to antibiotics is personalized and depends on baseline microbiota. Microbiome. 2021;9(1):211. doi:10.1186/s40168-021-01170-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40168-021-01170-2</ArticleId><ArticleId IdType="pmc">PMC8549152</ArticleId><ArticleId IdType="pubmed">34702350</ArticleId></ArticleIdList></Reference><Reference><Citation>Salminen S, Collado MC, Endo A, Hill C, Lebeer S, Quigley EMM, Sanders ME, Shamir R, Swann JR, Szajewska H, et al. The international scientific association of probiotics and prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol. 2021;18(9):649&#x2013;667. doi:10.1038/s41575-021-00440-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-021-00440-6</ArticleId><ArticleId IdType="pmc">PMC8387231</ArticleId><ArticleId IdType="pubmed">33948025</ArticleId></ArticleIdList></Reference><Reference><Citation>Veiga P, Suez J, Derrien M, Elinav E. Moving from probiotics to precision probiotics. Nat Microbiol. 2020;5(7):878&#x2013;880. doi:10.1038/s41564-020-0721-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-0721-1</ArticleId><ArticleId IdType="pubmed">32393856</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, Li X, Zhang G, Sadiq FA, Simal&#x2010;Gandara J, Xiao J, Sang Y. Probiotics in the dairy industry-advances and opportunities. Compr Rev Food Sci Food Saf. 2021;20(4):3937&#x2013;3982. doi:10.1111/1541-4337.12755.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1541-4337.12755</ArticleId><ArticleId IdType="pubmed">33938124</ArticleId></ArticleIdList></Reference><Reference><Citation>Suez J, Zmora N, Segal E, Elinav E. The pros, cons, and many unknowns of probiotics. Nat Med. 2019;25(5):716&#x2013;729. doi:10.1038/s41591-019-0439-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0439-x</ArticleId><ArticleId IdType="pubmed">31061539</ArticleId></ArticleIdList></Reference><Reference><Citation>Wie&#xeb;rs G, Belkhir L, Enaud R, Leclercq S, Philippart de Foy J-M, Dequenne I, de Timary P, Cani PD. How probiotics affect the microbiota. Front Cell Infect Microbiol. 2020;9(454). doi:10.3389/fcimb.2019.00454.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2019.00454</ArticleId><ArticleId IdType="pmc">PMC6974441</ArticleId><ArticleId IdType="pubmed">32010640</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou Q, Zhao F, Liu W, Lv R, Khine WWT, Han J, Sun Z, Lee Y-K, Zhang H. Probiotic-directed modulation of gut microbiota is basal microbiome dependent. Gut Microbes. 2020;12(1):1736974. doi:10.1080/19490976.2020.1736974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2020.1736974</ArticleId><ArticleId IdType="pmc">PMC7524168</ArticleId><ArticleId IdType="pubmed">32200683</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh TP, Natraj BH. Next-generation probiotics: a promising approach towards designing personalized medicine. Crit Rev Microbiol. 2021;47(4):479&#x2013;498. doi:10.1080/1040841X.2021.1902940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1040841X.2021.1902940</ArticleId><ArticleId IdType="pubmed">33822669</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai Q, Feng S, Arjan N, Chen W. A next generation probiotic, Akkermansia muciniphila. Crit Rev Food Sci Nutr. 2019;59(19):3227&#x2013;3236. doi:10.1080/10408398.2018.1517725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10408398.2018.1517725</ArticleId><ArticleId IdType="pubmed">30373382</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshavarz Azizi Raftar S, Abdollahiyan S, Azimirad M, Yadegar A, Vaziri F, Moshiri A, Siadat SD, Zali MR. The anti-fibrotic effects of heat-killed akkermansia muciniphila muct on liver fibrosis markers and activation of hepatic stellate cells. Probiotics Antimicrob Proteins. 2021;13(3):776&#x2013;787. doi:10.1007/s12602-020-09733-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12602-020-09733-9</ArticleId><ArticleId IdType="pubmed">33433897</ArticleId></ArticleIdList></Reference><Reference><Citation>Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, Falony G, Raes J, Maiter D, Delzenne NM, et al. Supplementation with akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019;25(7):1096&#x2013;1103. doi:10.1038/s41591-019-0495-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0495-2</ArticleId><ArticleId IdType="pmc">PMC6699990</ArticleId><ArticleId IdType="pubmed">31263284</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma G, Nadal I, Medina M, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y. Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children. BMC Microbiol. 2010;10(1):63. doi:10.1186/1471-2180-10-63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2180-10-63</ArticleId><ArticleId IdType="pmc">PMC2843610</ArticleId><ArticleId IdType="pubmed">20181275</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajilic-Stojanovic M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011;141(5):1792&#x2013;1801. doi:10.1053/j.gastro.2011.07.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2011.07.043</ArticleId><ArticleId IdType="pubmed">21820992</ArticleId></ArticleIdList></Reference><Reference><Citation>Balamurugan R, Rajendiran E, George S, Samuel GV, Ramakrishna BS. Real-time polymerase chain reaction quantification of specific butyrate-producing bacteria, desulfovibrio and Enterococcus faecalis in the feces of patients with colorectal cancer. J Gastroenterol Hepatol. 2008;23(8 Pt 1):1298&#x2013;1303. doi:10.1111/j.1440-1746.2008.05490.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1746.2008.05490.x</ArticleId><ArticleId IdType="pubmed">18624900</ArticleId></ArticleIdList></Reference><Reference><Citation>Furet J-P, Kong L-C, Tap J, Poitou C, Basdevant A, Bouillot J-L, Mariat D, Corthier G, Dor&#xe9; J, Henegar C, et al. Differential adaptation of human gut microbiota to bariatric surgery&#x2013;induced weight loss. Diabetes. 2010;59(12):3049&#x2013;3057. doi:10.2337/db10-0253.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db10-0253</ArticleId><ArticleId IdType="pmc">PMC2992765</ArticleId><ArticleId IdType="pubmed">20876719</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin R, Miquel S, Benevides L, Bridonneau C, Robert V, Hudault S, Chain F, Berteau O, Azevedo V, Chatel JM, et al. Functional characterization of novel faecalibacterium prausnitzii strains isolated from healthy volunteers: a step forward in the use of F. prausnitzii as a next-generation probiotic. Front Microbiol. 2017;8:1226. doi:10.3389/fmicb.2017.01226.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2017.01226</ArticleId><ArticleId IdType="pmc">PMC5492426</ArticleId><ArticleId IdType="pubmed">28713353</ArticleId></ArticleIdList></Reference><Reference><Citation>Fei Y, Chen Z, Han S, Zhang S, Zhang T, Lu Y, Berglund B, Xiao H, Li L, Yao M, et al. Role of prebiotics in enhancing the function of next-generation probiotics in gut microbiota. Crit Rev Food Sci Nutr. pp.1&#x2013;18. 2021. doi:10.1080/10408398.2021.1958744</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10408398.2021.1958744</ArticleId><ArticleId IdType="pubmed">34323634</ArticleId></ArticleIdList></Reference><Reference><Citation>Min S, Kim S, Cho SW. Gastrointestinal tract modeling using organoids engineered with cellular and microbiota niches. Exp Mol Med. 2020;52(2):227&#x2013;237. doi:10.1038/s12276-020-0386-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-020-0386-0</ArticleId><ArticleId IdType="pmc">PMC7062772</ArticleId><ArticleId IdType="pubmed">32103122</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah SC, Iyer PG, Moss SF. AGA clinical practice update on the management of refractory Helicobacter pylori infection: expert review. Gastroenterology. 2021;160(5):1831&#x2013;1841. doi:10.1053/j.gastro.2020.11.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.11.059</ArticleId><ArticleId IdType="pmc">PMC8281326</ArticleId><ArticleId IdType="pubmed">33524402</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151(1):51&#x2013;69.e14. doi:10.1053/j.gastro.2016.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.04.006</ArticleId><ArticleId IdType="pubmed">27102658</ArticleId></ArticleIdList></Reference><Reference><Citation>Liou JM, Chen CC, Chang CM, Fang Y-J, Bair M-J, Chen P-Y, Chang C-Y, Hsu Y-C, Chen M-J, Chen -C-C, et al. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial. Lancet Infect Dis. 2019;19(10):1109&#x2013;1120. doi:10.1016/S1473-3099(19)30272-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(19)30272-5</ArticleId><ArticleId IdType="pubmed">31559966</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut. 2020;69(12):2113&#x2013;2121. doi:10.1136/gutjnl-2020-320839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-320839</ArticleId><ArticleId IdType="pubmed">32205420</ArticleId></ArticleIdList></Reference><Reference><Citation>Tshibangu-Kabamba E, Yamaoka Y. Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications. Nat Rev Gastroenterol Hepatol. 2021;18(9):613&#x2013;629. doi:10.1038/s41575-021-00449-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-021-00449-x</ArticleId><ArticleId IdType="pubmed">34002081</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut. 2018;67(1):28&#x2013;35. doi:10.1136/gutjnl-2017-314605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2017-314605</ArticleId><ArticleId IdType="pubmed">29089382</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J, He Q, Nguyen LH, Wong MCS, Huang J, Yu Y, Xia B, Tang Y, He Y, Zhang C, et al. Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies. Gut. 2021;70(6):1070&#x2013;1077. doi:10.1136/gutjnl-2020-322557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-322557</ArticleId><ArticleId IdType="pubmed">32989021</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Q, Shao X, Shen R, Chen D, Shen J. Changes in the human gut microbiota composition caused by Helicobacter pylori eradication therapy: a systematic review and meta-analysis. Helicobacter. 2020;25(4):e12713. doi:10.1111/hel.12713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hel.12713</ArticleId><ArticleId IdType="pubmed">32515529</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. BMJ. 2018;361:k2179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6000740</ArticleId><ArticleId IdType="pubmed">29899036</ArticleId></ArticleIdList></Reference><Reference><Citation>Handa O, Naito Y, Osawa M. Nutrients and probiotics: current trends in their use to eradicate Helicobacter pylori. J Clin Biochem Nutr. 2020;67(1):26&#x2013;28. doi:10.3164/jcbn.20-51.</Citation><ArticleIdList><ArticleId IdType="doi">10.3164/jcbn.20-51</ArticleId><ArticleId IdType="pmc">PMC7417805</ArticleId><ArticleId IdType="pubmed">32801465</ArticleId></ArticleIdList></Reference><Reference><Citation>Montassier E, Valdes-Mas R, Batard E. Probiotics impact the antibiotic resistance gene reservoir along the human GI tract in a person-specific and antibiotic-dependent manner. Nat Microbiol. 2021;6(8):1043&#x2013;1054. doi:10.1038/s41564-021-00920-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-021-00920-0</ArticleId><ArticleId IdType="pmc">PMC8318886</ArticleId><ArticleId IdType="pubmed">34226711</ArticleId></ArticleIdList></Reference><Reference><Citation>Cifuentes SG, Prado MB, Fornasini M, Cohen H, Baldeon ME, Cardenas PA. Saccharomyces boulardii CNCM I-745 supplementation modifies the fecal resistome during Helicobacter pylori eradication therapy. Helicobacter. 2022;27(2):e12870. doi:10.1111/hel.12870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hel.12870</ArticleId><ArticleId IdType="pubmed">34990038</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Zhang C, Zhao J, Zhang H, Zhai Q, Chen W. Meta-analysis of the efficacy of probiotic-supplemented therapy on the eradication of H. pylori and incidence of therapy-associated side effects. Microb Pathog. 2020;147:104403. doi:10.1016/j.micpath.2020.104403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2020.104403</ArticleId><ArticleId IdType="pubmed">32707316</ArticleId></ArticleIdList></Reference><Reference><Citation>Losurdo G, Cubisino R, Barone M, Principi M, Leandro G, Ierardi E, Leo AD. Probiotic monotherapy and Helicobacter pylori eradication: a systematic review with pooled-data analysis. World J Gastroenterol. 2018;24(1):139&#x2013;149. doi:10.3748/wjg.v24.i1.139.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v24.i1.139</ArticleId><ArticleId IdType="pmc">PMC5757118</ArticleId><ArticleId IdType="pubmed">29358890</ArticleId></ArticleIdList></Reference><Reference><Citation>Kori M, Daugule I, Urbonas V. Helicobacter pylori and some aspects of gut microbiota in children. Helicobacter. 2018;23(Suppl 1):e12524. doi:10.1111/hel.12524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hel.12524</ArticleId><ArticleId IdType="pubmed">30203591</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng JR, Wang F, Qiu X, McFarland LV, Chen P-F, Zhou R, Liu J, Zhao Q, Li J. Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis. Eur J Clin Pharmacol. 2017;73(10):1199&#x2013;1208. doi:10.1007/s00228-017-2291-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-017-2291-6</ArticleId><ArticleId IdType="pubmed">28681177</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamiya S, Yonezawa H, Osaki T. Role of probiotics in eradication therapy for Helicobacter pylori infection. Adv Exp Med Biol. 2019;1149:243&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">31016634</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang HR, Zhang GQ, Cheng JY, Li ZY. Efficacy of lactobacillus-supplemented triple therapy for Helicobacter pylori infection in children: a meta-analysis of randomized controlled trials. Eur J Pediatr. 2019;178(1):7&#x2013;16. doi:10.1007/s00431-018-3282-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-018-3282-z</ArticleId><ArticleId IdType="pubmed">30446816</ArticleId></ArticleIdList></Reference><Reference><Citation>McElrath C, Espinosa V, Lin JD. Critical role of interferons in gastrointestinal injury repair. Nat Commun. 2021;12(1):2624. doi:10.1038/s41467-021-22928-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-22928-0</ArticleId><ArticleId IdType="pmc">PMC8113246</ArticleId><ArticleId IdType="pubmed">33976143</ArticleId></ArticleIdList></Reference><Reference><Citation>George S, Lucero Y, Torres JP, Lagomarcino AJ, O&#x2019;Ryan M. Gastric damage and cancer-associated biomarkers in Helicobacter pylori-infected children. Front Microbiol. 2020;11(90). doi:10.3389/fmicb.2020.00090.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.00090</ArticleId><ArticleId IdType="pmc">PMC7029740</ArticleId><ArticleId IdType="pubmed">32117120</ArticleId></ArticleIdList></Reference><Reference><Citation>Paone P, Cani PD. Mucus barrier, mucins and gut microbiota: the expected slimy partners? Gut. 2020;69(12):2232&#x2013;2243. doi:10.1136/gutjnl-2020-322260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-322260</ArticleId><ArticleId IdType="pmc">PMC7677487</ArticleId><ArticleId IdType="pubmed">32917747</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh S, Whitley CS, Haribabu B, Jala VR. Regulation of intestinal barrier function by microbial metabolites. Cell Mol Gastroenterol Hepatol. 2021;11(5):1463&#x2013;1482. doi:10.1016/j.jcmgh.2021.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmgh.2021.02.007</ArticleId><ArticleId IdType="pmc">PMC8025057</ArticleId><ArticleId IdType="pubmed">33610769</ArticleId></ArticleIdList></Reference><Reference><Citation>Qureshi N, Li P, Gu Q. Probiotic therapy in Helicobacter pylori infection: a potential strategy against a serious pathogen? Appl Microbiol Biotechnol. 2019;103(4):1573&#x2013;1588. doi:10.1007/s00253-018-09580-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00253-018-09580-3</ArticleId><ArticleId IdType="pubmed">30610283</ArticleId></ArticleIdList></Reference><Reference><Citation>Azimirad M, Krutova M, Yadegar A, Shahrokh S, Olfatifar M, Aghdaei HA, Fawley WN, Wilcox MH, Zali MR. Clostridioides difficile ribotypes 001 and 126 were predominant in Tehran healthcare settings from 2004 to 2018: a 14-year-long cross-sectional study. Emerg Microbes Infect. 2020;9(1):1432&#x2013;1443. doi:10.1080/22221751.2020.1780949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1780949</ArticleId><ArticleId IdType="pmc">PMC7473134</ArticleId><ArticleId IdType="pubmed">32520657</ArticleId></ArticleIdList></Reference><Reference><Citation>Cristofori F, Dargenio VN, Dargenio C, Miniello VL, Barone M, Francavilla R. Anti-inflammatory and immunomodulatory effects of probiotics in gut inflammation: a door to the body. Front Immunol. 2021;12:578386. doi:10.3389/fimmu.2021.578386.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.578386</ArticleId><ArticleId IdType="pmc">PMC7953067</ArticleId><ArticleId IdType="pubmed">33717063</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques MS, Costa AC, Os&#xf3;rio H, Pinto ML, Relvas S, Dinis-Ribeiro M, Carneiro F, Leite M, Figueiredo C. Helicobacter pylori PqqE is a new virulence factor that cleaves junctional adhesion molecule A and disrupts gastric epithelial integrity. Gut Microbes. 2021;13(1):1921928. doi:10.1080/19490976.2021.1921928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2021.1921928</ArticleId><ArticleId IdType="pmc">PMC8115454</ArticleId><ArticleId IdType="pubmed">33970782</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose EC, Odle J, Blikslager AT, Ziegler AL. Probiotics, prebiotics and epithelial tight junctions: a promising approach to modulate intestinal barrier function. Int J Mol Sci. 2021;22(13):6729. doi:10.3390/ijms22136729.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22136729</ArticleId><ArticleId IdType="pmc">PMC8268081</ArticleId><ArticleId IdType="pubmed">34201613</ArticleId></ArticleIdList></Reference><Reference><Citation>Llewellyn A, Foey A. Probiotic Modulation of Innate Cell Pathogen Sensing and Signaling Events. Nutrients. 2017;9(10):1156. doi:10.3390/nu9101156.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu9101156</ArticleId><ArticleId IdType="pmc">PMC5691772</ArticleId><ArticleId IdType="pubmed">29065562</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji J, Yang H. Using probiotics as supplementation for helicobacter pylori antibiotic therapy. Int J Mol Sci. 2020;21(3):1136. doi:10.3390/ijms21031136.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21031136</ArticleId><ArticleId IdType="pmc">PMC7037652</ArticleId><ArticleId IdType="pubmed">32046317</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng T, Wang J. Oxidative stress tolerance and antioxidant capacity of lactic acid bacteria as probiotic: a systematic review. Gut Microbes. 2020;12(1):1801944. doi:10.1080/19490976.2020.1801944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2020.1801944</ArticleId><ArticleId IdType="pmc">PMC7524341</ArticleId><ArticleId IdType="pubmed">32795116</ArticleId></ArticleIdList></Reference><Reference><Citation>van Zyl WF, Deane SM, Dicks LMT. Molecular insights into probiotic mechanisms of action employed against intestinal pathogenic bacteria. Gut Microbes. 2020;12(1):1831339. doi:10.1080/19490976.2020.1831339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2020.1831339</ArticleId><ArticleId IdType="pmc">PMC7595611</ArticleId><ArticleId IdType="pubmed">33112695</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders ME, Merenstein DJ, Reid G, Gibson GR, Rastall RA. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat Rev Gastroenterol Hepatol. 2019;16(10):605&#x2013;616. doi:10.1038/s41575-019-0173-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-019-0173-3</ArticleId><ArticleId IdType="pubmed">31296969</ArticleId></ArticleIdList></Reference><Reference><Citation>van Baarlen P, Troost FJ, van Hemert S, van der Meer C, de Vos WM, de Groot PJ, Hooiveld GJEJ, Brummer RJM, Kleerebezem M. Differential NF-&#x3ba;B pathways induction by Lactobacillus plantarum in the duodenum of healthy humans correlating with immune tolerance. Proc Natl Acad Sci U S A. 2009;106(7):2371&#x2013;2376. doi:10.1073/pnas.0809919106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0809919106</ArticleId><ArticleId IdType="pmc">PMC2650163</ArticleId><ArticleId IdType="pubmed">19190178</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong W, Li Q, Yu J. Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer. Oncogene. 2020;39(26):4925&#x2013;4943. doi:10.1038/s41388-020-1341-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41388-020-1341-1</ArticleId><ArticleId IdType="pmc">PMC7314664</ArticleId><ArticleId IdType="pubmed">32514151</ArticleId></ArticleIdList></Reference><Reference><Citation>Hrd&#xfd; J, Alard J, Couturier-Maillard A, Boulard O, Boutillier D, Delacre M, Lapadatescu C, Cesaro A, Blanc P, Pot B, et al. Lactobacillus reuteri 5454 and Bifidobacterium animalis ssp. lactis 5764 improve colitis while differentially impacting dendritic cells maturation and antimicrobial responses. Sci Rep. 2020;10(1):5345. doi:10.1038/s41598-020-62161-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-62161-1</ArticleId><ArticleId IdType="pmc">PMC7093418</ArticleId><ArticleId IdType="pubmed">32210304</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu K, Dong S, Wu X, Jin R, Chen H. Probiotics in Cancer. Front Oncol. 2021;11:638148. doi:10.3389/fonc.2021.638148.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.638148</ArticleId><ArticleId IdType="pmc">PMC8006328</ArticleId><ArticleId IdType="pubmed">33791223</ArticleId></ArticleIdList></Reference><Reference><Citation>Tezuka H, Ohteki T. Regulation of IgA Production by Intestinal Dendritic Cells and Related Cells. Front Immunol. 2019;10:1891. doi:10.3389/fimmu.2019.01891.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01891</ArticleId><ArticleId IdType="pmc">PMC6700333</ArticleId><ArticleId IdType="pubmed">31456802</ArticleId></ArticleIdList></Reference><Reference><Citation>Eslami M, Yousefi B, Kokhaei P, Jazayeri Moghadas A, Sadighi Moghadam B, Arabkari V, Niazi Z. Are probiotics useful for therapy of Helicobacter pylori diseases? Comp Immunol Microbiol Infect Dis. 2019;64:99&#x2013;108. doi:10.1016/j.cimid.2019.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cimid.2019.02.010</ArticleId><ArticleId IdType="pubmed">31174707</ArticleId></ArticleIdList></Reference><Reference><Citation>Motta JP, Wallace JL, Buret AG, Deraison C, Vergnolle N. Gastrointestinal biofilms in health and disease. Nat Rev Gastroenterol Hepatol. 2021;18(5):314&#x2013;334. doi:10.1038/s41575-020-00397-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-020-00397-y</ArticleId><ArticleId IdType="pubmed">33510461</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh B, Kim BS, Kim JW, Kim JS, Koh S-J, Kim BG, Lee KL, Chun J. The effect of probiotics on gut microbiota during the Helicobacter pylori eradication: randomized controlled trial. Helicobacter. 2016;21(3):165&#x2013;174. doi:10.1111/hel.12270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hel.12270</ArticleId><ArticleId IdType="pubmed">26395781</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh B, Kim JW, Kim BS. Changes in the functional potential of the gut microbiome following probiotic supplementation during Helicobacter Pylori treatment. Helicobacter. 2016;21:493&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">26991862</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L, Wang Z, Sun G. Effects of anti-H. pylori triple therapy and a probiotic complex on intestinal microbiota in duodenal ulcer. Sci Rep. 2019;9(1):12874. doi:10.1038/s41598-019-49415-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-49415-3</ArticleId><ArticleId IdType="pmc">PMC6731296</ArticleId><ArticleId IdType="pubmed">31492912</ArticleId></ArticleIdList></Reference><Reference><Citation>C&#xe1;rdenas PA, Garc&#xe9;s D, Prado-Vivar B, Flores N, Fornasini M, Cohen H, Salvador I, Cargua O, Balde&#xf3;n ME. Effect of Saccharomyces boulardii CNCM I-745 as complementary treatment of Helicobacter pylori infection on gut microbiome. Eur J Clin Microbiol Infect Dis. 2020;39(7):1365&#x2013;1372. doi:10.1007/s10096-020-03854-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-020-03854-3</ArticleId><ArticleId IdType="pubmed">32125555</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakiuchi T, Mizoe A, Yamamoto K, Imamura I, Hashiguchi K, Kawakubo H, Yamaguchi D, Fujioka Y, Nakayama A, Okuda M, et al. Effect of probiotics during vonoprazan-containing triple therapy on gut microbiota in Helicobacter pylori infection: a randomized controlled trial. Helicobacter. 2020;25(3):e12690. doi:10.1111/hel.12690.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hel.12690</ArticleId><ArticleId IdType="pubmed">32207209</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang B, Tang L, Huang C, Tian C, Chen L, He Z, Yang G, Zuo L, Zhao G, Liu E, et al. The effect of probiotics supplementation on gut microbiota after Helicobacter pylori eradication: a multicenter randomized controlled trial. Infect Dis Ther. 2021;10(1):317&#x2013;333. doi:10.1007/s40121-020-00372-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-020-00372-9</ArticleId><ArticleId IdType="pmc">PMC7955021</ArticleId><ArticleId IdType="pubmed">33270205</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillemard E, Poirel M, Sch&#xe4;fer F, Quinquis L, Rossoni C, Keicher C, Wagner F, Szajewska H, Barbut F, Derrien M, et al. A randomised, controlled trial: effect of a multi-strain fermented milk on the gut microbiota recovery after helicobacter pylori therapy. Nutrients. 2021;13(9):3171. doi:10.3390/nu13093171.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13093171</ArticleId><ArticleId IdType="pmc">PMC8466689</ArticleId><ArticleId IdType="pubmed">34579049</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Liang L, Lv P, Liu L, Wang S, Wang Z, Chen Y. Effects of non-viable Lactobacillus reuteri combining with 14-day standard triple therapy on Helicobacter pylori eradication: a randomized double-blind placebo-controlled trial. Helicobacter. 2021;26(6):e12856. doi:10.1111/hel.12856.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hel.12856</ArticleId><ArticleId IdType="pubmed">34628695</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Z, Xiao S, Li S, Suo B, Wang Y, Meng L, Liu Z, Yin Z, Xue Y, Zhou L, et al. The impact of Helicobacter pylori infection, eradication therapy, and probiotics intervention on gastric microbiota in young adults. Helicobacter. 2021;26(6):e12848. doi:10.1111/hel.12848.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hel.12848</ArticleId><ArticleId IdType="pubmed">34448282</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoeva MK, Garcia-So J, Justice N, Myers J, Tyagi S, Nemchek M, McMurdie PJ, Kolterman O, Eid J. Butyrate-producing human gut symbiont, Clostridium butyricum, and its role in health and disease. Gut Microbes. 2021;13(1):1&#x2013;28. doi:10.1080/19490976.2021.1907272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2021.1907272</ArticleId><ArticleId IdType="pmc">PMC8078720</ArticleId><ArticleId IdType="pubmed">33874858</ArticleId></ArticleIdList></Reference><Reference><Citation>Ariyoshi T, Hagihara M, Tomono S, Eguchi S, Minemura A, Miura D, Oka K, Takahashi M, Yamagishi Y, Mikamo H, et al. Clostridium butyricum MIYAIRI 588 modifies bacterial composition under antibiotic-induced dysbiosis for the activation of interactions via lipid metabolism between the gut microbiome and the host. Biomedicines. 2021;9(8):1065. doi:10.3390/biomedicines9081065.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9081065</ArticleId><ArticleId IdType="pmc">PMC8391242</ArticleId><ArticleId IdType="pubmed">34440269</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Huang JM, Zhou YL, Almeida A, Finn RD, Danchin A, He L-S. Phylogenomics of expanding uncultured environmental Tenericutes provides insights into their pathogenicity and evolutionary relationship with Bacilli. BMC Genomics. 2020;21(1):408. doi:10.1186/s12864-020-06807-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12864-020-06807-4</ArticleId><ArticleId IdType="pmc">PMC7301438</ArticleId><ArticleId IdType="pubmed">32552739</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan X, Chen R, McCormick KL, Zhang Y, Lin X, Yang X. The role of the gut microbiota on the metabolic status of obese children. Microb Cell Fact. 2021;20(1):53. doi:10.1186/s12934-021-01548-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12934-021-01548-9</ArticleId><ArticleId IdType="pmc">PMC7916301</ArticleId><ArticleId IdType="pubmed">33639944</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeoh YK, Chen Z, Wong MCS, Hui M, Yu J, Ng SC, Sung JJY, Chan FKL, Chan PKS. Southern Chinese populations harbour non-nucleatum Fusobacteria possessing homologues of the colorectal cancer-associated FadA virulence factor. Gut. 2020;69(11):1998&#x2013;2007. doi:10.1136/gutjnl-2019-319635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2019-319635</ArticleId><ArticleId IdType="pmc">PMC7569397</ArticleId><ArticleId IdType="pubmed">32051205</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrandah AM, Chukkapalli SS, Bhattacharyya I, Progulske-Fox A, Chan EKL. Fusobacteria modulate oral carcinogenesis and promote cancer progression. J Oral Microbiol. 2020;13:1849493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7717872</ArticleId><ArticleId IdType="pubmed">33391626</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding CM, Hennon SW, Feldman MF. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat Rev Microbiol. 2018;16(2):91&#x2013;102. doi:10.1038/nrmicro.2017.148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro.2017.148</ArticleId><ArticleId IdType="pmc">PMC6571207</ArticleId><ArticleId IdType="pubmed">29249812</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WY, Kim HJ. Current biochemical understanding regarding the metabolism of acinetobactin, the major siderophore of the human pathogen Acinetobacter baumannii, and outlook for discovery of novel anti-infectious agents based thereon. Nat Prod Rep. 2020;37(4):477&#x2013;487. doi:10.1039/C9NP00046A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C9NP00046A</ArticleId><ArticleId IdType="pubmed">31661538</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Zhong X, Liu X, Wang X, Gao X. Therapeutic and improving function of lactobacilli in the prevention and treatment of cardiovascular-related diseases: a novel perspective from gut microbiota. Frontiers in Nutrition. 2021;8(299). doi:10.3389/fnut.2021.693412.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2021.693412</ArticleId><ArticleId IdType="pmc">PMC8215129</ArticleId><ArticleId IdType="pubmed">34164427</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanchi H, Mottawea W, Sebei K, Hammami R. The genus enterococcus: between probiotic potential and safety concerns&#x2014;an update. Front Microbiol. 2018;9(1791). doi:10.3389/fmicb.2018.01791.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.01791</ArticleId><ArticleId IdType="pmc">PMC6085487</ArticleId><ArticleId IdType="pubmed">30123208</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Mao B, Gu J, Wu J, Cui S, Wang G, Zhao J, Zhang H, Chen W. Blautia &#x2014;a new functional genus with potential probiotic properties? Gut Microbes. 2021;13(1):1&#x2013;21. doi:10.1080/19490976.2021.1875796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2021.1875796</ArticleId><ArticleId IdType="pmc">PMC7872077</ArticleId><ArticleId IdType="pubmed">33525961</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang H, Gan J, Zeng D, Li J, Yu H, Zhao H, Yang Y, Tan S, Li G, Luo C, et al. Specific microbial taxa and functional capacity contribute to chicken abdominal fat deposition. Front Microbiol. 2021;12:643025. doi:10.3389/fmicb.2021.643025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.643025</ArticleId><ArticleId IdType="pmc">PMC8010200</ArticleId><ArticleId IdType="pubmed">33815329</ArticleId></ArticleIdList></Reference><Reference><Citation>Goris T, Cuadrat RRC, Braune A. Flavonoid-modifying capabilities of the human gut microbiome-an in silico study. Nutrients. 2021;13(8):2688. doi:10.3390/nu13082688.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13082688</ArticleId><ArticleId IdType="pmc">PMC8398226</ArticleId><ArticleId IdType="pubmed">34444848</ArticleId></ArticleIdList></Reference><Reference><Citation>Engevik MA, Danhof HA, Ruan W, Engevik AC, Chang-Graham AL, Engevik KA, Shi Z, Zhao Y, Brand CK, Krystofiak ES, et al. Fusobacterium nucleatum Secretes outer membrane vesicles and promotes intestinal inflammation. mBio. 2021;12(2). doi:10.1128/mBio.02706-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.02706-20</ArticleId><ArticleId IdType="pmc">PMC8092269</ArticleId><ArticleId IdType="pubmed">33653893</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranjbar M, Salehi R, Haghjooy Javanmard S, Rafiee L, Faraji H, Jafarpor S, Ferns GA, Ghayour-Mobarhan M, Manian M, Nedaeinia R, et al. The dysbiosis signature of fusobacterium nucleatum in colorectal cancer-cause or consequences? A systematic review. Cancer Cell Int. 2021;21(1):194. doi:10.1186/s12935-021-01886-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-021-01886-z</ArticleId><ArticleId IdType="pmc">PMC8025348</ArticleId><ArticleId IdType="pubmed">33823861</ArticleId></ArticleIdList></Reference><Reference><Citation>Murros KE, Huynh VA, Takala TM, Saris PEJ. Desulfovibrio bacteria are associated with parkinson&#x2019;s disease. Front Cell Infect Microbiol. 2021;11:652617. doi:10.3389/fcimb.2021.652617.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.652617</ArticleId><ArticleId IdType="pmc">PMC8126658</ArticleId><ArticleId IdType="pubmed">34012926</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosario D, Bidkhori G, Lee S, Bedarf J, Hildebrand F, Le Chatelier E, Uhlen M, Ehrlich SD, Proctor G, W&#xfc;llner U, et al. Systematic analysis of gut microbiome reveals the role of bacterial folate and homocysteine metabolism in Parkinson&#x2019;s disease. Cell Rep. 2021;34(9):108807. doi:10.1016/j.celrep.2021.108807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.108807</ArticleId><ArticleId IdType="pubmed">33657381</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao J, Li Z, Gao Y, Zhao K, Lin M, Li Y, Wang S, Liu Y, Chen L. Construction of a &#x201c;Bacteria-Metabolites&#x201d; co-expression network to clarify the anti-ulcerative colitis effect of flavonoids of sophora flavescens aiton by regulating the &#x201c;Host-Microbe&#x201d; interaction. Front Pharmacol. 2021;12:710052. doi:10.3389/fphar.2021.710052.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.710052</ArticleId><ArticleId IdType="pmc">PMC8553221</ArticleId><ArticleId IdType="pubmed">34721011</ArticleId></ArticleIdList></Reference><Reference><Citation>Caulier S, Nannan C, Gillis A, Licciardi F, Bragard C, Mahillon J. Overview of the antimicrobial compounds produced by members of the Bacillus subtilis group. Front Microbiol. 2019;10:302. doi:10.3389/fmicb.2019.00302.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2019.00302</ArticleId><ArticleId IdType="pmc">PMC6401651</ArticleId><ArticleId IdType="pubmed">30873135</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin RM, Bachman MA. Colonization, infection, and the accessory genome of Klebsiella pneumoniae. Front Cell Infect Microbiol. 2018;8:4. doi:10.3389/fcimb.2018.00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2018.00004</ArticleId><ArticleId IdType="pmc">PMC5786545</ArticleId><ArticleId IdType="pubmed">29404282</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong S, Jiao J, Jia S, Li G, Zhang W, Yang K, Wang Z, Liu C, Li D, Wang X, et al. 16S rDNA full-length assembly sequencing technology analysis of intestinal microbiome in polycystic ovary syndrome. Front Cell Infect Microbiol. 2021;11:634981. doi:10.3389/fcimb.2021.634981.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.634981</ArticleId><ArticleId IdType="pmc">PMC8141595</ArticleId><ArticleId IdType="pubmed">34041041</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X, &#xc5;vall-J&#xe4;&#xe4;skel&#xe4;inen S, Koort J, Lindholm A, Rintahaka J, von Ossowski I, Palva A, Hyn&#xf6;nen U. A comparative characterization of different host-sourced lactobacillus ruminis strains and their adhesive, inhibitory, and immunomodulating functions. Front Microbiol. 2017;8(657). doi:10.3389/fmicb.2017.00657.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2017.00657</ArticleId><ArticleId IdType="pmc">PMC5390032</ArticleId><ArticleId IdType="pubmed">28450859</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Li Y, Wen Z, Liu W, Meng L, Huang H. Oscillospira - a candidate for the next-generation probiotics. Gut Microbes. 2021;13(1):1987783. doi:10.1080/19490976.2021.1987783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2021.1987783</ArticleId><ArticleId IdType="pmc">PMC8547878</ArticleId><ArticleId IdType="pubmed">34693878</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartley A, Yang T, Arocha R, Malphurs WL, Larkin R, Magee KL, Vickroy TW, Zubcevic J. Increased abundance of lactobacillales in the colon of beta-adrenergic receptor knock out mouse is associated with increased gut bacterial production of short chain fatty acids and reduced IL17 expression in circulating CD4+ immune cells. Front Physiol. 2018;9(1593). doi:10.3389/fphys.2018.01593.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2018.01593</ArticleId><ArticleId IdType="pmc">PMC6242911</ArticleId><ArticleId IdType="pubmed">30483153</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Xie Y, Zhou F, Zhang B, Wu J, Yang L, Xu S, Stedtfeld R, Chen Q, Liu J, et al. Featured Gut Microbiomes Associated With the Progression of Chronic Hepatitis B Disease. Front Microbiol. 2020;11:383. doi:10.3389/fmicb.2020.00383.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.00383</ArticleId><ArticleId IdType="pmc">PMC7098974</ArticleId><ArticleId IdType="pubmed">32265857</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Chen C, Yu H, Yang Z. Fecal microbiota changes in patients with postpartum depressive disorder. Front Cell Infect Microbiol. 2020;10:567268. doi:10.3389/fcimb.2020.567268.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.567268</ArticleId><ArticleId IdType="pmc">PMC7550660</ArticleId><ArticleId IdType="pubmed">33134190</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagao-Kitamoto H, Leslie JL, Kitamoto S, Jin C, Thomsson KA, Gillilland MG, Kuffa P, Goto Y, Jenq RR, Ishii C, et al. Interleukin-22-mediated host glycosylation prevents clostridioides difficile infection by modulating the metabolic activity of the gut microbiota. Nat Med. 2020;26(4):608&#x2013;617. doi:10.1038/s41591-020-0764-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0764-0</ArticleId><ArticleId IdType="pmc">PMC7160049</ArticleId><ArticleId IdType="pubmed">32066975</ArticleId></ArticleIdList></Reference><Reference><Citation>Tito RY, Cypers H, Joossens M, Varkas G, Van Praet L, Glorieus E, Van den Bosch F, De Vos M, Raes J, Elewaut D, et al. Brief report: dialister as a microbial marker of disease activity in spondyloarthritis. Arthritis &amp; Rheumatology. 2017;69(1):114&#x2013;121. doi:10.1002/art.39802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39802</ArticleId><ArticleId IdType="pubmed">27390077</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaakoush NO. Sutterella species, iga-degrading bacteria in ulcerative colitis. Trends Microbiol. 2020;28(7):519&#x2013;522. doi:10.1016/j.tim.2020.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2020.02.018</ArticleId><ArticleId IdType="pubmed">32544438</ArticleId></ArticleIdList></Reference><Reference><Citation>Astbury S, Atallah E, Vijay A, Aithal GP, Grove JI, Valdes AM. Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis. Gut Microbes. 2020;11(3):569&#x2013;580. doi:10.1080/19490976.2019.1681861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2019.1681861</ArticleId><ArticleId IdType="pmc">PMC7524262</ArticleId><ArticleId IdType="pubmed">31696774</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailen M, Bressa C, Martinez-Lopez S, Gonz&#xe1;lez-Soltero R, Montalvo Lominchar MG, San Juan C, Larrosa M. Microbiota features associated with a high-fat/low-fiber diet in healthy adults. Front Nutr. 2020;7:583608. doi:10.3389/fnut.2020.583608.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2020.583608</ArticleId><ArticleId IdType="pmc">PMC7775391</ArticleId><ArticleId IdType="pubmed">33392236</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Coker OO, Chu ES, Fu K, Lau HCH, Wang Y-X, Chan AWH, Wei H, Yang X, Sung JJY, et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut. 2021;70(4):761&#x2013;774. doi:10.1136/gutjnl-2019-319664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2019-319664</ArticleId><ArticleId IdType="pmc">PMC7948195</ArticleId><ArticleId IdType="pubmed">32694178</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan C, Yin Z, Wang J, Qian C, Wei Y, Zhang S, Jiang L, Liu B. Comparative genomic analysis of citrobacter and key genes essential for the pathogenicity of Citrobacter koseri. Front Microbiol. 2019;10:2774. doi:10.3389/fmicb.2019.02774.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2019.02774</ArticleId><ArticleId IdType="pmc">PMC6908497</ArticleId><ArticleId IdType="pubmed">31866966</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X, Ma L, Wang Z, Liu Y, Long L, Ma X, Chen H, Chen Z, Lin X, Si L, et al. Clinical features and gut microbial alterations in anti-leucine-rich glioma-inactivated 1 encephalitis-a pilot study. Front Neurol. 2020;11:585977. doi:10.3389/fneur.2020.585977.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.585977</ArticleId><ArticleId IdType="pmc">PMC7655127</ArticleId><ArticleId IdType="pubmed">33193049</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerqueira FM, Photenhauer AL, Pollet RM, Brown HA, Koropatkin NM. Starch Digestion by Gut Bacteria: crowdsourcing for Carbs. Trends Microbiol. 2020;28(2):95&#x2013;108. doi:10.1016/j.tim.2019.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2019.09.004</ArticleId><ArticleId IdType="pubmed">31624005</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurung M, Li Z, You H, Rodrigues R, Jump DB, Morgun A, Shulzhenko N. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine. 2020;51:102590. doi:10.1016/j.ebiom.2019.11.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2019.11.051</ArticleId><ArticleId IdType="pmc">PMC6948163</ArticleId><ArticleId IdType="pubmed">31901868</ArticleId></ArticleIdList></Reference><Reference><Citation>Schirmer M, Garner A, Vlamakis H, Xavier RJ. Microbial genes and pathways in inflammatory bowel disease. Nat Rev Microbiol. 2019;17(8):497&#x2013;511. doi:10.1038/s41579-019-0213-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-019-0213-6</ArticleId><ArticleId IdType="pmc">PMC6759048</ArticleId><ArticleId IdType="pubmed">31249397</ArticleId></ArticleIdList></Reference><Reference><Citation>Lordan C, Thapa D, Ross RP, Cotter PD. Potential for enriching next-generation health-promoting gut bacteria through prebiotics and other dietary components. Gut Microbes. 2020;11(1):1&#x2013;20. doi:10.1080/19490976.2019.1613124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2019.1613124</ArticleId><ArticleId IdType="pmc">PMC6973326</ArticleId><ArticleId IdType="pubmed">31116628</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomova A, Bukovsky I, Rembert E, Yonas W, Alwarith J, Barnard ND, Kahleova H. The effects of vegetarian and vegan diets on gut microbiota. Front Nutr. 2019;6:47. doi:10.3389/fnut.2019.00047.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2019.00047</ArticleId><ArticleId IdType="pmc">PMC6478664</ArticleId><ArticleId IdType="pubmed">31058160</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimokawa C, Kato T, Takeuchi T, Ohshima N, Furuki T, Ohtsu Y, Suzue K, Imai T, Obi S, Olia A, et al. CD8(+) regulatory T cells are critical in prevention of autoimmune-mediated diabetes. Nat Commun. 2020;11(1):1922. doi:10.1038/s41467-020-15857-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15857-x</ArticleId><ArticleId IdType="pmc">PMC7176710</ArticleId><ArticleId IdType="pubmed">32321922</ArticleId></ArticleIdList></Reference><Reference><Citation>Carey MA, Medlock GL, Alam M, Kabir M, Uddin MJ, Nayak U, Papin J, Faruque ASG, Haque R, Petri WA, et al. Megasphaera in the stool microbiota is negatively associated with diarrheal cryptosporidiosis. Clin Infect Dis. 2021;73(6):e1242&#x2013;e1251. doi:10.1093/cid/ciab207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab207</ArticleId><ArticleId IdType="pmc">PMC8442784</ArticleId><ArticleId IdType="pubmed">33684930</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Li J, Guan Y, Lou Y, Chen H, Xu M, Deng D, Chen J, Ni B, Zhao L, et al. Dysbiosis of the gut microbiome is associated with tumor biomarkers in lung cancer. Int J Biol Sci. 2019;15(11):2381&#x2013;2392. doi:10.7150/ijbs.35980.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.35980</ArticleId><ArticleId IdType="pmc">PMC6775324</ArticleId><ArticleId IdType="pubmed">31595156</ArticleId></ArticleIdList></Reference><Reference><Citation>Vascellari S, Palmas V, Melis M, Pisanu S, Cusano R, Uva P, Perra D, Madau V, Sarchioto M, Oppo V, et al. Gut microbiota and metabolome alterations associated with parkinson&#x2019;s disease. mSystems. 2020;5(5). doi:10.1128/mSystems.00561-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mSystems.00561-20</ArticleId><ArticleId IdType="pmc">PMC7498685</ArticleId><ArticleId IdType="pubmed">32934117</ArticleId></ArticleIdList></Reference><Reference><Citation>Valles-Colomer M, Falony G, Darzi Y, Tigchelaar EF, Wang J, Tito RY, Schiweck C, Kurilshikov A, Joossens M, Wijmenga C, et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol. 2019;4(4):623&#x2013;632. doi:10.1038/s41564-018-0337-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-018-0337-x</ArticleId><ArticleId IdType="pubmed">30718848</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Z, Zhang S, Wei Y, Wang M, Ma S, Yang S, Wang J, Yuan C, Jiang L, Du Y, et al. Horizontal gene transfer clarifies taxonomic confusion and promotes the genetic diversity and pathogenicity of plesiomonas shigelloides. mSystems. 2020;5(5). doi:10.1128/mSystems.00448-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mSystems.00448-20</ArticleId><ArticleId IdType="pmc">PMC7498682</ArticleId><ArticleId IdType="pubmed">32934114</ArticleId></ArticleIdList></Reference><Reference><Citation>Suez J, Zmora N, Elinav E. Probiotics in the next-generation sequencing era. Gut Microbes. 2020;11(1):77&#x2013;93. doi:10.1080/19490976.2019.1586039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2019.1586039</ArticleId><ArticleId IdType="pmc">PMC6973336</ArticleId><ArticleId IdType="pubmed">30951391</ArticleId></ArticleIdList></Reference><Reference><Citation>Zmora N, Zilberman-Schapira G, Suez J, Mor U, Dori-Bachash M, Bashiardes S, Kotler E, Zur M, Regev-Lehavi D, Brik RBZ, et al. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell. 2018;174(6):1388&#x2013;1405.e1321. doi:10.1016/j.cell.2018.08.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.08.041</ArticleId><ArticleId IdType="pubmed">30193112</ArticleId></ArticleIdList></Reference><Reference><Citation>Zafar H, Saier MH Jr. Gut bacteroides species in health and disease. Gut Microbes. 2021;13(1):1&#x2013;20. doi:10.1080/19490976.2020.1848158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2020.1848158</ArticleId><ArticleId IdType="pmc">PMC7872030</ArticleId><ArticleId IdType="pubmed">33535896</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Y, Lin X, Xue W. Characterization and description of Faecalibacterium butyricigenerans sp. nov. and F. longum sp. nov., isolated from human faeces. Sci Rep. 2021;11(1):11340. doi:10.1038/s41598-021-90786-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-90786-3</ArticleId><ArticleId IdType="pmc">PMC8166934</ArticleId><ArticleId IdType="pubmed">34059761</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hul M, Le Roy T, Prifti E, Dao MC, Paquot A, Zucker J-D, Delzenne NM, Muccioli GG, Cl&#xe9;ment K, Cani PD, et al. From correlation to causality: the case of subdoligranulum. Gut Microbes. 2020;12(1):1&#x2013;13. doi:10.1080/19490976.2020.1849998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2020.1849998</ArticleId><ArticleId IdType="pmc">PMC7744154</ArticleId><ArticleId IdType="pubmed">33323004</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Li N, Chen Q, Qin H. Fecal microbiota transplantation modulates the gut flora favoring patients with functional constipation. Front Microbiol. 2021;12:700718. doi:10.3389/fmicb.2021.700718.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.700718</ArticleId><ArticleId IdType="pmc">PMC8529243</ArticleId><ArticleId IdType="pubmed">34690948</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashida H, Suzuki T, Sasakawa C. Shigella infection and host cell death: a double-edged sword for the host and pathogen survival. Curr Opin Microbiol. 2021;59:1&#x2013;7. doi:10.1016/j.mib.2020.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mib.2020.07.007</ArticleId><ArticleId IdType="pubmed">32784063</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrant RL, Bolick DT, Swann JR. Modeling enteropathy or diarrhea with the top bacterial and protozoal pathogens: differential determinants of outcomes. ACS Infect Dis. 2021;7(5):1020&#x2013;1031. doi:10.1021/acsinfecdis.0c00831.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.0c00831</ArticleId><ArticleId IdType="pmc">PMC8154416</ArticleId><ArticleId IdType="pubmed">33901398</ArticleId></ArticleIdList></Reference><Reference><Citation>Diling C, Longkai Q, Yinrui G, Yadi L, Xiaocui T, Xiangxiang Z, Miao Z, Ran L, Ou S, Dongdong W, et al. CircNF1-419 improves the gut microbiome structure and function in AD-like mice. Aging (Albany NY). 2020;12(1):260&#x2013;287. doi:10.18632/aging.102614.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.102614</ArticleId><ArticleId IdType="pmc">PMC6977659</ArticleId><ArticleId IdType="pubmed">31905172</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee A, Lordan C, Ross RP, Cotter PD. Gut microbes from the phylogenetically diverse genus Eubacterium and their various contributions to gut health. Gut Microbes. 2020;12(1):1802866. doi:10.1080/19490976.2020.1802866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2020.1802866</ArticleId><ArticleId IdType="pmc">PMC7524325</ArticleId><ArticleId IdType="pubmed">32835590</ArticleId></ArticleIdList></Reference><Reference><Citation>van Trijp MPH, Schutte S, Esser D. Minor changes in the composition and function of the gut microbiota during a 12-week whole grain wheat or refined wheat intervention correlate with liver fat in overweight and obese adults. J Nutr. 2021;151(3):491&#x2013;502. doi:10.1093/jn/nxaa312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jn/nxaa312</ArticleId><ArticleId IdType="pmc">PMC7948209</ArticleId><ArticleId IdType="pubmed">33188417</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zhang C, Hou S, Wu X, Liu J, Wan X. Analyses of potential driver and passenger bacteria in human colorectal cancer. Cancer Manag Res. 2020;12:11553&#x2013;11561. doi:10.2147/CMAR.S275316.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CMAR.S275316</ArticleId><ArticleId IdType="pmc">PMC7669530</ArticleId><ArticleId IdType="pubmed">33209059</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan X, Alekseyenko AV, Wu J, Peters BA, Jacobs EJ, Gapstur SM, Purdue MP, Abnet CC, Stolzenberg-Solomon R, Miller G, et al. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut. 2018;67(1):120&#x2013;127. doi:10.1136/gutjnl-2016-312580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2016-312580</ArticleId><ArticleId IdType="pmc">PMC5607064</ArticleId><ArticleId IdType="pubmed">27742762</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoilew K, Ueffing H, Dalpke A, Wolff B, Frese C, Wolff D, Boutin S. Bacterial biofilm composition in healthy subjects with and without caries experience. J Oral Microbiol. 2019;11(1):1633194. doi:10.1080/20002297.2019.1633194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/20002297.2019.1633194</ArticleId><ArticleId IdType="pmc">PMC6598481</ArticleId><ArticleId IdType="pubmed">31275531</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa D, Iraola G. Pathogenomics of Emerging Campylobacter Species. Clin Microbiol Rev. 2019;32(4). doi:10.1128/CMR.00072-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00072-18</ArticleId><ArticleId IdType="pmc">PMC6750134</ArticleId><ArticleId IdType="pubmed">31270126</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurwara S, Ajami NJ, Jang A, Hessel F, Chen L, Plew S, Wang Z, Graham D, Hair C, White D, et al. Dietary nutrients involved in one-carbon metabolism and colonic mucosa-associated gut microbiome in individuals with an endoscopically normal colon. Nutrients. 2019;11(3):613. doi:10.3390/nu11030613.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11030613</ArticleId><ArticleId IdType="pmc">PMC6470629</ArticleId><ArticleId IdType="pubmed">30871224</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Li W, Yang H. Leveraging 16S rRNA microbiome sequencing data to identify bacterial signatures for irritable bowel syndrome. Front Cell Infect Microbiol. 2021;11:645951. doi:10.3389/fcimb.2021.645951.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.645951</ArticleId><ArticleId IdType="pmc">PMC8231010</ArticleId><ArticleId IdType="pubmed">34178718</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JM, Rim JH, Kim DH. Microbiome analysis reveals that ralstonia is responsible for decreased renal function in patients with ulcerative colitis. Clin Transl Med. 2021;11(3):e322. doi:10.1002/ctm2.322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.322</ArticleId><ArticleId IdType="pmc">PMC7933010</ArticleId><ArticleId IdType="pubmed">33784015</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez-Jaramillo A, Balde&#xf3;n ME, Prado B, Fornasini M, Cohen H, Flores N, Salvador I, Cargua O, Realpe J, C&#xe1;rdenas PA, et al. Duodenal microbiome in patients with or without Helicobacter pylori infection. Helicobacter. 2020;25(6):e12753. doi:10.1111/hel.12753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hel.12753</ArticleId><ArticleId IdType="pubmed">32896972</ArticleId></ArticleIdList></Reference><Reference><Citation>Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol. 2010;7(9):503&#x2013;514. doi:10.1038/nrgastro.2010.117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2010.117</ArticleId><ArticleId IdType="pmc">PMC4748966</ArticleId><ArticleId IdType="pubmed">20664519</ArticleId></ArticleIdList></Reference><Reference><Citation>Sniffen JC, McFarland LV, Evans CT, Goldstein EJC. Choosing an appropriate probiotic product for your patient: an evidence-based practical guide. PLoS One. 2018;13(12):e0209205. doi:10.1371/journal.pone.0209205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0209205</ArticleId><ArticleId IdType="pmc">PMC6306248</ArticleId><ArticleId IdType="pubmed">30586435</ArticleId></ArticleIdList></Reference><Reference><Citation>Quin C, Estaki M, Vollman DM, Barnett JA, Gill SK, Gibson DL. Probiotic supplementation and associated infant gut microbiome and health: a cautionary retrospective clinical comparison. Sci Rep. 2018;8(1):8283. doi:10.1038/s41598-018-26423-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-26423-3</ArticleId><ArticleId IdType="pmc">PMC5974413</ArticleId><ArticleId IdType="pubmed">29844409</ArticleId></ArticleIdList></Reference><Reference><Citation>Suez J, Zmora N, Zilberman-Schapira G, Mor U, Dori-Bachash M, Bashiardes S, Zur M, Regev-Lehavi D, Ben-Zeev Brik R, Federici S, et al. Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell. 2018;174(6):1406&#x2013;1423.e1416. doi:10.1016/j.cell.2018.08.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.08.047</ArticleId><ArticleId IdType="pubmed">30193113</ArticleId></ArticleIdList></Reference><Reference><Citation>Donaldson GP, Lee SM, Mazmanian SK. Gut biogeography of the bacterial microbiota. Nat Rev Microbiol. 2016;14(1):20&#x2013;32. doi:10.1038/nrmicro3552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro3552</ArticleId><ArticleId IdType="pmc">PMC4837114</ArticleId><ArticleId IdType="pubmed">26499895</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau HCH, Kranenburg O, Xiao H, Yu J. Organoid models of gastrointestinal cancers in basic and translational research. Nat Rev Gastroenterol Hepatol. 2020;17(4):203&#x2013;222. doi:10.1038/s41575-019-0255-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-019-0255-2</ArticleId><ArticleId IdType="pubmed">32099092</ArticleId></ArticleIdList></Reference><Reference><Citation>Jalili-Firoozinezhad S, Gazzaniga FS, Calamari EL, Camacho DM, Fadel CW, Bein A, Swenor B, Nestor B, Cronce MJ, Tovaglieri A, et al. A complex human gut microbiome cultured in an anaerobic intestine-on-a-chip. Nat Biomed Eng. 2019;3(7):520&#x2013;531. doi:10.1038/s41551-019-0397-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41551-019-0397-0</ArticleId><ArticleId IdType="pmc">PMC6658209</ArticleId><ArticleId IdType="pubmed">31086325</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Toole PW, Marchesi JR, Hill C. Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. Nat Microbiol. 2017;2(5):17057. doi:10.1038/nmicrobiol.2017.57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmicrobiol.2017.57</ArticleId><ArticleId IdType="pubmed">28440276</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37049488</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6643</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>28</Day></PubDate></JournalIssue><Title>Nutrients</Title><ISOAbbreviation>Nutrients</ISOAbbreviation></Journal><ArticleTitle>Constipation-Predominant Irritable Bowel Syndrome (IBS-C): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1647</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nu15071647</ELocationID><Abstract><AbstractText>Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by abdominal pain associated with defecation or a change in bowel habits. The pathogenesis of IBS is not completely clear, but it is known to be multifactorial and complex. Endogenous and exogenous factors such as abnormal GI motility, low-grade inflammation, increased epithelial permeability and visceral hypersensitivity, but diet and psychosocial aspects are also recognized as important actors. Furthermore, the interaction between diet and gut microbiota has gained interest as a potential contributor to the pathophysiology of IBS. To date, there is no specific diet for IBS with constipation (IBS-C); however, many studies show that fiber intake, especially soluble fiber such as inulin, could have a positive effect on symptoms. This review aims to evaluate the effects of some nutritional components such as fibers but also functional foods, prebiotics, probiotics and symbiotics on symptoms and microbiota in IBS-C subjects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Di Rosa</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-5465-5657</Identifier><AffiliationInfo><Affiliation>Research Unit of Food Science and Human Nutrition, Department of Science and Technology for Humans and the Environment, Universit&#xe0; Campus Bio-Medico di Roma, Via Alvaro del Portillo, 21-00128 Roma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altomare</LastName><ForeName>Annamaria</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8630-7836</Identifier><AffiliationInfo><Affiliation>Research Unit of Gastroenterology, Universit&#xe0; Campus Bio-Medico di Roma, Via Alvaro del Portillo, 21-00128 Roma, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Operative Research Unit of Gastroenterology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200-00128 Roma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terrigno</LastName><ForeName>Vittoria</ForeName><Initials>V</Initials><Identifier Source="ORCID">0009-0006-1093-1628</Identifier><AffiliationInfo><Affiliation>Research Unit of Food Science and Human Nutrition, Department of Science and Technology for Humans and the Environment, Universit&#xe0; Campus Bio-Medico di Roma, Via Alvaro del Portillo, 21-00128 Roma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carbone</LastName><ForeName>Florencia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, University Hospitals Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tack</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, University Hospitals Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cicala</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research Unit of Gastroenterology, Universit&#xe0; Campus Bio-Medico di Roma, Via Alvaro del Portillo, 21-00128 Roma, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Operative Research Unit of Gastroenterology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200-00128 Roma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guarino</LastName><ForeName>Michele Pier Luca</ForeName><Initials>MPL</Initials><AffiliationInfo><Affiliation>Research Unit of Gastroenterology, Universit&#xe0; Campus Bio-Medico di Roma, Via Alvaro del Portillo, 21-00128 Roma, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Operative Research Unit of Gastroenterology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200-00128 Roma, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nutrients</MedlineTA><NlmUniqueID>101521595</NlmUniqueID><ISSNLinking>2072-6643</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D056692">Prebiotics</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064806" MajorTopicYN="N">Dysbiosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003248" MajorTopicYN="N">Constipation</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056692" MajorTopicYN="N">Prebiotics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IBS and diet</Keyword><Keyword MajorTopicYN="N">IBS and microbiota</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome and diet</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome with constipation</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>13</Day><Hour>1</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37049488</ArticleId><ArticleId IdType="pmc">PMC10096616</ArticleId><ArticleId IdType="doi">10.3390/nu15071647</ArticleId><ArticleId IdType="pii">nu15071647</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Drossman D.A. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016;150:1262&#x2013;1279.e2. doi: 10.1053/j.gastro.2016.02.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.032</ArticleId><ArticleId IdType="pubmed">27144617</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy B.E., Mearin F., Chang L., Lembo J.A., Simren M., Spiller R., Chey D.W. Bowel disorders. Gastroenterology. 2016;150:1393&#x2013;1407. doi: 10.1053/j.gastro.2016.02.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.031</ArticleId><ArticleId IdType="pubmed">27144627</ArticleId></ArticleIdList></Reference><Reference><Citation>Kindt S., Louis H., De Schepper H., Arts J., Caenepeel P., De Looze D., Gerkens A., Holvoet T., Latour P., Mahler T., et al. Belgian consensus on irritable bowel syndrome. Acta Gastroenterol. Belg. 2022;85:360&#x2013;382. doi: 10.51821/85.2.10100.</Citation><ArticleIdList><ArticleId IdType="doi">10.51821/85.2.10100</ArticleId><ArticleId IdType="pubmed">35709780</ArticleId></ArticleIdList></Reference><Reference><Citation>Chey W.D., Kurlander J., Eswaran S. Irritable bowel syndrome: A clinical review. J. Am. Med. Assoc. 2015;313:949&#x2013;958. doi: 10.1001/jama.2015.0954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.0954</ArticleId><ArticleId IdType="pubmed">25734736</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperber A.D., Bangdiwala S.I., Drossman D.A., Ghoshal U.C., Simren M., Tack J., Whitehead W.E., Dumitrascu D.L., Fang X., Fukudo S., et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160:99&#x2013;114. doi: 10.1053/j.gastro.2020.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.04.014</ArticleId><ArticleId IdType="pubmed">32294476</ArticleId></ArticleIdList></Reference><Reference><Citation>Canavan C., West J., Card T. The epidemiology of irritable bowel syndrome. Clin. Epidemiol. 2014;6:71&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3921083</ArticleId><ArticleId IdType="pubmed">24523597</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer E.A. Irritable Bowel Syndrome. N. Engl. J. Med. 2008;358:1692&#x2013;1699. doi: 10.1056/NEJMcp0801447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcp0801447</ArticleId><ArticleId IdType="pmc">PMC3816529</ArticleId><ArticleId IdType="pubmed">18420501</ArticleId></ArticleIdList></Reference><Reference><Citation>Scalera A., Loguercio C. Focus on irritable bowel syndrome. Eur. Rev. Med. Pharmacol. Sci. 2012;16:1155&#x2013;1171.</Citation><ArticleIdList><ArticleId IdType="pubmed">23047498</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperber A.D., Freud T., Aziz I., Palsson O.S., Drossman D.A., Dumitrascu D.L., Fang X., Fukudo S., Ghoshal U.C., Kellow J., et al. Greater Overlap of Rome IV Disorders of Gut-Brain Interactions Leads to Increased Disease Severity and Poorer Quality of Life. Clin. Gastroenterol. Hepatol. 2022;20:e945&#x2013;e956. doi: 10.1016/j.cgh.2021.05.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2021.05.042</ArticleId><ArticleId IdType="pubmed">34052391</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtmann G., Ford A., Talley N. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol. Hepatol. 2016;1:133&#x2013;146. doi: 10.1016/S2468-1253(16)30023-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(16)30023-1</ArticleId><ArticleId IdType="pubmed">28404070</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares R.L. Irritable bowel syndrome: A clinical review. World J. Gastroenterol. 2014;20:12144&#x2013;12160. doi: 10.3748/wjg.v20.i34.12144.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i34.12144</ArticleId><ArticleId IdType="pmc">PMC4161800</ArticleId><ArticleId IdType="pubmed">25232249</ArticleId></ArticleIdList></Reference><Reference><Citation>Alammar N., Stein E. Irritable Bowel Syndrome. What treatments really work. Med. Clin. N. Am. 2019;103:137&#x2013;152. doi: 10.1016/j.mcna.2018.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcna.2018.08.006</ArticleId><ArticleId IdType="pubmed">30466670</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Presti A., Zorzi F., Del Chierico F., Altomare A., Cocca S., Avola A., De Biasio F., Russo A., Cella E., Reddel S., et al. Fecal and Mucosal Microbiota Profiling in Irritable Bowel Syndrome and Inflammatory Bowel Disease. Front. Microbiol. 2019;10:1655. doi: 10.3389/fmicb.2019.01655.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2019.01655</ArticleId><ArticleId IdType="pmc">PMC6650632</ArticleId><ArticleId IdType="pubmed">31379797</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennet S., Ohman L., Simren M. Gut microbiota as potential orchestrators of irritable bowel syndrome. Gut Liver. 2015;9:318&#x2013;931. doi: 10.5009/gnl14344.</Citation><ArticleIdList><ArticleId IdType="doi">10.5009/gnl14344</ArticleId><ArticleId IdType="pmc">PMC4413965</ArticleId><ArticleId IdType="pubmed">25918261</ArticleId></ArticleIdList></Reference><Reference><Citation>Altomare A., Del Chierico F., Rocchi G., Emerenziani S., Nuglio C., Putignani L., Angeletti S., Lo Presti A., Ciccozzi M., Russo A., et al. Association between Dietary Habits and Fecal Microbiota Composition in Irritable Bowel Syndrome Patients: A Pilot Study. Nutrients. 2021;13:1479. doi: 10.3390/nu13051479.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13051479</ArticleId><ArticleId IdType="pmc">PMC8170891</ArticleId><ArticleId IdType="pubmed">33925672</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinninella E., Cintoni M., Raoul P., Gasbarrini A., Mele M.C. Food Additives, Gut Microbiota, and Irritable Bowel Syndrome: A Hidden Track. Int. J. Environ. Res. Public Health. 2020;17:8816. doi: 10.3390/ijerph17238816.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph17238816</ArticleId><ArticleId IdType="pmc">PMC7730902</ArticleId><ArticleId IdType="pubmed">33260947</ArticleId></ArticleIdList></Reference><Reference><Citation>Melchior C., Algera J., Colomier E., Tornblom H., Simren M. Irritable bowel syndrome with food-related symptoms: Future directions in the clinical management. United Eur. Gastroenterol. J. 2022;10:594&#x2013;600. doi: 10.1002/ueg2.12265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ueg2.12265</ArticleId><ArticleId IdType="pmc">PMC9278572</ArticleId><ArticleId IdType="pubmed">35727703</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;hn L., St&#xf6;rsrud S., Tornblom H., Bengtsson U., Simren M. Self&#x2013;reported food&#x2013;related gastrointestinal symptoms in IBS are 842 common and associated with more severe symptoms and reduced quality of life. Am. J. Gastroenterol. 2013;108:634&#x2013;641. doi: 10.1038/ajg.2013.105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2013.105</ArticleId><ArticleId IdType="pubmed">23644955</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe4;ckhed F., Ley R.E., Sonnenburg J.L., Peterson D.A., Gordon J.I. Host-bacterial mutualism in the human intestine. Science. 2005;307:1915&#x2013;1920. doi: 10.1126/science.1104816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1104816</ArticleId><ArticleId IdType="pubmed">15790844</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig J.E., Spor A., Scalfone N., Fricker A.D., Stombaugh J., Knight R., Angenent L.T., Ley R.E. Succession of microbial consortia in the developing infant gut microbiome. Proc. Natl. Acad. Sci. USA. 2011;108((Suppl. 1)):4578&#x2013;4585. doi: 10.1073/pnas.1000081107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1000081107</ArticleId><ArticleId IdType="pmc">PMC3063592</ArticleId><ArticleId IdType="pubmed">20668239</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholtens P.A., Oozeer R., Martin R., Amor K.B., Knol J. The early settlers: Intestinal microbiology in early life. Annu. Rev. Food Sci. Technol. 2012;3:425&#x2013;447. doi: 10.1146/annurev-food-022811-101120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-food-022811-101120</ArticleId><ArticleId IdType="pubmed">22224552</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajili&#x107;-Stojanovi&#x107; M., Heilig H.G., Molenaar D., Kajander K., Surakka A., Smidt H., de Vos W.M. Development and application of the human intestinal tract chip, a phylogenetic microarray: Analysis of universally conserved phylotypes in the abundant microbiota of young and elderly adults. Environ. Microbiol. 2009;11:1736&#x2013;1751. doi: 10.1111/j.1462-2920.2009.01900.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1462-2920.2009.01900.x</ArticleId><ArticleId IdType="pmc">PMC2784037</ArticleId><ArticleId IdType="pubmed">19508560</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills&#x2019; S., Stanton C., Lane J., Smith G., Ross R. Precision nutrition and the microbiome, Part I current state of the science. Nutrients. 2019;11:923. doi: 10.3390/nu11040923.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11040923</ArticleId><ArticleId IdType="pmc">PMC6520976</ArticleId><ArticleId IdType="pubmed">31022973</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothschild D., Weissbrod O., Barkan E., Kurilshikov A., Korem T., Zeevi D., Costea P.I., Godneva A., Kalka I.N., Bar N., et al. Environment dominates over host genetics in shaping human gut microbiota. Nature. 2018;555:210&#x2013;215. doi: 10.1038/nature25973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25973</ArticleId><ArticleId IdType="pubmed">29489753</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiley N., Dinan T., Ross R., Stanton C., Clarke G., Cryan J. The microbiota-gut-brain axis as a key regulator of neural function and the stress response: Implications for human and animal health. J. Anim. Sci. 2017;95:3225&#x2013;3246.</Citation><ArticleIdList><ArticleId IdType="pubmed">28727115</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly C., Zheng L., Campbell E., Saeedi B., Scholz C., Bayless A., Wilson K., Glover L., Kominsky D., Magnuson A., et al. Crosstalk between microbiota-derived shortchain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host Microbe. 2015;17:662&#x2013;671. doi: 10.1016/j.chom.2015.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2015.03.005</ArticleId><ArticleId IdType="pmc">PMC4433427</ArticleId><ArticleId IdType="pubmed">25865369</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozupone C.A., Stombaugh J.I., Gordon J.I., Jansson J.K., Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489:220&#x2013;230. doi: 10.1038/nature11550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11550</ArticleId><ArticleId IdType="pmc">PMC3577372</ArticleId><ArticleId IdType="pubmed">22972295</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland I.R. Toxicological implications of the normal microflora. In: Tannock G.W., editor. Medical Importance of the Normal Microflora. Springer; Boston, MA, USA: 1999.</Citation></Reference><Reference><Citation>Zoetendal E.G., von Wright A., Vilpponen-Salmela T., Ben-Amor K., Akkermans A.D., de Vos W.M. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl. Environ. Microbiol. 2002;68:3401&#x2013;3407. doi: 10.1128/AEM.68.7.3401-3407.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.68.7.3401-3407.2002</ArticleId><ArticleId IdType="pmc">PMC126800</ArticleId><ArticleId IdType="pubmed">12089021</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter J., Ley R. The human gut microbiome: Ecology and recent evolutionary changes. Annu. Rev. Microbiol. 2011;65:411&#x2013;429. doi: 10.1146/annurev-micro-090110-102830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-micro-090110-102830</ArticleId><ArticleId IdType="pubmed">21682646</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepage P., Seksik P., Sutren M., de la Cocheti&#xe8;re M.F., Jian R., Marteau P., Dor&#xe9; J. Biodiversity of the mucosa-associated microbiota is stable along the distal digestive tract in healthy individuals and patients with IBD. Inflamm. Bowel Dis. 2005;11:473&#x2013;480. doi: 10.1097/01.MIB.0000159662.62651.06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.MIB.0000159662.62651.06</ArticleId><ArticleId IdType="pubmed">15867587</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;hman L., T&#xf6;rnblom H., Simr&#xe9;n M. Crosstalk at the mucosal border: Importance of the gut microenvironment in IBS. Nat. Rev. Gastroenterol. Hepatol. 2015;12:36&#x2013;49. doi: 10.1038/nrgastro.2014.200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2014.200</ArticleId><ArticleId IdType="pubmed">25446728</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Hara A.M., Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006;7:688&#x2013;693. doi: 10.1038/sj.embor.7400731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.embor.7400731</ArticleId><ArticleId IdType="pmc">PMC1500832</ArticleId><ArticleId IdType="pubmed">16819463</ArticleId></ArticleIdList></Reference><Reference><Citation>Villmones H.C., Halland A., Stendstad T., Ulvestad E., Weedon-Fekj&#xe6;r H., Kommedal &#xd8;. The cultivable microbiota of the human distal ileum. Clin. Microbiol. Infect. 2021;27:912.e7&#x2013;912.e13. doi: 10.1016/j.cmi.2020.08.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.08.021</ArticleId><ArticleId IdType="pubmed">32835795</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison D.J., Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7:189&#x2013;200. doi: 10.1080/19490976.2015.1134082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2015.1134082</ArticleId><ArticleId IdType="pmc">PMC4939913</ArticleId><ArticleId IdType="pubmed">26963409</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Presti A., Del Chierico F., Altomare A., Zorzi F., Cella E., Putignani L., Guarino M.P.L., Monteleone G., Cicala M., Angeletti S., et al. Exploring the genetic diversity of the 16S rRNA gene of Akkermansia muciniphila in IBD and IBS. Future Microbiol. 2019;14:1497&#x2013;1509. doi: 10.2217/fmb-2019-0175.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb-2019-0175</ArticleId><ArticleId IdType="pubmed">31850811</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Houte K., Colomier E., Schol J., Carbone F., Tack J. Recent advances in diagnosis and management of irritable bowel syndrome. Curr. Opin. Psychiatry. 2020;33:460&#x2013;466. doi: 10.1097/YCO.0000000000000628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/YCO.0000000000000628</ArticleId><ArticleId IdType="pubmed">32639360</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawrelak J.A., Myers S.P. The causes of intestinal dysbiosis: A review. Altern. Med. Rev. 2004;9:180&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">15253677</ArticleId></ArticleIdList></Reference><Reference><Citation>Tack J., Stanghellini V., Mearin F., Yiannakou Y., Layer P., Coffin B., Simren M., Mackinnon J., Wiseman G., Marciniak A., et al. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries. BMC Gastroenterol. 2019;19:69. doi: 10.1186/s12876-019-0985-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-019-0985-1</ArticleId><ArticleId IdType="pmc">PMC6505116</ArticleId><ArticleId IdType="pubmed">31064345</ArticleId></ArticleIdList></Reference><Reference><Citation>Malinen E., Rinttil&#xe4; T., Kajander K., M&#xe4;tt&#xf6; J., Kassinen A., Krogius L., Saarela M., Korpela R., Palva A. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am. J. Gastroenterol. 2005;100:373&#x2013;382. doi: 10.1111/j.1572-0241.2005.40312.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2005.40312.x</ArticleId><ArticleId IdType="pubmed">15667495</ArticleId></ArticleIdList></Reference><Reference><Citation>Maukonen J., Satokari R., M&#xe4;tt&#xf6; J., S&#xf6;derlund H., Mattila-Sandholm T., Saarela M. Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria. J. Med. Microbiol. 2006;55:625&#x2013;633. doi: 10.1099/jmm.0.46134-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jmm.0.46134-0</ArticleId><ArticleId IdType="pubmed">16585652</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajili&#x107;-Stojanovi&#x107; M., Biagi E., Heilig H.G., Kajander K., Kekkonen R.A., Tims S., de Vos W.M. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011;141:1792&#x2013;1801. doi: 10.1053/j.gastro.2011.07.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2011.07.043</ArticleId><ArticleId IdType="pubmed">21820992</ArticleId></ArticleIdList></Reference><Reference><Citation>Chassard C., Dapoigny M., Scott K.P., Crouzet L., Del&#x2019;homme C., Marquet P., Martin J.C., Pickering G., Ardid D., Eschalier A., et al. Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment. Pharmacol. Ther. 2012;35:828&#x2013;838. doi: 10.1111/j.1365-2036.2012.05007.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2012.05007.x</ArticleId><ArticleId IdType="pubmed">22315951</ArticleId></ArticleIdList></Reference><Reference><Citation>Durb&#xe1;n A., Abell&#xe1;n J.J., Jim&#xe9;nez-Hern&#xe1;ndez N., Salgado P., Ponce M., Ponce J., Garrigues V., Latorre A., Moya A. Structural alterations of faecal and mucosa-associated bacterial communities in irritable bowel syndrome. Environ. Microbiol. Rep. 2012;4:242&#x2013;247. doi: 10.1111/j.1758-2229.2012.00327.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1758-2229.2012.00327.x</ArticleId><ArticleId IdType="pubmed">23757279</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkes G.C., Rayment N.B., Hudspith B.N., Petrovska L., Lomer M.C., Brostoff J., Whelan K., Sanderson J.D. Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome. Neurogastroenterol. Motil. 2012;24:31&#x2013;39. doi: 10.1111/j.1365-2982.2011.01803.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2011.01803.x</ArticleId><ArticleId IdType="pubmed">22070725</ArticleId></ArticleIdList></Reference><Reference><Citation>Villanueva-Millan M.J., Leite G., Wang J., Morales W., Parodi G., Pimentel M.L., Barlow G.M., Mathur R., Rezaie A., Sanchez M., et al. Methanogens and Hydrogen Sulfide Producing Bacteria Guide Distinct Gut Microbe Profiles and Irritable Syndrome Subtypes. Am. J. Gastroenterol. 2022;117:2055&#x2013;2066. doi: 10.14309/ajg.0000000000001997.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000001997</ArticleId><ArticleId IdType="pmc">PMC9722381</ArticleId><ArticleId IdType="pubmed">36114762</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G., Deepinder F., Morales W., Hwang L., Weitsman S., Chang C., Gunsalus R., Pimentel M. Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath. Dig. Dis. Sci. 2012;57:3213&#x2013;3218. doi: 10.1007/s10620-012-2197-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-012-2197-1</ArticleId><ArticleId IdType="pubmed">22573345</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkel D., Basseri R.J., Makhani M.D., Chong K., Chang C., Pimentel M. Methane on breath testing is associated with constipation: A systematic review and meta-analysis. Dig. Dis. Sci. 2011;56:1612&#x2013;1618. doi: 10.1007/s10620-011-1590-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-011-1590-5</ArticleId><ArticleId IdType="pubmed">21286935</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozma-Petru&#x163; A., Loghin F., Miere D., Dumitra&#x15f;cu D.L. Diet in irritable bowel syndrome: What to recommend, not what to forbid to patients! World J. Gastroenterol. 2017;23:3771. doi: 10.3748/wjg.v23.i21.3771.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v23.i21.3771</ArticleId><ArticleId IdType="pmc">PMC5467063</ArticleId><ArticleId IdType="pubmed">28638217</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE  . Irritable Bowel Syndrome in Adults: Diagnosis and Management of Irritable Bowel Syndrome in Primary Care (CG61) NICE; London, UK: 2008.  [(accessed on 20 July 2022)].  Available online:  https://www.nice.org.uk/guidance/cg61.</Citation></Reference><Reference><Citation>McKenzie Y.A., Bowyer R.K., Leach H., Gulia P., Horobin J., O&#x2019;Sullivan N.A., Pettitt C., Reeves L.B., Seamark L., Williams M., et al. British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults. J. Hum. Nutr. Diet. 2016;29:549&#x2013;575. doi: 10.1111/jhn.12385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jhn.12385</ArticleId><ArticleId IdType="pubmed">27272325</ArticleId></ArticleIdList></Reference><Reference><Citation>Carding S., Verbeke K., Vipond D.T., Corfe B.M., Owen L.J. Dysbiosis of the gut microbiota in disease. Microb. Ecol. Health Dis. 2015;26:26191. doi: 10.3402/mehd.v26.26191.</Citation><ArticleIdList><ArticleId IdType="doi">10.3402/mehd.v26.26191</ArticleId><ArticleId IdType="pmc">PMC4315779</ArticleId><ArticleId IdType="pubmed">25651997</ArticleId></ArticleIdList></Reference><Reference><Citation>Nibacka S., St&#xf6;rsrud S., Lindqvist H.M., Tornbl&#xf6;m H., Simr&#xe9;n M., Winkvist A. Habitual FODMAP Intake in Relation to Symptom Severity and Pattern in Patients with Irritable Bowel Syndrome. Nutrients. 2020;13:27. doi: 10.3390/nu13010027.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13010027</ArticleId><ArticleId IdType="pmc">PMC7824325</ArticleId><ArticleId IdType="pubmed">33374779</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong D.K., Mitchell S.B., Barrett J.S., Sheperd S.J., Irving P.M., Biesiekierski J.R., Smith S., Gibson P.R., Muir J.G. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J. Gastroenterol. Hepatol. 2010;25:1366&#x2013;1373. doi: 10.1111/j.1440-1746.2010.06370.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1746.2010.06370.x</ArticleId><ArticleId IdType="pubmed">20659225</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuck C.J., Taylor K.M., Gibson P.R., Barrett J.S., Muir J.G. Increasing Symptoms in Irritable Bowel Symptoms with Ingestion of Galacto-Oligosaccharides Are Mitigated by &#x3b1;-Galactosidase Treatment. Am. J. Gastroenterol. 2018;113:124&#x2013;134. doi: 10.1038/ajg.2017.245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2017.245</ArticleId><ArticleId IdType="pubmed">28809383</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbone F., Van den Houte K., Besard L., Tack C., Arts J., Caenepeel P., Piessevaux H., Vandenberghe A., Matthys C., Biesiekierski J., et al. Diet or medication in primary care patients with IBS: The DOMINO study&#x2014;A randomised trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute. Gut. 2022;71:2226&#x2013;2232. doi: 10.1136/gutjnl-2021-325821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-325821</ArticleId><ArticleId IdType="pmc">PMC9554021</ArticleId><ArticleId IdType="pubmed">35483886</ArticleId></ArticleIdList></Reference><Reference><Citation>Isakov V.A., Pilipenko V.I., Shakhovskaya A., Tutelyan V. Efficacy of inulin enriched yogurt on bowel habits in patients with irritable bowel syndrome with constipation: A pilot study. FASEB J. 2013;27:lb426. doi: 10.1096/fasebj.27.1_supplement.lb426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fasebj.27.1_supplement.lb426</ArticleId></ArticleIdList></Reference><Reference><Citation>Saulnier D.M., Riehle K., Mistretta T.-A., Diaz M.-A., Mandal D., Raza S., Weidler E.M., Qin X., Coarfa C., Milosavljevic A., et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology. 2011;141:1782&#x2013;1791. doi: 10.1053/j.gastro.2011.06.072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2011.06.072</ArticleId><ArticleId IdType="pmc">PMC3417828</ArticleId><ArticleId IdType="pubmed">21741921</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephen A.M., Cummings J.H. Mechanism of action of dietary fibre in the human colon. Nature. 1980;284:283&#x2013;284. doi: 10.1038/284283a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/284283a0</ArticleId><ArticleId IdType="pubmed">7360261</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber T.M., Kabisch S., Pfeiffer A.F.H., Weickert M.O. The Health Benefits of Dietary Fibre. Nutrients. 2020;12:3209. doi: 10.3390/nu12103209.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12103209</ArticleId><ArticleId IdType="pmc">PMC7589116</ArticleId><ArticleId IdType="pubmed">33096647</ArticleId></ArticleIdList></Reference><Reference><Citation>Altomare A., Di Rosa C., Imperia E., Emerenziani S., Cicala M., Guarino M.P.L. Diarrhea Predominant-Irritable Bowel Syndrome (IBS-D): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms. Nutrients. 2021;13:1506. doi: 10.3390/nu13051506.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13051506</ArticleId><ArticleId IdType="pmc">PMC8146452</ArticleId><ArticleId IdType="pubmed">33946961</ArticleId></ArticleIdList></Reference><Reference><Citation>Marlett J.A., Fischer M.H. The active fraction of psyllium seed husk. Proc. Nutr. Soc. 2003;62:207&#x2013;209. doi: 10.1079/PNS2002201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1079/PNS2002201</ArticleId><ArticleId IdType="pubmed">12749348</ArticleId></ArticleIdList></Reference><Reference><Citation>Rees G., Davies J., Thompson R., Parker M., Liepins P. Randomised-controlled trial of a fibre supplement on the symptoms of irritable bowel syndrome. J. R. Soc. Promot. Health. 2005;125:30&#x2013;34. doi: 10.1177/146642400512500112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/146642400512500112</ArticleId><ArticleId IdType="pubmed">15712850</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S.C., Kim B.J., Rhee P.L., Chang D.K., Son H.J., Kim J.J., Rhee J.C., Kim S.I., Han Y.S., Sim K.H., et al. Probiotic Fermented Milk Containing Dietary Fiber Has Additive Effects in IBS with Constipation Compared to Plain Probiotic Fermented Milk. Gut Liver. 2011;5:22&#x2013;28. doi: 10.5009/gnl.2011.5.1.22.</Citation><ArticleIdList><ArticleId IdType="doi">10.5009/gnl.2011.5.1.22</ArticleId><ArticleId IdType="pmc">PMC3065089</ArticleId><ArticleId IdType="pubmed">21461068</ArticleId></ArticleIdList></Reference><Reference><Citation>Min Y.W., Park S.U., Jang Y.S., Kim Y.H., Rhee P.L., Ko S.H., Joo N., Kim S.I., Kim C.H., Chang D.K. Effect of composite yogurt enriched with acacia fiber and Bifidobacterium lactis. World J. Gastroenterol. 2012;18:4563&#x2013;4569. doi: 10.3748/wjg.v18.i33.4563.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v18.i33.4563</ArticleId><ArticleId IdType="pmc">PMC3435782</ArticleId><ArticleId IdType="pubmed">22969230</ArticleId></ArticleIdList></Reference><Reference><Citation>Neyrinck A.M., Rodriguez J., Taminiau B., Herpin F., Cani P.D., Daube G., Bindels L.B., Delzenne N.M. Constipation Mitigation by Rhubarb Extract in Middle-Aged Adults Is Linked to Gut Microbiome Modulation: A Double-Blind Randomized Placebo-Controlled Trial. Int. J. Mol. Sci. 2022;23:14685. doi: 10.3390/ijms232314685.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232314685</ArticleId><ArticleId IdType="pmc">PMC9738964</ArticleId><ArticleId IdType="pubmed">36499011</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh P., Tuck C., Gibson P.R., Chey W.D. The Role of Food in the Treatment of Bowel Disorders: Focus on Irritable Bowel Syndrome and Functional Constipation. Am. J. Gastroenterol. 2022;117:947&#x2013;957. doi: 10.14309/ajg.0000000000001767.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000001767</ArticleId><ArticleId IdType="pmc">PMC9169760</ArticleId><ArticleId IdType="pubmed">35435179</ArticleId></ArticleIdList></Reference><Reference><Citation>Pourmasoumi M., Ghiasvand R., Darvishi L., Hadi A., Bahreini N., Keshavarzpour Z. Comparison and assessment of flixweed and fig effects on irritable bowel syndrome with predominant constipation: A single-blind randomized clinical trial. Explore. 2019;15:198&#x2013;205. doi: 10.1016/j.explore.2018.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.explore.2018.09.003</ArticleId><ArticleId IdType="pubmed">30318190</ArticleId></ArticleIdList></Reference><Reference><Citation>Henare S.J., Rutherfurd S.M. Digestion of kiwifruit fiber. Adv. Food Nutr. Res. 2013;68:187&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">23394988</ArticleId></ArticleIdList></Reference><Reference><Citation>Montoya C.A., Rutherfurd S.M., Olson T.D., Purba A.S., Drummond L.N., Boland M.J., Moughan P.J. Actinidin from kiwifruit (Actinidia deliciosa cv. Hayward) increases the digestion and rate of gastric emptying of meat proteins in the growing pig. Br. J. Nutr. 2014;111:957&#x2013;967. doi: 10.1017/S0007114513003401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0007114513003401</ArticleId><ArticleId IdType="pubmed">24252432</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y.K., Low K.Y., Siah K., Drummond L.M., Gwee K.-A. Kiwifruit (Actinidia deliciosa) changes intestinal microbial profile. Microb. Ecol. Health Dis. 2012;18:23. doi: 10.3402/mehd.v23i0.18572.</Citation><ArticleIdList><ArticleId IdType="doi">10.3402/mehd.v23i0.18572</ArticleId><ArticleId IdType="pmc">PMC3747767</ArticleId><ArticleId IdType="pubmed">23990838</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkar S.G., Rosendale D., Paturi G., Herath T.D., Stoklosinski H., Phipps J.E., Hedderley D., Ansell J. In vitro utilization of gold and green kiwifruit oligosaccharides by human gut microbial populations. Plant Foods Hum. Nutr. 2012;67:200&#x2013;207. doi: 10.1007/s11130-012-0293-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11130-012-0293-1</ArticleId><ArticleId IdType="pubmed">22576129</ArticleId></ArticleIdList></Reference><Reference><Citation>Han K., Balan P., Molist Gasa F., Boland M. Green kiwifruit modulates the colonic microbiota in growing pigs. Lett. Appl. Microbiol. 2011;52:379&#x2013;385. doi: 10.1111/j.1472-765X.2011.03012.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1472-765X.2011.03012.x</ArticleId><ArticleId IdType="pubmed">21255058</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer S.B., Frampton C.M., Gearry R.B., Barbara G. Habitual Green Kiwifruit Consumption Is Associated with a Reduction in Upper Gastrointestinal Symptoms: A Systematic Scoping Review. Adv. Nutr. 2022;13:846&#x2013;856. doi: 10.1093/advances/nmac025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/advances/nmac025</ArticleId><ArticleId IdType="pmc">PMC9156379</ArticleId><ArticleId IdType="pubmed">35266507</ArticleId></ArticleIdList></Reference><Reference><Citation>Stacewicz-Sapuntzakis M., Bowen P.E., Hussain E.A., Damayanti-Wood B.I., Farnsworth N.R. Chemical composition and potential health effects of prunes: A functional food? Crit. Rev. Food Sci. Nutr. 2001;41:251&#x2013;286. doi: 10.1080/20014091091814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/20014091091814</ArticleId><ArticleId IdType="pubmed">11401245</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson G.R., Roberfroid M.B. Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics. J. Nutr. 1995;125:1401&#x2013;1412. doi: 10.1093/jn/125.6.1401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jn/125.6.1401</ArticleId><ArticleId IdType="pubmed">7782892</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett J.S. How to institute the low-FODMAP diet. J. Gastroenterol. Hepatol. 2017;32:8&#x2013;10. doi: 10.1111/jgh.13686.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.13686</ArticleId><ArticleId IdType="pubmed">28244669</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher H.M., Whelan K. Altered gastrointestinal microbiota in irritable bowel syndrome and its modification by diet: Probiotics, prebiotics and the low FODMAP diet. Proc. Nutr. Soc. 2016;75:306&#x2013;318. doi: 10.1017/S0029665116000021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0029665116000021</ArticleId><ArticleId IdType="pubmed">26908093</ArticleId></ArticleIdList></Reference><Reference><Citation>Tett A., Pasolli E., Masetti G., Ercolini D., Segata N. Prevotella diversity, niches and interactions with the human host. Nat. Rev. Microbiol. 2021;19:585&#x2013;599. doi: 10.1038/s41579-021-00559-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00559-y</ArticleId><ArticleId IdType="pmc">PMC11290707</ArticleId><ArticleId IdType="pubmed">34050328</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Presti A., Del Chierico F., Altomare A., Zorzi F., Monteleone G., Putignani L., Angeletti S., Cicala M., Guarino M.P.L., Ciccozzi M. Phylogenetic analysis of Prevotella copri from fecal and mucosal microbiota of IBS and IBD patients. Ther. Adv Gastroenterol. 2023;16:17562848221136328. doi: 10.1177/17562848221136328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17562848221136328</ArticleId><ArticleId IdType="pmc">PMC9837282</ArticleId><ArticleId IdType="pubmed">36644130</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn S., Datta A., Kallis S., Law E., Myers C.E., Whelan K. Validation of a food frequency questionnaire to measure intakes of inulin and oligofructose. Eur. J. Clin. Nutr. 2011;65:402&#x2013;408. doi: 10.1038/ejcn.2010.272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejcn.2010.272</ArticleId><ArticleId IdType="pubmed">21179053</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarino M.P.L., Altomare A., Emerenziani S., Di Rosa C., Ribolsi M., Balestrieri P., Iovino P., Rocchi G., Cicala M. Mechanisms of Action of Prebiotics and Their Effects on Gastro-Intestinal Disorders in Adults. Nutrients. 2020;12:1037. doi: 10.3390/nu12041037.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12041037</ArticleId><ArticleId IdType="pmc">PMC7231265</ArticleId><ArticleId IdType="pubmed">32283802</ArticleId></ArticleIdList></Reference><Reference><Citation>Slavin J. Fiber and prebiotics: Mechanisms and health benefits. Nutrients. 2013;5:1417&#x2013;1435. doi: 10.3390/nu5041417.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu5041417</ArticleId><ArticleId IdType="pmc">PMC3705355</ArticleId><ArticleId IdType="pubmed">23609775</ArticleId></ArticleIdList></Reference><Reference><Citation>Micka A., Siepelmeyer A., Holz A., Theis S., Sch&#xf6;n C. Effect of consumption of chicory inulin on bowel function in healthy subjects with constipation: A randomized, double-blind, placebo-controlled trial. Int. J. Food Sci. Nutr. 2017;68:82&#x2013;89. doi: 10.1080/09637486.2016.1212819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09637486.2016.1212819</ArticleId><ArticleId IdType="pubmed">27492975</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;hman L., Simr&#xe9;n M. Intestinal microbiota and its role in irritable bowel syndrome (IBS) Curr. Gastroenterol. Rep. 2013;15:323. doi: 10.1007/s11894-013-0323-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11894-013-0323-7</ArticleId><ArticleId IdType="pubmed">23580243</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilipenko V.I., Teplyuk D.A., Shakhovskaya A.K., Isakov V.A., Vorobyova V.M., Vorobyova I.S., Sarkisyan V.A., Kochetkova A.A., Mikheeva G.A., Yudina A.V. Using a multicomponent functional food in IBS patients with constipation a comparative controlled study. Vopr Pitan. 2016;85:84&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">27455604</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilipenko V.I., Teplyuk D.A., Shakhovskaya A.K., Isakov V.A., Vorobyova V.M., Vorobyova I.S., Glazkova I.V., Kochetkova A.A., Mikheeva G.A., Yudina A.V. Dry jelly concentrate with vitamins and dietary fiber in patients with IBS with constipation: A comparative controlled study. Vopr Pitan. 2015;84:83&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">29378102</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuller R. Probiotics in man and animals. J. Appl. Bacteriol. 1989;66:365&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">2666378</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher H.M., Lomer M.C.E., Farquharson F.M., Louis P., Fava F., Franciosi E., Scholz M., Tuohy K.M., Lindsay J.O., Irving P.M., et al. A Diet Low in FODMAPs Reduces Symptoms in Patients with Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial. Gastroenterology. 2017;153:936&#x2013;947. doi: 10.1053/j.gastro.2017.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2017.06.010</ArticleId><ArticleId IdType="pubmed">28625832</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott K.P., Antoine J.M., Midtvedt T., van Hemert S. Manipulating the gut microbiota to maintain health and treat disease. Microb. Ecol. Health Dis. 2015;26:25877. doi: 10.3402/mehd.v26.25877.</Citation><ArticleIdList><ArticleId IdType="doi">10.3402/mehd.v26.25877</ArticleId><ArticleId IdType="pmc">PMC4315778</ArticleId><ArticleId IdType="pubmed">25651995</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller L.E., Ouwehand A.C. Probiotic supplementation decreases intestinal transit time: Meta-analysis of randomized controlled trials. World J. Gastroenterol. 2013;19:4718&#x2013;4725. doi: 10.3748/wjg.v19.i29.4718.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v19.i29.4718</ArticleId><ArticleId IdType="pmc">PMC3732843</ArticleId><ArticleId IdType="pubmed">23922468</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng J., Li Y.Q., Zuo X.L., Zhen Y.B., Yang J., Liu C.H. Clinical trial: Effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharm. Ther. 2008;28:994&#x2013;1002. doi: 10.1111/j.1365-2036.2008.03818.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2008.03818.x</ArticleId><ArticleId IdType="pubmed">18671775</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahony L., McCarthy J., Kelly P., Hurley G., Luo F., Chen K., O&#x2019;Sullivan G.C., Kiely B., Collins J.K., Shanahan F., et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541&#x2013;551. doi: 10.1053/j.gastro.2004.11.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2004.11.050</ArticleId><ArticleId IdType="pubmed">15765388</ArticleId></ArticleIdList></Reference><Reference><Citation>Tillisch K., Labus J., Kilpatrick L., Jiang Z., Stains J., Ebrat B., Guyonnet D., Legrain-Raspaud S., Trotin B., Naliboff B., et al. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology. 2013;144:1394&#x2013;1401; 1401.e1&#x2013;4. doi: 10.1053/j.gastro.2013.02.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2013.02.043</ArticleId><ArticleId IdType="pmc">PMC3839572</ArticleId><ArticleId IdType="pubmed">23474283</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen Y., Li J., Long Q., Yue C.-C., He B., Tang X.-G. The efficacy and safety of probiotics for patients with constipation-predominant irritable bowel syndrome: A systematic review and meta-analysis based on seventeen randomized controlled trials. Int. J. Surg. 2020;79:111&#x2013;119. doi: 10.1016/j.ijsu.2020.04.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2020.04.063</ArticleId><ArticleId IdType="pubmed">32387213</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller R., P&#xe9;lerin F., Cayzeele Decherf A., Maudet C., Housez B., Cazaubiel M., J&#xfc;sten P. Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: Improvement in abdominal pain and bloating in those with predominant constipation. United Eur. Gastroenterol J. 2016;4:353&#x2013;362. doi: 10.1177/2050640615602571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2050640615602571</ArticleId><ArticleId IdType="pmc">PMC4924426</ArticleId><ArticleId IdType="pubmed">27403301</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezzasalma V., Manfrini E., Ferri E., Sandionigi A., La Ferla B., Schiano I., Michelotti A., Nobile V., Labra M., Di Gennaro P. A Randomized, Double-Blind, Placebo-Controlled Trial: The Efficacy of Multispecies Probiotic Supplementation in Alleviating Symptoms of Irritable Bowel Syndrome Associated with Constipation. BioMed Res. Int. 2016;2016:4740907. doi: 10.1155/2016/4740907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/4740907</ArticleId><ArticleId IdType="pmc">PMC4993960</ArticleId><ArticleId IdType="pubmed">27595104</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahrudin M.F., Abdul Rani R., Tamil A.M., Mokhtar N.M., Raja Ali R.A. Effectiveness of Sterilized Symbiotic Drink Containing Lactobacillus helveticus Comparable to Probiotic Alone in Patients with Constipation-Predominant Irritable Bowel Syndrome. Dig. Dis. Sci. 2020;65:541&#x2013;549. doi: 10.1007/s10620-019-05695-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-019-05695-3</ArticleId><ArticleId IdType="pmc">PMC6995448</ArticleId><ArticleId IdType="pubmed">31209720</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#x103;rboi O.B., Chiril&#x103; I., Ciortescu I., Anton C., Drug V.L. Inulin, Choline and Silymarin in the Treatment of Irritable Bowel Syndrome with Constipation-Randomized Case-Control Study. J. Clin. Med. 2022;11:2248. doi: 10.3390/jcm11082248.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11082248</ArticleId><ArticleId IdType="pmc">PMC9027095</ArticleId><ArticleId IdType="pubmed">35456341</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappello C., Tremolaterra F., Pascariello A., Ciacci C., Iovino P. A randomized clinical trial (RCT) of a symbiotic mixture in patients with irritable bowel syndrome (IBS): Effects on symptoms, colonic transit and quality of life. Int. J. Color. Dis. 2013;28:349&#x2013;358. doi: 10.1007/s00384-012-1552-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-012-1552-1</ArticleId><ArticleId IdType="pmc">PMC3587687</ArticleId><ArticleId IdType="pubmed">22885882</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui J., Lin Z., Tian H., Yang B., Zhao D., Ye C., Li N., Qin H., Chen Q. Long&#x2013;term follow up results of fecal microbiota transplantation for irritable bowel syndrome: A single&#x2013;center, retrospective study. Front. Med. 2021;8:710452. doi: 10.3389/fmed.2021.710452.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.710452</ArticleId><ArticleId IdType="pmc">PMC8362996</ArticleId><ArticleId IdType="pubmed">34395484</ArticleId></ArticleIdList></Reference><Reference><Citation>El&#x2013;Salhy M., Casen C., Valeur J., Hausken T., Hatlebakk J.G. Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome. World J. Gastroenterol. 2021;27:2219&#x2013;2237. doi: 10.3748/wjg.v27.i18.2219.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v27.i18.2219</ArticleId><ArticleId IdType="pmc">PMC8117742</ArticleId><ArticleId IdType="pubmed">34025075</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy B.E. The Science, evidence, and practice of dietary interventions in irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 2015;13:1899&#x2013;1906. doi: 10.1016/j.cgh.2015.02.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2015.02.043</ArticleId><ArticleId IdType="pubmed">25769411</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill P., Muir J.G., Gibson P.R. Controversies and Recent Developments of the Low-FODMAP Diet. Gastroenterol. Hepatol. 2017;13:36&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5390324</ArticleId><ArticleId IdType="pubmed">28420945</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M., Hatlebakk J.G., Hausken T. Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones. Nutrients. 2019;11:1824. doi: 10.3390/nu11081824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11081824</ArticleId><ArticleId IdType="pmc">PMC6723613</ArticleId><ArticleId IdType="pubmed">31394793</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">30294792</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2036</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>10</Issue><PubDate><Year>2018</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Alimentary pharmacology &amp; therapeutics</Title><ISOAbbreviation>Aliment Pharmacol Ther</ISOAbbreviation></Journal><ArticleTitle>Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome.</ArticleTitle><Pagination><StartPage>1044</StartPage><EndPage>1060</EndPage><MedlinePgn>1044-1060</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/apt.15001</ELocationID><Abstract><AbstractText Label="BACKGROUND">Irritable bowel syndrome (IBS) is a chronic functional bowel disorder. Disturbances in the gastrointestinal microbiome may be involved in its aetiology.</AbstractText><AbstractText Label="AIM">To perform a systematic review and meta-analysis to examine the efficacy of prebiotics, probiotics, synbiotics and antibiotics in IBS.</AbstractText><AbstractText Label="METHODS">MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched (up to July 2017). Randomised controlled trials (RCTs) recruiting adults with IBS, comparing prebiotics, probiotics, synbiotics or antibiotics with placebo or no therapy were eligible. Dichotomous symptom data were pooled to obtain a relative risk (RR) of remaining symptomatic after therapy, with a 95% confidence interval (CI). Continuous data were pooled using a standardised mean difference with a 95% CI.</AbstractText><AbstractText Label="RESULTS">The search identified 4017 citations. Data for prebiotics and synbiotics were sparse. Fifty-three RCTs of probiotics, involving 5545 patients, were eligible. Particular combinations of probiotics, or specific species and strains, appeared to have beneficial effects on global IBS symptoms and abdominal pain, but it was not possible to draw definitive conclusions about their efficacy. There were five trials of similar design that used rifaximin in non-constipated IBS patients, which was more effective than placebo (RR of symptoms persisting&#xa0;=&#xa0;0.84; 95% CI 0.79-0.90). Adverse events were no more common with probiotics or antibiotics.</AbstractText><AbstractText Label="CONCLUSIONS">Which particular combination, species or strains of probiotics are effective for IBS remains, for the most part, unclear. Rifaximin has modest efficacy in improving symptoms in non-constipated IBS.</AbstractText><CopyrightInformation>&#xa9; 2018 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ford</LastName><ForeName>Alexander C</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0001-6371-4359</Identifier><AffiliationInfo><Affiliation>Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Lucinda A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Mayo School of Medicine, Scottsdale, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacy</LastName><ForeName>Brian E</ForeName><Initials>BE</Initials><Identifier Source="ORCID">0000-0003-4121-7970</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quigley</LastName><ForeName>Eamonn M M</ForeName><Initials>EMM</Initials><Identifier Source="ORCID">0000-0003-4151-7180</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Lynda K and David M Underwood Center for Digestive Disorders, Houston Methodist Hospital and Weill Cornell Medical College, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moayyedi</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Gastroenterology Division, Health Sciences Center, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>American College of Gastroenterology</Agency><Country>International</Country></Grant><Grant><Agency>Canadian Institute for Health Research</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aliment Pharmacol Ther</MedlineTA><NlmUniqueID>8707234</NlmUniqueID><ISSNLinking>0269-2813</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005765">Gastrointestinal Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D056692">Prebiotics</NameOfSubstance></Chemical><Chemical><RegistryNumber>L36O5T016N</RegistryNumber><NameOfSubstance UI="D000078262">Rifaximin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Aliment Pharmacol Ther. 2019 May;49(9):1253-1254. doi: 10.1111/apt.15230.</RefSource><PMID Version="1">30977173</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Aliment Pharmacol Ther. 2019 May;49(9):1254-1255. doi: 10.1111/apt.15234.</RefSource><PMID Version="1">30977174</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Aliment Pharmacol Ther. 2023 Nov;58(9):950-951. doi: 10.1111/apt.17724.</RefSource><PMID Version="1">37831529</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015746" MajorTopicYN="N">Abdominal Pain</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005765" MajorTopicYN="N">Gastrointestinal Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056692" MajorTopicYN="N">Prebiotics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078262" MajorTopicYN="N">Rifaximin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058616" MajorTopicYN="N">Synbiotics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30294792</ArticleId><ArticleId IdType="doi">10.1111/apt.15001</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38999862</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6643</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>13</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>02</Day></PubDate></JournalIssue><Title>Nutrients</Title><ISOAbbreviation>Nutrients</ISOAbbreviation></Journal><ArticleTitle>The Efficacy of Probiotics, Prebiotics, Synbiotics, and Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2114</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nu16132114</ELocationID><Abstract><AbstractText>Irritable bowel syndrome (IBS) is a common gastrointestinal disorder with gut microbiota imbalance playing a significant role. There are increasing numbers of research studies exploring treatment options involving probiotics, prebiotics, synbiotics, and fecal microbiota transplantation (FMT), but it is still uncertain which treatment option is superior. The research was conducted on various databases and unpublished trial data (up to February 2023). Randomized controlled trials (RCTs) were screened for adult patients with IBS comparing interventions with placebo. Probiotics, prebiotics, synbiotics, and FMT were assessed for their impact using mean difference and Bayesian network meta-analysis. Out of 6528 articles, 54 were included for probiotics, 7 for prebiotics/synbiotics, and 6 for FMT. Probiotics showed improvement in IBS symptoms, particularly with <i>Bifidobacterium</i> and <i>Lactobacillus</i> strains. Prebiotics and synbiotics did not show significant improvement. Network meta-analysis indicated the favorable effects of probiotics (OR = 0.53, 95% CI, 0.48 to 0.59) and FMT (OR = 0.46, 95% CI, 0.33 to 0.64) on IBS, with no serious adverse events reported. In short, probiotics and FMT are effective for managing IBS, with <i>Bifidobacterium</i> and <i>Lactobacillus</i> being dominant strains. However, the most effective probiotic combination or strain remains unclear, while prebiotics and synbiotics did not show significant improvement.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Youhe</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Rd., Hangzhou 310003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuetong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Rd., Hangzhou 310003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0009-0009-1848-7519</Identifier><AffiliationInfo><Affiliation>State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Rd., Hangzhou 310003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Lanjuan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Rd., Hangzhou 310003, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>No. 2022ZFJH003</GrantID><Agency>The Fundamental Research Funds for the Central Universities</Agency><Country/></Grant><Grant><GrantID>SYS202202</GrantID><Agency>Shandong Provincial Laboratory Project</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D000099094">Network Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nutrients</MedlineTA><NlmUniqueID>101521595</NlmUniqueID><ISSNLinking>2072-6643</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D056692">Prebiotics</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056692" MajorTopicYN="Y">Prebiotics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058616" MajorTopicYN="Y">Synbiotics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069467" MajorTopicYN="Y">Fecal Microbiota Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001644" MajorTopicYN="N">Bifidobacterium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007778" MajorTopicYN="N">Lactobacillus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">fecal microbiota transplantation</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">network meta-analysis</Keyword><Keyword MajorTopicYN="N">prebiotic</Keyword><Keyword MajorTopicYN="N">probiotic</Keyword><Keyword MajorTopicYN="N">synbiotic</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>13</Day><Hour>7</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>13</Day><Hour>7</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>13</Day><Hour>1</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38999862</ArticleId><ArticleId IdType="pmc">PMC11243554</ArticleId><ArticleId IdType="doi">10.3390/nu16132114</ArticleId><ArticleId IdType="pii">nu16132114</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lovell R.M., Ford A.C. Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis. Clin. Gastroenterol. Hepatol. 2012;10:712&#x2013;721.e714. doi: 10.1016/j.cgh.2012.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2012.02.029</ArticleId><ArticleId IdType="pubmed">22426087</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer E.A., Ryu H.J., Bhatt R.R. The neurobiology of irritable bowel syndrome. Mol. Psychiatry. 2023;28:1451&#x2013;1465. doi: 10.1038/s41380-023-01972-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-023-01972-w</ArticleId><ArticleId IdType="pmc">PMC10208985</ArticleId><ArticleId IdType="pubmed">36732586</ArticleId></ArticleIdList></Reference><Reference><Citation>Petitfils C., Maurel S., Payros G., Hueber A., Agaiz B., Gazzo G., Marrocco R., Auvray F., Langevin G., Motta J.P., et al. Identification of bacterial lipopeptides as key players in IBS. Gut. 2023;72:939&#x2013;950. doi: 10.1136/gutjnl-2022-328084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2022-328084</ArticleId><ArticleId IdType="pmc">PMC10086498</ArticleId><ArticleId IdType="pubmed">36241390</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Sperber A.D., Corsetti M., Camilleri M. Irritable bowel syndrome. Lancet. 2020;396:1675&#x2013;1688. doi: 10.1016/S0140-6736(20)31548-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31548-8</ArticleId><ArticleId IdType="pubmed">33049223</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringel Y., Maharshak N. Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol. 2013;305:G529&#x2013;G541. doi: 10.1152/ajpgi.00207.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00207.2012</ArticleId><ArticleId IdType="pmc">PMC3798736</ArticleId><ArticleId IdType="pubmed">23886861</ArticleId></ArticleIdList></Reference><Reference><Citation>Camilleri M. Management Options for Irritable Bowel Syndrome. Mayo Clin. Proc. 2018;93:1858&#x2013;1872. doi: 10.1016/j.mayocp.2018.04.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2018.04.032</ArticleId><ArticleId IdType="pmc">PMC6314474</ArticleId><ArticleId IdType="pubmed">30522596</ArticleId></ArticleIdList></Reference><Reference><Citation>Macsharry J., O&#x2019;Mahony L., Fanning A., Bairead E., Sherlock G., Tiesman J., Fulmer A., Kiely B., Dinan T.G., Shanahan F., et al. Mucosal cytokine imbalance in irritable bowel syndrome. Scand. J. Gastroenterol. 2008;43:1467&#x2013;1476. doi: 10.1080/00365520802276127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365520802276127</ArticleId><ArticleId IdType="pubmed">18752146</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtmann G.J., Ford A.C., Talley N.J. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol. Hepatol. 2016;1:133&#x2013;146. doi: 10.1016/S2468-1253(16)30023-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(16)30023-1</ArticleId><ArticleId IdType="pubmed">28404070</ArticleId></ArticleIdList></Reference><Reference><Citation>Bischoff S.C., Barbara G., Buurman W., Ockhuizen T., Schulzke J.D., Serino M., Tilg H., Watson A., Wells J.M. Intestinal permeability&#x2014;A new target for disease prevention and therapy. BMC Gastroenterol. 2014;14:189. doi: 10.1186/s12876-014-0189-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-014-0189-7</ArticleId><ArticleId IdType="pmc">PMC4253991</ArticleId><ArticleId IdType="pubmed">25407511</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez C., Lobo B., Pigrau M., Ramos L., Gonz&#xe1;lez-Castro A.M., Alonso C., Guilarte M., Guil&#xe1; M., de Torres I., Azpiroz F., et al. Diarrhoea-predominant irritable bowel syndrome: An organic disorder with structural abnormalities in the jejunal epithelial barrier. Gut. 2013;62:1160&#x2013;1168. doi: 10.1136/gutjnl-2012-302093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2012-302093</ArticleId><ArticleId IdType="pubmed">22637702</ArticleId></ArticleIdList></Reference><Reference><Citation>Enck P., Aziz Q., Barbara G., Farmer A.D., Fukudo S., Mayer E.A., Niesler B., Quigley E.M., Rajili&#x107;-Stojanovi&#x107; M., Schemann M., et al. Irritable bowel syndrome. Nat. Rev. Dis. Primers. 2016;2:16014. doi: 10.1038/nrdp.2016.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.14</ArticleId><ArticleId IdType="pmc">PMC5001845</ArticleId><ArticleId IdType="pubmed">27159638</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin H.Y., Cheng C.W., Tang X.D., Bian Z.X. Impact of psychological stress on irritable bowel syndrome. World J. Gastroenterol. 2014;20:14126&#x2013;14131. doi: 10.3748/wjg.v20.i39.14126.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i39.14126</ArticleId><ArticleId IdType="pmc">PMC4202343</ArticleId><ArticleId IdType="pubmed">25339801</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbara G., Stanghellini V., Cremon C., De Giorgio R., Corinaldesi R. What is the effect of inflammation on intestinal function? Inflamm. Bowel Dis. 2008;14((Suppl. S2)):S140&#x2013;S144. doi: 10.1097/00054725-200810001-00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00054725-200810001-00068</ArticleId><ArticleId IdType="pubmed">18816685</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbara G., Cremon C., Carini G., Bellacosa L., Zecchi L., De Giorgio R., Corinaldesi R., Stanghellini V. The immune system in irritable bowel syndrome. J. Neurogastroenterol. Motil. 2011;17:349&#x2013;359. doi: 10.5056/jnm.2011.17.4.349.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm.2011.17.4.349</ArticleId><ArticleId IdType="pmc">PMC3228974</ArticleId><ArticleId IdType="pubmed">22148103</ArticleId></ArticleIdList></Reference><Reference><Citation>Buhner S., Li Q., Vignali S., Barbara G., De Giorgio R., Stanghellini V., Cremon C., Zeller F., Langer R., Daniel H., et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology. 2009;137:1425&#x2013;1434. doi: 10.1053/j.gastro.2009.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2009.07.005</ArticleId><ArticleId IdType="pubmed">19596012</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbara G., Wang B., Stanghellini V., de Giorgio R., Cremon C., Di Nardo G., Trevisani M., Campi B., Geppetti P., Tonini M., et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132:26&#x2013;37. doi: 10.1053/j.gastro.2006.11.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2006.11.039</ArticleId><ArticleId IdType="pubmed">17241857</ArticleId></ArticleIdList></Reference><Reference><Citation>Canakis A., Haroon M., Weber H.C. Irritable bowel syndrome and gut microbiota. Curr. Opin. Endocrinol. Diabetes Obes. 2020;27:28&#x2013;35. doi: 10.1097/MED.0000000000000523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MED.0000000000000523</ArticleId><ArticleId IdType="pubmed">31789724</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassinen A., Krogius-Kurikka L., M&#xe4;kivuokko H., Rinttil&#xe4; T., Paulin L., Corander J., Malinen E., Apajalahti J., Palva A. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133:24&#x2013;33. doi: 10.1053/j.gastro.2007.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2007.04.005</ArticleId><ArticleId IdType="pubmed">17631127</ArticleId></ArticleIdList></Reference><Reference><Citation>Su T., Liu R., Lee A., Long Y., Du L., Lai S., Chen X., Wang L., Si J., Owyang C., et al. Altered Intestinal Microbiota with Increased Abundance of Prevotella Is Associated with High Risk of Diarrhea-Predominant Irritable Bowel Syndrome. Gastroenterol. Res. Pract. 2018;2018:6961783. doi: 10.1155/2018/6961783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/6961783</ArticleId><ArticleId IdType="pmc">PMC6008816</ArticleId><ArticleId IdType="pubmed">29967640</ArticleId></ArticleIdList></Reference><Reference><Citation>Salonen A., de Vos W.M., Palva A. Gastrointestinal microbiota in irritable bowel syndrome: Present state and perspectives. Microbiology. 2010;156:3205&#x2013;3215. doi: 10.1099/mic.0.043257-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/mic.0.043257-0</ArticleId><ArticleId IdType="pubmed">20705664</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciavilla P., Strati F., Di Paola M., Modesto M., Vitali F., Cavalieri D., Prati G.M., Di Vito M., Aragona G., De Filippo C., et al. Gut microbiota profiles and characterization of cultivable fungal isolates in IBS patients. Appl. Microbiol. Biotechnol. 2021;105:3277&#x2013;3288. doi: 10.1007/s00253-021-11264-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00253-021-11264-4</ArticleId><ArticleId IdType="pmc">PMC8053167</ArticleId><ArticleId IdType="pubmed">33839797</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuang X., Xiong L., Li L., Li M., Chen M. Alterations of gut microbiota in patients with irritable bowel syndrome: A systematic review and meta-analysis. J. Gastroenterol. Hepatol. 2017;32:28&#x2013;38. doi: 10.1111/jgh.13471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.13471</ArticleId><ArticleId IdType="pubmed">27300149</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuang X., Tian Z., Li L., Zeng Z., Chen M., Xiong L. Fecal Microbiota Alterations Associated with Diarrhea-Predominant Irritable Bowel Syndrome. Front. Microbiol. 2018;9:1600. doi: 10.3389/fmicb.2018.01600.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.01600</ArticleId><ArticleId IdType="pmc">PMC6068233</ArticleId><ArticleId IdType="pubmed">30090090</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeffery I.B., O&#x2019;Toole P.W., &#xd6;hman L., Claesson M.J., Deane J., Quigley E.M., Simr&#xe9;n M. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2012;61:997&#x2013;1006. doi: 10.1136/gutjnl-2011-301501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2011-301501</ArticleId><ArticleId IdType="pubmed">22180058</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittayanon R., Lau J.T., Yuan Y., Leontiadis G.I., Tse F., Surette M., Moayyedi P. Gut Microbiota in Patients with Irritable Bowel Syndrome-A Systematic Review. Gastroenterology. 2019;157:97&#x2013;108. doi: 10.1053/j.gastro.2019.03.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2019.03.049</ArticleId><ArticleId IdType="pubmed">30940523</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahony L., McCarthy J., Kelly P., Hurley G., Luo F., Chen K., O&#x2019;Sullivan G.C., Kiely B., Collins J.K., Shanahan F., et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541&#x2013;551. doi: 10.1053/j.gastro.2004.11.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2004.11.050</ArticleId><ArticleId IdType="pubmed">15765388</ArticleId></ArticleIdList></Reference><Reference><Citation>Verd&#xfa; E.F., Bercik P., Verma-Gandhu M., Huang X.X., Blennerhassett P., Jackson W., Mao Y., Wang L., Rochat F., Collins S.M. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut. 2006;55:182&#x2013;190. doi: 10.1136/gut.2005.066100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2005.066100</ArticleId><ArticleId IdType="pmc">PMC1856497</ArticleId><ArticleId IdType="pubmed">16105890</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Li S., Lv L., Jiang S., Xu L., Chen H., Li L. Protective effect of Pediococcus pentosaceus Li05 on diarrhea-predominant irritable bowel syndrome in rats. Food Funct. 2024;15:3692&#x2013;3708. doi: 10.1039/D3FO04904C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D3FO04904C</ArticleId><ArticleId IdType="pubmed">38488110</ArticleId></ArticleIdList></Reference><Reference><Citation>Simr&#xe9;n M., Barbara G., Flint H.J., Spiegel B.M., Spiller R.C., Vanner S., Verdu E.F., Whorwell P.J., Zoetendal E.G. Intestinal microbiota in functional bowel disorders: A Rome foundation report. Gut. 2013;62:159&#x2013;176. doi: 10.1136/gutjnl-2012-302167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2012-302167</ArticleId><ArticleId IdType="pmc">PMC3551212</ArticleId><ArticleId IdType="pubmed">22730468</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher H.M., Whelan K. The low FODMAP diet: Recent advances in understanding its mechanisms and efficacy in IBS. Gut. 2017;66:1517&#x2013;1527. doi: 10.1136/gutjnl-2017-313750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2017-313750</ArticleId><ArticleId IdType="pubmed">28592442</ArticleId></ArticleIdList></Reference><Reference><Citation>Chey W.D., Kurlander J., Eswaran S. Irritable bowel syndrome: A clinical review. JAMA. 2015;313:949&#x2013;958. doi: 10.1001/jama.2015.0954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.0954</ArticleId><ArticleId IdType="pubmed">25734736</ArticleId></ArticleIdList></Reference><Reference><Citation>Herndon C.C., Wang Y.P., Lu C.L. Targeting the gut microbiota for the treatment of irritable bowel syndrome. Kaohsiung J. Med. Sci. 2020;36:160&#x2013;170. doi: 10.1002/kjm2.12154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/kjm2.12154</ArticleId><ArticleId IdType="pmc">PMC11896346</ArticleId><ArticleId IdType="pubmed">31782606</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Harris L.A., Lacy B.E., Quigley E.M.M., Moayyedi P. Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2018;48:1044&#x2013;1060. doi: 10.1111/apt.15001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15001</ArticleId><ArticleId IdType="pubmed">30294792</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooijevaar R.E., Terveer E.M., Verspaget H.W., Kuijper E.J., Keller J.J. Clinical Application and Potential of Fecal Microbiota Transplantation. Annu. Rev. Med. 2019;70:335&#x2013;351. doi: 10.1146/annurev-med-111717-122956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-111717-122956</ArticleId><ArticleId IdType="pubmed">30403550</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne J.A.C., Savovic J., Page M.J., Elbers R.G., Blencowe N.S., Boutron I., Cates C.J., Cheng H.Y., Corbett M.S., Eldridge S.M., et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l4898</ArticleId><ArticleId IdType="pubmed">31462531</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat. Med. 2000;19:3127&#x2013;3131. doi: 10.1002/1097-0258(20001130)19:22&lt;3127::AID-SIM784&gt;3.0.CO;2-M.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1097-0258(20001130)19:22&lt;3127::AID-SIM784&gt;3.0.CO;2-M</ArticleId><ArticleId IdType="pubmed">11113947</ArticleId></ArticleIdList></Reference><Reference><Citation>Murad M.H., Wang Z., Chu H., Lin L. When continuous outcomes are measured using different scales: Guide for meta-analysis and interpretation. BMJ. 2019;364:k4817. doi: 10.1136/bmj.k4817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.k4817</ArticleId><ArticleId IdType="pmc">PMC6890471</ArticleId><ArticleId IdType="pubmed">30670455</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002;21:1539&#x2013;1558. doi: 10.1002/sim.1186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.1186</ArticleId><ArticleId IdType="pubmed">12111919</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglielmetti S., Mora D., Gschwender M., Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study. Aliment. Pharmacol. Ther. 2011;33:1123&#x2013;1132. doi: 10.1111/j.1365-2036.2011.04633.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2011.04633.x</ArticleId><ArticleId IdType="pubmed">21418261</ArticleId></ArticleIdList></Reference><Reference><Citation>Martoni C.J., Srivastava S., Leyer G.J. Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial. Nutrients. 2020;12:363. doi: 10.3390/nu12020363.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12020363</ArticleId><ArticleId IdType="pmc">PMC7071206</ArticleId><ArticleId IdType="pubmed">32019158</ArticleId></ArticleIdList></Reference><Reference><Citation>Andresen V., Gschossmann J., Layer P. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: A multicentre, randomised, double-blind, placebo-controlled clinical trial. Lancet Gastroenterol. Hepatol. 2020;5:658&#x2013;666. doi: 10.1016/S2468-1253(20)30056-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30056-X</ArticleId><ArticleId IdType="pubmed">32277872</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajander K., Myllyluoma E., Rajilic-Stojanovic M., Kyronpalo S., Rasmussen M., Jarvenpaa S., Zoetendal E.G., de Vos W.M., Vapaatalo H., Korpela R. Clinical trial: Multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment. Pharmacol. Ther. 2008;27:48&#x2013;57. doi: 10.1111/j.1365-2036.2007.03542.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2007.03542.x</ArticleId><ArticleId IdType="pubmed">17919270</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisson G., Ayis S., Sherwood R.A., Bjarnason I. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome--a 12 week double-blind study. Aliment. Pharmacol. Ther. 2014;40:51&#x2013;62. doi: 10.1111/apt.12787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.12787</ArticleId><ArticleId IdType="pubmed">24815298</ArticleId></ArticleIdList></Reference><Reference><Citation>Urgesi R., Casale C., Pistelli R., Rapaccini G.L., de Vitis I. A randomized double-blind placebo-controlled clinical trial on efficacy and safety of association of simethicone and Bacillus coagulans (Colinox(R)) in patients with irritable bowel syndrome. Eur. Rev. Med. Pharmacol. Sci. 2014;18:1344&#x2013;1353.</Citation><ArticleIdList><ArticleId IdType="pubmed">24867512</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.J., Camilleri M., McKinzie S., Lempke M.B., Burton D.D., Thomforde G.M., Zinsmeister A.R. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 2003;17:895&#x2013;904. doi: 10.1046/j.1365-2036.2003.01543.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.2003.01543.x</ArticleId><ArticleId IdType="pubmed">12656692</ArticleId></ArticleIdList></Reference><Reference><Citation>Helo A.A. Treatment of Irritable Bowel Syndrome with Saccharomyces Cerevisiae. J. Gastroenterol. Hepatol. Res. 2019;8:2919&#x2013;2922. doi: 10.17554/j.issn.2224-3992.2019.08.818.</Citation><ArticleIdList><ArticleId IdType="doi">10.17554/j.issn.2224-3992.2019.08.818</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller R., Pelerin F., Cayzeele Decherf A., Maudet C., Housez B., Cazaubiel M., Justen P. Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: Improvement in abdominal pain and bloating in those with predominant constipation. United Eur. Gastroenterol. J. 2016;4:353&#x2013;362. doi: 10.1177/2050640615602571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2050640615602571</ArticleId><ArticleId IdType="pmc">PMC4924426</ArticleId><ArticleId IdType="pubmed">27403301</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong K.S., Kang H.W., Im J.P., Ji G.E., Kim S.G., Jung H.C., Song I.S., Kim J.S. Effect of probiotics on symptoms in korean adults with irritable bowel syndrome. Gut Liver. 2009;3:101&#x2013;107. doi: 10.5009/gnl.2009.3.2.101.</Citation><ArticleIdList><ArticleId IdType="doi">10.5009/gnl.2009.3.2.101</ArticleId><ArticleId IdType="pmc">PMC2852694</ArticleId><ArticleId IdType="pubmed">20431731</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui S., Hu Y. Multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Int. J. Clin. Exp. Med. 2012;5:238&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3403550</ArticleId><ArticleId IdType="pubmed">22837798</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai T., Xu Z., Xia P., Feng Y., Liu B., Liu H., Chen Y., Yan G., Lv B., Yan Z., et al. The Short-Term Efficacy of Bifidobacterium Quadruple Viable Tablet in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: Potentially Mediated by Metabolism Rather Than Diversity Regulation. Am. J. Gastroenterol. 2023;118:1256&#x2013;1267. doi: 10.14309/ajg.0000000000002147.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000002147</ArticleId><ArticleId IdType="pubmed">36717369</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen A.Y., Clemens C.H., Vankerckhoven V., Goossens H., Jonkers D.M., Masclee A.A. Efficacy of Lactobacillus casei Shirota for patients with irritable bowel syndrome. Eur. J. Gastroenterol. Hepatol. 2016;28:8&#x2013;14. doi: 10.1097/MEG.0000000000000484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000000484</ArticleId><ArticleId IdType="pubmed">26469356</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon J.S., Sohn W., Lee O.Y., Lee S.P., Lee K.N., Jun D.W., Lee H.L., Yoon B.C., Choi H.S., Chung W.S., et al. Effect of multispecies probiotics on irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. J. Gastroenterol. Hepatol. 2014;29:52&#x2013;59. doi: 10.1111/jgh.12322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.12322</ArticleId><ArticleId IdType="pubmed">23829297</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludidi S., Jonkers D.M., Koning C.J., Kruimel J.W., Mulder L., van der Vaart I.B., Conchillo J.M., Masclee A.A. Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients. Neurogastroenterol. Motil. 2014;26:705&#x2013;714. doi: 10.1111/nmo.12320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12320</ArticleId><ArticleId IdType="pubmed">24588932</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts L.M., McCahon D., Holder R., Wilson S., Hobbs F.D. A randomised controlled trial of a probiotic &#x2018;functional food&#x2019; in the management of irritable bowel syndrome. BMC Gastroenterol. 2013;13:45. doi: 10.1186/1471-230X-13-45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-230X-13-45</ArticleId><ArticleId IdType="pmc">PMC3605320</ArticleId><ArticleId IdType="pubmed">23496803</ArticleId></ArticleIdList></Reference><Reference><Citation>Enck P., Zimmermann K., Menke G., M&#xfc;ller-Lissner S., Martens U., Klosterhalfen S. A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome--a randomized controlled trial with primary care physicians. Neurogastroenterol. Motil. 2008;20:1103&#x2013;1109. doi: 10.1111/j.1365-2982.2008.01156.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2008.01156.x</ArticleId><ArticleId IdType="pubmed">18565142</ArticleId></ArticleIdList></Reference><Reference><Citation>Drouault-Holowacz S., Bieuvelet S., Burckel A., Cazaubiel M., Dray X., Marteau P. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol. Clin. Biol. 2008;32:147&#x2013;152. doi: 10.1016/j.gcb.2007.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gcb.2007.06.001</ArticleId><ArticleId IdType="pubmed">18387426</ArticleId></ArticleIdList></Reference><Reference><Citation>Whorwell P.J., Altringer L., Morel J., Bond Y., Charbonneau D., O&#x2019;Mahony L., Kiely B., Shanahan F., Quigley E.M. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am. J. Gastroenterol. 2006;101:1581&#x2013;1590. doi: 10.1111/j.1572-0241.2006.00734.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2006.00734.x</ArticleId><ArticleId IdType="pubmed">16863564</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajander K., Hatakka K., Poussa T., F&#xe4;rkkil&#xe4; M., Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: A controlled 6-month intervention. Aliment. Pharmacol. Ther. 2005;22:387&#x2013;394. doi: 10.1111/j.1365-2036.2005.02579.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2005.02579.x</ArticleId><ArticleId IdType="pubmed">16128676</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyra A., Hillila M., Huttunen T., Mannikko S., Taalikka M., Tennila J., Tarpila A., Lahtinen S., Ouwehand A.C., Veijola L. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. World J. Gastroenterol. 2016;22:10631&#x2013;10642. doi: 10.3748/wjg.v22.i48.10631.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i48.10631</ArticleId><ArticleId IdType="pmc">PMC5192275</ArticleId><ArticleId IdType="pubmed">28082816</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh J.H., Jang Y.S., Kang D., Chang D.K., Min Y.W. Efficacy and Safety of New Lactobacilli Probiotics for Unconstipated Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients. 2019;11:2887. doi: 10.3390/nu11122887.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11122887</ArticleId><ArticleId IdType="pmc">PMC6950464</ArticleId><ArticleId IdType="pubmed">31783597</ArticleId></ArticleIdList></Reference><Reference><Citation>Mourey F., Decherf A., Jeanne J.F., Clement-Ziza M., Grisoni M.L., Machuron F., Legrain-Raspaud S., Bourreille A., Desreumaux P. Saccharomyces cerevisiae I-3856 in irritable bowel syndrome with predominant constipation. World J. Gastroenterol. 2022;28:2509&#x2013;2522. doi: 10.3748/wjg.v28.i22.2509.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v28.i22.2509</ArticleId><ArticleId IdType="pmc">PMC9258277</ArticleId><ArticleId IdType="pubmed">35979259</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinn D.H., Song J.H., Kim H.J., Lee J.H., Son H.J., Chang D.K., Kim Y.H., Kim J.J., Rhee J.C., Rhee P.L. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig. Dis. Sci. 2008;53:2714&#x2013;2718. doi: 10.1007/s10620-007-0196-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-007-0196-4</ArticleId><ArticleId IdType="pubmed">18274900</ArticleId></ArticleIdList></Reference><Reference><Citation>Madempudi R.S., Ahire J.J., Neelamraju J., Tripathi A., Nanal S. Randomized clinical trial: The effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults. Sci. Rep. 2019;9:12210. doi: 10.1038/s41598-019-48554-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-48554-x</ArticleId><ArticleId IdType="pmc">PMC6704184</ArticleId><ArticleId IdType="pubmed">31434935</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruis W., Chrubasik S., Boehm S., Stange C., Schulze J. A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. Int. J. Colorectal. Dis. 2012;27:467&#x2013;474. doi: 10.1007/s00384-011-1363-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-011-1363-9</ArticleId><ArticleId IdType="pmc">PMC3307993</ArticleId><ArticleId IdType="pubmed">22130826</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung K., Kim A., Lee J.H., Cho D., Seo J., Jung E.S., Kang H.J., Roh J., Kim W. Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1(TM)) on Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study. Nutrients. 2022;14:2015. doi: 10.3390/nu14102015.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14102015</ArticleId><ArticleId IdType="pmc">PMC9144213</ArticleId><ArticleId IdType="pubmed">35631156</ArticleId></ArticleIdList></Reference><Reference><Citation>Skrzydlo-Radomanska B., Prozorow-Krol B., Cichoz-Lach H., Majsiak E., Bierla J.B., Kanarek E., Sowinska A., Cukrowska B. The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study. Nutrients. 2021;13:756. doi: 10.3390/nu13030756.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13030756</ArticleId><ArticleId IdType="pmc">PMC7996889</ArticleId><ArticleId IdType="pubmed">33652763</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedzielin K., Kordecki H., Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur. J. Gastroenterol. Hepatol. 2001;13:1143&#x2013;1147. doi: 10.1097/00042737-200110000-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00042737-200110000-00004</ArticleId><ArticleId IdType="pubmed">11711768</ArticleId></ArticleIdList></Reference><Reference><Citation>Barraza-Ortiz D.A., Perez-Lopez N., Medina-Lopez V.M., Minero-Alfaro J.I., Zamarripa-Dorsey F., Fernandez-Martinez N.D.C., Llorente-Ramon A., Ramos-Aguilar G.A. Combination of a Probiotic and an Antispasmodic Increases Quality of Life and Reduces Symptoms in Patients with Irritable Bowel Syndrome: A Pilot Study. Dig. Dis. 2021;39:294&#x2013;300. doi: 10.1159/000510950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000510950</ArticleId><ArticleId IdType="pubmed">32810850</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzo-Zuniga V., Llop E., Suarez C., Alvarez B., Abreu L., Espadaler J., Serra J. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J. Gastroenterol. 2014;20:8709&#x2013;8716. doi: 10.3748/wjg.v20.i26.8709.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i26.8709</ArticleId><ArticleId IdType="pmc">PMC4093724</ArticleId><ArticleId IdType="pubmed">25024629</ArticleId></ArticleIdList></Reference><Reference><Citation>Pineton de Chambrun G., Neut C., Chau A., Cazaubiel M., Pelerin F., Justen P., Desreumaux P. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Dig. Liver Dis. 2015;47:119&#x2013;124. doi: 10.1016/j.dld.2014.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2014.11.007</ArticleId><ArticleId IdType="pubmed">25488056</ArticleId></ArticleIdList></Reference><Reference><Citation>Simr&#xe9;n M., Ohman L., Olsson J., Svensson U., Ohlson K., Posserud I., Strid H. Clinical trial: The effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome&#x2014;A randomized, double-blind, controlled study. Aliment. Pharmacol. Ther. 2010;31:218&#x2013;227. doi: 10.1111/j.1365-2036.2009.04183.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2009.04183.x</ArticleId><ArticleId IdType="pubmed">19863495</ArticleId></ArticleIdList></Reference><Reference><Citation>Dapoigny M., Piche T., Ducrotte P., Lunaud B., Cardot J.M., Bernalier-Donadille A. Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: A randomized, double-blind study. World J. Gastroenterol. 2012;18:2067&#x2013;2075. doi: 10.3748/wjg.v18.i17.2067.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v18.i17.2067</ArticleId><ArticleId IdType="pmc">PMC3342605</ArticleId><ArticleId IdType="pubmed">22563194</ArticleId></ArticleIdList></Reference><Reference><Citation>Ki Cha B., Mun Jung S., Hwan Choi C., Song I.D., Woong Lee H., Joon Kim H., Hyuk J., Kyung Chang S., Kim K., Chung W.S., et al. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. J. Clin. Gastroenterol. 2012;46:220&#x2013;227. doi: 10.1097/MCG.0b013e31823712b1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0b013e31823712b1</ArticleId><ArticleId IdType="pubmed">22157240</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y.Y., Li M., Li Y.Y., Li L.X., Zhai W.Z., Wang P., Yang X.X., Gu X., Song L.J., Li Z., et al. The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. Sci. Rep. 2018;8:2964. doi: 10.1038/s41598-018-21241-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-21241-z</ArticleId><ArticleId IdType="pmc">PMC5813237</ArticleId><ArticleId IdType="pubmed">29445178</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafari E., Vahedi H., Merat S., Momtahen S., Riahi A. Therapeutic effects, tolerability and safety of a multi-strain probiotic in Iranian adults with irritable bowel syndrome and bloating. Arch. Iran. Med. 2014;17:466&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">24979556</ArticleId></ArticleIdList></Reference><Reference><Citation>Gayathri R., Aruna T., Malar S., Shilpa B., Dhanasekar K.R. Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndrome. Int. J. Color. Dis. 2020;35:139&#x2013;145. doi: 10.1007/s00384-019-03462-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-019-03462-4</ArticleId><ArticleId IdType="pubmed">31807856</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbas Z., Yakoob J., Jafri W., Ahmad Z., Azam Z., Usman M.W., Shamim S., Islam M. Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: A randomized trial. Eur. J. Gastroenterol. Hepatol. 2014;26:630&#x2013;639. doi: 10.1097/MEG.0000000000000094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000000094</ArticleId><ArticleId IdType="pubmed">24722560</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S., Chang L. Diagnosis and management of IBS. Nat. Rev. Gastroenterol. Hepatol. 2010;7:565&#x2013;581. doi: 10.1038/nrgastro.2010.137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2010.137</ArticleId><ArticleId IdType="pubmed">20890316</ArticleId></ArticleIdList></Reference><Reference><Citation>Preston K., Krumian R., Hattner J., de Montigny D., Stewart M., Gaddam S. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: A double-blind, randomised, placebo-controlled study. Benef. Microbes. 2018;9:697&#x2013;706. doi: 10.3920/BM2017.0105.</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2017.0105</ArticleId><ArticleId IdType="pubmed">29888656</ArticleId></ArticleIdList></Reference><Reference><Citation>Iribarren C., Tornblom H., Aziz I., Magnusson M.K., Sundin J., Vigsnaes L.K., Amundsen I.D., McConnell B., Seitzberg D., Ohman L., et al. Human milk oligosaccharide supplementation in irritable bowel syndrome patients: A parallel, randomized, double-blind, placebo-controlled study. Neurogastroenterol. Motil. 2020;32:e13920. doi: 10.1111/nmo.13920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13920</ArticleId><ArticleId IdType="pubmed">32536023</ArticleId></ArticleIdList></Reference><Reference><Citation>Olesen M., Gudmand-Hoyer E. Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome. Am. J. Clin. Nutr. 2000;72:1570&#x2013;1575. doi: 10.1093/ajcn/72.6.1570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/72.6.1570</ArticleId><ArticleId IdType="pubmed">11101487</ArticleId></ArticleIdList></Reference><Reference><Citation>Niv E., Halak A., Tiommny E., Yanai H., Strul H., Naftali T., Vaisman N. Randomized clinical study: Partially hydrolyzed guar gum (PHGG) versus placebo in the treatment of patients with irritable bowel syndrome. Nutr. Metab. 2016;13:10. doi: 10.1186/s12986-016-0070-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12986-016-0070-5</ArticleId><ArticleId IdType="pmc">PMC4744437</ArticleId><ArticleId IdType="pubmed">26855665</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexea O., Bacarea V., Pique N. The combination of oligo- and polysaccharides and reticulated protein for the control of symptoms in patients with irritable bowel syndrome: Results of a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial. United Eur. Gastroenterol. J. 2016;4:455&#x2013;465. doi: 10.1177/2050640615615050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2050640615615050</ArticleId><ArticleId IdType="pmc">PMC4924437</ArticleId><ArticleId IdType="pubmed">27403313</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson B., Rossi M., Kanno T., Parkes G.C., Anderson S., Mason A.J., Irving P.M., Lomer M.C., Whelan K. beta-Galactooligosaccharide in Conjunction with Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal Bifidobacteria. Am. J. Gastroenterol. 2020;115:906&#x2013;915. doi: 10.14309/ajg.0000000000000641.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000000641</ArticleId><ArticleId IdType="pubmed">32433273</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., Yu W., Jiang J., Feng X., Li N. Efficacy of pectin in the treatment of diarrhea predominant irritable bowel syndrome. Zhonghua Wei Chang Wai Ke Za Zhi. 2015;18:267&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">25809332</ArticleId></ArticleIdList></Reference><Reference><Citation>Azpiroz F., Dubray C., Bernalier-Donadille A., Cardot J.M., Accarino A., Serra J., Wagner A., Respondek F., Dapoigny M. Effects of scFOS on the composition of fecal microbiota and anxiety in patients with irritable bowel syndrome: A randomized, double blind, placebo controlled study. Neurogastroenterol. Motil. 2017;29:e12911. doi: 10.1111/nmo.12911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12911</ArticleId><ArticleId IdType="pubmed">27477485</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogha M., Esfahani M.Z., Zargarzadeh A.H. The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: A randomized placebo-controlled trial. Gastroenterol. Hepatol. Bed Bench. 2014;7:156&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4129566</ArticleId><ArticleId IdType="pubmed">25120896</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S.H., Cho D.Y., Lee S.H., Han K.S., Yang S.W., Kim J.H., Lee S.H., Kim S.M., Kim K.N. A Randomized Clinical Trial of Synbiotics in Irritable Bowel Syndrome: Dose-Dependent Effects on Gastrointestinal Symptoms and Fatigue. Korean J. Fam. Med. 2019;40:2&#x2013;8. doi: 10.4082/kjfm.17.0064.</Citation><ArticleIdList><ArticleId IdType="doi">10.4082/kjfm.17.0064</ArticleId><ArticleId IdType="pmc">PMC6351792</ArticleId><ArticleId IdType="pubmed">30360032</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappello C., Tremolaterra F., Pascariello A., Ciacci C., Iovino P. A randomised clinical trial (RCT) of a symbiotic mixture in patients with irritable bowel syndrome (IBS): Effects on symptoms, colonic transit and quality of life. Int. J. Color. Dis. 2013;28:349&#x2013;358. doi: 10.1007/s00384-012-1552-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-012-1552-1</ArticleId><ArticleId IdType="pmc">PMC3587687</ArticleId><ArticleId IdType="pubmed">22885882</ArticleId></ArticleIdList></Reference><Reference><Citation>Skrzydlo-Radomanska B., Prozorow-Krol B., Cichoz-Lach H., Majsiak E., Bierla J.B., Kosikowski W., Szczerbinski M., Gantzel J., Cukrowska B. The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant Irritable Bowel Syndrome-A Randomized Double-Blind, Placebo-Controlled Study. Nutrients. 2020;12:1999. doi: 10.3390/nu12071999.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12071999</ArticleId><ArticleId IdType="pmc">PMC7400954</ArticleId><ArticleId IdType="pubmed">32635661</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh J.H., Jang Y.S., Kang D., Kim H.S., Kim E.J., Park S.Y., Kim C.H., Min Y.W., Chang D.K. Efficacy of a Synbiotic Containing Lactobacillus paracasei DKGF1 and Opuntia humifusa in Elderly Patients with Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Gut Liver. 2023;17:100&#x2013;107. doi: 10.5009/gnl210478.</Citation><ArticleIdList><ArticleId IdType="doi">10.5009/gnl210478</ArticleId><ArticleId IdType="pmc">PMC9840930</ArticleId><ArticleId IdType="pubmed">35611667</ArticleId></ArticleIdList></Reference><Reference><Citation>Andriulli A., Neri M., Loguercio C., Terreni N., Merla A., Cardarella M.P., Federico A., Chilovi F., Milandri G.L., De Bona M., et al. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: A multicenter, randomized study. Pt 2J. Clin. Gastroenterol. 2008;42((Suppl. S3)):S218&#x2013;S223. doi: 10.1097/MCG.0b013e31817fadd6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0b013e31817fadd6</ArticleId><ArticleId IdType="pubmed">18685503</ArticleId></ArticleIdList></Reference><Reference><Citation>NCT02431533, I. The Efficacy of PX0612 in the Treatment of Irritable Bowel Syndrome.  [(accessed on 22 March 2024)]; Available online:  https://classic.clinicaltrials.gov/ct2/show/NCT02431533.</Citation></Reference><Reference><Citation>El-Salhy M., Mazzawi T., Hausken T., Hatlebakk J.G. The fecal microbiota transplantation response differs between patients with severe and moderate irritable bowel symptoms. Scand. J. Gastroenterol. 2022;57:1036&#x2013;1045. doi: 10.1080/00365521.2022.2064725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365521.2022.2064725</ArticleId><ArticleId IdType="pubmed">35486073</ArticleId></ArticleIdList></Reference><Reference><Citation>Holvoet T., Joossens M., Vazquez-Castellanos J.F., Christiaens E., Heyerick L., Boelens J., Verhasselt B., van Vlierberghe H., De Vos M., Raes J., et al. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients with Irritable Bowel Syndrome with Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial. Gastroenterology. 2021;160:145&#x2013;157 e148. doi: 10.1053/j.gastro.2020.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.07.013</ArticleId><ArticleId IdType="pubmed">32681922</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q., Lin H., Chen P., Tan S., Wen Z., Lin L., He J., Wen J., Lu S. Dynamic changes of intestinal flora in patients with irritable bowel syndrome combined with anxiety and depression after oral administration of enterobacteria capsules. Bioengineered. 2021;12:11885&#x2013;11897. doi: 10.1080/21655979.2021.1999374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21655979.2021.1999374</ArticleId><ArticleId IdType="pmc">PMC8810103</ArticleId><ArticleId IdType="pubmed">34923901</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnsen P.H., Hilp&#xfc;sch F., Cavanagh J.P., Leikanger I.S., Kolstad C., Valle P.C., Goll R. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: A double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol. Hepatol. 2018;3:17&#x2013;24. doi: 10.1016/S2468-1253(17)30338-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(17)30338-2</ArticleId><ArticleId IdType="pubmed">29100842</ArticleId></ArticleIdList></Reference><Reference><Citation>Madsen A.M.A., Halkjaer S.I., Christensen A.H., Gunther S., Browne P.D., Kallemose T., Hansen L.H., Petersen A.M. The effect of faecal microbiota transplantation on abdominal pain, stool frequency, and stool form in patients with moderate-to-severe irritable bowel syndrome: Results from a randomised, double-blind, placebo-controlled study. Scand. J. Gastroenterol. 2021;56:761&#x2013;769. doi: 10.1080/00365521.2021.1915375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365521.2021.1915375</ArticleId><ArticleId IdType="pubmed">34000958</ArticleId></ArticleIdList></Reference><Reference><Citation>Holster S., Lindqvist C.M., Repsilber D., Salonen A., de Vos W.M., Konig J., Brummer R.J. The Effect of Allogenic Versus Autologous Fecal Microbiota Transfer on Symptoms, Visceral Perception and Fecal and Mucosal Microbiota in Irritable Bowel Syndrome: A Randomized Controlled Study. Clin. Transl. Gastroenterol. 2019;10:e00034. doi: 10.14309/ctg.0000000000000034.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ctg.0000000000000034</ArticleId><ArticleId IdType="pmc">PMC6602784</ArticleId><ArticleId IdType="pubmed">31009405</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P.P., Chin V.K., Looi C.Y., Wong W.F., Madhavan P., Yong V.C. The Microbiome and Irritable Bowel Syndrome&#x2014;A Review on the Pathophysiology, Current Research and Future Therapy. Front. Microbiol. 2019;10:1136. doi: 10.3389/fmicb.2019.01136.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2019.01136</ArticleId><ArticleId IdType="pmc">PMC6579922</ArticleId><ArticleId IdType="pubmed">31244784</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon E., C&#x103;linoiu L.F., Mitrea L., Vodnar D.C. Probiotics, Prebiotics, and Synbiotics: Implications and Beneficial Effects against Irritable Bowel Syndrome. Nutrients. 2021;13:2112. doi: 10.3390/nu13062112.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13062112</ArticleId><ArticleId IdType="pmc">PMC8233736</ArticleId><ArticleId IdType="pubmed">34203002</ArticleId></ArticleIdList></Reference><Reference><Citation>Halkj&#xe6;r S.I., Christensen A.H., Lo B.Z.S., Browne P.D., G&#xfc;nther S., Hansen L.H., Petersen A.M. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: Results from a randomised, double-blind placebo-controlled study. Gut. 2018;67:2107&#x2013;2115. doi: 10.1136/gutjnl-2018-316434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2018-316434</ArticleId><ArticleId IdType="pubmed">29980607</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M., Hatlebakk J.G., Gilja O.H., Br&#xe5;then Kristoffersen A., Hausken T. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2020;69:859&#x2013;867. doi: 10.1136/gutjnl-2019-319630.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2019-319630</ArticleId><ArticleId IdType="pmc">PMC7229896</ArticleId><ArticleId IdType="pubmed">31852769</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Quigley E.M., Lacy B.E., Lembo A.J., Saito Y.A., Schiller L.R., Soffer E.E., Spiegel B.M., Moayyedi P. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: Systematic review and meta-analysis. Am. J. Gastroenterol. 2014;109:1547&#x2013;1561. doi: 10.1038/ajg.2014.202. quiz 1546, 1562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2014.202</ArticleId><ArticleId IdType="pubmed">25070051</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T., Zhang C., Zhang J., Sun F., Duan L. Efficacy of Probiotics for Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis. Front. Cell. Infect. Microbiol. 2022;12:859967. doi: 10.3389/fcimb.2022.859967.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.859967</ArticleId><ArticleId IdType="pmc">PMC9010660</ArticleId><ArticleId IdType="pubmed">35433498</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Q., Tun H.M., Liu Q., Yeoh Y.K., Mak J.W.Y., Chan F.K., Ng S.C. Gut microbiome signatures reflect different subtypes of irritable bowel syndrome. Gut Microbes. 2023;15:2157697. doi: 10.1080/19490976.2022.2157697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2022.2157697</ArticleId><ArticleId IdType="pmc">PMC9809927</ArticleId><ArticleId IdType="pubmed">36573834</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Schoot A., Helander C., Whelan K., Dimidi E. Probiotics and synbiotics in chronic constipation in adults: A systematic review and meta-analysis of randomized controlled trials. Clin. Nutr. 2022;41:2759&#x2013;2777. doi: 10.1016/j.clnu.2022.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2022.10.015</ArticleId><ArticleId IdType="pubmed">36372047</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Gong J., Wang W., Long Y., Fu X., Fu Y., Qian W., Hou X. Are there any different effects of Bifidobacterium, Lactobacillus and Streptococcus on intestinal sensation, barrier function and intestinal immunity in PI-IBS mouse model? PLoS ONE. 2014;9:e90153. doi: 10.1371/journal.pone.0090153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0090153</ArticleId><ArticleId IdType="pmc">PMC3940848</ArticleId><ArticleId IdType="pubmed">24595218</ArticleId></ArticleIdList></Reference><Reference><Citation>Constante M., De Palma G., Lu J., Jury J., Rondeau L., Caminero A., Collins S.M., Verdu E.F., Bercik P. Saccharomyces boulardii CNCM I-745 modulates the microbiota-gut-brain axis in a humanized mouse model of Irritable Bowel Syndrome. Neurogastroenterol. Motil. 2021;33:e13985. doi: 10.1111/nmo.13985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13985</ArticleId><ArticleId IdType="pubmed">32955166</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., Lv L., Wang C. Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials. Front. Cell. Infect. Microbiol. 2022;12:827395. doi: 10.3389/fcimb.2022.827395.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.827395</ArticleId><ArticleId IdType="pmc">PMC8919053</ArticleId><ArticleId IdType="pubmed">35295757</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M., Mazzawi T. Fecal microbiota transplantation for managing irritable bowel syndrome. Expert. Rev. Gastroenterol. Hepatol. 2018;12:439&#x2013;445. doi: 10.1080/17474124.2018.1447380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17474124.2018.1447380</ArticleId><ArticleId IdType="pubmed">29493330</ArticleId></ArticleIdList></Reference><Reference><Citation>Holvoet T., Joossens M., Wang J., Boelens J., Verhasselt B., Laukens D., van Vlierberghe H., Hindryckx P., De Vos M., De Looze D., et al. Assessment of faecal microbial transfer in irritable bowel syndrome with severe bloating. Gut. 2017;66:980&#x2013;982. doi: 10.1136/gutjnl-2016-312513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2016-312513</ArticleId><ArticleId IdType="pmc">PMC5531219</ArticleId><ArticleId IdType="pubmed">27511198</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J.P.T., Savovi&#x107; J., Page M.J., Elbers R.G., Sterne J.A.C. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins J.P.T., Thomas J., Chandler J., Cumpston M., Li T., Page M.J., Welch V.A., editors. Cochrane Handbook for Systematic Reviews of Interventions. Cochrane; London, UK: 2023.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28483500</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1528-0012</ISSN><JournalIssue CitedMedium="Internet"><Volume>153</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Gastroenterology</Title><ISOAbbreviation>Gastroenterology</ISOAbbreviation></Journal><ArticleTitle>Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome.</ArticleTitle><Pagination><StartPage>448</StartPage><EndPage>459.e8</EndPage><MedlinePgn>448-459.e8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1053/j.gastro.2017.05.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0016-5085(17)35557-9</ELocationID><Abstract><AbstractText Label="BACKGROUND &amp; AIMS">Probiotics can reduce symptoms of irritable bowel syndrome (IBS), but little is known about their effects on psychiatric comorbidities. We performed a prospective study to evaluate the effects of Bifidobacterium longum NCC3001 (BL) on anxiety and depression in patients with IBS.</AbstractText><AbstractText Label="METHODS">We performed a randomized, double-blind, placebo-controlled study of 44 adults with IBS and diarrhea or a mixed-stool pattern (based on Rome III criteria) and mild to moderate anxiety and/or depression (based on the Hospital Anxiety and Depression scale) at McMaster University in Canada, from March 2011 to May 2014. At the screening visit, clinical history and symptoms were assessed and blood samples were collected. Patients were then randomly assigned to groups and given daily BL (n&#xa0;= 22) or placebo (n&#xa0;= 22) for 6 weeks. At weeks 0, 6, and 10, we determined patients' levels of anxiety and depression, IBS symptoms, quality of life, and somatization using validated questionnaires. At weeks 0 and 6, stool, urine and blood samples were collected, and functional magnetic resonance imaging (fMRI) test was performed. We assessed brain activation patterns, fecal microbiota, urine metabolome profiles, serum markers of inflammation, neurotransmitters, and neurotrophin levels.</AbstractText><AbstractText Label="RESULTS">At week 6, 14 of 22 patients in the BL group had reduction in depression scores of 2 points or more on the Hospital Anxiety and Depression scale, vs 7 of 22 patients in the placebo group (P&#xa0;=&#xa0;.04). BL had no significant effect on anxiety or IBS symptoms. Patients in the BL group had a mean increase in quality of life score compared with the placebo group. The fMRI analysis showed that BL reduced responses to negative emotional stimuli in multiple brain areas, including amygdala and fronto-limbic regions, compared with placebo. The groups had similar fecal microbiota profiles, serum markers of inflammation, and levels of neurotrophins and neurotransmitters, but the BL group had reduced urine levels of methylamines and aromatic amino acids metabolites. At week 10, depression scores were reduced in patients given BL vs placebo.</AbstractText><AbstractText Label="CONCLUSION">In a placebo-controlled trial, we found that the probiotic BL reduces depression but not anxiety scores and increases quality of life in patients with IBS. These improvements were associated with changes in brain activation patterns that indicate that this probiotic reduces limbic reactivity. ClinicalTrials.gov no. NCT01276626.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pinto-Sanchez</LastName><ForeName>Maria Ines</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Geoffrey B</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>Department of Psychology, Neuroscience, and Behavior, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghajar</LastName><ForeName>Kathy</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychology, Neuroscience, and Behavior, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nardelli</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolino</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Jennifer T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Francois-Pierre</ForeName><Initials>FP</Initials><AffiliationInfo><Affiliation>Nestl&#xe9; Institute of Health Sciences SA, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cominetti</LastName><ForeName>Ornella</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Nestl&#xe9; Institute of Health Sciences SA, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Welsh</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rieder</LastName><ForeName>Amber</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychology, Neuroscience, and Behavior, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Traynor</LastName><ForeName>Jenna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychology, Neuroscience, and Behavior, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gregory</LastName><ForeName>Caitlin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychology, Neuroscience, and Behavior, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Palma</LastName><ForeName>Giada</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pigrau</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ford</LastName><ForeName>Alexander C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Leeds Gastroenterology Institute, St. James's University Hospital, and Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macri</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>Bernard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Nestl&#xe9; Research Center, Nutrition Institute, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergonzelli</LastName><ForeName>Gabriela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Nestl&#xe9; Research Center, Nutrition Institute, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Surette</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moayyedi</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bercik</LastName><ForeName>Premysl</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada. Electronic address: bercikp@mcmaster.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01276626</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Gastroenterology</MedlineTA><NlmUniqueID>0374630</NlmUniqueID><ISSNLinking>0016-5085</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Gastroenterol Hepatol. 2017 Jul;14(7):386-387. doi: 10.1038/nrgastro.2017.70.</RefSource><PMID Version="1">28536484</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Gastroenterology. 2018 Feb;154(3):764-765. doi: 10.1053/j.gastro.2018.01.022.</RefSource><PMID Version="1">29351832</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Gastroenterology. 2018 Feb;154(3):765. doi: 10.1053/j.gastro.2017.09.056.</RefSource><PMID Version="1">29352955</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Gastroenterology. 2018 Feb;154(3):764. doi: 10.1053/j.gastro.2017.09.055.</RefSource><PMID Version="1">29352957</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069978" MajorTopicYN="Y">Bifidobacterium longum</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anxiety</Keyword><Keyword MajorTopicYN="N">Depression</Keyword><Keyword MajorTopicYN="N">IBS</Keyword><Keyword MajorTopicYN="N">fMRI</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28483500</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2017.05.003</ArticleId><ArticleId IdType="pii">S0016-5085(17)35557-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31480656</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6643</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>9</Issue><PubDate><Year>2019</Year><Month>Sep</Month><Day>02</Day></PubDate></JournalIssue><Title>Nutrients</Title><ISOAbbreviation>Nutrients</ISOAbbreviation></Journal><ArticleTitle>Probiotics in Irritable Bowel Syndrome: An Up-to-Date Systematic Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2048</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nu11092048</ELocationID><Abstract><AbstractText>Irritable bowel syndrome (IBS) is a frequent functional gastrointestinal disorder, and alterations in the gut microbiota composition contributes to symptom generation. The exact mechanisms of probiotics in the human body are not fully understood, but probiotic supplements are thought to improve IBS symptoms through manipulation of the gut microbiota. The aim of this systematic review was to assess the latest randomized controlled trials (RCTs) evaluating the effect of probiotic supplementation on symptoms in IBS patients. A literature search was conducted in Medline (PubMed) until March 2019. RCTs published within the last five years evaluating effects of probiotic supplements on IBS symptoms were eligible. The search identified in total 35 studies, of which 11 met the inclusion criteria and were included in the systematic review. Seven studies (63.6%) reported that supplementation with probiotics in IBS patients significantly improved symptoms compared to placebo, whereas the remaining four studies (36.4%) did not report any significant improvement in symptoms after probiotic supplementation. Of note, three studies evaluated the effect of a mono-strain supplement, whereas the remaining eight trials used a multi-strain probiotic. Overall, the beneficial effects were more distinct in the trials using multi-strain supplements with an intervention of 8 weeks or more, suggesting that multi-strain probiotics supplemented over a period of time have the potential to improve IBS symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dale</LastName><ForeName>Hanna Fjeldheim</ForeName><Initials>HF</Initials><Identifier Source="ORCID">0000-0002-0710-6057</Identifier><AffiliationInfo><Affiliation>Centre for Nutrition, Department of Clinical Medicine, University of Bergen, 5009 Bergen, Norway. hanna.dale@outlook.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway. hanna.dale@outlook.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Centre of Functional Gastrointestinal Disorders, Haukeland University Hospital, 5021 Bergen, Norway. hanna.dale@outlook.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasmussen</LastName><ForeName>Stella Hellgren</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Centre for Nutrition, Department of Clinical Medicine, University of Bergen, 5009 Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asiller</LastName><ForeName>&#xd6;zg&#xfc;n &#xd6;mer</ForeName><Initials>&#xd6;&#xd6;</Initials><Identifier Source="ORCID">0000-0002-9573-4730</Identifier><AffiliationInfo><Affiliation>Centre for Nutrition, Department of Clinical Medicine, University of Bergen, 5009 Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gastroenterology, Ankara University Faculty of Medicine, Mamak Ankara 06620, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lied</LastName><ForeName>G&#xfc;len Arslan</ForeName><Initials>GA</Initials><Identifier Source="ORCID">0000-0002-1827-5008</Identifier><AffiliationInfo><Affiliation>Centre for Nutrition, Department of Clinical Medicine, University of Bergen, 5009 Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Centre of Functional Gastrointestinal Disorders, Haukeland University Hospital, 5021 Bergen, Norway.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nutrients</MedlineTA><NlmUniqueID>101521595</NlmUniqueID><ISSNLinking>2072-6643</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001419" MajorTopicYN="N">Bacteria</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">gut microbiota</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">probiotics</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31480656</ArticleId><ArticleId IdType="pmc">PMC6769995</ArticleId><ArticleId IdType="doi">10.3390/nu11092048</ArticleId><ArticleId IdType="pii">nu11092048</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lovell R.M., Ford A.C. Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis. Clin. Gastroenterol. Hepatol. 2012;10:712&#x2013;721. doi: 10.1016/j.cgh.2012.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2012.02.029</ArticleId><ArticleId IdType="pubmed">22426087</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R. Bowel disorders. Gastroenterology. 2016;150:1393&#x2013;1407. doi: 10.1053/j.gastro.2016.02.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.031</ArticleId><ArticleId IdType="pubmed">27144627</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbara G., Feinle-Bisset C., Ghoshal U.C., Quigley E.M., Santos J., Vanner S., Vergnolle N., Zoetendal E.G. The intestinal microenvironment and functional gastrointestinal disorders. Gastroenterology. 2016;150:1305&#x2013;1318. doi: 10.1053/j.gastro.2016.02.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.028</ArticleId><ArticleId IdType="pubmed">27144620</ArticleId></ArticleIdList></Reference><Reference><Citation>Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C. Functional bowel disorders. Gastroenterology. 2006;130:1480&#x2013;1491. doi: 10.1053/j.gastro.2005.11.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2005.11.061</ArticleId><ArticleId IdType="pubmed">16678561</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh A., Eslick E.M., Eslick G.D. Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis. Eur. J. Nutr. 2016;55:897&#x2013;906. doi: 10.1007/s00394-015-0922-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00394-015-0922-1</ArticleId><ArticleId IdType="pubmed">25982757</ArticleId></ArticleIdList></Reference><Reference><Citation>Lea R., Whorwell P.J. New insights into the psychosocial aspects of irritable bowel syndrome. Curr. Gastroenterol. Rep. 2003;5:343&#x2013;350. doi: 10.1007/s11894-003-0073-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11894-003-0073-z</ArticleId><ArticleId IdType="pubmed">12864966</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtmann G.J., Ford A.C., Talley N.J. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol. Hepatol. 2016;1:133&#x2013;146. doi: 10.1016/S2468-1253(16)30023-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(16)30023-1</ArticleId><ArticleId IdType="pubmed">28404070</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall J.K., Thabane M., Garg A.X., Clark W.F., Salvadori M., Collins S.M. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology. 2006;131:445&#x2013;450. doi: 10.1053/j.gastro.2006.05.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2006.05.053</ArticleId><ArticleId IdType="pubmed">16890598</ArticleId></ArticleIdList></Reference><Reference><Citation>Klem F., Wadhwa A., Prokop L.J., Sundt W.J., Farrugia G., Camilleri M., Singh S., Grover M. Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: A systematic review and meta-analysis. Gastroenterology. 2017;152:1042&#x2013;1054. doi: 10.1053/j.gastro.2016.12.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.12.039</ArticleId><ArticleId IdType="pmc">PMC5367939</ArticleId><ArticleId IdType="pubmed">28069350</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H.C. Small intestinal bacterial overgrowth: A framework for understanding irritable bowel syndrome. Jama. 2004;292:852&#x2013;858. doi: 10.1001/jama.292.7.852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.292.7.852</ArticleId><ArticleId IdType="pubmed">15316000</ArticleId></ArticleIdList></Reference><Reference><Citation>Tana C., Umesaki Y., Imaoka A., Handa T., Kanazawa M., Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol. Motil. 2010;22:512&#x2013;519. doi: 10.1111/j.1365-2982.2009.01427.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2009.01427.x</ArticleId><ArticleId IdType="pubmed">19903265</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerckhoffs A.P., Samsom M., van der Rest M.E., de Vogel J., Knol J., Ben-Amor K., Akkermans L.M. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J. Gastroenterol. 2009;15:2887&#x2013;2892. doi: 10.3748/wjg.15.2887.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.15.2887</ArticleId><ArticleId IdType="pmc">PMC2699007</ArticleId><ArticleId IdType="pubmed">19533811</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassinen A., Krogius-Kurikka L., Makivuokko H., Rinttila T., Paulin L., Corander J., Malinen E., Apajalahti J., Palva A. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133:24&#x2013;33. doi: 10.1053/j.gastro.2007.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2007.04.005</ArticleId><ArticleId IdType="pubmed">17631127</ArticleId></ArticleIdList></Reference><Reference><Citation>Durban A., Abellan J.J., Jimenez-Hernandez N., Artacho A., Garrigues V., Ortiz V., Ponce J., Latorre A., Moya A. Instability of the faecal microbiota in diarrhoea-predominant irritable bowel syndrome. FEMS Microbiol. Ecol. 2013;86:581&#x2013;589. doi: 10.1111/1574-6941.12184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1574-6941.12184</ArticleId><ArticleId IdType="pubmed">23889283</ArticleId></ArticleIdList></Reference><Reference><Citation>Tap J., Derrien M., Tornblom H., Brazeilles R., Cools-Portier S., Dore J., Storsrud S., Le Neve B., Ohman L., Simren M. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology. 2017;152:111&#x2013;123. doi: 10.1053/j.gastro.2016.09.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.09.049</ArticleId><ArticleId IdType="pubmed">27725146</ArticleId></ArticleIdList></Reference><Reference><Citation>Malinen E., Krogius-Kurikka L., Lyra A., Nikkila J., Jaaskelainen A., Rinttila T., Vilpponen-Salmela T., von Wright A.J., Palva A. Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome. World J. Gastroenterol. 2010;16:4532&#x2013;4540. doi: 10.3748/wjg.v16.i36.4532.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v16.i36.4532</ArticleId><ArticleId IdType="pmc">PMC2945484</ArticleId><ArticleId IdType="pubmed">20857523</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill C., Guarner F., Reid G., Gibson G.R., Merenstein D.J., Pot B., Morelli L., Canani R.B., Flint H.J., Salminen S., et al. Expert consensus document. The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014;11:506&#x2013;514. doi: 10.1038/nrgastro.2014.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2014.66</ArticleId><ArticleId IdType="pubmed">24912386</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown A.C., Valiere A. Probiotics and medical nutrition therapy. Nutr. Clin. Care. 2004;7:56&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1482314</ArticleId><ArticleId IdType="pubmed">15481739</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins T., Sequoia J. Probiotics for gastrointestinal conditions: A summary of the evidence. Am. Fam. Phys. 2017;96:170&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">28762696</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie M.L., Romanuk T.N. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS ONE. 2012;7:e34938. doi: 10.1371/journal.pone.0034938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0034938</ArticleId><ArticleId IdType="pmc">PMC3329544</ArticleId><ArticleId IdType="pubmed">22529959</ArticleId></ArticleIdList></Reference><Reference><Citation>Cremon C., Barbaro M.R., Ventura M., Barbara G. Pre-and probiotic overview. Curr. Opin. Pharmacol. 2018;43:87&#x2013;92. doi: 10.1016/j.coph.2018.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2018.08.010</ArticleId><ArticleId IdType="pubmed">30219638</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseaux C., Thuru X., Gelot A., Barnich N., Neut C., Dubuquoy L., Dubuquoy C., Merour E., Geboes K., Chamaillard M., et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat. Med. 2007;13:35&#x2013;37. doi: 10.1038/nm1521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1521</ArticleId><ArticleId IdType="pubmed">17159985</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdu E.F., Bercik P., Verma-Gandhu M., Huang X.X., Blennerhassett P., Jackson W., Mao Y., Wang L., Rochat F., Collins S.M. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut. 2006;55:182&#x2013;190. doi: 10.1136/gut.2005.066100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2005.066100</ArticleId><ArticleId IdType="pmc">PMC1856497</ArticleId><ArticleId IdType="pubmed">16105890</ArticleId></ArticleIdList></Reference><Reference><Citation>Madsen K., Cornish A., Soper P., McKaigney C., Jijon H., Yachimec C., Doyle J., Jewell L., De Simone C. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001;121:580&#x2013;591. doi: 10.1053/gast.2001.27224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/gast.2001.27224</ArticleId><ArticleId IdType="pubmed">11522742</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahony L., McCarthy J., Kelly P., Hurley G., Luo F., Chen K., O&#x2019;Sullivan G.C., Kiely B., Collins J.K., Shanahan F., et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541&#x2013;551. doi: 10.1053/j.gastro.2004.11.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2004.11.050</ArticleId><ArticleId IdType="pubmed">15765388</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbara G., Cremon C., Azpiroz F. Probiotics in irritable bowel syndrome: Where are we? Neurogastroenterol. Motil. 2018;30:e13513. doi: 10.1111/nmo.13513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13513</ArticleId><ArticleId IdType="pubmed">30460770</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann. Intern. Med. 2009;151:264&#x2013;269. doi: 10.7326/0003-4819-151-4-200908180-00135.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-151-4-200908180-00135</ArticleId><ArticleId IdType="pubmed">19622511</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyra A., Hillila M., Huttunen T., Mannikko S., Taalikka M., Tennila J., Tarpila A., Lahtinen S., Ouwehand A.C., Veijola L. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. World J. Gastroenterol. 2016;22:10631&#x2013;10642. doi: 10.3748/wjg.v22.i48.10631.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i48.10631</ArticleId><ArticleId IdType="pmc">PMC5192275</ArticleId><ArticleId IdType="pubmed">28082816</ArticleId></ArticleIdList></Reference><Reference><Citation>Majeed M., Nagabhushanam K., Natarajan S., Sivakumar A., Ali F., Pande A., Majeed S., Karri S.K. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: A double blind randomized placebo controlled pilot clinical study. Nutr. J. 2016;15:21. doi: 10.1186/s12937-016-0140-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12937-016-0140-6</ArticleId><ArticleId IdType="pmc">PMC4769834</ArticleId><ArticleId IdType="pubmed">26922379</ArticleId></ArticleIdList></Reference><Reference><Citation>Pineton de Chambrun G., Neut C., Chau A., Cazaubiel M., Pelerin F., Justen P., Desreumaux P. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Dig. Liver Dis. 2015;47:119&#x2013;124. doi: 10.1016/j.dld.2014.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2014.11.007</ArticleId><ArticleId IdType="pubmed">25488056</ArticleId></ArticleIdList></Reference><Reference><Citation>Hod K., Sperber A.D., Ron Y., Boaz M., Dickman R., Berliner S., Halpern Z., Maharshak N., Dekel R. A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS. Neurogastroenterol. Motil. 2017;29:e13037. doi: 10.1111/nmo.13037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13037</ArticleId><ArticleId IdType="pubmed">28271623</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishaque S.M., Khosruzzaman S.M., Ahmed D.S., Sah M.P. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult(R)) in the management of diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol. 2018;18:71. doi: 10.1186/s12876-018-0788-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-018-0788-9</ArticleId><ArticleId IdType="pmc">PMC5970461</ArticleId><ArticleId IdType="pubmed">29801486</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafari E., Vahedi H., Merat S., Momtahen S., Riahi A. Therapeutic effects, tolerability and safety of a multi-strain probiotic in Iranian adults with irritable bowel syndrome and bloating. Arch. Iran. Med. 2014;17:466&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">24979556</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludidi S., Jonkers D.M., Koning C.J., Kruimel J.W., Mulder L., van der Vaart I.B., Conchillo J.M., Masclee A.A. Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients. Neurogastroenterol. Motil. 2014;26:705&#x2013;714. doi: 10.1111/nmo.12320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12320</ArticleId><ArticleId IdType="pubmed">24588932</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezzasalma V., Manfrini E., Ferri E., Sandionigi A., La Ferla B., Schiano I., Michelotti A., Nobile V., Labra M., Di Gennaro P. A randomized, double-blind, placebo-controlled trial: The efficacy of multispecies probiotic supplementation in alleviating symptoms of irritable bowel syndrome associated with constipation. Biomed. Res. Int. 2016;2016:4740907. doi: 10.1155/2016/4740907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/4740907</ArticleId><ArticleId IdType="pmc">PMC4993960</ArticleId><ArticleId IdType="pubmed">27595104</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisson G., Ayis S., Sherwood R.A., Bjarnason I. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome&#x2013;A 12 week double-blind study. Aliment. Pharmacol. Ther. 2014;40:51&#x2013;62. doi: 10.1111/apt.12787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.12787</ArticleId><ArticleId IdType="pubmed">24815298</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher H.M., Lomer M.C.E., Farquharson F.M., Louis P., Fava F., Franciosi E., Scholz M., Tuohy K.M., Lindsay J.O., Irving P.M., et al. A diet low in FODMAPs reduces symptoms in patients with irritable bowel syndrome and a probiotic restores bifidobacterium species: A randomized controlled trial. Gastroenterology. 2017;153:936&#x2013;947. doi: 10.1053/j.gastro.2017.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2017.06.010</ArticleId><ArticleId IdType="pubmed">28625832</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong R.K., Yang C., Song G.H., Wong J., Ho K.Y. Melatonin regulation as a possible mechanism for probiotic (VSL#3) in irritable bowel syndrome: A randomized double-blinded placebo study. Dig. Dis. Sci. 2015;60:186&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">25092036</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Harris L.A., Lacy B.E., Quigley E.M.M., Moayyedi P. Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2018;48:1044&#x2013;1060. doi: 10.1111/apt.15001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15001</ArticleId><ArticleId IdType="pubmed">30294792</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Quigley E.M., Lacy B.E., Lembo A.J., Saito Y.A., Schiller L.R., Soffer E.E., Spiegel B.M., Moayyedi P. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: Systematic review and meta-analysis. Am. J. Gastroenterol. 2014;109:1547&#x2013;1561. doi: 10.1038/ajg.2014.202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2014.202</ArticleId><ArticleId IdType="pubmed">25070051</ArticleId></ArticleIdList></Reference><Reference><Citation>Hungin A.P.S., Mitchell C.R., Whorwell P., Mulligan C., Cole O., Agreus L., Fracasso P., Lionis C., Mendive J., Philippart de Foy J.M., et al. Systematic review: Probiotics in the management of lower gastrointestinal symptoms&#x2014;An updated evidence-based international consensus. Aliment. Pharmacol. Ther. 2018;47:1054&#x2013;1070. doi: 10.1111/apt.14539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.14539</ArticleId><ArticleId IdType="pmc">PMC5900870</ArticleId><ArticleId IdType="pubmed">29460487</ArticleId></ArticleIdList></Reference><Reference><Citation>Balsari A., Ceccarelli A., Dubini F., Fesce E., Poli G. The fecal microbial population in the irritable bowel syndrome. Microbiologica. 1982;5:185&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">7121297</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajilic-Stojanovic M., Biagi E., Heilig H.G., Kajander K., Kekkonen R.A., Tims S., de Vos W.M. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011;141:1792&#x2013;1801. doi: 10.1053/j.gastro.2011.07.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2011.07.043</ArticleId><ArticleId IdType="pubmed">21820992</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis C.Y., Morris J., Whorwell P.J. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment. Pharmacol. Ther. 1997;11:395&#x2013;402. doi: 10.1046/j.1365-2036.1997.142318000.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.1997.142318000.x</ArticleId><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>Eswaran S.L., Chey W.D., Han-Markey T., Ball S., Jackson K. A randomized controlled trial comparing the low FODMAP diet vs. modified NICE guidelines in US adults with IBS-D. Am. J. Gastroenterol. 2016;111:1824&#x2013;1832. doi: 10.1038/ajg.2016.434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2016.434</ArticleId><ArticleId IdType="pubmed">27725652</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Moayyedi P., Lacy B.E., Lembo A.J., Saito Y.A., Schiller L.R., Soffer E.E., Spiegel B.M., Quigley E.M. American college of gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am. J. Gastroenterol. 2014;109 doi: 10.1038/ajg.2014.187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2014.187</ArticleId><ArticleId IdType="pubmed">25091148</ArticleId></ArticleIdList></Reference><Reference><Citation>Camilleri M., Mayer E.A., Drossman D.A., Heath A., Dukes G.E., McSorley D., Kong S., Mangel A.W., Northcutt A.R. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment. Pharmacol. Ther. 1999;13:1149&#x2013;1159. doi: 10.1046/j.1365-2036.1999.00610.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.1999.00610.x</ArticleId><ArticleId IdType="pubmed">10468696</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Toole P.W., Marchesi J.R., Hill C. Next-generation probiotics: The spectrum from probiotics to live biotherapeutics. Nat. Microbiol. 2017;2:17057. doi: 10.1038/nmicrobiol.2017.57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmicrobiol.2017.57</ArticleId><ArticleId IdType="pubmed">28440276</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31122802</PMID><DateCompleted><Year>2020</Year><Month>05</Month><Day>27</Day></DateCompleted><DateRevised><Year>2020</Year><Month>05</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2468-1253</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>8</Issue><PubDate><Year>2019</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The lancet. Gastroenterology &amp; hepatology</Title><ISOAbbreviation>Lancet Gastroenterol Hepatol</ISOAbbreviation></Journal><ArticleTitle>The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment.</ArticleTitle><Pagination><StartPage>632</StartPage><EndPage>642</EndPage><MedlinePgn>632-642</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S2468-1253(19)30089-5</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2468-1253(19)30089-5</ELocationID><Abstract><AbstractText>Brain-gut interactions affect psychological wellbeing and symptom reporting in functional gastrointestinal disorders; the presence of anxiety or depression is associated with the development of new-onset gastrointestinal symptoms, and the presence of gastrointestinal symptoms is associated with the development of psychological disorders de novo. In inflammatory bowel diseases (IBD), the reporting of irritable bowel syndrome (IBS)-type symptoms by patients with quiescent disease is common, and is associated with psychological disorders, impaired quality of life, and increased health-care use. In IBD, data from observational studies suggest that psychological disorders might be associated with relapse of disease activity, and that inflammatory activity is associated with the development of new psychological disorders, as has been described for functional gastrointestinal disorders such as IBS and functional dyspepsia. The brain-gut axis provides the physiological link between the CNS and gastrointestinal tract that might facilitate these relationships. In IBS, treatments targeting disordered brain-gut axis activity, including psychological therapies and antidepressants, might lead to improved symptoms and quality of life. However, in IBD, the benefit of these treatments is less certain because of a scarcity of interventional studies. Despite the scarcity of trials, observational data suggest that the effect of disordered brain-gut axis activity in IBD is substantial, and scope remains for further well designed trials of psychological therapies and antidepressants, particularly in the subset of patients who have coexistent psychological disorders, or in those who report IBS-type symptoms. Integrating these treatments into a biopsychosocial model of care has the potential to improve both psychological wellbeing and quality of life in some patients with IBD, reducing health-care use and altering the natural history of disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gracie</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Leeds Gastroenterology Institute, St James's University Hospital, Leeds Teaching Hospitals National Health Service Trust, Leeds, UK. Electronic address: djgracie1982@doctors.org.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamlin</LastName><ForeName>P John</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Leeds Gastroenterology Institute, St James's University Hospital, Leeds Teaching Hospitals National Health Service Trust, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ford</LastName><ForeName>Alexander C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Leeds Gastroenterology Institute, St James's University Hospital, Leeds Teaching Hospitals National Health Service Trust, Leeds, UK; Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>05</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Lancet Gastroenterol Hepatol</MedlineTA><NlmUniqueID>101690683</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004032" MajorTopicYN="N">Diet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D041981" MajorTopicYN="N">Gastrointestinal Tract</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015212" MajorTopicYN="N">Inflammatory Bowel Diseases</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008603" MajorTopicYN="N">Mental Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31122802</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(19)30089-5</ArticleId><ArticleId IdType="pii">S2468-1253(19)30089-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33903147</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-3288</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>7</Issue><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Gut</Title><ISOAbbreviation>Gut</ISOAbbreviation></Journal><ArticleTitle>British Society of Gastroenterology guidelines on the management of irritable bowel syndrome.</ArticleTitle><Pagination><StartPage>1214</StartPage><EndPage>1240</EndPage><MedlinePgn>1214-1240</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/gutjnl-2021-324598</ELocationID><Abstract><AbstractText>Irritable bowel syndrome (IBS) remains one of the most common gastrointestinal disorders seen by clinicians in both primary and secondary care. Since publication of the last British Society of Gastroenterology (BSG) guideline in 2007, substantial advances have been made in understanding its complex pathophysiology, resulting in its re-classification as a disorder of gut-brain interaction, rather than a functional gastrointestinal disorder. Moreover, there has been a considerable amount of new evidence published concerning the diagnosis, investigation and management of IBS. The primary aim of this guideline, commissioned by the BSG, is to review and summarise the current evidence to inform and guide clinical practice, by providing a practical framework for evidence-based management of patients. One of the strengths of this guideline is that the recommendations for treatment are based on evidence derived from a comprehensive search of the medical literature, which was used to inform an update of a series of trial-based and network meta-analyses assessing the efficacy of dietary, pharmacological and psychological therapies in treating IBS. Specific recommendations have been made according to the Grading of Recommendations Assessment, Development and Evaluation system, summarising both the strength of the recommendations and the overall quality of evidence. Finally, this guideline identifies novel treatments that are in development, as well as highlighting areas of unmet need for future research.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vasant</LastName><ForeName>Dipesh H</ForeName><Initials>DH</Initials><Identifier Source="ORCID">0000-0002-2329-0616</Identifier><AffiliationInfo><Affiliation>Neurogastroenterology Unit, Gastroenterology, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Diabetes, Endocrinology and Gastroenterology, University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paine</LastName><ForeName>Peter A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Division of Diabetes, Endocrinology and Gastroenterology, University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gastroenterology, Salford Royal Foundation Trust, Salford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0001-5449-3603</Identifier><AffiliationInfo><Affiliation>Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houghton</LastName><ForeName>Lesley A</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0002-5351-0229</Identifier><AffiliationInfo><Affiliation>Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Everitt</LastName><ForeName>Hazel A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Primary Care and Population Sciences, University of Southampton, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corsetti</LastName><ForeName>Maura</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nottingham Digestive Diseases Biomedical Research Unit, University of Nottingham, Nottingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agrawal</LastName><ForeName>Anurag</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Gastroenterology, Doncaster and Bassetlaw Hospitals NHS Trust, Armthorpe Road, Doncaster, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aziz</LastName><ForeName>Imran</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-3833-2302</Identifier><AffiliationInfo><Affiliation>Academic Unit of Gastroenterology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farmer</LastName><ForeName>Adam D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Keele University, Keele, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eugenicos</LastName><ForeName>Maria P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, University of Edinburgh, Western General Hospital, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moss-Morris</LastName><ForeName>Rona</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yiannakou</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, County Durham and Darlington NHS Foundation Trust, Durham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ford</LastName><ForeName>Alexander C</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0001-6371-4359</Identifier><AffiliationInfo><Affiliation>Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK alexf12399@yahoo.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017065">Practice Guideline</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Gut</MedlineTA><NlmUniqueID>2985108R</NlmUniqueID><ISSNLinking>0017-5749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012702">Serotonin Antagonists</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="N">Biomedical Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="Y">Cognitive Behavioral Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003142" MajorTopicYN="N">Communication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003248" MajorTopicYN="N">Constipation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004032" MajorTopicYN="N">Diet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076722" MajorTopicYN="N">Drug Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006990" MajorTopicYN="N">Hypnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="N">Patient Education as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010817" MajorTopicYN="N">Physician-Patient Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012702" MajorTopicYN="N">Serotonin Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword></KeywordList><CoiStatement>Competing interests: Please see the attached supplement of declarations of conflicts of interest for all authors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33903147</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2021-324598</ArticleId><ArticleId IdType="pii">gutjnl-2021-324598</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28274108</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2005-1212</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>Gut and liver</Title><ISOAbbreviation>Gut Liver</ISOAbbreviation></Journal><ArticleTitle>Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy.</ArticleTitle><Pagination><StartPage>196</StartPage><EndPage>208</EndPage><MedlinePgn>196-208</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5009/gnl16126</ELocationID><Abstract><AbstractText>The pathogenesis of irritable bowel syndrome (IBS), once thought to be largely psychogenic in origin, is now understood to be multifactorial. One of the reasons for this paradigm shift is the realization that gut dysbiosis, including small intestinal bacterial overgrowth (SIBO), causes IBS symptoms. Between 4% and 78% of patients with IBS and 1% and 40% of controls have SIBO; such wide variations in prevalence might result from population differences, IBS diagnostic criteria, and, most importantly, methods to diagnose SIBO. Although quantitative jejunal aspirate culture is considered the gold standard for the diagnosis of SIBO, noninvasive hydrogen breath tests have been popular. Although the glucose hydrogen breath test is highly specific, its sensitivity is low; in contrast, the early-peak criteria in the lactulose hydrogen breath test are highly nonspecific. Female gender, older age, diarrhea-predominant IBS, bloating and flatulence, proton pump inhibitor and narcotic intake, and low hemoglobin are associated with SIBO among IBS patients. Several therapeutic trials targeting gut microbes using antibiotics and probiotics have further demonstrated that not all symptoms in patients with IBS originate in the brain but rather in the gut, providing support for the micro-organic basis of IBS. A recent proof-of-concept study showing the high frequency of symptom improvement in patients with IBS with SIBO further supports this hypothesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ghoshal</LastName><ForeName>Uday C</ForeName><Initials>UC</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shukla</LastName><ForeName>Ratnakar</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghoshal</LastName><ForeName>Ujjala</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Gut Liver</MedlineTA><NlmUniqueID>101316452</NlmUniqueID><ISSNLinking>1976-2283</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001765" MajorTopicYN="N">Blind Loop Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001944" MajorTopicYN="N">Breath Tests</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007421" MajorTopicYN="N">Intestine, Small</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bacterial overgrowth</Keyword><Keyword MajorTopicYN="N">Breath tests</Keyword><Keyword MajorTopicYN="N">Dysbiosis</Keyword><Keyword MajorTopicYN="N">Gastrointestinal microbiota</Keyword><Keyword MajorTopicYN="N">Probiotics</Keyword><Keyword MajorTopicYN="N">Rifaximin</Keyword></KeywordList><CoiStatement><b>CONFLICTS OF INTEREST</b>. No potential conflict of interest relevant to this article was reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28274108</ArticleId><ArticleId IdType="pmc">PMC5347643</ArticleId><ArticleId IdType="doi">10.5009/gnl16126</ArticleId><ArticleId IdType="pii">gnl16126</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wall GC, Bryant GA, Bottenberg MM, Maki ED, Miesner AR. Irritable bowel syndrome: a concise review of current treatment concepts. World J Gastroenterol. 2014;20:8796&#x2013;8806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4112883</ArticleId><ArticleId IdType="pubmed">25083054</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal UC, Shukla R, Ghoshal U, Gwee KA, Ng SC, Quigley EM. The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam. 2012;2012:151085. doi: 10.1155/2012/151085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/151085</ArticleId><ArticleId IdType="pmc">PMC3346986</ArticleId><ArticleId IdType="pubmed">22577594</ArticleId></ArticleIdList></Reference><Reference><Citation>Malinen E, Krogius-Kurikka L, Lyra A, et al. Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome. World J Gastroenterol. 2010;16:4532&#x2013;4540. doi: 10.3748/wjg.v16.i36.4532.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v16.i36.4532</ArticleId><ArticleId IdType="pmc">PMC2945484</ArticleId><ArticleId IdType="pubmed">20857523</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddymasu SC, Sostarich S, McCallum RW. Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors? BMC Gastroenterol. 2010;10:23. doi: 10.1186/1471-230X-10-23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-230X-10-23</ArticleId><ArticleId IdType="pmc">PMC2838757</ArticleId><ArticleId IdType="pubmed">20175924</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA. 2004;292:852&#x2013;858. doi: 10.1001/jama.292.7.852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.292.7.852</ArticleId><ArticleId IdType="pubmed">15316000</ArticleId></ArticleIdList></Reference><Reference><Citation>Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol (N Y) 2007;3:112&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3099351</ArticleId><ArticleId IdType="pubmed">21960820</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal UC, Srivastava D. Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype. World J Gastroenterol. 2014;20:2482&#x2013;2491. doi: 10.3748/wjg.v20.i10.2482.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i10.2482</ArticleId><ArticleId IdType="pmc">PMC3949258</ArticleId><ArticleId IdType="pubmed">24627585</ArticleId></ArticleIdList></Reference><Reference><Citation>Grover M, Kanazawa M, Palsson OS, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: association with colon motility, bowel symptoms, and psychological distress. Neurogastroenterol Motil. 2008;20:998&#x2013;1008. doi: 10.1111/j.1365-2982.2008.01142.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2008.01142.x</ArticleId><ArticleId IdType="pmc">PMC3856223</ArticleId><ArticleId IdType="pubmed">18482250</ArticleId></ArticleIdList></Reference><Reference><Citation>Levenstein S, Rosenstock S, Jacobsen RK, Jorgensen T. Psychological stress increases risk for peptic ulcer, regardless of Helicobacter pylori infection or use of nonsteroidal anti-inflammatory drugs. Clin Gastroenterol Hepatol. 2015;13:498&#x2013;506.e1. doi: 10.1016/j.cgh.2014.07.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2014.07.052</ArticleId><ArticleId IdType="pubmed">25111233</ArticleId></ArticleIdList></Reference><Reference><Citation>Safavi M, Sabourian R, Foroumadi A. Treatment of Helicobacter pylori infection: current and future insights. World J Clin Cases. 2016;4:5&#x2013;19. doi: 10.12998/wjcc.v4.i1.5.</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v4.i1.5</ArticleId><ArticleId IdType="pmc">PMC4714294</ArticleId><ArticleId IdType="pubmed">26798626</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Tan RZ, Chen Y, et al. CagA promotes proliferation and secretion of extracellular matrix by inhibiting signaling pathway of apoptosis in rat glomerular mesangial cells. Ren Fail. 2016;38:458&#x2013;464. doi: 10.3109/0886022X.2016.1138831.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/0886022X.2016.1138831</ArticleId><ArticleId IdType="pubmed">26837331</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerritsen J, Smidt H, Rijkers GT, de Vos WM. Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr. 2011;6:209&#x2013;240. doi: 10.1007/s12263-011-0229-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12263-011-0229-7</ArticleId><ArticleId IdType="pmc">PMC3145058</ArticleId><ArticleId IdType="pubmed">21617937</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90:859&#x2013;904. doi: 10.1152/physrev.00045.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00045.2009</ArticleId><ArticleId IdType="pubmed">20664075</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal UC, Park H, Gwee KA. Bugs and irritable bowel syndrome: the good, the bad and the ugly. J Gastroenterol Hepatol. 2010;25:244&#x2013;251. doi: 10.1111/j.1440-1746.2009.06133.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1746.2009.06133.x</ArticleId><ArticleId IdType="pubmed">20074148</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier JC, Million M, Hugon P, Armougom F, Raoult D. Human gut microbiota: repertoire and variations. Front Cell Infect Microbiol. 2012;2:136. doi: 10.3389/fcimb.2012.00136.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2012.00136</ArticleId><ArticleId IdType="pmc">PMC3487222</ArticleId><ArticleId IdType="pubmed">23130351</ArticleId></ArticleIdList></Reference><Reference><Citation>Nigam D. Microbial interactions with humans and animals. Int J Microbiol Allied Sci. 2015;2:1&#x2013;17.</Citation></Reference><Reference><Citation>Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005;308:1635&#x2013;1638. doi: 10.1126/science.1110591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1110591</ArticleId><ArticleId IdType="pmc">PMC1395357</ArticleId><ArticleId IdType="pubmed">15831718</ArticleId></ArticleIdList></Reference><Reference><Citation>Schloss PD, Handelsman J. Status of the microbial census. Microbiol Mol Biol Rev. 2004;68:686&#x2013;691. doi: 10.1128/MMBR.68.4.686-691.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MMBR.68.4.686-691.2004</ArticleId><ArticleId IdType="pmc">PMC539005</ArticleId><ArticleId IdType="pubmed">15590780</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006;7:688&#x2013;693. doi: 10.1038/sj.embor.7400731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.embor.7400731</ArticleId><ArticleId IdType="pmc">PMC1500832</ArticleId><ArticleId IdType="pubmed">16819463</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyas U, Ranganathan N. Probiotics, prebiotics, and synbiotics: gut and beyond. Gastroenterol Res Pract. 2012;2012:872716. doi: 10.1155/2012/872716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/872716</ArticleId><ArticleId IdType="pmc">PMC3459241</ArticleId><ArticleId IdType="pubmed">23049548</ArticleId></ArticleIdList></Reference><Reference><Citation>Goulet O, Joly F. Intestinal microbiota in short bowel syndrome. Gastroenterol Clin Biol. 2010;34(Suppl 1):S37&#x2013;S43. doi: 10.1016/S0399-8320(10)70019-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0399-8320(10)70019-1</ArticleId><ArticleId IdType="pubmed">20889003</ArticleId></ArticleIdList></Reference><Reference><Citation>Bures J, Cyrany J, Kohoutova D, et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010;16:2978&#x2013;2990. doi: 10.3748/wjg.v16.i24.2978.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v16.i24.2978</ArticleId><ArticleId IdType="pmc">PMC2890937</ArticleId><ArticleId IdType="pubmed">20572300</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderhoof JA, Young RJ. Etiology and pathogenesis of bacterial overgrowth. Clinical manifestations and diagnosis of bacterial overgrowth: treatment of bacterial overgrowth. UpToDate Online. 2010;18</Citation></Reference><Reference><Citation>Gabrielli M, D&#x2019;Angelo G, Di Rienzo T, Scarpellini E, Ojetti V. Diagnosis of small intestinal bacterial overgrowth in the clinical practice. Eur Rev Med Pharmacol Sci. 2013;17(Suppl 2):30&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">24443065</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao WL, Lee YK. Microflora of the gastrointestinal tract: a review. Methods Mol Biol. 2004;268:491&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">15156063</ArticleId></ArticleIdList></Reference><Reference><Citation>Riordan SM, McIver CJ, Wakefield D, Duncombe VM, Thomas MC, Bolin TD. Small intestinal mucosal immunity and morphometry in luminal overgrowth of indigenous gut flora. Am J Gastroenterol. 2001;96:494&#x2013;500. doi: 10.1111/j.1572-0241.2001.03533.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2001.03533.x</ArticleId><ArticleId IdType="pubmed">11232696</ArticleId></ArticleIdList></Reference><Reference><Citation>Erdogan A, Rao SS, Gulley D, Jacobs C, Lee YY, Badger C. Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test. Neurogastroenterol Motil. 2015;27:481&#x2013;489. doi: 10.1111/nmo.12516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12516</ArticleId><ArticleId IdType="pubmed">25600077</ArticleId></ArticleIdList></Reference><Reference><Citation>Chey WD, Maneerattaporn M, Saad R. Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome. Gut Liver. 2011;5:253&#x2013;266. doi: 10.5009/gnl.2011.5.3.253.</Citation><ArticleIdList><ArticleId IdType="doi">10.5009/gnl.2011.5.3.253</ArticleId><ArticleId IdType="pmc">PMC3166664</ArticleId><ArticleId IdType="pubmed">21927652</ArticleId></ArticleIdList></Reference><Reference><Citation>Peralta S, Cottone C, Doveri T, Almasio PL, Craxi A. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with rifaximin. World J Gastroenterol. 2009;15:2628&#x2013;2631. doi: 10.3748/wjg.15.2628.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.15.2628</ArticleId><ArticleId IdType="pmc">PMC2691494</ArticleId><ArticleId IdType="pubmed">19496193</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler TR, Cole CR. Small bowel bacterial overgrowth in adults: a potential contributor to intestinal failure. Curr Gastroenterol Rep. 2007;9:463&#x2013;467. doi: 10.1007/s11894-007-0060-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11894-007-0060-x</ArticleId><ArticleId IdType="pubmed">18377796</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal UC, Ghoshal U, Das K, Misra A. Utility of hydrogen breath tests in diagnosis of small intestinal bacterial overgrowth in malabsorption syndrome and its relationship with orocecal transit time. Indian J Gastroenterol. 2006;25:6&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">16567886</ArticleId></ArticleIdList></Reference><Reference><Citation>Britton E, McLaughlin JT. Ageing and the gut. Proc Nutr Soc. 2013;72:173&#x2013;177. doi: 10.1017/S0029665112002807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0029665112002807</ArticleId><ArticleId IdType="pubmed">23146206</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal U, Ghoshal UC, Ranjan P, Naik SR, Ayyagari A. Spectrum and antibiotic sensitivity of bacteria contaminating the upper gut in patients with malabsorption syndrome from the tropics. BMC Gastroenterol. 2003;3:9. doi: 10.1186/1471-230X-3-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-230X-3-9</ArticleId><ArticleId IdType="pmc">PMC165422</ArticleId><ArticleId IdType="pubmed">12769832</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier JC, Armougom F, Million M, et al. Microbial culturomics: paradigm shift in the human gut microbiome study. Clin Microbiol Infect. 2012;18:1185&#x2013;1193. doi: 10.1111/1469-0691.12023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1469-0691.12023</ArticleId><ArticleId IdType="pubmed">23033984</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokcha S, Mishra AK, Lagier JC, et al. Non contiguous-finished genome sequence and description of Bacillus timonensis sp. nov. Stand Genomic Sci. 2012;6:346&#x2013;355. doi: 10.4056/sigs.2776064.</Citation><ArticleIdList><ArticleId IdType="doi">10.4056/sigs.2776064</ArticleId><ArticleId IdType="pmc">PMC3558959</ArticleId><ArticleId IdType="pubmed">23408487</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal UC. How to interpret hydrogen breath tests. J Neurogastroenterol Motil. 2011;17:312&#x2013;317. doi: 10.5056/jnm.2011.17.3.312.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm.2011.17.3.312</ArticleId><ArticleId IdType="pmc">PMC3155069</ArticleId><ArticleId IdType="pubmed">21860825</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucera G, Gabrielli M, Lupascu A, et al. Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;21:1391&#x2013;1395. doi: 10.1111/j.1365-2036.2005.02493.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2005.02493.x</ArticleId><ArticleId IdType="pubmed">15932370</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraczinskas D, Goldfinger SE. Intestinal gas and bloating. Up-ToDate Online. 2010:18.</Citation></Reference><Reference><Citation>Ghoshal UC, Srivastava D, Ghoshal U, Misra A. Breath tests in the diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture. Eur J Gastroenterol Hepatol. 2014;26:753&#x2013;760. doi: 10.1097/MEG.0000000000000122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000000122</ArticleId><ArticleId IdType="pubmed">24849768</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95:3503&#x2013;3506. doi: 10.1111/j.1572-0241.2000.03368.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2000.03368.x</ArticleId><ArticleId IdType="pubmed">11151884</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerlin P, Wong L. Breath hydrogen testing in bacterial overgrowth of the small intestine. Gastroenterology. 1988;95:982&#x2013;988. doi: 10.1016/0016-5085(88)90173-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0016-5085(88)90173-4</ArticleId><ArticleId IdType="pubmed">3410238</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah ED, Basseri RJ, Chong K, Pimentel M. Abnormal breath testing in IBS: a meta-analysis. Dig Dis Sci. 2010;55:2441&#x2013;2449. doi: 10.1007/s10620-010-1276-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-010-1276-4</ArticleId><ArticleId IdType="pubmed">20467896</ArticleId></ArticleIdList></Reference><Reference><Citation>Simr&#xe9;n M, Stotzer PO. Use and abuse of hydrogen breath tests. Gut. 2006;55:297&#x2013;303. doi: 10.1136/gut.2005.075127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2005.075127</ArticleId><ArticleId IdType="pmc">PMC1856094</ArticleId><ArticleId IdType="pubmed">16474100</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojetti V, Di Rienzo TA, D&#x2019;Angelo G, et al. Early peak of hydrogen during lactose breath test predicts intestinal motility. Open J Gastroenterol. 2014;4:40&#x2013;44. doi: 10.4236/ojgas.2014.41007.</Citation><ArticleIdList><ArticleId IdType="doi">10.4236/ojgas.2014.41007</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu D, Cheeseman F, Vanner S. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut. 2011;60:334&#x2013;340. doi: 10.1136/gut.2009.205476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2009.205476</ArticleId><ArticleId IdType="pubmed">21112950</ArticleId></ArticleIdList></Reference><Reference><Citation>Santavirta J. Lactulose hydrogen and [14C]xylose breath tests in patients with ileoanal anastomosis. Int J Colorectal Dis. 1991;6:208&#x2013;211. doi: 10.1007/BF00341392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00341392</ArticleId><ArticleId IdType="pubmed">1770288</ArticleId></ArticleIdList></Reference><Reference><Citation>Banik GD, Maity A, Som S, et al. Diagnosis of small intestinal bacterial overgrowth in irritable bowel syndrome patients using high-precision stable 13 CO 2/12 CO 2 isotope ratios in exhaled breath. J Anal At Spectrom. 2014;29:1918&#x2013;1924. doi: 10.1039/C4JA00186A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C4JA00186A</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal UC, Ghoshal U, Ayyagari A, et al. Tropical sprue is associated with contamination of small bowel with aerobic bacteria and reversible prolongation of orocecal transit time. J Gastroenterol Hepatol. 2003;18:540&#x2013;547. doi: 10.1046/j.1440-1746.2003.03006.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1440-1746.2003.03006.x</ArticleId><ArticleId IdType="pubmed">12702046</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CL, Chen CY, Chang FY, Lee SD. Characteristics of small bowel motility in patients with irritable bowel syndrome and normal humans: an Oriental study. Clin Sci (Lond) 1998;95:165&#x2013;169. doi: 10.1042/cs0950165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/cs0950165</ArticleId><ArticleId IdType="pubmed">9680498</ArticleId></ArticleIdList></Reference><Reference><Citation>Moraru IG, Portincasa P, Moraru AG, Diculescu M, Dumitra&#x15f;cu DL. Small intestinal bacterial overgrowth produces symptoms in irritable bowel syndrome which are improved by rifaximin: a pilot study. Rom J Intern Med. 2013;51:143&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">24620626</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal UC, Kumar S, Mehrotra M, Lakshmi C, Misra A. Frequency of small intestinal bacterial overgrowth in patients with irritable bowel syndrome and chronic non-specific diarrhea. J Neurogastroenterol Motil. 2010;16:40&#x2013;46. doi: 10.5056/jnm.2010.16.1.40.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm.2010.16.1.40</ArticleId><ArticleId IdType="pmc">PMC2879828</ArticleId><ArticleId IdType="pubmed">20535325</ArticleId></ArticleIdList></Reference><Reference><Citation>Posserud I, Stotzer PO, Bj&#xf6;rnsson ES, Abrahamsson H, Simr&#xe9;n M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56:802&#x2013;808. doi: 10.1136/gut.2006.108712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2006.108712</ArticleId><ArticleId IdType="pmc">PMC1954873</ArticleId><ArticleId IdType="pubmed">17148502</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerckhoffs AP, Visser MR, Samsom M, et al. Critical evaluation of diagnosing bacterial overgrowth in the proximal small intestine. J Clin Gastroenterol. 2008;42:1095&#x2013;1102. doi: 10.1097/MCG.0b013e31818474d7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0b013e31818474d7</ArticleId><ArticleId IdType="pubmed">18936644</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, Koussoulas V, Barbatzas C, Pimentel M. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci. 2012;57:1321&#x2013;1329. doi: 10.1007/s10620-012-2033-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-012-2033-7</ArticleId><ArticleId IdType="pubmed">22262197</ArticleId></ArticleIdList></Reference><Reference><Citation>Walters B, Vanner SJ. Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls. Am J Gastroenterol. 2005;100:1566&#x2013;1570. doi: 10.1111/j.1572-0241.2005.40795.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2005.40795.x</ArticleId><ArticleId IdType="pubmed">15984983</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Zheng X, Chu H, et al. A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic orocecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients. Neurogastroenterol Motil. 2014;26:794&#x2013;802. doi: 10.1111/nmo.12331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12331</ArticleId><ArticleId IdType="pubmed">24641100</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JS, Yu JH, Lim HC, et al. Usefulness of lactulose breath test for the prediction of small intestinal bacterial overgrowth in irritable bowel syndrome. Korean J Gastroenterol. 2010;56:242&#x2013;248. doi: 10.4166/kjg.2010.56.4.242.</Citation><ArticleIdList><ArticleId IdType="doi">10.4166/kjg.2010.56.4.242</ArticleId><ArticleId IdType="pubmed">20962560</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarpellini E, Giorgio V, Gabrielli M, et al. Prevalence of small intestinal bacterial overgrowth in children with irritable bowel syndrome: a case-control study. J Pediatr. 2009;155:416&#x2013;420. doi: 10.1016/j.jpeds.2009.03.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2009.03.033</ArticleId><ArticleId IdType="pubmed">19535093</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrara M, Desideri S, Azzurro M, et al. Small intestine bacterial overgrowth in patients with irritable bowel syndrome. Eur Rev Med Pharmacol Sci. 2008;12:197&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">18700692</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann NS, Limoges-Gonzales M. The prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome. Hepatogastroenterology. 2009;56:718&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pubmed">19621689</ArticleId></ArticleIdList></Reference><Reference><Citation>Rana SV, Sinha SK, Sikander A, Bhasin DK, Singh K. Study of small intestinal bacterial overgrowth in North Indian patients with irritable bowel syndrome: a case control study. Trop Gastroenterol. 2008;29:23&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">18564663</ArticleId></ArticleIdList></Reference><Reference><Citation>Yakoob J, Abbas Z, Khan R, Hamid S, Awan S, Jafri W. Small intestinal bacterial overgrowth and lactose intolerance contribute to irritable bowel syndrome symptomatology in Pakistan. Saudi J Gastroenterol. 2011;17:371&#x2013;375. doi: 10.4103/1319-3767.87176.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1319-3767.87176</ArticleId><ArticleId IdType="pmc">PMC3221109</ArticleId><ArticleId IdType="pubmed">22064333</ArticleId></ArticleIdList></Reference><Reference><Citation>Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci. 2007;52:139&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">18217406</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachdeva S, Rawat AK, Reddy RS, Puri AS. Small intestinal bacterial overgrowth (SIBO) in irritable bowel syndrome: frequency and predictors. J Gastroenterol Hepatol. 2011;26(Suppl 3):135&#x2013;138. doi: 10.1111/j.1440-1746.2011.06654.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1746.2011.06654.x</ArticleId><ArticleId IdType="pubmed">21443727</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuoco L, Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol Dietol. 2006;52:89&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">16554709</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupascu A, Gabrielli M, Lauritano EC, et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22:1157&#x2013;1160. doi: 10.1111/j.1365-2036.2005.02690.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2005.02690.x</ArticleId><ArticleId IdType="pubmed">16305730</ArticleId></ArticleIdList></Reference><Reference><Citation>Rana SV, Sharma S, Kaur J, Sinha SK, Singh K. Comparison of lactulose and glucose breath test for diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Digestion. 2012;85:243&#x2013;247. doi: 10.1159/000336174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000336174</ArticleId><ArticleId IdType="pubmed">22472730</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbasi MH, Zahedi M, Darvish Moghadam S, Shafieipour S, HayatBakhsh Abbasi M. Small bowel bacterial overgrowth in patients with irritable bowel syndrome: the first study in iran. Middle East J Dig Dis. 2015;7:36&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4293799</ArticleId><ArticleId IdType="pubmed">25628852</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7:1279&#x2013;1286. doi: 10.1016/j.cgh.2009.06.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2009.06.031</ArticleId><ArticleId IdType="pubmed">19602448</ArticleId></ArticleIdList></Reference><Reference><Citation>Moraru IG, Moraru AG, Andrei M, et al. Small intestinal bacterial overgrowth is associated to symptoms in irritable bowel syndrome: evidence from a multicentre study in Romania. Rom J Intern Med. 2014;52:143&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">25509557</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh VV, Toskes PP. Small bowel bacterial overgrowth: presentation, diagnosis, and treatment. Curr Treat Options Gastroenterol. 2004;7:19&#x2013;28. doi: 10.1007/s11938-004-0022-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11938-004-0022-4</ArticleId><ArticleId IdType="pubmed">14723835</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandeputte D, Falony G, Vieira-Silva S, Tito RY, Joossens M, Raes J. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut. 2016;65:57&#x2013;62. doi: 10.1136/gutjnl-2015-309618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-309618</ArticleId><ArticleId IdType="pmc">PMC4717365</ArticleId><ArticleId IdType="pubmed">26069274</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel BM, Chey WD, Chang L. Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors? Am J Gastroenterol. 2008;103:2972&#x2013;2976. doi: 10.1111/j.1572-0241.2008.01992.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2008.01992.x</ArticleId><ArticleId IdType="pmc">PMC2949084</ArticleId><ArticleId IdType="pubmed">19086951</ArticleId></ArticleIdList></Reference><Reference><Citation>Choung RS, Ruff KC, Malhotra A, et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther. 2011;33:1059&#x2013;1067. doi: 10.1111/j.1365-2036.2011.04625.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2011.04625.x</ArticleId><ArticleId IdType="pubmed">21395630</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasbarrini A, Scarpellini E, Gabrielli M, Tortora A, Purchiaroni F, Ojetti V. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther. 2011;33:1378&#x2013;1379. doi: 10.1111/j.1365-2036.2011.04657.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2011.04657.x</ArticleId><ArticleId IdType="pubmed">21569063</ArticleId></ArticleIdList></Reference><Reference><Citation>Haderstorfer B, Psycholgin D, Whitehead WE, Schuster MM. Intestinal gas production from bacterial fermentation of undigested carbohydrate in irritable bowel syndrome. Am J Gastroenterol. 1989;84:375&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">2929557</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachdev AH, Pimentel M. Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. Ther Adv Chronic Dis. 2013;4:223&#x2013;231. doi: 10.1177/2040622313496126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2040622313496126</ArticleId><ArticleId IdType="pmc">PMC3752184</ArticleId><ArticleId IdType="pubmed">23997926</ArticleId></ArticleIdList></Reference><Reference><Citation>Shukla R, Ghoshal U, Dhole TN, Ghoshal UC. Fecal microbiota in patients with irritable bowel syndrome compared with healthy controls using real-time polymerase chain reaction: an evidence of dysbiosis. Dig Dis Sci. 2015;60:2953&#x2013;2962. doi: 10.1007/s10620-015-3607-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-015-3607-y</ArticleId><ArticleId IdType="pubmed">25784074</ArticleId></ArticleIdList></Reference><Reference><Citation>Park H. The role of small intestinal bacterial overgrowth in the pathophysiology of irritable bowel syndrome. J Neurogastroenterol Motil. 2010;16:3&#x2013;4. doi: 10.5056/jnm.2010.16.1.3.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm.2010.16.1.3</ArticleId><ArticleId IdType="pmc">PMC2879822</ArticleId><ArticleId IdType="pubmed">20535319</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi CH, Chang SK. Role of small intestinal bacterial overgrowth in functional gastrointestinal disorders. J Neurogastroenterol Motil. 2016;22:3&#x2013;5. doi: 10.5056/jnm15196.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm15196</ArticleId><ArticleId IdType="pmc">PMC4699716</ArticleId><ArticleId IdType="pubmed">26717927</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbara G, Feinle-Bisset C, Ghoshal UC, et al. The intestinal microenvironment and functional gastrointestinal disorders. Gastroenterology. 2016;150:1305&#x2013;1318.e8. doi: 10.1053/j.gastro.2016.02.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.028</ArticleId><ArticleId IdType="pubmed">27144620</ArticleId></ArticleIdList></Reference><Reference><Citation>Francisconi CF, Sperber AD, Fang X, et al. Multicultural aspects in functional gastrointestinal disorders (FGIDs) Gastroenterology. 2016;150:1344&#x2013;1354. doi: 10.1053/j.gastro.2016.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.013</ArticleId><ArticleId IdType="pubmed">27144623</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150:1393&#x2013;1407. doi: 10.1053/j.gastro.2016.02.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.031</ArticleId><ArticleId IdType="pubmed">27144627</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M, Gunsalus RP, Rao SS, Zhang H. Methanogens in human health and disease. Am J Gastroenterol Suppl. 2012;1:28&#x2013;33. doi: 10.1038/ajgsup.2012.6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajgsup.2012.6</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan X, Sellin JH. Review article: small intestinal bacterial overgrowth, bile acid malabsorption and gluten intolerance as possible causes of chronic watery diarrhoea. Aliment Pharmacol Ther. 2009;29:1069&#x2013;1077. doi: 10.1111/j.1365-2036.2009.03970.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2009.03970.x</ArticleId><ArticleId IdType="pubmed">19222407</ArticleId></ArticleIdList></Reference><Reference><Citation>Riepe SP, Goldstein J, Alpers DH. Effect of secreted Bacteroides proteases on human intestinal brush border hydrolases. J Clin Invest. 1980;66:314&#x2013;322. doi: 10.1172/JCI109859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI109859</ArticleId><ArticleId IdType="pmc">PMC371713</ArticleId><ArticleId IdType="pubmed">6995483</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaidel O, Lin HC. Uninvited guests: the impact of small intestinal bacterial overgrowth on nutritional status. Pract Gastroenterol. 2003;27:27&#x2013;34.</Citation></Reference><Reference><Citation>Bala L, Ghoshal UC, Ghoshal U, et al. Malabsorption syndrome with and without small intestinal bacterial overgrowth: a study on upper-gut aspirate using 1H NMR spectroscopy. Magn Reson Med. 2006;56:738&#x2013;744. doi: 10.1002/mrm.21041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mrm.21041</ArticleId><ArticleId IdType="pubmed">16972311</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal UC, Kumar S, Misra A, Choudhuri G. Pathogenesis of tropical sprue: a pilot study of antroduodenal manometry, duodenocaecal transit time &amp; fat-induced ileal brake. Indian J Med Res. 2013;137:63&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3657900</ArticleId><ArticleId IdType="pubmed">23481053</ArticleId></ArticleIdList></Reference><Reference><Citation>Donowitz JR, Petri WA., Jr Pediatric small intestine bacterial overgrowth in low-income countries. Trends Mol Med. 2015;21:6&#x2013;15. doi: 10.1016/j.molmed.2014.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2014.11.001</ArticleId><ArticleId IdType="pmc">PMC4402728</ArticleId><ArticleId IdType="pubmed">25486880</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol. 2009;6:306&#x2013;314. doi: 10.1038/nrgastro.2009.35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2009.35</ArticleId><ArticleId IdType="pmc">PMC3817714</ArticleId><ArticleId IdType="pubmed">19404271</ArticleId></ArticleIdList></Reference><Reference><Citation>Malbert CH. The ileocolonic sphincter. Neurogastroenterol Motil. 2005;17(Suppl 1):41&#x2013;49. doi: 10.1111/j.1365-2982.2005.00657.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2005.00657.x</ArticleId><ArticleId IdType="pubmed">15836454</ArticleId></ArticleIdList></Reference><Reference><Citation>Dass NB, John AK, Bassil AK, et al. The relationship between the effects of short-chain fatty acids on intestinal motility in vitro and GPR43 receptor activation. Neurogastroenterol Motil. 2007;19:66&#x2013;74. doi: 10.1111/j.1365-2982.2006.00853.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2006.00853.x</ArticleId><ArticleId IdType="pubmed">17187590</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbara G, Stanghellini V, Brandi G, et al. Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am J Gastroenterol. 2005;100:2560&#x2013;2568. doi: 10.1111/j.1572-0241.2005.00230.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2005.00230.x</ArticleId><ArticleId IdType="pubmed">16279914</ArticleId></ArticleIdList></Reference><Reference><Citation>Dibaise JK, Young RJ, Vanderhoof JA. Enteric microbial flora, bacterial overgrowth, and short-bowel syndrome. Clin Gastroenterol Hepatol. 2006;4:11&#x2013;20. doi: 10.1016/j.cgh.2005.10.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2005.10.020</ArticleId><ArticleId IdType="pubmed">16431299</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava D, Ghoshal U, Mittal RD, Ghoshal UC. Associations between IL-1RA polymorphisms and small intestinal bacterial overgrowth among patients with irritable bowel syndrome from India. Neurogastroenterol Motil. 2014;26:1408&#x2013;1416. doi: 10.1111/nmo.12399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12399</ArticleId><ArticleId IdType="pubmed">25073651</ArticleId></ArticleIdList></Reference><Reference><Citation>Rana SV, Sharma S, Sinha SK, Parsad KK, Malik A, Singh K. Pro-inflammatory and anti-inflammatory cytokine response in diarrhoea-predominant irritable bowel syndrome patients. Trop Gastroenterol. 2012;33:251&#x2013;256. doi: 10.7869/tg.2012.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.7869/tg.2012.66</ArticleId><ArticleId IdType="pubmed">23923350</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinucci G, Guidetti M, Lanzoni E, Pironi L. Endogenous ethanol production in a patient with chronic intestinal pseudo-obstruction and small intestinal bacterial overgrowth. Eur J Gastroenterol Hepatol. 2006;18:799&#x2013;802. doi: 10.1097/01.meg.0000223906.55245.61.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.meg.0000223906.55245.61</ArticleId><ArticleId IdType="pubmed">16772842</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmulson M, Bielsa MV, Carmona-S&#xe1;nchez R, et al. Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome: an evidence-based review. Rev Gastroenterol Mex. 2014;79:96&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">24857420</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Talley NJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol. 2011;46:421&#x2013;431. doi: 10.1007/s00535-011-0379-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00535-011-0379-9</ArticleId><ArticleId IdType="pubmed">21331765</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasler WL. Traditional thoughts on the pathophysiology of irritable bowel syndrome. Gastroenterol Clin North Am. 2011;40:21&#x2013;43. doi: 10.1016/j.gtc.2010.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gtc.2010.12.004</ArticleId><ArticleId IdType="pubmed">21333899</ArticleId></ArticleIdList></Reference><Reference><Citation>Patacchini R, Santicioli P, Giuliani S, Maggi CA. Pharmacological investigation of hydrogen sulfide (H2S) contractile activity in rat detrusor muscle. Eur J Pharmacol. 2005;509:171&#x2013;177. doi: 10.1016/j.ejphar.2005.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2005.01.005</ArticleId><ArticleId IdType="pubmed">15733553</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstock LB, Klutke CG, Lin HC. Small intestinal bacterial overgrowth in patients with interstitial cystitis and gastrointestinal symptoms. Dig Dis Sci. 2008;53:1246&#x2013;1251. doi: 10.1007/s10620-007-0022-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-007-0022-z</ArticleId><ArticleId IdType="pubmed">17932763</ArticleId></ArticleIdList></Reference><Reference><Citation>Banik GD, De A, Som S, et al. Hydrogen sulphide in exhaled breath: a potential biomarker for small intestinal bacterial overgrowth in IBS. J Breath Res. 2016;10:026010. doi: 10.1088/1752-7155/10/2/026010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1088/1752-7155/10/2/026010</ArticleId><ArticleId IdType="pubmed">27163246</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M, Wallace D, Hallegua D, et al. A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. Ann Rheum Dis. 2004;63:450&#x2013;452. doi: 10.1136/ard.2003.011502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2003.011502</ArticleId><ArticleId IdType="pmc">PMC1754959</ArticleId><ArticleId IdType="pubmed">15020342</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon JG, Park KS, Park JH, et al. Guidelines for the treatment of irritable bowel syndrome. Korean J Gastroenterol. 2011;57:82&#x2013;99. doi: 10.4166/kjg.2011.57.2.82.</Citation><ArticleIdList><ArticleId IdType="doi">10.4166/kjg.2011.57.2.82</ArticleId><ArticleId IdType="pubmed">21350320</ArticleId></ArticleIdList></Reference><Reference><Citation>Neale G, Gompertz D, Sch&#xf6;nsby H, Tabaqchali S, Booth CC. The metabolic and nutritional consequences of bacterial overgrowth in the small intestine. Am J Clin Nutr. 1972;25:1409&#x2013;1417.</Citation><ArticleIdList><ArticleId IdType="pubmed">4571741</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarpellini E, Gabrielli M, Lauritano CE, et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2007;25:781&#x2013;786. doi: 10.1111/j.1365-2036.2007.03259.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2007.03259.x</ArticleId><ArticleId IdType="pubmed">17373916</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stefano M, Miceli E, Missanelli A, Corazza GR. Treatment of small intestine bacterial overgrowth. Eur Rev Med Pharmacol Sci. 2005;9:217&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">16128041</ArticleId></ArticleIdList></Reference><Reference><Citation>Quigley EM, Quera R. Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology. 2006;130(2 Suppl1):S78&#x2013;S90. doi: 10.1053/j.gastro.2005.11.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2005.11.046</ArticleId><ArticleId IdType="pubmed">16473077</ArticleId></ArticleIdList></Reference><Reference><Citation>Chedid V, Dhalla S, Clarke JO, et al. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med. 2014;3:16&#x2013;24. doi: 10.7453/gahmj.2014.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.7453/gahmj.2014.019</ArticleId><ArticleId IdType="pmc">PMC4030608</ArticleId><ArticleId IdType="pubmed">24891990</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauritano EC, Gabrielli M, Lupascu A, et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;22:31&#x2013;35. doi: 10.1111/j.1365-2036.2005.02516.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2005.02516.x</ArticleId><ArticleId IdType="pubmed">15963077</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">12591062</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal UC, Srivastava D, Misra A, Ghoshal U. A proof-of-concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small-intestinal bacterial overgrowth: a randomized, double-blind, placebo-controlled trial. Eur J Gastroenterol Hepatol. 2016;28:281&#x2013;289. doi: 10.1097/MEG.0000000000000557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000000557</ArticleId><ArticleId IdType="pubmed">26731696</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22&#x2013;32. doi: 10.1056/NEJMoa1004409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1004409</ArticleId><ArticleId IdType="pubmed">21208106</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(Suppl 1):S2&#x2013;S26. doi: 10.1038/ajg.2014.187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2014.187</ArticleId><ArticleId IdType="pubmed">25091148</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy BE, Chey WD, Lembo AJ. New and emerging treatment options for irritable bowel syndrome. Gastroenterol Hepatol (N Y) 2015;11(4 Suppl 2):1&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4612133</ArticleId><ArticleId IdType="pubmed">26491416</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinberg DS, Smalley W, Heidelbaugh JJ, Sultan S American Gastroenterological Association. American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome. Gastroenterology. 2014;147:1146&#x2013;1148. doi: 10.1053/j.gastro.2014.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2014.09.001</ArticleId><ArticleId IdType="pubmed">25224526</ArticleId></ArticleIdList></Reference><Reference><Citation>Attar A, Flouri&#xe9; B, Rambaud JC, Franchisseur C, Ruszniewski P, Bouhnik Y. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology. 1999;117:794&#x2013;797. doi: 10.1016/S0016-5085(99)70336-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0016-5085(99)70336-7</ArticleId><ArticleId IdType="pubmed">10500060</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatta L, Scarpignato C. Mo2055 Rifaximin for treatment of small intestine bacterial overgrowth (SIBO): a systematic review and meta-analysis. Gastroenterology. 2013;144(5 Suppl 1):S729. doi: 10.1016/S0016-5085(13)62707-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0016-5085(13)62707-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah SC, Day LW, Somsouk M, Sewell JL. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2013;38:925&#x2013;934. doi: 10.1111/apt.12479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.12479</ArticleId><ArticleId IdType="pmc">PMC3819138</ArticleId><ArticleId IdType="pubmed">24004101</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee BJ, Bak YT. Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil. 2011;17:252&#x2013;266. doi: 10.5056/jnm.2011.17.3.252.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm.2011.17.3.252</ArticleId><ArticleId IdType="pmc">PMC3155061</ArticleId><ArticleId IdType="pubmed">21860817</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy BE, Weiser K, De Lee R. The treatment of irritable bowel syndrome. Therap Adv Gastroenterol. 2009;2:221&#x2013;238. doi: 10.1177/1756283X09104794.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756283X09104794</ArticleId><ArticleId IdType="pmc">PMC3002524</ArticleId><ArticleId IdType="pubmed">21180545</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541&#x2013;551. doi: 10.1053/j.gastro.2004.11.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2004.11.050</ArticleId><ArticleId IdType="pubmed">15765388</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen AY, Jonkers D, Clemens CH, Masclee A. Effect of probiotic treatment on visceral hypersensitivity in irritable bowel syndrome. Gastroenterology. 2011;140(5 Suppl 1):S852.</Citation></Reference><Reference><Citation>Lyszkowska M, Popinska K, Idzik M, Ksiazyk P. Probiotics in children with gut failure. J Pediatr Gastroenterol Nutr. 2008;46:543.</Citation></Reference><Reference><Citation>Rosania R, Giorgio F, Principi M, et al. Effect of probiotic or prebiotic supplementation on antibiotic therapy in the small intestinal bacterial overgrowth: a comparative evaluation. Curr Clin Pharmacol. 2013;8:169&#x2013;172. doi: 10.2174/15748847113089990048.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/15748847113089990048</ArticleId><ArticleId IdType="pubmed">23244247</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2003;17:895&#x2013;904. doi: 10.1046/j.1365-2036.2003.01543.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.2003.01543.x</ArticleId><ArticleId IdType="pubmed">12656692</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 2005;17:687&#x2013;696. doi: 10.1111/j.1365-2982.2005.00695.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2005.00695.x</ArticleId><ArticleId IdType="pubmed">16185307</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M, Soffer EE, Chow EJ, Kong Y, Lin HC. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci. 2002;47:2639&#x2013;2643. doi: 10.1023/A:1021039032413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1021039032413</ArticleId><ArticleId IdType="pubmed">12498278</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M, Morales W, Lezcano S, Sun-Chuan D, Low K, Yang J. Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. Gastroenterol Hepatol (N Y) 2009;5:435&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886395</ArticleId><ArticleId IdType="pubmed">20574504</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepherd SJ, Halmos E, Glance S. The role of FODMAPs in irritable bowel syndrome. Curr Opin Clin Nutr Metab Care. 2014;17:605&#x2013;609. doi: 10.1097/MCO.0000000000000116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCO.0000000000000116</ArticleId><ArticleId IdType="pubmed">25255126</ArticleId></ArticleIdList></Reference><Reference><Citation>Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146:67&#x2013;75.e5. doi: 10.1053/j.gastro.2013.09.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2013.09.046</ArticleId><ArticleId IdType="pubmed">24076059</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett JS, Gibson PR. Fermentable oligosaccharides, disaccha-rides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals? Therap Adv Gastroenterol. 2012;5:261&#x2013;268. doi: 10.1177/1756283X11436241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756283X11436241</ArticleId><ArticleId IdType="pmc">PMC3388522</ArticleId><ArticleId IdType="pubmed">22778791</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes PA, Fraher MH, Quigley EM. Irritable bowel syndrome: the role of food in pathogenesis and management. Gastroenterol Hepatol (N Y) 2014;10:164&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4014048</ArticleId><ArticleId IdType="pubmed">24829543</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong DK, Mitchell SB, Barrett JS, et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol. 2010;25:1366&#x2013;1373. doi: 10.1111/j.1440-1746.2010.06370.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1746.2010.06370.x</ArticleId><ArticleId IdType="pubmed">20659225</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metage-nomic analysis in humanized gnotobiotic mice. Sci Transl Med. 2009;1:6ra14. doi: 10.1126/scitranslmed.3000322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3000322</ArticleId><ArticleId IdType="pmc">PMC2894525</ArticleId><ArticleId IdType="pubmed">20368178</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown K, DeCoffe D, Molcan E, Gibson DL. Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. Nutrients. 2012;4:1095&#x2013;1119. doi: 10.3390/nu4081095.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu4081095</ArticleId><ArticleId IdType="pmc">PMC3448089</ArticleId><ArticleId IdType="pubmed">23016134</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmer J, Lange B, Frick JS, et al. A vegan or vegetarian diet substantially alters the human colonic faecal microbiota. Eur J Clin Nutr. 2012;66:53&#x2013;60. doi: 10.1038/ejcn.2011.141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejcn.2011.141</ArticleId><ArticleId IdType="pubmed">21811294</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal UC, Singh R. Frequency and risk factors of functional gastro-intestinal disorders in a rural Indian population. J Gastroenterol Hepatol.  Epub 2016 Jun 5.  https://doi.org/10.1111/jgh.13465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.13465</ArticleId><ArticleId IdType="pubmed">27262283</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman DA. Guidelines for use of the multi-dimensional clinical profile. In: Drossman DA, Azpiroz F, Chang L, et al., editors. Multi-dimensional clinical profile (MDCP): for functional gastrointestinal disorders. Raleigh: Rome Foundation; 2015. pp. 7&#x2013;14.</Citation></Reference><Reference><Citation>Lindberg DA. Hydrogen breath testing in adults: what is it and why is it performed? Gastroenterol Nurs. 2009;32:19&#x2013;24. doi: 10.1097/SGA.0b013e3181965d2d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SGA.0b013e3181965d2d</ArticleId><ArticleId IdType="pubmed">19197185</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2010;8:504&#x2013;508. doi: 10.1016/j.cgh.2009.12.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2009.12.022</ArticleId><ArticleId IdType="pubmed">20060064</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34578939</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6643</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Aug</Month><Day>31</Day></PubDate></JournalIssue><Title>Nutrients</Title><ISOAbbreviation>Nutrients</ISOAbbreviation></Journal><ArticleTitle>Irritable Bowel Syndrome, Depression, and Neurodegeneration: A Bidirectional Communication from Gut to Brain.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3061</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nu13093061</ELocationID><Abstract><AbstractText>Patients with irritable bowel syndrome (IBS) are increasingly presenting with a wide range of neuropsychiatric symptoms, such as deterioration in gastroenteric physiology, including visceral hypersensitivity, altered intestinal membrane permeability, and gastrointestinal motor dysfunction. Functional imaging of IBS patients has revealed several abnormalities in various brain regions, such as significant activation of amygdala, thinning of insular and anterior cingulate cortex, and increase in hypothalamic gray matter, which results in poor psychiatric and cognitive outcomes. Interrelations between the enteric and central events in IBS-related gastrointestinal, neurological, and psychiatric pathologies have compelled researchers to study the gut-brain axis-a bidirectional communication that maintains the homeostasis of the gastrointestinal and central nervous system with gut microbiota as the protagonist. Thus, it can be disrupted by any alteration owing to the gut dysbiosis or loss of diversity in microbial composition. Available evidence indicates that the use of probiotics as a part of a balanced diet is effective in the management of IBS and IBS-associated neurodegenerative and psychiatric comorbidities. In this review, we delineate the pathogenesis and complications of IBS from gastrointestinal and neuropsychiatric standpoints while also discussing the neurodegenerative events in enteric and central nervous systems of IBS patients and the therapeutic potential of gut microbiota-based therapy established on clinical and preclinical data.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aziz</LastName><ForeName>Muhammad Nazirul Mubin</ForeName><Initials>MNM</Initials><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Jaya</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gut Research Group, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muhammad Nawawi</LastName><ForeName>Khairul Najmi</ForeName><Initials>KN</Initials><Identifier Source="ORCID">0000-0002-5309-5301</Identifier><AffiliationInfo><Affiliation>Gut Research Group, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raja Ali</LastName><ForeName>Raja Affendi</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Gut Research Group, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mokhtar</LastName><ForeName>Norfilza M</ForeName><Initials>NM</Initials><Identifier Source="ORCID">0000-0002-4863-100X</Identifier><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gut Research Group, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>FF-2019-064/1</GrantID><Agency>Faculty of Medicine, Universiti Kebangsaan Malaysia</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nutrients</MedlineTA><NlmUniqueID>101521595</NlmUniqueID><ISSNLinking>2072-6643</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003142" MajorTopicYN="N">Communication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064806" MajorTopicYN="N">Dysbiosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">gut dysbiosis</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">microbiota-gut-immune-glia axis</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34578939</ArticleId><ArticleId IdType="pmc">PMC8468817</ArticleId><ArticleId IdType="doi">10.3390/nu13093061</ArticleId><ArticleId IdType="pii">nu13093061</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Black C.J., Ford A.C. Global burden of irritable bowel syndrome: Trends, predictions and risk factors. Nat. Rev. Gastroenterol. Hepatol. 2020;17:473&#x2013;486. doi: 10.1038/s41575-020-0286-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-020-0286-8</ArticleId><ArticleId IdType="pubmed">32296140</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvernale C., Kuo B., Staller K. Racial disparity in healthcare utilization among patients with Irritable Bowel Syndrome: Results from a multicenter cohort. Neurogastroenterol. Motil. 2020;33:e14039. doi: 10.1111/nmo.14039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.14039</ArticleId><ArticleId IdType="pubmed">33263195</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell R.M., Ford A.C. Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis. Clin. Gastroenterol. Hepatol. 2012;10:712&#x2013;721. doi: 10.1016/j.cgh.2012.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2012.02.029</ArticleId><ArticleId IdType="pubmed">22426087</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka P., Parr H., Barberio B., Black C.J., Savarino E.V., Ford A.C. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2020;5:908&#x2013;917. doi: 10.1016/S2468-1253(20)30217-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30217-X</ArticleId><ArticleId IdType="pubmed">32702295</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y.-M., Goh K.L., Muhidayah R., Ooi C.L., Salem O. Prevalence of irritable bowel syndrome in young adult Malaysians: A survey among medical students. J. Gastroenterol. Hepatol. 2003;18:1412&#x2013;1416. doi: 10.1046/j.1440-1746.2003.03212.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1440-1746.2003.03212.x</ArticleId><ArticleId IdType="pubmed">14675271</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y.Y., Waid A., Tan H.J., Chua A.S.B., Whitehead W.E. Rome III survey of irritable bowel syndrome among ethnic Malays. World J. Gastroenterol. 2012;18:6475&#x2013;6480. doi: 10.3748/wjg.v18.i44.6475.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v18.i44.6475</ArticleId><ArticleId IdType="pmc">PMC3508643</ArticleId><ArticleId IdType="pubmed">23197894</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajendra S., Alahuddin S. Prevalence of irritable bowel syndrome in a multi-ethnic Asian population. Aliment. Pharmacol. Ther. 2004;19:704&#x2013;706. doi: 10.1111/j.1365-2036.2004.01891.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2004.01891.x</ArticleId><ArticleId IdType="pubmed">15023175</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x15b;wi&#x119;cimska J., Szymlak A., Roczniak W., Girczys-Po&#x142;edniok K., Kwiecie&#x144; J. New insights into the pathogenesis and treatment of irritable bowel syndrome. Adv. Med. Sci. 2017;62:17&#x2013;30. doi: 10.1016/j.advms.2016.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.advms.2016.11.001</ArticleId><ArticleId IdType="pubmed">28135659</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjivasilis A., Tsioutis C., Michalinos A., Ntourakis D., Christodoulou D.K., Agouridis A.P. New insights into irritable bowel syndrome: From pathophysiology to treatment. Ann. Gastroenterol. 2019;32:554&#x2013;564. doi: 10.20524/aog.2019.0428.</Citation><ArticleIdList><ArticleId IdType="doi">10.20524/aog.2019.0428</ArticleId><ArticleId IdType="pmc">PMC6826071</ArticleId><ArticleId IdType="pubmed">31700231</ArticleId></ArticleIdList></Reference><Reference><Citation>Defrees D.N., Bailey J. Irritable bowel syndrome. Prim. Care: Clin. Off. Pr. 2017;44:655&#x2013;671. doi: 10.1016/j.pop.2017.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pop.2017.07.009</ArticleId><ArticleId IdType="pubmed">29132527</ArticleId></ArticleIdList></Reference><Reference><Citation>Grad S., Dumitrascu D.L. Irritable bowel syndrome subtypes: New names for old medical conditions. Dig. Dis. 2019;38:122&#x2013;127. doi: 10.1159/000505287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000505287</ArticleId><ArticleId IdType="pubmed">31851972</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtmann G., Ford A., Talley N.J. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol. Hepatol. 2016;1:133&#x2013;146. doi: 10.1016/S2468-1253(16)30023-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(16)30023-1</ArticleId><ArticleId IdType="pubmed">28404070</ArticleId></ArticleIdList></Reference><Reference><Citation>Farzaei M.H., Bahramsoltani R., Abdollahi M., Rahimi R. The Role of visceral hypersensitivity in irritable bowel syndrome: Pharmacological targets and novel treatments. J. Neurogastroenterol. Motil. 2016;22:558&#x2013;574. doi: 10.5056/jnm16001.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm16001</ArticleId><ArticleId IdType="pmc">PMC5056566</ArticleId><ArticleId IdType="pubmed">27431236</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lezCastro A.M., Mart&#xed;nez C., SalvoRomero E., Fortea M., PardoCamacho C., Perez M.V., AlonsoCotoner C., Santos J., Vicario M. Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome. J. Gastroenterol. Hepatol. 2017;32:53&#x2013;63. doi: 10.1111/jgh.13417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.13417</ArticleId><ArticleId IdType="pubmed">27087165</ArticleId></ArticleIdList></Reference><Reference><Citation>Camilleri M., Madsen K., Spiller R., Meerveld B.G.-V., Verne G.N. Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol. Motil. 2012;24:503&#x2013;512. doi: 10.1111/j.1365-2982.2012.01921.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2012.01921.x</ArticleId><ArticleId IdType="pmc">PMC5595063</ArticleId><ArticleId IdType="pubmed">22583600</ArticleId></ArticleIdList></Reference><Reference><Citation>Canavan C., West J., Card T. Review article: The economic impact of the irritable bowel syndrome. Aliment. Pharmacol. Ther. 2014;40:1023&#x2013;1034. doi: 10.1111/apt.12938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.12938</ArticleId><ArticleId IdType="pubmed">25199904</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F., Xiang W., Li C.-Y., Li S.-C. Economic burden of irritable bowel syndrome in China. World J. Gastroenterol. 2016;22:10450&#x2013;10460. doi: 10.3748/wjg.v22.i47.10450.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i47.10450</ArticleId><ArticleId IdType="pmc">PMC5175258</ArticleId><ArticleId IdType="pubmed">28058026</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman D.A., Chang L., Schneck S., Blackman C., Norton W.F., Norton N.J. A Focus Group Assessment of Patient Perspectives on Irritable Bowel Syndrome and Illness Severity. Dig. Dis. Sci. 2009;54:1532&#x2013;1541. doi: 10.1007/s10620-009-0792-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-009-0792-6</ArticleId><ArticleId IdType="pubmed">19337833</ArticleId></ArticleIdList></Reference><Reference><Citation>Thursby E., Juge N. Introduction to the human gut microbiota. Biochem. J. 2017;474:1823&#x2013;1836. doi: 10.1042/BCJ20160510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20160510</ArticleId><ArticleId IdType="pmc">PMC5433529</ArticleId><ArticleId IdType="pubmed">28512250</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P.P., Chin V.K., Looi C.Y., Wong W.F., Madhavan P., Yong V.C. The microbiome and irritable bowel syndrome&#x2014;A review on the pathophysiology, current research and future therapy. Front. Microbiol. 2019;10:1136. doi: 10.3389/fmicb.2019.01136.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2019.01136</ArticleId><ArticleId IdType="pmc">PMC6579922</ArticleId><ArticleId IdType="pubmed">31244784</ArticleId></ArticleIdList></Reference><Reference><Citation>Zmora N., Suez J., Elinav E. You are what you eat: Diet, health and the gut microbiota. Nat. Rev. Gastroenterol. Hepatol. 2018;16:35&#x2013;56. doi: 10.1038/s41575-018-0061-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-018-0061-2</ArticleId><ArticleId IdType="pubmed">30262901</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinninella E., Raoul P., Cintoni M., Franceschi F., Miggiano G.A.D., Gasbarrini A., Mele M.C., Rinninella E., Raoul P., Cintoni M., et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019;7:14. doi: 10.3390/microorganisms7010014.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms7010014</ArticleId><ArticleId IdType="pmc">PMC6351938</ArticleId><ArticleId IdType="pubmed">30634578</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Y., Zhou G., Qin X., Huang S., Wang B., Cao H. The potential role of gut mycobiome in irritable bowel syndrome. Front. Microbiol. 2019;10:1894. doi: 10.3389/fmicb.2019.01894.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2019.01894</ArticleId><ArticleId IdType="pmc">PMC6712173</ArticleId><ArticleId IdType="pubmed">31497000</ArticleId></ArticleIdList></Reference><Reference><Citation>Herndon C.C., Wang Y., Lu C. Targeting the gut microbiota for the treatment of irritable bowel syndrome. Kaohsiung J. Med. Sci. 2019;36:160&#x2013;170. doi: 10.1002/kjm2.12154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/kjm2.12154</ArticleId><ArticleId IdType="pmc">PMC11896346</ArticleId><ArticleId IdType="pubmed">31782606</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews C.N., Sidani S., Marshall J.K. Clinical management of the microbiome in irritable bowel syndrome. J. Can. Assoc. Gastroenterol. 2020;4:36&#x2013;43. doi: 10.1093/jcag/gwz037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jcag/gwz037</ArticleId><ArticleId IdType="pmc">PMC7898379</ArticleId><ArticleId IdType="pubmed">33644675</ArticleId></ArticleIdList></Reference><Reference><Citation>Carco C., Young W., Gearry R.B., Talley N.J., McNabb W.C., Roy N.C. Increasing evidence that irritable bowel syndrome and functional gastrointestinal disorders have a microbial pathogenesis. Front. Cell. Infect. Microbiol. 2020;10 doi: 10.3389/fcimb.2020.00468.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.00468</ArticleId><ArticleId IdType="pmc">PMC7509092</ArticleId><ArticleId IdType="pubmed">33014892</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Siles M., Duncan S., Garcia-Gil L.J., Martinez-Medina M. Faecalibacterium prausnitzii: From microbiology to diagnostics and prognostics. ISME J. 2017;11:841&#x2013;852. doi: 10.1038/ismej.2016.176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ismej.2016.176</ArticleId><ArticleId IdType="pmc">PMC5364359</ArticleId><ArticleId IdType="pubmed">28045459</ArticleId></ArticleIdList></Reference><Reference><Citation>Shariati A., Fallah F., Pormohammad A., Taghipour A., Safari H., Chirani A.S., Sabour S., AlizadehSani M., Azimi T. The possible role of bacteria, viruses, and parasites in initiation and exacerbation of irritable bowel syndrome. J. Cell. Physiol. 2018;234:8550&#x2013;8569. doi: 10.1002/jcp.27828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.27828</ArticleId><ArticleId IdType="pubmed">30480810</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayananda P., Wilcox M.H. Irritable bowel syndrome following Clostridium difficile infection. Curr. Opin. Gastroenterol. 2019;35:1&#x2013;5. doi: 10.1097/MOG.0000000000000490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOG.0000000000000490</ArticleId><ArticleId IdType="pubmed">30335629</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y.-A., Cho Y.J., Kwak S.G. The association between Helicobacter pylori infection and irritable bowel syndrome: A meta-analysis. Int. J. Environ. Res. Public Health. 2020;17:2524. doi: 10.3390/ijerph17072524.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph17072524</ArticleId><ArticleId IdType="pmc">PMC7177688</ArticleId><ArticleId IdType="pubmed">32272678</ArticleId></ArticleIdList></Reference><Reference><Citation>Dogan B., Belcher-Timme H.F., I Dogan E., Jiang Z.-D., Dupont H.L., Synder N., Yang S., Chandler B., Scherl E.J., Simpson K.W. Evaluation of Escherichia coli pathotypes associated with Irritable Bowel Syndrome. FEMS Microbiol. Lett. 2018;365 doi: 10.1093/femsle/fny249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/femsle/fny249</ArticleId><ArticleId IdType="pubmed">30299475</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly J.R., Borre Y., O&#x2019;Brien C., Patterson E., El Aidy S., Deane J., Dinan T.G., Kennedy P.J., Beers S., Scott K., et al. Transferring the blues: Depres-sion-associated gut microbiota induces neurobehavioural changes in the rat. J. Psychiatr. Res. 2016;82:109&#x2013;118. doi: 10.1016/j.jpsychires.2016.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2016.07.019</ArticleId><ArticleId IdType="pubmed">27491067</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu S., Li A., Huang T., Lai J., Li J., Sublette M.E., Lu H., Lu Q., Du Y., Hu Z., et al. Gut microbiota changes in patients with bipolar depression. Adv. Sci. 2019;6:1900752. doi: 10.1002/advs.201900752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.201900752</ArticleId><ArticleId IdType="pmc">PMC6662053</ArticleId><ArticleId IdType="pubmed">31380217</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H., Ling Z., Zhang Y., Mao H., Ma Z., Yin Y., Wang W., Tang W., Tan Z., Shi J., et al. Altered fecal mi-crobiota composition in patients with major depressive disorder. Brain Behav. Immun. 2015;48:186&#x2013;194. doi: 10.1016/j.bbi.2015.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2015.03.016</ArticleId><ArticleId IdType="pubmed">25882912</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . Depression and Other Common Mental Disorders: Global Health Estimates. World Health Organization; Geneva, Switzerland: 2017.</Citation></Reference><Reference><Citation>Gardner A., Boles R.G. Beyond the serotonin hypothesis: Mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2011;35:730&#x2013;743. doi: 10.1016/j.pnpbp.2010.07.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2010.07.030</ArticleId><ArticleId IdType="pubmed">20691744</ArticleId></ArticleIdList></Reference><Reference><Citation>Mokhtar N.M., Bahrudin M.F., Ghani N.A., Rani R.A., Ali R.A.R. Prevalence of subthreshold depression among constipation-predominant irritable bowel syndrome patients. Front. Psychol. 2020;11:1936. doi: 10.3389/fpsyg.2020.01936.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2020.01936</ArticleId><ArticleId IdType="pmc">PMC7423989</ArticleId><ArticleId IdType="pubmed">32849137</ArticleId></ArticleIdList></Reference><Reference><Citation>Fond G., Loundou A., Hamdani N., Boukouaci W., Dargel A., Oliveira J., Roger M., Tamouza R., Leboyer M., Boyer L. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): A systematic review and meta-analysis. Eur. Arch. Psychiatry Clin. Neurosci. 2014;264:651&#x2013;660. doi: 10.1007/s00406-014-0502-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00406-014-0502-z</ArticleId><ArticleId IdType="pubmed">24705634</ArticleId></ArticleIdList></Reference><Reference><Citation>Roohafza H., Bidaki E.Z., Hasanzadeh-Keshteli A., Daghaghzade H., Afshar H., Adibi P. Anxiety, depression and distress among irritable bowel syndrome and their subtypes: An epidemiological population based study. Adv. Biomed. Res. 2016;5:183. doi: 10.4103/2277-9175.190938.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2277-9175.190938</ArticleId><ArticleId IdType="pmc">PMC5156966</ArticleId><ArticleId IdType="pubmed">28028523</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C., Doo E., Choi J.M., Jang S.H., Ryu H.S., Lee J.Y., Oh J.H., Park J.H., Kim Y.S., Brain-Gut Axis Research Group of Korean Society of N., et al. The increased level of depression and anxiety in irritable bowel syndrome patients compared with healthy controls: Systematic review and meta-analysis. J. Neurogastroenterol. Motil. 2017;23:349&#x2013;362. doi: 10.5056/jnm16220.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm16220</ArticleId><ArticleId IdType="pmc">PMC5503284</ArticleId><ArticleId IdType="pubmed">28672433</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamani M., Alizadeh-Tabari S., Zamani V. Systematic review with meta-analysis: The prevalence of anxiety and depression in patients with irritable bowel syndrome. Aliment. Pharmacol. Ther. 2019;50:132&#x2013;143. doi: 10.1111/apt.15325.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15325</ArticleId><ArticleId IdType="pubmed">31157418</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng Q., Zhang Q.-E., Wang F., Zheng W., Ng C.H., Ungvari G.S., Wang G., Xiang Y.-T. Comparison of comorbid depression between irritable bowel syndrome and inflammatory bowel disease: A meta-analysis of comparative studies. J. Affect. Disord. 2018;237:37&#x2013;46. doi: 10.1016/j.jad.2018.04.111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2018.04.111</ArticleId><ArticleId IdType="pubmed">29758449</ArticleId></ArticleIdList></Reference><Reference><Citation>Midenfjord I., Polster A., Sj&#xf6;vall H., T&#xf6;rnblom H., Simr&#xe9;n M. Anxiety and depression in irritable bowel syndrome: Exploring the interaction with other symptoms and pathophysiology using multivariate analyses. Neurogastroenterol. Motil. 2019;31:1&#x2013;14. doi: 10.1111/nmo.13619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13619</ArticleId><ArticleId IdType="pubmed">31056802</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibelli A., Chalder T., Everitt H., Workman P., Windgassen S., Moss-Morris R. A systematic review with meta-analysis of the role of anxiety and depression in irritable bowel syndrome onset. Psychol. Med. 2016;46:3065&#x2013;3080. doi: 10.1017/S0033291716001987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291716001987</ArticleId><ArticleId IdType="pubmed">27605134</ArticleId></ArticleIdList></Reference><Reference><Citation>Takajo T., Tomita K., Tsuchihashi H., Enomoto S., Tanichi M., Toda H., Okada Y., Furuhashi H., Sugihara N., Wada A., et al. Depression promotes the onset of irritable bowel syndrome through unique dysbiosis in rats. Gut Liver. 2019;13:325&#x2013;332. doi: 10.5009/gnl18296.</Citation><ArticleIdList><ArticleId IdType="doi">10.5009/gnl18296</ArticleId><ArticleId IdType="pmc">PMC6529174</ArticleId><ArticleId IdType="pubmed">30602220</ArticleId></ArticleIdList></Reference><Reference><Citation>Attree E.A., Dancey C.P., Keeling D., Wilson C. Cognitive function in people with chronic illness: Inflammatory bowel disease and irritable bowel syndrome. Appl. Neuropsychol. 2003;10:96&#x2013;104. doi: 10.1207/S15324826AN1002_05.</Citation><ArticleIdList><ArticleId IdType="doi">10.1207/S15324826AN1002_05</ArticleId><ArticleId IdType="pubmed">12788684</ArticleId></ArticleIdList></Reference><Reference><Citation>Farup P.G., Hestad K. Cognitive functions and depression in patients with irritable bowel syndrome. Gastroenterol. Res. Pr. 2015;2015:1&#x2013;9. doi: 10.1155/2015/438329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/438329</ArticleId><ArticleId IdType="pmc">PMC4454748</ArticleId><ArticleId IdType="pubmed">26089869</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam N.C.-Y., Yeung H.-Y., Li W.-K., Lo H.-Y., Yuen C.-F., Chang R.C.-C., Ho Y.-S. Cognitive impairment in irritable bowel syndrome (IBS): A systematic review. Brain Res. 2019;1719:274&#x2013;284. doi: 10.1016/j.brainres.2019.05.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2019.05.036</ArticleId><ArticleId IdType="pubmed">31150650</ArticleId></ArticleIdList></Reference><Reference><Citation>Blankstein U., Chen J., Diamant N.E., Davis K.D. Altered brain structure in irritable bowel syndrome: Potential contributions of pre-existing and disease-driven factors. Gastroenterology. 2010;138:1783&#x2013;1789. doi: 10.1053/j.gastro.2009.12.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2009.12.043</ArticleId><ArticleId IdType="pubmed">20045701</ArticleId></ArticleIdList></Reference><Reference><Citation>Nan J., Yang W., Meng P., Huang W., Zheng Q., Xia Y., Liu F. Changes of the postcentral cortex in irritable bowel syndrome patients. Brain Imaging Behav. 2019;14:1566&#x2013;1576. doi: 10.1007/s11682-019-00087-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11682-019-00087-7</ArticleId><ArticleId IdType="pubmed">30927201</ArticleId></ArticleIdList></Reference><Reference><Citation>Seminowicz D.A., Labus J.S., Bueller J.A., Tillisch K., Naliboff B.D., Bushnell M.C., Mayer E.A. Regional gray matter density changes in brains of patients with irritable bowel syndrome. Gastroenterology. 2010;139:48&#x2013;57.e2. doi: 10.1053/j.gastro.2010.03.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2010.03.049</ArticleId><ArticleId IdType="pmc">PMC2902717</ArticleId><ArticleId IdType="pubmed">20347816</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X., Li S., Tian J., Jiang G., Wen H., Wang T., Fang J., Zhan W., Xu Y. Altered brain spontaneous activity and connectivity network in irritable bowel syndrome patients: A resting-state fMRI study. Clin. Neurophysiol. 2015;126:1190&#x2013;1197. doi: 10.1016/j.clinph.2014.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2014.10.004</ArticleId><ArticleId IdType="pubmed">25454279</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi R., Liu C., Ke J., Xu Q., Ye Y., Jia L., Wang F., Zhang L., Lu G. Abnormal amygdala resting-state functional connectivity in irritable bowel syndrome. Am. J. Neuroradiol. 2016;37:1139&#x2013;1145. doi: 10.3174/ajnr.A4655.</Citation><ArticleIdList><ArticleId IdType="doi">10.3174/ajnr.A4655</ArticleId><ArticleId IdType="pmc">PMC7963559</ArticleId><ArticleId IdType="pubmed">26767708</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong J.-Y., Naliboff B., Labus J.S., Gupta A., Kilpatrick L.A., Ashe-McNalley C., Stains J., Heendeniya N., Smith S.R., Tillisch K., et al. Altered brain responses in subjects with irritable bowel syndrome during cued and uncued pain expectation. Neurogastroenterol. Motil. 2015;28:127&#x2013;138. doi: 10.1111/nmo.12710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12710</ArticleId><ArticleId IdType="pmc">PMC4943658</ArticleId><ArticleId IdType="pubmed">26526698</ArticleId></ArticleIdList></Reference><Reference><Citation>Tillisch K., Mayer E.A., Labus J.S. Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome. Gastroenterology. 2011;140:91&#x2013;100. doi: 10.1053/j.gastro.2010.07.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2010.07.053</ArticleId><ArticleId IdType="pmc">PMC3253553</ArticleId><ArticleId IdType="pubmed">20696168</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellingson B.M., Mayer E., Harris R.J., Ashe-McNally C., Naliboff B.D., Labus J.S., Tillisch K. Diffusion tensor imaging detects microstructural reorganization in the brain associated with chronic irritable bowel syndrome. Pain. 2013;154:1528&#x2013;1541. doi: 10.1016/j.pain.2013.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pain.2013.04.010</ArticleId><ArticleId IdType="pmc">PMC3758125</ArticleId><ArticleId IdType="pubmed">23721972</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubbard C.S., Becerra L., Heinz N., Ludwick A., Rasooly T., Yendiki A., Wu R., Schechter N.L., Nurko S., Borsook D. Microstructural white matter abnormalities in the dorsal cingulum of adolescents with IBS. eNeuro. 2018;5:1&#x2013;11. doi: 10.1523/ENEURO.0354-17.2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/ENEURO.0354-17.2018</ArticleId><ArticleId IdType="pmc">PMC6090517</ArticleId><ArticleId IdType="pubmed">30109260</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempton M.J., Salvador Z., Munafo M., Geddes J.R., Simmons A., Frangou S., Williams S. Structural neuroimaging studies in major depressive disorder. Arch. Gen. Psychiatry. 2011;68:675&#x2013;690. doi: 10.1001/archgenpsychiatry.2011.60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archgenpsychiatry.2011.60</ArticleId><ArticleId IdType="pubmed">21727252</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai C.-H. Gray matter volume in major depressive disorder: A meta-analysis of voxel-based morphometry studies. Psychiatry Res. Neuroimaging. 2013;211:37&#x2013;46. doi: 10.1016/j.pscychresns.2012.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pscychresns.2012.06.006</ArticleId><ArticleId IdType="pubmed">23146253</ArticleId></ArticleIdList></Reference><Reference><Citation>Lener M.S., Iosifescu D.V. In pursuit of neuroimaging biomarkers to guide treatment selection in major depressive disorder: A review of the literature. Ann. N. Y. Acad. Sci. 2015;1344:50&#x2013;65. doi: 10.1111/nyas.12759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nyas.12759</ArticleId><ArticleId IdType="pubmed">25854817</ArticleId></ArticleIdList></Reference><Reference><Citation>Bremner J.D., Narayan M., Anderson E.R., Staib L., Miller H.L., Charney D.S. Hippocampal volume reduction in major depression. Am. J. Psychiatry. 2000;157:115&#x2013;118. doi: 10.1176/ajp.157.1.115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/ajp.157.1.115</ArticleId><ArticleId IdType="pubmed">10618023</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinnon M.C., Yucel K., Nazarov A., MacQueen G.M. A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J. Psychiatry Neurosci. 2009;34:41&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2612082</ArticleId><ArticleId IdType="pubmed">19125212</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmaal L., for the ENIGMA-Major Depressive Disorder Working Group. Hibar D., S&#xe4;mann P., Hall G., Baune B., Jahanshad N., Cheung J., Van Erp T., Bos D., et al. Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA major depressive disorder working group. Mol. Psychiatry. 2016;22:900&#x2013;909. doi: 10.1038/mp.2016.60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2016.60</ArticleId><ArticleId IdType="pmc">PMC5444023</ArticleId><ArticleId IdType="pubmed">27137745</ArticleId></ArticleIdList></Reference><Reference><Citation>De Giorgio R., Volta U., Stanghellini V., Cogliandro R.F., Barbara G., Corinaldesi R., Towns R., Guo C., Hong S., Wiley J.W. Neurogenic chronic intestinal pseudo-obstruction: Antineuronal antibody-mediated activation of autophagy via fas. Gastroenterology. 2008;135:601&#x2013;609. doi: 10.1053/j.gastro.2008.05.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2008.05.034</ArticleId><ArticleId IdType="pmc">PMC2662388</ArticleId><ArticleId IdType="pubmed">18582468</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostertag D., Buhner S., Michel K., Pehl C., Kurjak M., Gotzberger M., Schulte-Frohlinde E., Frieling T., Enck P., Phillip J., et al. Reduced responses of submucous neurons from irritable bowel syndrome patients to a cocktail containing histamine, serotonin, TNFalpha, and Tryptase (IBS-Cocktail) Front. Neurosci. 2015;9:465. doi: 10.3389/fnins.2015.00465.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2015.00465</ArticleId><ArticleId IdType="pmc">PMC4679876</ArticleId><ArticleId IdType="pubmed">26733780</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S., Fei G., Fang X., Yang X., Sun X., Qian J., Wood J.D., Ke M. Changes in enteric neurons of small intestine in a rat model of irritable bowel syndrome with diarrhea. J. Neurogastroenterol. Motil. 2016;22:310&#x2013;320. doi: 10.5056/jnm15082.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm15082</ArticleId><ArticleId IdType="pmc">PMC4819870</ArticleId><ArticleId IdType="pubmed">26645247</ArticleId></ArticleIdList></Reference><Reference><Citation>Palsson O.S., Morteau O., Bozymski E.M., Woosley J.T., Sartor R.B., Davies M.J., Johnson D.A., Turner M.J., Whitehead W.E. Elevated vasoactive intestinal peptide concentrations in patients with irritable bowel syndrome. Dig. Dis. Sci. 2004;49:1236&#x2013;1243. doi: 10.1023/B:DDAS.0000037818.64577.ef.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/B:DDAS.0000037818.64577.ef</ArticleId><ArticleId IdType="pubmed">15387352</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye L., Li G., Goebel A., Raju A.V., Kong F., Lv Y., Li K., Zhu Y., Raja S., He P., et al. Caspase-11&#x2013;mediated enteric neuronal pyroptosis underlies Western diet&#x2013;induced colonic dysmotility. J. Clin. Investig. 2020;130:3621&#x2013;3636. doi: 10.1172/JCI130176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI130176</ArticleId><ArticleId IdType="pmc">PMC7324173</ArticleId><ArticleId IdType="pubmed">32484462</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan W., Fei G., Li X., Wang X., Hu C., Xin H., Sun X., Li Y., Wood J.D., Fang X. Sera with anti-enteric neuronal antibodies from patients with irritable bowel syndrome promote apoptosis in myenteric neurons of guinea pigs and human SH-Sy5Y cells. Neurogastroenterol. Motil. 2018;30:e13457. doi: 10.1111/nmo.13457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13457</ArticleId><ArticleId IdType="pubmed">30230140</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittock S.J., Lennon V.A., Dege C.L., Talley N.J., Locke G.R. Neural autoantibody evaluation in functional gastrointestinal disorders: A population-based case&#x2013;control study. Dig. Dis. Sci. 2010;56:1452&#x2013;1459. doi: 10.1007/s10620-010-1514-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-010-1514-9</ArticleId><ArticleId IdType="pmc">PMC3089890</ArticleId><ArticleId IdType="pubmed">21181442</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai S.-W., Liao K.-F., Lin C.-L., Sung F.-C. Irritable bowel syndrome correlates with increased risk of Parkinson&#x2019;s disease in Taiwan. Eur. J. Epidemiol. 2014;29:57&#x2013;62. doi: 10.1007/s10654-014-9878-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-014-9878-3</ArticleId><ArticleId IdType="pubmed">24442494</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B., Sjolander A., Pedersen N.L., Ludvigsson J.F., Chen H., Fang F., Wirdefeldt K. Irritable bowel syndrome and Parkinson&#x2019;s disease risk: Register-based studies. NPJ Parkinsons Dis. 2021;7:1&#x2013;7. doi: 10.1038/s41531-020-00145-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-020-00145-8</ArticleId><ArticleId IdType="pmc">PMC7785733</ArticleId><ArticleId IdType="pubmed">33402695</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C.-H., Lin C.-L., Kao C.-H. Irritable bowel syndrome is associated with an increased risk of dementia: A nationwide population-based study. PLoS ONE. 2016;11:e0144589. doi: 10.1371/journal.pone.0144589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0144589</ArticleId><ArticleId IdType="pmc">PMC4701489</ArticleId><ArticleId IdType="pubmed">26731277</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng Y., Qi R., Liu C., Ke J., Xu Q., Wang F., Zhang L.J., Lu G.M. Disrupted functional connectivity density in irritable bowel syndrome patients. Brain Imaging Behav. 2016;11:1812&#x2013;1822. doi: 10.1007/s11682-016-9653-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11682-016-9653-z</ArticleId><ArticleId IdType="pubmed">27848148</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang J., Li S., Li M., Chan Q., Ma X., Su H., Wang T., Zhan W., Yan J., Xu M., et al. Altered white matter microstructure identified with tract-based spatial statistics in irritable bowel syndrome: A diffusion tensor imaging study. Brain Imaging Behav. 2016;11:1110&#x2013;1116. doi: 10.1007/s11682-016-9573-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11682-016-9573-y</ArticleId><ArticleId IdType="pubmed">27627891</ArticleId></ArticleIdList></Reference><Reference><Citation>Edlow B.L., Copen W.A., Izzy S., van der Kouwe A., Glenn M.B., Greenberg S.M., Greer D.M., Wu O. Longitudinal Diffusion Tensor Imaging Detects Recovery of Fractional Anisotropy Within Traumatic Axonal Injury Lesions. Neurocrit. Care. 2016;24:342&#x2013;352. doi: 10.1007/s12028-015-0216-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12028-015-0216-8</ArticleId><ArticleId IdType="pmc">PMC4884487</ArticleId><ArticleId IdType="pubmed">26690938</ArticleId></ArticleIdList></Reference><Reference><Citation>Moayedi M., Weissman-Fogel I., Salomons T.V., Crawley A.P., Goldberg M.B., Freeman B.V., Tenenbaum H.C., Davis K.D. White matter brain and trigeminal nerve abnormalities in temporomandibular disorder. Pain. 2012;153:1467&#x2013;1477. doi: 10.1016/j.pain.2012.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pain.2012.04.003</ArticleId><ArticleId IdType="pubmed">22647428</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarman J., Fernandez M., Davies P.T., Glover V., Steiner T.J., Thompson C., Rose F.C., Sandler M. High incidence of endogenous depression in migraine: Confirmation by tyramine test. J. Neurol. Neurosurg. Psychiatry. 1990;53:573&#x2013;575. doi: 10.1136/jnnp.53.7.573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.53.7.573</ArticleId><ArticleId IdType="pmc">PMC488132</ArticleId><ArticleId IdType="pubmed">2391520</ArticleId></ArticleIdList></Reference><Reference><Citation>Nan J., Zhang L., Chen Q., Zong N., Zhang P., Ji X., Ma S., Zhang Y., Huang W., Du Z., et al. White matter microstructural similarity and diversity of functional constipation and constipation-predominant irritable bowel syndrome. J. Neurogastroenterol. Motil. 2018;24:107&#x2013;118. doi: 10.5056/jnm17038.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm17038</ArticleId><ArticleId IdType="pmc">PMC5753909</ArticleId><ArticleId IdType="pubmed">29291612</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Qian S., Liu K., Li B., Li M., Xin K., Sun G. Reduced white matter integrity and its correlation with clinical symptom in first-episode, treatment-naive generalized anxiety disorder. Behav. Brain Res. 2016;314:159&#x2013;164. doi: 10.1016/j.bbr.2016.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2016.08.017</ArticleId><ArticleId IdType="pubmed">27515289</ArticleId></ArticleIdList></Reference><Reference><Citation>Won E., Choi S., Kang J., Kim A., Han K.M., Chang H.S., Tae W.S., Son K.R., Joe S.H., Lee M.S., et al. Association between reduced white matter integrity in the corpus callosum and serotonin transporter gene DNA methylation in medication-naive patients with major depressive disorder. Transl. Psychiatry. 2016;6:e866. doi: 10.1038/tp.2016.137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/tp.2016.137</ArticleId><ArticleId IdType="pmc">PMC5022083</ArticleId><ArticleId IdType="pubmed">27505229</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedetti F., Yeh P.H., Bellani M., Radaelli D., Nicoletti M.A., Poletti S., Falini A., Dallaspezia S., Colombo C., Scotti G., et al. Disruption of white matter integrity in bipolar depression as a possible structural marker of illness. Biol. Psychiatry. 2011;69:309&#x2013;317. doi: 10.1016/j.biopsych.2010.07.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2010.07.028</ArticleId><ArticleId IdType="pubmed">20926068</ArticleId></ArticleIdList></Reference><Reference><Citation>Elahi S., Bachman A.H., Lee S.H., Sidtis J.J., Ardekani B.A., Alzheimer&#x2019;s Disease Neuroimaging I. Corpus callosum atrophy rate in mild cognitive impairment and prodromal Alzheimer&#x2019;s disease. J. Alzheimers Dis. 2015;45:921&#x2013;931. doi: 10.3233/JAD-142631.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-142631</ArticleId><ArticleId IdType="pmc">PMC4451933</ArticleId><ArticleId IdType="pubmed">25633676</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Paola M., Phillips O., Orfei M.D., Piras F., Cacciari C., Caltagirone C., Spalletta G. Corpus callosum structure is topographically correlated with the early course of cognition and depression in Alzheimer&#x2019;s disease. J. Alzheimers Dis. 2015;45:1097&#x2013;1108. doi: 10.3233/JAD-142895.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-142895</ArticleId><ArticleId IdType="pubmed">25649657</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabri M., Pierpaoli C., Barbaresi P., Polonara G. Functional topography of the corpus callosum investigated by DTI and fMRI. World J. Radiol. 2014;6:895&#x2013;906. doi: 10.4329/wjr.v6.i12.895.</Citation><ArticleIdList><ArticleId IdType="doi">10.4329/wjr.v6.i12.895</ArticleId><ArticleId IdType="pmc">PMC4278150</ArticleId><ArticleId IdType="pubmed">25550994</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenlon L., Richards L.J. Contralateral targeting of the corpus callosum in normal and pathological brain function. Trends Neurosci. 2015;38:264&#x2013;272. doi: 10.1016/j.tins.2015.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2015.02.007</ArticleId><ArticleId IdType="pubmed">25841797</ArticleId></ArticleIdList></Reference><Reference><Citation>Gershon M.D. Plasticity in serotonin control mechanisms in the gut. Curr. Opin. Pharmacol. 2003;3:600&#x2013;607. doi: 10.1016/j.coph.2003.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2003.07.005</ArticleId><ArticleId IdType="pubmed">14644011</ArticleId></ArticleIdList></Reference><Reference><Citation>Creed F. How do SSRIs help patients with irritable bowel syndrome? Gut. 2006;55:1065&#x2013;1067. doi: 10.1136/gut.2005.086348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2005.086348</ArticleId><ArticleId IdType="pmc">PMC1856284</ArticleId><ArticleId IdType="pubmed">16849340</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreiter D., Drukker M., Mujagic Z., Vork L., Rutten B.P.F., van Os J., Masclee A.A.M., Kruimel J.W., Leue C. Symptom-network dynamics in irritable bowel syndrome with comorbid panic disorder using electronic momentary assessment: A randomized controlled trial of escitalopram vs. placebo. J. Psychosom Res. 2021;141:110351. doi: 10.1016/j.jpsychores.2020.110351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychores.2020.110351</ArticleId><ArticleId IdType="pubmed">33412422</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonard B.E. The immune system, depression and the action of antidepressants. Prof. Neuropsychopharmacol. Biol. Psychiatry. 2001;25:767&#x2013;780. doi: 10.1016/S0278-5846(01)00155-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0278-5846(01)00155-5</ArticleId><ArticleId IdType="pubmed">11383977</ArticleId></ArticleIdList></Reference><Reference><Citation>Galecki P., Mossakowska-Wojcik J., Talarowska M. The anti-inflammatory mechanism of antidepressants&#x2014;SSRIs, SNRIs. Prof. Neuropsychopharmacol. Biol. Psychiatry. 2018;80:291&#x2013;294. doi: 10.1016/j.pnpbp.2017.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2017.03.016</ArticleId><ArticleId IdType="pubmed">28342944</ArticleId></ArticleIdList></Reference><Reference><Citation>Sitges M., Gomez C.D., Aldana B.I. Sertraline reduce IL-1&#x3b2; and TNF-&#x3b1; mRNA expression and overcomes their rise induced by seizures in the rat hippocampus. PLoS ONE. 2014;9:e111665. doi: 10.1371/journal.pone.0111665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0111665</ArticleId><ArticleId IdType="pmc">PMC4218797</ArticleId><ArticleId IdType="pubmed">25364907</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafiee L., Hajhashemi V., Javanmard S.H. Fluvoxaminne inhibits some inflammatory gene expression in LPS/stimulated human endothelial cells, U937 macrophages, and carrageenan-induced paw edema in rat. Iran. J. Basic Med. Sci. 2016;19:977&#x2013;984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5080428</ArticleId><ArticleId IdType="pubmed">27803785</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubovicky M., Csaszar E., Melichercikova K., Rackova L. Modulation of microglial function by the antidepressant drug venlafaxine. Interdiscip. Toxicol. 2014;7:201&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4436209</ArticleId><ArticleId IdType="pubmed">26109901</ArticleId></ArticleIdList></Reference><Reference><Citation>Vara E.J., Brokstad K.A., Hausken T., Lied G.A. Altered levels of cytokines in patients with irritable bowel syndrome are not correlated with fatigue. Int. J. Gen. Med. 2018;11:285&#x2013;291. doi: 10.2147/IJGM.S166600.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S166600</ArticleId><ArticleId IdType="pmc">PMC6038856</ArticleId><ArticleId IdType="pubmed">30013383</ArticleId></ArticleIdList></Reference><Reference><Citation>Heefner J.D., Wilder R.M., Wilson I.D. Irritable colon and depression. Psychosomatics. 1978;19:540&#x2013;547. doi: 10.1016/S0033-3182(78)70930-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0033-3182(78)70930-8</ArticleId><ArticleId IdType="pubmed">360266</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Lacy B.E., Harris L.A., Quigley E.M.M., Moayyedi P. Effect of antidepressants and psychological therapies in irritable bowel syndrome: An updated systematic review and meta-analysis. Am. J. Gastroenterol. 2019;114:21&#x2013;39. doi: 10.1038/s41395-018-0222-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41395-018-0222-5</ArticleId><ArticleId IdType="pubmed">30177784</ArticleId></ArticleIdList></Reference><Reference><Citation>Brennan B.P., Fogarty K.V., Roberts J.L., Reynolds K.A., Pope H.G., Jr., Hudson J.I. Duloxetine in the treatment of irritable bowel syndrome: An open-label pilot study. Hum. Psychopharmacol. Clin. Exp. 2009;24:423&#x2013;428. doi: 10.1002/hup.1038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hup.1038</ArticleId><ArticleId IdType="pubmed">19548294</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan A., Franzen M.D., Nickell P.V., Ransom D., Lebovitz P.J. An open-label trial of duloxetine in patients with irritable bowel syndrome and comorbid generalized anxiety disorder. Int. J. Psychiatry Clin. Pr. 2014;18:11&#x2013;15. doi: 10.3109/13651501.2013.838632.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/13651501.2013.838632</ArticleId><ArticleId IdType="pubmed">23980534</ArticleId></ArticleIdList></Reference><Reference><Citation>Seddighnia A., Tadayon Najafabadi B., Ghamari K., Noorbala A.A., Ebrahimi Daryani N., Kashani L., Akhondzadeh S. Vortioxetine effects on quality of life of irritable bowel syndrome patients: A randomized, double-blind, placebo-controlled trial. J. Clin. Pharm. Ther. 2020;45:97&#x2013;104. doi: 10.1111/jcpt.13032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcpt.13032</ArticleId><ArticleId IdType="pubmed">31486103</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer E.A., Bradesi S. Alosetron and irritable bowel syndrome. Expert Opin. Pharm. 2003;4:2089&#x2013;2098. doi: 10.1517/14656566.4.11.2089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14656566.4.11.2089</ArticleId><ArticleId IdType="pubmed">14596662</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsueda K., Harasawa S., Hongo M., Hiwatashi N., Sasaki D. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand. J. Gastroenterol. 2008;43:1202&#x2013;1211. doi: 10.1080/00365520802240255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365520802240255</ArticleId><ArticleId IdType="pubmed">18618371</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalilian A., Ahmadimoghaddam D., Saki S., Mohammadi Y., Mehrpooya M. A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome. Biopsychosoc. Med. 2021;15:1&#x2013;12. doi: 10.1186/s13030-021-00205-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13030-021-00205-2</ArticleId><ArticleId IdType="pmc">PMC7860197</ArticleId><ArticleId IdType="pubmed">33536043</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu G.D., Chen J., Hoffmann C., Bittinger K., Chen Y.Y., Keilbaugh S.A., Bewtra M., Knights D., Walters W.A., Knight R., et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334:105&#x2013;108. doi: 10.1126/science.1208344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1208344</ArticleId><ArticleId IdType="pmc">PMC3368382</ArticleId><ArticleId IdType="pubmed">21885731</ArticleId></ArticleIdList></Reference><Reference><Citation>Propst E.L., Flickinger E.A., Bauer L.L., Merchen N.R., Fahey G.C., Jr. A dose-response experiment evaluating the effects of oligofructose and inulin on nutrient digestibility, stool quality, and fecal protein catabolites in healthy adult dogs. J. Anim. Sci. 2003;81:3057&#x2013;3066. doi: 10.2527/2003.81123057x.</Citation><ArticleIdList><ArticleId IdType="doi">10.2527/2003.81123057x</ArticleId><ArticleId IdType="pubmed">14677862</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders M.E., Merenstein D.J., Reid G., Gibson G.R., Rastall R.A. Probiotics and prebiotics in intestinal health and disease: From biology to the clinic. Nat. Rev. Gastroenterol. Hepatol. 2019;16:605&#x2013;616. doi: 10.1038/s41575-019-0173-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-019-0173-3</ArticleId><ArticleId IdType="pubmed">31296969</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Quigley E.M., Lacy B.E., Lembo A.J., Saito Y.A., Schiller L.R., Soffer E.E., Spiegel B.M., Moayyedi P. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: Systematic review and meta-analysis. Am. J. Gastroenterol. 2014;109:1547&#x2013;1561; quiz 1546, 1562. doi: 10.1038/ajg.2014.202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2014.202</ArticleId><ArticleId IdType="pubmed">25070051</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarino M.P.L., Altomare A., Emerenziani S., Di Rosa C., Ribolsi M., Balestrieri P., Iovino P., Rocchi G., Cicala M. Mechanisms of action of prebiotics and their effects on gastro-intestinal disorders in adults. Nutrients. 2020;12:1037. doi: 10.3390/nu12041037.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12041037</ArticleId><ArticleId IdType="pmc">PMC7231265</ArticleId><ArticleId IdType="pubmed">32283802</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins S., Reid G. Distant site effects of ingested prebiotics. Nutrients. 2016;8:523. doi: 10.3390/nu8090523.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu8090523</ArticleId><ArticleId IdType="pmc">PMC5037510</ArticleId><ArticleId IdType="pubmed">27571098</ArticleId></ArticleIdList></Reference><Reference><Citation>Whelan K. Probiotics and prebiotics in the management of irritable bowel syndrome: A review of recent clinical trials and systematic reviews. Curr. Opin. Clin. Nutr. Metab. Care. 2011;14:581&#x2013;587. doi: 10.1097/MCO.0b013e32834b8082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCO.0b013e32834b8082</ArticleId><ArticleId IdType="pubmed">21892075</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahrudin M.F., Abdul Rani R., Tamil A.M., Mokhtar N.M., Raja Ali R.A. Effectiveness of sterilized symbiotic drink containing lactobacillus helveticus comparable to probiotic alone in patients with constipation-predominant irritable bowel syndrome. Dig. Dis. Sci. 2020;65:541&#x2013;549. doi: 10.1007/s10620-019-05695-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-019-05695-3</ArticleId><ArticleId IdType="pmc">PMC6995448</ArticleId><ArticleId IdType="pubmed">31209720</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill C., Guarner F., Reid G., Gibson G.R., Merenstein D.J., Pot B., Morelli L., Canani R.B., Flint H.J., Salminen S., et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014;11:506&#x2013;514. doi: 10.1038/nrgastro.2014.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2014.66</ArticleId><ArticleId IdType="pubmed">24912386</ArticleId></ArticleIdList></Reference><Reference><Citation>Power S.E., O&#x2019;Toole P.W., Stanton C., Ross R.P., Fitzgerald G.F. Intestinal microbiota, diet and health. Br. J. Nutr. 2014;111:387&#x2013;402. doi: 10.1017/S0007114513002560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0007114513002560</ArticleId><ArticleId IdType="pubmed">23931069</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman C.M., Gibson G.R., Rowland I. Health benefits of probiotics: Are mixtures more effective than single strains? Eur. J. Nutr. 2011;50:1&#x2013;17. doi: 10.1007/s00394-010-0166-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00394-010-0166-z</ArticleId><ArticleId IdType="pubmed">21229254</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy J., O&#x2019;Mahony L., O&#x2019;Callaghan L., Sheil B., Vaughan E.E., Fitzsimons N., Fitzgibbon J., O&#x2019;Sullivan G.C., Kiely B., Collins J.K., et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut. 2003;52:975&#x2013;980. doi: 10.1136/gut.52.7.975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.52.7.975</ArticleId><ArticleId IdType="pmc">PMC1773705</ArticleId><ArticleId IdType="pubmed">12801954</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohman L., Simren M. Pathogenesis of IBS: Role of inflammation, immunity and neuroimmune interactions. Nat. Rev. Gastroenterol. Hepatol. 2010;7:163&#x2013;173. doi: 10.1038/nrgastro.2010.4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2010.4</ArticleId><ArticleId IdType="pubmed">20101257</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D.M., Moeller M.J., Chey W.D., Schoenfeld P.S. The utility of probiotics in the treatment of irritable bowel syndrome: A systematic review. Am. J. Gastroenterol. 2009;104:1033&#x2013;1049; quiz 1050. doi: 10.1038/ajg.2009.25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2009.25</ArticleId><ArticleId IdType="pubmed">19277023</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan F., Ni H., Asche C.V., Kim M., Walayat S., Ren J. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: A meta-analysis. Curr. Med. Res. Opin. 2017;33:1191&#x2013;1197. doi: 10.1080/03007995.2017.1292230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03007995.2017.1292230</ArticleId><ArticleId IdType="pubmed">28166427</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinan T.G., Stanton C., Cryan J.F. Psychobiotics: A novel class of psychotropic. Biol. Psychiatry. 2013;74:720&#x2013;726. doi: 10.1016/j.biopsych.2013.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2013.05.001</ArticleId><ArticleId IdType="pubmed">23759244</ArticleId></ArticleIdList></Reference><Reference><Citation>Han K., Wang J., Seo J.G., Kim H. Efficacy of double-coated probiotics for irritable bowel syndrome: A randomized double-blind controlled trial. J. Gastroenterol. 2017;52:432&#x2013;443. doi: 10.1007/s00535-016-1224-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00535-016-1224-y</ArticleId><ArticleId IdType="pubmed">27178566</ArticleId></ArticleIdList></Reference><Reference><Citation>Yano J.M., Yu K., Donaldson G.P., Shastri G.G., Ann P., Ma L., Nagler C.R., Ismagilov R.F., Mazmanian S.K., Hsiao E.Y. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015;161:264&#x2013;276. doi: 10.1016/j.cell.2015.02.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.02.047</ArticleId><ArticleId IdType="pmc">PMC4393509</ArticleId><ArticleId IdType="pubmed">25860609</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25070051</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1572-0241</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><Issue>10</Issue><PubDate><Year>2014</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The American journal of gastroenterology</Title><ISOAbbreviation>Am J Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>1547</StartPage><EndPage>1562</EndPage><MedlinePgn>1547-61; quiz 1546, 1562</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ajg.2014.202</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Irritable bowel syndrome (IBS) and chronic idiopathic constipation (CIC) are functional bowel disorders. Evidence suggests that disturbance in the gastrointestinal microbiota may be implicated in both conditions. We performed a systematic review and meta-analysis to examine the efficacy of prebiotics, probiotics, and synbiotics in IBS and CIC.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched (up to December 2013). Randomized controlled trials (RCTs) recruiting adults with IBS or CIC, which compared prebiotics, probiotics, or synbiotics with placebo or no therapy, were eligible. Dichotomous symptom data were pooled to obtain a relative risk (RR) of remaining symptomatic after therapy, with a 95% confidence interval (CI). Continuous data were pooled using a standardized or weighted mean difference with a 95% CI.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The search strategy identified 3,216 citations. Forty-three RCTs were eligible for inclusion. The RR of IBS symptoms persisting with probiotics vs. placebo was 0.79 (95% CI 0.70-0.89). Probiotics had beneficial effects on global IBS, abdominal pain, bloating, and flatulence scores. Data for prebiotics and synbiotics in IBS were sparse. Probiotics appeared to have beneficial effects in CIC (mean increase in number of stools per week=1.49; 95% CI=1.02-1.96), but there were only two RCTs. Synbiotics also appeared beneficial (RR of failure to respond to therapy=0.78; 95% CI 0.67-0.92). Again, trials for prebiotics were few in number, and no definite conclusions could be drawn.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Probiotics are effective treatments for IBS, although which individual species and strains are the most beneficial remains unclear. Further evidence is required before the role of prebiotics or synbiotics in IBS is known. The efficacy of all three therapies in CIC is also uncertain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ford</LastName><ForeName>Alexander C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>1] Leeds Gastroenterology Institute, St James's University Hospital, Leeds, UK [2] Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quigley</LastName><ForeName>Eamonn M M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacy</LastName><ForeName>Brian E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Dartmouth-Hitchcock Medical Center, Gastroenterology, One Medical Center Drive, Lebanon, New Hampshire, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lembo</LastName><ForeName>Anthony J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>The Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Yuri A</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiller</LastName><ForeName>Lawrence R</ForeName><Initials>LR</Initials><AffiliationInfo><Affiliation>Digestive Health Associates of Texas, Baylor University Medical Center, Dallas, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soffer</LastName><ForeName>Edy E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology at Cedars-Sinai, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spiegel</LastName><ForeName>Brennan M R</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, VA Greater Los Angeles Healthcare System, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moayyedi</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Gastroenterology Division, McMaster University, Health Sciences Center, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Gastroenterol</MedlineTA><NlmUniqueID>0421030</NlmUniqueID><ISSNLinking>0002-9270</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D056692">Prebiotics</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Gastroenterol. 2014 Oct;109(10):1563-5. doi: 10.1038/ajg.2014.258.</RefSource><PMID Version="1">25287086</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Am J Gastroenterol. 2014 Nov;109(11):1838-9. doi: 10.1038/ajg.2014.304.</RefSource><PMID Version="1">25373592</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015746" MajorTopicYN="N">Abdominal Pain</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003248" MajorTopicYN="N">Constipation</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019587" MajorTopicYN="Y">Dietary Supplements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056692" MajorTopicYN="N">Prebiotics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058616" MajorTopicYN="N">Synbiotics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25070051</ArticleId><ArticleId IdType="doi">10.1038/ajg.2014.202</ArticleId><ArticleId IdType="pii">ajg2014202</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39940404</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6643</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Jan</Month><Day>31</Day></PubDate></JournalIssue><Title>Nutrients</Title><ISOAbbreviation>Nutrients</ISOAbbreviation></Journal><ArticleTitle>Low-FODMAP Diet for Irritable Bowel Syndrome: Insights from Microbiome.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">544</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nu17030544</ELocationID><Abstract><AbstractText>Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder characterized by chronic abdominal pain, bloating, and altered bowel habits. Low-FODMAP diets, which involve restricting fermentable oligosaccharides, disaccharides, monosaccharides, and polyols, have emerged as an effective dietary intervention for alleviating IBS symptoms. This review paper aims to synthesize current insights into the impact of a low-FODMAP diet on the gut microbiome and its mechanisms of action in managing IBS. We explore the alterations in microbial composition and function associated with a low-FODMAP diet and discuss the implications of these changes for gut health and symptom relief. Additionally, we examine the balance between symptom improvement and potential negative effects on microbial diversity and long-term gut health. Emerging evidence suggests that while a low-FODMAP diet can significantly reduce IBS symptoms, it may also lead to reductions in beneficial microbial populations. Strategies to mitigate these effects, such as the reintroduction phase and the use of probiotics, are evaluated. This review highlights the importance of a personalized approach to dietary management in IBS, considering individual variations in microbiome responses. Understanding the intricate relationship between diet, the gut microbiome, and IBS symptomatology will guide the development of more effective, sustainable dietary strategies for IBS patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Haoshuai</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Microbiota I-Center (MagIC), Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0001-9100-387X</Identifier><AffiliationInfo><Affiliation>Microbiota I-Center (MagIC), Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CUHK14104124</GrantID><Agency>Research Grants Council of the Hong Kong Special Administrative Region</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nutrients</MedlineTA><NlmUniqueID>101521595</NlmUniqueID><ISSNLinking>2072-6643</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009844">Oligosaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009005">Monosaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004187">Disaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C024617">polyol</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011108">Polymers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050528" MajorTopicYN="Y">Diet, Carbohydrate-Restricted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009844" MajorTopicYN="N">Oligosaccharides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009005" MajorTopicYN="N">Monosaccharides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005285" MajorTopicYN="N">Fermentation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004187" MajorTopicYN="N">Disaccharides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011108" MajorTopicYN="N">Polymers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000092622" MajorTopicYN="N">FODMAP Diet</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">dietary personalization</Keyword><Keyword MajorTopicYN="N">gut microbiota</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">low-FODMAP diet</Keyword><Keyword MajorTopicYN="N">probiotics</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>13</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>13</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>13</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39940404</ArticleId><ArticleId IdType="pmc">PMC11819959</ArticleId><ArticleId IdType="doi">10.3390/nu17030544</ArticleId><ArticleId IdType="pii">nu17030544</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C. Functional bowel disorders. Gastroenterology. 2006;130:1480&#x2013;1491. doi: 10.1053/j.gastro.2005.11.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2005.11.061</ArticleId><ArticleId IdType="pubmed">16678561</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall J.K., Thabane M., Garg A.X., Clark W.F., Salvadori M., Collins S.M. Walkerton Health Study Investigators Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology. 2006;131:445&#x2013;660. doi: 10.1053/j.gastro.2006.05.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2006.05.053</ArticleId><ArticleId IdType="pubmed">16890598</ArticleId></ArticleIdList></Reference><Reference><Citation>Thabane M., Simunovic M., Akhtar-Danesh N., Garg A.X., Clark W.F., Collins S.M., Salvadori M., Marshall J.K. An outbreak of acute bacterial gastroenteritis is associated with an increased incidence of irritable bowel syndrome in children. Am. J. Gastroenterol. 2010;105:933&#x2013;939. doi: 10.1038/ajg.2010.74.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2010.74</ArticleId><ArticleId IdType="pubmed">20179687</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller R., Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology. 2009;136:1979&#x2013;1988. doi: 10.1053/j.gastro.2009.02.074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2009.02.074</ArticleId><ArticleId IdType="pubmed">19457422</ArticleId></ArticleIdList></Reference><Reference><Citation>Mearin F., Lacy B.E., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R. Bowel Disorders. Gastroenterology. 2016;13:501&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">27144627</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman D.A., Dumitrascu D.L. Rome III: New standard for functional gastrointestinal disorders. J. Gastrointest. Liver Dis. 2006;15:237</Citation><ArticleIdList><ArticleId IdType="pubmed">17013448</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka P., Parr H., Barberio B., Black C.J., Savarino E.V., Ford A.C. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2020;5:908&#x2013;917. doi: 10.1016/S2468-1253(20)30217-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30217-X</ArticleId><ArticleId IdType="pubmed">32702295</ArticleId></ArticleIdList></Reference><Reference><Citation>Canavan C., West J., Card T. The epidemiology of irritable bowel syndrome. Clin. Epidemiol. 2014;6:71&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3921083</ArticleId><ArticleId IdType="pubmed">24523597</ArticleId></ArticleIdList></Reference><Reference><Citation>Husain N., Chaudhry I.B., Jafri F., Niaz S.K., Tomenson B., Creed F. A population-based study of irritable bowel syndrome in a non-Western population. Neurogastroenterol. Motil. 2008;20:1022&#x2013;1029. doi: 10.1111/j.1365-2982.2008.01143.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2008.01143.x</ArticleId><ArticleId IdType="pubmed">18492027</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeoka A., Kimura T., Hara S., Hamaguchi T., Fukudo S., Tayama J. Prevalence of Irritable Bowel Syndrome in Japan, China, and South Korea: An International Cross-sectional Study. J. Neurogastroenterol. Motil. 2023;29:229&#x2013;237. doi: 10.5056/jnm22037.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm22037</ArticleId><ArticleId IdType="pmc">PMC10083109</ArticleId><ArticleId IdType="pubmed">37019867</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R., Li Z., Liu S., Zhang D. Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: A systematic analysis based on the Global Burden of Disease Study 2019. BMJ Open. 2023;13:e065186. doi: 10.1136/bmjopen-2022-065186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-065186</ArticleId><ArticleId IdType="pmc">PMC10069527</ArticleId><ArticleId IdType="pubmed">36977543</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwan A.C., Hu W.H., Chan Y.K., Yeung Y.W., Lai T.S., Yuen H. Prevalence of irritable bowel syndrome in Hong Kong. J. Gastroenterol. Hepatol. 2002;17:1180&#x2013;1186. doi: 10.1046/j.1440-1746.2002.02871.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1440-1746.2002.02871.x</ArticleId><ArticleId IdType="pubmed">12453277</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell R.M., Ford A.C. Effect of gender on prevalence of irritable bowel syndrome in the community: Systematic review and meta-analysis. Am. J. Gastroenterol. 2012;107:991&#x2013;1000. doi: 10.1038/ajg.2012.131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2012.131</ArticleId><ArticleId IdType="pubmed">22613905</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell R.M., Ford A.C. Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 2012;10:712&#x2013;721.e4. doi: 10.1016/j.cgh.2012.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2012.02.029</ArticleId><ArticleId IdType="pubmed">22426087</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones J., Boorman J., Cann P., Forbes A., Gomborone J., Heaton K., Hungin P., Kumar D., Libby G., Spiller R., et al. British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut. 2000;47((Suppl. 2)):ii1&#x2013;ii19. doi: 10.1136/gut.47.suppl_2.ii1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.47.suppl_2.ii1</ArticleId><ArticleId IdType="pmc">PMC1766762</ArticleId><ArticleId IdType="pubmed">11053260</ArticleId></ArticleIdList></Reference><Reference><Citation>Maxion-Bergemann S., Thielecke F., Abel F., Bergemann R. Costs of irritable bowel syndrome in the UK and US. PharmacoEconomics. 2006;24:21&#x2013;37. doi: 10.2165/00019053-200624010-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00019053-200624010-00002</ArticleId><ArticleId IdType="pubmed">16445300</ArticleId></ArticleIdList></Reference><Reference><Citation>Lea R., Whorwell P.J. Quality of life in irritable bowel syndrome. Pharmacoeconomics. 2001;19:643&#x2013;653. doi: 10.2165/00019053-200119060-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00019053-200119060-00003</ArticleId><ArticleId IdType="pubmed">11456212</ArticleId></ArticleIdList></Reference><Reference><Citation>Black C.J., Ford A.C. Global burden of irritable bowel syndrome: Trends, predictions and risk factors. Nat. Rev. Gastroenterol. Hepatol. 2020;17:473&#x2013;486. doi: 10.1038/s41575-020-0286-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-020-0286-8</ArticleId><ArticleId IdType="pubmed">32296140</ArticleId></ArticleIdList></Reference><Reference><Citation>Buono J.L., Carson R.T., Flores N.M. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual. Life Outcomes. 2017;15:35. doi: 10.1186/s12955-017-0611-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-017-0611-2</ArticleId><ArticleId IdType="pmc">PMC5310011</ArticleId><ArticleId IdType="pubmed">28196491</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey R.F., Pomare E.W., Heaton K.W. Effects of increased dietary fibre on intestinal transit. Lancet. 1973;1:1278&#x2013;1280. doi: 10.1016/S0140-6736(73)91294-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(73)91294-4</ArticleId><ArticleId IdType="pubmed">4126073</ArticleId></ArticleIdList></Reference><Reference><Citation>Bijkerk C.J., de Wit N.J., Muris J.W., Whorwell P.J., Knottnerus J.A., Hoes A.W. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo-controlled trial. BMJ Clin. Res. Ed. 2009;339:b3154. doi: 10.1136/bmj.b3154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b3154</ArticleId><ArticleId IdType="pmc">PMC3272664</ArticleId><ArticleId IdType="pubmed">19713235</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Talley N.J., Spiegel B.M., Foxx-Orenstein A.E., Schiller L., Quigley E.M., Moayyedi P. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: Systematic review and meta-analysis. BMJ Clin. Res. Ed. 2008;337:a2313. doi: 10.1136/bmj.a2313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.a2313</ArticleId><ArticleId IdType="pmc">PMC2583392</ArticleId><ArticleId IdType="pubmed">19008265</ArticleId></ArticleIdList></Reference><Reference><Citation>Camilleri M., Boeckxstaens G. Dietary and pharmacological treatment of abdominal pain in IBS. Gut. 2017;66:966&#x2013;974. doi: 10.1136/gutjnl-2016-313425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2016-313425</ArticleId><ArticleId IdType="pubmed">28232472</ArticleId></ArticleIdList></Reference><Reference><Citation>Majewski M., McCallum R.W. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: Clinical profiles and effects of antibiotic trial. Adv. Med. Sci. 2007;52:139&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">18217406</ArticleId></ArticleIdList></Reference><Reference><Citation>Asha M.Z., Khalil S.F.H. Efficacy and Safety of Probiotics, Prebiotics and Synbiotics in the Treatment of Irritable Bowel Syndrome: A systematic review and meta-analysis. Sultan Qaboos Univ. Med. J. 2020;20:e13&#x2013;e24. doi: 10.18295/squmj.2020.20.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.18295/squmj.2020.20.01.003</ArticleId><ArticleId IdType="pmc">PMC7065695</ArticleId><ArticleId IdType="pubmed">32190365</ArticleId></ArticleIdList></Reference><Reference><Citation>Shavakhi A., Minakari M., Farzamnia S., Peykar M.S., Taghipour G., Tayebi A., Hashemi H., Shavakhi S. The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial. Adv. Biomed. Res. 2014;3:140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4139977</ArticleId><ArticleId IdType="pubmed">25161987</ArticleId></ArticleIdList></Reference><Reference><Citation>Whorwell P.J., Altringer L., Morel J., Bond Y., Charbonneau D., O&#x2019;Mahony L., Kiely B., Shanahan F., Quigley E.M. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am. J. Gastroenterol. 2006;101:1581&#x2013;1590. doi: 10.1111/j.1572-0241.2006.00734.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2006.00734.x</ArticleId><ArticleId IdType="pubmed">16863564</ArticleId></ArticleIdList></Reference><Reference><Citation>Drouault-Holowacz S., Bieuvelet S., Burckel A., Cazaubiel M., Dray X., Marteau P. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol. Clin. Et Biol. 2008;32:147&#x2013;152. doi: 10.1016/j.gcb.2007.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gcb.2007.06.001</ArticleId><ArticleId IdType="pubmed">18387426</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappello C., Tremolaterra F., Pascariello A., Ciacci C., Iovino P. A randomised clinical trial (RCT) of a symbiotic mixture in patients with irritable bowel syndrome (IBS): Effects on symptoms, colonic transit and quality of life. Int. J. Color. Dis. 2013;28:349&#x2013;358. doi: 10.1007/s00384-012-1552-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-012-1552-1</ArticleId><ArticleId IdType="pmc">PMC3587687</ArticleId><ArticleId IdType="pubmed">22885882</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe4;ckhed F., Ley R.E., Sonnenburg J.L., Peterson D.A., Gordon J.I. Host-bacterial mutualism in the human intestine. Science. 2005;307:1915&#x2013;1920. doi: 10.1126/science.1104816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1104816</ArticleId><ArticleId IdType="pubmed">15790844</ArticleId></ArticleIdList></Reference><Reference><Citation>Neish A.S. Microbes in gastrointestinal health and disease. Gastroenterology. 2009;136:65&#x2013;80. doi: 10.1053/j.gastro.2008.10.080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2008.10.080</ArticleId><ArticleId IdType="pmc">PMC2892787</ArticleId><ArticleId IdType="pubmed">19026645</ArticleId></ArticleIdList></Reference><Reference><Citation>Sender R., Fuchs S., Milo R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol. 2016;14:e1002533. doi: 10.1371/journal.pbio.1002533.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1002533</ArticleId><ArticleId IdType="pmc">PMC4991899</ArticleId><ArticleId IdType="pubmed">27541692</ArticleId></ArticleIdList></Reference><Reference><Citation>Warnecke F., Luginbuhl P., Ivanova N., Ghassemian M., Richardson T.H., Stege J.T., Cayouette M., McHardy A.C., Djordjevic G., Aboushadi N., et al. Metagenomic and functional analysis of hindgut microbiota of a wood-feeding higher termite. Nature. 2007;450:560&#x2013;565. doi: 10.1038/nature06269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06269</ArticleId><ArticleId IdType="pubmed">18033299</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A., Wu H., Collier-Hyams L.S., Hansen J.M., Li T., Yamoah K., Pan Z.Q., Jones D.P., Neish A.S. Commensal bacteria modulate cullin-dependent signaling via generation of reactive oxygen species. EMBO J. 2007;26:4457&#x2013;4466. doi: 10.1038/sj.emboj.7601867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7601867</ArticleId><ArticleId IdType="pmc">PMC2063476</ArticleId><ArticleId IdType="pubmed">17914462</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazmanian S.K., Round J.L., Kasper D.L. Microbial symbiosis factor prevents intestinal inflammatory disease. Nature. 2008;453:620&#x2013;625. doi: 10.1038/nature07008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07008</ArticleId><ArticleId IdType="pubmed">18509436</ArticleId></ArticleIdList></Reference><Reference><Citation>Natividad J.M., Verdu E.F. Modulation of intestinal barrier by intestinal microbiota: Pathological and therapeutic implications. Pharmacol. Res. 2013;69:42&#x2013;51. doi: 10.1016/j.phrs.2012.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2012.10.007</ArticleId><ArticleId IdType="pubmed">23089410</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav S., Dwivedi A., Tripathi A., Tripathi A.K. Therapeutic potential of short-chain fatty acid production by gut microbiota in neurodegenerative disorders. Nutr. Res. 2022;106:72&#x2013;84. doi: 10.1016/j.nutres.2022.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nutres.2022.07.007</ArticleId><ArticleId IdType="pubmed">36152586</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangan K.J., Hang H.C. Biochemical Mechanisms of Pathogen Restriction by Intestinal Bacteria. Trends Biochem. Sci. 2017;42:887&#x2013;898. doi: 10.1016/j.tibs.2017.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2017.08.005</ArticleId><ArticleId IdType="pmc">PMC6038137</ArticleId><ArticleId IdType="pubmed">28927699</ArticleId></ArticleIdList></Reference><Reference><Citation>Donaldson G.P., Lee S.M., Mazmanian S.K. Gut biogeography of the bacterial microbiota. Nat. Rev. Microbiol. 2015;14:20&#x2013;32. doi: 10.1038/nrmicro3552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro3552</ArticleId><ArticleId IdType="pmc">PMC4837114</ArticleId><ArticleId IdType="pubmed">26499895</ArticleId></ArticleIdList></Reference><Reference><Citation>Charbonneau M.R., O&#x2019;Donnell D., Blanton L.V., Totten S.M., Davis J.C., Barratt M.J., Cheng J., Guruge J., Talcott M., Bain J.R., et al. Sialylated Milk Oligosaccharides Promote Microbiota-Dependent Growth in Models of Infant Undernutrition. Cell. 2016;164:859&#x2013;871. doi: 10.1016/j.cell.2016.01.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.01.024</ArticleId><ArticleId IdType="pmc">PMC4793393</ArticleId><ArticleId IdType="pubmed">26898329</ArticleId></ArticleIdList></Reference><Reference><Citation>Laursen M.F. Gut Microbiota Development: Influence of Diet from Infancy to Toddlerhood. Ann. Nutr. Metab. 2021;77((Suppl. 3)):1&#x2013;14. doi: 10.1159/000517912. Advance Online Publication .</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000517912</ArticleId><ArticleId IdType="pubmed">34461613</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinross J., Nicholson J.K. Gut microbiota: Dietary and social modulation of gut microbiota in the elderly. Nature reviews. Gastroenterol. Hepatol. 2012;9:563&#x2013;564. doi: 10.1038/nrgastro.2012.169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2012.169</ArticleId><ArticleId IdType="pubmed">22945446</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyleris E., Giamarellos-Bourboulis E.J., Tzivras D., Koussoulas V., Barbatzas C., Pimentel M. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: Relationship with irritable bowel syndrome. Dig. Dis. Sci. 2012;57:1321&#x2013;1329. doi: 10.1007/s10620-012-2033-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-012-2033-7</ArticleId><ArticleId IdType="pubmed">22262197</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Spiegel B.M., Talley N.J., Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: Systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 2009;7:1279&#x2013;1286. doi: 10.1016/j.cgh.2009.06.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2009.06.031</ArticleId><ArticleId IdType="pubmed">19602448</ArticleId></ArticleIdList></Reference><Reference><Citation>Camilleri M. Diagnosis and Treatment of Irritable Bowel Syndrome: A Review. JAMA. 2021;325:865&#x2013;877. doi: 10.1001/jama.2020.22532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.22532</ArticleId><ArticleId IdType="pubmed">33651094</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson P.R., Shepherd S.J. Personal view: Food for thought--western lifestyle and susceptibility to Crohn&#x2019;s disease. The FODMAP hypothesis. Aliment. Pharmacol. Ther. 2005;21:1399&#x2013;1409. doi: 10.1111/j.1365-2036.2005.02506.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2005.02506.x</ArticleId><ArticleId IdType="pubmed">15948806</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue S., Zhao D., Peng C., Tan C., Wang Q., Gong J. Effects of theabrownin on serum metabolites and gut microbiome in rats with a high-sugar diet. Food Funct. 2019;10:7063&#x2013;7080. doi: 10.1039/C9FO01334B.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C9FO01334B</ArticleId><ArticleId IdType="pubmed">31621728</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett J.S., Gearry R.B., Muir J.G., Irving P.M., Rose R., Rosella O., Haines M.L., Shepherd S.J., Gibson P.R. Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon. Aliment. Pharmacol. Ther. 2010;31:874&#x2013;882. doi: 10.1111/j.1365-2036.2010.04237.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2010.04237.x</ArticleId><ArticleId IdType="pubmed">20102355</ArticleId></ArticleIdList></Reference><Reference><Citation>Halmos E.P., Christophersen C.T., Bird A.R., Shepherd S.J., Gibson P.R., Muir J.G. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut. 2015;64:93&#x2013;100. doi: 10.1136/gutjnl-2014-307264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2014-307264</ArticleId><ArticleId IdType="pubmed">25016597</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariadason J.M., Catto-Smith A., Gibson P.R. Modulation of distal colonic epithelial barrier function by dietary fibre in normal rats. Gut. 1999;44:394&#x2013;399. doi: 10.1136/gut.44.3.394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.44.3.394</ArticleId><ArticleId IdType="pmc">PMC1727405</ArticleId><ArticleId IdType="pubmed">10026327</ArticleId></ArticleIdList></Reference><Reference><Citation>Prospero L., Riezzo G., Linsalata M., Orlando A., D&#x2019;Attoma B., Russo F. Psychological and Gastrointestinal Symptoms of Patients with Irritable Bowel Syndrome Undergoing a Low-FODMAP Diet: The Role of the Intestinal Barrier. Nutrients. 2021;13:2469. doi: 10.3390/nu13072469.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13072469</ArticleId><ArticleId IdType="pmc">PMC8308851</ArticleId><ArticleId IdType="pubmed">34371976</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou S.Y., Gillilland M., Wu X., 3rd, Leelasinjaroen P., Zhang G., Zhou H., Ye B., Lu Y., Owyang C. FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction. J. Clin. Investig. 2018;128:267&#x2013;280. doi: 10.1172/JCI92390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI92390</ArticleId><ArticleId IdType="pmc">PMC5749529</ArticleId><ArticleId IdType="pubmed">29202473</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter J.F., Pieper R., Zakrzewski S.S., G&#xfc;nzel D., Schulzke J.D., Van Kessel A.G. Diets high in fermentable protein and fibre alter tight junction protein composition with minor effects on barrier function in piglet colon. Br. J. Nutr. 2014;111:1040&#x2013;1049. doi: 10.1017/S0007114513003498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0007114513003498</ArticleId><ArticleId IdType="pubmed">24229735</ArticleId></ArticleIdList></Reference><Reference><Citation>Irritable Bowel Syndrome in Adults: Diagnosis and Management. National Institute for Health and Care Excellence (NICE); London, UK: 2017.</Citation><ArticleIdList><ArticleId IdType="pubmed">32073807</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox S.R., Lindsay J.O., Fromentin S., Stagg A.J., McCarthy N.E., Galleron N., Ibraim S.B., Roume H., Levenez F., Pons N., et al. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients with Quiescent Inflammatory Bowel Disease in a Randomized Trial. Gastroenterology. 2020;158:176&#x2013;188.e7. doi: 10.1053/j.gastro.2019.09.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2019.09.024</ArticleId><ArticleId IdType="pubmed">31586453</ArticleId></ArticleIdList></Reference><Reference><Citation>Milajerdi A., Sadeghi O., Siadat S.D., Keshavarz S.A., Sima A., Vahedi H., Adibi P., Esmaillzadeh A. A randomized controlled trial investigating the effect of a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols on the intestinal microbiome and inflammation in patients with ulcerative colitis: Study protocol for a randomized controlled trial. Trials. 2020;21:201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7029518</ArticleId><ArticleId IdType="pubmed">32070388</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher H.M., Whelan K. Altered gastrointestinal microbiota in irritable bowel syndrome and its modification by diet: Probiotics, prebiotics and the low FODMAP diet. Proc. Nutr. Soc. 2016;75:306&#x2013;318. doi: 10.1017/S0029665116000021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0029665116000021</ArticleId><ArticleId IdType="pubmed">26908093</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntosh K., Reed D.E., Schneider T., Dang F., Keshteli A.H., De Palma G., Madsen K., Bercik P., Vanner S. FODMAPs alter symptoms and the metabolome of patients with IBS: A randomised controlled trial. Gut. 2017;66:1241&#x2013;1251. doi: 10.1136/gutjnl-2015-311339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-311339</ArticleId><ArticleId IdType="pubmed">26976734</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohseni F., Agah S., Ebrahimi-Daryani N., Taher M., Nattagh-Eshtivani E., Karimi S., Rastgoo S., Bourbour F., Hekmatdoost A. The effect of low FODMAP diet with and without gluten on irritable bowel syndrome: A double blind, placebo controlled randomized clinical trial. Clin. Nutr. ESPEN. 2022;47:45&#x2013;50. doi: 10.1016/j.clnesp.2021.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnesp.2021.12.019</ArticleId><ArticleId IdType="pubmed">35063241</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;hn L., St&#xf6;rsrud S., T&#xf6;rnblom H., Bengtsson U., Simr&#xe9;n M. Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. Am. J. Gastroenterol. 2013;108:634&#x2013;641. doi: 10.1038/ajg.2013.105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2013.105</ArticleId><ArticleId IdType="pubmed">23644955</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson P.R., Varney J.E., Muir J.G. Diet therapy for irritable bowel syndrome: Is a diet low in FODMAPS really similar in efficacy to traditional dietary advice? Gastroenterology. 2016;150:1046&#x2013;1047. doi: 10.1053/j.gastro.2015.10.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2015.10.053</ArticleId><ArticleId IdType="pubmed">26944508</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacovou M., Tan V., Muir J.G., Gibson P.R. The low FODMAP diet and its application in East and Southeast Asia. J. Neurogastroenterol. Motil. 2015;21:459. doi: 10.5056/jnm15111.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm15111</ArticleId><ArticleId IdType="pmc">PMC4622128</ArticleId><ArticleId IdType="pubmed">26350937</ArticleId></ArticleIdList></Reference><Reference><Citation>Hewawasam S.P., Iacovou M., Muir J.G., Gibson P.R. Dietary practices and FODMAPs in South Asia: Applicability of the low FODMAP diet to patients with irritable bowel syndrome. J. Gastroenterol. Hepatol. 2018;33:365&#x2013;374. doi: 10.1111/jgh.13885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.13885</ArticleId><ArticleId IdType="pubmed">28700090</ArticleId></ArticleIdList></Reference><Reference><Citation>Eswaran S.L., Chey W.D., Han-Markey T., Ball S., Jackson K. A randomized controlled trial comparing the low FODMAP diet vs. modified NICE guidelines in US adults with IBS-D. Off. J. Am. Coll. Gastroenterol.|ACG. 2016;111:1824&#x2013;1832. doi: 10.1038/ajg.2016.434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2016.434</ArticleId><ArticleId IdType="pubmed">27725652</ArticleId></ArticleIdList></Reference><Reference><Citation>Halmos E.P., Power V.A., Shepherd S.J., Gibson P.R., Muir J.G. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146:67&#x2013;75. doi: 10.1053/j.gastro.2013.09.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2013.09.046</ArticleId><ArticleId IdType="pubmed">24076059</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson P.R. The evidence base for efficacy of the low FODMAP diet in irritable bowel syndrome: Is it ready for prime time as a first-line therapy? J. Gastroenterol. Hepatol. 2017;32((Suppl. 1)):32&#x2013;35. doi: 10.1111/jgh.13693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.13693</ArticleId><ArticleId IdType="pubmed">28244668</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong D.K., Mitchell S.B., Barrett J.S., Shepherd S.J., Irving P.M., Biesiekierski J.R., Smith S., Gibson P.R., Muir J.G. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J. Gastroenterol. Hepatol. 2010;25:1366&#x2013;1373. doi: 10.1111/j.1440-1746.2010.06370.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1746.2010.06370.x</ArticleId><ArticleId IdType="pubmed">20659225</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumpitazi B.P., Cope J.L., Hollister E.B., Tsai C.M., McMeans A.R., Luna R.A., Versalovic J., Shulman R.J. Randomised clinical trial: Gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Aliment. Pharmacol. Ther. 2015;42:418&#x2013;427. doi: 10.1111/apt.13286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.13286</ArticleId><ArticleId IdType="pmc">PMC4514898</ArticleId><ArticleId IdType="pubmed">26104013</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen N., Andersen N.N., V&#xe9;gh Z., Jensen L., Ankersen D.V., Felding M., Simonsen M.H., Burisch J., Munkholm P. Ehealth: Low FODMAP diet vs. Lactobacillus rhamnosus GG in irritable bowel syndrome. World J. Gastroenterol. 2014;20:16215&#x2013;16226. doi: 10.3748/wjg.v20.i43.16215.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i43.16215</ArticleId><ArticleId IdType="pmc">PMC4239510</ArticleId><ArticleId IdType="pubmed">25473176</ArticleId></ArticleIdList></Reference><Reference><Citation>Undseth R., Berstad A., Kl&#xf8;w N.E., Arnljot K., Moi K.S., Valeur J. Abnormal accumulation of intestinal fluid following ingestion of an unabsorbable carbohydrate in patients with irritable bowel syndrome: An MRI study. Neurogastroenterol. Motil. 2014;26:1686&#x2013;1693. doi: 10.1111/nmo.12449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12449</ArticleId><ArticleId IdType="pubmed">25271767</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu C., Yan C., Wu Y., Tao E., Guo R., Zhu Z., Chen X., Fang M., Jiang M. Low FODMAP Diet relieves visceral hypersensitivity and is Associated with changes in Colonic Microcirculation in Water Avoidance mice Model. Nutrients. 2023;15:1155. doi: 10.3390/nu15051155.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu15051155</ArticleId><ArticleId IdType="pmc">PMC10004816</ArticleId><ArticleId IdType="pubmed">36904154</ArticleId></ArticleIdList></Reference><Reference><Citation>Hibberd M.C., Wu M., Rodionov D.A., Li X., Cheng J., Griffin N.W., Barratt M.J., Giannone R.J., Hettich R.L., Osterman A.L., et al. The effects of micronutrient deficiencies on bacterial species from the human gut microbiota. Sci. Transl. Med. 2017;9:eaal4069. doi: 10.1126/scitranslmed.aal4069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aal4069</ArticleId><ArticleId IdType="pmc">PMC5524138</ArticleId><ArticleId IdType="pubmed">28515336</ArticleId></ArticleIdList></Reference><Reference><Citation>Vervier K., Moss S., Kumar N., Adoum A., Barne M., Browne H., Kaser A., Kiely C.J., Neville B.A., Powell N., et al. Two microbiota subtypes identified in irritable bowel syndrome with distinct responses to the low FODMAP diet. Gut. 2022;71:1821&#x2013;1830. doi: 10.1136/gutjnl-2021-325177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-325177</ArticleId><ArticleId IdType="pmc">PMC9380505</ArticleId><ArticleId IdType="pubmed">34810234</ArticleId></ArticleIdList></Reference><Reference><Citation>Dieterich W., Schuppan D., Schink M., Schwappacher R., Wirtz S., Agaimy A., Neurath M.F., Zopf Y. Influence of low FODMAP and gluten-free diets on disease activity and intestinal microbiota in patients with non-celiac gluten sensitivity. Clin. Nutr. 2019;38:697&#x2013;707. doi: 10.1016/j.clnu.2018.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2018.03.017</ArticleId><ArticleId IdType="pubmed">29653862</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher H.M. Nutritional, microbiological and psychosocial implications of the low FODMAP diet. J. Gastroenterol. Hepatol. 2017;32:16&#x2013;19. doi: 10.1111/jgh.13688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.13688</ArticleId><ArticleId IdType="pubmed">28244658</ArticleId></ArticleIdList></Reference><Reference><Citation>Eswaran S., Chey W., Jackson K., Pillai S., Chey S., Han-Markey T. A low FODMAP diet improves quality of life, reduces activity impairment, and improves sleep quality in patients with irritable bowel syndrome and diarrhea: Results from a U.S. randomized, controlled trial. Gastroenterology. 2016;150:S172. doi: 10.1016/S0016-5085(16)30665-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0016-5085(16)30665-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke G., Quigley E.M., Cryan J.F., Dinan T.G. Irritable bowel syndrome: Towards biomarker identification. Trends Mol. Med. 2009;15:478&#x2013;489. doi: 10.1016/j.molmed.2009.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2009.08.001</ArticleId><ArticleId IdType="pubmed">19811951</ArticleId></ArticleIdList></Reference><Reference><Citation>Conley T.E., Slater R., Moss S., Bulmer D.C., de la Revilla Negro J., Ijaz U.Z., Pritchard D.M., Parkes M., Probert C. Microbiome-driven IBS metabotypes influence response to the low FODMAP diet: Insights from the faecal volatome. Ebiomedicine. 2024;107:105282. doi: 10.1016/j.ebiom.2024.105282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2024.105282</ArticleId><ArticleId IdType="pmc">PMC11388012</ArticleId><ArticleId IdType="pubmed">39173527</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;hn L., St&#xf6;rsrud S., Liljebo T., Collin L., Lindfors P., T&#xf6;rnblom H., Simr&#xe9;n M. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: A randomized controlled trial. Gastroenterology. 2015;149:1399&#x2013;1407.e2. doi: 10.1053/j.gastro.2015.07.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2015.07.054</ArticleId><ArticleId IdType="pubmed">26255043</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepherd S.J., Lomer M.C., Gibson P.R. Short-chain carbohydrates and functional gastrointestinal disorders. Off. J. Am. Coll. Gastroenterol.|ACG. 2013;108:707&#x2013;717. doi: 10.1038/ajg.2013.96.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2013.96</ArticleId><ArticleId IdType="pubmed">23588241</ArticleId></ArticleIdList></Reference><Reference><Citation>De Roest R.H., Dobbs B.R., Chapman B.A., Batman B., O&#x2019;brien L.A., Leeper J.A., Hebblethwaite C.R., Gearry R.B. The low FODMAP diet improves gastrointestinal symptoms in patients with irritable bowel syndrome: A prospective study. Int. J. Clin. Pract. 2013;67:895&#x2013;903. doi: 10.1111/ijcp.12128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.12128</ArticleId><ArticleId IdType="pubmed">23701141</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepherd S.J., Gibson P.R. Fructose malabsorption and symptoms of irritable bowel syndrome: Guidelines for effective dietary management. J. Am. Diet Assoc. 2006;106:1631&#x2013;1639. doi: 10.1016/j.jada.2006.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jada.2006.07.010</ArticleId><ArticleId IdType="pubmed">17000196</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennet SM P., B&#xf6;hn L., St&#xf6;rsrud S., Liljebo T., Collin L., Lindfors P., T&#xf6;rnblom H., &#xd6;hman L., Simr&#xe9;n M. Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs. Gut. 2018;67:872&#x2013;881. doi: 10.1136/gutjnl-2016-313128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2016-313128</ArticleId><ArticleId IdType="pubmed">28416515</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher H.M., Lomer M.C., Anderson J.L., Barrett J.S., Muir J.G., Irving P.M., Whelan K. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J. Nutr. 2012;142:1510&#x2013;1518. doi: 10.3945/jn.112.159285.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/jn.112.159285</ArticleId><ArticleId IdType="pubmed">22739368</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdez-Palomares F., Nambo-Venegas R., Uribe-Garc&#xed;a J., Mendoza-Vargas A., Granados-Portillo O., Meraz-Cruz N., Palacios-Gonz&#xe1;lez B. Intestinal microbiota fingerprint in subjects with irritable bowel syndrome responders to a low FODMAP diet. Food Funct. 2021;12:3206&#x2013;3218. doi: 10.1039/D0FO03162C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D0FO03162C</ArticleId><ArticleId IdType="pubmed">33877245</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher H.M., Lomer M.C.E., Farquharson F.M., Louis P., Fava F., Franciosi E., Scholz M., Tuohy K.M., Lindsay J.O., Irving P.M., et al. A Diet Low in FODMAPs Reduces Symptoms in Patients with Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial. Gastroenterology. 2017;153:936&#x2013;947. doi: 10.1053/j.gastro.2017.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2017.06.010</ArticleId><ArticleId IdType="pubmed">28625832</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu&#xf1;oz J.A., Chenoll E., Casinos B., Bataller E., Ram&#xf3;n D., Genov&#xe9;s S., Montava R., Ribes J.M., Buesa J., F&#xe0;brega J., et al. Novel probiotic Bifidobacterium longum subsp. infantis CECT 7210 strain active against rotavirus infections. Appl. Environ. Microbiol. 2011;77:8775&#x2013;8783. doi: 10.1128/AEM.05548-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.05548-11</ArticleId><ArticleId IdType="pmc">PMC3233071</ArticleId><ArticleId IdType="pubmed">22003027</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuda S., Toh H., Hase K., Oshima K., Nakanishi Y., Yoshimura K., Tobe T., Clarke J.M., Topping D.L., Suzuki T., et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature. 2011;469:543&#x2013;547. doi: 10.1038/nature09646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09646</ArticleId><ArticleId IdType="pubmed">21270894</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsuoka T. Bifidobacteria and their role in human health. J. Ind. Microbiol. 1990;6:263&#x2013;267. doi: 10.1007/BF01575871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01575871</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroni O., Kheadr E., Boutin Y., Lacroix C., Fliss I. Inactivation of adhesion and invasion of food-borne Listeria monocytogenes by bacteriocin-producing Bifidobacterium strains of human origin. Appl. Environ. Microbiol. 2006;72:6894&#x2013;6901. doi: 10.1128/AEM.00928-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.00928-06</ArticleId><ArticleId IdType="pmc">PMC1636179</ArticleId><ArticleId IdType="pubmed">16936051</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotar A.I., Chifiriuc M.C., Dinu S., Pelinescu D., Banu O., Laz&#x103;r V. Quantitative real-time PCR study of the influence of probiotic culture soluble fraction on the expression of Pseudomonas aeruginosa quorum sensing genes. Roum. Arch. Microbiol. Immunol. 2010;69:213&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">21462836</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanning S., Hall L.J., Cronin M., Zomer A., MacSharry J., Goulding D., Motherway M.O., Shanahan F., Nally K., Dougan G., et al. Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection. Proc. Natl. Acad. Sci. USA. 2012;109:2108&#x2013;2113. doi: 10.1073/pnas.1115621109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1115621109</ArticleId><ArticleId IdType="pmc">PMC3277520</ArticleId><ArticleId IdType="pubmed">22308390</ArticleId></ArticleIdList></Reference><Reference><Citation>Manning L.P., Yao C.K., Biesiekierski J.R. Therapy of IBS: Is a low FODMAP diet the answer? Front. Psychiatry. 2020;11:865. doi: 10.3389/fpsyt.2020.00865.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2020.00865</ArticleId><ArticleId IdType="pmc">PMC7488954</ArticleId><ArticleId IdType="pubmed">33110411</ArticleId></ArticleIdList></Reference><Reference><Citation>Halmos E.P., Gibson P.R. Controversies and reality of the FODMAP diet for patients with irritable bowel syndrome. J. Gastroenterol. Hepatol. 2019;34:1134&#x2013;1142. doi: 10.1111/jgh.14650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.14650</ArticleId><ArticleId IdType="pubmed">30945376</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson B., Rossi M., Kanno T., Parkes G.C., Anderson S., Mason A.J., Whelan K. &#x3b2;-Galactooligosaccharide in conjunction with low FODMAP diet improves irritable bowel syndrome symptoms but reduces fecal bifidobacteria. Off. J. Am. Coll. Gastroenterol.|ACG. 2020;115:906&#x2013;915. doi: 10.14309/ajg.0000000000000641.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000000641</ArticleId><ArticleId IdType="pubmed">32433273</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvaraj S.M., Wong S.H., Ser H.L., Lee L.H. Role of low FODMAP diet and probiotics on gut microbiome in irritable bowel syndrome (IBS) Prog. Microbes Mol. Biol. 2020;3:a0000069. doi: 10.36877/pmmb.a0000069.</Citation><ArticleIdList><ArticleId IdType="doi">10.36877/pmmb.a0000069</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellini M., Tonarelli S., Nagy A.G., Pancetti A., Costa F., Ricchiuti A., de Bortoli N., Mosca M., Marchi S., Rossi A. Low FODMAP Diet: Evidence, Doubts, and Hopes. Nutrients. 2020;12:148. doi: 10.3390/nu12010148.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12010148</ArticleId><ArticleId IdType="pmc">PMC7019579</ArticleId><ArticleId IdType="pubmed">31947991</ArticleId></ArticleIdList></Reference><Reference><Citation>Whelan K., Martin L.D., Staudacher H.M., Lomer M. The low FODMAP diet in the management of irritable bowel syndrome: An evidence-based review of FODMAP restriction, reintroduction and personalisation in clinical practice. J. Hum. Nutr. Diet. 2018;31:239&#x2013;255. doi: 10.1111/jhn.12530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jhn.12530</ArticleId><ArticleId IdType="pubmed">29336079</ArticleId></ArticleIdList></Reference><Reference><Citation>Chey W.D. Food: The main course to wellness and illness in patients with irritable bowel syndrome. Off. J. Am. Coll. Gastroenterol. ACG. 2016;111:366&#x2013;371. doi: 10.1038/ajg.2016.12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2016.12</ArticleId><ArticleId IdType="pubmed">26856749</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson P.R., Shepherd S.J. Evidence-based dietary management of functional gastrointestinal symptoms: The FODMAP approach. J. Gastroenterol. Hepatol. 2010;25:252&#x2013;258. doi: 10.1111/j.1440-1746.2009.06149.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1746.2009.06149.x</ArticleId><ArticleId IdType="pubmed">20136989</ArticleId></ArticleIdList></Reference><Reference><Citation>Whigham L., Joyce T., Harper G., Irving P.M., Staudacher H.M., Whelan K., Lomer M.C. Clinical effectiveness and economic costs of group versus one-to-one education for short-chain fermentable carbohydrate restriction (low FODMAP diet) in the management of irritable bowel syndrome. J. Hum. Nutr. Diet. Off. J. Br. Diet. Assoc. 2015;28:687&#x2013;696. doi: 10.1111/jhn.12318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jhn.12318</ArticleId><ArticleId IdType="pubmed">25871564</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuck C., Barrett J. Re-challenging FODMAPs: The low FODMAP diet phase two. J. Gastroenterol. Hepatol. 2017;32((Suppl. 1)):11&#x2013;15. doi: 10.1111/jgh.13687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.13687</ArticleId><ArticleId IdType="pubmed">28244664</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson P.R., Shepherd S.J. Food choice as a key management strategy for functional gastrointestinal symptoms. Am. J. Gastroenterol. 2012;107:657&#x2013;667. doi: 10.1038/ajg.2012.49.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2012.49</ArticleId><ArticleId IdType="pubmed">22488077</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher H.M., Rossi M., Kaminski T., Dimidi E., Ralph F.S.E., Wilson B., Martin L.D., Louis P., Lomer M.C.E., Irving P.M., et al. Long-term personalized low FODMAP diet improves symptoms and maintains luminal Bifidobacteria abundance in irritable bowel syndrome. Neurogastroenterol. Motil. 2022;34:e14241. doi: 10.1111/nmo.14241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.14241</ArticleId><ArticleId IdType="pubmed">34431172</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomer M.C.E. The low FODMAP diet in clinical practice: Where are we and what are the long-term considerations? Proc. Nutr. Soc. 2024;83:17&#x2013;27. doi: 10.1017/S0029665123003579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0029665123003579</ArticleId><ArticleId IdType="pubmed">37415490</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellini M., Tonarelli S., Barracca F., Morganti R., Pancetti A., Bertani L., de Bortoli N., Costa F., Mosca M., Marchi S., et al. A Low-FODMAP Diet for Irritable Bowel Syndrome: Some Answers to the Doubts from a Long-Term Follow-Up. Nutrients. 2020;12:2360. doi: 10.3390/nu12082360.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12082360</ArticleId><ArticleId IdType="pmc">PMC7468924</ArticleId><ArticleId IdType="pubmed">32784614</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Keeffe M., Jansen C., Martin L., Williams M., Seamark L., Staudacher H.M., Irving P.M., Whelan K., Lomer M.C. Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome. Neurogastroenterol. Motil. 2018;30:e13154. doi: 10.1111/nmo.13154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13154</ArticleId><ArticleId IdType="pubmed">28707437</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer S.J., Korosi A., Lay&#xe9; S., Shukitt-Hale B., Barrientos R.M. Food for thought: How nutrition impacts cognition and emotion. Npj Sci. Food. 2017;1:7. doi: 10.1038/s41538-017-0008-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41538-017-0008-y</ArticleId><ArticleId IdType="pmc">PMC6550267</ArticleId><ArticleId IdType="pubmed">31304249</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumann D., Anheyer D., Lauche R., Dobos G., Langhorst J., Cramer H. Effect of yoga in the therapy of irritable bowel syndrome: A systematic review. Clin. Gastroenterol. Hepatol. 2016;14:1720&#x2013;1731. doi: 10.1016/j.cgh.2016.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2016.04.026</ArticleId><ArticleId IdType="pubmed">27112106</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuttner L., Chambers C.T., Hardial J., Israel D.M., Jacobson K., Evans K. A randomized trial of yoga for adolescents with irritable bowel syndrome. Pain Res. Manag. 2006;11:217&#x2013;224. doi: 10.1155/2006/731628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2006/731628</ArticleId><ArticleId IdType="pmc">PMC2673138</ArticleId><ArticleId IdType="pubmed">17149454</ArticleId></ArticleIdList></Reference><Reference><Citation>Palsson O.S., Turner M.J., Johnson D.A., Burnett C.K., Whitehead W.E. Hypnosis treatment for severe irritable bowel syndrome: Investigation of mechanism and effects on symptoms. Dig. Dis. Sci. 2002;47:2605&#x2013;2614. doi: 10.1023/A:1020545017390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1020545017390</ArticleId><ArticleId IdType="pubmed">12452403</ArticleId></ArticleIdList></Reference><Reference><Citation>Moser G., Tr&#xe4;gner S., Gajowniczek E.E., Mikulits A., Michalski M., Kazemi-Shirazi L., F&#xfc;hrer M., Ponocny-Seliger E., Dejaco C., Miehsler W. Long-term success of GUT-directed group hypnosis for patients with refractory irritable bowel syndrome: A randomized controlled trial. Off. J. Am. Coll. Gastroenterol.|ACG. 2013;108:602&#x2013;609. doi: 10.1038/ajg.2013.19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2013.19</ArticleId><ArticleId IdType="pubmed">23419384</ArticleId></ArticleIdList></Reference><Reference><Citation>So D., Loughman A., Staudacher H.M. Effects of a low FODMAP diet on the colonic microbiome in irritable bowel syndrome: A systematic review with meta-analysis. Am. J. Clin. Nutr. 2022;116:943&#x2013;952. doi: 10.1093/ajcn/nqac176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/nqac176</ArticleId><ArticleId IdType="pmc">PMC9535515</ArticleId><ArticleId IdType="pubmed">35728042</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36269141</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1949-0984</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Gut microbes</Title><ISOAbbreviation>Gut Microbes</ISOAbbreviation></Journal><ArticleTitle>The probiotic <i>Bacillus subtilis</i> BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial.</ArticleTitle><Pagination><StartPage>2122668</StartPage><MedlinePgn>2122668</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2122668</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/19490976.2022.2122668</ELocationID><Abstract><AbstractText Label="ABSTRACT">Durable spore-forming probiotics are increasingly formulated into foods, beverages, and dietary supplements. To help meet this demand, the safety and efficacy of daily supplementation of Bacillus subtilis BS50 for 6 weeks was investigated in a randomized, double-blind, placebo-controlled, parallel clinical trial of 76 healthy adults. Before and during supplementation, gastrointestinal symptoms were recorded daily using a multi-symptom questionnaire. Clinical chemistry, hematology, plasma lipids, and intestinal permeability and inflammation markers were measured at baseline and end of study. Compared to placebo, 2 &#xd7; 10<sup>9</sup> colony-forming units (CFU) BS50 per day increased the proportion of participants showing improvement from baseline to week 6 in the composite score for bloating, burping, and flatulence (47.4% vs. 22.2%), whereby the odds of detecting an improvement were higher with BS50 (OR [95% CI]: 3.2 [1.1, 8.7], p = .024). Analyses of individual gastrointestinal symptoms indicate that BS50 increased the proportion of participants showing an improvement at week 6 compared to placebo for burping (44.7% vs. 22.2%, p = .041) and bloating (31.6% vs. 13.9%, p = .071), without affecting other symptoms. There were no clinically meaningful changes in clinical chemistry, hematology, plasma lipids and intestinal permeability and other inflammation markers. In conclusion, the results suggest that dietary supplementation of 2 &#xd7; 10<sup>9</sup> CFU Bacillus subtilis BS50 per day is a well-tolerated and safe strategy to alleviate gas-related gastrointestinal symptoms in healthy adults.</AbstractText><AbstractText Label="ABBREVIATIONS">AE adverse event; BHD bowel habits diary; BMI body mass index; BSS Bristol Stool Scale; CFU colony-forming unit; CRP C-reactive protein; FGID functional gastrointestinal disorder; GI gastrointestinal; GITQ Gastrointestinal Tolerance Questionnaire; GLP-1 glucagon-like peptide 1; GSRS Gastrointestinal Symptom Rating Scale; HDL-C high-density lipoprotein-cholesterol; IBS irritable bowel syndrome; IL-10 interleukin-10; ITT intent-to-treat; LBP lipopolysaccharide binding protein; LDL-C low-density lipoprotein-cholesterol; PP per protocol; PYY peptide YY; TG triglyceride; total-C total cholesterol.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garvey</LastName><ForeName>Sean M</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0003-1013-7871</Identifier><AffiliationInfo><Affiliation>BIO-CAT Microbials, LLC, Shakopee, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>BIO-CAT, Inc., Troy, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mah</LastName><ForeName>Eunice</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Biofortis Research, Inc., Addison, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blonquist</LastName><ForeName>Traci M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Biofortis Research, Inc., Addison, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaden</LastName><ForeName>Valerie N</ForeName><Initials>VN</Initials><AffiliationInfo><Affiliation>Biofortis Research, Inc., Addison, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spears</LastName><ForeName>Jessica L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>BIO-CAT Microbials, LLC, Shakopee, MN, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Gut Microbes</MedlineTA><NlmUniqueID>101495343</NlmUniqueID><ISSNLinking>1949-0976</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>89750-14-1</RegistryNumber><NameOfSubstance UI="D052216">Glucagon-Like Peptide 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>130068-27-8</RegistryNumber><NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008075">Lipoproteins, HDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>106388-42-5</RegistryNumber><NameOfSubstance UI="D019894">Peptide YY</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001412" MajorTopicYN="Y">Bacillus subtilis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008078" MajorTopicYN="N">Cholesterol, LDL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005767" MajorTopicYN="Y">Gastrointestinal Diseases</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052216" MajorTopicYN="N">Glucagon-Like Peptide 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008075" MajorTopicYN="N">Lipoproteins, HDL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019894" MajorTopicYN="N">Peptide YY</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014280" MajorTopicYN="N">Triglycerides</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bacillus subtilis</Keyword><Keyword MajorTopicYN="N">bloating</Keyword><Keyword MajorTopicYN="N">burping</Keyword><Keyword MajorTopicYN="N">digestion</Keyword><Keyword MajorTopicYN="N">gastrointestinal</Keyword><Keyword MajorTopicYN="N">probiotic</Keyword></KeywordList><CoiStatement>Sean Garvey is an employee of BIO-CAT, Inc., which provided funding for this study. Jessica Spears is an employee of BIO-CAT Microbials, LLC, which provided funding and manufactures the investigated probiotic strain. BIO-CAT Microbials, LLC provided the <i>B. subtilis</i>-containing test and placebo control products. BIO-CAT Microbials, LLC filed a patent application related to the enclosed findings (Patent Application No. PCT/US2022/040239). The funders were involved in the design of the study, in the writing of the manuscript, and in the decision to publish the results. Eunice Mah, Traci Blonquist, and Valerie Kaden are employees of Biofortis Research, Inc., a contract research organization. The authors declare no other conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>21</Day><Hour>10</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36269141</ArticleId><ArticleId IdType="pmc">PMC9590435</ArticleId><ArticleId IdType="doi">10.1080/19490976.2022.2122668</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ringel Y, Williams RE, Kalilani L, Cook SF.. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2009;7(1):68&#x2013;16. doi:10.1016/j.cgh.2008.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2008.07.008</ArticleId><ArticleId IdType="pubmed">19124113</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo AY, Kim N, Oh DH. Abdominal bloating: pathophysiology and treatment. J Neurogastroenterol Motil. 2013;19(4):433&#x2013;453. doi:10.5056/jnm.2013.19.4.433.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm.2013.19.4.433</ArticleId><ArticleId IdType="pmc">PMC3816178</ArticleId><ArticleId IdType="pubmed">24199004</ArticleId></ArticleIdList></Reference><Reference><Citation>Almario CV, Ballal ML, Chey WD, Nordstrom C, Khanna D, Spiegel BMR. Burden of gastrointestinal symptoms in the United States: results of a nationally representative survey of over 71,000 Americans. Am J Gastroenterol. 2018;113(11):1701&#x2013;1710. doi:10.1038/s41395-018-0256-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41395-018-0256-8</ArticleId><ArticleId IdType="pmc">PMC6453579</ArticleId><ArticleId IdType="pubmed">30323268</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandler RS, Stewart WF, Liberman JN, Ricci JA, Zorich NL. Abdominal pain, bloating, and diarrhea in the United States: prevalence and impact. Dig Dis Sci. 2000;45(6):1166&#x2013;1171. doi:10.1023/a:1005554103531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/a:1005554103531</ArticleId><ArticleId IdType="pubmed">10877233</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang X, Locke GR 3rd, Choung RS, Zinsmeister AR, Schleck CD, Talley NJ. Prevalence and risk factors for abdominal bloating and visible distention: a population-based study. Gut. 2008;57(6):756&#x2013;763. doi:10.1136/gut.2007.142810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2007.142810</ArticleId><ArticleId IdType="pmc">PMC2581929</ArticleId><ArticleId IdType="pubmed">18477677</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy BE, Cangemi DJ. A pragmatic approach to the evaluation and treatment of abdominal bloating. Am J Gastroenterol. 2022;117(5):701&#x2013;705. doi:10.14309/ajg.0000000000001665.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000001665</ArticleId><ArticleId IdType="pubmed">35103019</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy BE, Gabbard SL, Crowell MD. Pathophysiology, evaluation, and treatment of bloating: hope, hype, or hot air?
Gastroenterol Hepatol (N Y). 2011;7(11):729&#x2013;739. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3264926</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264926</ArticleId><ArticleId IdType="pubmed">22298969</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson JM, Cozine EW, Loftus CG. Gas, bloating, and belching: approach to evaluation and management. Am Fam Physician. 2019;99(5):301&#x2013;309. https://pubmed.ncbi.nlm.nih.gov/30811160</Citation><ArticleIdList><ArticleId IdType="pubmed">30811160</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendez&#xfa; RA, Barba E, Burri E, Cisternas D, Malagelada C, Segui S, Accarino A, Quiroga S, Monclus E, Navazo I, et al. Intestinal gas content and distribution in health and in patients with functional gut symptoms. Neurogastroenterol Motil. 2015;27(9):1249&#x2013;1257. doi:10.1111/nmo.12618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12618</ArticleId><ArticleId IdType="pubmed">26095329</ArticleId></ArticleIdList></Reference><Reference><Citation>Bredenoord AJ. Management of belching, hiccups, and aerophagia. Clin Gastroenterol Hepatol. 2013;11(1):6&#x2013;12. doi:10.1016/j.cgh.2012.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2012.09.006</ArticleId><ArticleId IdType="pubmed">22982101</ArticleId></ArticleIdList></Reference><Reference><Citation>Council for Responsible Nutrition (CRN) . 2021. 
CRN consumer survey on dietary supplements. [accessed 20
April 2022]. www.crnusa.org/2021survey</Citation></Reference><Reference><Citation>Mishra S, Stierman B, Gahche JJ, Potischman N. Dietary supplement use among adults: United States, 2017&#x2013;2018. NCHS data brief; no. 399. Hyattsville (MD): National Center for Health Statistics (U.S.). 2021. doi:10.15620/cdc:101131.</Citation><ArticleIdList><ArticleId IdType="doi">10.15620/cdc:101131</ArticleId><ArticleId IdType="pubmed">33663653</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, et al. Expert consensus document. The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506&#x2013;514. doi:10.1038/nrgastro.2014.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2014.66</ArticleId><ArticleId IdType="pubmed">24912386</ArticleId></ArticleIdList></Reference><Reference><Citation>Plaza-Diaz J, Ruiz-Ojeda FJ, Gil-Campos M, Gil A. Mechanisms of action of probiotics. Adv Nutr. 2019;10(suppl_1):S49&#x2013;S66. doi:10.1093/advances/nmy063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/advances/nmy063</ArticleId><ArticleId IdType="pmc">PMC6363529</ArticleId><ArticleId IdType="pubmed">30721959</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders ME, Merenstein DJ, Reid G, Gibson GR, Rastall RA. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat Rev Gastroenterol Hepatol. 2019;16(10):605&#x2013;616. doi:10.1038/s41575-019-0173-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-019-0173-3</ArticleId><ArticleId IdType="pubmed">31296969</ArticleId></ArticleIdList></Reference><Reference><Citation>Colom J, Freitas D, Simon A, Brodkorb A, Buckley M, Deaton J, Winger AM. Presence and germination of the probiotic Bacillus subtilis DE111&#xae; in the human small intestinal tract: a randomized, crossover, double-blind, and placebo-controlled study. Front Microbiol. 2021;12:715863. doi:10.3389/fmicb.2021.715863.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.715863</ArticleId><ArticleId IdType="pmc">PMC8366289</ArticleId><ArticleId IdType="pubmed">34408741</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutting SM. Bacillus probiotics. Food Microbiol. 2011;28(2):214&#x2013;220. doi:10.1016/j.fm.2010.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fm.2010.03.007</ArticleId><ArticleId IdType="pubmed">21315976</ArticleId></ArticleIdList></Reference><Reference><Citation>United States Food and Drug Administration . GRN No. 399. Preparation of Bacillus coagulans strain GBI-30, 6086 spores. 2012.  [accessed 6
July 2022]. https://www.cfsanappsexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&amp;id=399</Citation></Reference><Reference><Citation>United States Food and Drug Administration. GRN No. 526 . Bacillus coagulans strain Unique IS2 spores preparation. 2015. [accessed 6 July 2022]. https://www.cfsanappsexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&amp;id=526.</Citation></Reference><Reference><Citation>United States Food and Drug Administration . GRN No. 597. Bacillus coagulans SNZ1969 spore preparation. 2016.  [accessed 6
July 2022]. https://www.cfsanappsexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&amp;id=597</Citation></Reference><Reference><Citation>United States Food and Drug Administration . GRN No. 601. Bacillus coagulans SBC37-01 spore preparation. 2016.  [accessed 6
July 2022]. https://www.cfsanappsexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&amp;id=601</Citation></Reference><Reference><Citation>United States Food and Drug Administration . GRN No. 691. Bacillus subtilis SANK 70258 spore preparation. 2017.  [accessed 6
July 2022]. https://www.cfsanappsexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&amp;id=691</Citation></Reference><Reference><Citation>United States Food and Drug Administration . GRN No. 831. Bacillus subtilis DE111. 2019.  [accessed 6
July 2022]. https://www.cfsanappsexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&amp;id=831</Citation></Reference><Reference><Citation>United States Food and Drug Administration . GRN No. 905. Bacillus subtilis strain SG188. 2020.  [accessed 6
July 2022]. https://www.cfsanappsexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&amp;id=905</Citation></Reference><Reference><Citation>United States Food and Drug Administration . GRN No. 949. Bacillus coagulans strain DSM 17654 spore preparation. 2021.  [accessed 6
July 2022]. https://www.cfsanappsexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&amp;id=949</Citation></Reference><Reference><Citation>United States Food and Drug Administration . GRN No. 955. Bacillus subtilis strain BS-MB40 PTA-122264 spore preparation. 2021.  [accessed 6
July 2022]. https://www.cfsanappsexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&amp;id=955</Citation></Reference><Reference><Citation>United States Food and Drug Administration . GRN No. 956. Bacillus subtilis ATCC SD-7280. 2021.  [accessed 6
July 2022]. https://www.cfsanappsexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&amp;id=956</Citation></Reference><Reference><Citation>United States Food and Drug Administration . GRN No. 969. Bacillus subtilis &#x201c;Bss-19&#x201d; spore preparation. 2021.  [accessed 6
July 2022]. https://www.cfsanappsexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&amp;id=969</Citation></Reference><Reference><Citation>Koutsoumanis K, Allende A, Alvarez-Ord&#xf3;&#xf1;ez A, Bolton D, Bover-Cid S, Chemaly M, Davies R, De Cesare A, Hilbert F, Lindqvist R, et al. EFSA Panel on Biological Hazards . Update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA 14: suitability of taxonomic units notified to EFSA until March 2021. EFSA J. 2021;19(7):e06689. doi:10.2903/j.efsa.2021.6689.</Citation><ArticleIdList><ArticleId IdType="doi">10.2903/j.efsa.2021.6689</ArticleId><ArticleId IdType="pmc">PMC8262138</ArticleId><ArticleId IdType="pubmed">34257732</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolin BJ. Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find Exp Clin Pharmacol. 2009;31(10):655&#x2013;659. doi:10.1358/mf.2009.31.10.1441078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1358/mf.2009.31.10.1441078</ArticleId><ArticleId IdType="pubmed">20140275</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta AK, Maity C. Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: a prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT Compliant]. Medicine (Baltimore). 2021;100(3):e23641. doi:10.1097/MD.0000000000023641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000023641</ArticleId><ArticleId IdType="pmc">PMC7837859</ArticleId><ArticleId IdType="pubmed">33545934</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatanaka M, Yamamoto K, Suzuki N, Iio S, Takara T, Morita H, Takimoto T, Nakamura T. Effect of Bacillus subtilis C-3102 on loose stools in healthy volunteers. Benef Microbes. 2018;9(3):357&#x2013;365. doi:10.3920/BM2017.0103.</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2017.0103</ArticleId><ArticleId IdType="pubmed">29482338</ArticleId></ArticleIdList></Reference><Reference><Citation>Hun L. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med. 2009;121(2):119&#x2013;124. doi:10.3810/pgm.2009.03.1984.</Citation><ArticleIdList><ArticleId IdType="doi">10.3810/pgm.2009.03.1984</ArticleId><ArticleId IdType="pubmed">19332970</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalman DS, Schwartz HI, Alvarez P, Feldman S, Pezzullo JC, Krieger DR. A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms. BMC Gastroenterol. 2009;9:85. doi:10.1186/1471-230X-9-85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-230X-9-85</ArticleId><ArticleId IdType="pmc">PMC2784472</ArticleId><ArticleId IdType="pubmed">19922649</ArticleId></ArticleIdList></Reference><Reference><Citation>Madempudi RS, Ahire JJ, Neelamraju J, Tripathi A, Nanal S. Randomized clinical trial: the effect of probiotic Bacillus coagulans unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults. Sci Rep. 2019;9(1):12210. doi:10.1038/s41598-019-48554-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-48554-x</ArticleId><ArticleId IdType="pmc">PMC6704184</ArticleId><ArticleId IdType="pubmed">31434935</ArticleId></ArticleIdList></Reference><Reference><Citation>Maity C, Gupta AK. A prospective, interventional, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of Bacillus coagulans LBSC in the treatment of acute diarrhea with abdominal discomfort. Eur J Clin Pharmacol. 2019;75(1):21&#x2013;31. doi:10.1007/s00228-018-2562-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-018-2562-x</ArticleId><ArticleId IdType="pubmed">30264164</ArticleId></ArticleIdList></Reference><Reference><Citation>Majeed M, Nagabhushanam K, Natarajan S, Sivakumar A, Ali F, Pande A, Majeed S, Karri SK. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant irritable bowel syndrome: a double blind randomized placebo controlled pilot clinical study. Nutr J. 2016;15:21. doi:10.1186/s12937-016-0140-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12937-016-0140-6</ArticleId><ArticleId IdType="pmc">PMC4769834</ArticleId><ArticleId IdType="pubmed">26922379</ArticleId></ArticleIdList></Reference><Reference><Citation>Wauters L, Slaets H, De Paepe K, Ceulemans M, Wetzels S, Geboers K, Toth J, Thys W, Dybajlo R, Walgraeve D, et al. Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2021;6(10):784&#x2013;792. doi:10.1016/S2468-1253(21)00226-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(21)00226-0</ArticleId><ArticleId IdType="pubmed">34358486</ArticleId></ArticleIdList></Reference><Reference><Citation>Penet C, Kramer R, Little R, Spears JL, Parker J, Iyer JK, Guthrie N, Evans M. A randomized, double-blind, placebo-controlled, parallel study evaluating the efficacy of Bacillus subtilis MB40 to reduce abdominal discomfort, gas, and bloating. Altern Ther Health Med. 2021;27(S1):146&#x2013;157. https://pubmed.ncbi.nlm.nih.gov/31719214/</Citation><ArticleIdList><ArticleId IdType="pubmed">31719214</ArticleId></ArticleIdList></Reference><Reference><Citation>Stecker RA, Moon JM, Russo TJ, Ratliff KM, Mumford PW, J&#xe4;ger R, Purpura M, Kerksick CM. Bacillus coagulans GBI-30, 6086 improves amino acid absorption from milk protein. Nutr Metab (Lond). 2020;17:93. doi:10.1186/s12986-020-00515-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12986-020-00515-2</ArticleId><ArticleId IdType="pmc">PMC7585191</ArticleId><ArticleId IdType="pubmed">33110439</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarik M, Ramakrishnan L, Bhatia N, Goswami R, Kandasamy D, Roy A, Chandran DS, Singh A, Upadhyay AD, Kalaivani M, et al. The effect of Bacillus coagulans unique IS-2 supplementation on plasma amino acid levels and muscle strength in resistance trained males consuming whey protein: a double-blind, placebo-controlled study. Eur J Nutr. 2022;61(5):2673&#x2013;2685. doi:10.1007/s00394-022-02844-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00394-022-02844-9</ArticleId><ArticleId IdType="pubmed">35249118</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran C, Cock IE, Chen X, Feng Y. Antimicrobial Bacillus: metabolites and their mode of action. Antibiotics (Basel). 2022;11(1). doi:10.3390/antibiotics11010088.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics11010088</ArticleId><ArticleId IdType="pmc">PMC8772736</ArticleId><ArticleId IdType="pubmed">35052965</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilinskaya ON, Ulyanova VV, Yarullina DR, Gataullin IG. Secretome of intestinal Bacilli: a natural guard against pathologies. Front Microbiol. 2017;8:1666. doi:10.3389/fmicb.2017.01666.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2017.01666</ArticleId><ArticleId IdType="pmc">PMC5586196</ArticleId><ArticleId IdType="pubmed">28919884</ArticleId></ArticleIdList></Reference><Reference><Citation>Brutscher LM, Brogmeier C, Garvey SM, Spears JL. Preclinical safety assessment of Bacillus subtilis BS50 for probiotic and food applications. Microorganisms. 2022;10(5):1038. doi:10.3390/microorganisms10051038.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms10051038</ArticleId><ArticleId IdType="pmc">PMC9144164</ArticleId><ArticleId IdType="pubmed">35630480</ArticleId></ArticleIdList></Reference><Reference><Citation>Pariza MW, Gillies KO, Kraak-Ripple SF, Leyer G, Smith AB. Determining the safety of microbial cultures for consumption by humans and animals. Regul Toxicol Pharmacol. 2015;73(1):164&#x2013;171. doi:10.1016/j.yrtph.2015.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yrtph.2015.07.003</ArticleId><ArticleId IdType="pubmed">26165564</ArticleId></ArticleIdList></Reference><Reference><Citation>Boler BM, Serao MC, Bauer LL, Staeger MA, Boileau TW, Swanson KS, Fahey GC Jr. Digestive physiological outcomes related to polydextrose and soluble maize fibre consumption by healthy adult men. Br J Nutr. 2011;106(12):1864&#x2013;1871. doi:10.1017/S0007114511002388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0007114511002388</ArticleId><ArticleId IdType="pubmed">21736814</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Donnell LJ, Virjee J, Heaton KW. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. BMJ. 1990;300(6722):439&#x2013;440. doi:10.1136/bmj.300.6722.439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.300.6722.439</ArticleId><ArticleId IdType="pmc">PMC1662249</ArticleId><ArticleId IdType="pubmed">2107897</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder E, Cai B, DeMuro C, Morrison MF, Ball W. A new single-item sleep quality scale: results of psychometric evaluation in patients with chronic primary insomnia and depression. J Clin Sleep Med. 2018;14(11):1849&#x2013;1857. doi:10.5664/jcsm.7478.</Citation><ArticleIdList><ArticleId IdType="doi">10.5664/jcsm.7478</ArticleId><ArticleId IdType="pmc">PMC6223557</ArticleId><ArticleId IdType="pubmed">30373688</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499&#x2013;502. https://pubmed.ncbi.nlm.nih.gov/4337382/.</Citation><ArticleIdList><ArticleId IdType="pubmed">4337382</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman KE, Hill JL, Wei Y, Vazquez AR, Grubb DS, Trotter RE, Wrigley SD, Johnson SA, Foster MT, Weir TL. Examining the gastrointestinal and immunomodulatory effects of the novel probiotic Bacillus subtilis DE111. Int J Mol Sci. 2021;22(5):2453. doi:10.3390/ijms22052453.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22052453</ArticleId><ArticleId IdType="pmc">PMC7957723</ArticleId><ArticleId IdType="pubmed">33671071</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanifi A, Culpepper T, Mai V, Anand A, Ford AL, Ukhanova M, Christman M, Tompkins TA, Dahl WJ. Evaluation of Bacillus subtilis R0179 on gastrointestinal viability and general wellness: a randomised, double-blind, placebo-controlled trial in healthy adults. Benef Microbes. 2015;6(1):19&#x2013;27. doi:10.3920/BM2014.0031.</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2014.0031</ArticleId><ArticleId IdType="pubmed">25062611</ArticleId></ArticleIdList></Reference><Reference><Citation>Fakhry S, Sorrentini I, Ricca E, De Felice M, Baccigalupi L. Characterization of spore forming Bacilli isolated from the human gastrointestinal tract. J Appl Microbiol. 2008;105(6):2178&#x2013;2186. doi:10.1111/j.1365-2672.2008.03934.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2672.2008.03934.x</ArticleId><ArticleId IdType="pubmed">19120663</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong HA, To E, Fakhry S, Baccigalupi L, Ricca E, Cutting SM. Defining the natural habitat of Bacillus spore-formers. Res Microbiol. 2009;160(6):375&#x2013;379. doi:10.1016/j.resmic.2009.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resmic.2009.06.006</ArticleId><ArticleId IdType="pubmed">19589385</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyles L, Honda H, Logan NA, Halket G, La Ragione RM, McCartney AL. Recognition of greater diversity of Bacillus species and related bacteria in human faeces. Res Microbiol. 2012;163(1):3&#x2013;13. doi:10.1016/j.resmic.2011.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resmic.2011.10.004</ArticleId><ArticleId IdType="pubmed">22041546</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam NK, Uyen NQ, Hong HA, Duc le H, Hoa TT, Serra CR, Henriques AO, Cutting SM. The intestinal life cycle of Bacillus subtilis and close relatives. J Bacteriol. 2006;188(7):2692&#x2013;2700. doi:10.1128/JB.188.7.2692-2700.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JB.188.7.2692-2700.2006</ArticleId><ArticleId IdType="pmc">PMC1428398</ArticleId><ArticleId IdType="pubmed">16547057</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;ger R, Zaragoza J, Purpura M, Iametti S, Marengo M, Tinsley GM, Anzalone AJ, Oliver JM, Fiore W, Biffi A, et al. Probiotic administration increases amino acid absorption from plant protein: a placebo-controlled, randomized, double-blind, multicenter, crossover Study. Probiotics Antimicrob Proteins. 2020;12(4):1330&#x2013;1339. doi:10.1007/s12602-020-09656-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12602-020-09656-5</ArticleId><ArticleId IdType="pmc">PMC7641926</ArticleId><ArticleId IdType="pubmed">32358640</ArticleId></ArticleIdList></Reference><Reference><Citation>Tom Dieck H, Sch&#xf6;n C, Wagner T, Pankoke HC, Fluegel M, Speckmann B. A synbiotic formulation comprising Bacillus subtilis DSM 32315 and l-alanyl-l-glutamine improves intestinal butyrate levels and lipid metabolism in healthy humans. Nutrients. 2021;14(1):143. doi:10.3390/nu14010143.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14010143</ArticleId><ArticleId IdType="pmc">PMC8747176</ArticleId><ArticleId IdType="pubmed">35011015</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodnaruc AM, Prud&#x2019;homme D, Blanchet R, Giroux I. Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review. Nutr Metab (Lond). 2016;13:92. doi:10.1186/s12986-016-0153-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12986-016-0153-3</ArticleId><ArticleId IdType="pmc">PMC5148911</ArticleId><ArticleId IdType="pubmed">27990172</ArticleId></ArticleIdList></Reference><Reference><Citation>Seon MJ, Hwang SY, Son Y, Song J, Kim OY. Circulating GLP-1 levels as a potential indicator of metabolic syndrome risk in adult women. Nutrients. 2021;13(3):865. doi:10.3390/nu13030865.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13030865</ArticleId><ArticleId IdType="pmc">PMC8001839</ArticleId><ArticleId IdType="pubmed">33800785</ArticleId></ArticleIdList></Reference><Reference><Citation>Koopen A, Witjes J, Wortelboer K, Majait S, Prodan A, Levin E, Herrema H, Winkelmeijer M, Aalvink S, Jjghm B, et al. Duodenal Anaerobutyricum soehngenii infusion stimulates GLP-1 production, ameliorates glycaemic control and beneficially shapes the duodenal transcriptome in metabolic syndrome subjects: a randomised double-blind placebo-controlled cross-over study. Gut. 2022;71(8):1577&#x2013;1587. doi:10.1136/gutjnl-2020-323297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-323297</ArticleId><ArticleId IdType="pmc">PMC9279853</ArticleId><ArticleId IdType="pubmed">34697034</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon MC, Strassburger K, Nowotny B, Kolb H, Nowotny P, Burkart V, Zivehe F, Hwang JH, Stehle P, Pacini G, et al. Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: a proof of concept. Diabetes Care. 2015;38(10):1827&#x2013;1834. doi:10.2337/dc14-2690.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc14-2690</ArticleId><ArticleId IdType="pubmed">26084343</ArticleId></ArticleIdList></Reference><Reference><Citation>Balakumar M, Prabhu D, Sathishkumar C, Prabu P, Rokana N, Kumar R, Raghavan S, Soundarajan A, Grover S, Batish VK, et al. Improvement in glucose tolerance and insulin sensitivity by probiotic strains of Indian gut origin in high-fat diet-fed C57BL/6J mice. Eur J Nutr. 2018;57(1):279&#x2013;295. doi:10.1007/s00394-016-1317-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00394-016-1317-7</ArticleId><ArticleId IdType="pubmed">27757592</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Sharma RK, Malhotra S, Pothuraju R, Shandilya UK. Lactobacillus rhamnosus NCDC17 ameliorates type-2 diabetes by improving gut function, oxidative stress and inflammation in high-fat-diet fed and streptozotocintreated rats. Benef Microbes. 2017;8(2):243&#x2013;255. doi:10.3920/BM2016.0090.</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2016.0090</ArticleId><ArticleId IdType="pubmed">28008783</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Jiang J, Wang C, Li S, Yu L, Tian F, Zhao J, Zhang H, Chen W, Zhai Q. Meta-analysis of randomized controlled trials of the effects of probiotics on type 2 diabetes in adults. Clin Nutr. 2022;41(2):365&#x2013;373. doi:10.1016/j.clnu.2021.11.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2021.11.037</ArticleId><ArticleId IdType="pubmed">34999331</ArticleId></ArticleIdList></Reference><Reference><Citation>Labellarte G, Maher M. Tolerance and effect of a probiotic supplement delivered in capsule form. Food Nutr Sci. 2019;10:626&#x2013;634. doi:10.4236/fns.2019.106046.</Citation><ArticleIdList><ArticleId IdType="doi">10.4236/fns.2019.106046</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuentas A, Deaton J, Davidson J, Ardita C. The effect of Bacillus subtilis DE111 on the daily bowel movement profile for people with occasional gastrointestinal irregularity. J Prob Health. 2017;5(4). https://www.longdom.org/open-access/the-effect-of-embacillus-subtilisem-de111-on-the-daily-bowel-movement-profile-for-people-with-occasional-gastrointestina-36720.html.</Citation></Reference><Reference><Citation>Abhari K, Saadati S, Hosseini-Oskouiee F, Yari Z, Hosseini H, Sohrab G, Hejazi E, Agah S, Sadeghi A, Hekmatdoost A. Is Bacillus coagulans supplementation plus low FODMAP diet superior to low FODMAP diet in irritable bowel syndrome management? Eur J Nutr. 2020;59(5):2111&#x2013;2117. doi:10.1007/s00394-019-02060-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00394-019-02060-y</ArticleId><ArticleId IdType="pubmed">31327047</ArticleId></ArticleIdList></Reference><Reference><Citation>Saraiva M, O&#x2019;Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10(3):170&#x2013;181. doi:10.1038/nri2711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2711</ArticleId><ArticleId IdType="pubmed">20154735</ArticleId></ArticleIdList></Reference><Reference><Citation>Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. J Immunol. 2008;180(9):5771&#x2013;5777. doi:10.4049/jimmunol.180.9.5771.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.180.9.5771</ArticleId><ArticleId IdType="pubmed">18424693</ArticleId></ArticleIdList></Reference><Reference><Citation>Choghakhori R, Abbasnezhad A, Amani R, Alipour M. Sex-related differences in clinical symptoms, quality of life, and biochemical factors in irritable bowel syndrome. Dig Dis Sci. 2017;62(6):1550&#x2013;1560. doi:10.1007/s10620-017-4554-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-017-4554-6</ArticleId><ArticleId IdType="pubmed">28374085</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Shukla R, Ranjan P, Kumar A. Interleukin-10: a compelling therapeutic target in patients with irritable bowel syndrome. Clin Ther. 2017;39(3):632&#x2013;643. doi:10.1016/j.clinthera.2017.01.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2017.01.030</ArticleId><ArticleId IdType="pubmed">28237672</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivashkin V, Poluektov Y, Kogan E, Shifrin O, Sheptulin A, Kovaleva A, Kurbatova A, Krasnov G, Poluektova E. Disruption of the pro-inflammatory, anti-inflammatory cytokines and tight junction proteins expression, associated with changes of the composition of the gut microbiota in patients with irritable bowel syndrome. PLoS One. 2021;16(6):e0252930. doi:10.1371/journal.pone.0252930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0252930</ArticleId><ArticleId IdType="pmc">PMC8195381</ArticleId><ArticleId IdType="pubmed">34115808</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong HX, Yusoff NAA, Hor YY, Lew LC, Jaafar MH, Choi SB, Yusoff MSB, Wahid N, Abdullah MFIL, Zakaria N, et al. Lactobacillus plantarum DR7 improved upper respiratory tract infections via enhancing immune and inflammatory parameters: a randomized, double-blind, placebo-controlled study. J Dairy Sci. 2019;102(6):4783&#x2013;4797. doi:10.3168/jds.2018-16103.</Citation><ArticleIdList><ArticleId IdType="doi">10.3168/jds.2018-16103</ArticleId><ArticleId IdType="pubmed">30954261</ArticleId></ArticleIdList></Reference><Reference><Citation>Mageswary MU, Ang XY, Lee BK, Chung YF, Azhar SNA, Hamid IJA, Bakar HA, Roslan NS, Liu X, Kang X, et al. Probiotic Bifidobacterium lactis probio-M8 treated and prevented acute RTI, reduced antibiotic use and hospital stay in hospitalized young children: a randomized, double-blind, placebo-controlled study. Eur J Nutr. 2022;61(3):1679&#x2013;1691. doi:10.1007/s00394-021-02689-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00394-021-02689-8</ArticleId><ArticleId IdType="pmc">PMC8616720</ArticleId><ArticleId IdType="pubmed">34825264</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei LH, Zheng WX, Zhao ZT, Meng N, Zhang QR, Zhu WJ, Li RD, Liang XL, Li QY. A pilot study of the effect of Lactobacillus casei obtained from long-lived elderly on blood biochemical, oxidative, and inflammatory markers, and on gut microbiota in young volunteers. Nutrients. 2021;13(11):3891. doi:10.3390/nu13113891.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13113891</ArticleId><ArticleId IdType="pmc">PMC8622130</ArticleId><ArticleId IdType="pubmed">34836153</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz M, Linde HJ, Lehn N, Zimmermann K, Grossmann J, Falk W, Sch&#xf6;lmerich J. Immunomodulatory consequences of oral administration of Lactobacillus rhamnosus strain GG in healthy volunteers. J Dairy Res. 2003;70(2):165&#x2013;173. doi:10.1017/s0022029903006034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/s0022029903006034</ArticleId><ArticleId IdType="pubmed">12800870</ArticleId></ArticleIdList></Reference><Reference><Citation>Spaiser SJ, Culpepper T, Nieves C Jr, Ukhanova M, Mai V, Percival SS, Christman MC, Langkamp-Henken B. Lactobacillus gasseri KS-13, Bifidobacterium bifidum G9-1, and Bifidobacterium longum MM-2 ingestion induces a less inflammatory cytokine profile and a potentially beneficial shift in gut microbiota in older adults: a randomized, double-blind, placebo-controlled, crossover study. J Am Coll Nutr. 2015;34(6):459&#x2013;469. doi:10.1080/07315724.2014.983249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07315724.2014.983249</ArticleId><ArticleId IdType="pubmed">25909149</ArticleId></ArticleIdList></Reference><Reference><Citation>Parada Venegas D, De la Fuente MK, Landskron G, Gonz&#xe1;lez MJ, Quera R, Dijkstra G, Harmsen HJM, Faber KN, Hermoso MA. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol. 2019;10:277. doi:10.3389/fimmu.2019.00277.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00277</ArticleId><ArticleId IdType="pmc">PMC6421268</ArticleId><ArticleId IdType="pubmed">30915065</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazemi A, Soltani S, Ghorabi S, Keshtkar A, Daneshzad E, Nasri F, Mazloomi SM. Effect of probiotic and synbiotic supplementation on inflammatory markers in health and disease status: a systematic review and meta-analysis of clinical trials. Clin Nutr. 2020;39(3):789&#x2013;819. doi:10.1016/j.clnu.2019.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2019.04.004</ArticleId><ArticleId IdType="pubmed">31060892</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu M, Hashiguchi M, Shiga T, Tamura HO, Mochizuki M. Meta-Analysis: effects of probiotic supplementation on lipid profiles in normal to mildly hypercholesterolemic individuals. PLoS One. 2015;10(10):e0139795. doi:10.1371/journal.pone.0139795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0139795</ArticleId><ArticleId IdType="pmc">PMC4608827</ArticleId><ArticleId IdType="pubmed">26473340</ArticleId></ArticleIdList></Reference><Reference><Citation>Trotter RE, Vazquez AR, Grubb DS, Freedman KE, Grabos LE, Jones S, Gentile CL, Melby CL, Johnson SA, Weir TL. Bacillus subtilis DE111 intake may improve blood lipids and endothelial function in healthy adults. Benef Microbes. 2020;11(7):621&#x2013;630. doi:10.3920/BM2020.0039.</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2020.0039</ArticleId><ArticleId IdType="pmc">PMC8773468</ArticleId><ArticleId IdType="pubmed">33161737</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38331656</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2530-0180</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Endocrinologia, diabetes y nutricion</Title><ISOAbbreviation>Endocrinol Diabetes Nutr (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Evaluation of the efficacy of probiotics as treatment in irritable bowel syndrome.</ArticleTitle><Pagination><StartPage>19</StartPage><EndPage>30</EndPage><MedlinePgn>19-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.endien.2024.01.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2530-0180(24)00003-9</ELocationID><Abstract><AbstractText>Irritable bowel syndrome (IBS) is a gastrointestinal functional disorder mainly characterised by abdominal pain, bloating and altered bowel habits. Dysbiosis might seem to be involved in the pathogenesis of the disease. Probiotics represent a potential treatment, since these could favour the functional microbiota and improve symptoms. The aim was to review the effectiveness of the use of probiotics in IBS symptomatology, analysing the influence of duration and dose. 18 articles were included. At the individual level, Lactobacillus, Bifidobacterium and Bacillus could be useful in the treatment of symptoms. Bifidobacterium bifidum reported the best results (1&#x202f;&#xd7;&#x202f;10<sup>9</sup> CFU/day for 4 weeks). The most effective combination was 2 Lactobacillus strains, one of Bifidobacterium and one of Streptococcus (4&#x202f;&#xd7;&#x202f;10<sup>9</sup> CFU/day for 4 weeks). Future clinical trials should confirm these results and analyse the difference between individual and combined treatments.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ruiz-S&#xe1;nchez</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>&#xc1;rea de Nutrici&#xf3;n y Bromatolog&#xed;a, Departamento de Biolog&#xed;a Molecular e Ingenier&#xed;a Bioqu&#xed;mica, Universidad Pablo de Olavide, Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escudero-L&#xf3;pez</LastName><ForeName>Blanca</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>&#xc1;rea de Nutrici&#xf3;n y Bromatolog&#xed;a, Departamento de Biolog&#xed;a Molecular e Ingenier&#xed;a Bioqu&#xed;mica, Universidad Pablo de Olavide, Seville, Spain. Electronic address: besclop@upo.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Pach&#xf3;n</LastName><ForeName>Mar&#xed;a-Soledad</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>&#xc1;rea de Nutrici&#xf3;n y Bromatolog&#xed;a, Departamento de Biolog&#xed;a Molecular e Ingenier&#xed;a Bioqu&#xed;mica, Universidad Pablo de Olavide, Seville, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Endocrinol Diabetes Nutr (Engl Ed)</MedlineTA><NlmUniqueID>101717565</NlmUniqueID><ISSNLinking>2530-0180</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007778" MajorTopicYN="N">Lactobacillus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001644" MajorTopicYN="N">Bifidobacterium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015746" MajorTopicYN="N">Abdominal Pain</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">Microbiota</Keyword><Keyword MajorTopicYN="N">Probiotics</Keyword><Keyword MajorTopicYN="N">Probi&#xf3;ticos</Keyword><Keyword MajorTopicYN="N">S&#xed;ndrome del intestino irritable</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>9</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>8</Day><Hour>21</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38331656</ArticleId><ArticleId IdType="doi">10.1016/j.endien.2024.01.003</ArticleId><ArticleId IdType="pii">S2530-0180(24)00003-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34365915</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-2891</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Beneficial microbes</Title><ISOAbbreviation>Benef Microbes</ISOAbbreviation></Journal><ArticleTitle><i>Lactiplantibacillus plantarum</i> 299v (LP299V<sup>&#xae;</sup>): three decades of research.</ArticleTitle><Pagination><StartPage>441</StartPage><EndPage>465</EndPage><MedlinePgn>441-465</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3920/BM2020.0191</ELocationID><Abstract><AbstractText>This review aims to provide a comprehensive overview of the <i>in vitro</i>, animal, and clinical studies with the bacterial strain <i>Lactiplantibacillus plantarum</i> 299v (<i>L. plantarum</i> 299v; formerly named <i>Lactobacillus plantarum</i> 299v) published up until June 30, 2020. <i>L. plantarum</i> 299v is the most documented <i>L. plantarum</i> strain in the world, described in over 170 scientific publications out of which more than 60 are human clinical studies. The genome sequence of <i>L. plantarum</i> 299v has been determined and is available in the public domain (GenBank Accession number: NZ_LEAV01000004). The probiotic strain <i>L. plantarum</i> 299v was isolated from healthy human intestinal mucosa three decades ago by scientists at Lund University, Sweden. Thirty years later, a wealth of data coming from <i>in vitro</i>, animal, and clinical studies exist, showing benefits primarily for gastrointestinal health, such as reduced flatulence and abdominal pain in patients with irritable bowel syndrome (IBS). Moreover, several clinical studies have shown positive effects of <i>L. plantarum</i> 299v on iron absorption and more recently also on iron status. <i>L. plantarum</i> 299v is safe for human consumption and does not confer antibiotic resistance. It survives the harsh conditions of the human gastrointestinal tract, adheres to mannose residues on the intestinal epithelial cells and has in some cases been re-isolated more than ten days after administration ceased. Besides studying health benefits, research groups around the globe have investigated <i>L. plantarum</i> 299v in a range of applications and processes. <i>L. plantarum</i> 299v is used in many different food applications as well as in various dietary supplements. In a freeze-dried format, <i>L. plantarum</i> 299v is robust and stable at room temperature, enabling long shelf-lives of consumer healthcare products such as capsules, tablets, or powder sachets. The strain is patent protected for a wide range of indications and applications worldwide as well as trademarked as LP299V<sup>&#xae;</sup>.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nordstr&#xf6;m</LastName><ForeName>E Arvidsson</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Probi AB, Ideongatan 1A, 22370 Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teixeira</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Probi AB, Ideongatan 1A, 22370 Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montelius</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Probi AB, Ideongatan 1A, 22370 Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeppsson</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Surgery, Lund University, Universitetssjukhuset, 22184 Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larsson</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Probi AB, Ideongatan 1A, 22370 Lund, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Benef Microbes</MedlineTA><NlmUniqueID>101507616</NlmUniqueID><ISSNLinking>1876-2883</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>E1UOL152H7</RegistryNumber><NameOfSubstance UI="D007501">Iron</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019587" MajorTopicYN="N">Dietary Supplements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007422" MajorTopicYN="N">Intestines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048191" MajorTopicYN="Y">Lactobacillus plantarum</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">digestive health</Keyword><Keyword MajorTopicYN="N">iron absorption</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">probiotic</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>9</Day><Hour>5</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34365915</ArticleId><ArticleId IdType="doi">10.3920/BM2020.0191</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38717445</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1949-0984</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Gut microbes</Title><ISOAbbreviation>Gut Microbes</ISOAbbreviation></Journal><ArticleTitle>Metabolome-associated psychological comorbidities improvement in irritable bowel syndrome patients receiving a probiotic.</ArticleTitle><Pagination><StartPage>2347715</StartPage><MedlinePgn>2347715</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2347715</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/19490976.2024.2347715</ELocationID><Abstract><AbstractText>Our recent randomized, placebo-controlled study in Irritable Bowel Syndrome (IBS) patients with diarrhea or alternating bowel habits showed that the probiotic <i>Bifidobacterium longum</i> (BL) NCC3001 improves depression scores and decreases brain emotional reactivity. However, the involved metabolic pathways remain unclear. This analysis aimed to investigate the biochemical pathways underlying the beneficial effects of BL NCC3001 using metabolomic profiling. Patients received probiotic (1x 10<sup>10</sup>CFU, n=16) or placebo (n=19) daily for 6 weeks. Anxiety and depression were measured using the Hospital Anxiety and Depression Scale. Brain activity in response to negative emotional stimuli was assessed by functional Magnetic Resonance Imaging. Probiotic fecal abundance was quantified by qPCR. Quantitative measurement of specific panels of plasma host-microbial metabolites was performed by mass spectrometry-based metabolomics. Probiotic abundance in feces was associated with improvements in anxiety and depression scores, and a decrease in amygdala activation. The probiotic treatment increased the levels of butyric acid, tryptophan, N-acetyl tryptophan, glycine-conjugated bile acids, and free fatty acids. Butyric acid concentration correlated with lower anxiety and depression scores, and decreased amygdala activation. Furthermore, butyric acid concentration correlated with the probiotic abundance in feces. In patients with non-constipation IBS, improvements in psychological comorbidities and brain emotional reactivity were associated with an increased abundance of BL NCC3001 in feces and specific plasma metabolites, mainly butyric acid. These findings suggest the importance of a probiotic to thrive in the gut and highlight butyric acid as a potential biochemical marker linking microbial metabolism with beneficial effects on the gut-brain axis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Francois-Pierre</ForeName><Initials>FP</Initials><AffiliationInfo><Affiliation>Nestl&#xe9; Institute of Health Sciences, Soci&#xe9;t&#xe9; des Produits Nestl&#xe9; S.A, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cominetti</LastName><ForeName>Ornella</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Nestl&#xe9; Institute of Food Safety and Analytical Sciences, Soci&#xe9;t&#xe9; des Produits Nestl&#xe9; S.A, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>Bernard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Nestl&#xe9; Institute of Health Sciences, Soci&#xe9;t&#xe9; des Produits Nestl&#xe9; S.A, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Combremont</LastName><ForeName>S&#xe9;verine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Nestl&#xe9; Institute of Health Sciences, Soci&#xe9;t&#xe9; des Produits Nestl&#xe9; S.A, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marquis</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Nestl&#xe9; Institute of Health Sciences, Soci&#xe9;t&#xe9; des Produits Nestl&#xe9; S.A, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Guoxiang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>University of Hawaii Cancer Center (UHCC), Honolulu, HI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Human Metabolomics Institute, Inc, Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>University of Hawaii Cancer Center (UHCC), Honolulu, HI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinto-Sanchez</LastName><ForeName>Maria In&#xe9;s</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bercik</LastName><ForeName>Premysl</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergonzelli</LastName><ForeName>Gabriela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Nestl&#xe9; Institute of Health Sciences, Soci&#xe9;t&#xe9; des Produits Nestl&#xe9; S.A, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Gut Microbes</MedlineTA><NlmUniqueID>101495343</NlmUniqueID><ISSNLinking>1949-0976</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055442" MajorTopicYN="Y">Metabolome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="Y">Feces</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069978" MajorTopicYN="N">Bifidobacterium longum</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055432" MajorTopicYN="N">Metabolomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Irritable bowel syndrome (IBS)</Keyword><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">emotional reactivity</Keyword><Keyword MajorTopicYN="N">metabolomics, butyrate</Keyword><Keyword MajorTopicYN="N">probiotic</Keyword></KeywordList><CoiStatement>GB, BB, SC, JM, FPM, and OC are employees of Soci&#xe9;t&#xe9; des Produits Nestl&#xe9; S.A., Switzerland. WJ, GX, and PB received research support from Soci&#xe9;t&#xe9; des Produits Nestl&#xe9;, SA. PB holds the Richard Hunt-AstraZeneca Chair in Gastroenterology.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>8</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>8</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>8</Day><Hour>10</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38717445</ArticleId><ArticleId IdType="pmc">PMC11085950</ArticleId><ArticleId IdType="doi">10.1080/19490976.2024.2347715</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Collins SM, Surette M, Bercik P.. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol. 2012;10(11):735&#x2013;12. doi:10.1038/nrmicro2876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro2876</ArticleId><ArticleId IdType="pubmed">23000955</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L, Zhang J. Role of intestinal microbiota and metabolites on gut homeostasis and human diseases. BMC Immunol. 2017;18(1):2. doi:10.1186/s12865-016-0187-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12865-016-0187-3</ArticleId><ArticleId IdType="pmc">PMC5219689</ArticleId><ArticleId IdType="pubmed">28061847</ArticleId></ArticleIdList></Reference><Reference><Citation>Cryan JF, O&#x2019;Riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M, Codagnone MG, Cussotto S, Fulling C, Golubeva AV. et al. The microbiota-gut-brain axis. Physiol Rev. 2019;99(4):1877&#x2013;2013. doi:10.1152/physrev.00018.2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00018.2018</ArticleId><ArticleId IdType="pubmed">31460832</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyte M, Brown DR, Yamashita A. Evidence for PMAT- and OCT-like biogenic amine transporters in a probiotic strain of lactobacillus: implications for interkingdom communication within the microbiota-gut-brain axis. PloS One. 2018;13(1):e0191037. doi:10.1371/journal.pone.0191037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0191037</ArticleId><ArticleId IdType="pmc">PMC5764344</ArticleId><ArticleId IdType="pubmed">29324833</ArticleId></ArticleIdList></Reference><Reference><Citation>Strandwitz P, Kim KH, Terekhova D, Liu JK, Sharma A, Levering J, McDonald D, Dietrich D, Ramadhar TR, Lekbua A. et al. GABA-modulating bacteria of the human gut microbiota. Nat Microbiol. 2019;4(3):396&#x2013;403. doi:10.1038/s41564-018-0307-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-018-0307-3</ArticleId><ArticleId IdType="pmc">PMC6384127</ArticleId><ArticleId IdType="pubmed">30531975</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahony SM, Clarke G, Borre YE, Dinan TG, Cryan JF. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav Brain Res. 2015;277:32&#x2013;48. doi:10.1016/j.bbr.2014.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2014.07.027</ArticleId><ArticleId IdType="pubmed">25078296</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalile B, Van Oudenhove L, Vervliet B, Verbeke K. The role of short-chain fatty acids in microbiota&#x2013;gut&#x2013;brain communication. Nat Rev Gastroenterol Hepatol. 2019;16(8):461&#x2013;478. doi:10.1038/s41575-019-0157-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-019-0157-3</ArticleId><ArticleId IdType="pubmed">31123355</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer EA. Gut feelings: the emerging biology of gut&#x2013;brain communication. Nat Rev Neurosci. 2011;12(8):453&#x2013;466. doi:10.1038/nrn3071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3071</ArticleId><ArticleId IdType="pmc">PMC3845678</ArticleId><ArticleId IdType="pubmed">21750565</ArticleId></ArticleIdList></Reference><Reference><Citation>Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel Disorders. Gastroenterology. 2016;150:1393&#x2013;1407.</Citation><ArticleIdList><ArticleId IdType="pubmed">27144627</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman DA, Hasler WL. Rome IV&#x2014;functional GI disorders: disorders of gut-brain interaction. Gastroenterology. 2016;150(6):1257&#x2013;1261. doi:10.1053/j.gastro.2016.03.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.03.035</ArticleId><ArticleId IdType="pubmed">27147121</ArticleId></ArticleIdList></Reference><Reference><Citation>Karantanos T, Markoutsaki T, Gazouli M, Anagnou NP, Karamanolis DG. Current insights in to the pathophysiology of irritable bowel syndrome. Gut Pathog. 2010;2(1):3. doi:10.1186/1757-4749-2-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1757-4749-2-3</ArticleId><ArticleId IdType="pmc">PMC2876056</ArticleId><ArticleId IdType="pubmed">20465787</ArticleId></ArticleIdList></Reference><Reference><Citation>Stasi C, Rosselli M, Bellini M, Laffi G, Milani S. Altered neuro-endocrine&#x2013;immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model. J Gastroenterol. 2012;47(11):1177&#x2013;1185. doi:10.1007/s00535-012-0627-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00535-012-0627-7</ArticleId><ArticleId IdType="pubmed">22766747</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma G, Lynch MD, Lu J, Dang VT, Deng Y, Jury J, Umeh G, Miranda PM, Pigrau Pastor M, Sidani S. et al. Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice. Sci Transl Med. 2017;9(379):eaaf6397. doi:10.1126/scitranslmed.aaf6397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf6397</ArticleId><ArticleId IdType="pubmed">28251905</ArticleId></ArticleIdList></Reference><Reference><Citation>Durack J, Lynch SV. The gut microbiome: relationships with disease and opportunities for therapy. J Exp Med. 2019;216(1):20&#x2013;40. doi:10.1084/jem.20180448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20180448</ArticleId><ArticleId IdType="pmc">PMC6314516</ArticleId><ArticleId IdType="pubmed">30322864</ArticleId></ArticleIdList></Reference><Reference><Citation>Salami M. Interplay of good bacteria and central nervous system: cognitive aspects and mechanistic considerations. Front Neurosci. 2021;15:613120. doi:10.3389/fnins.2021.613120.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.613120</ArticleId><ArticleId IdType="pmc">PMC7904897</ArticleId><ArticleId IdType="pubmed">33642976</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto-Sanchez MI, Hall GB, Ghajar K, Nardelli A, Bolino C, Lau JT, Martin F-P, Cominetti O, Welsh C, Rieder A. et al. Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome. Gastroenterology. 2017;153(2):448&#x2013;59 e8. doi:10.1053/j.gastro.2017.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2017.05.003</ArticleId><ArticleId IdType="pubmed">28483500</ArticleId></ArticleIdList></Reference><Reference><Citation>Arboleya S, Watkins C, Stanton C, Ross RP. Gut bifidobacteria populations in human health and aging. Front Microbiol. 2016;7:1204. doi:10.3389/fmicb.2016.01204.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2016.01204</ArticleId><ArticleId IdType="pmc">PMC4990546</ArticleId><ArticleId IdType="pubmed">27594848</ArticleId></ArticleIdList></Reference><Reference><Citation>Bautzova T, Hockley JRF, Perez-Berezo T, Pujo J, Tranter MM, Desormeaux C, Barbaro MR, Basso L, Le Faouder P, Rolland C. et al. 5-oxoETE triggers nociception in constipation-predominant irritable bowel syndrome through MAS-related G protein&#x2013;coupled receptor D. Sci Signal. 2018;11(561):eaal2171. doi:10.1126/scisignal.aal2171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.aal2171</ArticleId><ArticleId IdType="pmc">PMC6411128</ArticleId><ArticleId IdType="pubmed">30563864</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyall SC. Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Front Aging Neurosci. 2015;7:52. doi:10.3389/fnagi.2015.00052.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2015.00052</ArticleId><ArticleId IdType="pmc">PMC4404917</ArticleId><ArticleId IdType="pubmed">25954194</ArticleId></ArticleIdList></Reference><Reference><Citation>Song C. Essential fatty acids as potential anti-inflammatory agents in the treatment of affective disorders. Mod Trends Pharmacopsychiatry. 2013;28:75&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">25224892</ArticleId></ArticleIdList></Reference><Reference><Citation>Provensi G, Schmidt SD, Boehme M, Bastiaanssen TFS, Rani B, Costa A, Busca K, Fouhy F, Strain C, Stanton C. et al. Preventing adolescent stress-induced cognitive and microbiome changes by diet. Proc Natl Acad Sci U S A. 2019;116(19):9644&#x2013;9651. doi:10.1073/pnas.1820832116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1820832116</ArticleId><ArticleId IdType="pmc">PMC6511019</ArticleId><ArticleId IdType="pubmed">31010921</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopaldas M, Zanderigo F, Zhan S, Ogden RT, Miller JM, Rubin-Falcone H, Cooper TB, Oquendo MA, Sullivan G, Mann JJ. et al. Brain serotonin transporter binding, plasma arachidonic acid and depression severity: a positron emission tomography study of major depression. J Affect Disord. 2019;257:495&#x2013;503. doi:10.1016/j.jad.2019.07.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2019.07.035</ArticleId><ArticleId IdType="pmc">PMC6886679</ArticleId><ArticleId IdType="pubmed">31319341</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuboi H, Watanabe M, Kobayashi F, Kimura K, Kinae N. Associations of depressive symptoms with serum proportions of palmitic and arachidonic acids, and &#x3b1;-tocopherol effects among male population &#x2013; a preliminary study. Clin Nutr. 2013;32(2):289&#x2013;293. doi:10.1016/j.clnu.2012.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2012.07.011</ArticleId><ArticleId IdType="pubmed">22901744</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe AR, Ogbonna EM, Lim S, Li Y, Zhang J. Dietary linoleic and oleic fatty acids in relation to severe depressed mood: 10 years follow-up of a national cohort. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(6):972&#x2013;977. doi:10.1016/j.pnpbp.2009.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2009.05.002</ArticleId><ArticleId IdType="pubmed">19427349</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes MF, Mutch DM, Leri F. The relationship between fatty acids and different depression-related brain regions, and their potential role as biomarkers of response to antidepressants. Nutrients. 2017;9(3):298. doi:10.3390/nu9030298.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu9030298</ArticleId><ArticleId IdType="pmc">PMC5372961</ArticleId><ArticleId IdType="pubmed">28304335</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain G, Schmitt F, Loeffler J-P, Gonzalez De Aguilar J. Fatting the brain: a brief of recent research. Front Cell Neurosci. 2013;7. doi:10.3389/fncel.2013.00144.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2013.00144</ArticleId><ArticleId IdType="pmc">PMC3766822</ArticleId><ArticleId IdType="pubmed">24058332</ArticleId></ArticleIdList></Reference><Reference><Citation>Bercik P, Verdu EF, Foster JA, Macri J, Potter M, Huang X, Malinowski P, Jackson W, Blennerhassett P, Neufeld KA. et al. Chronic gastrointestinal inflammation induces anxiety-like behavior and alters central nervous system biochemistry in mice. Gastroenterology. 2010;139(6):2102&#x2013;12 e1. doi:10.1053/j.gastro.2010.06.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2010.06.063</ArticleId><ArticleId IdType="pubmed">20600016</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeffery IB, Das A, O&#x2019;Herlihy E, Coughlan S, Cisek K, Moore M, Bradley F, Carty T, Pradhan M, Dwibedi C. et al. Differences in fecal microbiomes and metabolomes of people with vs without irritable bowel syndrome and bile acid malabsorption. Gastroenterology. 2020;158(4):1016&#x2013;28 e8. doi:10.1053/j.gastro.2019.11.301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2019.11.301</ArticleId><ArticleId IdType="pubmed">31843589</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong MJ, Carey MC. The hydrophobic-hydrophilic balance of bile salts. Inverse correlation between reverse-phase high performance liquid chromatographic mobilities and micellar cholesterol-solubilizing capacities. J Lipid Res. 1982;23(1):70&#x2013;80. doi:10.1016/S0022-2275(20)38175-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2275(20)38175-X</ArticleId><ArticleId IdType="pubmed">7057113</ArticleId></ArticleIdList></Reference><Reference><Citation>Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WC. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington&#x2019;s disease. Proc Natl Acad Sci U S A. 2002;99(16):10671&#x2013;10676. doi:10.1073/pnas.162362299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.162362299</ArticleId><ArticleId IdType="pmc">PMC125009</ArticleId><ArticleId IdType="pubmed">12149470</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramalho RM, Viana RJ, Low WC, Steer CJ, Rodrigues CM. Bile acids and apoptosis modulation: an emerging role in experimental Alzheimer&#x2019;s disease. Trends Mol Med. 2008;14(2):54&#x2013;62. doi:10.1016/j.molmed.2007.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2007.12.001</ArticleId><ArticleId IdType="pubmed">18218342</ArticleId></ArticleIdList></Reference><Reference><Citation>Sola S, Amaral JD, Borralho PM, Ramalho RM, Castro RE, Aranha MM, Steer CJ, Rodrigues CMP. Functional modulation of nuclear steroid receptors by tauroursodeoxycholic acid reduces amyloid &#x3b2;-peptide-induced apoptosis. Mol Endocrinol. 2006;20(10):2292&#x2013;2303. doi:10.1210/me.2006-0063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/me.2006-0063</ArticleId><ArticleId IdType="pubmed">16728529</ArticleId></ArticleIdList></Reference><Reference><Citation>Keitel V, Gorg B, Bidmon HJ, Zemtsova I, Spomer L, Zilles K, H&#xe4;ussinger D. The bile acid receptor TGR5 (gpbar-1) acts as a neurosteroid receptor in brain. Glia. 2010;58(15):1794&#x2013;1805. doi:10.1002/glia.21049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.21049</ArticleId><ArticleId IdType="pubmed">20665558</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertens KL, Kalsbeek A, Soeters MR, Eggink HM. Bile acid signaling pathways from the enterohepatic circulation to the central nervous system. Front Neurosci. 2017;11:617. doi:10.3389/fnins.2017.00617.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2017.00617</ArticleId><ArticleId IdType="pmc">PMC5681992</ArticleId><ArticleId IdType="pubmed">29163019</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosie AM, Wilkins ME, da Silva HM, Smart TG. Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites. Nature. 2006;444(7118):486&#x2013;489. doi:10.1038/nature05324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05324</ArticleId><ArticleId IdType="pubmed">17108970</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkins TA, Nguyen JC, Polglaze KE, Bertrand PP. Influence of tryptophan and serotonin on mood and cognition with a possible role of the gut-brain axis. Nutrients. 2016;8(1):56. doi:10.3390/nu8010056.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu8010056</ArticleId><ArticleId IdType="pmc">PMC4728667</ArticleId><ArticleId IdType="pubmed">26805875</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes J, Mudgal J, Rao CM, Arora D, Basu Mallik S, Pai KSR, Nampoothiri M. N-acetyl-L-tryptophan, a substance-P receptor antagonist attenuates aluminum-induced spatial memory deficit in rats. Toxicol Mech Methods. 2018;28(5):328&#x2013;334. doi:10.1080/15376516.2017.1411412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15376516.2017.1411412</ArticleId><ArticleId IdType="pubmed">29185389</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirianni AC, Jiang J, Zeng J, Mao LL, Zhou S, Sugarbaker P, Zhang X, Li W, Friedlander RM, Wang X. et al. N-acetyl-l-tryptophan, but not N-acetyl-d-tryptophan, rescues neuronal cell death in models of amyotrophic lateral sclerosis. J Neurochem. 2015;134(5):956&#x2013;968. doi:10.1111/jnc.13190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13190</ArticleId><ArticleId IdType="pubmed">26031348</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vuyst L, Leroy F. Cross-feeding between bifidobacteria and butyrate-producing colon bacteria explains bifdobacterial competitiveness, butyrate production, and gas production. Int J Food Microbiol. 2011;149(1):73&#x2013;80. doi:10.1016/j.ijfoodmicro.2011.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijfoodmicro.2011.03.003</ArticleId><ArticleId IdType="pubmed">21450362</ArticleId></ArticleIdList></Reference><Reference><Citation>Caspani G, Kennedy S, Foster JA, Swann J. Gut microbial metabolites in depression: understanding the biochemical mechanisms. Microb Cell. 2019;6(10):454&#x2013;481. doi:10.15698/mic2019.10.693.</Citation><ArticleIdList><ArticleId IdType="doi">10.15698/mic2019.10.693</ArticleId><ArticleId IdType="pmc">PMC6780009</ArticleId><ArticleId IdType="pubmed">31646148</ArticleId></ArticleIdList></Reference><Reference><Citation>Braniste V, Al-Asmakh M, Kowal C, Anuar F, Abbaspour A, Toth M, Korecka A, Bakocevic N, Ng LG, Kundu P. et al. The gut microbiota influences blood-brain barrier permeability in mice. Sci Transl Med. 2014;6(263):263ra158. doi:10.1126/scitranslmed.3009759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3009759</ArticleId><ArticleId IdType="pmc">PMC4396848</ArticleId><ArticleId IdType="pubmed">25411471</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyles L, Snelling T, Umlai UK, Nicholson JK, Carding SR, Glen RC, McArthur S. Microbiome&#x2013;host systems interactions: protective effects of propionate upon the blood&#x2013;brain barrier. Microbiome. 2018;6(1):55. doi:10.1186/s40168-018-0439-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40168-018-0439-y</ArticleId><ArticleId IdType="pmc">PMC5863458</ArticleId><ArticleId IdType="pubmed">29562936</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehme M, Guzzetta KE, Was&#xe9;n C, Cox LM. The gut microbiota is an emerging target for improving brain health during ageing. Gut Microbiome. 2023;4:e2. doi:10.1017/gmb.2022.11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/gmb.2022.11</ArticleId><ArticleId IdType="pmc">PMC10174391</ArticleId><ArticleId IdType="pubmed">37179659</ArticleId></ArticleIdList></Reference><Reference><Citation>Papanicolas LE, Wang Y, Choo JM, Gordon DL, Wesselingh SL, Rogers GB. Optimisation of a propidium monoazide based method to determine the viability of microbes in faecal slurries for transplantation. J Microbiol Methods. 2019;156:40&#x2013;45. doi:10.1016/j.mimet.2018.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mimet.2018.12.001</ArticleId><ArticleId IdType="pubmed">30529117</ArticleId></ArticleIdList></Reference><Reference><Citation>Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5):1480&#x2013;1491. doi:10.1053/j.gastro.2005.11.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2005.11.061</ArticleId><ArticleId IdType="pubmed">16678561</ArticleId></ArticleIdList></Reference><Reference><Citation>Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361&#x2013;370. doi:10.1111/j.1600-0447.1983.tb09716.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0447.1983.tb09716.x</ArticleId><ArticleId IdType="pubmed">6880820</ArticleId></ArticleIdList></Reference><Reference><Citation>Puhan MA, Frey M, Buchi S, Schunemann HJ. The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. Health Qual Life Outcomes. 2008;6(1):46. doi:10.1186/1477-7525-6-46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7525-6-46</ArticleId><ArticleId IdType="pmc">PMC2459149</ArticleId><ArticleId IdType="pubmed">18597689</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie G, Zhong W, Li H, Li Q, Qiu Y, Zheng X, Chen H, Zhao X, Zhang S, Zhou Z. et al. Alteration of bile acid metabolism in the rat induced by chronic ethanol consumption. Faseb J. 2013;27(9):3583&#x2013;3593. doi:10.1096/fj.13-231860.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.13-231860</ArticleId><ArticleId IdType="pmc">PMC3752538</ArticleId><ArticleId IdType="pubmed">23709616</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Ni Y, Su M, Li H, Dong F, Chen W, Wei R, Zhang L, Guiraud SP, Martin F-P. et al. High throughput and quantitative measurement of microbial metabolome by gas chromatography/mass spectrometry using automated alkyl chloroformate derivatization. Anal Chem. 2017;89(10):5565&#x2013;5577. doi:10.1021/acs.analchem.7b00660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.7b00660</ArticleId><ArticleId IdType="pmc">PMC5663283</ArticleId><ArticleId IdType="pubmed">28437060</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferslew BC, Xie G, Johnston CK, Su M, Stewart PW, Jia W, Brouwer KLR, Sidney Barritt A. Altered bile acid metabolome in patients with Nonalcoholic Steatohepatitis. Dig Dis Sci. 2015;60(11):3318&#x2013;3328. doi:10.1007/s10620-015-3776-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-015-3776-8</ArticleId><ArticleId IdType="pmc">PMC4864493</ArticleId><ArticleId IdType="pubmed">26138654</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouge C, Goldenberg O, Ferraris L, Berger B, Rochat F, Legrand A, G&#xf6;bel UB, Vodovar M, Voyer M, Roz&#xe9; J-C. et al. Investigation of the intestinal microbiota in preterm infants using different methods. Anaerobe. 2010;16(4):362&#x2013;370. doi:10.1016/j.anaerobe.2010.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.anaerobe.2010.06.002</ArticleId><ArticleId IdType="pubmed">20541022</ArticleId></ArticleIdList></Reference><Reference><Citation>Bercik P, Park AJ, Sinclair D, Khoshdel A, Lu J, Huang X, Deng Y, Blennerhassett PA, Fahnestock M, Moine D. et al. The anxiolytic effect of Bifidobacterium longum NCC3001 involves vagal pathways for gut-brain communication. Neurogastroenterol Motil. 2011;23(12):1132&#x2013;1139. doi:10.1111/j.1365-2982.2011.01796.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2011.01796.x</ArticleId><ArticleId IdType="pmc">PMC3413724</ArticleId><ArticleId IdType="pubmed">21988661</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CM, Aziz M, Kachur S, Hsueh PR, Huang YT, Keim P, Price LB. BactQuant: an enhanced broad-coverage bacterial quantitative real-time PCR assay. BMC Microbiol. 2012;12(1):56. doi:10.1186/1471-2180-12-56.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2180-12-56</ArticleId><ArticleId IdType="pmc">PMC3464140</ArticleId><ArticleId IdType="pubmed">22510143</ArticleId></ArticleIdList></Reference><Reference><Citation>Trygg J, Wold S. O2-PLS, a two-block (X&#x2013;Y) latent variable regression (LVR) method with an integral OSC filter. JChemom. 2003;17(1):53&#x2013;64. doi:10.1002/cem.775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cem.775</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37868345</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>31</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2235-2988</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in cellular and infection microbiology</Title><ISOAbbreviation>Front Cell Infect Microbiol</ISOAbbreviation></Journal><ArticleTitle>Review of microbiota gut brain axis and innate immunity in inflammatory and infective diseases.</ArticleTitle><Pagination><StartPage>1282431</StartPage><MedlinePgn>1282431</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1282431</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcimb.2023.1282431</ELocationID><Abstract><AbstractText>The microbiota gut brain (MGB) axis has been shown to play a significant role in the regulation of inflammatory and infective diseases. Exploring the structure and communication mode of MGB axis is crucial for understanding its role in diseases, and studying the signaling pathways and regulatory methods of MGB axis regulation in diseases is also of profound significance for future clinical research. This article reviews the composition, communication mechanism of MGB axis and its role in inflammatory and infective diseases, including Parkinson's disease (PD), Alzheimer's disease (AD), multiple sclerosis (MS), autism spectrum disorder (ASD), depression, psoriasis, irritable bowel syndrome (IBS), and inflammatory bowel diseases (IBD). In addition, our investigation delved into the regulatory functions of the inflammasome, IFN-I, NF-&#x3ba;B, and PARK7/DJ-1 innate immune signaling pathway in the context of inflammatory and infective diseases. Ultimately, we discussed the efficacy of various interventions, including fecal microbiota transplantation (FMT), antibiotics, probiotics, prebiotics, synbiotics, and postbiotics, in the management of inflammatory and infective diseases. Understanding the role and mechanism of the MGB axis might make positive effects in the treatment of inflammatory and infective diseases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Yuan, He, Xie, Feng, Gao and Cai.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Chongshan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Obstetrics, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, Changchun, Jilin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Yuhong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, Changchun, Jilin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Kunyu</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, Changchun, Jilin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Lianjun</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, Changchun, Jilin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Shouyang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Obstetrics, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Lifu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Obstetrics, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cell Infect Microbiol</MedlineTA><NlmUniqueID>101585359</NlmUniqueID><ISSNLinking>2235-2988</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087502" MajorTopicYN="N">Brain-Gut Axis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067877" MajorTopicYN="Y">Autism Spectrum Disorder</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003141" MajorTopicYN="Y">Communicable Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">infective diseases</Keyword><Keyword MajorTopicYN="N">inflammatory diseases</Keyword><Keyword MajorTopicYN="N">innate immune</Keyword><Keyword MajorTopicYN="N">microbiota gut brain axis</Keyword><Keyword MajorTopicYN="N">pathogenesis</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>23</Day><Hour>4</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37868345</ArticleId><ArticleId IdType="pmc">PMC10585369</ArticleId><ArticleId IdType="doi">10.3389/fcimb.2023.1282431</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adolph T. E., Meyer M., Schwarzler J., Mayr L., Grabherr F., Tilg H. (2022). The metabolic nature of inflammatory bowel diseases. Nat. Rev. Gastroenterol. Hepatol. 19 (12), 753&#x2013;767. doi:&#xa0; 10.1038/s41575-022-00658-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-022-00658-y</ArticleId><ArticleId IdType="pubmed">35906289</ArticleId></ArticleIdList></Reference><Reference><Citation>Agirman G., Hsiao E. Y. (2021). SnapShot: The microbiota-gut-brain axis. Cell 184 (9), 2524&#x2013;2524.e1. doi:&#xa0; 10.1016/j.cell.2021.03.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.03.022</ArticleId><ArticleId IdType="pubmed">33930299</ArticleId></ArticleIdList></Reference><Reference><Citation>Agusti A., Garcia-Pardo M. P., Lopez-Almela I., Campillo I., Maes M., Romani-Perez M., et al. (2018). Interplay between the gut-brain axis, obesity and cognitive function. Front. Neurosci. 12. doi:&#xa0; 10.3389/fnins.2018.00155</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00155</ArticleId><ArticleId IdType="pmc">PMC5864897</ArticleId><ArticleId IdType="pubmed">29615850</ArticleId></ArticleIdList></Reference><Reference><Citation>Aleem D., Tohid H. (2018). Pro-inflammatory cytokines, biomarkers, genetics and the immune system: A mechanistic approach of depression and psoriasis. Rev. Colomb Psiquiatr (Engl Ed) 47 (3), 177&#x2013;186. doi:&#xa0; 10.1016/j.rcp.2017.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rcp.2017.03.002</ArticleId><ArticleId IdType="pubmed">30017041</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida P. P., Tavares-Gomes A. L., Stockler-Pinto M. B. (2022). Relaxing the "second brain": nutrients and bioactive compounds as a therapeutic and preventive strategy to alleviate oxidative stress in the enteric nervous system. Nutr. Rev. 80 (11), 2206&#x2013;2224. doi:&#xa0; 10.1093/nutrit/nuac030</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nutrit/nuac030</ArticleId><ArticleId IdType="pubmed">35609566</ArticleId></ArticleIdList></Reference><Reference><Citation>Altomare A., Di Rosa C., Imperia E., Emerenziani S., Cicala M., Guarino M. (2021). Diarrhea predominant-irritable bowel syndrome (IBS-D): effects of different nutritional patterns on intestinal dysbiosis and symptoms. Nutrients 13 (5), 1506&#x2013;1530. doi:&#xa0; 10.3390/nu13051506</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13051506</ArticleId><ArticleId IdType="pmc">PMC8146452</ArticleId><ArticleId IdType="pubmed">33946961</ArticleId></ArticleIdList></Reference><Reference><Citation>Ancona A., Petito C., Iavarone I., Petito V., Galasso L., Leonetti A., et al. (2021). The gut-brain axis in irritable bowel syndrome and inflammatory bowel disease. Dig Liver Dis. 53 (3), 298&#x2013;305. doi:&#xa0; 10.1016/j.dld.2020.11.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2020.11.026</ArticleId><ArticleId IdType="pubmed">33303315</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreo-Martinez P., Rubio-Aparicio M., Sanchez-Meca J., Veas A., Martinez-Gonzalez A. E. (2022). A meta-analysis of gut microbiota in children with autism. J. Autism Dev. Disord. 52 (3), 1374&#x2013;1387. doi:&#xa0; 10.1007/s10803-021-05002-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10803-021-05002-y</ArticleId><ArticleId IdType="pubmed">33948825</ArticleId></ArticleIdList></Reference><Reference><Citation>Anselmi L., Bove C., Coleman F. H., Le K M. P., Venkiteswaran K., T. Subramanian and R. A. (2018). Travagli: Ingestion of subthreshold doses of environmental toxins induces ascending Parkinsonism in the rat. NPJ Parkinsons Dis. 4, 30. doi:&#xa0; 10.1038/s41531-018-0066-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-018-0066-0</ArticleId><ArticleId IdType="pmc">PMC6160447</ArticleId><ArticleId IdType="pubmed">30302391</ArticleId></ArticleIdList></Reference><Reference><Citation>Arentsen T., Qian Y., Gkotzis S., Femenia T., Wang T., Udekwu K., et al. (2017). The bacterial peptidoglycan-sensing molecule Pglyrp2 modulates brain development and behavior. Mol. Psychiatry 22 (2), 257&#x2013;266. doi:&#xa0; 10.1038/mp.2016.182</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2016.182</ArticleId><ArticleId IdType="pmc">PMC5285465</ArticleId><ArticleId IdType="pubmed">27843150</ArticleId></ArticleIdList></Reference><Reference><Citation>Arotcarena M. L., Dovero S., Prigent A., Bourdenx M., Camus S., Porras G., et al. (2020). Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. Brain 143 (5), 1462&#x2013;1475. doi:&#xa0; 10.1093/brain/awaa096</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa096</ArticleId><ArticleId IdType="pubmed">32380543</ArticleId></ArticleIdList></Reference><Reference><Citation>Asadi A., Shadab M. N., Mohamadi M. H., Shokri F., Heidary M., Sadeghifard N., et al. (2022). Obesity and gut-microbiota-brain axis: A narrative review. J. Clin. Lab. Anal. 36 (5), e24420. doi:&#xa0; 10.1002/jcla.24420</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.24420</ArticleId><ArticleId IdType="pmc">PMC9102524</ArticleId><ArticleId IdType="pubmed">35421277</ArticleId></ArticleIdList></Reference><Reference><Citation>Aygun H. (2020). Trazodone increases seizures in a genetic WAG/Rij rat model of absence epilepsy while decreasing them in penicillin-evoked focal seizure model. Epilepsy Behav. 103 (Pt A), 106847. doi:&#xa0; 10.1016/j.yebeh.2019.106847</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yebeh.2019.106847</ArticleId><ArticleId IdType="pubmed">31864946</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachurin S. O., Gavrilova S. I., Samsonova A., Barreto G. E., Aliev G. (2018). Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention. Pharmacol. Res. 129, 216&#x2013;226. doi:&#xa0; 10.1016/j.phrs.2017.11.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2017.11.021</ArticleId><ArticleId IdType="pubmed">29170097</ArticleId></ArticleIdList></Reference><Reference><Citation>Balmus I. M., Ciobica A., Cojocariu R., Luca A. C., Gorgan L. (2020). Irritable bowel syndrome and neurological deficiencies: is there A relationship? The possible relevance of the oxidative stress status. Medicina (Kaunas) 56 (4), 175&#x2013;192. doi:&#xa0; 10.3390/medicina56040175</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina56040175</ArticleId><ArticleId IdType="pmc">PMC7230401</ArticleId><ArticleId IdType="pubmed">32295083</ArticleId></ArticleIdList></Reference><Reference><Citation>Bamigbade G. B., Subhash A. J., Kamal-Eldin A., Nystrom L., Ayyash M. (2022). An updated review on prebiotics: insights on potentials of food seeds waste as source of potential prebiotics. Molecules 27 (18), 5947&#x2013;5980. doi:&#xa0; 10.3390/molecules27185947</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27185947</ArticleId><ArticleId IdType="pmc">PMC9505924</ArticleId><ArticleId IdType="pubmed">36144679</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao C. H., Wang C. Y., Li G. N., Yan Y. L., Wang D., Jin X. M., et al. (2019). Effect of mild moxibustion on intestinal microbiota and NLRP6 inflammasome signaling in rats with post-inflammatory irritable bowel syndrome. World J. Gastroenterol. 25 (32), 4696&#x2013;4714. doi:&#xa0; 10.3748/wjg.v25.i32.4696</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v25.i32.4696</ArticleId><ArticleId IdType="pmc">PMC6718040</ArticleId><ArticleId IdType="pubmed">31528095</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastiaanssen T., Cowan C., Claesson M. J., Dinan T. G., Cryan J. F. (2019). Making sense of ... the microbiome in psychiatry. Int. J. Neuropsychopharmacol. 22 (1), 37&#x2013;52. doi:&#xa0; 10.1093/ijnp/pyy067</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ijnp/pyy067</ArticleId><ArticleId IdType="pmc">PMC6313131</ArticleId><ArticleId IdType="pubmed">30099552</ArticleId></ArticleIdList></Reference><Reference><Citation>Berer K., Gerdes L. A., Cekanaviciute E., Jia X., Xiao L., Xia Z., et al. (2017). Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc. Natl. Acad. Sci. U.S.A. 114 (40), 10719&#x2013;10724. doi:&#xa0; 10.1073/pnas.1711233114</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1711233114</ArticleId><ArticleId IdType="pmc">PMC5635914</ArticleId><ArticleId IdType="pubmed">28893994</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyder A. (2018). In pursuit of the epithelial mechanosensitivity mechanisms. Front. Endocrinol. (Lausanne) 9. doi:&#xa0; 10.3389/fendo.2018.00804</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2018.00804</ArticleId><ArticleId IdType="pmc">PMC6340920</ArticleId><ArticleId IdType="pubmed">30697191</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt S., Devadoss T., Jha N. K., Baidya M., Gupta G., Chellappan D. K., et al. (2023). Targeting inflammation: a potential approach for the treatment of depression. Metab. Brain Dis. 38 (1), 45&#x2013;59. doi:&#xa0; 10.1007/s11011-022-01095-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-022-01095-1</ArticleId><ArticleId IdType="pubmed">36239867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattarai Y., Williams B. B., Battaglioli E. J., Whitaker W. R., Till L., Grover M., et al. (2018). Gut microbiota-produced tryptamine activates an epithelial G-protein-coupled receptor to increase colonic secretion. Cell Host Microbe 23 (6), 775&#x2013;785.e5. doi:&#xa0; 10.1016/j.chom.2018.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2018.05.004</ArticleId><ArticleId IdType="pmc">PMC6055526</ArticleId><ArticleId IdType="pubmed">29902441</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaz B., Bazin T., Pellissier S. (2018). The vagus nerve at the interface of the microbiota-gut-brain axis. Front. Neurosci. 12. doi:&#xa0; 10.3389/fnins.2018.00049</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00049</ArticleId><ArticleId IdType="pmc">PMC5808284</ArticleId><ArticleId IdType="pubmed">29467611</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaz B., Sinniger V., Pellissier S. (2017). The vagus nerve in the neuro-immune axis: implications in the pathology of the gastrointestinal tract. Front. Immunol. 8. doi:&#xa0; 10.3389/fimmu.2017.01452</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01452</ArticleId><ArticleId IdType="pmc">PMC5673632</ArticleId><ArticleId IdType="pubmed">29163522</ArticleId></ArticleIdList></Reference><Reference><Citation>Braakman H., van Ingen J. (2018). Can epilepsy be treated by antibiotics? J. Neurol. 265 (8), 1934&#x2013;1936. doi:&#xa0; 10.1007/s00415-018-8943-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8943-3</ArticleId><ArticleId IdType="pubmed">29931545</ArticleId></ArticleIdList></Reference><Reference><Citation>Brummelte S., Mc G. E., Bonnin A., Oberlander T. F. (2017). Developmental changes in serotonin signaling: Implications for early brain function, behavior and adaptation. Neuroscience 342, 212&#x2013;231. doi:&#xa0; 10.1016/j.neuroscience.2016.02.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2016.02.037</ArticleId><ArticleId IdType="pmc">PMC5310545</ArticleId><ArticleId IdType="pubmed">26905950</ArticleId></ArticleIdList></Reference><Reference><Citation>
Cai L., Gong Q., Qi L., Xu T., Suo Q., Li X., et al. (2022). ACT001 attenuates microglia-mediated neuroinflammation after traumatic brain injury <i>via</i> inhibiting AKT/NFkappaB/NLRP3 pathway. Cell Commun. Signal.
20 (1), 56. doi:&#xa0; 10.1186/s12964-022-00862-y
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12964-022-00862-y</ArticleId><ArticleId IdType="pmc">PMC9035258</ArticleId><ArticleId IdType="pubmed">35461293</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell C., Kandalgaonkar M. R., Golonka R. M., Yeoh B. S., Vijay-Kumar M., Saha P. (2023). Crosstalk between gut microbiota and host immunity: impact on inflammation and immunotherapy. Biomedicines 11 (2), 274&#x2013;334. doi:&#xa0; 10.3390/biomedicines11020294</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11020294</ArticleId><ArticleId IdType="pmc">PMC9953403</ArticleId><ArticleId IdType="pubmed">36830830</ArticleId></ArticleIdList></Reference><Reference><Citation>Caputi V., Giron M. C. (2018). Microbiome-gut-brain axis and toll-like receptors in parkinson's disease. Int. J. Mol. Sci. 19 (6), 1689&#x2013;1707. doi:&#xa0; 10.3390/ijms19061689</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19061689</ArticleId><ArticleId IdType="pmc">PMC6032048</ArticleId><ArticleId IdType="pubmed">29882798</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlessi A. S., Borba L. A., Zugno A. I., Quevedo J., Reus G. Z. (2021). Gut microbiota-brain axis in depression: The role of neuroinflammation. Eur. J. Neurosci. 53 (1), 222&#x2013;235. doi:&#xa0; 10.1111/ejn.14631</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejn.14631</ArticleId><ArticleId IdType="pubmed">31785168</ArticleId></ArticleIdList></Reference><Reference><Citation>Carthy E., Ellender T. (2021). Histamine, neuroinflammation and neurodevelopment: A review. Front. Neurosci. 15. doi:&#xa0; 10.3389/fnins.2021.680214</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.680214</ArticleId><ArticleId IdType="pmc">PMC8317266</ArticleId><ArticleId IdType="pubmed">34335160</ArticleId></ArticleIdList></Reference><Reference><Citation>Cattaneo A., Cattane N., Galluzzi S., Provasi S., Lopizzo N., Festari C., et al. (2017). Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol. Aging 49, 60&#x2013;68. doi:&#xa0; 10.1016/j.neurobiolaging.2016.08.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.08.019</ArticleId><ArticleId IdType="pubmed">27776263</ArticleId></ArticleIdList></Reference><Reference><Citation>Cekanaviciute E., Yoo B. B., Runia T. F., Debelius J. W., Singh S., Nelson C. A., et al. (2017). Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc. Natl. Acad. Sci. U.S.A. 114 (40), 10713&#x2013;10718. doi:&#xa0; 10.1073/pnas.1711235114</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1711235114</ArticleId><ArticleId IdType="pmc">PMC5635915</ArticleId><ArticleId IdType="pubmed">28893978</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan K. L., Cathomas F., Russo S. J. (2019). Central and peripheral inflammation link metabolic syndrome and major depressive disorder. Physiol. (Bethesda) 34 (2), 123&#x2013;133. doi:&#xa0; 10.1152/physiol.00047.2018</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physiol.00047.2018</ArticleId><ArticleId IdType="pmc">PMC6586832</ArticleId><ArticleId IdType="pubmed">30724127</ArticleId></ArticleIdList></Reference><Reference><Citation>Channer B., Matt S. M., Nickoloff-Bybel E. A., Pappa V., Agarwal Y., Wickman J., et al. (2023). Dopamine, immunity, and disease. Pharmacol. Rev. 75 (1), 62&#x2013;158. doi:&#xa0; 10.1124/pharmrev.122.000618</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pharmrev.122.000618</ArticleId><ArticleId IdType="pmc">PMC9832385</ArticleId><ArticleId IdType="pubmed">36757901</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G., Chen Z. M., Fan X. Y., Jin Y. L., Li X., Wu S. R., et al. (2021). Gut-brain-skin axis in psoriasis: A review. Dermatol. Ther. (Heidelb) 11 (1), 25&#x2013;38. doi:&#xa0; 10.1007/s13555-020-00466-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13555-020-00466-9</ArticleId><ArticleId IdType="pmc">PMC7859123</ArticleId><ArticleId IdType="pubmed">33206326</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T., Ding R., Chen X., Lu Y., Shi J., Lu Y., et al. (2021). Firmicutes and Blautia in gut microbiota lessened in chronic liver diseases and hepatocellular carcinoma patients: a pilot study. Bioengineered 12 (1), 8233&#x2013;8246. doi:&#xa0; 10.1080/21655979.2021.1982273</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21655979.2021.1982273</ArticleId><ArticleId IdType="pmc">PMC8806631</ArticleId><ArticleId IdType="pubmed">34592890</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Hou S., Zhao F., Wu B., Liu T., Zhang Z., et al. (2022). Application of bevacizumab combined with chemotherapy in patients with colorectal cancer and its effects on brain-gut peptides, intestinal flora, and oxidative stress. Front. Surg. 9. doi:&#xa0; 10.3389/fsurg.2022.872112</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fsurg.2022.872112</ArticleId><ArticleId IdType="pmc">PMC9035672</ArticleId><ArticleId IdType="pubmed">35478726</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K., Lai C., Su Y., Bao W. D., Yang L. N., Xu P. P., et al. (2022). cGAS-STING-mediated IFN-I response in host defense and neuroinflammatory diseases. Curr. Neuropharmacol. 20 (2), 362&#x2013;371. doi:&#xa0; 10.2174/1570159X19666210924110144</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X19666210924110144</ArticleId><ArticleId IdType="pmc">PMC9413793</ArticleId><ArticleId IdType="pubmed">34561985</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y. S., Tseng P. T., Chen Y. W., Stubbs B., Yang W. C., Chen T. Y., et al. (2017). Supplementation of omega 3 fatty acids may improve hyperactivity, lethargy, and stereotypy in children with autism spectrum disorders: a meta-analysis of randomized controlled trials. Neuropsychiatr. Dis. Treat 13, 2531&#x2013;2543. doi:&#xa0; 10.2147/NDT.S147305</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/NDT.S147305</ArticleId><ArticleId IdType="pmc">PMC5634395</ArticleId><ArticleId IdType="pubmed">29042783</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung Y. E., Chen H. C., Chou H. L., Chen I. M., Lee M. S., Chuang L. C., et al. (2019). Exploration of microbiota targets for major depressive disorder and mood related traits. J. Psychiatr. Res. 111, 74&#x2013;82. doi:&#xa0; 10.1016/j.jpsychires.2019.01.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2019.01.016</ArticleId><ArticleId IdType="pubmed">30685565</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti P., Pregliasco F. E., Bellomo R. G., Gallenga C. E., Caraffa A., Kritas S. K., et al. (2021). Mast cell cytokines IL-1, IL-33, and IL-36 mediate skin inflammation in psoriasis: A novel therapeutic approach with the anti-inflammatory cytokines IL-37, IL-38, and IL-1Ra. Int. J. Mol. Sci. 22 (15), 8076&#x2013;8087. doi:&#xa0; 10.3390/ijms22158076</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22158076</ArticleId><ArticleId IdType="pmc">PMC8348737</ArticleId><ArticleId IdType="pubmed">34360845</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow M. K. (2023). Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. Ann. Rheumatol. Dis. 82 (8), 999&#x2013;1014. doi:&#xa0; 10.1136/ard-2022-223741</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-223741</ArticleId><ArticleId IdType="pubmed">36792346</ArticleId></ArticleIdList></Reference><Reference><Citation>Cryan J. F., O'Riordan K. J., Cowan C., Sandhu K. V., Bastiaanssen T., Boehme M., et al. (2019). The microbiota-gut-brain axis. Physiol. Rev. 99 (4), 1877&#x2013;2013. doi:&#xa0; 10.1152/physrev.00018.2018</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00018.2018</ArticleId><ArticleId IdType="pubmed">31460832</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardiotis E., Tsouris Z., Mentis A. A., Siokas V., Michalopoulou A., Sokratous M., et al. (2018). H. pylori and Parkinson's disease: Meta-analyses including clinical severity. Clin. Neurol. Neurosurg. 175, 16&#x2013;24. doi:&#xa0; 10.1016/j.clineuro.2018.09.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2018.09.039</ArticleId><ArticleId IdType="pubmed">30308319</ArticleId></ArticleIdList></Reference><Reference><Citation>Demirci M., Bahar T. H., Taner Z., Keskin F. E., Cagatay P., Ozturk B. Y., et al. (2020). Bacteroidetes and Firmicutes levels in gut microbiota and effects of hosts TLR2/TLR4 gene expression levels in adult type 1 diabetes patients in Istanbul, Turkey. J. Diabetes Complications 34 (2), 107449. doi:&#xa0; 10.1016/j.jdiacomp.2019.107449</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdiacomp.2019.107449</ArticleId><ArticleId IdType="pubmed">31677982</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma G., Lynch M. D., Lu J., Dang V. T., Deng Y., Jury J., et al. (2017). Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice. Sci. Transl. Med. 9 (379), eaaf6397. doi:&#xa0; 10.1126/scitranslmed.aaf6397</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf6397</ArticleId><ArticleId IdType="pubmed">28251905</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma G., Shimbori C., Reed D. E., Yu Y., Rabbia V., Lu J., et al. (2022). Histamine production by the gut microbiota induces visceral hyperalgesia through histamine 4 receptor signaling in mice. Sci. Transl. Med. 14 (655), eabj1895. doi:&#xa0; 10.1126/scitranslmed.abj1895</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abj1895</ArticleId><ArticleId IdType="pubmed">35895832</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinan T. G., Cryan J. F. (2017). The microbiome-gut-brain axis in health and disease. Gastroenterol. Clin. North Am. 46 (1), 77&#x2013;89. doi:&#xa0; 10.1016/j.gtc.2016.09.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gtc.2016.09.007</ArticleId><ArticleId IdType="pubmed">28164854</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Narzo A. F., Brodmerkel C., Telesco S. E., Argmann C., Peters L. A., Li K., et al. (2019). High-throughput identification of the plasma proteomic signature of inflammatory bowel disease. J. Crohns Colitis 13 (4), 462&#x2013;471. doi:&#xa0; 10.1093/ecco-jcc/jjy190</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjy190</ArticleId><ArticleId IdType="pmc">PMC6441306</ArticleId><ArticleId IdType="pubmed">30445421</ArticleId></ArticleIdList></Reference><Reference><Citation>
Dong X. L., Wang X., Liu F., Liu X., Du ZR R. W., Xue C. H., et al. (2020). Tang: Polymannuronic acid prevents dopaminergic neuronal loss <i>via</i> brain-gut-microbiota axis in Parkinson's disease model. Int. J. Biol. Macromol.
164, 994&#x2013;1005. doi:&#xa0; 10.1016/j.ijbiomac.2020.07.180
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2020.07.180</ArticleId><ArticleId IdType="pubmed">32710966</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan H., Yu L., Tian F., Zhai Q., Fan L., Chen W. (2022). Antibiotic-induced gut dysbiosis and barrier disruption and the potential protective strategies. Crit. Rev. Food Sci. Nutr. 62 (6), 1427&#x2013;1452. doi:&#xa0; 10.1080/10408398.2020.1843396</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10408398.2020.1843396</ArticleId><ArticleId IdType="pubmed">33198506</ArticleId></ArticleIdList></Reference><Reference><Citation>Erny D., Hrabe D. A. A., Jaitin D., Wieghofer P., Staszewski O., David E., et al. (2015). Host microbiota constantly control maturation and function of microglia in the CNS. Nat. Neurosci. 18 (7), 965&#x2013;977. doi:&#xa0; 10.1038/nn.4030</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4030</ArticleId><ArticleId IdType="pmc">PMC5528863</ArticleId><ArticleId IdType="pubmed">26030851</ArticleId></ArticleIdList></Reference><Reference><Citation>
Fan X., Deng H., Qiu J., Ji H., Shen X. (2022). Antibiotics-induced depression in mice <i>via</i> the microbiota-gut-brain axis. J. Affect. Disord.
318, 152&#x2013;158. doi:&#xa0; 10.1016/j.jad.2022.08.059
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2022.08.059</ArticleId><ArticleId IdType="pubmed">36075400</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores-Clemente C., Nicolas-Vazquez M. I., Mera J. E., Hernandez-Rodriguez M. (2021). Inhibition of astrocytic histamine N-methyltransferase as a possible target for the treatment of alzheimer's disease. Biomolecules 11 (10), 1408&#x2013;1428. doi:&#xa0; 10.3390/biom11101408</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11101408</ArticleId><ArticleId IdType="pmc">PMC8533269</ArticleId><ArticleId IdType="pubmed">34680041</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster J. A., Rinaman L., Cryan J. F. (2017). Stress &amp; the gut-brain axis: Regulation by the microbiome. Neurobiol. Stress. 19 (7), 124&#x2013;136. doi:&#xa0; 10.1016/j.ynstr.2017.03.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ynstr.2017.03.001</ArticleId><ArticleId IdType="pmc">PMC5736941</ArticleId><ArticleId IdType="pubmed">29276734</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu B. M. (2018). Transport across the blood-brain barrier. Adv. Exp. Med. Biol. 1097, 235&#x2013;259. doi:&#xa0; 10.1007/978-3-319-96445-4_13</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-96445-4_13</ArticleId><ArticleId IdType="pubmed">30315549</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita Y., Fujita A., Ishima T., Hirai A., Suzuki S., Suganuma H., et al. (2020). Dietary intake of glucoraphanin during pregnancy and lactation prevents the behavioral abnormalities in the offspring after maternal immune activation. Neuropsychopharmacol. Rep. 40 (3), 268&#x2013;274. doi:&#xa0; 10.1002/npr2.12112</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/npr2.12112</ArticleId><ArticleId IdType="pmc">PMC7722647</ArticleId><ArticleId IdType="pubmed">32463181</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara H., Docampo M. D., Riwes M., Peltier D., Toubai T., Henig I., et al. (2018). Microbial metabolite sensor GPR43 controls severity of experimental GVHD. Nat. Commun. 9 (1), 3674. doi:&#xa0; 10.1038/s41467-018-06048-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06048-w</ArticleId><ArticleId IdType="pmc">PMC6131147</ArticleId><ArticleId IdType="pubmed">30201970</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulling C., Dinan T. G., Cryan J. F. (2019). Gut microbe to brain signaling: what happens in vagus. Neuron 101 (6), 998&#x2013;1002. doi:&#xa0; 10.1016/j.neuron.2019.02.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.02.008</ArticleId><ArticleId IdType="pubmed">30897366</ArticleId></ArticleIdList></Reference><Reference><Citation>
Gao J., Xiong T., Grabauskas G., Owyang C. (2022). Mucosal serotonin reuptake transporter expression in irritable bowel syndrome is modulated by gut microbiota <i>via</i> mast cell-prostaglandin E2. Gastroenterology
162 (7), 1962&#x2013;1974.e6. doi:&#xa0; 10.1053/j.gastro.2022.02.016
</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.02.016</ArticleId><ArticleId IdType="pmc">PMC9117493</ArticleId><ArticleId IdType="pubmed">35167867</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X., Zhao X., Liu M., Zhao H., Sun Y. (2023). Lycopene prevents non-alcoholic fatty liver disease through regulating hepatic NF-kappaB/NLRP3 inflammasome pathway and intestinal microbiota in mice fed with high-fat and high-fructose diet. Front. Nutr. 10. doi:&#xa0; 10.3389/fnut.2023.1120254</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2023.1120254</ArticleId><ArticleId IdType="pmc">PMC10076551</ArticleId><ArticleId IdType="pubmed">37032779</ArticleId></ArticleIdList></Reference><Reference><Citation>Gheorghe C. E., Martin J. A., Manriquez F. V., Dinan T. G., Cryan J. F., Clarke G. (2019). Focus on the essentials: tryptophan metabolism and the microbiome-gut-brain axis. Curr. Opin. Pharmacol. 48, 137&#x2013;145. doi:&#xa0; 10.1016/j.coph.2019.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2019.08.004</ArticleId><ArticleId IdType="pubmed">31610413</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert J. A., Blaser M. J., Caporaso J. G., Jansson J. K., Lynch S. V., Knight R. (2018). Current understanding of the human microbiome. Nat. Med. 24 (4), 392&#x2013;400. doi:&#xa0; 10.1038/nm.4517</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4517</ArticleId><ArticleId IdType="pmc">PMC7043356</ArticleId><ArticleId IdType="pubmed">29634682</ArticleId></ArticleIdList></Reference><Reference><Citation>Giles E. M., Stagg A. J. (2017). Type 1 interferon in the human intestine-A co-ordinator of the immune response to the microbiota. Inflamm. Bowel Dis. 23 (4), 524&#x2013;533. doi:&#xa0; 10.1097/MIB.0000000000001078</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MIB.0000000000001078</ArticleId><ArticleId IdType="pubmed">28296819</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomaa E. Z. (2020). Human gut microbiota/microbiome in health and diseases: a review. Antonie Van Leeuwenhoek 113 (12), 2019&#x2013;2040. doi:&#xa0; 10.1007/s10482-020-01474-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10482-020-01474-7</ArticleId><ArticleId IdType="pubmed">33136284</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Parra S., Dauden E. (2019). Psoriasis and depression: the role of inflammation. Actas Dermosifiliogr (Engl Ed) 110 (1), 12&#x2013;19. doi:&#xa0; 10.1016/j.ad.2018.05.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ad.2018.05.009</ArticleId><ArticleId IdType="pubmed">30509759</ArticleId></ArticleIdList></Reference><Reference><Citation>Guldenpfennig C., Teixeiro E., Daniels M. (2023). NF-kB's contribution to B cell fate decisions. Front. Immunol. 14. doi:&#xa0; 10.3389/fimmu.2023.1214095</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1214095</ArticleId><ArticleId IdType="pmc">PMC10391175</ArticleId><ArticleId IdType="pubmed">37533858</ArticleId></ArticleIdList></Reference><Reference><Citation>Haneishi Y., Furuya Y., Hasegawa M., Picarelli A., Rossi M., Miyamoto J. (2023). Inflammatory bowel diseases and gut microbiota. Int. J. Mol. Sci. 24 (4), 3817&#x2013;3829. doi:&#xa0; 10.3390/ijms24043817</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24043817</ArticleId><ArticleId IdType="pmc">PMC9958622</ArticleId><ArticleId IdType="pubmed">36835245</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillestad E., van der Meeren A., Nagaraja B. H., Bjorsvik B. R., Haleem N., Benitez-Paez A., et al. (2022). Gut bless you: The microbiota-gut-brain axis in irritable bowel syndrome. World J. Gastroenterol. 28 (4), 412&#x2013;431. doi:&#xa0; 10.3748/wjg.v28.i4.412</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v28.i4.412</ArticleId><ArticleId IdType="pmc">PMC8790555</ArticleId><ArticleId IdType="pubmed">35125827</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman K., Doyle W. J., Schumacher S. M., Ochoa-Reparaz J. (2023). Gut microbiome-modulated dietary strategies in EAE and multiple sclerosis. Front. Nutr. 10. doi:&#xa0; 10.3389/fnut.2023.1146748</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2023.1146748</ArticleId><ArticleId IdType="pmc">PMC10090556</ArticleId><ArticleId IdType="pubmed">37063324</ArticleId></ArticleIdList></Reference><Reference><Citation>Honarpisheh P., Reynolds C. R., Blasco C. M., Moruno M. J., Putluri N., Bhattacharjee M. B., et al. (2020). Dysregulated gut homeostasis observed prior to the accumulation of the brain amyloid-beta in tg2576 mice. Int. J. Mol. Sci. 21 (5), 1711&#x2013;1733. doi:&#xa0; 10.3390/ijms21051711</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21051711</ArticleId><ArticleId IdType="pmc">PMC7084806</ArticleId><ArticleId IdType="pubmed">32138161</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu N., Wang C., Dai X., Zhou M., Gong L., Yu L., et al. (2020). Phillygenin inhibits LPS-induced activation and inflammation of LX2 cells by TLR4/MyD88/NF-kappaB signaling pathway. J. Ethnopharmacol. 248, 112361. doi:&#xa0; 10.1016/j.jep.2019.112361</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2019.112361</ArticleId><ArticleId IdType="pubmed">31683033</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H., Xu H., Luo Q., He J., Li M., Chen H., et al. (2019). Fecal microbiota transplantation to treat Parkinson's disease with constipation: A case report. Med. (Baltimore) 98 (26), e16163. doi:&#xa0; 10.1097/MD.0000000000016163</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000016163</ArticleId><ArticleId IdType="pmc">PMC6616439</ArticleId><ArticleId IdType="pubmed">31261545</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung C. C., Chang C. C., Huang C. W., Nouchi R., Cheng C. H. (2022). Gut microbiota in patients with Alzheimer's disease spectrum: a systematic review and meta-analysis. Aging (Albany NY) 14 (1), 477&#x2013;496. doi:&#xa0; 10.18632/aging.203826</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.203826</ArticleId><ArticleId IdType="pmc">PMC8791218</ArticleId><ArticleId IdType="pubmed">35027502</ArticleId></ArticleIdList></Reference><Reference><Citation>Idunkova A., Lacinova L., Dubiel-Hoppanova L. (2023). Stress, depression, and hippocampus: from biochemistry to electrophysiology. Gen. Physiol. Biophys. 42 (2), 107&#x2013;122. doi:&#xa0; 10.4149/gpb_2023001</Citation><ArticleIdList><ArticleId IdType="doi">10.4149/gpb_2023001</ArticleId><ArticleId IdType="pubmed">36896941</ArticleId></ArticleIdList></Reference><Reference><Citation>Jandhyala S. M., Talukdar R., Subramanyam C., Vuyyuru H., Sasikala M., Nageshwar R. D. (2015). Role of the normal gut microbiota. World J. Gastroenterol. 21 (29), 8787&#x2013;8803. doi:&#xa0; 10.3748/wjg.v21.i29.8787</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v21.i29.8787</ArticleId><ArticleId IdType="pmc">PMC4528021</ArticleId><ArticleId IdType="pubmed">26269668</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang H. M., Kim J. K., Joo M. K., Shin Y. J., Lee K. E., Lee C. K., et al. (2022). Enterococcus faecium and Pediococcus acidilactici deteriorate Enterobacteriaceae-induced depression and colitis in mice. Sci. Rep. 12 (1), 9389. doi:&#xa0; 10.1038/s41598-022-13629-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-13629-9</ArticleId><ArticleId IdType="pmc">PMC9174183</ArticleId><ArticleId IdType="pubmed">35672451</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang H. M., Lee K. E., Kim D. H. (2019). The Preventive and Curative Effects of Lactobacillus reuteri NK33 and Bifidobacterium adolescentis NK98 on Immobilization Stress-Induced Anxiety/Depression and Colitis in Mice. Nutrients 11 (4), 819&#x2013;834. doi:&#xa0; 10.3390/nu11040819</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11040819</ArticleId><ArticleId IdType="pmc">PMC6521032</ArticleId><ArticleId IdType="pubmed">30979031</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang S. E., Lim S. M., Jeong J. J., Jang H. M., Lee H. J., Han M. J., et al. (2018). Gastrointestinal inflammation by gut microbiota disturbance induces memory impairment in mice. Mucosal Immunol. 11 (2), 369&#x2013;379. doi:&#xa0; 10.1038/mi.2017.49</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mi.2017.49</ArticleId><ArticleId IdType="pubmed">28612842</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarret A., Jackson R., Duizer C., Healy M. E., Zhao J., Rone J. M., et al. (2020). Enteric nervous system-derived IL-18 orchestrates mucosal barrier immunity. Cell 180 (1), 50&#x2013;63.e12. doi:&#xa0; 10.1016/j.cell.2019.12.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.12.016</ArticleId><ArticleId IdType="pmc">PMC7339937</ArticleId><ArticleId IdType="pubmed">31923399</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayasinghe M., Prathiraja O., Kayani A., Jena R., Caldera D., Silva M. S., et al. (2022). The role of diet and gut microbiome in multiple sclerosis. Cureus 14 (9), e28975. doi:&#xa0; 10.7759/cureus.28975</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.28975</ArticleId><ArticleId IdType="pmc">PMC9548326</ArticleId><ArticleId IdType="pubmed">36237764</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeffery I. B., O'Herlihy E., Shanahan F., O' T. P. (2020). Microbiome alterations in IBS. Gut 69 (12), 2263&#x2013;2264. doi:&#xa0; 10.1136/gutjnl-2020-320919</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-320919</ArticleId><ArticleId IdType="pubmed">32139549</ArticleId></ArticleIdList></Reference><Reference><Citation>
Jin M. Y., Wu X. Y., Li M. Y., Li X. T., Huang R. M., Sun Y. M., et al. (2021). Noni (Morinda citrifolia L.) fruit polysaccharides regulated IBD mice <i>via</i> targeting gut microbiota: association of JNK/ERK/NF-kappaB signaling pathways. J. Agric. Food Chem.
69 (35), 10151&#x2013;10162. doi:&#xa0; 10.1021/acs.jafc.1c03833
</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jafc.1c03833</ArticleId><ArticleId IdType="pubmed">34432454</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnsen P. H., Hilpusch F., Cavanagh J. P., Leikanger I. S., Kolstad C., Valle P. C., et al. (2018). Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol. Hepatol. 3 (1), 17&#x2013;24. doi:&#xa0; 10.1016/S2468-1253(17)30338-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(17)30338-2</ArticleId><ArticleId IdType="pubmed">29100842</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaelberer M. M., Buchanan K. L., Klein M. E., Barth B. B., Montoya M. M., Shen X., et al. (2018). A gut-brain neural circuit for nutrient sensory transduction. Science. 361 (6408), eaat5236. doi:&#xa0; 10.1126/science.aat5236</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aat5236</ArticleId><ArticleId IdType="pmc">PMC6417812</ArticleId><ArticleId IdType="pubmed">30237325</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang D. W., Adams J. B., Coleman D. M., Pollard E. L., Maldonado J., McDonough-Means S., et al. (2019). Long-term benefit of Microbiota Transfer Therapy on autism symptoms and gut microbiota. Sci. Rep. 9 (1), 5821. doi:&#xa0; 10.1038/s41598-019-42183-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-42183-0</ArticleId><ArticleId IdType="pmc">PMC6456593</ArticleId><ArticleId IdType="pubmed">30967657</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang D. W., Adams J. B., Gregory A. C., Borody T., Chittick L., Fasano A., et al. (2017). Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome 5 (1), 10. doi:&#xa0; 10.1186/s40168-016-0225-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40168-016-0225-7</ArticleId><ArticleId IdType="pmc">PMC5264285</ArticleId><ArticleId IdType="pubmed">28122648</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato K., Omura H., Ishitani R., Nureki O. (2017). Cyclic GMP-AMP as an endogenous second messenger in innate immune signaling by cytosolic DNA. Annu. Rev. Biochem. 86, 541&#x2013;566. doi:&#xa0; 10.1146/annurev-biochem-061516-044813</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-biochem-061516-044813</ArticleId><ArticleId IdType="pubmed">28399655</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann M., Evans H., Schaupp A. L., Engler J. B., Kaur G., Willing A., et al. (2021). Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis. Med 2 (3), 296&#x2013;312.e8. doi:&#xa0; 10.1016/j.medj.2021.01.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2021.01.006</ArticleId><ArticleId IdType="pmc">PMC7966680</ArticleId><ArticleId IdType="pubmed">33748804</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazemi A., Noorbala A. A., Azam K., Eskandari M. H., Djafarian K. (2019). Effect of probiotic and prebiotic vs placebo on psychological outcomes in patients with major depressive disorder: A randomized clinical trial. Clin. Nutr. 38 (2), 522&#x2013;528. doi:&#xa0; 10.1016/j.clnu.2018.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2018.04.010</ArticleId><ArticleId IdType="pubmed">29731182</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy P. J., Cryan J. F., Dinan T. G., Clarke G. (2017). Kynurenine pathway metabolism and the microbiota-gut-brain axis. Neuropharmacology 112 (Pt B), 399&#x2013;412. doi:&#xa0; 10.1016/j.neuropharm.2016.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2016.07.002</ArticleId><ArticleId IdType="pubmed">27392632</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesika P., Suganthy N., Sivamaruthi B. S., Chaiyasut C. (2021). Role of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer's disease. Life Sci. 264, 118627. doi:&#xa0; 10.1016/j.lfs.2020.118627</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.118627</ArticleId><ArticleId IdType="pubmed">33169684</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S., Moore R. J., Stanley D., Chousalkar K. K. (2020). The gut microbiota of laying hens and its manipulation with prebiotics and probiotics to enhance gut health and food safety. Appl. Environ. Microbiol. 86 (13), e00600-20. doi:&#xa0; 10.1128/AEM.00600-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.00600-20</ArticleId><ArticleId IdType="pmc">PMC7301851</ArticleId><ArticleId IdType="pubmed">32332137</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S., Eun H. S., Jo E. K. (2019). Roles of autophagy-related genes in the pathogenesis of inflammatory bowel disease. Cells 8 (1), 77&#x2013;100. doi:&#xa0; 10.3390/cells8010077</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8010077</ArticleId><ArticleId IdType="pmc">PMC6356351</ArticleId><ArticleId IdType="pubmed">30669622</ArticleId></ArticleIdList></Reference><Reference><Citation>
Kim H. J., Song H. K., Park S. H., Jang S., Park K. S., Song K. H., et al. (2022). Terminalia chebula Retz. extract ameliorates the symptoms of atopic dermatitis by regulating anti-inflammatory factors in <i>vivo</i> and suppressing STAT1/3 and NF-kB signaling in <i>vitro</i>
. Phytomedicine
104, 154318. doi:&#xa0; 10.1016/j.phymed.2022.154318
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phymed.2022.154318</ArticleId><ArticleId IdType="pubmed">35830757</ArticleId></ArticleIdList></Reference><Reference><Citation>Krautkramer K. A., Fan J., Backhed F. (2021). Gut microbial metabolites as multi-kingdom intermediates. Nat. Rev. Microbiol. 19 (2), 77&#x2013;94. doi:&#xa0; 10.1038/s41579-020-0438-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-0438-4</ArticleId><ArticleId IdType="pubmed">32968241</ArticleId></ArticleIdList></Reference><Reference><Citation>Kronborg H. A., Dubik M., Marczynska J., Ojha B., Nistal-Villan E., Gonzalez A. G., et al. (2022). Targeting signaling pathway downstream of RIG-I/MAVS in the CNS stimulates production of endogenous type I IFN and suppresses EAE. Int. J. Mol. Sci. 23 (19), 11292&#x2013;11302. doi:&#xa0; 10.3390/ijms231911292</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms231911292</ArticleId><ArticleId IdType="pmc">PMC9570082</ArticleId><ArticleId IdType="pubmed">36232593</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari S., Deshmukh R. (2021). beta-lactam antibiotics to tame down molecular pathways of Alzheimer's disease. Eur. J. Pharmacol. 895, 173877. doi:&#xa0; 10.1016/j.ejphar.2021.173877</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2021.173877</ArticleId><ArticleId IdType="pubmed">33453224</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurokawa S., Kishimoto T., Mizuno S., Masaoka T., Naganuma M., Liang K. C., et al. (2018). The effect of fecal microbiota transplantation on psychiatric symptoms among patients with irritable bowel syndrome, functional diarrhea and functional constipation: An open-label observational study. J. Affect. Disord. 235, 506&#x2013;512. doi:&#xa0; 10.1016/j.jad.2018.04.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2018.04.038</ArticleId><ArticleId IdType="pubmed">29684865</ArticleId></ArticleIdList></Reference><Reference><Citation>Labanski A., Langhorst J., Engler H., Elsenbruch S. (2020). Stress and the brain-gut axis in functional and chronic-inflammatory gastrointestinal diseases: A transdisciplinary challenge. Psychoneuroendocrino 111, 104501. doi:&#xa0; 10.1016/j.psyneuen.2019.104501</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2019.104501</ArticleId><ArticleId IdType="pubmed">31715444</ArticleId></ArticleIdList></Reference><Reference><Citation>Lach G., Schellekens H., Dinan T. G., Cryan J. F. (2018). Anxiety, depression, and the microbiome: A role for gut peptides. Neurotherapeutics 15 (1), 36&#x2013;59. doi:&#xa0; 10.1007/s13311-017-0585-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-017-0585-0</ArticleId><ArticleId IdType="pmc">PMC5794698</ArticleId><ArticleId IdType="pubmed">29134359</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier J. C., Dubourg G., Million M., Cadoret F., Bilen M., Fenollar F., et al. (2018). Culturing the human microbiota and culturomics. Nat. Rev. Microbiol. 16, 540&#x2013;550. doi:&#xa0; 10.1038/s41579-018-0041-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0041-0</ArticleId><ArticleId IdType="pubmed">29937540</ArticleId></ArticleIdList></Reference><Reference><Citation>Langen U. H., Ayloo S., Gu C. (2019). Development and cell biology of the blood-brain barrier. Annu. Rev. Cell Dev. Biol. 35, 591&#x2013;613. doi:&#xa0; 10.1146/annurev-cellbio-100617-062608</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-cellbio-100617-062608</ArticleId><ArticleId IdType="pmc">PMC8934576</ArticleId><ArticleId IdType="pubmed">31299172</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavelle A., Sokol H. (2020). Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 17 (4), 223&#x2013;237. doi:&#xa0; 10.1038/s41575-019-0258-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-019-0258-z</ArticleId><ArticleId IdType="pubmed">32076145</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J. Y., Cevallos S. A., Byndloss M. X., Tiffany C. R., Olsan E. E., Butler B. P., et al. (2020). High-fat diet and antibiotics cooperatively impair mitochondrial bioenergetics to trigger dysbiosis that exacerbates pre-inflammatory bowel disease. Cell Host Microbe 28 (2), 273&#x2013;284.e6. doi:&#xa0; 10.1016/j.chom.2020.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.06.001</ArticleId><ArticleId IdType="pmc">PMC7429289</ArticleId><ArticleId IdType="pubmed">32668218</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee T., Clavel T., Smirnov K., Schmidt A., Lagkouvardos I., Walker A., et al. (2017). Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut 66 (5), 863&#x2013;871. doi:&#xa0; 10.1136/gutjnl-2015-309940</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-309940</ArticleId><ArticleId IdType="pmc">PMC5531225</ArticleId><ArticleId IdType="pubmed">26848182</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H. J., Li D. Q., Zhang Y. L., Ding X. F., Gao H. T., Zhu Y., et al. (2023). Modulation of gut microbiota alleviates cerebral ischemia/reperfusion injury in rats by inhibiting M1 polarization of microglia. Front. Pharmacol. 14. doi:&#xa0; 10.3389/fphar.2023.1123387</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2023.1123387</ArticleId><ArticleId IdType="pmc">PMC10203402</ArticleId><ArticleId IdType="pubmed">37229259</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H. Y., Zhou D. D., Gan R. Y., Huang S. Y., Zhao C. N., Shang A., et al. (2021). Effects and mechanisms of probiotics, prebiotics, synbiotics, and postbiotics on metabolic diseases targeting gut microbiota: A narrative review. Nutrients. 13 (9), 3211&#x2013;3232. doi:&#xa0; 10.3390/nu13093211</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13093211</ArticleId><ArticleId IdType="pmc">PMC8470858</ArticleId><ArticleId IdType="pubmed">34579087</ArticleId></ArticleIdList></Reference><Reference><Citation>Lian N., Zhang L., Chen M. (2020). Tumor necrosis factors-alpha inhibition-induced paradoxical psoriasis: A case series and literature review. Dermatol. Ther. 33 (6), e14225. doi:&#xa0; 10.1111/dth.14225</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dth.14225</ArticleId><ArticleId IdType="pubmed">32844554</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin M. S., Wang Y. C., Chen W. J., Kung W. M. (2023). Impact of gut-brain interaction in emerging neurological disorders. World J. Clin. cases 11 (1), 1&#x2013;6. doi:&#xa0; 10.12998/wjcc.v11.i1.1</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v11.i1.1</ArticleId><ArticleId IdType="pmc">PMC9846976</ArticleId><ArticleId IdType="pubmed">36687174</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippai R., Veres-Szekely A., Sziksz E., Iwakura Y., Pap D., Rokonay R., et al. (2021). Immunomodulatory role of Parkinson's disease 7 in inflammatory bowel disease. Sci. Rep. 11 (1), 14582. doi:&#xa0; 10.1038/s41598-021-93671-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-93671-1</ArticleId><ArticleId IdType="pmc">PMC8285373</ArticleId><ArticleId IdType="pubmed">34272410</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B., Fang F., Pedersen N. L., Tillander A., Ludvigsson J. F., Ekbom A., et al. (2017). Vagotomy and Parkinson disease: A Swedish register-based matched-cohort study. Neurology 88 (21), 1996&#x2013;2002. doi:&#xa0; 10.1212/WNL.0000000000003961</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003961</ArticleId><ArticleId IdType="pmc">PMC5440238</ArticleId><ArticleId IdType="pubmed">28446653</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S., Gao J., Zhu M., Liu K., Zhang H. L. (2020. a). Gut microbiota and dysbiosis in alzheimer's disease: implications for pathogenesis and treatment. Mol. Neurobiol. 57 (12), 5026&#x2013;5043. doi:&#xa0; 10.1007/s12035-020-02073-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-020-02073-3</ArticleId><ArticleId IdType="pmc">PMC7541367</ArticleId><ArticleId IdType="pubmed">32829453</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S., Guo R., Liu F., Yuan Q., Yu Y., Ren F. (2020. b). Gut microbiota regulates depression-like behavior in rats through the neuroendocrine-immune-mitochondrial pathway. Neuropsychiatr. Dis. Treat 16, 859&#x2013;869. doi:&#xa0; 10.2147/NDT.S243551</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/NDT.S243551</ArticleId><ArticleId IdType="pmc">PMC7127849</ArticleId><ArticleId IdType="pubmed">32280227</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S., Li E., Sun Z., Fu D., Duan G., Jiang M., et al. (2019). Altered gut microbiota and short chain fatty acids in Chinese children with autism spectrum disorder. Sci. Rep. 9 (1), 287. doi:&#xa0; 10.1038/s41598-018-36430-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-36430-z</ArticleId><ArticleId IdType="pmc">PMC6342986</ArticleId><ArticleId IdType="pubmed">30670726</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B., Piao X., Niu W., Zhang Q., Ma C., Wu T., et al. (2020). Kuijieyuan decoction improved intestinal barrier injury of ulcerative colitis by affecting TLR4-dependent PI3K/AKT/NF-kappaB oxidative and inflammatory signaling and gut microbiota. Front. Pharmacol. 11. doi:&#xa0; 10.3389/fphar.2020.01036</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.01036</ArticleId><ArticleId IdType="pmc">PMC7403404</ArticleId><ArticleId IdType="pubmed">32848725</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Sanderson D., Mian M. F., McVey N. K., Forsythe P. (2021). Loss of vagal integrity disrupts immune components of the microbiota-gut-brain axis and inhibits the effect of Lactobacillus rhamnosus on behavior and the corticosterone stress response. Neuropharmacology 195, 108682. doi:&#xa0; 10.1016/j.neuropharm.2021.108682</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2021.108682</ArticleId><ArticleId IdType="pubmed">34175326</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H. N., Wu H., Chen Y. Z., Chen Y. J., Shen X. Z., Liu T. T. (2017). Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis. Dig Liver Dis. 49 (4), 331&#x2013;337. doi:&#xa0; 10.1016/j.dld.2017.01.142</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2017.01.142</ArticleId><ArticleId IdType="pubmed">28179092</ArticleId></ArticleIdList></Reference><Reference><Citation>Logsdon A. F., Erickson M. A., Rhea E. M., Salameh T. S., Banks W. A. (2018). Gut reactions: How the blood-brain barrier connects the microbiome and the brain. Exp. Biol. Med. (Maywood) 243 (2), 159&#x2013;165. doi:&#xa0; 10.1177/1535370217743766</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1535370217743766</ArticleId><ArticleId IdType="pmc">PMC5788145</ArticleId><ArticleId IdType="pubmed">29169241</ArticleId></ArticleIdList></Reference><Reference><Citation>Long-Smith C., O'Riordan K. J., Clarke G., Stanton C., Dinan T. G., Cryan J. F. (2020). Microbiota-gut-brain axis: new therapeutic opportunities. Annu. Rev. Pharmacol. Toxicol. 60, 477&#x2013;502. doi:&#xa0; 10.1146/annurev-pharmtox-010919-023628</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-010919-023628</ArticleId><ArticleId IdType="pubmed">31506009</ArticleId></ArticleIdList></Reference><Reference><Citation>Lord C., Elsabbagh M., Baird G., Veenstra-Vanderweele J. (2018). Autism spectrum disorder. Lancet 392 (10146), 508&#x2013;520. doi:&#xa0; 10.1016/S0140-6736(18)31129-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)31129-2</ArticleId><ArticleId IdType="pmc">PMC7398158</ArticleId><ArticleId IdType="pubmed">30078460</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo M., Zhuang X., Tian Z., Xiong L. (2021). Alterations in short-chain fatty acids and serotonin in irritable bowel syndrome: a systematic review and meta-analysis. BMC Gastroenterol. 21 (1), 14. doi:&#xa0; 10.1186/s12876-020-01577-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-020-01577-5</ArticleId><ArticleId IdType="pmc">PMC7788881</ArticleId><ArticleId IdType="pubmed">33407171</ArticleId></ArticleIdList></Reference><Reference><Citation>Maaser C., Sturm A., Vavricka S. R., Kucharzik T., Fiorino G., Annese V., et al. (2019). ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J. Crohns Colitis 13 (2), 144&#x2013;164. doi:&#xa0; 10.1093/ecco-jcc/jjy113</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjy113</ArticleId><ArticleId IdType="pubmed">30137275</ArticleId></ArticleIdList></Reference><Reference><Citation>Madan A., Thompson D., Fowler J. C., Ajami N. J., Salas R., Frueh B. C., et al. (2020). The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness. J. Affect. Disord. 264, 98&#x2013;106. doi:&#xa0; 10.1016/j.jad.2019.12.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2019.12.020</ArticleId><ArticleId IdType="pubmed">32056780</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandaliya D. K., Seshadri S. (2019). Short Chain Fatty Acids, pancreatic dysfunction and type 2 diabetes. Pancreatology 19 (2), 280&#x2013;284. doi:&#xa0; 10.1016/j.pan.2019.01.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pan.2019.01.021</ArticleId><ArticleId IdType="pubmed">30713129</ArticleId></ArticleIdList></Reference><Reference><Citation>Manderino L., Carroll I., Azcarate-Peril M. A., Rochette A., Heinberg L., Peat C., et al. (2017). Preliminary evidence for an association between the composition of the gut microbiome and cognitive function in neurologically healthy older adults. J. Int. Neuropsychol. Soc. 23 (8), 700&#x2013;705. doi:&#xa0; 10.1017/S1355617717000492</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1355617717000492</ArticleId><ArticleId IdType="pmc">PMC6111127</ArticleId><ArticleId IdType="pubmed">28641593</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin P. K., Marchiando A., Xu R., Rudensky E., Yeung F., Schuster S. L., et al. (2018). Autophagy proteins suppress protective type I interferon signalling in response to the murine gut microbiota. Nat. Microbiol. 3 (10), 1131&#x2013;1141. doi:&#xa0; 10.1038/s41564-018-0229-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-018-0229-0</ArticleId><ArticleId IdType="pmc">PMC6179362</ArticleId><ArticleId IdType="pubmed">30202015</ArticleId></ArticleIdList></Reference><Reference><Citation>McVey N. K., Bienenstock J., Bharwani A., Champagne-Jorgensen K., Mao Y., West C., et al. (2019). Oral selective serotonin reuptake inhibitors activate vagus nerve dependent gut-brain signalling. Sci. Rep. 9 (1), 14290. doi:&#xa0; 10.1038/s41598-019-50807-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-50807-8</ArticleId><ArticleId IdType="pmc">PMC6776512</ArticleId><ArticleId IdType="pubmed">31582799</ArticleId></ArticleIdList></Reference><Reference><Citation>Merola J. F., Qureshi A., Husni M. E. (2018). Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol. Ther. 31 (3), e12589. doi:&#xa0; 10.1111/dth.12589</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dth.12589</ArticleId><ArticleId IdType="pmc">PMC6901032</ArticleId><ArticleId IdType="pubmed">29512290</ArticleId></ArticleIdList></Reference><Reference><Citation>Metta V., Leta V., Mrudula K. R., Prashanth L. K., Goyal V., Borgohain R., et al. (2022). Gastrointestinal dysfunction in Parkinson's disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation. J. Neurol. 269 (3), 1154&#x2013;1163. doi:&#xa0; 10.1007/s00415-021-10567-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10567-w</ArticleId><ArticleId IdType="pubmed">33881598</ArticleId></ArticleIdList></Reference><Reference><Citation>Morais L. H., Schreiber H. T., Mazmanian S. K. (2021). The gut microbiota-brain axis in behaviour and brain disorders. Nat. Rev. Microbiol. 19 (4), 241&#x2013;255. doi:&#xa0; 10.1038/s41579-020-00460-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00460-0</ArticleId><ArticleId IdType="pubmed">33093662</ArticleId></ArticleIdList></Reference><Reference><Citation>Mossad O., Blank T. (2021). Getting on in old age: how the gut microbiota interferes with brain innate immunity. Front. Cell. Neurosci. 15. doi:&#xa0; 10.3389/fncel.2021.698126</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2021.698126</ArticleId><ArticleId IdType="pmc">PMC8290125</ArticleId><ArticleId IdType="pubmed">34295223</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee S., Kumar R., Tsakem L. E., Basrur V., Kontoyiannis D. L., Ioakeimidis F., et al. (2020). Deubiquitination of NLRP6 inflammasome by Cyld critically regulates intestinal inflammation. Nat. Immunol. 21 (6), 626&#x2013;635. doi:&#xa0; 10.1038/s41590-020-0681-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0681-x</ArticleId><ArticleId IdType="pmc">PMC7881443</ArticleId><ArticleId IdType="pubmed">32424362</ArticleId></ArticleIdList></Reference><Reference><Citation>
Muller P. A., Schneeberger M., Matheis F., Wang P., Kerner Z., Ilanges A., et al. (2020). Microbiota modulate sympathetic neurons <i>via</i> a gut-brain circuit. Nature
583 (7816), 441&#x2013;446. doi:&#xa0; 10.1038/s41586-020-2474-7
</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2474-7</ArticleId><ArticleId IdType="pmc">PMC7367767</ArticleId><ArticleId IdType="pubmed">32641826</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock M. H., Tsai L. H. (2023). Insights into Alzheimer's disease from single-cell genomic approaches. Nat. Neurosci. 26 (2), 181&#x2013;195. doi:&#xa0; 10.1038/s41593-022-01222-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-022-01222-2</ArticleId><ArticleId IdType="pmc">PMC10155598</ArticleId><ArticleId IdType="pubmed">36593328</ArticleId></ArticleIdList></Reference><Reference><Citation>
Nadeem A., Ahmad S. F., Al-Harbi N. O., Fardan A. S., El-Sherbeeny A. M., Ibrahim K. E., et al. (2017). IL-17A causes depression-like symptoms <i>via</i> NFkappaB and p38MAPK signaling pathways in mice: Implications for psoriasis associated depression. Cytokine
97, 14&#x2013;24. doi:&#xa0; 10.1016/j.cyto.2017.05.018
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2017.05.018</ArticleId><ArticleId IdType="pubmed">28570931</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagarajan A., Srivastava H., Morrow C. D., Sun L. Y. (2023). Characterizing the gut microbiome changes with aging in a novel Alzheimer's disease rat model. Aging (Albany NY) 15 (2), 459&#x2013;471. doi:&#xa0; 10.18632/aging.204484</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.204484</ArticleId><ArticleId IdType="pmc">PMC9925685</ArticleId><ArticleId IdType="pubmed">36640271</ArticleId></ArticleIdList></Reference><Reference><Citation>Naomi R., Embong H., Othman F., Ghazi H. F., Maruthey N., Bahari H. (2021). Probiotics for alzheimer's disease: A systematic review. Nutrients. 14 (1), 20&#x2013;43. doi:&#xa0; 10.3390/nu14010020</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14010020</ArticleId><ArticleId IdType="pmc">PMC8746506</ArticleId><ArticleId IdType="pubmed">35010895</ArticleId></ArticleIdList></Reference><Reference><Citation>Netea M. G., Balkwill F., Chonchol M., Cominelli F., Donath M. Y., Giamarellos-Bourboulis E. J., et al. (2017). A guiding map for inflammation. Nat. Immunol. 18 (8), 826&#x2013;831. doi:&#xa0; 10.1038/ni.3790</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3790</ArticleId><ArticleId IdType="pmc">PMC5939996</ArticleId><ArticleId IdType="pubmed">28722720</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng Q. X., Soh A., Loke W., Lim D. Y., Yeo W. S. (2018). The role of inflammation in irritable bowel syndrome (IBS). J. Inflamm. Res. 11, 345&#x2013;349. doi:&#xa0; 10.2147/JIR.S174982</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S174982</ArticleId><ArticleId IdType="pmc">PMC6159811</ArticleId><ArticleId IdType="pubmed">30288077</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen L. H., Ortqvist A. K., Cao Y., Simon T. G., Roelstraete B., Song M., et al. (2020). Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden. Lancet Gastroenterol. Hepatol. 5 (11), 986&#x2013;995. doi:&#xa0; 10.1016/S2468-1253(20)30267-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30267-3</ArticleId><ArticleId IdType="pmc">PMC8034612</ArticleId><ArticleId IdType="pubmed">32818437</ArticleId></ArticleIdList></Reference><Reference><Citation>Nho K., Kueider-Paisley A., MahmoudianDehkordi S., Arnold M., Risacher S. L., Louie G., et al. (2019). Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers. Alzheimers Dement. 15 (2), 232&#x2013;244. doi:&#xa0; 10.1016/j.jalz.2018.08.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.08.012</ArticleId><ArticleId IdType="pmc">PMC6454538</ArticleId><ArticleId IdType="pubmed">30337152</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson S. E., Watts L. T., Burmeister D. M., Merrill D., Scroggins S., Zou Y., et al. (2019). Moderate traumatic brain injury alters the gastrointestinal microbiome in a time-dependent manner. Shock 52 (2), 240&#x2013;248. doi:&#xa0; 10.1097/SHK.0000000000001211</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000001211</ArticleId><ArticleId IdType="pubmed">29953417</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiwaki H., Ito M., Ishida T., Hamaguchi T., Maeda T., Kashihara K., et al. (2020). Meta-analysis of gut dysbiosis in parkinson's disease. Mov Disord. 35 (9), 1626&#x2013;1635. doi:&#xa0; 10.1002/mds.28119</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28119</ArticleId><ArticleId IdType="pubmed">32557853</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble E. E., Hsu T. M., Kanoski S. E. (2017). Gut to brain dysbiosis: mechanisms linking western diet consumption, the microbiome, and cognitive impairment. Front. Behav. Neurosci. 11. doi:&#xa0; 10.3389/fnbeh.2017.00009</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnbeh.2017.00009</ArticleId><ArticleId IdType="pmc">PMC5277010</ArticleId><ArticleId IdType="pubmed">28194099</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyul-Toth A., Kozma M., Nagyoszi P., Nagy K., Fazakas C., Hasko J., et al. (2017). Expression of pattern recognition receptors and activation of the non-canonical inflammasome pathway in brain pericytes. Brain Behav. Immun. 64, 220&#x2013;231. doi:&#xa0; 10.1016/j.bbi.2017.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2017.04.010</ArticleId><ArticleId IdType="pubmed">28432035</ArticleId></ArticleIdList></Reference><Reference><Citation>Obrenovich M. (2018). Leaky gut, leaky brain? Microorganisms. 6 (4), 107&#x2013;119. doi:&#xa0; 10.3390/microorganisms6040107</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms6040107</ArticleId><ArticleId IdType="pmc">PMC6313445</ArticleId><ArticleId IdType="pubmed">30340384</ArticleId></ArticleIdList></Reference><Reference><Citation>Ochs J., Nissimov N., Torke S., Freier M., Grondey K., Koch J., et al. (2022). Proinflammatory CD20(+) T cells contribute to CNS-directed autoimmunity. Sci. Transl. Med. 14 (638), eabi4632. doi:&#xa0; 10.1126/scitranslmed.abi4632</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abi4632</ArticleId><ArticleId IdType="pubmed">35353539</ArticleId></ArticleIdList></Reference><Reference><Citation>Osadchiy V., Martin C. R., Mayer E. A. (2019). Gut microbiome and modulation of CNS function. Compr. Physiol. 10 (1), 57&#x2013;72. doi:&#xa0; 10.1002/cphy.c180031</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cphy.c180031</ArticleId><ArticleId IdType="pubmed">31853944</ArticleId></ArticleIdList></Reference><Reference><Citation>Oswiecimska J., Szymlak A., Roczniak W., Girczys-Poledniok K., Kwiecien J. (2017). New insights into the pathogenesis and treatment of irritable bowel syndrome. Adv. Med. Sci. 62 (1), 17&#x2013;30. doi:&#xa0; 10.1016/j.advms.2016.11.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.advms.2016.11.001</ArticleId><ArticleId IdType="pubmed">28135659</ArticleId></ArticleIdList></Reference><Reference><Citation>
Ozcaglayan O., Kurtoglu O. T., Dogru M., Mete R. (2020). Vagus nerve assessment <i>via</i> ultrasonography in irritable bowel syndrome. Are there any changes of dimension in the vagus nerve? Turk. J. Gastroenterol.
31 (7), 503&#x2013;507. doi:&#xa0; 10.5152/tjg.2020.19353
</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/tjg.2020.19353</ArticleId><ArticleId IdType="pmc">PMC7480199</ArticleId><ArticleId IdType="pubmed">32897223</ArticleId></ArticleIdList></Reference><Reference><Citation>Pap D., Veres-Szekely A., Szebeni B., Vannay A. (2022). PARK7/DJ-1 as a therapeutic target in gut-brain axis diseases. Int. J. Mol. Sci. 23 (12), 6626&#x2013;6648. doi:&#xa0; 10.3390/ijms23126626</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23126626</ArticleId><ArticleId IdType="pmc">PMC9223539</ArticleId><ArticleId IdType="pubmed">35743072</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearson-Leary J., Zhao C., Bittinger K., Eacret D., Luz S., Vigderman A. S., et al. (2020). The gut microbiome regulates the increases in depressive-type behaviors and in inflammatory processes in the ventral hippocampus of stress vulnerable rats. Mol. Psychiatry 25 (5), 1068&#x2013;1079. doi:&#xa0; 10.1038/s41380-019-0380-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-019-0380-x</ArticleId><ArticleId IdType="pubmed">30833676</ArticleId></ArticleIdList></Reference><Reference><Citation>Peirce J. M., Alvina K. (2019). The role of inflammation and the gut microbiome in depression and anxiety. J. Neurosci. Res. 97 (10), 1223&#x2013;1241. doi:&#xa0; 10.1002/jnr.24476</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.24476</ArticleId><ArticleId IdType="pubmed">31144383</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrini C., Antonioli L., Calderone V., Colucci R., Fornai M., Blandizzi C. (2020). Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications? Prog. Neurobiol. 191, 101806. doi:&#xa0; 10.1016/j.pneurobio.2020.101806</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2020.101806</ArticleId><ArticleId IdType="pubmed">32473843</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrini C., Antonioli L., Colucci R., Blandizzi C., Fornai M. (2018). Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases? Acta Neuropathol. 136 (3), 345&#x2013;361. doi:&#xa0; 10.1007/s00401-018-1856-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1856-5</ArticleId><ArticleId IdType="pubmed">29797112</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrini C., Antonioli L., Lopez-Castejon G., Blandizzi C., Fornai M. (2017). Canonical and non-canonical activation of NLRP3 inflammasome at the crossroad between immune tolerance and intestinal inflammation. Front. Immunol. 8. doi:&#xa0; 10.3389/fimmu.2017.00036</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00036</ArticleId><ArticleId IdType="pmc">PMC5263152</ArticleId><ArticleId IdType="pubmed">28179906</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Pardo P., Dodiya H. B., Broersen L. M., Douna H., van Wijk N., Lopes D. S. S., et al. (2018). Gut-brain and brain-gut axis in Parkinson's disease models: Effects of a uridine and fish oil diet. Nutr. Neurosci. 21 (6), 391&#x2013;402. doi:&#xa0; 10.1080/1028415X.2017.1294555</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1028415X.2017.1294555</ArticleId><ArticleId IdType="pubmed">28276272</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittayanon R., Lau J. T., Leontiadis G. I., Tse F., Yuan Y., Surette M., et al. (2020). Differences in gut microbiota in patients with vs without inflammatory bowel diseases: A systematic review. Gastroenterology 158 (4), 930&#x2013;946.e1. doi:&#xa0; 10.1053/j.gastro.2019.11.294</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2019.11.294</ArticleId><ArticleId IdType="pubmed">31812509</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittayanon R., Lau J. T., Yuan Y., Leontiadis G. I., Tse F., Surette M., et al. (2019). Gut microbiota in patients with irritable bowel syndrome-A systematic review. Gastroenterology 157 (1), 97&#x2013;108. doi:&#xa0; 10.1053/j.gastro.2019.03.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2019.03.049</ArticleId><ArticleId IdType="pubmed">30940523</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu J., Xu B., Ye D., Ren D., Wang S., Benci J. L., et al. (2023). Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction. Nat. Cancer 4 (1), 43&#x2013;61. doi:&#xa0; 10.1038/s43018-022-00490-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43018-022-00490-y</ArticleId><ArticleId IdType="pubmed">36646856</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren M., Zhang H., Qi J., Hu A., Jiang Q., Hou Y., et al. (2020). An almond-based low carbohydrate diet improves depression and glycometabolism in patients with type 2 diabetes through modulating gut microbiota and GLP-1: A randomized controlled trial. Nutrients 12 (10), 3036&#x2013;3052. doi:&#xa0; 10.3390/nu12103036</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12103036</ArticleId><ArticleId IdType="pmc">PMC7601479</ArticleId><ArticleId IdType="pubmed">33022991</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano S., Savva G. M., Bedarf J. R., Charles I. G., Hildebrand F., Narbad A. (2021). Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ Parkinsons Dis. 7 (1), 27. doi:&#xa0; 10.1038/s41531-021-00156-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-021-00156-z</ArticleId><ArticleId IdType="pmc">PMC7946946</ArticleId><ArticleId IdType="pubmed">33692356</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo C., Valle M. S., Russo A., Malaguarnera L. (2022). The interplay between ghrelin and microglia in neuroinflammation: implications for obesity and neurodegenerative diseases. Int. J. Mol. Sci. 23 (21), 13432&#x2013;13452. doi:&#xa0; 10.3390/ijms232113432</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232113432</ArticleId><ArticleId IdType="pmc">PMC9654207</ArticleId><ArticleId IdType="pubmed">36362220</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutsch A., Kantsjo J. B., Ronchi F. (2020). The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology. Front. Immunol. 11. doi:&#xa0; 10.3389/fimmu.2020.604179</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.604179</ArticleId><ArticleId IdType="pmc">PMC7758428</ArticleId><ArticleId IdType="pubmed">33362788</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampson T. R., Debelius J. W., Thron T., Janssen S., Shastri G. G., Ilhan Z. E., et al. (2016). Gut microbiota regulate motor deficits and neuroinflammation in a model of parkinson's disease. Cell 167 (6), 1469&#x2013;1480.e12. doi:&#xa0; 10.1016/j.cell.2016.11.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.11.018</ArticleId><ArticleId IdType="pmc">PMC5718049</ArticleId><ArticleId IdType="pubmed">27912057</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt E., Torres-Espin A., Raposo P., Madsen K. L., Kigerl K. A., Popovich P. G., et al. (2020). Fecal transplant prevents gut dysbiosis and anxiety-like behaviour after spinal cord injury in rats. PloS One 15 (1), e0226128. doi:&#xa0; 10.1371/journal.pone.0226128</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0226128</ArticleId><ArticleId IdType="pmc">PMC6961833</ArticleId><ArticleId IdType="pubmed">31940312</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider S. A., Alcalay R. N. (2017). Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature. Mov Disord. 32 (11), 1504&#x2013;1523. doi:&#xa0; 10.1002/mds.27193</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27193</ArticleId><ArticleId IdType="pmc">PMC5726430</ArticleId><ArticleId IdType="pubmed">29124790</ArticleId></ArticleIdList></Reference><Reference><Citation>Sgritta M., Dooling S. W., Buffington S. A., Momin E. N., Francis M. B., Britton R. A., et al. (2019). Mechanisms underlying microbial-mediated changes in social behavior in mouse models of autism spectrum disorder. Neuron 101 (2), 246&#x2013;259.e6. doi:&#xa0; 10.1016/j.neuron.2018.11.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.11.018</ArticleId><ArticleId IdType="pmc">PMC6645363</ArticleId><ArticleId IdType="pubmed">30522820</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaaban S. Y., El G. Y., Mehanna N. S., El-Senousy W. M., El-Feki H., Saad K., et al. (2018). The role of probiotics in children with autism spectrum disorder: A prospective, open-label study. Nutr. Neurosci. 21 (9), 676&#x2013;681. doi:&#xa0; 10.1080/1028415X.2017.1347746</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1028415X.2017.1347746</ArticleId><ArticleId IdType="pubmed">28686541</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A. R., Batra G., Saini L., Sharma S., Mishra A., Singla R., et al. (2022). Valproic acid and propionic acid modulated mechanical pathways associated with autism spectrum disorder at prenatal and neonatal exposure. CNS Neurol. Disord. Drug Targets 21 (5), 399&#x2013;408. doi:&#xa0; 10.2174/1871527320666210806165430</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527320666210806165430</ArticleId><ArticleId IdType="pubmed">34365961</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen T., Yue Y., He T., Huang C., Qu B., Lv W., et al. (2021). The association between the gut microbiota and parkinson's disease, a meta-analysis. Front. Aging Neurosci. 13. doi:&#xa0; 10.3389/fnagi.2021.636545</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2021.636545</ArticleId><ArticleId IdType="pmc">PMC7907649</ArticleId><ArticleId IdType="pubmed">33643026</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi M., Chu F., Zhu F., Zhu J. (2022). Impact of anti-amyloid-beta monoclonal antibodies on the pathology and clinical profile of alzheimer's disease: A focus on aducanumab and lecanemab. Front. Aging Neurosci. 14. doi:&#xa0; 10.3389/fnagi.2022.870517</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2022.870517</ArticleId><ArticleId IdType="pmc">PMC9039457</ArticleId><ArticleId IdType="pubmed">35493943</ArticleId></ArticleIdList></Reference><Reference><Citation>Shukla P. K., Delotterie D. F., Xiao J., Pierre J. F., Rao R., McDonald M. P., et al. (2021). Alterations in the gut-microbial-inflammasome-brain axis in a mouse model of alzheimer's disease. Cells 10 (4), 779&#x2013;795. doi:&#xa0; 10.3390/cells10040779</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10040779</ArticleId><ArticleId IdType="pmc">PMC8067249</ArticleId><ArticleId IdType="pubmed">33916001</ArticleId></ArticleIdList></Reference><Reference><Citation>Si W., Liang H., Bugno J., Xu Q., Ding X., Yang K., et al. (2022). Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade. Gut 71 (3), 521&#x2013;533. doi:&#xa0; 10.1136/gutjnl-2020-323426</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-323426</ArticleId><ArticleId IdType="pmc">PMC8710942</ArticleId><ArticleId IdType="pubmed">33685966</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S. S., Rai S. N., Birla H., Zahra W., Rathore A. S., Singh S. P. (2020). NF-kappaB-mediated neuroinflammation in parkinson's disease and potential therapeutic effect of polyphenols. Neurotox. Res. 37 (3), 491&#x2013;507. doi:&#xa0; 10.1007/s12640-019-00147-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-019-00147-2</ArticleId><ArticleId IdType="pubmed">31823227</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinopoulou V., Gordon M., Dovey T. M., Akobeng A. K. (2021). Interventions for the management of abdominal pain in ulcerative colitis. Cochrane Database Syst. Rev. 7 (7), CD013589. doi:&#xa0; 10.1002/14651858.CD013589.pub2</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD013589.pub2</ArticleId><ArticleId IdType="pmc">PMC8407332</ArticleId><ArticleId IdType="pubmed">34291816</ArticleId></ArticleIdList></Reference><Reference><Citation>Socala K., Doboszewska U., Szopa A., Serefko A., Wlodarczyk M., Zielinska A., et al. (2021). The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders. Pharmacol. Res. 172, 105840. doi:&#xa0; 10.1016/j.phrs.2021.105840</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2021.105840</ArticleId><ArticleId IdType="pubmed">34450312</ArticleId></ArticleIdList></Reference><Reference><Citation>Song J., Kim Y. K. (2021). Animal models for the study of depressive disorder. CNS Neurosci. Ther. 27 (6), 633&#x2013;642. doi:&#xa0; 10.1111/cns.13622</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.13622</ArticleId><ArticleId IdType="pmc">PMC8111503</ArticleId><ArticleId IdType="pubmed">33650178</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W., Zhang M., Teng L., Wang Y., Zhu L. (2022). Prebiotics and probiotics for autism spectrum disorder: a systematic review and meta-analysis of controlled clinical trials. J. Med. Microbiol. 71 (4), 001510. doi:&#xa0; 10.1099/jmm.0.001510</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jmm.0.001510</ArticleId><ArticleId IdType="pubmed">35438624</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonner J. K., Keil M., Falk-Paulsen M., Mishra N., Rehman A., Kramer M., et al. (2019). Dietary tryptophan links encephalogenicity of autoreactive T cells with gut microbial ecology. Nat. Commun. 10 (1), 4877. doi:&#xa0; 10.1038/s41467-019-12776-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-12776-4</ArticleId><ArticleId IdType="pmc">PMC6814758</ArticleId><ArticleId IdType="pubmed">31653831</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa A., Meyer K. A., Santpere G., Gulden F. O., Sestan N. (2017). Evolution of the human nervous system function, structure, and development. Cell 170 (2), 226&#x2013;247. doi:&#xa0; 10.1016/j.cell.2017.06.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.06.036</ArticleId><ArticleId IdType="pmc">PMC5647789</ArticleId><ArticleId IdType="pubmed">28708995</ArticleId></ArticleIdList></Reference><Reference><Citation>Steed A. L., Christophi G. P., Kaiko G. E., Sun L., Goodwin V. M., Jain U., et al. (2017). The microbial metabolite desaminotyrosine protects from influenza through type I interferon. Science 357 (6350), 498&#x2013;502. doi:&#xa0; 10.1126/science.aam5336</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aam5336</ArticleId><ArticleId IdType="pmc">PMC5753406</ArticleId><ArticleId IdType="pubmed">28774928</ArticleId></ArticleIdList></Reference><Reference><Citation>Stojkovic D., Kostic M., Smiljkovic M., Aleksic M., Vasiljevic P., Nikolic M., et al. (2020). Linking antimicrobial potential of natural products derived from aquatic organisms and microbes involved in alzheimer's disease - A review. Curr. Med. Chem. 27 (26), 4372&#x2013;4391. doi:&#xa0; 10.2174/0929867325666180309103645</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867325666180309103645</ArticleId><ArticleId IdType="pubmed">29521212</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Q., Tun H. M., Liu Q., Yeoh Y. K., Mak J., Chan F. K., et al. (2023). Gut microbiome signatures reflect different subtypes of irritable bowel syndrome. Gut Microbes 15 (1), 2157697. doi:&#xa0; 10.1080/19490976.2022.2157697</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2022.2157697</ArticleId><ArticleId IdType="pmc">PMC9809927</ArticleId><ArticleId IdType="pubmed">36573834</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumida T. S., Dulberg S., Schupp J. C., Lincoln M. R., Stillwell H. A., Axisa P. P., et al. (2022). Type I interferon transcriptional network regulates expression of coinhibitory receptors in human T cells. Nat. Immunol. 23 (4), 632&#x2013;642. doi:&#xa0; 10.1038/s41590-022-01152-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-022-01152-y</ArticleId><ArticleId IdType="pmc">PMC8989655</ArticleId><ArticleId IdType="pubmed">35301508</ArticleId></ArticleIdList></Reference><Reference><Citation>
Sun J., Li H., Jin Y., Yu J., Mao S., Su K. P., et al. (2021). Probiotic Clostridium butyricum ameliorated motor deficits in a mouse model of Parkinson's disease <i>via</i> gut microbiota-GLP-1 pathway. Brain Behav. Immun.
91, 703&#x2013;715. doi:&#xa0; 10.1016/j.bbi.2020.10.014
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.10.014</ArticleId><ArticleId IdType="pubmed">33148438</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L., Zhang H., Cao Y., Wang C., Zhao C., Wang H., et al. (2019). Fluoxetine ameliorates dysbiosis in a depression model induced by chronic unpredicted mild stress in mice. Int. J. Med. Sci. 16 (9), 1260&#x2013;1270. doi:&#xa0; 10.7150/ijms.37322</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.37322</ArticleId><ArticleId IdType="pmc">PMC6775263</ArticleId><ArticleId IdType="pubmed">31588192</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun M. F., Zhu Y. L., Zhou Z. L., Jia X. B., Xu Y. D., Yang Q., et al. (2018). Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-alpha signaling pathway. Brain Behav. Immun. 70, 48&#x2013;60. doi:&#xa0; 10.1016/j.bbi.2018.02.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2018.02.005</ArticleId><ArticleId IdType="pubmed">29471030</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki T. (2020). Regulation of the intestinal barrier by nutrients: The role of tight junctions. Anim. Sci. J. 91 (1), e13357. doi:&#xa0; 10.1111/asj.13357</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/asj.13357</ArticleId><ArticleId IdType="pmc">PMC7187240</ArticleId><ArticleId IdType="pubmed">32219956</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson K. S., Gibson G. R., Hutkins R., Reimer R. A., Reid G., Verbeke K., et al. (2020). The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nat. Rev. Gastroenterol. Hepatol. 17 (11), 687&#x2013;701. doi:&#xa0; 10.1038/s41575-020-0344-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-020-0344-2</ArticleId><ArticleId IdType="pmc">PMC7581511</ArticleId><ArticleId IdType="pubmed">32826966</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney M. D., Sagare A. P., Zlokovic B. V. (2018). Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat. Rev. Neurol. 14 (3), 133&#x2013;150. doi:&#xa0; 10.1038/nrneurol.2017.188</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2017.188</ArticleId><ArticleId IdType="pmc">PMC5829048</ArticleId><ArticleId IdType="pubmed">29377008</ArticleId></ArticleIdList></Reference><Reference><Citation>Taj A., Jamil N. (2018). Bioconversion of tyrosine and tryptophan derived biogenic amines by neuropathogenic bacteria. Biomolecules. 8 (1), 10&#x2013;18. doi:&#xa0; 10.3390/biom8010010</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom8010010</ArticleId><ArticleId IdType="pmc">PMC5871979</ArticleId><ArticleId IdType="pubmed">29438351</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamtaji O. R., Taghizadeh M., Daneshvar K. R., Kouchaki E., Bahmani F., Borzabadi S., et al. (2019). Clinical and metabolic response to probiotic administration in people with Parkinson's disease: A randomized, double-blind, placebo-controlled trial. Clin. Nutr. 38 (3), 1031&#x2013;1035. doi:&#xa0; 10.1016/j.clnu.2018.05.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2018.05.018</ArticleId><ArticleId IdType="pubmed">29891223</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan H. E. (2023). The microbiota-gut-brain axis in stress and depression. Front. Neurosci. 17. doi:&#xa0; 10.3389/fnins.2023.1151478</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2023.1151478</ArticleId><ArticleId IdType="pmc">PMC10140437</ArticleId><ArticleId IdType="pubmed">37123352</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang J., Xu L., Zeng Y., Gong F. (2021). Effect of gut microbiota on LPS-induced acute lung injury by regulating the TLR4/NF-kB signaling pathway. Int. Immunopharmacol. 91, 107272. doi:&#xa0; 10.1016/j.intimp.2020.107272</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.107272</ArticleId><ArticleId IdType="pubmed">33360370</ArticleId></ArticleIdList></Reference><Reference><Citation>Tankou S. K., Regev K., Healy B. C., Cox L. M., Tjon E., Kivisakk P., et al. (2018). Investigation of probiotics in multiple sclerosis. Mult Scler 24 (1), 58&#x2013;63. doi:&#xa0; 10.1177/1352458517737390</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458517737390</ArticleId><ArticleId IdType="pubmed">29307299</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor J. M., Moore Z., Minter M. R., Crack P. J. (2018). Type-I interferon pathway in neuroinflammation and neurodegeneration: focus on Alzheimer's disease. J. Neural Transm (Vienna) 125 (5), 797&#x2013;807. doi:&#xa0; 10.1007/s00702-017-1745-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-017-1745-4</ArticleId><ArticleId IdType="pubmed">28676934</ArticleId></ArticleIdList></Reference><Reference><Citation>Tierney B. T., Yang Z., Luber J. M., Beaudin M., Wibowo M. C., Baek C., et al. (2019). The landscape of genetic content in the gut and oral human microbiome. Cell Host Microbe 26 (2), 283&#x2013;295.e8. doi:&#xa0; 10.1016/j.chom.2019.07.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2019.07.008</ArticleId><ArticleId IdType="pmc">PMC6716383</ArticleId><ArticleId IdType="pubmed">31415755</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolosa E., Garrido A., Scholz S. W., Poewe W. (2021). Challenges in the diagnosis of Parkinson's disease. Lancet Neurol. 20 (5), 385&#x2013;397. doi:&#xa0; 10.1016/S1474-4422(21)00030-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00030-2</ArticleId><ArticleId IdType="pmc">PMC8185633</ArticleId><ArticleId IdType="pubmed">33894193</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremlett H., Waubant E. (2018). The gut microbiota and pediatric multiple sclerosis: recent findings. Neurotherapeutics 15 (1), 102&#x2013;108. doi:&#xa0; 10.1007/s13311-017-0574-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-017-0574-3</ArticleId><ArticleId IdType="pmc">PMC5794692</ArticleId><ArticleId IdType="pubmed">28940049</ArticleId></ArticleIdList></Reference><Reference><Citation>Trone K., Rahman S., Green C. H., Venegas C., Martindale R., Stroud A. (2023). Synbiotics and surgery: can prebiotics and probiotics affect inflammatory surgical outcomes? Curr. Nutr. Rep. 12 (2), 238&#x2013;246. doi:&#xa0; 10.1007/s13668-023-00464-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13668-023-00464-1</ArticleId><ArticleId IdType="pmc">PMC10060133</ArticleId><ArticleId IdType="pubmed">36991238</ArticleId></ArticleIdList></Reference><Reference><Citation>Truax A. D., Chen L., Tam J. W., Cheng N., Guo H., Koblansky A. A., et al. (2018). The inhibitory innate immune sensor NLRP12 maintains a threshold against obesity by regulating gut microbiota homeostasis. Cell Host Microbe 24 (3), 364&#x2013;378.e6. doi:&#xa0; 10.1016/j.chom.2018.08.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2018.08.009</ArticleId><ArticleId IdType="pmc">PMC6161752</ArticleId><ArticleId IdType="pubmed">30212649</ArticleId></ArticleIdList></Reference><Reference><Citation>Valles-Colomer M., Falony G., Darzi Y., Tigchelaar E. F., Wang J., Tito R. Y., et al. (2019). The neuroactive potential of the human gut microbiota in quality of life and depression. Nat. Microbiol. 4 (4), 623&#x2013;632. doi:&#xa0; 10.1038/s41564-018-0337-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-018-0337-x</ArticleId><ArticleId IdType="pubmed">30718848</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Wouw M., Boehme M., Lyte J. M., Wiley N., Strain C., O'Sullivan O., et al. (2018). Short-chain fatty acids: microbial metabolites that alleviate stress-induced brain-gut axis alterations. J. Physiol. 596 (20), 4923&#x2013;4944. doi:&#xa0; 10.1113/JP276431</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP276431</ArticleId><ArticleId IdType="pmc">PMC6187046</ArticleId><ArticleId IdType="pubmed">30066368</ArticleId></ArticleIdList></Reference><Reference><Citation>van Langelaar J., Rijvers L., Smolders J., van Luijn M. M. (2020). B and T cells driving multiple sclerosis: identity, mechanisms and potential triggers. Front. Immunol. 11. doi:&#xa0; 10.3389/fimmu.2020.00760</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00760</ArticleId><ArticleId IdType="pmc">PMC7225320</ArticleId><ArticleId IdType="pubmed">32457742</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkhnyatskaya S., Ferrari M., de Vos P., Walvoort M. (2019). Shaping the infant microbiome with non-digestible carbohydrates. Front. Microbiol. 10. doi:&#xa0; 10.3389/fmicb.2019.00343</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2019.00343</ArticleId><ArticleId IdType="pmc">PMC6397869</ArticleId><ArticleId IdType="pubmed">30858844</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt N. M., Kerby R. L., Dill-McFarland K. A., Harding S. J., Merluzzi A. P., Johnson S. C., et al. (2017). Gut microbiome alterations in Alzheimer's disease. Sci. Rep. 7 (1), 13537. doi:&#xa0; 10.1038/s41598-017-13601-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-13601-y</ArticleId><ArticleId IdType="pmc">PMC5648830</ArticleId><ArticleId IdType="pubmed">29051531</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuong H. E., Hsiao E. Y. (2017). Emerging roles for the gut microbiome in autism spectrum disorder. Biol. Psychiatry 81 (5), 411&#x2013;423. doi:&#xa0; 10.1016/j.biopsych.2016.08.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2016.08.024</ArticleId><ArticleId IdType="pmc">PMC5285286</ArticleId><ArticleId IdType="pubmed">27773355</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Alammar N., Singh R., Nanavati J., Song Y., Chaudhary R., et al. (2020). Gut microbial dysbiosis in the irritable bowel syndrome: A systematic review and meta-analysis of case-control studies. J. Acad. Nutr. Diet. 120 (4), 565&#x2013;586. doi:&#xa0; 10.1016/j.jand.2019.05.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jand.2019.05.015</ArticleId><ArticleId IdType="pubmed">31473156</ArticleId></ArticleIdList></Reference><Reference><Citation>
Wang C., Chen S., Guo H., Jiang H., Liu H., Fu H., et al. (2022). Forsythoside A mitigates alzheimer's-like pathology by inhibiting ferroptosis-mediated neuroinflammation <i>via</i> nrf2/GPX4 axis activation. Int. J. Biol. Sci.
18 (5), 2075&#x2013;2090. doi:&#xa0; 10.7150/ijbs.69714
</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.69714</ArticleId><ArticleId IdType="pmc">PMC8935224</ArticleId><ArticleId IdType="pubmed">35342364</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Dou S., Zhu J., Shao Z., Wang C., Xu X., et al. (2021). Ghrelin protects against rotenone-induced cytotoxicity: Involvement of mitophagy and the AMPK/SIRT1/PGC1alpha pathway. Neuropeptides 87, 102134. doi:&#xa0; 10.1016/j.npep.2021.102134</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.npep.2021.102134</ArticleId><ArticleId IdType="pubmed">33639357</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Li N., Yang J. J., Zhao D. M., Chen B., Zhang G. Q., et al. (2020). Probiotics and fructo-oligosaccharide intervention modulate the microbiota-gut brain axis to improve autism spectrum reducing also the hyper-serotonergic state and the dopamine metabolism disorder. Pharmacol. Res. 157, 104784. doi:&#xa0; 10.1016/j.phrs.2020.104784</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2020.104784</ArticleId><ArticleId IdType="pubmed">32305492</ArticleId></ArticleIdList></Reference><Reference><Citation>Wastyk H. C., Fragiadakis G. K., Perelman D., Dahan D., Merrill B. D., Yu F. B., et al. (2021). Gut-microbiota-targeted diets modulate human immune status. Cell 184 (16), 4137&#x2013;4153.e14. doi:&#xa0; 10.1016/j.cell.2021.06.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.06.019</ArticleId><ArticleId IdType="pmc">PMC9020749</ArticleId><ArticleId IdType="pubmed">34256014</ArticleId></ArticleIdList></Reference><Reference><Citation>
Wei G. Z., Martin K. A., Xing P. Y., Agrawal R., Whiley L., Wood T. K., et al. (2021). Tryptophan-metabolizing gut microbes regulate adult neurogenesis <i>via</i> the aryl hydrocarbon receptor. Proc. Natl. Acad. Sci. U.S.A.
118 (27), e2021091118. doi:&#xa0; 10.1073/pnas.2021091118
</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2021091118</ArticleId><ArticleId IdType="pmc">PMC8271728</ArticleId><ArticleId IdType="pubmed">34210797</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenzel T. J., Gates E. J., Ranger A. L., Klegeris A. (2020). Short-chain fatty acids (SCFAs) alone or in combination regulate select immune functions of microglia-like cells. Mol. Cell. Neurosci. 105, 103493. doi:&#xa0; 10.1016/j.mcn.2020.103493</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2020.103493</ArticleId><ArticleId IdType="pubmed">32333962</ArticleId></ArticleIdList></Reference><Reference><Citation>Woelfer M., Kasties V., Kahlfuss S., Walter M. (2019). The role of depressive subtypes within the neuroinflammation hypothesis of major depressive disorder. Neuroscience 403, 93&#x2013;110. doi:&#xa0; 10.1016/j.neuroscience.2018.03.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2018.03.034</ArticleId><ArticleId IdType="pubmed">29604382</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S. C., Chen W. T., Muo C. H., Hsu C. Y. (2020). A population-based cohort study examining the long-term risk of repeated surgery in non-helicobacter pylori-infected PPU patients who underwent simple closure. J. Gastrointest. Surg. 24 (11), 2587&#x2013;2595. doi:&#xa0; 10.1007/s11605-019-04442-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11605-019-04442-3</ArticleId><ArticleId IdType="pubmed">31745904</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Wang Y., Hu A., Shu X., Huang W., Liu J., et al. (2022). Lactobacillus plantarum-derived postbiotics prevent Salmonella-induced neurological dysfunctions by modulating gut-brain axis in mice. Front. Nutr. 9. doi:&#xa0; 10.3389/fnut.2022.946096</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2022.946096</ArticleId><ArticleId IdType="pmc">PMC9365972</ArticleId><ArticleId IdType="pubmed">35967771</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao W., Su J., Gao X., Yang H., Weng R., Ni W., et al. (2022). The microbiota-gut-brain axis participates in chronic cerebral hypoperfusion by disrupting the metabolism of short-chain fatty acids. Microbiome 10 (1), 62. doi:&#xa0; 10.1186/s40168-022-01255-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40168-022-01255-6</ArticleId><ArticleId IdType="pmc">PMC9013454</ArticleId><ArticleId IdType="pubmed">35430804</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao L., Yan J., Yang T., Zhu J., Li T., Wei H., et al. (2021). Fecal microbiome transplantation from children with autism spectrum disorder modulates tryptophan and serotonergic synapse metabolism and induces altered behaviors in germ-free mice. mSystems 6 (2), e01343-20. doi:&#xa0; 10.1128/mSystems.01343-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mSystems.01343-20</ArticleId><ArticleId IdType="pmc">PMC8547010</ArticleId><ArticleId IdType="pubmed">33824200</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu F., Han L., Wang Y., Deng D., Ding Y., Zhao S., et al. (2023). Prolonged anesthesia induces neuroinflammation and complement-mediated microglial synaptic elimination involved in neurocognitive dysfunction and anxiety-like behaviors. BMC Med. 21 (1), 7. doi:&#xa0; 10.1186/s12916-022-02705-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02705-6</ArticleId><ArticleId IdType="pmc">PMC9814183</ArticleId><ArticleId IdType="pubmed">36600274</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu T., Liu J., Li X. R., Yu Y., Luo X., Zheng X., et al. (2021). The mTOR/NF-kappaB pathway mediates neuroinflammation and synaptic plasticity in diabetic encephalopathy. Mol. Neurobiol. 58 (8), 3848&#x2013;3862. doi:&#xa0; 10.1007/s12035-021-02390-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-021-02390-1</ArticleId><ArticleId IdType="pubmed">33860440</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav M. K., Kumari I., Singh B., Sharma K. K., Tiwari S. K. (2022). Probiotics, prebiotics and synbiotics: Safe options for next-generation therapeutics. Appl. Microbiol. Biotechnol. 106 (2), 505&#x2013;521. doi:&#xa0; 10.1007/s00253-021-11646-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00253-021-11646-8</ArticleId><ArticleId IdType="pmc">PMC8749913</ArticleId><ArticleId IdType="pubmed">35015145</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan F., Polk D. B. (2020). Probiotics and probiotic-derived functional factors-mechanistic insights into applications for intestinal homeostasis. Front. Immunol. 11. doi:&#xa0; 10.3389/fimmu.2020.01428</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01428</ArticleId><ArticleId IdType="pmc">PMC7348054</ArticleId><ArticleId IdType="pubmed">32719681</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao C., Li Y., Luo L., Xie F., Xiong Q., Li T., et al. (2023). Significant differences in gut microbiota between irritable bowel syndrome with diarrhea and healthy controls in southwest China. Dig Dis. Sci. 68 (1), 106&#x2013;127. doi:&#xa0; 10.1007/s10620-022-07500-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-022-07500-0</ArticleId><ArticleId IdType="pubmed">35503487</ArticleId></ArticleIdList></Reference><Reference><Citation>
Yarandi S. S., Kulkarni S., Saha M., Sylvia K. E., Sears C. L., Pasricha P. J. (2020). Intestinal bacteria maintain adult enteric nervous system and nitrergic neurons <i>via</i> toll-like receptor 2-induced neurogenesis in mice. Gastroenterology
159 (1), 200&#x2013;213.e8. doi:&#xa0; 10.1053/j.gastro.2020.03.050
</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.03.050</ArticleId><ArticleId IdType="pmc">PMC7387157</ArticleId><ArticleId IdType="pubmed">32234538</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan M., Jiang Z., Bi G., Nomura K., Liu M., Wang Y., et al. (2021). Pattern-recognition receptors are required for NLR-mediated plant immunity. Nature 592 (7852), 105&#x2013;109. doi:&#xa0; 10.1038/s41586-021-03316-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03316-6</ArticleId><ArticleId IdType="pmc">PMC8016741</ArticleId><ArticleId IdType="pubmed">33692546</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan M. J., Li W., Zhong P. (2021). Research progress of ghrelin on cardiovascular disease. Biosci. Rep. 41 (1), BSR20203387. doi:&#xa0; 10.1042/BSR20203387</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20203387</ArticleId><ArticleId IdType="pmc">PMC7823193</ArticleId><ArticleId IdType="pubmed">33427286</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaky A., Glastras S. J., Wong M., Pollock C. A., Saad S. (2021). The role of the gut microbiome in diabetes and obesity-related kidney disease. Int. J. Mol. Sci. 22 (17), 9641&#x2013;9666. doi:&#xa0; 10.3390/ijms22179641</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22179641</ArticleId><ArticleId IdType="pmc">PMC8431784</ArticleId><ArticleId IdType="pubmed">34502562</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Wang J., Wang J., Yang B., He Q., Weng Q. (2020). Role of DJ-1 in immune and inflammatory diseases. Front. Immunol. 11. doi:&#xa0; 10.3389/fimmu.2020.00994</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00994</ArticleId><ArticleId IdType="pmc">PMC7308417</ArticleId><ArticleId IdType="pubmed">32612601</ArticleId></ArticleIdList></Reference><Reference><Citation>
Zhang J., Xu M., Zhou W., Li D., Zhang H., Chen Y., et al. (2020). Deficiency in the anti-apoptotic protein DJ-1 promotes intestinal epithelial cell apoptosis and aggravates inflammatory bowel disease <i>via</i> p53. J. Biol. Chem.
295 (13), 4237&#x2013;4251. doi:&#xa0; 10.1074/jbc.RA119.010143
</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA119.010143</ArticleId><ArticleId IdType="pmc">PMC7105307</ArticleId><ArticleId IdType="pubmed">32075910</ArticleId></ArticleIdList></Reference><Reference><Citation>
Zhao Z., Ning J., Bao X. Q., Shang M., Ma J., Li G., et al. (2021). Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice <i>via</i> suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis. Microbiome
9 (1), 226. doi:&#xa0; 10.1186/s40168-021-01107-9
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40168-021-01107-9</ArticleId><ArticleId IdType="pmc">PMC8597301</ArticleId><ArticleId IdType="pubmed">34784980</ArticleId></ArticleIdList></Reference><Reference><Citation>
Zhao X., Wu H., Zhu R., Shang G., Wei J., Shang H., et al. (2023). Combination of thalidomide and Clostridium butyricum relieves chemotherapy-induced nausea and vomiting <i>via</i> gut microbiota and vagus nerve activity modulation. Front. Immunol.
14. doi:&#xa0; 10.3389/fimmu.2023.1220165
</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1220165</ArticleId><ArticleId IdType="pmc">PMC10327820</ArticleId><ArticleId IdType="pubmed">37426650</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M., Karki R., Williams E. P., Yang D., Fitzpatrick E., Vogel P., et al. (2021). TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat. Immunol. 22 (7), 829&#x2013;838. doi:&#xa0; 10.1038/s41590-021-00937-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-00937-x</ArticleId><ArticleId IdType="pmc">PMC8882317</ArticleId><ArticleId IdType="pubmed">33963333</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng S. Y., Li H. X., Xu R. C., Miao W. T., Dai M. Y., Ding S. T., et al. (2021). Potential roles of gut microbiota and microbial metabolites in Parkinson's disease. Ageing Res. Rev. 69, 101347. doi:&#xa0; 10.1016/j.arr.2021.101347</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2021.101347</ArticleId><ArticleId IdType="pubmed">33905953</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong J. G., Lan W. T., Feng Y. Q., Li Y. H., Shen Y. Y., Gong J. H., et al. (2023). Associations between dysbiosis gut microbiota and changes of neurotransmitters and short-chain fatty acids in valproic acid model rats. Front. Physiol. 14. doi:&#xa0; 10.3389/fphys.2023.1077821</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2023.1077821</ArticleId><ArticleId IdType="pmc">PMC10073564</ArticleId><ArticleId IdType="pubmed">37035670</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou C., Chen L. L., Lu R. Q., Ma W. W., Xiao R. (2021). Alteration of intestinal microbiota composition in oral sensitized C3H/heJ mice is associated with changes in dendritic cells and T cells in mesenteric lymph nodes. Front. Immunol. 12. doi:&#xa0; 10.3389/fimmu.2021.631494</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.631494</ArticleId><ArticleId IdType="pmc">PMC8222730</ArticleId><ArticleId IdType="pubmed">34177885</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu M., Liu X., Ye Y., Yan X., Cheng Y., Zhao L., et al. (2022). Gut microbiota: A novel therapeutic target for parkinson's disease. Front. Immunol. 13. doi:&#xa0; 10.3389/fimmu.2022.937555</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.937555</ArticleId><ArticleId IdType="pmc">PMC9263276</ArticleId><ArticleId IdType="pubmed">35812394</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou R., Xu F., Wang Y., Duan M., Guo M., Zhang Q., et al. (2020). Changes in the gut microbiota of children with autism spectrum disorder. Autism Res. 13 (9), 1614&#x2013;1625. doi:&#xa0; 10.1002/aur.2358</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/aur.2358</ArticleId><ArticleId IdType="pubmed">32830918</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T., Ng S. C. (2018). The gut microbiota in the pathogenesis and therapeutics of inflammatory bowel disease. Front. Microbiol. 9. doi:&#xa0; 10.3389/fmicb.2018.02247</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.02247</ArticleId><ArticleId IdType="pmc">PMC6167487</ArticleId><ArticleId IdType="pubmed">30319571</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32635661</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6643</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>05</Day></PubDate></JournalIssue><Title>Nutrients</Title><ISOAbbreviation>Nutrients</ISOAbbreviation></Journal><ArticleTitle>The Effectiveness of Synbiotic Preparation Containing <i>Lactobacillus</i> and <i>Bifidobacterium</i> Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant Irritable Bowel Syndrome-A Randomized Double-Blind, Placebo-Controlled Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1999</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nu12071999</ELocationID><Abstract><AbstractText>The purpose of the randomized double-blind placebo-controlled trial was to assess the effectiveness of synbiotic preparation containing probiotic <i>Lactobacillus rhamnosus</i> FloraActive&#x2122; 19070-2, <i>Lactobacillus acidophilus</i> DSMZ 32418, <i>Bifidobacterium lactis</i> DSMZ 32269, <i>Bifidobacterium longum</i> DSMZ 32946, <i>Bifidobacterium bifidum</i> DSMZ 32403 and fructooligosaccharides in adult patients with diarrhea-dominant IBS (IBS-D). The study included eighty patients with moderate and severe IBS-D who were randomized to receive synbiotics or placebo for eight weeks. Finally, a total of sixty-eight patients finished the study. The primary endpoints included the assessment of the symptoms' severity with IBS symptom severity scale (IBS-SSS), an improvement of IBS global symptoms with Global Improvement Scale (IBS-GIS) and adequate relief of symptoms after four and eight weeks of therapy. Secondary endpoints, which were collected by telephone interviewers three times a week included the assessment of individual IBS symptoms and adverse events. Synbiotic treatment in comparison to placebo significantly improved IBS-GIS (<i>p</i> = 0.043), and IBS-SSS score inducing a decrease in the total IBS-SSS (<i>p</i> = 0.042) and in domain-specific scores related to flatulence (<i>p</i> = 0.028) and bowel habit (<i>p</i> = 0.028) after four and eight weeks. Patients treated with synbiotics reported in weekly observations a significant amelioration in a feeling of incomplete bowel movements, flatulence, pain, stool pressure and diarrheal stools compared to those receiving placebo. There were no differences in adverse events between both groups. Concluding, the multi-strain synbiotic preparation was associated with a significant improvement in symptoms in IBS-D patients and was well-tolerated. These results suggest that the use of synbiotics offers a benefit for IBS-D patients. [Clinicaltrials.gov NCT04206410 registered 20 December 2019].</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Skrzyd&#x142;o-Radoma&#x144;ska</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Medical University of Lublin, Jaczewskiego 8, 20-950 Lublin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prozorow-Kr&#xf3;l</LastName><ForeName>Beata</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Medical University of Lublin, Jaczewskiego 8, 20-950 Lublin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cicho&#x17c;-Lach</LastName><ForeName>Halina</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Medical University of Lublin, Jaczewskiego 8, 20-950 Lublin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Majsiak</LastName><ForeName>Emilia</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-3638-9292</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Cardinal Stefan Wyszynski University, W&#xf3;ycickiego 1/3, 01-938 Warszaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bier&#x142;a</LastName><ForeName>Joanna B</ForeName><Initials>JB</Initials><Identifier Source="ORCID">0000-0002-5772-5091</Identifier><AffiliationInfo><Affiliation>Department of Pathology, The Children Memorial Health Institute, Aleja Dzieci Polskich 20, 04-730 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosikowski</LastName><ForeName>Wojciech</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Out-Patient Clinic, Konopnica 96L, 21-030 Motycz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szczerbi&#x144;ski</LastName><ForeName>Mariusz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Medical University of Lublin, Jaczewskiego 8, 20-950 Lublin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gantzel</LastName><ForeName>Jesper</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1897-0841</Identifier><AffiliationInfo><Affiliation>Biocare Copenhagen, Ole Maaloes Vej 3, DK-2200 Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cukrowska</LastName><ForeName>Bo&#x17c;ena</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology, The Children Memorial Health Institute, Aleja Dzieci Polskich 20, 04-730 Warsaw, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04206410</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>6/KBE/2018</GrantID><Agency>Biocare, Copenhagen, Denmark</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nutrients</MedlineTA><NlmUniqueID>101521595</NlmUniqueID><ISSNLinking>2072-6643</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009844">Oligosaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C116580">fructooligosaccharide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069982" MajorTopicYN="N">Bifidobacterium animalis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069985" MajorTopicYN="N">Bifidobacterium bifidum</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069978" MajorTopicYN="N">Bifidobacterium longum</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003672" MajorTopicYN="N">Defecation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005414" MajorTopicYN="N">Flatulence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007779" MajorTopicYN="N">Lactobacillus acidophilus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052201" MajorTopicYN="N">Lacticaseibacillus rhamnosus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009844" MajorTopicYN="N">Oligosaccharides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058616" MajorTopicYN="N">Synbiotics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bifidobacterium</Keyword><Keyword MajorTopicYN="N">Lactobacillus</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">prebiotics</Keyword><Keyword MajorTopicYN="N">probiotics</Keyword><Keyword MajorTopicYN="N">short chain fructooligosaccharides</Keyword><Keyword MajorTopicYN="N">synbiotics</Keyword></KeywordList><CoiStatement>B.C. has served as a speaker for Nutricia, Danone, Bayer, Apotex, Polpharma, and Mead Johnson. J.G. is the co-founder of Biocare Copenhagen, a company acquired by DSM Nutritional Products in 2017, but was not involved in conducting the study and data analyses. Other authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32635661</ArticleId><ArticleId IdType="pmc">PMC7400954</ArticleId><ArticleId IdType="doi">10.3390/nu12071999</ArticleId><ArticleId IdType="pii">nu12071999</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ford A.C., Lacy B.E., Talley N.J. Irritable bowel syndrome. N. Engl. J. Med. 2017;376:2566&#x2013;2578. doi: 10.1056/NEJMra1607547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1607547</ArticleId><ArticleId IdType="pubmed">28657875</ArticleId></ArticleIdList></Reference><Reference><Citation>Canavan C., West J., Card T. The epidemiology of irritable bowel syndrome. Clin. Epidemiol. 2014;6:71&#x2013;80. doi: 10.1007/s40273-015-0339-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40273-015-0339-y</ArticleId><ArticleId IdType="pmc">PMC3921083</ArticleId><ArticleId IdType="pubmed">24523597</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel B.M., Farid M., Esrailian E., Talley J., Chang L. Is Irritable bowel syndrome a diagnosis of exclusion? A survey of primary care providers, gastroenterologists, and IBS experts. Am. J. Gastroenterol. 2010;105:848&#x2013;858. doi: 10.1038/ajg.2010.47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2010.47</ArticleId><ArticleId IdType="pmc">PMC2887205</ArticleId><ArticleId IdType="pubmed">20197761</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattarai Y., Pedrogo D.A.M., Kashyap P.C. Irritable bowel syndrome: A gut microbiota-related disorder? Am. J. Physiol.-Gastrointest. Liver Physiol. 2016;312:G52&#x2013;G62. doi: 10.1152/ajpgi.00338.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00338.2016</ArticleId><ArticleId IdType="pmc">PMC5283907</ArticleId><ArticleId IdType="pubmed">27881403</ArticleId></ArticleIdList></Reference><Reference><Citation>Distrutti E., Monaldi L., Ricci P., Fiorucci S. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World J. Gastroenterol. 2016;22:2219&#x2013;2241. doi: 10.3748/wjg.v22.i7.2219.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i7.2219</ArticleId><ArticleId IdType="pmc">PMC4734998</ArticleId><ArticleId IdType="pubmed">26900286</ArticleId></ArticleIdList></Reference><Reference><Citation>Mari A., Baker F.A., Mahamid M., Sbeit W., Khoury T. The Evolving role of gut microbiota in the management of irritable bowel syndrome: An overview of the current knowledge. J. Clin. Med. 2020;9:685. doi: 10.3390/jcm9030685.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9030685</ArticleId><ArticleId IdType="pmc">PMC7141230</ArticleId><ArticleId IdType="pubmed">32143424</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivinus-N&#xe9;bot M., Frin-Mathy G., Bzioueche H., Dainese R., Bernard G., Anty R., Filippi J., Saint-Paul M.C., Tulic M.K., Verhasselt V., et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: Role of epithelial barrier disruption and low-grade inflammation. Gut. 2013;63:744&#x2013;752. doi: 10.1136/gutjnl-2012-304066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2012-304066</ArticleId><ArticleId IdType="pubmed">23878165</ArticleId></ArticleIdList></Reference><Reference><Citation>Pusceddu M.M., Gareau M.G. Visceral pain: Gut microbiota, a new hope? J. Biomed. Sci. 2018;25:73. doi: 10.1186/s12929-018-0476-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-018-0476-7</ArticleId><ArticleId IdType="pmc">PMC6182804</ArticleId><ArticleId IdType="pubmed">30309367</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou S., Gillilland M.G., Wu X., Leelasinjaroen P., Zhang G., Zhou H., Ye B., Lu Y., Owyang C. FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction. J. Clin. Investig. 2017;128:267&#x2013;280. doi: 10.1172/JCI92390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI92390</ArticleId><ArticleId IdType="pmc">PMC5749529</ArticleId><ArticleId IdType="pubmed">29202473</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.R., Pimentel M. Bacteria and irritable bowel syndrome: The evidence for small intestinal bacterial overgrowth. Curr. Gastroenterol. Rep. 2006;8:305&#x2013;311. doi: 10.1007/s11894-006-0051-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11894-006-0051-3</ArticleId><ArticleId IdType="pubmed">16836942</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll I.M., Ringel-Kulka T., Siddle J.P., Ringel Y. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol. Motil. 2012;24:521&#x2013;530.e248. doi: 10.1111/j.1365-2982.2012.01891.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2012.01891.x</ArticleId><ArticleId IdType="pmc">PMC3975596</ArticleId><ArticleId IdType="pubmed">22339879</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll I.M., Ringel-Kulka T., Keku T.O., Chang Y.-H., Packey C.D., Sartor R.B., Ringel Y. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am. J. Physiol.-Gastrointest. Liver Physiol. 2011;301:G799&#x2013;G807. doi: 10.1152/ajpgi.00154.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00154.2011</ArticleId><ArticleId IdType="pmc">PMC3220325</ArticleId><ArticleId IdType="pubmed">21737778</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerckhoffs A.P.M., Samsom M., van der Rest M.E., de Vogel J., Knol J., Ben-Amor K., Akkermans L.M. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J. Gastroenterol. 2009;15:2887&#x2013;2892. doi: 10.3748/wjg.15.2887.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.15.2887</ArticleId><ArticleId IdType="pmc">PMC2699007</ArticleId><ArticleId IdType="pubmed">19533811</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozuelo M., Panda S., Santiago A., Mendez S., Accarino A., Santos J., Guarner F., Azpiroz F., Manichanh C. Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome. Sci. Rep. 2015;5:12693. doi: 10.1038/srep12693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep12693</ArticleId><ArticleId IdType="pmc">PMC4523847</ArticleId><ArticleId IdType="pubmed">26239401</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill C., Guarner F., Reid G., Gibson G.R., Merenstein D.J., Pot B., Morelli L., Canani R.B., Flint H.J., Salminen S., et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014;11:506&#x2013;514. doi: 10.1038/nrgastro.2014.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2014.66</ArticleId><ArticleId IdType="pubmed">24912386</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson G.R., Hutkins R., Sanders M.E., Prescott S.L., Reimer R.A., Salminen S.J., Scott K., Stanton C., Swanson K.S., Cani P.D., et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat. Rev. Gastroenterol. Hepatol. 2017;14:491&#x2013;502. doi: 10.1038/nrgastro.2017.75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2017.75</ArticleId><ArticleId IdType="pubmed">28611480</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B., Liang L., Deng H., Guo J., Shu H., Zhang L. Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Front. Pharmacol. 2020;11:332. doi: 10.3389/fphar.2020.00332.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.00332</ArticleId><ArticleId IdType="pmc">PMC7147251</ArticleId><ArticleId IdType="pubmed">32317962</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Harris L.A., Lacy B.E., Quigley E., Moayyedi P. Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2018;48:1044&#x2013;1060. doi: 10.1111/apt.15001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15001</ArticleId><ArticleId IdType="pubmed">30294792</ArticleId></ArticleIdList></Reference><Reference><Citation>Asha M.Z., Khalil S.F.H. Efficacy and safety of probiotics, prebiotics and synbiotics in the treatment of irritable bowel syndrome: A systematic review and meta-analysis. Sultan Qaboos Univ. Med. J. 2020;20:e13&#x2013;e24. doi: 10.18295/squmj.2020.20.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.18295/squmj.2020.20.01.003</ArticleId><ArticleId IdType="pmc">PMC7065695</ArticleId><ArticleId IdType="pubmed">32190365</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Li L., Guo C., Mu D., Feng B., Zuo X., Li Y. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: A meta-analysis. BMC Gastroenterol. 2016;16:62. doi: 10.1186/s12876-016-0470-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-016-0470-z</ArticleId><ArticleId IdType="pmc">PMC4907258</ArticleId><ArticleId IdType="pubmed">27296254</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchiya J., Barreto R., Okura R., Kawakita S., Fesce E., Marotta F. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin. J. Dig. Dis. 2004;5:169&#x2013;174. doi: 10.1111/j.1443-9573.2004.00176.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1443-9573.2004.00176.x</ArticleId><ArticleId IdType="pubmed">15612887</ArticleId></ArticleIdList></Reference><Reference><Citation>Min Y.W., Park S.U., Jang Y.S., Kim Y.-H., Rhee P.-L., Ko S.H., Joo N., Kim S.I., Kim C.-H., Chang D.K. Effect of composite yogurt enriched with acacia fiber and Bifidobacterium lactis. World J. Gastroenterol. 2012;18:4563&#x2013;4569. doi: 10.3748/wjg.v18.i33.4563.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v18.i33.4563</ArticleId><ArticleId IdType="pmc">PMC3435782</ArticleId><ArticleId IdType="pubmed">22969230</ArticleId></ArticleIdList></Reference><Reference><Citation>A Drossman U., Dumitrascu D.L. Rome III: New standard for functional gastrointestinal disorders. J. Gastrointest. Liver Dis. 2006;15:237&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">17013448</ArticleId></ArticleIdList></Reference><Reference><Citation>Riegler G., Esposito I. Bristol scale stool form. A still valid help in medical practice and clinical research. Tech. Coloproctology. 2001;5:163&#x2013;164. doi: 10.1007/s101510100019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s101510100019</ArticleId><ArticleId IdType="pubmed">11875684</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis C.Y., Morris J., Whorwell P. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment. Pharmacol. Ther. 1997;11:395&#x2013;402. doi: 10.1046/j.1365-2036.1997.142318000.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.1997.142318000.x</ArticleId><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagala R., Routray C. Clinical case study&#x2014;Multispecies probiotic supplement minimizes symptoms of irritable bowel syndrome. US Gastroenterol. Hepatol. Rev. 2011;7:36&#x2013;37.</Citation></Reference><Reference><Citation>Gerasimov S., Gantzel J., Dementieva N., Schevchenko O., Tsitsura O., Guta N., Bobyk V., Kaprus V. Role of Lactobacillus rhamnosus (FloraActive&#x2122;) 19070-2 and Lactobacillus reuteri (FloraActive&#x2122;) 12246 in Infant Colic: A Randomized Dietary Study. Nutrients. 2018;10:1975. doi: 10.3390/nu10121975.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu10121975</ArticleId><ArticleId IdType="pmc">PMC6315585</ArticleId><ArticleId IdType="pubmed">30551654</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang D., Longgui N., Guoqiang X. Efficacy of different probiotic protocols in irritable bowel syndrome: A network meta-analysis. Medicine. 2019;98:e16068. doi: 10.1097/MD.0000000000016068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000016068</ArticleId><ArticleId IdType="pmc">PMC6635271</ArticleId><ArticleId IdType="pubmed">31277101</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon S., Ameen V., Bagby B., Shahan B., Jhingran P., Carter E. Validation of irritable bowel syndrome Global Improvement Scale: An integrated symptom end point for assessing treatment efficacy. Dig. Dis. Sci. 2003;48:1317&#x2013;1323. doi: 10.1023/A:1024159226274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1024159226274</ArticleId><ArticleId IdType="pubmed">12870789</ArticleId></ArticleIdList></Reference><Reference><Citation>Gracie D.J., Ford A.C. Symbiotics in irritable bowel syndrome&#x2014;Better than probiotics alone? Curr. Opin. Clin. Nutr. Metab. Care. 2015;18:485&#x2013;489. doi: 10.1097/MCO.0000000000000199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCO.0000000000000199</ArticleId><ArticleId IdType="pubmed">26107141</ArticleId></ArticleIdList></Reference><Reference><Citation>Shavakhi A., Minakari M., Farzamnia S., Peykar M.S., Taghipour G., Tayebi A., Hashemi H., Shavakhi S. The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial. Adv. Biomed. Res. 2014;3:139. doi: 10.4103/2277-9175.135157.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2277-9175.135157</ArticleId><ArticleId IdType="pmc">PMC4139977</ArticleId><ArticleId IdType="pubmed">25161987</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappello C., Tremolaterra F., Pascariello A., Ciacci C., Iovino P. A randomised clinical trial (RCT) of a symbiotic mixture in patients with irritable bowel syndrome (IBS): Effects on symptoms, colonic transit and quality of life. Int. J. Colorectal Dis. 2012;28:349&#x2013;358. doi: 10.1007/s00384-012-1552-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-012-1552-1</ArticleId><ArticleId IdType="pmc">PMC3587687</ArticleId><ArticleId IdType="pubmed">22885882</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogha M., Esfahani M.Z., Zargarzadeh A.H. The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: A randomized placebo-controlled trial. Gastroenterol. Hepatol. Bed Bench. 2014;7:156&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4129566</ArticleId><ArticleId IdType="pubmed">25120896</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarino M.P.L., Altomare A., Emerenziani S., Di Rosa C., Ribolsi M., Balestrieri P., Iovino P., Rocchi G., Cicala M. Mechanisms of action of prebiotics and their effects on gastro-intestinal disorders in adults. Nutrients. 2020;12:1037. doi: 10.3390/nu12041037.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12041037</ArticleId><ArticleId IdType="pmc">PMC7231265</ArticleId><ArticleId IdType="pubmed">32283802</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am. J. Gastroenterol. 2006;101:1288&#x2013;1294. doi: 10.1111/j.1572-0241.2006.00672.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2006.00672.x</ArticleId><ArticleId IdType="pubmed">16771951</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouhnik Y., Raskine L., Simoneau G., Paineau D., Bornet F. The capacity of short-chain fructo-oligosaccharides to stimulate faecal bifidobacteria: A dose-response relationship study in healthy humans. Nutr. J. 2006;5:8. doi: 10.1186/1475-2891-5-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1475-2891-5-8</ArticleId><ArticleId IdType="pmc">PMC1448190</ArticleId><ArticleId IdType="pubmed">16569219</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukahara T., Iwasaki Y., Nakayama K., Ushida K. Stimulation of butyrate production in the large intestine of weaning piglets by dietary fructooligosaccharides and its influence on the histological variables of the large intestinal mucosa. J. Nutr. Sci. Vitaminol. 2003;49:414&#x2013;421. doi: 10.3177/jnsv.49.414.</Citation><ArticleIdList><ArticleId IdType="doi">10.3177/jnsv.49.414</ArticleId><ArticleId IdType="pubmed">14974732</ArticleId></ArticleIdList></Reference><Reference><Citation>Paineau D., Payen F., Panserieu S., Coulombier G., Sobaszek A., Lartigau I., Brabet M., Galmiche J.-P., Tripodi D., Sacher-Huvelin S., et al. The effects of regular consumption of short-chain fructo-oligosaccharides on digestive comfort of subjects with minor functional bowel disorders. Br. J. Nutr. 2008;99:311&#x2013;318. doi: 10.1017/S000711450779894X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S000711450779894X</ArticleId><ArticleId IdType="pubmed">17697398</ArticleId></ArticleIdList></Reference><Reference><Citation>Azpiroz F., DuBray C., Bernalier-Donadille A., Cardot J.M., Accarino A., Serra J., Wagner A., Respondek F., Dapoigny M. Effects of scFOS on the composition of fecal microbiota and anxiety in patients with irritable bowel syndrome: A randomized, double blind, placebo controlled study. Neurogastroenterol. Motil. 2016;29:e12911. doi: 10.1111/nmo.12911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12911</ArticleId><ArticleId IdType="pubmed">27477485</ArticleId></ArticleIdList></Reference><Reference><Citation>Basturk A., Artan R., Y&#x131;lmaz A. Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: A randomized controlled trial. Turk. J. Gastroenterol. 2020;27:439&#x2013;443. doi: 10.5152/tjg.2016.16301.</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/tjg.2016.16301</ArticleId><ArticleId IdType="pubmed">27782892</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahrudin M.F., Rani R.A., Tamil A.M., Mokhtar N.M., Ali R.A.R. Effectiveness of sterilized symbiotic drink containing Lactobacillus helveticus comparable to probiotic alone in patients with constipation-predominant irritable bowel syndrome. Dig. Dis. Sci. 2019;65:541&#x2013;549. doi: 10.1007/s10620-019-05695-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-019-05695-3</ArticleId><ArticleId IdType="pmc">PMC6995448</ArticleId><ArticleId IdType="pubmed">31209720</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32019158</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6643</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Jan</Month><Day>30</Day></PubDate></JournalIssue><Title>Nutrients</Title><ISOAbbreviation>Nutrients</ISOAbbreviation></Journal><ArticleTitle><i>Lactobacillus acidophilus</i> DDS-1 and <i>Bifidobacterium lactis</i> UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">363</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nu12020363</ELocationID><Abstract><AbstractText>This randomized, double-blind, placebo-controlled, multi-center study investigated the clinical efficacy of two probiotic strains on abdominal pain severity and symptomology in irritable bowel syndrome (IBS). Three hundred and thirty adults, aged 18 to 70 years, with IBS according to Rome IV criteria were allocated (1:1:1) to receive placebo, <i>L</i><i>actobacillus</i> <i>acidophilus</i> DDS-1 (1 &#xd7; 10<sup>10</sup> CFU/day) or <i>B</i><i>ifidobacterium</i> <i>animalis</i> subsp. <i>lactis</i> UABla-12 (1 &#xd7; 10<sup>10</sup> CFU/day) over six weeks. The primary outcome was the change in Abdominal Pain Severity - Numeric Rating Scale (APS-NRS). Over the intervention period, APS-NRS was significantly improved in both probiotic groups vs. placebo in absolute terms (DDS-1: -2.59 &#xb1; 2.07, p = 0.001; UABla-12: -1.56 &#xb1; 1.83, p = 0.001) and in percentage of significant responders (DDS-1: 52.3%, p &lt; 0.001); UABla-12 (28.2%, p = 0.031). Significant amelioration vs. placebo was observed in IBS Symptom Severity Scale (IBS-SSS) scores for L. acidophilus DDS-1 (-133.4 &#xb1; 95.19, p &lt; 0.001) and B. lactis UABla-12 (-104.5 &#xb1; 96.08, p &lt; 0.001) groups, including sub-scores related to abdominal pain, abdominal distension, bowel habits and quality of life. Additionally, a significant normalization was observed in stool consistency in both probiotic groups over time and as compared to placebo. In conclusion, L. acidophilus DDS-1 and B. lactis UABla-12 improved abdominal pain and symptom severity scores with a corresponding normalization of bowel habits in adults with IBS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martoni</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>UAS Laboratories LLC, 4375 Duraform Lane, Windsor, WI 53598, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srivastava</LastName><ForeName>Shalini</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Vedic Lifesciences, 203 Morya Landmark1, New Link Road, Andheri W, Mumbai 400053, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leyer</LastName><ForeName>Gregory J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>UAS Laboratories LLC, 4375 Duraform Lane, Windsor, WI 53598, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nutrients</MedlineTA><NlmUniqueID>101521595</NlmUniqueID><ISSNLinking>2072-6643</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015746" MajorTopicYN="N">Abdominal Pain</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069982" MajorTopicYN="Y">Bifidobacterium animalis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007779" MajorTopicYN="Y">Lactobacillus acidophilus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Randomized controlled trial</Keyword><Keyword MajorTopicYN="N">abdominal pain</Keyword><Keyword MajorTopicYN="N">bowel habits</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">microbiome</Keyword><Keyword MajorTopicYN="N">probiotic</Keyword></KeywordList><CoiStatement>Christopher J. Martoni and Gregory Leyer are employees of UAS Laboratories but were not involved in the study conduct, data management or statistical analysis.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32019158</ArticleId><ArticleId IdType="pmc">PMC7071206</ArticleId><ArticleId IdType="doi">10.3390/nu12020363</ArticleId><ArticleId IdType="pii">nu12020363</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Holtmann G.J., Ford A.C., Talley N.J. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol. Hepatol. 2016;1:133&#x2013;146. doi: 10.1016/S2468-1253(16)30023-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(16)30023-1</ArticleId><ArticleId IdType="pubmed">28404070</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbara G., Feinle-Bisset C., Ghoshal U.C., Santos J., Vanner S.J., Vergnolle N., Zoetendal E.G., Quigley E.M. The intestinal microenvironment and functional gastrointestinal disorders. Gastroenterology. 2016;150:1305&#x2013;1318. doi: 10.1053/j.gastro.2016.02.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.028</ArticleId><ArticleId IdType="pubmed">27144620</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale H.F., Rasmussen S.H., Asiller &#xd6;.&#xd6;., Lied G.A. Probiotics in Irritable Bowel Syndrome: An Up-to-Date Systematic Review. Nutrients. 2019;11:2048. doi: 10.3390/nu11092048.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11092048</ArticleId><ArticleId IdType="pmc">PMC6769995</ArticleId><ArticleId IdType="pubmed">31480656</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy B., Patel N. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J. Clin. Med. 2017;6:99. doi: 10.3390/jcm6110099.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm6110099</ArticleId><ArticleId IdType="pmc">PMC5704116</ArticleId><ArticleId IdType="pubmed">29072609</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Moayyedi P., Chey W.D., Harris L.A., Lacy B.E., Saito Y.A., Quigley E.M.M. ACG Task Force on Management of Irritable Bowel Syndrome American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. Am. J. Gastroenterol. 2018;113:1&#x2013;18. doi: 10.1038/s41395-018-0084-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41395-018-0084-x</ArticleId><ArticleId IdType="pubmed">29950604</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbara G., Cremon C., Azpiroz F. Probiotics in irritable bowel syndrome: Where are we? Neurogastroenterol. Motil. 2018;30:1&#x2013;6. doi: 10.1111/nmo.13513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13513</ArticleId><ArticleId IdType="pubmed">30460770</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Harris L.A., Lacy B.E., Quigley E.M.M., Moayyedi P. Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2018;48:1044&#x2013;1060. doi: 10.1111/apt.15001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15001</ArticleId><ArticleId IdType="pubmed">30294792</ArticleId></ArticleIdList></Reference><Reference><Citation>Didari T., Mozaffari S., Nikfar S., Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World J. Gastroenterol. 2015;21:3072&#x2013;3084. doi: 10.3748/wjg.v21.i10.3072.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v21.i10.3072</ArticleId><ArticleId IdType="pmc">PMC4356930</ArticleId><ArticleId IdType="pubmed">25780308</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Li L., Guo C., Mu D., Feng B., Zuo X., Li Y. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: A meta-analysis. BMC Gastroenterol. 2016;16:1&#x2013;11. doi: 10.1186/s12876-016-0470-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-016-0470-z</ArticleId><ArticleId IdType="pmc">PMC4907258</ArticleId><ArticleId IdType="pubmed">27296254</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill C., Guarner F., Reid G., Gibson G.R., Merenstein D.J., Pot B., Morelli L., Canani R.B., Flint H.J., Salminen S., et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014;11:506&#x2013;514. doi: 10.1038/nrgastro.2014.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2014.66</ArticleId><ArticleId IdType="pubmed">24912386</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Moayyedi P., Lacy B.E., Lembo A.J., Saito Y.A., Schiller L.R., Soffer E.E., Spiegel B.M.R., Quigley E.M.M. American college of gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am. J. Gastroenterol. 2014;109:S2&#x2013;S26. doi: 10.1038/ajg.2014.187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2014.187</ArticleId><ArticleId IdType="pubmed">25091148</ArticleId></ArticleIdList></Reference><Reference><Citation>Martoni C.J., Evans M., Chow C.T., Chan L.S., Leyer G. Impact of a probiotic product on bowel habits and microbial profile in participants with functional constipation: A randomized controlled trial. J. Dig. Dis. 2019;20:435&#x2013;446. doi: 10.1111/1751-2980.12797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1751-2980.12797</ArticleId><ArticleId IdType="pmc">PMC6851827</ArticleId><ArticleId IdType="pubmed">31271261</ArticleId></ArticleIdList></Reference><Reference><Citation>Pakdaman M.N., Udani J.K., Molina J.P., Shahani M. The effects of the DDS-1 strain of lactobacillus on symptomatic relief for lactose intolerance - A randomized, double-blind, placebo-controlled, crossover clinical trial. Nutr. J. 2016;15 doi: 10.1186/s12937-016-0172-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12937-016-0172-y</ArticleId><ArticleId IdType="pmc">PMC4875742</ArticleId><ArticleId IdType="pubmed">27207411</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerasimov S.V., Ivantsiv V.A., Bobryk L.M., Tsitsura O.O., Dedyshin L.P., Guta N.V., Yandyo B.V. Role of short-term use of L. acidophilus DDS-1 and B. lactis UABLA-12 in acute respiratory infections in children: A randomized controlled trial. Eur. J. Clin. Nutr. 2016;70:463&#x2013;469. doi: 10.1038/ejcn.2015.171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejcn.2015.171</ArticleId><ArticleId IdType="pubmed">26463725</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerasimov S.V., Vasjuta V.V., Myhovych O.O., Bondarchuk L.I. Probiotic supplement reduces Atopic Dermatitis in preschool children: A randomized, double-blind, placebo-controlled, clinical trial. Am. J. Clin. Dermatol. 2010;11:351&#x2013;361. doi: 10.2165/11531420-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11531420-000000000-00000</ArticleId><ArticleId IdType="pubmed">20642296</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri R., Shinde T., Shastri M.D., Perera A.P., Tristram S., Martoni C.J., Gundamaraju R., Ahuja K.D.K., Ball M., Eri R. A human origin strain Lactobacillus acidophilus DDS-1 exhibits superior in vitro probiotic efficacy in comparison to plant or dairy origin probiotics. Int. J. Med. Sci. 2018;15:840&#x2013;848. doi: 10.7150/ijms.25004.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.25004</ArticleId><ArticleId IdType="pmc">PMC6036100</ArticleId><ArticleId IdType="pubmed">30008595</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri R., Shinde T., Gundamaraju R., Gondalia S.V., Karpe A.V., Beale D.J., Martoni C.J., Eri R. Lactobacillus acidophilus DDS-1 modulates the gut microbiota and improves metabolic profiles in aging mice. Nutrients. 2018;10:1255. doi: 10.3390/nu10091255.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu10091255</ArticleId><ArticleId IdType="pmc">PMC6165029</ArticleId><ArticleId IdType="pubmed">30200669</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri R., Gundamaraju R., Shinde T., Perera A.P., Basheer W., Southam B., Gondalia S.V., Karpe A.V., Beale D.J., Tristram S., et al. Lactobacillus acidophilus DDS-1 modulates intestinal-specific microbiota, short-chain fatty acid and immunological profiles in aging mice. Nutrients. 2019;11:1297. doi: 10.3390/nu11061297.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11061297</ArticleId><ArticleId IdType="pmc">PMC6627711</ArticleId><ArticleId IdType="pubmed">31181695</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagala R., Routray C. Clinical Case Study&#x2014;Multispecies probiotic supplement minimizes symptoms of irritable bowel syndrome. US Gastroenterol. Hepatol. Rev. 2011;7:1&#x2013;2.</Citation></Reference><Reference><Citation>Spiegel B.M.R., Bolus R., Harris L.A., Lucak S., Chey W.D., Sayuk G., Esrailian E., Lembo A., Karsan H., Tillisch K., et al. Characterizing abdominal pain in IBS: Guidance for study inclusion criteria, outcome measurement and clinical practice. Aliment. Pharmacol. Ther. 2010;32:1192&#x2013;1202. doi: 10.1111/j.1365-2036.2010.04443.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2010.04443.x</ArticleId><ArticleId IdType="pmc">PMC4118306</ArticleId><ArticleId IdType="pubmed">20807217</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel B., Bolus R., Harris L.A., Lucak S., Naliboff B., Esrailian E., Chey W.D., Lembo A., Karsan H., Tillisch K., et al. Measuring IBS patient reported outcomes with an abdominal pain numeric rating scale: Results from the proof cohort. Aliment. Pharmacol. Ther. 2009;30:1159&#x2013;1170. doi: 10.1111/j.1365-2036.2009.04144.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2009.04144.x</ArticleId><ArticleId IdType="pmc">PMC2793273</ArticleId><ArticleId IdType="pubmed">19751360</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel B.M.R., Bolus R., Agarwal N., Sayuk G., Harris L.A., Lucak S., Esrailian E., Chey W.D., Lembo A., Karsan H., et al. Measuring symptoms in the irritable bowel syndrome: Development of a framework for clinical trials. Aliment. Pharmacol. Ther. 2010;32:1275&#x2013;1291. doi: 10.1111/j.1365-2036.2010.04464.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2010.04464.x</ArticleId><ArticleId IdType="pubmed">20955447</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis C.Y., Morris J., Whorwell P.J. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment. Pharmacol. Ther. 1997;11:395&#x2013;402. doi: 10.1046/j.1365-2036.1997.142318000.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.1997.142318000.x</ArticleId><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>Blake M.R., Raker J.M., Whelan K. Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 2016;44:693&#x2013;703. doi: 10.1111/apt.13746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.13746</ArticleId><ArticleId IdType="pubmed">27492648</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick D.L., Drossman D.A., Frederick I.O., Dicesare J., Puder K.L. Quality of life in persons with irritable bowel syndrome: Development and validation of a new measure. Dig. Dis. Sci. 1998;43:400&#x2013;411. doi: 10.1023/A:1018831127942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1018831127942</ArticleId><ArticleId IdType="pubmed">9512138</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen S., Williamson G. Perceived stress in a probability sample of the United States. Soc. Psychol. Heal. 1988:31&#x2013;67.</Citation></Reference><Reference><Citation>Ghoshal U.C., Abraham P., Bhatt C., Choudhuri G., Bhatia S.J., Shenoy K.T., Banka N.H., Bose K., Bohidar N.P., Chakravartty K., et al. Epidemiological and clinical profile of irritable bowel syndrome in India: Report of the Indian Society of Gastroenterology Task Force. Indian J. Gastroenterol. 2008;27:22&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">18541934</ArticleId></ArticleIdList></Reference><Reference><Citation>Masudur Rahman M., Mahadeva S., Ghoshal U.C. Epidemiological and clinical perspectives on irritable bowel syndrome in India, Bangladesh and Malaysia: A review. World J. Gastroenterol. 2017;23:6788&#x2013;6801. doi: 10.3748/wjg.v23.i37.6788.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v23.i37.6788</ArticleId><ArticleId IdType="pmc">PMC5645613</ArticleId><ArticleId IdType="pubmed">29085223</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration . Guidance for Industry: Irritable Bowel Syndrome-Clinical Evaluation of Drugs for Treatment. Food and Drug Administration; Silver Spring, MD, USA: 2012. pp. 32124&#x2013;32125.</Citation></Reference><Reference><Citation>Ford A.C., Moayyedi P. Meta-analysis: Factors affecting placebo response rate in the irritable bowel syndrome. Aliment. Pharmacol. Ther. 2010;32:144&#x2013;158. doi: 10.1111/j.1365-2036.2010.04328.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2010.04328.x</ArticleId><ArticleId IdType="pubmed">20412064</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller R.C. Problems and challenges in the design of irritable bowel syndrome clinical trials: Experience from published trials. Am. J. Med. 1999;107:91S&#x2013;97S. doi: 10.1016/S0002-9343(99)00086-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9343(99)00086-8</ArticleId><ArticleId IdType="pubmed">10588179</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangel A.W. Study design issues in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2004;19:141&#x2013;142. doi: 10.1046/j.1365-2036.2003.01816.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.2003.01816.x</ArticleId><ArticleId IdType="pubmed">14687176</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller L.E. Study design considerations for irritable bowel syndrome clinical trials. Ann. Gastroenterol. Q. Publ. Hell. Soc. Gastroenterol. 2014;27:338&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4188930</ArticleId><ArticleId IdType="pubmed">25330749</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorn S.D., Kaptchuk T.J., Park J.B., Nguyen L.T., Canenguez K., Nam B.H., Woods K.B., Conboy L.A., Stason W.B., Lembo A.J. A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome. Neurogastroenterol. Motil. 2007;19:630&#x2013;637. doi: 10.1111/j.1365-2982.2007.00937.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2007.00937.x</ArticleId><ArticleId IdType="pubmed">17640177</ArticleId></ArticleIdList></Reference><Reference><Citation>Snapinn S.M., Jiang Q. Responder analyses and the assessment of a clinically relevant treatment effect. Trials. 2007;8:31. doi: 10.1186/1745-6215-8-31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1745-6215-8-31</ArticleId><ArticleId IdType="pmc">PMC2164942</ArticleId><ArticleId IdType="pubmed">17961249</ArticleId></ArticleIdList></Reference><Reference><Citation>European Food Safety Authority (EFSA) Guidance on the scientific requirements for health claims related to gut and immune function. EFSA J. 2011;9:1984. doi: 10.2903/j.efsa.2011.1984.</Citation><ArticleIdList><ArticleId IdType="doi">10.2903/j.efsa.2011.1984</ArticleId><ArticleId IdType="pmc">PMC7009729</ArticleId><ArticleId IdType="pubmed">32625715</ArticleId></ArticleIdList></Reference><Reference><Citation>Upadhyay R., Singh A. Irritable Bowel Syndrome: The Indian Scenario. Med. Updat. 2013:255&#x2013;258.</Citation></Reference><Reference><Citation>Chong P.P., Chin V.K., Looi C.Y., Wong W.F., Madhavan P., Yong V.C. The microbiome and irritable bowel syndrome - A review on the pathophysiology, current research and future therapy. Front. Microbiol. 2019;10:1&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579922</ArticleId><ArticleId IdType="pubmed">31244784</ArticleId></ArticleIdList></Reference><Reference><Citation>Distrutti E., Monaldi L., Ricci P., Fiorucci S. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World J. Gastroenterol. 2016;22:2219&#x2013;2241. doi: 10.3748/wjg.v22.i7.2219.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i7.2219</ArticleId><ArticleId IdType="pmc">PMC4734998</ArticleId><ArticleId IdType="pubmed">26900286</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellini M., Gambaccini D., Stasi C., Urbano M.T., Marchi S., Usai-Satta P. Irritable bowel syndrome: A disease still searching for pathogenesis, diagnosis and therapy. World J. Gastroenterol. 2014;20:8807&#x2013;8820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4112881</ArticleId><ArticleId IdType="pubmed">25083055</ArticleId></ArticleIdList></Reference><Reference><Citation>Simren M., Palsson O.S., Whitehead W.E. Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice. Curr. Gastroenterol. Rep. 2017;19 doi: 10.1007/s11894-017-0554-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11894-017-0554-0</ArticleId><ArticleId IdType="pmc">PMC5378729</ArticleId><ArticleId IdType="pubmed">28374308</ArticleId></ArticleIdList></Reference><Reference><Citation>Chadwick V.S., Chen W., Shu D., Paulus B., Bethwaite P., Tie A., Wilson I. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology. 2002;122:1778&#x2013;1783. doi: 10.1053/gast.2002.33579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/gast.2002.33579</ArticleId><ArticleId IdType="pubmed">12055584</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilarte M., Santos J., De Torres I., Alonso C., Vicario M., Ramos L., Martinez C., Casellas F., Saperas E., Malagelada J.R. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut. 2007;56:203&#x2013;209. doi: 10.1136/gut.2006.100594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2006.100594</ArticleId><ArticleId IdType="pmc">PMC1856785</ArticleId><ArticleId IdType="pubmed">17005763</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomax A.E., Pradhananga S., Sessenwein J.L., O&#x2019;Malley D. Bacterial modulation of visceral sensation: Mediators and mechanisms. Am. J. Physiol. Liver Physiol. 2019;317:G363&#x2013;G372. doi: 10.1152/ajpgi.00052.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00052.2019</ArticleId><ArticleId IdType="pubmed">31290688</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseaux C., Thuru X., Gelot A., Barnich N., Neut C., Dubuquoy L., Dubuquoy C., Merour E., Geboes K., Chamaillard M., et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat. Med. 2007;13:35&#x2013;37. doi: 10.1038/nm1521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1521</ArticleId><ArticleId IdType="pubmed">17159985</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringel-Kulka T., Palsson O.S., Maier D., Carroll I., Galanko J.A., Leyer G., Ringel Y. Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: A double-blind study. J. Clin. Gastroenterol. 2011;45:518&#x2013;525. doi: 10.1097/MCG.0b013e31820ca4d6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0b013e31820ca4d6</ArticleId><ArticleId IdType="pmc">PMC4372813</ArticleId><ArticleId IdType="pubmed">21436726</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringel-Kulka T., Goldsmith J.R., Carroll I.M., Barros S.P., Palsson O., Jobin C., Ringel Y. Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain - A randomised clinical study. Aliment. Pharmacol. Ther. 2014;40:200&#x2013;207. doi: 10.1111/apt.12800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.12800</ArticleId><ArticleId IdType="pmc">PMC4613798</ArticleId><ArticleId IdType="pubmed">24853043</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranuh R., Athiyyah A.F., Darma A., Risky V.P., Riawan W., Surono I.S., Sudarmo S.M. Effect of the probiotic lactobacillus plantarum is-10506 on bdnf and 5ht stimulation: Role of intestinal microbiota on the gut-brain axis. Iran. J. Microbiol. 2019;11:145&#x2013;150. doi: 10.18502/ijm.v11i2.1077.</Citation><ArticleIdList><ArticleId IdType="doi">10.18502/ijm.v11i2.1077</ArticleId><ArticleId IdType="pmc">PMC6635314</ArticleId><ArticleId IdType="pubmed">31341569</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin H.Y., Cheng C.W., Tang X.D., Bian Z.X. Impact of psychological stress on irritable bowel syndrome. World J. Gastroenterol. 2014;20:14126&#x2013;14131. doi: 10.3748/wjg.v20.i39.14126.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i39.14126</ArticleId><ArticleId IdType="pmc">PMC4202343</ArticleId><ArticleId IdType="pubmed">25339801</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhakan D.B., Maji A., Sharma A.K., Saxena R., Pulikkan J., Grace T., Gomez A., Scaria J., Amato K.R., Sharma V.K. The unique composition of Indian gut microbiome, gene catalogue, and associated fecal metabolome deciphered using multi-omics approaches. Gigascience. 2019;8:1&#x2013;20. doi: 10.1093/gigascience/giz004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gigascience/giz004</ArticleId><ArticleId IdType="pmc">PMC6394208</ArticleId><ArticleId IdType="pubmed">30698687</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29688915</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1539-2031</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of clinical gastroenterology</Title><ISOAbbreviation>J Clin Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Clinical and Microbiological Effect of a Multispecies Probiotic Supplementation in Celiac Patients With Persistent IBS-type Symptoms: A Randomized, Double-Blind, Placebo-controlled, Multicenter Trial.</ArticleTitle><Pagination><StartPage>e117</StartPage><EndPage>e125</EndPage><MedlinePgn>e117-e125</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MCG.0000000000001023</ELocationID><Abstract><AbstractText Label="GOALS">The goals of this study were to evaluate the efficacy and safety of a probiotic mixture in patients with celiac disease (CD) with irritable bowel syndrome (IBS)-type symptoms despite a strict gluten-free diet (GFD).</AbstractText><AbstractText Label="BACKGROUND">About 30% of patients with CD adherent to a GFD suffer from IBS-type symptoms; a possible cause resides in the imbalances of the intestinal microbiota in CD. Probiotics may represent a potential treatment.</AbstractText><AbstractText Label="STUDY">CD patients with IBS-type symptoms entered a prospective, double-blind, randomized placebo-controlled study. A 6-week treatment period was preceded by a 2-week run-in and followed by a 6-week follow-up phase. Clinical data were monitored throughout the study by validated questionnaires: IBS Severity Scoring System (IBS-SSS); Gastrointestinal Symptom Rating Scale (GSRS); Bristol Stool Form Scale (BSFS); and IBS Quality of Life Questionnaire (IBS-QOL). The fecal microbiota were assayed using plate counts and 16S rRNA gene-based analysis.</AbstractText><AbstractText Label="RESULTS">In total, 109 patients were randomized to probiotics (n=54) or placebo (n=55). IBS-SSS and GSRS decreased significantly in probiotics, as compared with placebo [(-15.9%&#xb1;14.8% vs. 8.2%&#xb1;25.9%; P&lt;0.001) and (-19.8%&#xb1;16.6% vs. 12.9%&#xb1;31.6%; P&lt;0.001)], respectively. Treatment success was significantly higher in patients receiving probiotics, as compared with placebo (15.3% vs. 3.8%; P&lt;0.04). Presumptive lactic acid bacteria, Staphylococcus and Bifidobacterium, increased in patients receiving probiotic treatment. No adverse events were reported.</AbstractText><AbstractText Label="CONCLUSIONS">A 6-week probiotic treatment is effective in improving the severity of IBS-type symptoms, in CD patients on strict GFD, and is associated with a modification of gut microbiota, characterized by an increase of bifidobacteria.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Francavilla</LastName><ForeName>Ruggiero</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Interdisciplinary Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piccolo</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Soil, Plant and Food Science.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Francavilla</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>IRCCS "Saverio De Bellis," Castellana Grotte.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polimeno</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Interdisciplinary Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Semeraro</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Gastroenterology Unit, PO Centrale Taranto, Taranto.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cristofori</LastName><ForeName>Fernanda</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Interdisciplinary Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castellaneta</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, PO San Paolo, Bari.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barone</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Emergency and Organ Transplantation, University of Bari Aldo Moro.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Indrio</LastName><ForeName>Flavia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Interdisciplinary Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gobbetti</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Science and Technology, Piazza Universit&#xe0;, Free University of Bozen, Bolzano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Angelis</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Soil, Plant and Food Science.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Gastroenterol</MedlineTA><NlmUniqueID>7910017</NlmUniqueID><ISSNLinking>0192-0790</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002446" MajorTopicYN="N">Celiac Disease</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="Y">diet therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055050" MajorTopicYN="Y">Diet, Gluten-Free</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="Y">diet therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>2</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29688915</ArticleId><ArticleId IdType="pmc">PMC6382041</ArticleId><ArticleId IdType="doi">10.1097/MCG.0000000000001023</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lebwohl B, Sanders DS, Green PHR. Lancet. Coeliac disease. 2017;S0140-6736:31796&#x2013;31798.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Sainsbury A, Sanders DS, Ford AC. Prevalence of irritable bowel syndrome-type symptoms in patients with celiac disease: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11:359&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">23246645</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz I, Sanders DS. The irritable bowel syndrome-celiac disease connection. Gastrointest Endosc Clin N Am. 2012;22:623&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pubmed">23083983</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagliari D, Urgesi R, Frosali S, et al. The interaction among microbiota, immunity, and genetic and dietary factors is the condicio sine qua non celiac disease can develop. J Immunol Res. 2015;2015:123653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4451297</ArticleId><ArticleId IdType="pubmed">26090475</ArticleId></ArticleIdList></Reference><Reference><Citation>Collado MC, Donat E, Ribes-Koninckx C, et al. Specific duodenal and faecal bacterial groups associated with paediatric coeliac disease. Austin J Clin Pathol. 2009;62:264&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">18996905</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadal I, Donat E, Ribes-Koninckx C, et al. Imbalance in the composition of the duodenal microbiota of children with coeliac disease. J Med Microbiol. 2007;56:1669&#x2013;1674.</Citation><ArticleIdList><ArticleId IdType="pubmed">18033837</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma G, Nadal I, Collado MC, et al. Effects of a gluten-free diet on gut microbiota and immune function in healthy adult human subjects. Br J Nutr. 2009;102:1154&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pubmed">19445821</ArticleId></ArticleIdList></Reference><Reference><Citation>De Graaf AA, Venema K. Gaining insight into microbial physiology in the large intestine: a special role for stable isotopes. Adv Microb Physiol. 2008;53:73&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">17707144</ArticleId></ArticleIdList></Reference><Reference><Citation>Wacklin P, Laurikka P, Lindfors K, et al. Altered duodenal microbiota composition in celiac disease patients suffering from persistent symptoms on a long-term gluten-free diet. Am J Gastroenterol. 2014;109:1933&#x2013;1941.</Citation><ArticleIdList><ArticleId IdType="pubmed">25403367</ArticleId></ArticleIdList></Reference><Reference><Citation>Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480&#x2013;1491.</Citation><ArticleIdList><ArticleId IdType="pubmed">16678561</ArticleId></ArticleIdList></Reference><Reference><Citation>Husby S, Koletzko S, Korponay-Szab&#xf3; IR, et al. ESPGHAN Working Group on Coeliac Disease Diagnosis; ESPGHAN Gastroenterology Committee; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr. 2012;54:136&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">22197856</ArticleId></ArticleIdList></Reference><Reference><Citation>Irvine EJ, Whitehead WE, Chey WD, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology. 2006;130:1538&#x2013;1551.</Citation><ArticleIdList><ArticleId IdType="pubmed">16678567</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11:395&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>Svedlund J, Sj&#xf6;din I, Dotevall G. GSRS&#x2014;a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988;33:129&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">3123181</ArticleId></ArticleIdList></Reference><Reference><Citation>Heaton KW, Lewis SJ. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32:920&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">9299672</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman DA, Patrick DL, Whitehead WE, et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol. 2000;95:999&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pubmed">10763950</ArticleId></ArticleIdList></Reference><Reference><Citation>De Angelis M, Piccolo M, Vannini L, et al. Faecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. PLoS One. 2013;8:e76993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3793965</ArticleId><ArticleId IdType="pubmed">24130822</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowen CM, Fong SS. Genome-scale metabolic model integrated with RNAseq data to identify metabolic states of Clostridium thermocellum. Biotechnol J. 2010;7:759&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pubmed">20665646</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchodolski JS, Markel ME, Garcia-Mazcorro JF, et al. The faecal microbiome in dogs with acute diarrhea and idiopathic inflammatory bowel disease. PLoS One. 2012;7:e51907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530590</ArticleId><ArticleId IdType="pubmed">23300577</ArticleId></ArticleIdList></Reference><Reference><Citation>Gontcharova V, Youn E, Wolcott RD, et al. Black box chimera check (B2C2): a windows-based software for batch depletion of chimeras from bacterial 16S rRNA gene datasets. Open Microbiol J. 2010;4:47&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3040993</ArticleId><ArticleId IdType="pubmed">21339894</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowd SE, Zaragoza J, Rodriguez JR, et al. Windows.NET network distributed basic local alignment search toolkit (W.ND-BLAST). BMC Bioinformatics. 2005;6:93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1087835</ArticleId><ArticleId IdType="pubmed">15819992</ArticleId></ArticleIdList></Reference><Reference><Citation>Milani C, Hevia A, Foroni E, et al. Assessing the faecal microbiota: an optimized ion torrent 16S rRNA gene-based analysis protocol. PLoS One. 2013;8:68739&#x2013;68739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3711900</ArticleId><ArticleId IdType="pubmed">23869230</ArticleId></ArticleIdList></Reference><Reference><Citation>Scannapieco FA. The oral microbiome: its role in health and in oral and systemic infections. Clin Microbiol Newsl. 2013;35:163&#x2013;169.</Citation></Reference><Reference><Citation>Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 2010;26:2460&#x2013;2461.</Citation><ArticleIdList><ArticleId IdType="pubmed">20709691</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole JR, Wang Q, Cardenas E, et al. The ribosomal database project: improved alignments and new tools for rRNA analysis. Nucleic Acids Res. 2009;37:D141&#x2013;D145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2686447</ArticleId><ArticleId IdType="pubmed">19004872</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewar DH, Donnelly SC, McLaughlin SD, et al. Celiac disease: management of persistent symptoms in patients on a gluten-free diet. World J Gastroenterol. 2012;18:1348&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319961</ArticleId><ArticleId IdType="pubmed">22493548</ArticleId></ArticleIdList></Reference><Reference><Citation>Midhagen G, Hallert C. High rate of gastrointestinal symptoms in celiac patients living on a gluten-free diet: controlled study. Am J Gastroenterol. 2003;98:2023&#x2013;2026.</Citation><ArticleIdList><ArticleId IdType="pubmed">14499782</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Leary C, Wieneke P, Buckley S, et al. Celiac disease and irritable bowel-type symptoms. Am J Gastroenterol. 2002;97:1463&#x2013;1467.</Citation><ArticleIdList><ArticleId IdType="pubmed">12094866</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M. Irritable bowel syndrome: diagnosis and pathogenesis. World J Gastroenterol. 2012;18:5151&#x2013;5163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3468846</ArticleId><ArticleId IdType="pubmed">23066308</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Cagno R, Rizello CG, Gagliardi F, et al. Different faecal microbiotas and volatile organic compounds in treated and untreated children with celiac disease. Appl Environ Microbiol. 2009;75:3963&#x2013;3971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2698361</ArticleId><ArticleId IdType="pubmed">19376912</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Cagno R, De Angelis M, De Pasquale I, et al. Duodenal and faecal microbiota of celiac children: molecular, phenotype and metabolome characterization. BMC Microbiol. 2011;11:219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3206437</ArticleId><ArticleId IdType="pubmed">21970810</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanz Y. Microbiome and gluten. Ann Nutr Metab. 2015;2:28&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">26605783</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson FW. Effects of a gluten-free diet on gut microbiota and immune function in healthy adult human subjects-comment by Jackson. Br J Nutr. 2010;104:773.</Citation><ArticleIdList><ArticleId IdType="pubmed">20465858</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajili&#x107;-Stojanovi&#x107; M, Biagi E, Heilig HG, et al. Global and deep molecular analysis of microbiota signatures in faecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011;141:1792&#x2013;1801.</Citation><ArticleIdList><ArticleId IdType="pubmed">21820992</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdu EF, Armstrong D, Murray JA. Between celiac disease and irritable bowel syndrome: the &#x201c;no man&#x2019;s land&#x201d; of gluten sensitivity. Am J Gastroenterol. 2009;104:1587&#x2013;1594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3480312</ArticleId><ArticleId IdType="pubmed">19455131</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattarai Y, Muniz Pedrogo DA, Kashyap PC. Irritable bowel syndrome: a gut microbiota-related disorder? Am J Physiol Gastrointest Liver Physiol. 2017;312:G52&#x2013;G62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5283907</ArticleId><ArticleId IdType="pubmed">27881403</ArticleId></ArticleIdList></Reference><Reference><Citation>Francavilla R, Ercolini D, Piccolo M, et al. Salivary microbiota and metabolome associated with celiac disease. Appl Environ Microbiol. 2014;80:3416&#x2013;3425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4018861</ArticleId><ArticleId IdType="pubmed">24657864</ArticleId></ArticleIdList></Reference><Reference><Citation>Toscano M, De Grandi R, Pastorelli L, et al. A consumer&#x2019;s guide for probiotics: 10 golden rules for a correct use. Dig Liver Dis. 2017;49:1177&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">28830747</ArticleId></ArticleIdList></Reference><Reference><Citation>Smecuol E, Hwang HJ, Sugai E, et al. Exploratory, randomized, double-blind, placebo-controlled study on the effects of Bifidobacterium infantis natren life start strain super strain in active celiac disease. J Clin Gastroenterol. 2013;47:139&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">23314670</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivares M, Castillejo G, Varea V, et al. Double-blind, randomised, placebo-controlled intervention trial to evaluate the effects of Bifidobacterium longum cect 7347 in children with newly diagnosed coeliac disease. Br J Nutr. 2014;112:30&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">24774670</ArticleId></ArticleIdList></Reference><Reference><Citation>Klemenak M, Dolin&#x161;ek J, Langerholc T, et al. Administration of Bifidobacterium breve decreases the production of TNF-&#x3b1; in children with celiac disease. Dig Dis Sci. 2015;60:3386&#x2013;3392.</Citation><ArticleIdList><ArticleId IdType="pubmed">26134988</ArticleId></ArticleIdList></Reference><Reference><Citation>Harnett J, Myers SP, Rolfe M. Probiotics and the microbiome in celiac disease: a randomised controlled trial. Evid Based Complement Alternat Med. 2016;2016:9048574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4972910</ArticleId><ArticleId IdType="pubmed">27525027</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurppa K, Collin P, M&#xe4;ki M, et al. Celiac disease and health-related quality of life. Expert Rev Gastroenterol Hepatol. 2011;5:83&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">21309674</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33183883</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-1983</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Clinical nutrition (Edinburgh, Scotland)</Title><ISOAbbreviation>Clin Nutr</ISOAbbreviation></Journal><ArticleTitle>Gut microbiota associations with diet in irritable bowel syndrome and the effect of low FODMAP diet and probiotics.</ArticleTitle><Pagination><StartPage>1861</StartPage><EndPage>1870</EndPage><MedlinePgn>1861-1870</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clnu.2020.10.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0261-5614(20)30541-0</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIMS">Diet is both a modulator of the gastrointestinal microbiota and an important therapy in irritable bowel syndrome (IBS). We aimed to comprehensively (i) identify diet-microbiota associations in adults with IBS consuming habitual diet; (ii) assess the impact of two nutritional interventions on the microbiota; and (iii) determine whether baseline microbiota can predict clinical response to diet or probiotic intervention.</AbstractText><AbstractText Label="METHODS">Data were analyzed from 95 individuals with IBS participating in a previously published 4-week 2x2 factorial design randomized controlled trial investigating the impact of the low FODMAP diet (LFD) and co-administration of a probiotic. Diet was assessed at four hierarchical levels and partial 16S rRNA gene sequencing was used to profile the microbiota.</AbstractText><AbstractText Label="RESULTS">There were numerous diet-microbiota associations especially at the nutrient level, including a negative association between protein and Bifidobacterium abundance (r<sub>s</sub>&#xa0;=&#xa0;-0.358, p&#xa0;&lt;&#xa0;0.001). After correction for multiple testing, the significance for this association (q&#xa0;=&#xa0;0.237) and all others was lost. Low FODMAP diet led to changes in abundance of major saccharolytic genera compared with sham diet, including higher Bacteroides (LFD 34.1% (15.7%) vs sham 23.3% (15.2%), q&#xa0;=&#xa0;0.01) and lower Bifidobacterium (0.9% (1.0%) vs 2.1%, (2.5%) q&#xa0;=&#xa0;0.029). Compared with placebo, probiotic supplementation led to higher Lactobacillus (probiotic 0.08% (0.1%) vs placebo 0.03% (0.2%), q&#xa0;&lt;&#xa0;0.001), and Streptococcus abundance (2.0% (2.2%) vs 0.6% (1.2%), q&#xa0;=&#xa0;0.001). The probiotic treatment buffered the impact of the low FODMAP diet on Bifidobacterium. Baseline microbiota did not predict clinical response to either intervention.</AbstractText><AbstractText Label="CONCLUSIONS">Although diet modifies the gut microbiota, bivariate correlation analysis may only provide a limited explanation of the complex diet interactions with individual gut bacteria in IBS. Some diet interventions modify the microbiota in IBS.</AbstractText><AbstractText Label="TRIAL REGISTRY">ISRCTN (http://www.isrctn.com) Registered under ISRCTN registry identifier no.ISRCTN02275221.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Staudacher</LastName><ForeName>Heidi M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>King's College London, Department of Nutritional Sciences, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scholz</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research and Innovation Centre, Department of Food Quality and Nutrition, Nutrition and Nutrigenomics Group, Fondazione Edmund Mach, Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lomer</LastName><ForeName>Miranda Ce</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>King's College London, Department of Nutritional Sciences, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, Department of Gastroenterology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ralph</LastName><ForeName>Frances S</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>King's College London, Department of Nutritional Sciences, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irving</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>King's College London, Department of Nutritional Sciences, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, Department of Gastroenterology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindsay</LastName><ForeName>James O</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>Barts Health NHS Trust, Department of Gastroenterology, Royal London Hospital, London, UK; Queen Mary University of London, Centre for Immunobiology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fava</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Research and Innovation Centre, Department of Food Quality and Nutrition, Nutrition and Nutrigenomics Group, Fondazione Edmund Mach, Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuohy</LastName><ForeName>Kieran</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Research and Innovation Centre, Department of Food Quality and Nutrition, Nutrition and Nutrigenomics Group, Fondazione Edmund Mach, Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whelan</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>King's College London, Department of Nutritional Sciences, London, United Kingdom. Electronic address: kevin.whelan@kcl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ISRCTN</DataBankName><AccessionNumberList><AccessionNumber>ISRCTN02275221</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>CDRF-2012-03-060</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Nutr</MedlineTA><NlmUniqueID>8309603</NlmUniqueID><ISSNLinking>0261-5614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004032" MajorTopicYN="N">Diet</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="Y">diet therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diet</Keyword><Keyword MajorTopicYN="N">Dietary pattern</Keyword><Keyword MajorTopicYN="N">Irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">Microbiota</Keyword><Keyword MajorTopicYN="N">Probiotic</Keyword></KeywordList><CoiStatement>Conflict of Interest ML and KW are co-inventors of a mobile application relating to the low FODMAP diet. KW has acted as a consultant for Danone, and received research funding from Danone. FR receives consultation fees from Lavida Food Co. that distributes low FODMAP food products in the UK. All other authors have no other relevant conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>13</Day><Hour>5</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33183883</ArticleId><ArticleId IdType="doi">10.1016/j.clnu.2020.10.013</ArticleId><ArticleId IdType="pii">S0261-5614(20)30541-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32326347</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6643</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Apr</Month><Day>21</Day></PubDate></JournalIssue><Title>Nutrients</Title><ISOAbbreviation>Nutrients</ISOAbbreviation></Journal><ArticleTitle>Efficacy of <i>Lactobacillus paracasei</i> HA-196 and <i>Bifidobacterium longum</i> R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1159</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nu12041159</ELocationID><Abstract><AbstractText>Specific probiotic strains can alleviate the gastrointestinal (GI) symptoms and psychiatric comorbidities of irritable bowel syndrome (IBS). In this randomized, double-blind, placebo-controlled study, the efficacy of <i>Lactobacillus paracasei</i> HA-196 (<i>L. paracasei</i>) and <i>Bifidobacterium longum</i> R0175 (<i>B. longum</i>) in reducing the GI and psychological symptoms of IBS was evaluated in 251 adults with either constipation (IBS-C), diarrhea (IBS-D), or mixed-pattern (IBS-M). Following a 2-week run-in period, participants were randomized to one of three interventions: <i>L. paracasei</i> (<i>n</i> = 84), <i>B. longum</i> (<i>n</i> = 83) or placebo (<i>n</i> = 81). IBS symptoms, stool frequency and consistency and quality of life were assessed by questionnaires. The differences from baseline in the severity of IBS symptoms at 4 and 8 weeks were similar between groups. Participants in this study were classified, after randomization, into subtypes according to Rome III. Within the <i>L. paracasei</i> group, complete spontaneous and spontaneous bowel movement frequency increased in participants with IBS-C (<i>n</i> = 10) after 8 weeks of supplementation (both <i>p</i> &lt; 0.05) and decreased in participants with IBS-D (<i>n</i> = 10, <i>p</i> = 0.013). Both <i>L. paracasei</i> and <i>B. longum</i> supplementation improved the quality of life in emotional well-being and social functioning compared with baseline (all <i>p</i> &lt; 0.05). In conclusion, <i>L. paracasei</i> and <i>B. longum</i> may reduce GI symptom severity and improve the psychological well-being of individuals with certain IBS subtypes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Erin D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>KGK Science Inc., London, ON N6A 5R8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antony</LastName><ForeName>Joseph M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>KGK Science Inc., London, ON N6A 5R8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crowley</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>KGK Science Inc., London, ON N6A 5R8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piano</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Lallemand Health Solutions, Montreal, QC H4P 2R2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhardwaj</LastName><ForeName>Renu</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Lallemand Health Solutions, Montreal, QC H4P 2R2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tompkins</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials><Identifier Source="ORCID">0000-0002-2990-2265</Identifier><AffiliationInfo><Affiliation>Lallemand Health Solutions, Montreal, QC H4P 2R2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Malkanthi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>KGK Science Inc., London, ON N6A 5R8, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nutrients</MedlineTA><NlmUniqueID>101521595</NlmUniqueID><ISSNLinking>2072-6643</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069978" MajorTopicYN="Y">Bifidobacterium longum</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019587" MajorTopicYN="Y">Dietary Supplements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069980" MajorTopicYN="Y">Lacticaseibacillus paracasei</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063189" MajorTopicYN="N">Symptom Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bifidobacterium longum</Keyword><Keyword MajorTopicYN="N">IBS</Keyword><Keyword MajorTopicYN="N">Irritable Bowel Syndrome</Keyword><Keyword MajorTopicYN="N">Lactobacillus paracasei</Keyword><Keyword MajorTopicYN="N">probiotics</Keyword></KeywordList><CoiStatement>LHS owns <i>Bifidobacterium longum</i> R0175 and <i>Lactobacillus paracasei</i> HA-196. TAT, RB and AP are employees of Lallemand Health Solutions. LHS was involved in the design of the study, revising the manuscript and decision to publish the results but was not involved in data collection and analyses, or writing the manuscript. The corresponding author oversaw collection and analysis of data and had final responsibility for the decision to submit for publication.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32326347</ArticleId><ArticleId IdType="pmc">PMC7230591</ArticleId><ArticleId IdType="doi">10.3390/nu12041159</ArticleId><ArticleId IdType="pii">nu12041159</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Card T., Canavan C., West J. The epidemiology of irritable bowel syndrome. Clin. Epidemiol. 2014;6:71. doi: 10.2147/CLEP.S40245.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S40245</ArticleId><ArticleId IdType="pmc">PMC3921083</ArticleId><ArticleId IdType="pubmed">24523597</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultan S., Malhotra A. Irritable Bowel Syndrome. Ann. Intern. Med. 2017;166:Itc81&#x2013;Itc96. doi: 10.7326/AITC201706060.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/AITC201706060</ArticleId><ArticleId IdType="pubmed">28586906</ArticleId></ArticleIdList></Reference><Reference><Citation>Occhipinti K., Smith J. Irritable Bowel Syndrome: A Review and Update. Clin. Colon Rectal Surg. 2012;25:46&#x2013;52. doi: 10.1055/s-0032-1301759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0032-1301759</ArticleId><ArticleId IdType="pmc">PMC3348735</ArticleId><ArticleId IdType="pubmed">23449495</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J.H. The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies. Drug Saf. 2011;34:545&#x2013;565. doi: 10.2165/11590690-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11590690-000000000-00000</ArticleId><ArticleId IdType="pubmed">21663331</ArticleId></ArticleIdList></Reference><Reference><Citation>Munjal A., Dedania B., Cash B. Update on Pharmacotherapy for Irritable Bowel Syndrome. Curr. Gastroenterol. Rep. 2019;21:25. doi: 10.1007/s11894-019-0692-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11894-019-0692-7</ArticleId><ArticleId IdType="pubmed">31025114</ArticleId></ArticleIdList></Reference><Reference><Citation>Tap J., Derrien M., T&#xf6;rnblom H., Brazeilles R., Cools-Portier S., Dor&#xe9; J., St&#xf6;rsrud S., Le Nev&#xe9; B., &#xd6;hman L., Simr&#xe9;n M. Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome. Gastroenterology. 2017;152:111&#x2013;123.e8. doi: 10.1053/j.gastro.2016.09.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.09.049</ArticleId><ArticleId IdType="pubmed">27725146</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee B.J., Bak Y.-T. Irritable Bowel Syndrome, Gut Microbiota and Probiotics. J. Neurogastroenterol. Motil. 2011;17:252&#x2013;266. doi: 10.5056/jnm.2011.17.3.252.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm.2011.17.3.252</ArticleId><ArticleId IdType="pmc">PMC3155061</ArticleId><ArticleId IdType="pubmed">21860817</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerckhoffs A.P., Samsom M., van der Rest M.E., de Vogel J., Knol J., Ben-Amor K., Akkermans L.M. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J. Gastroenterol. 2009;15:2887&#x2013;2892. doi: 10.3748/wjg.15.2887.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.15.2887</ArticleId><ArticleId IdType="pmc">PMC2699007</ArticleId><ArticleId IdType="pubmed">19533811</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinn D.H., Song J.H., Kim H.J., Lee J.H., Son H.J., Chang D.K., Kim Y.H., Kim J.J., Rhee J.C., Rhee P.L. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig. Dis. Sci. 2008;53:2714&#x2013;2718. doi: 10.1007/s10620-007-0196-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-007-0196-4</ArticleId><ArticleId IdType="pubmed">18274900</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouwehand A.C., Invernici M.M., Furlaneto F.A.C., Messora M.R. Effectiveness of Multi-strain Versus Single-strain Probiotics: Current Status and Recommendations for the Future. J. Clin. Gastroenterol. 2018;52:S35&#x2013;S40. doi: 10.1097/MCG.0000000000001052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0000000000001052</ArticleId><ArticleId IdType="pubmed">29734210</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbara G., Cremon C., Azpiroz F. Probiotics in irritable bowel syndrome: Where are we? Neurogastroenterol. Motil. 2018;30:e13513. doi: 10.1111/nmo.13513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13513</ArticleId><ArticleId IdType="pubmed">30460770</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanigliulo L., Comparato G., Aragona G., Cavallaro L., Iori V., Maino M., Cavestro G.M., Soliani P., Sianesi M., Franze A., et al. Role of gut microflora and probiotic effects in the irritable bowel syndrome. Acta Biomed. 2006;77:85&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">17172187</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardo L., Vernetto A., Blanco I. Clinical evaluation of Lactobacillus paracasei subsp. paracasei F19 with gluco-oligosaccharides in the short-term treatment of irritable bowel syndrome. Microb. Ecol. Health Dis. 2009;21:28&#x2013;32. doi: 10.1080/08910600802610815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08910600802610815</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland L.V., Evans C.T., Goldstein E.J.C. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. Front. Med. (Lausanne) 2018;5:124. doi: 10.3389/fmed.2018.00124.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2018.00124</ArticleId><ArticleId IdType="pmc">PMC5949321</ArticleId><ArticleId IdType="pubmed">29868585</ArticleId></ArticleIdList></Reference><Reference><Citation>Messaoudi M., Lalonde R., Violle N., Javelot H., Desor D., Nejdi A., Bisson J.-F., Rougeot C., Pichelin M., Cazaubiel M., et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br. J. Nutr. 2011;105:755&#x2013;764. doi: 10.1017/S0007114510004319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0007114510004319</ArticleId><ArticleId IdType="pubmed">20974015</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazemi A., Noorbala A.A., Azam K., Eskandari M.H., Djafarian K. Effect of probiotic and prebiotic vs placebo on psychological outcomes in patients with major depressive disorder: A randomized clinical trial. Clin. Nutr. 2019:522&#x2013;528. doi: 10.1016/j.clnu.2018.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2018.04.010</ArticleId><ArticleId IdType="pubmed">29731182</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D., Hopewell S., Schulz K.F., Montori V., Gotzsche P.C., Devereaux P.J., Elbourne D., Egger M., Altman D.G. CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials. Int. J. Surg. 2012;10:28&#x2013;55. doi: 10.1016/j.ijsu.2011.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2011.10.001</ArticleId><ArticleId IdType="pubmed">22036893</ArticleId></ArticleIdList></Reference><Reference><Citation>Blake M.R., Raker J.M., Whelan K. Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharm. Ther. 2016;44:693&#x2013;703. doi: 10.1111/apt.13746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.13746</ArticleId><ArticleId IdType="pubmed">27492648</ArticleId></ArticleIdList></Reference><Reference><Citation>Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C. Functional bowel disorders. Gastroenterology. 2006;130:1480&#x2013;1491. doi: 10.1053/j.gastro.2005.11.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2005.11.061</ArticleId><ArticleId IdType="pubmed">16678561</ArticleId></ArticleIdList></Reference><Reference><Citation>Brazier J.E., Harper R., Jones N.M., O&#x2019;Cathain A., Thomas K.J., Usherwood T., Westlake L. Validating the SF-36 health survey questionnaire: New outcome measure for primary care. BMJ. 1992;305:160&#x2013;164. doi: 10.1136/bmj.305.6846.160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.305.6846.160</ArticleId><ArticleId IdType="pmc">PMC1883187</ArticleId><ArticleId IdType="pubmed">1285753</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams V.S., Nelson L.M., Fehnel S.E., MacDougall J., Carson R.T., Tourkodimitris S., Kurtz C., Baird M.J., Johnston J.M. Psychometric validation of symptom severity measures in irritable bowel syndrome with constipation. Aliment. Pharm. Ther. 2014;40:298&#x2013;308. doi: 10.1111/apt.12830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.12830</ArticleId><ArticleId IdType="pubmed">24943204</ArticleId></ArticleIdList></Reference><Reference><Citation>Derrien M., Collado M.C., Ben-Amor K., Salminen S., de Vos W.M. The Mucin degrader Akkermansia muciniphila is an abundant resident of the human intestinal tract. Appl. Environ. Microbiol. 2008;74:1646&#x2013;1648. doi: 10.1128/AEM.01226-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.01226-07</ArticleId><ArticleId IdType="pmc">PMC2258631</ArticleId><ArticleId IdType="pubmed">18083887</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Siles M., Martinez-Medina M., Busquets D., Sabat-Mir M., Duncan S.H., Flint H.J., Aldeguer X., Garcia-Gil L.J. Mucosa-associated Faecalibacterium prausnitzii and Escherichia coli co-abundance can distinguish Irritable Bowel Syndrome and Inflammatory Bowel Disease phenotypes. Int. J. Med. Microbiol. 2014;304:464&#x2013;475. doi: 10.1016/j.ijmm.2014.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmm.2014.02.009</ArticleId><ArticleId IdType="pubmed">24713205</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartman A.L., Lough D.M., Barupal D.K., Fiehn O., Fishbein T., Zasloff M., Eisen J.A. Human gut microbiome adopts an alternative state following small bowel transplantation. Proc. Natl. Acad. Sci. USA. 2009;106:17187&#x2013;17192. doi: 10.1073/pnas.0904847106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0904847106</ArticleId><ArticleId IdType="pmc">PMC2746123</ArticleId><ArticleId IdType="pubmed">19805153</ArticleId></ArticleIdList></Reference><Reference><Citation>Dapoigny M., Piche T., Ducrotte P., Lunaud B., Cardot J.M., Bernalier-Donadille A. Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: A randomized, double-blind study. World J. Gastroenterol. 2012;18:2067&#x2013;2075. doi: 10.3748/wjg.v18.i17.2067.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v18.i17.2067</ArticleId><ArticleId IdType="pmc">PMC3342605</ArticleId><ArticleId IdType="pubmed">22563194</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams E.A., Stimpson J., Wang D., Plummer S., Garaiova I., Barker M.E., Corfe B.M. Clinical trial: A multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment. Pharm. Ther. 2009;29:97&#x2013;103. doi: 10.1111/j.1365-2036.2008.03848.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2008.03848.x</ArticleId><ArticleId IdType="pubmed">18785988</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha L. Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine. World J. Gastroenterol. 2014;20:6759&#x2013;6773. doi: 10.3748/wjg.v20.i22.6759.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i22.6759</ArticleId><ArticleId IdType="pmc">PMC4051916</ArticleId><ArticleId IdType="pubmed">24944467</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y.T., Hu L.Y., Shen C.C., Huang M.W., Tsai S.J., Yang A.C., Hu C.K., Perng C.L., Huang Y.S., Hung J.H. Risk of Psychiatric Disorders following Irritable Bowel Syndrome: A Nationwide Population-Based Cohort Study. PLoS ONE. 2015;10:e0133283. doi: 10.1371/journal.pone.0133283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0133283</ArticleId><ArticleId IdType="pmc">PMC4519183</ArticleId><ArticleId IdType="pubmed">26222511</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastiaanssen T.F.S., Cowan C.S.M., Claesson M.J., Dinan T.G., Cryan J.F. Making Sense of &#x2026; the Microbiome in Psychiatry. Int. J. Neuropsychopharmacol. 2019;22:37&#x2013;52. doi: 10.1093/ijnp/pyy067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ijnp/pyy067</ArticleId><ArticleId IdType="pmc">PMC6313131</ArticleId><ArticleId IdType="pubmed">30099552</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadeem I., Rahman M.Z., Ad-Dab&#x2019;bagh Y., Akhtar M. Effect of probiotic interventions on depressive symptoms: A narrative review evaluating systematic reviews. Psychiatry Clin. Neurosci. 2019;73:154&#x2013;162. doi: 10.1111/pcn.12804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pcn.12804</ArticleId><ArticleId IdType="pubmed">30499231</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto-Sanchez M.I., Hall G.B., Ghajar K., Nardelli A., Bolino C., Lau J.T., Martin F.P., Cominetti O., Welsh C., Rieder A., et al. Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. Gastroenterology. 2017;153:448&#x2013;459.e8. doi: 10.1053/j.gastro.2017.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2017.05.003</ArticleId><ArticleId IdType="pubmed">28483500</ArticleId></ArticleIdList></Reference><Reference><Citation>Aragon G., Graham D.B., Borum M., Doman D.B. Probiotic therapy for irritable bowel syndrome. Gastroenterol. Hepatol. (N Y) 2010;6:39&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886445</ArticleId><ArticleId IdType="pubmed">20567539</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz-Aguliar R.M., Wantia N., Clavel T., Vehreschild M., Buch T., Bajbouj M., Haller D., Busch D., Schmid R.M., Stein-Thoeringer C.K. An Open-Labeled Study on Fecal Microbiota Transfer in Irritable Bowel Syndrome Patients Reveals Improvement in Abdominal Pain Associated with the Relative Abundance of Akkermansia Muciniphila. Digestion. 2019;100:127&#x2013;138. doi: 10.1159/000494252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000494252</ArticleId><ArticleId IdType="pubmed">30423561</ArticleId></ArticleIdList></Reference><Reference><Citation>Miquel S., Martin R., Lashermes A., Gillet M., Meleine M., Gelot A., Eschalier A., Ardid D., Bermudez-Humaran L.G., Sokol H., et al. Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models. Sci. Rep. 2016;6:19399. doi: 10.1038/srep19399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep19399</ArticleId><ArticleId IdType="pmc">PMC4726104</ArticleId><ArticleId IdType="pubmed">26775847</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorn S.D., Kaptchuk T.J., Park J.B., Nguyen L.T., Canenguez K., Nam B.H., Woods K.B., Conboy L.A., Stason W.B., Lembo A.J. A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome. Neurogastroenterol. Motil. Off. J. Eur. Gastrointest. Motil. Soc. 2007;19:630&#x2013;637. doi: 10.1111/j.1365-2982.2007.00937.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2007.00937.x</ArticleId><ArticleId IdType="pubmed">17640177</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel S.M., Stason W.B., Legedza A., Ock S.M., Kaptchuk T.J., Conboy L., Canenguez K., Park J.K., Kelly E., Jacobson E., et al. The placebo effect in irritable bowel syndrome trials: A meta-analysis. Neurogastroenterol. Motil. 2005;17:332&#x2013;340. doi: 10.1111/j.1365-2982.2005.00650.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2005.00650.x</ArticleId><ArticleId IdType="pubmed">15916620</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman D.A. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features, and Rome IV. Gastroenterology. 2016;150:1262&#x2013;1279. doi: 10.1053/j.gastro.2016.02.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.032</ArticleId><ArticleId IdType="pubmed">27144617</ArticleId></ArticleIdList></Reference><Reference><Citation>Black C.J., Yiannakou Y., Houghton L.A., Ford A.C. Epidemiological, Clinical, and Psychological Characteristics of Individuals with Self-reported Irritable Bowel Syndrome Based on the Rome IV vs Rome III Criteria. Clin. Gastroenterol. Hepatol. 2020;18:392&#x2013;398. doi: 10.1016/j.cgh.2019.05.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2019.05.037</ArticleId><ArticleId IdType="pubmed">31154027</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Song J., Hou X. Mast Cells and Irritable Bowel Syndrome: From the Bench to the Bedside. J. Neurogastroenterol. Motil. 2016;22:181&#x2013;192. doi: 10.5056/jnm15137.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm15137</ArticleId><ArticleId IdType="pmc">PMC4819856</ArticleId><ArticleId IdType="pubmed">26755686</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33545934</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>100</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Jan</Month><Day>22</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT Compliant].</ArticleTitle><Pagination><StartPage>e23641</StartPage><MedlinePgn>e23641</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e23641</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000023641</ELocationID><Abstract><AbstractText Label="GOALS" NlmCategory="OBJECTIVE">To evaluate safety and efficacy of Bacillus coagulans LBSC [DSM17654] in irritable bowel syndrome (IBS) through a prospective, interventional, randomized, double-blind, and placebo-controlled, CONSORT compliant clinical trial.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bacteriotherapy shows promising impact on alleviating clinical conditions of IBS and associated functional gastrointestinal disorders. B coagulans LBSC is a genetically and phenotypically safe probiotic strain used in this study to study its impact on ameliorating IBS symptoms and improving quality of life.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this interventional, randomized, double-blind, placebo-controlled clinical study, total 40 subjects (18-65 years) were screened through Rome IV criteria and randomized into 2 groups, that is, interventional and placebo arm (n&#x200a;=&#x200a;20/arm). Similar dosages were received by both the arm, that is, placebo (vehicle) and interventional arm (B coagulans LBSC, 6&#x200a;billion/d) for a period of 80 days. Study completed with per protocol subjects (n&#x200a;=&#x200a;38) and results were considered to evaluate the primary and secondary endpoints.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Assessment through Digestive Symptom Frequency Questionnaire 5 point Likert scale showed significant improvement in interventional arm compared to placebo on symptoms such as bloating/cramping, abdominal pain, diarrhea, constipation, stomach rumbling, nausea, vomiting, headache, and anxiety. Maximum of "no symptoms" cases and mild to moderate gastrointestinal symptoms along with improved stool consistency were from interventional arm tested following IBS severity scoring system and Bristol stool form scale. Upper gastrointestinal endoscopy revealed no clinical difference of gastrointestinal mucosa between both the arms. B coagulans LBSC was well tolerated with no serious adverse events.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">B coagulans LBSC was safe for human consumption and efficacious in alleviating overall pathophysiological symptoms of IBS and thereby improving inclusive quality of life evaluated.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Anil Kumar</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Probiotics Laboratory, Advanced Enzyme Technologies Ltd., Sun Magnetica, Louiswadi, Thane (W), Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maity</LastName><ForeName>Chiranjit</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-9400-3947</Identifier></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>no</GrantID><Agency>Advanced Enzyme Technologies Ltd.</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000070000" MajorTopicYN="Y">Bacillus coagulans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>6</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33545934</ArticleId><ArticleId IdType="pmc">PMC7837859</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000023641</ArticleId><ArticleId IdType="pii">00005792-202101220-00014</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Talley NJ. A unifying hypothesis for the functional gastrointestinal disorders: really multiple diseases or one irritable gut? Rev Gastroenterol Disord 2006;6:72&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16699476</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy BE, Patel NK. Rome criteria and a diagnostic approach to irritable bowel syndrome. J Clin Med 2017;6:99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5704116</ArticleId><ArticleId IdType="pubmed">29072609</ArticleId></ArticleIdList></Reference><Reference><Citation>Babu S. A young woman with diarrhea predominant IBS showing improvement with probiotics. Med Update 2019;27:16&#x2013;8.</Citation></Reference><Reference><Citation>Enck P, Aziz Q, Barbara G, et al. Irritable bowel syndrome. Nat Rev Dis Primers 2016;2:16014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5001845</ArticleId><ArticleId IdType="pubmed">27159638</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjivasilis A, Tsioutis C, Michalinos A, et al. New insights into irritable bowel syndrome: from pathophysiology to treatment. Ann Gastroenterol 2019;32:554&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6826071</ArticleId><ArticleId IdType="pubmed">31700231</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer EA. Clinical practice. Irritable bowel syndrome. N Engl J Med 2008;358:1692&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3816529</ArticleId><ArticleId IdType="pubmed">18420501</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong PP, Chin VK, Looi CY, et al. The microbiome and irritable bowel syndrome - a review on the pathophysiology, current research and future therapy. Front Microbiol 2019;10:1136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579922</ArticleId><ArticleId IdType="pubmed">31244784</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher HM, Irving PM, Lomer MCE, et al. Mechanisms and efficacy of dietary FODMAP restriction in IBS. Nat Rev Gastroenterol Hepatol 2014;11:256&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">24445613</ArticleId></ArticleIdList></Reference><Reference><Citation>Frissora CL, Cash BD. Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. Aliment Pharmacol Ther 2007;25:1271&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">17509095</ArticleId></ArticleIdList></Reference><Reference><Citation>Basseri RJ, Weitsman S, Barlow GM, et al. Antibiotics for the treatment of irritable bowel syndrome. Gastroenterol Hepatol 2011;7:455&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264894</ArticleId><ArticleId IdType="pubmed">22298980</ArticleId></ArticleIdList></Reference><Reference><Citation>Molina-Infante J, Serra J, Fernandez-Banares F, et al. The low-FODMAP diet for irritable bowel syndrome: Lights and shadows. Gastroenterol Hepatol 2016;39:55&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">26548734</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001;1:101&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">11871461</ArticleId></ArticleIdList></Reference><Reference><Citation>Quigley EMM. Bacterial flora in irritable bowel syndrome: role in pathophysiology, implications for management. J Dig Dis 2007;8:2&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17261128</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy BE. Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome. Int J Gen Med 2016;9:7&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4755466</ArticleId><ArticleId IdType="pubmed">26929659</ArticleId></ArticleIdList></Reference><Reference><Citation>Jernberg C, L&#xf6;fmark S, Edlund C. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiol 2010;156:3216&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">20705661</ArticleId></ArticleIdList></Reference><Reference><Citation>Villarreal AA, Aberger FJ, Benrud R, et al. Use of broad-spectrum antibiotics and the development of irritable bowel syndrome. Wis Med J 2012;111:17&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">22533211</ArticleId></ArticleIdList></Reference><Reference><Citation>Menees S, Chey W. The gut microbiome and irritable bowel syndrome. F1000Res 2018;7: F1000 Faculty Rev-1029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6039952</ArticleId><ArticleId IdType="pubmed">30026921</ArticleId></ArticleIdList></Reference><Reference><Citation>James SC, Fraser K, Young W, et al. Gut microbial metabolites and biochemical pathways involved in irritable bowel syndrome: effects of diet and nutrition on the microbiome. J Nutr 2019;10.1093/jn/nxz302</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jn/nxz302</ArticleId><ArticleId IdType="pmc">PMC7198292</ArticleId><ArticleId IdType="pubmed">31891398</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittayanon R, Lau JT, Yuan Y, et al. Gut microbiota in patients with irritable bowel syndrome&#x2014;a systematic review. Gastroenterol 2019;157:97&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">30940523</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Ford AC. Probiotics for treating irritable bowel syndrome: are bugs the best drugs? Gastroenterol 2018;155:2019&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">30419203</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Agriculture Organization and World Health Organization Expert Consultation. Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria. C&#xf3;rdoba, Argentina. 2001.</Citation></Reference><Reference><Citation>Dale HF, Rasmussen SH, Asiller OO, et al. Probiotics in irritable bowel syndrome: an up-to-date systematic review. Nutrients 2019;11:2048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6769995</ArticleId><ArticleId IdType="pubmed">31480656</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurenka JS. Bacillus coagulans: monograph. Altern Med Rev 2012;17:76&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">22502625</ArticleId></ArticleIdList></Reference><Reference><Citation>Maity C, Gupta AK, Saroj DB, et al. Impact of a gastrointestinal stable probiotic supplement Bacillus coagulans LBSC on human gut microbiome modulation. J Diet Suppl 2020;10.1080/19390211.2020.1814931</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19390211.2020.1814931</ArticleId><ArticleId IdType="pubmed">32896190</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu Y, Cong Y. Bacillus coagulans and its applications in medicine. Benef Microbes 2019;10:679&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">31203635</ArticleId></ArticleIdList></Reference><Reference><Citation>Maity C, Gupta AK. A prospective, interventional, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of Bacillus coagulans LBSC in the treatment of acute diarrhea with abdominal discomfort. Eur J Clin Pharmacol 2019;75:21&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">30264164</ArticleId></ArticleIdList></Reference><Reference><Citation>Hungin APS, Mulligan C, Pot B, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice &#x2013; an evidence based international guide. Aliment Pharmacol Ther 2013;38:864&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3925990</ArticleId><ArticleId IdType="pubmed">23981066</ArticleId></ArticleIdList></Reference><Reference><Citation>La Rosa M, Bottaro G, Gulino N, et al. Prevention of antibiotic-associated diarrhea with Lactobacillus sporogens and fructo-oligosaccharides in children. A multicentric double-blind vs placebo study. Minerva Pediatr 2003;55:447&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">14608267</ArticleId></ArticleIdList></Reference><Reference><Citation>Hun L. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med 2009;121:119&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">19332970</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolin BJ. Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find Exp Clin Pharmacol 2009;31:655&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20140275</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogha M, Zahiri-Esfahani M, Zargarzadeh AH. The efficacy of a synbiotic containing Bacillus coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial. Gastroenterol Hepatol Bed Bench 2014;7:156&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4129566</ArticleId><ArticleId IdType="pubmed">25120896</ArticleId></ArticleIdList></Reference><Reference><Citation>Saneian H, Pourmoghaddas Z, Roohafza H, et al. Synbiotic containing Bacillus coagulans and fructo-oligosaccharides for functional abdominal pain in children. Gastroenterol Hepatol Bed Bench 2015;8:56&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285933</ArticleId><ArticleId IdType="pubmed">25584177</ArticleId></ArticleIdList></Reference><Reference><Citation>Majeed M, Nagabhushanam K, Natarajan S, et al. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant irritable bowel syndrome: a double blind randomized placebo controlled pilot clinical study. Nutr J 2016;15:21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4769834</ArticleId><ArticleId IdType="pubmed">26922379</ArticleId></ArticleIdList></Reference><Reference><Citation>Madempudi RS, Ahire JJ, Neelamraju J, et al. Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults. Sci Rep 2019;9:12210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6704184</ArticleId><ArticleId IdType="pubmed">31434935</ArticleId></ArticleIdList></Reference><Reference><Citation>Saroj DB, Gupta AK. Genome based safety assessment for Bacillus coagulans strain LBSC (DSM 17654) for probiotic application. Int J Food Microbiol 2020;318:108523.</Citation><ArticleIdList><ArticleId IdType="pubmed">31964505</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association (WMA) Declaration of Helsinki. Ethical principles for medical research involving human subjects. 52nd WMA general assembly. Scotland, Edinburgh. 2000.</Citation></Reference><Reference><Citation>International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for good clinical practice [E6(R1)], June 1996.</Citation></Reference><Reference><Citation>Indian Council of Medical Research (ICMR). Ethical guidelines for biomedical research on human participants. New Delhi. 2006. Available at: http://www.cns.iisc.ac.in/wordpress/wpcontent/uploads/2017/01/ethical_guidelines.pdf [access date March 2, 2018].</Citation></Reference><Reference><Citation>Azpiroz F, Guyonnet D, Donazzolo Y, et al. Digestive symptoms in healthy people and subjects with irritable bowel syndrome: validation of symptom frequency questionnaire. J Clin Gastroenterol 2015;49:e64&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4495859</ArticleId><ArticleId IdType="pubmed">25014236</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman DA, Chang L, Bellamy N, et al. Severity in irritable bowel syndrome: a Rome foundation working team report. Am J Gastroenterol 2011;106:1749&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">21747417</ArticleId></ArticleIdList></Reference><Reference><Citation>Azad MAK, Sarker M, Li T, et al. Probiotic species in the modulation of gut microbiota: an overview. Biomed Res Int 2018;2018:9478630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5964481</ArticleId><ArticleId IdType="pubmed">29854813</ArticleId></ArticleIdList></Reference><Reference><Citation>Bubnov RV, Babenko LP, Lazarenko LM, et al. Specific properties of probiotic strains: relevance and benefits for the host. EPMA J 2018;9:205&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5972142</ArticleId><ArticleId IdType="pubmed">29896319</ArticleId></ArticleIdList></Reference><Reference><Citation>Aragon G, Graham DB, Borum M, et al. Probiotic therapy for irritable bowel syndrome. Gastroenterol Hepatol 2010;6:39&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886445</ArticleId><ArticleId IdType="pubmed">20567539</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai C, Zheng CQ, Jiang M, et al. Probiotics and irritable bowel syndrome. World J Gastroenterol 2013;19:5973&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785618</ArticleId><ArticleId IdType="pubmed">24106397</ArticleId></ArticleIdList></Reference><Reference><Citation>Sniffen JC, McFarland LV, Evans CT, et al. Choosing an appropriate probiotic product for your patient: an evidence-based practical guide. PLoS One 2018;13:e0209205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6306248</ArticleId><ArticleId IdType="pubmed">30586435</ArticleId></ArticleIdList></Reference><Reference><Citation>Br&#xfc;ssow H. Probiotics and prebiotics in clinical tests: an update. F1000Res 2019;8: F1000 Faculty Rev-1157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6652097</ArticleId><ArticleId IdType="pubmed">31354938</ArticleId></ArticleIdList></Reference><Reference><Citation>Urgesi R, Casale C, Pistelli R, et al. A randomized double-blind placebo-controlled clinical trial on efficacy and safety of association of simethicone and Bacillus coagulans (Colinox&#xae;) in patients with irritable bowel syndrome. Eur Rev Med Pharmacol Sci 2014;18:1344&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">24867512</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudha MR, Jayanthi N, Aasin M, et al. Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled study. Benef Microbes 2018;9:563&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">29695183</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyra A, Hillil&#xe4; M, Huttunen T, et al. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. World J Gastroenterol 2016;22:10631&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5192275</ArticleId><ArticleId IdType="pubmed">28082816</ArticleId></ArticleIdList></Reference><Reference><Citation>Francavilla R, Piccolo M, Francavilla A, et al. Clinical and microbiological effect of a multispecies probiotic supplementation in celiac patients with persistent IBS-type symptoms: a randomized, double-blind, placebo-controlled, multicenter trial. J Clin Gastroenterol 2019;53:e117&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6382041</ArticleId><ArticleId IdType="pubmed">29688915</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishaque SM, Khosruzzaman SM, Ahmed DS, et al. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult&#xae;) in the management of diarrhea predominant irritable bowel syndrome. BMC Gastroenterol 2018;18:71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5970461</ArticleId><ArticleId IdType="pubmed">29801486</ArticleId></ArticleIdList></Reference><Reference><Citation>Minamida K, Nishimura M, Miwa K, et al. Effects of dietary fiber with Bacillus coagulans lilac-01 on bowel movement and fecal properties of healthy volunteers with a tendency for constipation. Biosci Biotechnol Biochem 2015;79:300&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25338680</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller LE, Ouweh AC, Ibarra A. Effects of probiotic-containing products on stool frequency and intestinal transit in constipated adults: systematic review and meta-analysis of randomized controlled trials. Ann Gastroenterol 2017;30:629&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5670282</ArticleId><ArticleId IdType="pubmed">29118557</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon JY, Cha JM, Oh JK, et al. Probiotics ameliorate stool consistency in patients with chronic constipation: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2018;63:2754&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">29876777</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Toole PW, Cooney JC. Probiotic bacteria influence the composition and function of the intestinal microbiota. Interdiscip Perspect Infect Dis 2008;175285:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2648622</ArticleId><ArticleId IdType="pubmed">19277099</ArticleId></ArticleIdList></Reference><Reference><Citation>Kho ZY, Lal SK. The human gut microbiome &#x2013; a potential controller of wellness and disease. Front Microbiol 2018;9:1835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6102370</ArticleId><ArticleId IdType="pubmed">30154767</ArticleId></ArticleIdList></Reference><Reference><Citation>GRAS Notice (GRN) No. 597.Bacillus coagulans SNZ1969 spore preparation. Available at: https://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&amp;id=597 [access date February 2018). 2015. in press.</Citation></Reference><Reference><Citation>Kalman DS, Schwartz HI, Alvarez P, et al. A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms. BMC Gastroenterol 2009;9:85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2784472</ArticleId><ArticleId IdType="pubmed">19922649</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandel DR, Eichas K, Holmes J. Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. BMC Complement Altern Med 2010;10:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2826289</ArticleId><ArticleId IdType="pubmed">20067641</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36362056</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>21</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>31</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>The Role of the Human Microbiome in the Pathogenesis of Pain.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">13267</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms232113267</ELocationID><Abstract><AbstractText>Understanding of the gut microbiome's role in human physiology developed rapidly in recent years. Moreover, any alteration of this microenvironment could lead to a pathophysiological reaction of numerous organs. It results from the bidirectional communication of the gastrointestinal tract with the central nervous system, called the gut-brain axis. The signals in the gut-brain axis are mediated by immunological, hormonal, and neural pathways. However, it is also influenced by microorganisms in the gut. The disturbances in the gut-brain axis are associated with gastrointestinal syndromes, but recently their role in the development of different types of pain was reported. The gut microbiome could be the factor in the central sensitization of chronic pain by regulating microglia, astrocytes, and immune cells. Dysbiosis could lead to incorrect immune responses, resulting in the development of inflammatory pain such as endometriosis. Furthermore, chronic visceral pain, associated with functional gastrointestinal disorders, could result from a disruption in the gut microenvironment. Any alteration in the gut-brain axis could also trigger migraine attacks by affecting cytokine expression. Understanding the gut microbiome's role in pain pathophysiology leads to the development of analgetic therapies targeting microorganisms. Probiotics, FODMAP diet, and fecal microbiota transplantation are reported to be beneficial in treating visceral pain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ustianowska</LastName><ForeName>Klaudia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ustianowski</LastName><ForeName>&#x141;ukasz</ForeName><Initials>&#x141;</Initials><Identifier Source="ORCID">0000-0002-4754-3235</Identifier><AffiliationInfo><Affiliation>Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machaj</LastName><ForeName>Filip</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biology, Medical University of Warsaw, 00-575 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gor&#x105;cy</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Independent Laboratory of Invasive Cardiology, Pomeranian Medical University, 70-111 Szczecin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosik</LastName><ForeName>Jakub</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-7377-4566</Identifier><AffiliationInfo><Affiliation>Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, The University of Chicago, Chicago, IL 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szostak</LastName><ForeName>Bartosz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szostak</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, 70-111 Szczecin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pawlik</LastName><ForeName>Andrzej</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6557-1208</Identifier><AffiliationInfo><Affiliation>Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059265" MajorTopicYN="Y">Visceral Pain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064806" MajorTopicYN="N">Dysbiosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064307" MajorTopicYN="Y">Microbiota</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059350" MajorTopicYN="Y">Chronic Pain</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IBS</Keyword><Keyword MajorTopicYN="N">microbiome</Keyword><Keyword MajorTopicYN="N">neuropathy</Keyword><Keyword MajorTopicYN="N">pain</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>11</Day><Hour>1</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36362056</ArticleId><ArticleId IdType="pmc">PMC9659276</ArticleId><ArticleId IdType="doi">10.3390/ijms232113267</ArticleId><ArticleId IdType="pii">ijms232113267</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sommer F., B&#xe4;ckhed F. The Gut Microbiota&#x2014;Masters of Host Development and Physiology. Nat. Rev. Microbiol. 2013;11:227&#x2013;238. doi: 10.1038/nrmicro2974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro2974</ArticleId><ArticleId IdType="pubmed">23435359</ArticleId></ArticleIdList></Reference><Reference><Citation>Karczewski J., Troost F.J., Konings I., Dekker J., Kleerebezem M., Brummer R.J.M., Wells J.M. Regulation of Human Epithelial Tight Junction Proteins by Lactobacillus plantarum In Vivo and Protective Effects on the Epithelial Barrier. Am. J. Physiol. Gastrointest. Liver. Physiol. 2010;298:G851&#x2013;G859. doi: 10.1152/ajpgi.00327.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00327.2009</ArticleId><ArticleId IdType="pubmed">20224007</ArticleId></ArticleIdList></Reference><Reference><Citation>Hugon P., Dufour J.C., Colson P., Fournier P.E., Sallah K., Raoult D. A Comprehensive Repertoire of Prokaryotic Species Identified in Human Beings. Lancet Infect. Dis. 2015;15:1211&#x2013;1219. doi: 10.1016/S1473-3099(15)00293-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(15)00293-5</ArticleId><ArticleId IdType="pubmed">26311042</ArticleId></ArticleIdList></Reference><Reference><Citation>Sender R., Fuchs S., Milo R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol. 2016:14. doi: 10.1371/journal.pbio.1002533.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1002533</ArticleId><ArticleId IdType="pmc">PMC4991899</ArticleId><ArticleId IdType="pubmed">27541692</ArticleId></ArticleIdList></Reference><Reference><Citation>Bengmark S. Ecological Control of the Gastrointestinal Tract. The Role of Probiotic Flora. Gut. 1998;42:2&#x2013;7. doi: 10.1136/gut.42.1.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.42.1.2</ArticleId><ArticleId IdType="pmc">PMC1726957</ArticleId><ArticleId IdType="pubmed">9505873</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuong H.E., Yano J.M., Fung T.C., Hsiao E.Y. The microbiome and host behavior. Annu. Rev. Neurosci. 2017;40:21&#x2013;49. doi: 10.1146/annurev-neuro-072116-031347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-072116-031347</ArticleId><ArticleId IdType="pmc">PMC6661159</ArticleId><ArticleId IdType="pubmed">28301775</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt T.S.B., Raes J., Bork P. The human gut microbiome: From association to modulation. Cell. 2018;172:1198&#x2013;1215. doi: 10.1016/j.cell.2018.02.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.02.044</ArticleId><ArticleId IdType="pubmed">29522742</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardmeh F., Nielsen H.I., Alipour H., Kjaergaard B., Brandsborg E., Gazerani P. Potential nociceptive regulatory effect of probiotic Lactobacillus rhamnosus PB01 (DSM 14870) on mechanical sensitivity in diet-induced obesity model. Pain Res. Manag. 2016;2016:5080438. doi: 10.1155/2016/5080438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/5080438</ArticleId><ArticleId IdType="pmc">PMC5014978</ArticleId><ArticleId IdType="pubmed">27647980</ArticleId></ArticleIdList></Reference><Reference><Citation>Belkaid Y., Hand T.W. Role of the microbiota in immunity and inflammation. Cell. 2014;157:121&#x2013;141. doi: 10.1016/j.cell.2014.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.03.011</ArticleId><ArticleId IdType="pmc">PMC4056765</ArticleId><ArticleId IdType="pubmed">24679531</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo R., Cristiano C., Avagliano C., De Caro C., La Rana G., Raso G.M., Canani R.B., Meli R., Calignano A. Gut&#x2013;brain axis: Role of lipids in the regulation of inflammation, pain and CNS diseases. Curr. Med. Chem. 2018;25:3930&#x2013;3952. doi: 10.2174/0929867324666170216113756.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867324666170216113756</ArticleId><ArticleId IdType="pubmed">28215162</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshavarzian A., Green S.J., Engen P.A., Voigt R.M., Naqib A., Forsyth C.B., Mutlu E., Shannon K.M. Colonic bacterial composition in Parkinson&#x2019;s disease. Mov. Disord. 2015;30:1351&#x2013;1360. doi: 10.1002/mds.26307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26307</ArticleId><ArticleId IdType="pubmed">26179554</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo R., Chen L.H., Xing C., Liu T. Pain Regulation by Gut Microbiota: Molecular Mechanisms and Therapeutic potential. Br. J. Anaesth. 2019;123:637&#x2013;654. doi: 10.1016/j.bja.2019.07.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bja.2019.07.026</ArticleId><ArticleId IdType="pubmed">31551115</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahony S.M., Clarke G., Borre Y.E., Dinan T.G., Cryan J.F. Serotonin, Tryptophan Metabolism and the Brain-Gut-Microbiome Axis. Behav. Brain Res. 2015;277:32&#x2013;48. doi: 10.1016/j.bbr.2014.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2014.07.027</ArticleId><ArticleId IdType="pubmed">25078296</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Watanabe K., Kimura I. Gut microbiota dysbiosis drives and implies novel therapeutic strategies for diabetes mellitus and related metabolic diseases. Front. Immunol. 2017;8:1882. doi: 10.3389/fimmu.2017.01882.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01882</ArticleId><ArticleId IdType="pmc">PMC5742320</ArticleId><ArticleId IdType="pubmed">29326727</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson J.K., Holmes E., Kinross J., Burcelin R., Gibson G., Jia W., Pettersson S. Host&#x2013;gut microbiota metabolic interactions. Science. 2012;336:1262&#x2013;1267. doi: 10.1126/science.1223813.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1223813</ArticleId><ArticleId IdType="pubmed">22674330</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiss C.N., Olofsson L.E. The role of the gut microbiota in development, function and disorders of the central nervous system and the enteric nervous system. J. Neuroendocrinol. 2019;31:e12684. doi: 10.1111/jne.12684.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jne.12684</ArticleId><ArticleId IdType="pubmed">30614568</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe9;a L.T., Caula C., Moulding T., Lyles A., Wohrer D., Titomanlio L. Brain to Belly: Abdominal variants of migraine and functional abdominal pain disorders associated with migraine. J. Neurogastroenterol. Motil. 2021;27:482&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8521460</ArticleId><ArticleId IdType="pubmed">34642268</ArticleId></ArticleIdList></Reference><Reference><Citation>Parada Venegas D., De la Fuente M.K., Landskron G., Gonz&#xe1;lez M.J., Quera R., Dijkstra G., Harmsen H.J.M., Faber K.N., Hermoso M.A. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Front. Immunol. 2019;10:277. doi: 10.3389/fimmu.2019.00277.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00277</ArticleId><ArticleId IdType="pmc">PMC6421268</ArticleId><ArticleId IdType="pubmed">30915065</ArticleId></ArticleIdList></Reference><Reference><Citation>Rea K., O&#x2019;Mahony S.M., Dinan T.G., Cryan J.F. The role of the gastrointestinal microbiota in visceral pain. Handb. Exp. Pharmacol. 2017;239:269&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pubmed">28035535</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolodziejczyk A.A., Zheng D., Shibolet O., Elinav E. The role of the microbiome in NAFLD and NASH. EMBO Mol. Med. 2019;11:e9302. doi: 10.15252/emmm.201809302.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201809302</ArticleId><ArticleId IdType="pmc">PMC6365925</ArticleId><ArticleId IdType="pubmed">30591521</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahlstrom A. Outside the liver box: The gut microbiota as pivotal modulator of liver diseases. Biochim. Biophys. Acta Mol. Basis Dis. 2019;1865:912&#x2013;919. doi: 10.1016/j.bbadis.2018.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2018.07.004</ArticleId><ArticleId IdType="pubmed">31007175</ArticleId></ArticleIdList></Reference><Reference><Citation>Massari F., Mollica V., di Nunno V., Gatto L., Santoni M., Scarpelli M., Cimadamore A., Lopez-Beltran A., Cheng L., Battelli N., et al. The Human Microbiota and Prostate Cancer: Friend or Foe? Cancers. 2019;11:459. doi: 10.3390/cancers11040459.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers11040459</ArticleId><ArticleId IdType="pmc">PMC6521295</ArticleId><ArticleId IdType="pubmed">30935126</ArticleId></ArticleIdList></Reference><Reference><Citation>Cimadamore A., Santoni M., Massari F., Gasparrini S., Cheng L., L&#xf3;pez-Beltr&#xe1;n A., Montironi R., Scarpelli M. Microbiome and Cancers, with Focus on Genitourinary Tumors. Front. Oncol. 2019;9:178. doi: 10.3389/fonc.2019.00178.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2019.00178</ArticleId><ArticleId IdType="pmc">PMC6443990</ArticleId><ArticleId IdType="pubmed">30972292</ArticleId></ArticleIdList></Reference><Reference><Citation>Neish A.S. Microbes in Gastrointestinal Health and Disease. Gastroenterology. 2009;136:65&#x2013;80. doi: 10.1053/j.gastro.2008.10.080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2008.10.080</ArticleId><ArticleId IdType="pmc">PMC2892787</ArticleId><ArticleId IdType="pubmed">19026645</ArticleId></ArticleIdList></Reference><Reference><Citation>Santoni M., Miccini F., Battelli N. Gut Microbiota, Immunity and Pain. Immunol. Lett. 2021;229:44&#x2013;47. doi: 10.1016/j.imlet.2020.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2020.11.010</ArticleId><ArticleId IdType="pubmed">33248167</ArticleId></ArticleIdList></Reference><Reference><Citation>Corr&#xea;a-Oliveira R., Fachi J.L., Vieira A., Sato F.T., Vinolo M.A.R. Regulation of Immune Cell Function by Short-Chain Fatty Acids. Clin. Transl. Immunol. 2016;5:e73. doi: 10.1038/cti.2016.17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cti.2016.17</ArticleId><ArticleId IdType="pmc">PMC4855267</ArticleId><ArticleId IdType="pubmed">27195116</ArticleId></ArticleIdList></Reference><Reference><Citation>Chey W.Y., Jin H.O., Lee M.H., Sun S.W., Lee K.Y. Colonic Motility Abnormality in Patients with Irritable Bowel Syndrome Exhibiting Abdominal Pain and Diarrhea. Am. J. Gastroenterol. 2001;96:1499&#x2013;1506. doi: 10.1111/j.1572-0241.2001.03804.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2001.03804.x</ArticleId><ArticleId IdType="pubmed">11374689</ArticleId></ArticleIdList></Reference><Reference><Citation>Psichas A., Reimann F., Gribble F.M. Gut Chemosensing Mechanisms. J. Clin. Invest. 2015;125:908&#x2013;917. doi: 10.1172/JCI76309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI76309</ArticleId><ArticleId IdType="pmc">PMC4362249</ArticleId><ArticleId IdType="pubmed">25664852</ArticleId></ArticleIdList></Reference><Reference><Citation>Amirkhanzadeh Barandouzi Z., Starkweather A.R., Henderson W.A., Gyamfi A., Cong X.S. Altered Composition of Gut Microbiota in Depression: A Systematic Review. Front. Psychiatry. 2020;11:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299157</ArticleId><ArticleId IdType="pubmed">32587537</ArticleId></ArticleIdList></Reference><Reference><Citation>Arzani M., Jahromi S.R., Ghorbani Z., Vahabizad F., Martelletti P., Ghaemi A., Sacco S., Togha M., EHF-SAS Gut-Brain Axis and Migraine Headache: A Comprehensive review. J. Headache Pain. 2020;21:15. doi: 10.1186/s10194-020-1078-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10194-020-1078-9</ArticleId><ArticleId IdType="pmc">PMC7020496</ArticleId><ArticleId IdType="pubmed">32054443</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudo N., Chida Y., Aiba Y., Sonoda J., Oyama N., Yu X.N., Kubo C., Koga Y. Postnatal Microbial Colonization Programs the Hypothalamic-Pituitary-Adrenal System for Stress Response in Mice. J. Physiol. 2004;558:263&#x2013;275. doi: 10.1113/jphysiol.2004.063388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2004.063388</ArticleId><ArticleId IdType="pmc">PMC1664925</ArticleId><ArticleId IdType="pubmed">15133062</ArticleId></ArticleIdList></Reference><Reference><Citation>Dro&#x17c;d&#x17c;al S., Rosik J., Lechowicz K., Machaj F., Szostak B., Majewski P., Rotter I., Kotfis K. COVID-19: Pain Management in Patients with SARS-CoV-2 Infection-Molecular Mechanisms, Challenges, and Perspectives. Brain Sci. 2020;10:465. doi: 10.3390/brainsci10070465.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci10070465</ArticleId><ArticleId IdType="pmc">PMC7407489</ArticleId><ArticleId IdType="pubmed">32698378</ArticleId></ArticleIdList></Reference><Reference><Citation>Neufeld K.A.M., Kang N., Bienenstock J., Foster J.A. Effects of Intestinal Microbiota on Anxiety-Like Behavior. Commun. Integr. Biol. 2011;4:492&#x2013;494. doi: 10.4161/cib.15702.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cib.15702</ArticleId><ArticleId IdType="pmc">PMC3181531</ArticleId><ArticleId IdType="pubmed">21966581</ArticleId></ArticleIdList></Reference><Reference><Citation>Bercik P., Verdu E.F., Foster J.A., Macri J., Potter M., Huang X., Malinowski P., Jackson W., Blennerhassett P., Neufeld K.A., et al. Chronic Gastrointestinal Inflammation Induces Anxiety-Like Behavior and Alters Central Nervous System Biochemistry in Mice. Gastroenterology. 2010;139:2102&#x2013;2112.e1. doi: 10.1053/j.gastro.2010.06.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2010.06.063</ArticleId><ArticleId IdType="pubmed">20600016</ArticleId></ArticleIdList></Reference><Reference><Citation>Bercik P., Denou E., Collins J., Jackson W., Lu J., Jury J., Deng Y., Blennerhassett P., Macri J., McCoy K.D., et al. The Intestinal Microbiota Affect Central Levels of Brain-Derived Neurotropic Factor and Behavior in Mice. Gastroenterology. 2011;141:599&#x2013;609.e3. doi: 10.1053/j.gastro.2011.04.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2011.04.052</ArticleId><ArticleId IdType="pubmed">21683077</ArticleId></ArticleIdList></Reference><Reference><Citation>Basbaum A.I., Bautista D.M., Scherrer G., Julius D. Cellular and molecular mechanisms of pain. Cell. 2009;139:267&#x2013;284. doi: 10.1016/j.cell.2009.09.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2009.09.028</ArticleId><ArticleId IdType="pmc">PMC2852643</ArticleId><ArticleId IdType="pubmed">19837031</ArticleId></ArticleIdList></Reference><Reference><Citation>Julius D., Basbaum A.I. Molecular mechanisms of nociception. Nature. 2001;413:203&#x2013;210. doi: 10.1038/35093019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35093019</ArticleId><ArticleId IdType="pubmed">11557989</ArticleId></ArticleIdList></Reference><Reference><Citation>Braz J., Solorzano C., Wang X., Basbaum A.I. Transmitting pain and itch messages: A contemporary view of the spinal cord circuits that generate gate control. Neuron. 2014;82:522&#x2013;536. doi: 10.1016/j.neuron.2014.01.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.01.018</ArticleId><ArticleId IdType="pmc">PMC4492533</ArticleId><ArticleId IdType="pubmed">24811377</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji R.R., Chamessian A., Zhang Y.Q. Pain regulation by non-neuronal cells and inflammation. Science. 2016;354:572&#x2013;577. doi: 10.1126/science.aaf8924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf8924</ArticleId><ArticleId IdType="pmc">PMC5488328</ArticleId><ArticleId IdType="pubmed">27811267</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossipov M.H., Dussor G.O., Porreca F. Central modulation of pain. J. Clin. Investig. 2010;120:3779&#x2013;3787. doi: 10.1172/JCI43766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI43766</ArticleId><ArticleId IdType="pmc">PMC2964993</ArticleId><ArticleId IdType="pubmed">21041960</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholz J., Woolf C.J. Can we conquer pain? Nat. Neurosci. 2002;5:1062&#x2013;1067. doi: 10.1038/nn942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn942</ArticleId><ArticleId IdType="pubmed">12403987</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron R., Binder A., Wasner G. Neuropathic Pain: Diagnosis, Pathophysiological Mechanisms, and Treatment. Lancet Neurol. 2010;9:807&#x2013;819. doi: 10.1016/S1474-4422(10)70143-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70143-5</ArticleId><ArticleId IdType="pubmed">20650402</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavaletti G., Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat. Rev. Neurol. 2010;6:657&#x2013;666. doi: 10.1038/nrneurol.2010.160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2010.160</ArticleId><ArticleId IdType="pubmed">21060341</ArticleId></ArticleIdList></Reference><Reference><Citation>Hershman D.L., Lacchetti C., Dworkin R.H., Lavoie Smith E.M., Bleeker J., Cavaletti G., Chauhan C., Gavin P., Lavino A., Lustberg M.B., et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 2014;32:1941&#x2013;1967. doi: 10.1200/JCO.2013.54.0914.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2013.54.0914</ArticleId><ArticleId IdType="pubmed">24733808</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan L., Zhang X.-D., Miao W.-Y., Sun Y.-J., Xiong G., Wu Q., Li G., Yang P., Yu H., Li H., et al. PDGFR&#x3b2; Cells Rapidly Relay Inflammatory Signal from the Circulatory System to Neurons via Chemokine CCL2. Neuron. 2018;100:183&#x2013;200.e8. doi: 10.1016/j.neuron.2018.08.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.08.030</ArticleId><ArticleId IdType="pubmed">30269986</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., Fang X., Zhan G., Huang N., Li S., Bi J., Jiang R., Yang L., Miao L., Zhu B., et al. Key role of gut microbiota in anhedonia-like phenotype in rodents with neuropathic pain. Transl. Psychiatry. 2019;9:57. doi: 10.1038/s41398-019-0379-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-019-0379-8</ArticleId><ArticleId IdType="pmc">PMC6355832</ArticleId><ArticleId IdType="pubmed">30705252</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y.J., Ji R.R. Chemokines, Neuronal-Glial Interactions, and Central Processing of Neuropathic Pain. Pharmacol. Ther. 2010;126:56&#x2013;68. doi: 10.1016/j.pharmthera.2010.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2010.01.002</ArticleId><ArticleId IdType="pmc">PMC2839017</ArticleId><ArticleId IdType="pubmed">20117131</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda M., Huh Y., Ji R.R. Roles of Inflammation, Neurogenic Inflammation, and Neuroinflammation in Pain. J. Anesth. 2019;33:131&#x2013;139. doi: 10.1007/s00540-018-2579-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00540-018-2579-4</ArticleId><ArticleId IdType="pmc">PMC6813778</ArticleId><ArticleId IdType="pubmed">30448975</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampson T.R., Debelius J.W., Thron T., Janssen S., Shastri G.G., Ilhan Z.E., Challis C., Schretter C.E., Rocha S., Gradinaru V., et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson&#x2019;s Disease. Cell. 2016;167:1469&#x2013;1480.e12. doi: 10.1016/j.cell.2016.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.11.018</ArticleId><ArticleId IdType="pmc">PMC5718049</ArticleId><ArticleId IdType="pubmed">27912057</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding W., You Z., Chen Q., Yang L., Doheny J., Zhou X., Li N., Wang S., Hu K., Chen L., et al. Gut Microbiota Influences Neuropathic Pain through Modulating Proinflammatory and Anti-inflammatory T Cells. Anesth. Analg. 2021;132:1146&#x2013;1155. doi: 10.1213/ANE.0000000000005155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ANE.0000000000005155</ArticleId><ArticleId IdType="pubmed">32889847</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J., Zhang C., Wang J., Guo Q., Zou W. Oral Lactobacillus reuteri LR06 or Bifidobacterium BL5b supplement do not produce analgesic effects on neuropathic and inflammatory pain in rats. Brain Behav. 2019;9:e01260. doi: 10.1002/brb3.1260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.1260</ArticleId><ArticleId IdType="pmc">PMC6456777</ArticleId><ArticleId IdType="pubmed">30839179</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukaida N. Intestinal microbiota: Unexpected alliance with tumor therapy. Immunotherapy. 2014;6:231&#x2013;233. doi: 10.2217/imt.13.170.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/imt.13.170</ArticleId><ArticleId IdType="pubmed">24762069</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe1;zquez-Baeza Y., Callewaert C., Debelius J., Hyde E., Marotz C., Morton J.T., Swafford A., Vrbanac A., Dorrestein P.C., Knight R. Impacts of the Human Gut Microbiome on Therapeutics. Annu. Rev. Pharmacol. Toxicol. 2018;58:253&#x2013;270. doi: 10.1146/annurev-pharmtox-042017-031849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-042017-031849</ArticleId><ArticleId IdType="pubmed">28968189</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen S., Lim G., You Z., Ding W., Huang P., Ran C., Doheny J., Caravan P., Tate S., Hu K., et al. Gut microbiota is critical for the induction of chemotherapy-induced pain. Nat. Neurosci. 2017;20:1213&#x2013;1216. doi: 10.1038/nn.4606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4606</ArticleId><ArticleId IdType="pmc">PMC5575957</ArticleId><ArticleId IdType="pubmed">28714953</ArticleId></ArticleIdList></Reference><Reference><Citation>Castelli V., Palumbo P., D&#x2019;Angelo M., Moorthy N.K., Antonosante A., Catanesi M., Lombardi F., Iannotta D., Cinque B., Benedetti E., et al. Probiotic DSF counteracts chemotherapy induced neuropathic pain. Oncotarget. 2018;9:27998&#x2013;28008. doi: 10.18632/oncotarget.25524.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.25524</ArticleId><ArticleId IdType="pmc">PMC6021327</ArticleId><ArticleId IdType="pubmed">29963257</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang I., Yong P.J., Allaire C., Bedaiwy M.A. Intricate Connections between the Microbiota and Endometriosis. Int. J. Mol. Sci. 2021;22:5644. doi: 10.3390/ijms22115644.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22115644</ArticleId><ArticleId IdType="pmc">PMC8198999</ArticleId><ArticleId IdType="pubmed">34073257</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper L.v., Littman D.R., Macpherson A.J. Interactions between the Microbiota and the Immune System. Science. 2012;336:1268&#x2013;1273. doi: 10.1126/science.1223490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1223490</ArticleId><ArticleId IdType="pmc">PMC4420145</ArticleId><ArticleId IdType="pubmed">22674334</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin D.H., Marrazzo J.M. The Vaginal Microbiome: Current Understanding and Future Directions. J. Infect. Dis. 2016;214((Suppl. 1)):S36&#x2013;S41. doi: 10.1093/infdis/jiw184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw184</ArticleId><ArticleId IdType="pmc">PMC4957511</ArticleId><ArticleId IdType="pubmed">27449871</ArticleId></ArticleIdList></Reference><Reference><Citation>Muzny C.A., &#x141;aniewski P., Schwebke J.R., Herbst-Kralovetz M.M. Host-Vaginal Microbiota Interactions in the Pathogenesis of Bacterial Vaginosis. Curr. Opin. Infect. Dis. 2020;33:59&#x2013;65. doi: 10.1097/QCO.0000000000000620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QCO.0000000000000620</ArticleId><ArticleId IdType="pmc">PMC7265982</ArticleId><ArticleId IdType="pubmed">31789672</ArticleId></ArticleIdList></Reference><Reference><Citation>Blander J.M., Longman R.S., Iliev I.D., Sonnenberg G.F., Artis D. Regulation of Inflammation by Microbiota Interactions with the Host. Nat. Immunol. 2017;18:851&#x2013;860. doi: 10.1038/ni.3780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3780</ArticleId><ArticleId IdType="pmc">PMC5800875</ArticleId><ArticleId IdType="pubmed">28722709</ArticleId></ArticleIdList></Reference><Reference><Citation>Dols J.A.M., Molenaar D., van der Helm J.J., Caspers M.P.M., Angelino-Bart A.d.K., Schuren F.H.J., Speksnijder A.G.C.L., Westerhoff H.V., Richardus J.H., Boon M.E., et al. Molecular Assessment of Bacterial Vaginosis by Lactobacillus Abundance and Species Diversity. BMC Infect. Dis. 2016;16:180. doi: 10.1186/s12879-016-1513-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-016-1513-3</ArticleId><ArticleId IdType="pmc">PMC4841971</ArticleId><ArticleId IdType="pubmed">27107961</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker J.M., Chase D.M., Herbst-Kralovetz M.M. Uterine Microbiota: Residents, Tourists, or Invaders? Front. Immunol. 2018;9:208. doi: 10.3389/fimmu.2018.00208.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00208</ArticleId><ArticleId IdType="pmc">PMC5840171</ArticleId><ArticleId IdType="pubmed">29552006</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf8;ller B.R., Kristiansen F.v., Thorsen P., Frost L., Mogensen S.C. Sterility of the Uterine Cavity. Acta Obstet. Gynecol. Scand. 1995;74:216&#x2013;219. doi: 10.3109/00016349509008942.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00016349509008942</ArticleId><ArticleId IdType="pubmed">7900526</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno I., Codo&#xf1;er F.M., Vilella F., Valbuena D., Martinez-Blanch J.F., Jimenez-Almaz&#xe1;n J., Alonso R., Alam&#xe1; P., Remoh&#xed; J., Pellicer A., et al. Evidence that the Endometrial Microbiota Has an Effect on Implantation Success or Failure. Am. J. Obstet. Gynecol. 2016;215:684&#x2013;703. doi: 10.1016/j.ajog.2016.09.075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2016.09.075</ArticleId><ArticleId IdType="pubmed">27717732</ArticleId></ArticleIdList></Reference><Reference><Citation>Ata B., Yildiz S., Turkgeldi E., Brocal V.P., Dinleyici E.C., Moya A., Urman B. The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls. Sci. Rep. 2019;9:2204. doi: 10.1038/s41598-019-39700-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-39700-6</ArticleId><ArticleId IdType="pmc">PMC6379373</ArticleId><ArticleId IdType="pubmed">30778155</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourlev V., Volkov N., Pavlovitch S., Lets N., Larsson A., Olovsson M. The relationship between microvessel density, proliferative activity and expression of vascular endothelial growth factor-A and its receptors in eutopic endometrium and endometriotic lesions. Reproduction. 2006;132:501&#x2013;509. doi: 10.1530/rep.1.01110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/rep.1.01110</ArticleId><ArticleId IdType="pubmed">16940291</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandes C., Silveira P., Rodrigues Sereia A.F., Christoff A.P., Mendes H., Valter de Oliveira L.F., Podgaec S. Microbiome Profile of Deep Endometriosis Patients: Comparison of Vaginal Fluid, Endometrium and Lesion. Diagnostics. 2020;10:163. doi: 10.3390/diagnostics10030163.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics10030163</ArticleId><ArticleId IdType="pmc">PMC7151170</ArticleId><ArticleId IdType="pubmed">32192080</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama K., Nishioka K., Khan K.N., Tanaka Y., Mori T., Nakaya T., Kitawaki J. Molecular detection of microbial colonization in cervical mucus of women with and without endometriosis. Am. J. Reprod. Immunol. 2019;82:e13147. doi: 10.1111/aji.13147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aji.13147</ArticleId><ArticleId IdType="pubmed">31087436</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W., Zhang X., Tang H., Zeng L., Wu R. Microbiota Composition and Distribution along the Female Reproductive Tract of Women with Endometriosis. Ann. Clin. Microbiol. Antimicrob. 2020;19:15. doi: 10.1186/s12941-020-00356-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12941-020-00356-0</ArticleId><ArticleId IdType="pmc">PMC7161132</ArticleId><ArticleId IdType="pubmed">32299442</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrotta A.R., Borrelli G.M., Martins C.O., Kallas E.G., Sanabani S.S., Griffith L.G., Alm E.J., Abrao M.S. The Vaginal Microbiome as a Tool to Predict rASRM Stage of Disease in Endometriosis: A Pilot Study. Reprod. Sci. 2020;27:1064&#x2013;1073. doi: 10.1007/s43032-019-00113-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43032-019-00113-5</ArticleId><ArticleId IdType="pmc">PMC7539818</ArticleId><ArticleId IdType="pubmed">32046455</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng T., Shang A., Zheng Y., Zhang L., Sun H., Wang W. Log (Lactobacillus crispatus/Gardnerella vaginalis): A new indicator of diagnosing bacterial vaginosis. Bioengineered. 2022;13:2981&#x2013;2991. doi: 10.1080/21655979.2022.2027059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21655979.2022.2027059</ArticleId><ArticleId IdType="pmc">PMC8974220</ArticleId><ArticleId IdType="pubmed">35038957</ArticleId></ArticleIdList></Reference><Reference><Citation>Tohill B.C., Heilig C.M., Klein R.S., Rompalo A., Cu-Uvin S., Brown W., Duerr A. Vaginal flora morphotypic profiles and assessment of bacterial vaginosis in women at risk for HIV infection. Infect. Dis. Obstet. Gynecol. 2004;12:121&#x2013;126. doi: 10.1080/10647440400020711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10647440400020711</ArticleId><ArticleId IdType="pmc">PMC1784599</ArticleId><ArticleId IdType="pubmed">15763911</ArticleId></ArticleIdList></Reference><Reference><Citation>Dols J.A., Smit P.W., Kort R., Reid G., Schuren F.H., Tempelman H., Bontekoe T.R., Korporaal H., Boon M.E. Microarray-Based Identification of Clinically Relevant Vaginal Bacteria in Relation to Bacterial Vaginosis. Am. J. Obstet. Gynecol. 2011;204:305.e1&#x2013;305.e7. doi: 10.1016/j.ajog.2010.11.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2010.11.012</ArticleId><ArticleId IdType="pubmed">21272848</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstraelen H., Verhelst R. Bacterial vaginosis: An update on Diagnosis and Treatment. Expert Rev. Anti Infect. Ther. 2009;7:1109&#x2013;1124. doi: 10.1586/eri.09.87.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/eri.09.87</ArticleId><ArticleId IdType="pubmed">19883331</ArticleId></ArticleIdList></Reference><Reference><Citation>James S.L., Abate D., Abate K.H., Abay S.M., Abbafati C., Abbasi N., Abbastar H., Abd-Allah F., Abdela J., Abdelalim A., et al. Global, Regional, and National Incidence, Prevalence, and Years Lived with Disability for 354 Diseases and Injuries for 195 Countries and Territories, 1990&#x2013;2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789&#x2013;1858. doi: 10.1016/S0140-6736(18)32279-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)32279-7</ArticleId><ArticleId IdType="pmc">PMC6227754</ArticleId><ArticleId IdType="pubmed">30496104</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaskin D.J., Richard P. The Economic Costs of Pain in the United States. J. Pain. 2012;13:715&#x2013;724. doi: 10.1016/j.jpain.2012.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpain.2012.03.009</ArticleId><ArticleId IdType="pubmed">22607834</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoskes D.A., Wang H., Polackwich A.S., Tucky B., Altemus J., Eng C. Analysis of Gut Microbiome Reveals Significant Differences between Men with Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Controls. J. Urol. 2016;196:435&#x2013;441. doi: 10.1016/j.juro.2016.02.2959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2016.02.2959</ArticleId><ArticleId IdType="pubmed">26930255</ArticleId></ArticleIdList></Reference><Reference><Citation>Du H.X., Yue S.Y., Niu D., Liu C., Zhang L.G., Chen J., Chen Y., Guan Y., Xiao-Liang H., Chun L., et al. Gut Microflora Modulates Th17/Treg Cell Differentiation in Experimental Autoimmune Prostatitis via the Short-Chain Fatty Acid Propionate. Front. Immunol. 2022;13:1. doi: 10.3389/fimmu.2022.915218.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.915218</ArticleId><ArticleId IdType="pmc">PMC9289123</ArticleId><ArticleId IdType="pubmed">35860242</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohadian Moghadam S., Momeni S.A. Human Microbiome and Prostate Cancer Development: Current Insights into the Prevention and Treatment. Front. Med. 2021;15:11&#x2013;32. doi: 10.1007/s11684-019-0731-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11684-019-0731-7</ArticleId><ArticleId IdType="pubmed">32607819</ArticleId></ArticleIdList></Reference><Reference><Citation>Crocetto F., Boccellino M., Barone B., di Zazzo E., Sciarra A., Galasso G., Settembre G., Quagliuolo L., Imbimbo C., Boffo S., et al. The Crosstalk between Prostate Cancer and Microbiota Inflammation: Nutraceutical Products Are Useful to Balance This Interplay? Nutrients. 2020;12:2648. doi: 10.3390/nu12092648.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12092648</ArticleId><ArticleId IdType="pmc">PMC7551491</ArticleId><ArticleId IdType="pubmed">32878054</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman-Enyart A., Yaggie R.E., Bollinger J.L., Arvanitis C., Winter D.R., Schaeffer A.J., Klumpp D.J. Acyloxyacyl Hydrolase Regulates Microglia-Mediated Pelvic Pain. Streicher JM, Editor. PLoS ONE. 2022;17:e0269140. doi: 10.1371/journal.pone.0269140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0269140</ArticleId><ArticleId IdType="pmc">PMC9387837</ArticleId><ArticleId IdType="pubmed">35980963</ArticleId></ArticleIdList></Reference><Reference><Citation>Moloney R.D., Johnson A.C., O&#x2019;Mahony S.M., Dinan T.G., Greenwood-Van Meerveld B., Cryan J.F. Stress and the Microbiota&#x2013;Gut&#x2013;Brain Axis in Visceral Pain: Relevance to Irritable Bowel Syndrome. CNS Neurosci. Ther. 2016;22:102. doi: 10.1111/cns.12490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.12490</ArticleId><ArticleId IdType="pmc">PMC6492884</ArticleId><ArticleId IdType="pubmed">26662472</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean M.H., Dieguez D., Miller L.M., Young H.A. Does the Microbiota Play a Role in the Pathogenesis of Autoimmune Diseases? Gut. 2015;64:332&#x2013;341. doi: 10.1136/gutjnl-2014-308514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2014-308514</ArticleId><ArticleId IdType="pmc">PMC6288812</ArticleId><ArticleId IdType="pubmed">25416067</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheehan D., Moran C., Shanahan F. The Microbiota in Inflammatory Bowel Disease. J. Gastroenterol. 2015;50:495&#x2013;507. doi: 10.1007/s00535-015-1064-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00535-015-1064-1</ArticleId><ArticleId IdType="pubmed">25808229</ArticleId></ArticleIdList></Reference><Reference><Citation>Valitutti F., Cucchiara S., Fasano A. Celiac disease and the microbiome. Nutrients. 2019;11:2403. doi: 10.3390/nu11102403.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11102403</ArticleId><ArticleId IdType="pmc">PMC6835875</ArticleId><ArticleId IdType="pubmed">31597349</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicentini F.A., Keenan C.M., Wallace L.E., Woods C., Cavin J.-B., Flockton A.R., Macklin W.B., Belkind-Gerson J., Hirota S.A., Sharkey K.A. Intestinal Microbiota Shapes Gut Physiology and Regulates Enteric Neurons and Glia. Microbiome. 2021;9:210. doi: 10.1186/s40168-021-01165-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40168-021-01165-z</ArticleId><ArticleId IdType="pmc">PMC8549243</ArticleId><ArticleId IdType="pubmed">34702353</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma G., Lynch M.D.J., Lu J., Dang V.T., Deng Y., Jury J., Umeh G., Miranda P.M., Pastor M.P., Sidani S., et al. Transplantation of Fecal Microbiota from Patients with Irritable Bowel Syndrome Alters Gut Function and Behavior in Recipient Mice. Sci. Transl. Med. 2017;9:eaaf6397. doi: 10.1126/scitranslmed.aaf6397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf6397</ArticleId><ArticleId IdType="pubmed">28251905</ArticleId></ArticleIdList></Reference><Reference><Citation>Crouzet L., Gaultier E., Del&#x2019;Homme C., Cartier C., Delmas E., Dapoigny M., Fioramonti J., Bernalier-Donadille A. The Hypersensitivity to Colonic Distension of IBS Patients Can Be Transferred to Rats through Their Fecal Microbiota. Neurogastroenterol. Motil. 2013;25:e272&#x2013;e282. doi: 10.1111/nmo.12103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12103</ArticleId><ArticleId IdType="pubmed">23433203</ArticleId></ArticleIdList></Reference><Reference><Citation>Malinen E., Rinttil&#xe4; T., Kajander K., M&#xe4;tt&#xf6; J., Kassinen A., Krogius L., Saarela M., Korpela R., Palva A. Analysis of the Fecal Microbiota of Irritable Bowel Syndrome Patients and Healthy Controls with Real-Time PCR. Am. J. Gastroenterol. 2005;100:373&#x2013;382. doi: 10.1111/j.1572-0241.2005.40312.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2005.40312.x</ArticleId><ArticleId IdType="pubmed">15667495</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyra A., Rinttil&#xe4; T., Nikkil&#xe4; J., Krogius-Kurikka L., Kajander K., Malinen E., M&#xe4;tt&#xf6; J., M&#xe4;kel&#xe4; L., Palva A. &#x2018;Diarrhoea-Predominant Irritable Bowel Syndrome Distinguishable by 16S rRNA Gene Phylotype Quantification. World J Gastroenterol. 2009;15:5936&#x2013;5945. doi: 10.3748/wjg.15.5936.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.15.5936</ArticleId><ArticleId IdType="pmc">PMC2795180</ArticleId><ArticleId IdType="pubmed">20014457</ArticleId></ArticleIdList></Reference><Reference><Citation>Tana C., Umesaki Y., Imaoka A., Handa T., Kanazawa M., Fukudo S. Altered Profiles of Intestinal Microbiota and Organic Acids May be the Origin of Symptoms in Irritable Bowel Syndrome. Neurogastroenterol. Motil. 2010;22:512-e115. doi: 10.1111/j.1365-2982.2009.01427.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2009.01427.x</ArticleId><ArticleId IdType="pubmed">19903265</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer E.A., Savidge T., Shulman R.J. Brain-Gut Microbiome Interactions and Functional Bowel Disorders. Gastroenterology. 2014;146:1500&#x2013;1512. doi: 10.1053/j.gastro.2014.02.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2014.02.037</ArticleId><ArticleId IdType="pmc">PMC4114504</ArticleId><ArticleId IdType="pubmed">24583088</ArticleId></ArticleIdList></Reference><Reference><Citation>Maccaferri S., Candela M., Turroni S., Centanni M., Severgnini M., Consolandi C., Cavina P., Brigidi P. IBS-Associated Phylogenetic Unbalances of the Intestinal Microbiota Are Not Reverted by Probiotic Supplementation. Gut Microbes. 2012;3:406&#x2013;413. doi: 10.4161/gmic.21009.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/gmic.21009</ArticleId><ArticleId IdType="pubmed">22713265</ArticleId></ArticleIdList></Reference><Reference><Citation>Noor S.O., Ridgway K., Scovell L., Kemsley E.K., Lund E.K., Jamieson C., Johnson I.T., Narbad A. Ulcerative Colitis and Irritable Bowel Patients Exhibit Distinct Abnormalities of the Gut Microbiota. BMC Gastroenterol. 2010;10:134. doi: 10.1186/1471-230X-10-134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-230X-10-134</ArticleId><ArticleId IdType="pmc">PMC3002299</ArticleId><ArticleId IdType="pubmed">21073731</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittayanon R., Lau J.T., Yuan Y., Leontiadis G.I., Tse F., Surette M., Moayyedi P. Gut Microbiota in Patients with Irritable Bowel Syndrome-A Systematic Review. Gastroenterology. 2019;157:97&#x2013;108. doi: 10.1053/j.gastro.2019.03.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2019.03.049</ArticleId><ArticleId IdType="pubmed">30940523</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisson G., Ayis S., Sherwood R.A., Bjarnason I. Randomised Clinical Trial: A Liquid Multi-Strain Probiotic vs. Placebo in the Irritable Bowel Syndrome&#x2014;A 12 Week Double-Blind Study. Aliment. Pharmacol. Ther. 2014;40:51&#x2013;62. doi: 10.1111/apt.12787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.12787</ArticleId><ArticleId IdType="pubmed">24815298</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglielmetti S., Mora D., Gschwender M., Popp K. Randomised Clinical Trial: Bifidobacterium bifidum MIMBb75 Significantly Alleviates Irritable Bowel Syndrome and Improves Quality of Life&#x2014;A Double-Blind, Placebo-Controlled Study. Aliment. Pharmacol. Ther. 2011;33:1123&#x2013;1132. doi: 10.1111/j.1365-2036.2011.04633.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2011.04633.x</ArticleId><ArticleId IdType="pubmed">21418261</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon J.S., Sohn W., Lee O.Y., Lee S.P., Lee K.N., Jun D.W., Lee H.L., Yoon B.C., Choi H.S., Chung W.S., et al. Effect of Multispecies Probiotics on Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. J. Gastroenterol. Hepatol. 2014;29:52&#x2013;59. doi: 10.1111/jgh.12322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.12322</ArticleId><ArticleId IdType="pubmed">23829297</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Siles M., Duncan S.H., Garcia-Gil L.J., Martinez-Medina M. Faecalibacterium prausnitzii: From Microbiology to Diagnostics and Prognostics. ISME J. 2017;11:841&#x2013;852. doi: 10.1038/ismej.2016.176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ismej.2016.176</ArticleId><ArticleId IdType="pmc">PMC5364359</ArticleId><ArticleId IdType="pubmed">28045459</ArticleId></ArticleIdList></Reference><Reference><Citation>Sessenwein J.L., Baker C.C., Pradhananga S., Maitland M.E., Petrof E.O., Allen-Vercoe E., Noordhof C., Reed D.E., Vanner S.J., Lomax A.E. Protease-Mediated Suppression of DRG Neuron Excitability by Commensal Bacteria. J. Neurosci. 2017;37:11758&#x2013;11768. doi: 10.1523/JNEUROSCI.1672-17.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1672-17.2017</ArticleId><ArticleId IdType="pmc">PMC5707769</ArticleId><ArticleId IdType="pubmed">29089436</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomax A.E., Pradhananga S., Sessenwein J.L., O&#x2019;Malley D. Bacterial modulation of visceral sensation: Mediators and mechanisms. Am. J. Physiol. Gastrointest. Liver Physiol. 2019;317:G363&#x2013;G372. doi: 10.1152/ajpgi.00052.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00052.2019</ArticleId><ArticleId IdType="pubmed">31290688</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradhananga S., Tashtush A.A., Allen-Vercoe E., Petrof E.O., Lomax A.E. Protease-dependent excitation of nodose ganglion neurons by commensal gut bacteria. J. Physiol. 2020;598:2137&#x2013;2151. doi: 10.1113/JP279075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP279075</ArticleId><ArticleId IdType="pubmed">32134496</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto-Sanchez M.I., Hall G.B., Ghajar K., Nardelli A., Bolino C., Lau J.T., Martin F.-P., Cominetti O., Welsh C., Rieder A., et al. Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients with Irritable Bowel Syndrome. Gastroenterology. 2017;153:448&#x2013;459.e8. doi: 10.1053/j.gastro.2017.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2017.05.003</ArticleId><ArticleId IdType="pubmed">28483500</ArticleId></ArticleIdList></Reference><Reference><Citation>Morreale C., Bresesti I., Bosi A., Baj A., Giaroni C., Agosti M., Salvatore S. Microbiota and Pain: Save Your Gut Feeling. Cells. 2022;11:971. doi: 10.3390/cells11060971.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11060971</ArticleId><ArticleId IdType="pmc">PMC8946251</ArticleId><ArticleId IdType="pubmed">35326422</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawe G.M., Hoffman J.M. Serotonin Signalling in the Gut-Functions, Dysfunctions and Therapeutic Targets. Nat. Rev. Gastroenterol. Hepatol. 2013;10:473&#x2013;486. doi: 10.1038/nrgastro.2013.105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2013.105</ArticleId><ArticleId IdType="pmc">PMC4048923</ArticleId><ArticleId IdType="pubmed">23797870</ArticleId></ArticleIdList></Reference><Reference><Citation>Gershon M.D. Review Article: Serotonin Receptors and Transporters&#x2014;Roles in Normal and Abnormal Gastrointestinal Motility. Aliment. Pharmacol. Ther. Supplement. 2004;20:3&#x2013;14. doi: 10.1111/j.1365-2036.2004.02180.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2004.02180.x</ArticleId><ArticleId IdType="pubmed">15521849</ArticleId></ArticleIdList></Reference><Reference><Citation>Costedio M.M., Hyman N., Mawe G.M. Serotonin and its role in colonic function and in gastrointestinal disorders. Dis. Colon. Rectum. 2007;50:376&#x2013;388. doi: 10.1007/s10350-006-0763-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10350-006-0763-3</ArticleId><ArticleId IdType="pubmed">17195902</ArticleId></ArticleIdList></Reference><Reference><Citation>Bistoletti M., Bosi A., Banfi D., Giaroni C., Baj A. The Microbiota-Gut-Brain Axis: Focus on the Fundamental Communication Pathways. Prog. Mol. Biol. Transl. Sci. 2020;176:43&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">33814115</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuwahara A., Matsuda K., Kuwahara Y., Asano S., Inui T., Marunaka Y. Microbiota-gut-brain axis: Enteroendocrine cells and the enteric nervous system form an interface between the microbiota and the central nervous system. Biomed. Res. 2020;41:199&#x2013;216. doi: 10.2220/biomedres.41.199.</Citation><ArticleIdList><ArticleId IdType="doi">10.2220/biomedres.41.199</ArticleId><ArticleId IdType="pubmed">33071256</ArticleId></ArticleIdList></Reference><Reference><Citation>Baj A., Moro E., Bistoletti M., Orlandi V., Crema F., Giaroni C. Glutamatergic Signaling Along the Microbiota-Gut-Brain Axis. Int. J. Mol. Sci. 2019;20:1482. doi: 10.3390/ijms20061482.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20061482</ArticleId><ArticleId IdType="pmc">PMC6471396</ArticleId><ArticleId IdType="pubmed">30934533</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosi A., Banfi D., Bistoletti M., Giaroni C., Baj A. Tryptophan Metabolites Along the Microbiota-Gut-Brain Axis: An Interkingdom Communication System Influencing the Gut in Health and Disease. Int. J. Tryptophan. Res. 2020;13:1178646920928984. doi: 10.1177/1178646920928984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1178646920928984</ArticleId><ArticleId IdType="pmc">PMC7290275</ArticleId><ArticleId IdType="pubmed">32577079</ArticleId></ArticleIdList></Reference><Reference><Citation>Varela R.B., Valvassori S.S., Lopes-Borges J., Mariot E., Dal-Pont G.C., Amboni R.T., Bianchini G., Quevedo J. Sodium butyrate and Mood Stabilizers Block Ouabain-Induced Hyperlocomotion and Increase BDNF, NGF and GDNF Levels in Brain of Wistar Rats. J. Psychiatr. Res. 2015;61:114&#x2013;121. doi: 10.1016/j.jpsychires.2014.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2014.11.003</ArticleId><ArticleId IdType="pubmed">25467060</ArticleId></ArticleIdList></Reference><Reference><Citation>Jornada L.K., Moretti M., Valvassori S.S., Ferreira C.L., Padilha P.T., Arent C.O., Fries G.R., Kapczinski F., Quevedo J. Effects of mood stabilizers on hippocampus and amygdala BDNF levels in an animal model of mania induced by ouabain. J. Psychiatr. Res. 2010;44:506&#x2013;510. doi: 10.1016/j.jpsychires.2009.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2009.11.002</ArticleId><ArticleId IdType="pubmed">19954800</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo C., Huo Y.J., Li Y., Han Y., Zhou D. Gut-Brain Axis: Focus on Gut Metabolites Short-Chain Fatty Acids. World J. Clin. Cases. 2022;10:1754&#x2013;1763. doi: 10.12998/wjcc.v10.i6.1754.</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v10.i6.1754</ArticleId><ArticleId IdType="pmc">PMC8891794</ArticleId><ArticleId IdType="pubmed">35317140</ArticleId></ArticleIdList></Reference><Reference><Citation>Agus A., Planchais J., Sokol H. Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease. Cell Host Microbe. 2018;23:716&#x2013;724. doi: 10.1016/j.chom.2018.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2018.05.003</ArticleId><ArticleId IdType="pubmed">29902437</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez S., Rodr&#xed;guez-Sanoja R., Ramos A., Demain A.L. Our Microbes Not Only Produce Antibiotics, They Also Overproduce Amino Acids. J. Antibiot. 2017;71:26&#x2013;36. doi: 10.1038/ja.2017.142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ja.2017.142</ArticleId><ArticleId IdType="pubmed">29089597</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendisch V.F., Jorge J.M.P., P&#xe9;rez-Garc&#xed;a F., Sgobba E. Updates on industrial production of amino acids using Corynebacterium glutamicum. World J. Microbiol. Biotechnol. 2016;32:105. doi: 10.1007/s11274-016-2060-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11274-016-2060-1</ArticleId><ArticleId IdType="pubmed">27116971</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayama Y., Hashimoto K.-i., Sawada Y., Sokabe M., Kawasaki H., Martinac B. Corynebacterium glutamicum Mechanosensitive Channels: Towards Unpuzzling &#x201c;Glutamate Efflux&#x201d; for Amino Acid Production. Biophys. Rev. 2018;10:1359&#x2013;1369. doi: 10.1007/s12551-018-0452-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12551-018-0452-1</ArticleId><ArticleId IdType="pmc">PMC6233337</ArticleId><ArticleId IdType="pubmed">30209745</ArticleId></ArticleIdList></Reference><Reference><Citation>Zareian M., Ebrahimpour A., Bakar F.A., Mohamed A.K.S., Forghani B., Ab-Kadir M.S.B., Saari M. A Glutamic Acid-Producing Lactic Acid Bacteria Isolated from Malaysian Fermented Foods. Int. J. Mol. Sci. 2012;13:5482&#x2013;5497. doi: 10.3390/ijms13055482.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms13055482</ArticleId><ArticleId IdType="pmc">PMC3382744</ArticleId><ArticleId IdType="pubmed">22754309</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Wang R., Bai T., Xiang X., Qian W., Song J., Hou X. EphrinB2/ephB2-Mediated Myenteric Synaptic Plasticity: Mechanisms Underlying the Persistent Muscle Hypercontractility and Pain in Postinfectious IBS. FASEB J. 2019;33:13644&#x2013;13659. doi: 10.1096/fj.201901192R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201901192R</ArticleId><ArticleId IdType="pubmed">31601124</ArticleId></ArticleIdList></Reference><Reference><Citation>Neunlist M., Michel K., Reiche D., Dobreva G., Huber K., Schemann M. Glycine Activates Myenteric Neurones in Adult Guinea-Pigs. J. Physiol. 2001;536:727&#x2013;739. doi: 10.1111/j.1469-7793.2001.00727.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-7793.2001.00727.x</ArticleId><ArticleId IdType="pmc">PMC2278892</ArticleId><ArticleId IdType="pubmed">11691868</ArticleId></ArticleIdList></Reference><Reference><Citation>Caputi V., Marsilio I., Filpa V., Cerantola S., Orso G., Bistoletti M., Paccagnella N., De Martin S., Montopoli M., Dall&#x2019;Acqua S., et al. Antibiotic-Induced Dysbiosis of the Microbiota Impairs Gut Neuromuscular Function in Juvenile Mice. Br. J. Pharmacol. 2017;174:3623&#x2013;3639. doi: 10.1111/bph.13965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.13965</ArticleId><ArticleId IdType="pmc">PMC5610159</ArticleId><ArticleId IdType="pubmed">28755521</ArticleId></ArticleIdList></Reference><Reference><Citation>Gronier B., Savignac H.M., Di Miceli M., Idriss S.M., Tzortzis G., Anthony D., Burnet P.W. Increased Cortical Neuronal Responses to NMDA and Improved Attentional Set-Shifting Performance in Rats following Prebiotic (B-GOS &#xae;) Ingestion. Eur. Neuropsychopharmacol. 2018;28:211&#x2013;224. doi: 10.1016/j.euroneuro.2017.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2017.11.001</ArticleId><ArticleId IdType="pmc">PMC5857269</ArticleId><ArticleId IdType="pubmed">29174530</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang C., Lin W.J., Salton S.R. Role of a VGF/BDNF/TrkB Autoregulatory Feedback Loop in Rapid-Acting Antidepressant Efficacy. J. Mol. Neurosci. 2019;68:504&#x2013;509. doi: 10.1007/s12031-018-1124-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-018-1124-0</ArticleId><ArticleId IdType="pmc">PMC6338529</ArticleId><ArticleId IdType="pubmed">30022437</ArticleId></ArticleIdList></Reference><Reference><Citation>Bravo J.A., Forsythe P., Chew M.V., Escaravage E., Savignac H.M., Dinan T.G., Bienenstock J., Cryan J.F. Ingestion of Lactobacillus Strain Regulates Emotional Behavior and Central GABA Receptor Expression in a Mouse Via the Vagus Nerve. Proc. Natl. Acad. Sci. USA. 2011;108:16050&#x2013;16055. doi: 10.1073/pnas.1102999108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1102999108</ArticleId><ArticleId IdType="pmc">PMC3179073</ArticleId><ArticleId IdType="pubmed">21876150</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Berezo T., Pujo J., Martin P., Le Faouder P., Galano J.-M., Guy A., Knauf C., Tabet J.C., Tronnet S., Barreau F., et al. Identification of an Analgesic Lipopeptide Produced by the Probiotic Escherichia coli Strain Nissle 1917. Nat. Commun. 2017;8:1314. doi: 10.1038/s41467-017-01403-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-01403-9</ArticleId><ArticleId IdType="pmc">PMC5670229</ArticleId><ArticleId IdType="pubmed">29101366</ArticleId></ArticleIdList></Reference><Reference><Citation>May A. Hints on Diagnosing and Treating Headache. Dtsch. Arztebl. Int. 2018;115:299&#x2013;308. doi: 10.3238/arztebl.2018.0299.</Citation><ArticleIdList><ArticleId IdType="doi">10.3238/arztebl.2018.0299</ArticleId><ArticleId IdType="pmc">PMC5974268</ArticleId><ArticleId IdType="pubmed">29789115</ArticleId></ArticleIdList></Reference><Reference><Citation>Aurora S.K., Shrewsbury S.B., Ray S., Hindiyeh N., Nguyen L. A Link between Gastrointestinal Disorders and Migraine: Insights into the Gut&#x2013;Brain Connection. Headache J. Head Face Pain. 2021;61:576&#x2013;589. doi: 10.1111/head.14099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/head.14099</ArticleId><ArticleId IdType="pmc">PMC8251535</ArticleId><ArticleId IdType="pubmed">33793965</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodick D.W. Migraine. Lancet. 2018;391:1315&#x2013;1330. doi: 10.1016/S0140-6736(18)30478-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)30478-1</ArticleId><ArticleId IdType="pubmed">29523342</ArticleId></ArticleIdList></Reference><Reference><Citation>Amaral F.A., Sachs D., Costa V.V., Fagundes C.T., Cisalpino D., Cunha T.M., Ferreira S.H., Cunha F.Q., Silva T.A., Nicoli J.R., et al. Commensal microbiota is fundamental for the development of inflammatory pain. Proc. Natl. Acad. Sci. USA. 2008;105:2193&#x2013;2197. doi: 10.1073/pnas.0711891105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0711891105</ArticleId><ArticleId IdType="pmc">PMC2538897</ArticleId><ArticleId IdType="pubmed">18268332</ArticleId></ArticleIdList></Reference><Reference><Citation>Sensenig J., Marrongelle J., Johnson M., Staverosky T. Permission Treatment of Migraine with Targeted Nutrition Focused on Improved Assimilation and Elimination. Altern. Med. Rev. 2001;6:488&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">11703169</ArticleId></ArticleIdList></Reference><Reference><Citation>De Roos N.M., van Hemert S., Rovers J.M.P., Smits M.G., Witteman B.J.M. The effects of a multispecies probiotic on migraine and markers of intestinal permeability&#x2013;results of a randomized placebo-controlled study. Eur. J. Clin. Nutr. 2017;71:1455&#x2013;1462. doi: 10.1038/ejcn.2017.57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejcn.2017.57</ArticleId><ArticleId IdType="pubmed">28537581</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith H.S. Opioid Metabolism. Mayo Clin. Proc. 2009;84:613&#x2013;624. doi: 10.1016/S0025-6196(11)60750-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0025-6196(11)60750-7</ArticleId><ArticleId IdType="pmc">PMC2704133</ArticleId><ArticleId IdType="pubmed">19567715</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappagallo M. Incidence, Prevalence, and Management of Opioid Bowel Dysfunction. Am. J. Surg. 2001;182:S11&#x2013;S18. doi: 10.1016/S0002-9610(01)00782-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9610(01)00782-6</ArticleId><ArticleId IdType="pubmed">11755892</ArticleId></ArticleIdList></Reference><Reference><Citation>Acharya C., Betrapally N.S., Gillevet P.M., Sterling R.K., Akbarali H., White M.B., Ganapathy D., Fagan A., Sikaroodi M., Bajaj J.S. Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis. Aliment. Pharmacol. Ther. 2017;45:319&#x2013;331. doi: 10.1111/apt.13858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.13858</ArticleId><ArticleId IdType="pubmed">27868217</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhave S., Gade A., Kang M., Hauser K.F., Dewey W.L., Akbarali H.I. Connexin-Purinergic Signaling in Enteric Glia Mediates the Prolonged Effect of Morphine on Constipation. FASEB J. 2017;31:2649&#x2013;2660. doi: 10.1096/fj.201601068R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201601068R</ArticleId><ArticleId IdType="pmc">PMC5434649</ArticleId><ArticleId IdType="pubmed">28280004</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang M., Mischel R.A., Bhave S., Komla E., Cho A., Huang C., Dewey W.L., Akbarali H.I. The Effect of Gut Microbiome on Tolerance to Morphine Mediated Antinociception in Mice. Sci. Rep. 2017;7:42658. doi: 10.1038/srep42658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep42658</ArticleId><ArticleId IdType="pmc">PMC5314392</ArticleId><ArticleId IdType="pubmed">28211545</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Meng J., Ban Y., Jalodia R., Chupikova I., Fernandez I., Brito N., Sharma U., Abreu M.T., Ramakrishnan S., et al. Morphine Tolerance is Attenuated in Germfree Mice and Reversed by Probiotics, Implicating the Role of Gut Microbiome. Proc. Natl. Acad. Sci. USA. 2019;116:13523&#x2013;13532. doi: 10.1073/pnas.1901182116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1901182116</ArticleId><ArticleId IdType="pmc">PMC6613141</ArticleId><ArticleId IdType="pubmed">31209039</ArticleId></ArticleIdList></Reference><Reference><Citation>Mischel R.A., Dewey W.L., Akbarali H.I. Tolerance to Morphine-Induced Inhibition of TTX-R Sodium Channels in Dorsal Root Ganglia Neurons Is Modulated by Gut-Derived Mediators. iScience. 2018;2:193&#x2013;209. doi: 10.1016/j.isci.2018.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2018.03.003</ArticleId><ArticleId IdType="pmc">PMC5993194</ArticleId><ArticleId IdType="pubmed">29888757</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams N.T. Probiotics. Am. J. Health Pharm. 2010;67:449&#x2013;458. doi: 10.2146/ajhp090168.</Citation><ArticleIdList><ArticleId IdType="doi">10.2146/ajhp090168</ArticleId><ArticleId IdType="pubmed">20208051</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora T., Singh S., Sharma R.K. Probiotics: Interaction with gut microbiome and antiobesity potential. Nutrition. 2013;29:591&#x2013;596. doi: 10.1016/j.nut.2012.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nut.2012.07.017</ArticleId><ArticleId IdType="pubmed">23287068</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng S.C., Hart A.L., Kamm M.A., Stagg A.J., Knight S.C. Mechanisms of action of probiotics: Recent advances. Inflamm. Bowel Dis. 2009;15:300&#x2013;310. doi: 10.1002/ibd.20602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ibd.20602</ArticleId><ArticleId IdType="pubmed">18626975</ArticleId></ArticleIdList></Reference><Reference><Citation>Abd El-Gawad I.A., El-Sayed E.M., Hafez S.A., El-Zeini H.M., Saleh F.A. The hypocholesterolaemic effect of milk yoghurt and soy-yoghurt containing bifidobacteria in rats fed on a cholesterol-enriched diet. Int. Dairy J. 2005;15:37&#x2013;44. doi: 10.1016/j.idairyj.2004.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idairyj.2004.06.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohland C.L., MacNaughton W.K. Probiotic bacteria and intestinal epithelial barrier function. Am. J. Physiol. Liver Physiol. 2010;298:G807&#x2013;G819. doi: 10.1152/ajpgi.00243.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00243.2009</ArticleId><ArticleId IdType="pubmed">20299599</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y.-J., Dai C., Jiang M. Mechanisms of Probiotic VSL#3 in a Rat Model of Visceral Hypersensitivity Involves the Mast Cell-PAR2-TRPV1 Pathway. Dig. Dis. Sci. 2019;64:1182&#x2013;1192. doi: 10.1007/s10620-018-5416-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-018-5416-6</ArticleId><ArticleId IdType="pubmed">30560330</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao K., Yu L., Wang X., He Y., Lu B. Clostridium butyricum regulates visceral hypersensitivity of irritable bowel syndrome by inhibiting colonic mucous low grade inflammation through its action on NLRP6. Acta Biochim. Biophys. Sin. 2018;50:216&#x2013;223. doi: 10.1093/abbs/gmx138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/abbs/gmx138</ArticleId><ArticleId IdType="pubmed">29329362</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Song L., Wang Y., Liu C., Zhang L., Zhu S., Liu S., Duan L. Beneficial effect of butyrate-producing Lachnospiraceae on stress-induced visceral hypersensitivity in rats. J. Gastroenterol. Hepatol. 2019;34:1368&#x2013;1376. doi: 10.1111/jgh.14536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.14536</ArticleId><ArticleId IdType="pmc">PMC7379616</ArticleId><ArticleId IdType="pubmed">30402954</ArticleId></ArticleIdList></Reference><Reference><Citation>Mckernan D.P., Fitzgerald P., Dinan T.G., Cryan J.F. The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat. Neurogastroenterol. Motil. 2010;22:1029-e268. doi: 10.1111/j.1365-2982.2010.01520.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2010.01520.x</ArticleId><ArticleId IdType="pubmed">20518856</ArticleId></ArticleIdList></Reference><Reference><Citation>Weizman Z., Abu-Abed J., Binsztok M. Lactobacillus reuteri DSM 17938 for the Management of Functional Abdominal Pain in Childhood: A Randomized, Double-Blind, Placebo-Controlled Trial. J. Pediatr. 2016;174:160&#x2013;164.e1. doi: 10.1016/j.jpeds.2016.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2016.04.003</ArticleId><ArticleId IdType="pubmed">27156182</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannetti E., Maglione M., Alessandrella A., Strisciuglio C., De Giovanni D., Campanozzi A., Miele E., Staiano A. A mixture of 3 bifidobacteria decreases abdominal pain and improves the quality of life in children with irritable bowel syndrome. J. Clin. Gastroenterol. 2017;51:e5&#x2013;e10. doi: 10.1097/MCG.0000000000000528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0000000000000528</ArticleId><ArticleId IdType="pubmed">27306945</ArticleId></ArticleIdList></Reference><Reference><Citation>Newlove-Delgado T., Abbott R.A., Martin A.E. Probiotics for Children with Recurrent Abdominal Pain. JAMA Pediatr. 2019;173:183&#x2013;184. doi: 10.1001/jamapediatrics.2018.4575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2018.4575</ArticleId><ArticleId IdType="pubmed">30592480</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller R., P&#xe9;lerin F., Decherf A.C., Maudet C., Housez B., Cazaubiel M., J&#xfc;sten P. Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: Improvement in abdominal pain and bloating in those with predominant constipation. United Eur. Gastroenterol. J. 2015;4:353&#x2013;362. doi: 10.1177/2050640615602571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2050640615602571</ArticleId><ArticleId IdType="pmc">PMC4924426</ArticleId><ArticleId IdType="pubmed">27403301</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannampalli P., Pochiraju S., Chichlowski M., Berg B.M., Rudolph C., Bruckert M., Miranda A., Sengupta J.N. Probiotic Lactobacillus rhamnosus GG (LGG) and prebiotic prevent neonatal inflammation-induced visceral hypersensitivity in adult rats. Neurogastroenterol. Motil. 2014;26:1694&#x2013;1704. doi: 10.1111/nmo.12450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12450</ArticleId><ArticleId IdType="pubmed">25298006</ArticleId></ArticleIdList></Reference><Reference><Citation>Vulevic J., Tzortzis G., Juric A., Gibson G.R. Effect of a prebiotic galactooligosaccharide mixture (B-GOS&#xae;) on gastrointestinal symptoms in adults selected from a general population who suffer with bloating, abdominal pain, or flatulence. Neurogastroenterol. Motil. 2018;30:e13440. doi: 10.1111/nmo.13440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13440</ArticleId><ArticleId IdType="pubmed">30109908</ArticleId></ArticleIdList></Reference><Reference><Citation>Saneian H., Pourmoghaddas Z., Roohafza H., Gholamrezaei A. Synbiotic containing Bacillus coagulans and fructo-oligosaccharides for functional abdominal pain in children. Gastroenterol. Hepatol. Bed Bench. 2015;8:56&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285933</ArticleId><ArticleId IdType="pubmed">25584177</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou S.-Y., Gillilland M., Wu X., Leelasinjaroen P., Zhang G., Zhou H., Ye B., Lu Y., Owyang C. FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction. J. Clin. Investig. 2018;128:267&#x2013;280. doi: 10.1172/JCI92390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI92390</ArticleId><ArticleId IdType="pmc">PMC5749529</ArticleId><ArticleId IdType="pubmed">29202473</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvie R. Ph.D. Thesis. University of Otago; Dunedin, New Zealand: 2014. A Reduction in FODMAP Intake Correlates Strongly with a Reduction in IBS Symptoms&#x2014;The FIBS Study.</Citation></Reference><Reference><Citation>Pedersen N., Andersen N.N., V&#xe9;gh Z., Jensen L., Ankersen D.V., Felding M., Simonsen M.H., Burisch J., Munkholm P. Ehealth: Low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome. World J. Gastroenterol. 2014;20:16215. doi: 10.3748/wjg.v20.i43.16215.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i43.16215</ArticleId><ArticleId IdType="pmc">PMC4239510</ArticleId><ArticleId IdType="pubmed">25473176</ArticleId></ArticleIdList></Reference><Reference><Citation>Hustoft T.N., Hausken T., Ystad S.O., Valeur J., Brokstad K., Hatlebakk J.G., Lied G.A. Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome. Neurogastroenterol. Motil. 2017;29:e12969. doi: 10.1111/nmo.12969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12969</ArticleId><ArticleId IdType="pubmed">27747984</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanayakkara W.S., Skidmore P.M., O&#x2019;Brien L., Wilkinson T.J., Gearry R.B. Efficacy of the low FODMAP diet for treating irritable bowel syndrome: The evidence to date. Clin. Exp. Gastroenterol. 2016;9:131&#x2013;142. doi: 10.2147/CEG.S86798.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CEG.S86798</ArticleId><ArticleId IdType="pmc">PMC4918736</ArticleId><ArticleId IdType="pubmed">27382323</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadizadeh F., Bonfiglio F., Belheouane M., Vallier M., Sauer S., Bang C., Bujanda L., Andreasson A., Agreus L., Engstrand L., et al. Faecal microbiota composition associates with abdominal pain in the general population. Gut. 2018;67:778&#x2013;779. doi: 10.1136/gutjnl-2017-314792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2017-314792</ArticleId><ArticleId IdType="pmc">PMC6058062</ArticleId><ArticleId IdType="pubmed">28765473</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucarini E., Di Pilato V., Parisio C., Micheli L., Toti A., Pacini A., Bartolucci G., Baldi S., Niccolai E., Amedei A., et al. Visceral sensitivity modulation by faecal microbiota transplantation: The active role of gut bacteria in pain persistence. Pain. 2022;163:861&#x2013;877. doi: 10.1097/j.pain.0000000000002438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/j.pain.0000000000002438</ArticleId><ArticleId IdType="pmc">PMC9009324</ArticleId><ArticleId IdType="pubmed">34393197</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoruts A., Sadowsky M.J. Understanding the mechanisms of faecal microbiota transplantation. Nat. Rev. Gastroenterol. Hepatol. 2016;13:508&#x2013;516. doi: 10.1038/nrgastro.2016.98.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2016.98</ArticleId><ArticleId IdType="pmc">PMC5909819</ArticleId><ArticleId IdType="pubmed">27329806</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz-Aguliar R.M., Wantia N., Clavel T., Vehreschild M.J.G.T., Buch T., Bajbouj M., Haller D., Busch D., Schmid R.M., Stein-Thoeringer C.K. An Open-Labeled Study on Fecal Microbiota Transfer in Irritable Bowel Syndrome Patients Reveals Improvement in Abdominal Pain Associated with the Relative Abundance of Akkermansia Muciniphila. Digestion. 2019;100:127&#x2013;138. doi: 10.1159/000494252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000494252</ArticleId><ArticleId IdType="pubmed">30423561</ArticleId></ArticleIdList></Reference><Reference><Citation>Holster S., Lindqvist C.M., Repsilber D., Salonen A., de Vos W.M., K&#xf6;nig J., Brummer R.J. The Effect of Allogenic Versus Autologous Fecal Microbiota Transfer on Symptoms, Visceral Perception and Fecal and Mucosal Microbiota in Irritable Bowel Syndrome: A Randomized Controlled Study. Clin. Transl. Gastroenterol. 2019;10:e00034. doi: 10.14309/ctg.0000000000000034.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ctg.0000000000000034</ArticleId><ArticleId IdType="pmc">PMC6602784</ArticleId><ArticleId IdType="pubmed">31009405</ArticleId></ArticleIdList></Reference><Reference><Citation>Goll R., Johnsen P.H., Hjerde E., Diab J., Valle P.C., Hilpusch F., Cavanagh J.P. Effects of fecal microbiota transplantation in subjects with irritable bowel syndrome are mirrored by changes in gut microbiome. Gut Microbes. 2020;12:1794263. doi: 10.1080/19490976.2020.1794263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2020.1794263</ArticleId><ArticleId IdType="pmc">PMC7583512</ArticleId><ArticleId IdType="pubmed">32991818</ArticleId></ArticleIdList></Reference><Reference><Citation>Borody T.J., Khoruts A. Fecal microbiota transplantation and emerging applications. Nat. Rev. Gastroenterol. Hepatol. 2011;20:88&#x2013;96. doi: 10.1038/nrgastro.2011.244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2011.244</ArticleId><ArticleId IdType="pubmed">22183182</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Nood E., Vrieze A., Nieuwdorp M., Fuentes S., Zoetendal E.G., De Vos W.M., Visser C.E., Kuijper E.J., Bartelsman J.F.W.M., Tijssen J.G.P., et al. Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile. N. Engl. J. Med. 2013;368:407&#x2013;415. doi: 10.1056/NEJMoa1205037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1205037</ArticleId><ArticleId IdType="pubmed">23323867</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S., Allen-Vercoe E., Petrof E.O. Fecal microbiota transplantation: In perspective. Therap. Adv. Gastroenterol. 2016;9:229&#x2013;239. doi: 10.1177/1756283X15607414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756283X15607414</ArticleId><ArticleId IdType="pmc">PMC4749851</ArticleId><ArticleId IdType="pubmed">26929784</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38653808</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1436-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>European journal of nutrition</Title><ISOAbbreviation>Eur J Nutr</ISOAbbreviation></Journal><ArticleTitle>Acacia fiber or probiotic supplements to relieve gastrointestinal complaints in patients with constipation-predominant IBS: a 4-week randomized double-blinded placebo-controlled intervention trial.</ArticleTitle><Pagination><StartPage>1983</StartPage><EndPage>1994</EndPage><MedlinePgn>1983-1994</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00394-024-03398-8</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To date, no adequate treatment for irritable bowel syndrome with predominant constipation complaints (IBS-C) is available. Fibers with prebiotic properties and probiotic compounds have shown promise in relieving IBS-C-related complaints. We aimed to determine the effects of a 4-week intervention with either an Acacia fiber (AF) with prebiotic properties or a probiotic Bifidobacterium Lactis (BLa80) supplement, compared to a control supplement, on stool pattern, IBS symptoms and Quality of Life (QoL), in IBS-C individuals.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A parallel, double-blind, randomized controlled trial involving 180 subjects meeting the ROME IV criteria for IBS-C was conducted. Following a 4-week observation period, subjects received either AF (10&#xa0;g), Probiotic BLa80 (4&#xa0;g; 2&#x2009;&#xd7;&#x2009;10<sup>11</sup> CFU/g) or a maltodextrin placebo (10&#xa0;g) daily for 4 weeks. Subjects reported daily information on stool pattern and gastrointestinal complaints. Before and after each 4-week period, questionnaires on symptom severity, constipation symptoms, anxiety and depression and QoL were completed. Stool mass was measured for 5-days before and after the intervention.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Stool frequency significantly improved in the AF and Probiotic BLa80 groups compared to placebo (P&#x2009;&lt;&#x2009;0.001, P&#x2009;=&#x2009;0.02, respectively). Probiotic BLa80 showed a significant reduction in IBS symptom severity (P&#x2009;=&#x2009;0.03), for AF a trend towards decreased constipation symptoms (PAC-SYM, P&#x2009;=&#x2009;0.10) was observed. No significant changes in stool consistency, stool mass or QoL measures were observed between the AF and Probiotic BLa80 compared to placebo.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Daily dietary supplementation with Acacia fiber and probiotic supplements might help IBS-C patients by relieving IBS-related complaints compared to a placebo supplement.</AbstractText><AbstractText Label="REGISTRATION NUMBER OF CLINICAL TRIAL" NlmCategory="UNASSIGNED">The trial is registered at ClinicalTrials.gov: NCT04798417: Study Details | Nutrition to Relieve IBS Constipation | ClinicalTrials.gov.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>JanssenDuijghuijsen</LastName><ForeName>Lonneke</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Wageningen Food and Biobased Research, Wageningen University &amp; Research, Wageningen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>van den Belt</LastName><ForeName>Maartje</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9679-6925</Identifier><AffiliationInfo><Affiliation>Wageningen Food and Biobased Research, Wageningen University &amp; Research, Wageningen, the Netherlands. maartje.vandenbelt@wur.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnaarts</LastName><ForeName>Iris</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Division of Human Nutrition and Health, Wageningen University &amp; Research, Wageningen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vos</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Wageningen Food and Biobased Research, Wageningen University &amp; Research, Wageningen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guillemet</LastName><ForeName>Damien</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Nexira, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Witteman</LastName><ForeName>Ben</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Human Nutrition and Health, Wageningen University &amp; Research, Wageningen, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gastroenterology and Hepatology department, Hospital Gelderse Vallei, Ede, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Wit</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Wageningen Food and Biobased Research, Wageningen University &amp; Research, Wageningen, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04798417</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>project AF16012</GrantID><Agency>Ministerie van Buitenlandse Zaken</Agency><Country/></Grant><Grant><GrantID>Nexira France</GrantID><Agency>Nexira France</Agency><Country/></Grant><Grant><GrantID>Wecare Probiotics Co., Ltd. (Suzhou, Jiangsu, China)</GrantID><Agency>Wecare Probiotics Co., Ltd. (Suzhou, Jiangsu, China)</Agency><Country/></Grant><Grant><GrantID>Naturex</GrantID><Agency>Naturex</Agency><Country/></Grant><Grant><GrantID>Winclove Probiotics B.V.</GrantID><Agency>Winclove Probiotics B.V.</Agency><Country/></Grant><Grant><GrantID>Bioiberica Spain</GrantID><Agency>Bioiberica Spain</Agency><Country/></Grant><Grant><GrantID>Roquette France</GrantID><Agency>Roquette France</Agency><Country/></Grant><Grant><GrantID>Ingredia, France</GrantID><Agency>Ingredia, France</Agency><Country/></Grant><Grant><GrantID>Ingredion USA</GrantID><Agency>Ingredion USA</Agency><Country/></Grant><Grant><GrantID>Darling Ingredients USA</GrantID><Agency>Darling Ingredients USA</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Nutr</MedlineTA><NlmUniqueID>100888704</NlmUniqueID><ISSNLinking>1436-6207</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004043">Dietary Fiber</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Eur J Nutr. 2025 Mar 22;64(3):135. doi: 10.1007/s00394-025-03586-0.</RefSource><PMID Version="1">40119929</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003248" MajorTopicYN="Y">Constipation</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004043" MajorTopicYN="Y">Dietary Fiber</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019587" MajorTopicYN="Y">Dietary Supplements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000045" MajorTopicYN="Y">Acacia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Constipation</Keyword><Keyword MajorTopicYN="N">Fiber</Keyword><Keyword MajorTopicYN="N">IBS symptoms</Keyword><Keyword MajorTopicYN="N">Irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">Probiotics</Keyword><Keyword MajorTopicYN="N">Stool frequency</Keyword></KeywordList><CoiStatement>DG is employed by Nexira, France, all other authors declare no conflict of interest. No brand names or specific products were communicated to the study subjects.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>17</Day><Hour>15</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>24</Day><Hour>1</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>23</Day><Hour>23</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38653808</ArticleId><ArticleId IdType="pmc">PMC11329592</ArticleId><ArticleId IdType="doi">10.1007/s00394-024-03398-8</ArticleId><ArticleId IdType="pii">10.1007/s00394-024-03398-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Camilleri M (2020) Sex as a biological variable in irritable bowel syndrome. Neurogastroenterol Motil 32(7):e13802</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7319890</ArticleId><ArticleId IdType="pubmed">31943595</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandar AK (2017) Diagnosis and treatment of irritable bowel syndrome with predominant constipation in the primary-care setting: focus on linaclotide. Int J Gen Med 10:385&#x2013;393</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5673039</ArticleId><ArticleId IdType="pubmed">29184433</ArticleId></ArticleIdList></Reference><Reference><Citation>Wald A et al (2007) The burden of constipation on quality of life: results of a multinational survey. Aliment Pharmacol Ther 26(2):227&#x2013;236</Citation><ArticleIdList><ArticleId IdType="pubmed">17593068</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu&#xe9;rin A et al (2014) Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation. Aliment Pharmacol Ther 40(1):83&#x2013;92</Citation><ArticleIdList><ArticleId IdType="pubmed">24832002</ArticleId></ArticleIdList></Reference><Reference><Citation>Svensson E et al (2016) Constipation and risk of Parkinson&#x2019;s disease: a Danish population-based cohort study. Parkinsonism Relat Disord 28:18&#x2013;22</Citation><ArticleIdList><ArticleId IdType="pubmed">27234704</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumida K et al (2019) Constipation and risk of death and cardiovascular events. Atherosclerosis 281:114&#x2013;120</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6399019</ArticleId><ArticleId IdType="pubmed">30658186</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A, Rao S (2017) Constipation: Pathophysiology and Current Therapeutic Approaches, in Gastrointestinal Pharmacology, B. Greenwood-Van Meerveld, Editor. Springer International Publishing: Cham. pp. 59&#x2013;74</Citation><ArticleIdList><ArticleId IdType="pubmed">28185025</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T et al (2022) Fecal microbiota signatures are not consistently related to Symptom Severity in Irritable Bowel Syndrome. Dig Dis Sci 67(11):5137&#x2013;5148</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9587953</ArticleId><ArticleId IdType="pubmed">35624331</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;hman L, T&#xf6;rnblom H, Simr&#xe9;n M (2015) Crosstalk at the mucosal border: importance of the gut microenvironment in IBS Nat Rev Gastroenterol Hepatol, 12(1): pp. 36&#x2013;49</Citation><ArticleIdList><ArticleId IdType="pubmed">25446728</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing JH, Soffer EE (2001) Adverse effects of laxatives. Dis Colon Rectum 44(8):1201&#x2013;1209</Citation><ArticleIdList><ArticleId IdType="pubmed">11535863</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes P et al (2014) A dietary survey of patients with irritable bowel syndrome. J Hum Nutr Diet 27(Suppl 2):36&#x2013;47</Citation><ArticleIdList><ArticleId IdType="pubmed">23659729</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadallah KA, Kullab SM, Sanders DS (2014) Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies. World J Gastroenterol 20(27):8898&#x2013;8909</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4112860</ArticleId><ArticleId IdType="pubmed">25083062</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC et al (2014) Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 109(10):1547&#x2013;1561 quiz 1546, 1562</Citation><ArticleIdList><ArticleId IdType="pubmed">25070051</ArticleId></ArticleIdList></Reference><Reference><Citation>Naseer M et al (2020) Therapeutic effects of Prebiotics on Constipation: a schematic review. Curr Clin Pharmacol 15(3):207&#x2013;215</Citation><ArticleIdList><ArticleId IdType="pubmed">32048977</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittayanon R et al (2019) Gut microbiota in patients with irritable bowel syndrome&#x2014;a systematic review. Gastroenterology 157(1):97&#x2013;108</Citation><ArticleIdList><ArticleId IdType="pubmed">30940523</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T et al (2022) Fecal microbiota signatures are not consistently related to Symptom Severity in Irritable Bowel Syndrome. Digestive Diseases and Sciences, pp 1&#x2013;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9587953</ArticleId><ArticleId IdType="pubmed">35624331</ArticleId></ArticleIdList></Reference><Reference><Citation>Andresen V, Gschossmann J, Layer P (2020) Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial. Lancet Gastroenterol Hepatol 5(7):658&#x2013;666</Citation><ArticleIdList><ArticleId IdType="pubmed">32277872</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherbut C et al (2003) Acacia Gum is a bifidogenic Dietary Fibre with High Digestive Tolerance in healthy humans. Microb Ecol Health Disease 15(1):43&#x2013;50</Citation></Reference><Reference><Citation>Calame W et al (2008) Gum arabic establishes prebiotic functionality in healthy human volunteers in a dose-dependent manner. Br J Nutr 100(6):1269&#x2013;1275</Citation><ArticleIdList><ArticleId IdType="pubmed">18466655</ArticleId></ArticleIdList></Reference><Reference><Citation>Terpend K, Possemiers S, Daguet D, Marzorati M (2013) Arabinogalactan and fructo-oligosaccharides have a different fermentation profile in the Simulator of the human intestinal microbial ecosystem (SHIME&#xae;). Environ Microbiol Rep 5(4):595&#x2013;603</Citation><ArticleIdList><ArticleId IdType="pubmed">23864575</ArticleId></ArticleIdList></Reference><Reference><Citation>Bharucha AE et al (2008) Insights into normal and disordered bowel habits from bowel diaries. Am J Gastroenterol 103(3):692</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2557101</ArticleId><ArticleId IdType="pubmed">18021288</ArticleId></ArticleIdList></Reference><Reference><Citation>Palaniappan U et al (2003) Implications of day-to-day variability on measurements of usual food and nutrient intakes. J Nutr 133(1):232&#x2013;235</Citation><ArticleIdList><ArticleId IdType="pubmed">12514296</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis CY, Morris J, Whorwell PJ (1997) The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 11(2):395&#x2013;402</Citation><ArticleIdList><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank L et al (1999) Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol 34(9):870&#x2013;877</Citation><ArticleIdList><ArticleId IdType="pubmed">10522604</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquis P et al (2005) Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol 40(5):540&#x2013;551</Citation><ArticleIdList><ArticleId IdType="pubmed">16036506</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinhoven PH et al (1997) A validation study of the hospital anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol Med 27(2):363&#x2013;370</Citation><ArticleIdList><ArticleId IdType="pubmed">9089829</ArticleId></ArticleIdList></Reference><Reference><Citation>Streppel MT et al (2013) Relative validity of the food frequency questionnaire used to assess dietary intake in the Leiden Longevity Study. Nutr J 12:75</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3680188</ArticleId><ArticleId IdType="pubmed">23758629</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis SJ, Heaton KW (1997) Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 32(9):920&#x2013;924</Citation><ArticleIdList><ArticleId IdType="pubmed">9299672</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy BE, Patel NK (2017) Rome criteria and a diagnostic approach to irritable bowel syndrome. J Clin Med 6(11):99</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5704116</ArticleId><ArticleId IdType="pubmed">29072609</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumpitazi BP et al (2018) Fructans exacerbate symptoms in a subset of children with irritable bowel syndrome. Clin Gastroenterol Hepatol 16(2):219&#x2013;225e1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5794652</ArticleId><ArticleId IdType="pubmed">28970147</ArticleId></ArticleIdList></Reference><Reference><Citation>McRorie JW et al (1998) Psyllium is superior to docusate sodium for treatment of chronic constipation. Aliment Pharmacol Ther 12(5):491&#x2013;497</Citation><ArticleIdList><ArticleId IdType="pubmed">9663731</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y-X et al (2008) Effect of a fermented milk containing Bifidobacterium lactis DN-173010 on Chinese constipated women. World J Gastroenterol 14(40):6237&#x2013;6243</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2761588</ArticleId><ArticleId IdType="pubmed">18985817</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA, Irritable Bowel Syndrome - Clinical Evaluation of Drugs for Treatment. (2012)</Citation></Reference><Reference><Citation>Drossman DA et al (2011) Severity in irritable bowel syndrome: a Rome Foundation Working Team report. Official J Am Coll Gastroenterology| ACG 106(10):1749&#x2013;1759</Citation><ArticleIdList><ArticleId IdType="pubmed">21747417</ArticleId></ArticleIdList></Reference><Reference><Citation>Yiannakou Y et al (2017) The PAC-SYM questionnaire for chronic constipation: defining the minimal important difference. Aliment Pharmacol Ther 46(11&#x2013;12):1103&#x2013;1111</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5698746</ArticleId><ArticleId IdType="pubmed">28983926</ArticleId></ArticleIdList></Reference><Reference><Citation>Camilleri M (2006) Probiotics and irritable bowel syndrome: Rationale, putative mechanisms, and evidence of clinical efficacy. J Clin Gastroenterol, 40(3)</Citation><ArticleIdList><ArticleId IdType="pubmed">16633134</ArticleId></ArticleIdList></Reference><Reference><Citation>Marteau P et al (2002) Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment Pharmacol Ther 16(3):587&#x2013;593</Citation><ArticleIdList><ArticleId IdType="pubmed">11876714</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M, Lembo A (2020) Microbiome and its role in irritable bowel syndrome. Dig Dis Sci 65(3):829&#x2013;839</Citation><ArticleIdList><ArticleId IdType="pubmed">32026278</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen Y et al (2020) The efficacy and safety of probiotics for patients with constipation-predominant irritable bowel syndrome: a systematic review and meta-analysis based on seventeen randomized controlled trials. Int J Surg 79:111&#x2013;119</Citation><ArticleIdList><ArticleId IdType="pubmed">32387213</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal A et al (2009) Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation, vol 29. Alimentary pharmacology &amp; therapeutics, pp 104&#x2013;114. 1</Citation><ArticleIdList><ArticleId IdType="pubmed">18801055</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisson G et al (2014) Randomised clinical trial: a liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome&#x2013;a 12 week double-blind study. Aliment Pharmacol Ther 40(1):51&#x2013;62</Citation><ArticleIdList><ArticleId IdType="pubmed">24815298</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkes GC, Chatoor D, Emmanuel A (2011) The probiotic VSL#3 increases scbm and reduces symptom severity scores in patients with functional constipation. Gut 60(Suppl 1):A163</Citation></Reference><Reference><Citation>Lyra A et al (2016) Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. World J Gastroenterol 22(48):10631&#x2013;10642</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5192275</ArticleId><ArticleId IdType="pubmed">28082816</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahora IS et al (2020) How serotonin level fluctuation affects the effectiveness of treatment in irritable bowel syndrome. Cureus 12(8):e9871</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7505258</ArticleId><ArticleId IdType="pubmed">32968548</ArticleId></ArticleIdList></Reference><Reference><Citation>Suares NC, Ford AC (2011) Systematic review: the effects of fibre in the management of chronic idiopathic constipation. Aliment Pharmacol Ther 33(8):895&#x2013;901</Citation><ArticleIdList><ArticleId IdType="pubmed">21332763</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu T et al (2017) Effects of Prebiotics and Synbiotics on Functional Constipation. Am J Med Sci 353(3):282&#x2013;292</Citation><ArticleIdList><ArticleId IdType="pubmed">28262216</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosman M et al (2021) The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 6(6):459&#x2013;473</Citation><ArticleIdList><ArticleId IdType="pubmed">33765447</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller LE (2014) Study design considerations for irritable bowel syndrome clinical trials. Annals Gastroenterology: Q Publication Hellenic Soc Gastroenterol 27(4):338</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4188930</ArticleId><ArticleId IdType="pubmed">25330749</ArticleId></ArticleIdList></Reference><Reference><Citation>Lackner JM et al (2014) The accuracy of patient-reported measures for GI symptoms: a comparison of real time and retrospective reports. Neurogastroenterol Motil 26(12):1802&#x2013;1811</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4247164</ArticleId><ArticleId IdType="pubmed">25424582</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller RC (1999) Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials. Am J Med 107(5a):91s&#x2013;97s</Citation><ArticleIdList><ArticleId IdType="pubmed">10588179</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28625832</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1528-0012</ISSN><JournalIssue CitedMedium="Internet"><Volume>153</Volume><Issue>4</Issue><PubDate><Year>2017</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Gastroenterology</Title><ISOAbbreviation>Gastroenterology</ISOAbbreviation></Journal><ArticleTitle>A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial.</ArticleTitle><Pagination><StartPage>936</StartPage><EndPage>947</EndPage><MedlinePgn>936-947</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1053/j.gastro.2017.06.010</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0016-5085(17)35744-X</ELocationID><Abstract><AbstractText Label="BACKGROUND &amp; AIMS">Dietary restriction of fermentable carbohydrates (a low FODMAP diet) has been reported to reduce symptoms in some patients with irritable bowel syndrome (IBS). We performed a randomized, placebo-controlled study to determine its effects on symptoms and the fecal microbiota in patients with IBS.</AbstractText><AbstractText Label="METHODS">We performed a 2&#xd7;2 factorial trial of 104 patients with IBS (18-65 years old), based on the Rome III criteria, at 2 hospitals in the United Kingdom. Patients were randomly assigned (blinded) to groups given counselling to follow a sham diet or diet low in FODMAPs for 4 weeks, along with a placebo or multistrain probiotic formulation, resulting in 4 groups (27 receiving sham diet/placebo, 26 receiving sham diet/probiotic, 24 receiving low FODMAP diet /placebo, and 27 receiving low FODMAP diet/probiotic). The sham diet restricted a similar number of staple and non-staple foods as the low FODMAP diet; the diets had similar degrees of difficulty to follow. Dietary counselling was given to patients in all groups and data on foods eaten and compliance were collected. The incidence and severity of 15 gastrointestinal symptoms and overall symptoms were measured daily for 7 days before the study period; along with stool frequency and consistency. At baseline, global and individual symptoms were measured, along with generic and disease-specific health-related quality of life, using standard scoring systems. All data were collected again at 4 weeks, and patients answered questions about adequate symptom relief. Fecal samples were collected at baseline and after 4 weeks and analyzed by quantitative PCR and 16S rRNA sequencing. The co-primary endpoints were adequate relief of symptoms and stool Bifidobacterium species abundance at 4 weeks.</AbstractText><AbstractText Label="RESULTS">There was no significant interaction between the interventions in adequate relief of symptoms (P = .52) or Bifidobacterium species (P = .68). In the intention-to-treat analysis, a higher proportion of patients in the low FODMAP diet had adequate symptom relief (57%) than in the sham diet group (38%), although the difference was not statistically significant (P = .051). In the per-protocol analysis, a significantly higher proportion of patients on the low FODMAP diet had adequate symptom relief (61%) than in the sham diet group (39%) (P = .042). Total mean IBS-Severity Scoring System score was significantly lower for patients on the low FODMAP diet (173&#xa0;&#xb1;&#xa0;95) than the sham diet (224 &#xb1; 89) (P = .001), but not different between those given probiotic (207 &#xb1; 98) or placebo (192 &#xb1; 93) (P = .721) Abundance of Bifidobacterium species was lower in fecal samples from patients on the low FODMAP diet (8.8 rRNA genes/g) than patients on the sham diet (9.2 rRNA genes/g) (P = .008), but higher in patients given probiotic (9.1 rRNA genes/g) than patients given placebo (8.8 rRNA genes/g) (P = .019). There was no effect of the low FODMAP diet on microbiota diversity in fecal samples.</AbstractText><AbstractText Label="CONCLUSIONS">In a placebo-controlled study of patients with IBS, a low FODMAP diet associates with adequate symptom relief and significantly reduced symptom scores compared with placebo. It is not clear whether changes resulted from collective FODMAP restriction or removal of a single component, such as lactose. Co-administration of the multistrain probiotic increased numbers of Bifidobacterium species, compared with placebo, and might be given to restore these bacteria to patients on a low FODMAP diet. Trial registration no: ISRCTN02275221.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Staudacher</LastName><ForeName>Heidi Maria</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Faculty of Life Sciences and Medicine, Diabetes and Nutritional Sciences Division, King's College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lomer</LastName><ForeName>Miranda C E</ForeName><Initials>MCE</Initials><AffiliationInfo><Affiliation>Faculty of Life Sciences and Medicine, Diabetes and Nutritional Sciences Division, King's College London, London, United Kingdom; Department of Gastroenterology, Guys and St Thomas' NHS Foundation Trust, London, United Kingdom; Department of Nutrition and Dietetics, Guys and St Thomas' NHS Foundation Trust, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farquharson</LastName><ForeName>Freda M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>The Rowett Institute, University of Aberdeen, Gut Health Group, Aberdeen, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Louis</LastName><ForeName>Petra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>The Rowett Institute, University of Aberdeen, Gut Health Group, Aberdeen, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fava</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Research and Innovation Centre, Department of Food Quality and Nutrition, Nutrition and Nutrigenomics Group, Fondazione Edmund Mach, Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franciosi</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Research and Innovation Centre, Department of Food Quality and Nutrition, Nutrition and Nutrigenomics Group, Fondazione Edmund Mach, Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scholz</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research and Innovation Centre, Department of Food Quality and Nutrition, Nutrition and Nutrigenomics Group, Fondazione Edmund Mach, Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuohy</LastName><ForeName>Kieran M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Research and Innovation Centre, Department of Food Quality and Nutrition, Nutrition and Nutrigenomics Group, Fondazione Edmund Mach, Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindsay</LastName><ForeName>James O</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>Blizard Institute, Queen Mary University of London, Centre for Immunobiology, London, United Kingdom; Barts Health NHS Trust, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irving</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Faculty of Life Sciences and Medicine, Diabetes and Nutritional Sciences Division, King's College London, London, United Kingdom; Department of Gastroenterology, Guys and St Thomas' NHS Foundation Trust, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whelan</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Faculty of Life Sciences and Medicine, Diabetes and Nutritional Sciences Division, King's College London, London, United Kingdom. Electronic address: kevin.whelan@kcl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CDRF-2012-03-060</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Gastroenterology</MedlineTA><NlmUniqueID>0374630</NlmUniqueID><ISSNLinking>0016-5085</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004040">Dietary Carbohydrates</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Gastroenterology. 2017 Oct;153(4):886-887. doi: 10.1053/j.gastro.2017.08.055.</RefSource><PMID Version="1">28867269</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Gastroenterology. 2018 Apr;154(5):1548. doi: 10.1053/j.gastro.2018.03.016.</RefSource><PMID Version="1">29526722</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001644" MajorTopicYN="N">Bifidobacterium</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000254" MajorTopicYN="Y">growth &amp; development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050528" MajorTopicYN="Y">Diet, Carbohydrate-Restricted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004040" MajorTopicYN="N">Dietary Carbohydrates</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005285" MajorTopicYN="N">Fermentation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007422" MajorTopicYN="N">Intestines</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000178" MajorTopicYN="Y">diet therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008131" MajorTopicYN="N">London</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021521" MajorTopicYN="N">Ribotyping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Food Sensitivity</Keyword><Keyword MajorTopicYN="N">Fructans</Keyword><Keyword MajorTopicYN="N">Galacto-oligosaccharides</Keyword><Keyword MajorTopicYN="N">Lactose</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28625832</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2017.06.010</ArticleId><ArticleId IdType="pii">S0016-5085(17)35744-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33652763</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6643</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>26</Day></PubDate></JournalIssue><Title>Nutrients</Title><ISOAbbreviation>Nutrients</ISOAbbreviation></Journal><ArticleTitle>The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">756</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nu13030756</ELocationID><Abstract><AbstractText>The aim of this randomized double-blind placebo-controlled study was to evaluate the effectiveness and safety of multi-strain probiotic in adults with diarrhea-predominant irritable bowel syndrome (IBS-D). The patients were randomized to receive a mixture of <i>Lactobacillus</i>, <i>Bifidobacterium</i>, and <i>Streptococcus thermophilus</i> strains or placebo for eight weeks. Primary endpoints included changes in symptom severity and improvement assessed with the IBS Severity Scoring System (IBS-SSS) and Global Improvement Scale (IBS-GIS). The probiotic in comparison with placebo significantly improved the IBS symptom severity (the change of total IBS-SSS score from baseline &#x2012;165.8 &#xb1; 78.9 in the probiotic group and &#x2012;105.6 &#xb1; 60.2 in the placebo group, <i>p</i> = 0.005) and in the specific scores related to the severity of pain (<i>p</i> = 0.015) and the quality of life (<i>p</i> = 0.016) after eight weeks of intervention. The probiotic group indicated an improvement in symptoms with the use of the IBS-GIS compared with the placebo group after four (<i>p</i> = 0.04) and eight weeks (<i>p</i> = 0.003). The occurrence of adverse events did not differ between study groups. In conclusion, the multi-strain probiotic intervention resulted in a significant improvement in IBS symptoms evaluated with the use of both IBS-SSS and IBS-GIS scales. The results suggest that the studied probiotic preparation is well tolerated and safe and can offer benefits for patients with IBS-D. (registration number in Clinicaltrials.gov NCT04662957).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Skrzyd&#x142;o-Radoma&#x144;ska</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Medical University of Lublin, Jaczewskiego 8, 20-950 Lublin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prozorow-Kr&#xf3;l</LastName><ForeName>Beata</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Medical University of Lublin, Jaczewskiego 8, 20-950 Lublin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cicho&#x17c;-Lach</LastName><ForeName>Halina</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-7337-835X</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, Medical University of Lublin, Jaczewskiego 8, 20-950 Lublin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Majsiak</LastName><ForeName>Emilia</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-3638-9292</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Cardinal Stefan Wyszynski University, W&#xf3;ycickiego 1/3, 01-938 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bier&#x142;a</LastName><ForeName>Joanna Beata</ForeName><Initials>JB</Initials><Identifier Source="ORCID">0000-0002-5772-5091</Identifier><AffiliationInfo><Affiliation>Department of Pathomorphology, The Children Memorial Health Institute, Aleja Dzieci Polskich 20, 04-730 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanarek</LastName><ForeName>Ewelina</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pathomorphology, The Children Memorial Health Institute, Aleja Dzieci Polskich 20, 04-730 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sowi&#x144;ska</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathomorphology, The Children Memorial Health Institute, Aleja Dzieci Polskich 20, 04-730 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cukrowska</LastName><ForeName>Bo&#x17c;ena</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathomorphology, The Children Memorial Health Institute, Aleja Dzieci Polskich 20, 04-730 Warsaw, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04662957</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>G02/MBM/2019</GrantID><Agency>MBM Biotix</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nutrients</MedlineTA><NlmUniqueID>101521595</NlmUniqueID><ISSNLinking>2072-6643</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001644" MajorTopicYN="Y">Bifidobacterium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007778" MajorTopicYN="Y">Lactobacillus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048249" MajorTopicYN="Y">Streptococcus thermophilus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bifidobacterium</Keyword><Keyword MajorTopicYN="N">IBS-GIS</Keyword><Keyword MajorTopicYN="N">IBS-SSS</Keyword><Keyword MajorTopicYN="N">Lactobacillus</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">probiotics</Keyword></KeywordList><CoiStatement>B.S.-R. has served as a speaker for Polpharma, Krka, Takeda, Bayer, Promed, and Alfasigma. B.C. conducted research financed by Danone, Biomed S.A., and conducted lectures sponsored by Nutricia, Danone, Mead Johnson, Bayer, Aurovitas, Polpharma, and Biomed S.A.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>3</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33652763</ArticleId><ArticleId IdType="pmc">PMC7996889</ArticleId><ArticleId IdType="doi">10.3390/nu13030756</ArticleId><ArticleId IdType="pii">nu13030756</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ford A.C., Lacy B.E., Talley N.J. Irritable bowel syndrome. N. Engl. J. Med. 2017;376:2566&#x2013;2578. doi: 10.1056/NEJMra1607547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1607547</ArticleId><ArticleId IdType="pubmed">28657875</ArticleId></ArticleIdList></Reference><Reference><Citation>Canavan C., West J., Card T. The epidemiology of irritable bowel syndrome. Clin. Epidemiol. 2014;6:71&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3921083</ArticleId><ArticleId IdType="pubmed">24523597</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell R.M., Ford A.C. Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis. Clin. Gastroenterol. Hepatol. 2012;10:712&#x2013;721. doi: 10.1016/j.cgh.2012.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2012.02.029</ArticleId><ArticleId IdType="pubmed">22426087</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai T., Xia J., Jiang Y., Cao H., Zhao Y., Zhang L., Wang H., Song J., Hou X. Comparison of the Rome IV and Rome III criteria for IBS diagnosis: A cross-sectional survey. J. Gastroenterol. Hepatol. 2017;32:1018&#x2013;1025. doi: 10.1111/jgh.13642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.13642</ArticleId><ArticleId IdType="pubmed">27862281</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperber A.D., Bangdiwala S.I., Drossman D.A., Ghoshal U.C., Imren M., Tack J., Whitehead W.E., Dumitrascu D.L., Fang X., Fukudo S., et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study. Gastroenterology. 2020;160:99&#x2013;114. doi: 10.1053/j.gastro.2020.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.04.014</ArticleId><ArticleId IdType="pubmed">32294476</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivinus-N&#xe9;bot M., Frin-Mathy G., Bzioueche H., Dainese R., Bernard G., Anty R., Filippi J., Saint-Paul M.C., Tulic M.K., Verhasselt V., et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: Role of epithelial barrier disruption and low-grade inflammation. Gut. 2014;63:744&#x2013;752. doi: 10.1136/gutjnl-2012-304066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2012-304066</ArticleId><ArticleId IdType="pubmed">23878165</ArticleId></ArticleIdList></Reference><Reference><Citation>Pusceddu M.M., Gareau M.G. Visceral pain: Gut microbiota, a new hope? J. Biomed. Sci. 2018;25:73. doi: 10.1186/s12929-018-0476-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-018-0476-7</ArticleId><ArticleId IdType="pmc">PMC6182804</ArticleId><ArticleId IdType="pubmed">30309367</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou S.Y., Gillilland M., Wu X., Leelasinjaroen P., Zhang G., Zhou H., Ye B., Lu Y., Owyang C. FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction. J. Clin. Investig. 2018;128:267&#x2013;280. doi: 10.1172/JCI92390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI92390</ArticleId><ArticleId IdType="pmc">PMC5749529</ArticleId><ArticleId IdType="pubmed">29202473</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattarai Y., Muniz Pedrogo D.A., Kashyap P.C. Irritable bowel syndrome: A gut microbiota-related disorder? Am. J. Physiol. Gastrointest. Liver. Physiol. 2017;312:G52&#x2013;G62. doi: 10.1152/ajpgi.00338.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00338.2016</ArticleId><ArticleId IdType="pmc">PMC5283907</ArticleId><ArticleId IdType="pubmed">27881403</ArticleId></ArticleIdList></Reference><Reference><Citation>Mari A., Baker F.A., Mahamid M., Sbeit W., Khoury T. The evolving role of gut microbiota in the management of irritable bowel syndrome: An overview of the current knowledge. J. Clin. Med. 2020;9:685. doi: 10.3390/jcm9030685.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9030685</ArticleId><ArticleId IdType="pmc">PMC7141230</ArticleId><ArticleId IdType="pubmed">32143424</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss G.A., Hennet T. Mechanisms and consequences of intestinal dysbiosis. Cell. Mol. Life Sci. 2017;74:2959&#x2013;2977. doi: 10.1007/s00018-017-2509-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-017-2509-x</ArticleId><ArticleId IdType="pmc">PMC11107543</ArticleId><ArticleId IdType="pubmed">28352996</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch S.V., Pedersen O. The human intestinal microbiome in health and disease. N. Engl. J. Med. 2016;375:2369&#x2013;2379. doi: 10.1056/NEJMra1600266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1600266</ArticleId><ArticleId IdType="pubmed">27974040</ArticleId></ArticleIdList></Reference><Reference><Citation>Moloney R.D., Johnson A.C., O&#x2019;Mahony S.M., Dinan T.G., Greenwood-Van Meerveld B., Cryan J.F. Stress and the microbiota-gut-brain axis in visceral pain: Relevance to irritable bowel syndrome. CNS Neurosci. Ther. 2016;22:102&#x2013;117. doi: 10.1111/cns.12490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.12490</ArticleId><ArticleId IdType="pmc">PMC6492884</ArticleId><ArticleId IdType="pubmed">26662472</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll I.M., Ringel-Kulka T., Siddle J.P., Ringel Y. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol. Motil. 2012;24:521&#x2013;530. doi: 10.1111/j.1365-2982.2012.01891.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2012.01891.x</ArticleId><ArticleId IdType="pmc">PMC3975596</ArticleId><ArticleId IdType="pubmed">22339879</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll I.M., Ringel-Kulka T., Keku T.O., Chang Y.H., Packey C.D., Sartor R.B., Ringel Y. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver. Physiol. 2011;301:G799&#x2013;G807. doi: 10.1152/ajpgi.00154.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00154.2011</ArticleId><ArticleId IdType="pmc">PMC3220325</ArticleId><ArticleId IdType="pubmed">21737778</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerckhoffs A.P., Samsom M., van der Rest M.E., de Vogel J., Knol J., Ben-Amor K., Akkermans L.M.A. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J. Gastroenterol. 2009;15:2887&#x2013;2892. doi: 10.3748/wjg.15.2887.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.15.2887</ArticleId><ArticleId IdType="pmc">PMC2699007</ArticleId><ArticleId IdType="pubmed">19533811</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozuelo M., Panda S., Santiago A., Mendez S., Accarino A., Santos J., Guarner F., Azpiroz F., Manichanh C. Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome. Sci. Rep. 2015;5:12693. doi: 10.1038/srep12693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep12693</ArticleId><ArticleId IdType="pmc">PMC4523847</ArticleId><ArticleId IdType="pubmed">26239401</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H.N., Wu H., Chen Y.C., Chen Y.J., Shen X.Z., Liu T. Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis. Dig. Liver Dis. 2017;49:331&#x2013;337. doi: 10.1016/j.dld.2017.01.142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2017.01.142</ArticleId><ArticleId IdType="pubmed">28179092</ArticleId></ArticleIdList></Reference><Reference><Citation>Distrutti E., Monaldi L., Ricci P., Fiorucci S. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World J. Gastroenterol. 2016;22:2219&#x2013;2241. doi: 10.3748/wjg.v22.i7.2219.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i7.2219</ArticleId><ArticleId IdType="pmc">PMC4734998</ArticleId><ArticleId IdType="pubmed">26900286</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill C., Guarner F., Reid G., Gibson G.R., Merenstein D.J., Pot B., Morelli L., Canani R.B., Flint H.J., Salminen S., et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol Hepatol. 2014;11:506&#x2013;514. doi: 10.1038/nrgastro.2014.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2014.66</ArticleId><ArticleId IdType="pubmed">24912386</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher H.M., Whelan K. Altered gastrointestinal microbiota in irritable bowel syndrome and its modification by diet: Probiotics, prebiotics and the low FODMAP diet. Proc. Nutr. Soc. 2016;75:306&#x2013;318. doi: 10.1017/S0029665116000021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0029665116000021</ArticleId><ArticleId IdType="pubmed">26908093</ArticleId></ArticleIdList></Reference><Reference><Citation>Verd&#xfa; E.F., Bercik P., Verma-Gandhu M., Huang X.X., Blennerhassett P., Jackson W., Mao Y., Wang L., Rochat F., Collins S.M. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut. 2006;55:182&#x2013;190. doi: 10.1136/gut.2005.066100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2005.066100</ArticleId><ArticleId IdType="pmc">PMC1856497</ArticleId><ArticleId IdType="pubmed">16105890</ArticleId></ArticleIdList></Reference><Reference><Citation>Plaza-D&#xed;az J., Ruiz-Ojeda F.J., Vilchez-Padial L.M., Gil A. Evidence of the anti-inflammatory effects of probiotics and synbiotics in intestinal chronic diseases. Nutrients. 2017;9:555. doi: 10.3390/nu9060555.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu9060555</ArticleId><ArticleId IdType="pmc">PMC5490534</ArticleId><ArticleId IdType="pubmed">28555037</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozakova H., Schwarzer M., Tuckova L., Srutkova D., Czarnowska E., Rosiak I., Hudcovic T., Schabussova I., Hermanova P., Zakostelska Z., et al. Colonization of germ-free mice with a mixture of three lactobacillus strains enhances the integrity of gut mucosa and ameliorates allergic sensitization. Cell. Mol. Immunol. 2016;13:251&#x2013;262. doi: 10.1038/cmi.2015.09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cmi.2015.09</ArticleId><ArticleId IdType="pmc">PMC4786630</ArticleId><ArticleId IdType="pubmed">25942514</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B., Liang L., Deng H., Guo J., Shu H., Zhang L. Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-Analysis. Front. Pharmacol. 2020;11:332. doi: 10.3389/fphar.2020.00332.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.00332</ArticleId><ArticleId IdType="pmc">PMC7147251</ArticleId><ArticleId IdType="pubmed">32317962</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Harris L.A., Lacy B.E., Quigley E.M.M., Moayyedi P. Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2018;48:1044&#x2013;1060. doi: 10.1111/apt.15001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15001</ArticleId><ArticleId IdType="pubmed">30294792</ArticleId></ArticleIdList></Reference><Reference><Citation>Asha M.Z., Khalil S.F.H. Efficacy and safety of probiotics, prebiotics and synbiotics in the treatment of irritable bowel syndrome: A systematic review and meta-analysis. Sultan Qaboos Univ. Med. J. 2020;20:e13&#x2013;e24. doi: 10.18295/squmj.2020.20.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.18295/squmj.2020.20.01.003</ArticleId><ArticleId IdType="pmc">PMC7065695</ArticleId><ArticleId IdType="pubmed">32190365</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang D., Longgui N., Guoqiang X. Efficacy of different probiotic protocols in irritable bowel syndrome: A network meta-analysis. Medicine. 2019;98:e16068. doi: 10.1097/MD.0000000000016068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000016068</ArticleId><ArticleId IdType="pmc">PMC6635271</ArticleId><ArticleId IdType="pubmed">31277101</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu H.L., Xiao J.Y. The efficacy and safety of probiotics in patients with irritable bowel syndrome: Evidence based on 35 randomized controlled trials. Int. J. Surg. 2020;75:116&#x2013;127. doi: 10.1016/j.ijsu.2020.01.142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2020.01.142</ArticleId><ArticleId IdType="pubmed">32014597</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Li L., Guo C., Mu D., Feng B., Zuo X., Li Y. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: A meta-analysis. BMC Gastroenterol. 2016;16:62. doi: 10.1186/s12876-016-0470-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-016-0470-z</ArticleId><ArticleId IdType="pmc">PMC4907258</ArticleId><ArticleId IdType="pubmed">27296254</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman D.A., Rome D.D.L. III New standard for functional gastrointestinal disorders. J. Gastrointestin. Liver Dis. 2006;15:237&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">17013448</ArticleId></ArticleIdList></Reference><Reference><Citation>Riegler G., Esposito I. Bristol scale stool form: A still valid help in medical practice and clinical research. Tech. Coloproctol. 2001;5:163&#x2013;164. doi: 10.1007/s101510100019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s101510100019</ArticleId><ArticleId IdType="pubmed">11875684</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis C.Y., Morris J., Whorwell P.J. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment. Pharmacol. Ther. 1997;11:395&#x2013;402. doi: 10.1046/j.1365-2036.1997.142318000.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.1997.142318000.x</ArticleId><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>Suresh K.P. An overview of randomization techniques: An unbiased assessment of outcome in clinical research. J. Hum. Reprod. Sci. 2011;4:8&#x2013;11. doi: 10.4103/0974-1208.82352.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0974-1208.82352</ArticleId><ArticleId IdType="pmc">PMC3136079</ArticleId><ArticleId IdType="pubmed">21772732</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon S., Ameen V., Bagby B., Shahan B., Jhingran P., Carter E. Validation of irritable bowel syndrome Global Improvement Scale: An integrated symptom end point for assessing treatment efficacy. Dig. Dis. Sci. 2003;48:1317&#x2013;1323. doi: 10.1023/A:1024159226274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1024159226274</ArticleId><ArticleId IdType="pubmed">12870789</ArticleId></ArticleIdList></Reference><Reference><Citation>Skrzyd&#x142;o-Radoma&#x144;ska B., Prozorow-Kr&#xf3;l B., Cicho&#x17c;-Lach H., Majsiak E., Bier&#x142;a J.B., Kosikowski W., Szczerbi&#x144;ski M., Gantzel J., Cukrowska B. The effectiveness of synbiotic preparation containing Lactobacillus and Bifidobacterium probiotic strains and short chain fructooligosaccharides in patients with diarrhea predominant irritable bowel syndrome-a randomized double-blind, placebo-controlled study. Nutrients. 2020;12:1999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7400954</ArticleId><ArticleId IdType="pubmed">32635661</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishaque S.M., Khosruzzaman S.M., Ahmed D.S., Sah M.P. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult) in the management of diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol. 2018;18:71. doi: 10.1186/s12876-018-0788-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-018-0788-9</ArticleId><ArticleId IdType="pmc">PMC5970461</ArticleId><ArticleId IdType="pubmed">29801486</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisson. G., Ayis S., Sherwood R.A., Bjarnason I. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome- a 12 week double-blind study. Aliment. Pharmacol. Ther. 2014;40:51&#x2013;62. doi: 10.1111/apt.12787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.12787</ArticleId><ArticleId IdType="pubmed">24815298</ArticleId></ArticleIdList></Reference><Reference><Citation>Hod K., Sperber A.D., Ron Y., Boaz M., Dickman R., Berliner S., Halpern Z., Maharshak N., Dekel R. A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS. Neurogastroenterol. Motil. 2017;29:e13037. doi: 10.1111/nmo.13037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13037</ArticleId><ArticleId IdType="pubmed">28271623</ArticleId></ArticleIdList></Reference><Reference><Citation>Arzani M., Jahromi S.R., Ghorbani Z., Vahabizad F., Martelletti P., Ghaemi A., Sacco S., Togha M. School of Advanced Studies of the European Headache Federation (EHF-SAS). Gut-brain Axis and migraine headache: A comprehensive review. J. Headache Pain. 2020;13:15. doi: 10.1186/s10194-020-1078-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10194-020-1078-9</ArticleId><ArticleId IdType="pmc">PMC7020496</ArticleId><ArticleId IdType="pubmed">32054443</ArticleId></ArticleIdList></Reference><Reference><Citation>Shavakhi A., Minakari M., Farzamnia S., Peykar M.S., Taghipour G., Tayebi A., Hashemi H., Shavakhi S. The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial. Adv. Biomed. Res. 2014;3:140. doi: 10.4103/2277-9175.135157.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2277-9175.135157</ArticleId><ArticleId IdType="pmc">PMC4139977</ArticleId><ArticleId IdType="pubmed">25161987</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick D.L., Drossman D.A., Frederick I.O., DiCesare J., Puder K.L. Quality of life in persons with irritable bowel syndrome: Development and validation of a new measure. Dig. Dis. Sci. 1998;43:400&#x2013;411. doi: 10.1023/A:1018831127942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1018831127942</ArticleId><ArticleId IdType="pubmed">9512138</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40546150</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2101-017X</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Apr</Month></PubDate></JournalIssue><Title>La Revue du praticien</Title><ISOAbbreviation>Rev Prat</ISOAbbreviation></Journal><ArticleTitle>[Irritable bowel syndrome].</ArticleTitle><Pagination><StartPage>408</StartPage><EndPage>413</EndPage><MedlinePgn>408-413</MedlinePgn></Pagination><Abstract><AbstractText>IRRITABLE BOWEL SYNDROME. Irritable bowel syndrome (IBS) is a common functional digestive disorder affecting 4 to 10% of the population, with a female gender predominance. Although it is a benign disease, it can sometimes considerably impair quality of life particularly in severe cases. Diagnosis should be clinical based on symptoms, with limited complementary examinations for the sole purpose of differential diagnosis elimination. A better understanding of IBS mechanisms has led to the development of various therapeutic strategies. Antispasmodics and transit modifiers are the most commonly strategies used. Dietary management with diets, probiotics, physical activity, alternative treatments such as hypnosis and therapeutic education can also improve IBS symptoms and reduce severity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sabat&#xe9;</LastName><ForeName>Jean-Marc</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Service de gastroent&#xe9;rologie, h&#xf4;pital Avicenne, AP-HP, Bobigny, France ; Universit&#xe9; Sorbonne Paris Nord et INSERM U-987, physiopathologie et pharmacologie clinique de la douleur ; h&#xf4;pital Ambroise Par&#xe9;, Boulogne-Billancourt, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType></PublicationTypeList><VernacularTitle>Syndrome de l&#x2019;intestin irritable.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Rev Prat</MedlineTA><NlmUniqueID>0404334</NlmUniqueID><ISSNLinking>0035-2640</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="fre"><AbstractText>SYNDROME DE L&#x2019;INTESTIN IRRITABLE. Le syndrome de l&#x2019;intestin irritable est un trouble fonctionnel digestif fr&#xe9;quent touchant 4 &#xe0; 10 % de la population, avec une pr&#xe9;dominance f&#xe9;minine qui, bien que b&#xe9;nin, peut parfois consid&#xe9;rablement alt&#xe9;rer la qualit&#xe9; de vie, notamment en cas de forme s&#xe9;v&#xe8;re. Son diagnostic est essentiellement clinique et fond&#xe9; sur les donn&#xe9;es de l&#x2019;interrogatoire avec des examens compl&#xe9;mentaires qui doivent rester limit&#xe9;s et &#xe0; seul but de diagnostic diff&#xe9;rentiel. Une meilleure connaissance des m&#xe9;canismes de la maladie a permis le d&#xe9;veloppement de diff&#xe9;rentes strat&#xe9;gies th&#xe9;rapeutiques. Les antispasmodiques et les modificateurs du transit sont les traitements les plus utilis&#xe9;s. La prise en charge di&#xe9;t&#xe9;tique avec des r&#xe9;gimes, la prise de probiotiques, l&#x2019;activit&#xe9; physique, des traitements compl&#xe9;mentaires, comme notamment l&#x2019;hypnose et l&#x2019;&#xe9;ducation th&#xe9;rapeutique, peuvent aussi diminuer les sympt&#xf4;mes de la maladie et r&#xe9;duire sa s&#xe9;v&#xe9;rit&#xe9;.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Irritable Bowel Syndrome</Keyword><Keyword MajorTopicYN="N">Pelvic Pain</Keyword></KeywordList><CoiStatement>L&#x2019;auteur d&#xe9;clare avoir particip&#xe9; &#xe0; des interventions ponctuelles pour Biocodex, Norgine, Kyowa Kirin (essais cliniques et travaux scientifiques), pour Novozymes/Precision Biotics, Kyowa Kirin, Devintec, Reckitt (rapports d&#x2019;expertise ou activit&#xe9;s de conseil) et pour Mayoly Spindler, Biocodex, Servier, Tillotts, Norgine (conf&#xe9;rences, colloques, actions de formation). Il d&#xe9;clare aussi avoir &#xe9;t&#xe9; pris en charge, &#xe0; l&#x2019;occasion de d&#xe9;placements pour congr&#xe8;s, par Biocodex, Merck et Viatris.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>24</Day><Hour>11</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>23</Day><Hour>8</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>23</Day><Hour>5</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40546150</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38700306</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-5772</ISSN><JournalIssue CitedMedium="Print"><Volume>71</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Journal of the Association of Physicians of India</Title><ISOAbbreviation>J Assoc Physicians India</ISOAbbreviation></Journal><ArticleTitle>Dysbiosis in Irritable Bowel Syndrome.</ArticleTitle><Pagination><StartPage>75</StartPage><EndPage>81</EndPage><MedlinePgn>75-81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.59556/japi.71.0353</ELocationID><Abstract><AbstractText>The human gut microbiota fosters the development of a dynamic group of microorganisms impacted by diverse variables that include genetics, diet, infection, stress, ingested drugs, such as antibiotics and small intestine bacterial overgrowth (SIBO) as well as the gut microbiota itself. These factors may influence the change in microbial composition, which results in dysbiosis (microbial imbalance) and exposes the gut to pathogenic insults. Dysbiosis is incidental to the etiology of inflammatory diseases such as irritable bowel syndrome (IBS) and metabolic diseases, including type 2 diabetes and obesity. IBS exhibits different symptoms like abdominal pain or discomfort, distention/bloating, and flatulence. To treat IBS, modification of dysregulated gut microbiota can be done using treatment strategies like a low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diet, antibiotics that cannot be absorbed like rifaximin and neomycin, probiotics and prebiotics, and fecal microbiota transplantation (FMT). The remedial modalities in the existing literature have been demonstrated to be efficacious in the prevention and mitigation of IBS. Additionally, newer curative approaches with serum-derived bovine immunoglobulin (SBI) are an effective option. The focal point of the review paper is the pathophysiology of IBS, mainly due to dysbiosis and the various factors that advance dysbiosis. Here, we have also discussed the different treatment strategies targeting dysbiosis that effectively treat IBS. How to cite this article: Abraham P, Pratap N. Dysbiosis in Irritable Bowel Syndrome. J Assoc Physicians India 2023;71(9):75-81.</AbstractText><CopyrightInformation>&#xa9; Journal of the Association of Physicians of India 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abraham</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Consultant Gastroenterologist, P. D. Hinduja Hospitals, Mumbai, Maharashtra, India, Corresponding Author.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pratap</LastName><ForeName>Nitesh</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Consultant Gastroenterologist, KIMS Hospital, Secunderabad, Telangana, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><MedlineTA>J Assoc Physicians India</MedlineTA><NlmUniqueID>7505585</NlmUniqueID><ISSNLinking>0004-5772</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D056692">Prebiotics</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064806" MajorTopicYN="Y">Dysbiosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069467" MajorTopicYN="N">Fecal Microbiota Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056692" MajorTopicYN="N">Prebiotics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>3</Day><Hour>12</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>3</Day><Hour>12</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38700306</ArticleId><ArticleId IdType="doi">10.59556/japi.71.0353</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39126817</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-6947</ISSN><JournalIssue CitedMedium="Internet"><Volume>57</Volume><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Complementary therapies in clinical practice</Title><ISOAbbreviation>Complement Ther Clin Pract</ISOAbbreviation></Journal><ArticleTitle>Interplay of yoga, physical activity, and probiotics in irritable bowel syndrome management: A double-blind randomized study.</ArticleTitle><Pagination><StartPage>101892</StartPage><MedlinePgn>101892</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ctcp.2024.101892</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1744-3881(24)00065-3</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study aimed to explore the synergistic impact of online yoga, mindfulness practices, and probiotics on irritable bowel syndrome (IBS) by evaluating changes in physical fitness, mental health, and gut microbiota composition.</AbstractText><AbstractText Label="DESIGN, SETTING AND INTERVENTIONS" NlmCategory="UNASSIGNED">The six-week randomized, double-blinded, placebo-controlled trial included 31 IBS patients categorized into three groups: online yoga with probiotics (EP), online yoga with a placebo (EC), and probiotics only (P). Assessments involved physical fitness tests, subjective questionnaires (IBS-QOL, BSRS-5), and gut microbiome analysis.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Participants self-collected stool samples and were given a set of questionnaires at baseline and after six weeks of intervention. Their symptoms were measured by changes in the gut microbiota, physical fitness and quality of life, and psychological well-being.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The EP group demonstrated improved cardiovascular endurance (P&#xa0;&lt;&#xa0;0.001) and a significant reduction in Klebsiella bacterial strains (P&#xa0;&lt;&#xa0;0.05). Both the EP and EC groups exhibited significantly decreased IBS-QOL scores (P&#xa0;&lt;&#xa0;0.001 and P&#xa0;&lt;&#xa0;0.05, respectively), indicating enhanced quality of life. While BSRS-5 scores decreased in both groups, the reduction was statistically insignificant.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Integrating online yoga, mindfulness practices, and probiotics demonstrated comprehensive benefits for IBS patients. This intervention improved physical fitness and mental well-being and positively influenced gut microbiota composition. The study highlights the potential of this multifaceted approach in managing IBS symptoms and enhancing overall health, emphasizing the relevance of the gut-muscle-brain axis in understanding and addressing IBS complexities.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Taiwanese Registry of Institutional Review Board IRBHP210009/CH11000259.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chao</LastName><ForeName>Wei-Cheng</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Ph.D. Program in Tissue Engineering and Regenerative Medicine, National Chung Hsing University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Jen-Chieh</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Cheng Ching Hospital, Chung Kang Branch, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>San-Land</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Culture Collection &amp; Research Institute, Synbio Tech Inc, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Ching-Lin</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Graduate Institute of Sports and Health Management, National Chung Hsing University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shih</LastName><ForeName>Jui-Chi</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Graduate Institute of Sports and Health Management, National Chung Hsing University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Lun-De</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Engineering and Nanomedicine, National Health Research Institutes, Miaoli, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Bill</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Graduate Institute of Biomedical Engineering, National Chung Hsing University, Taichung, Taiwan. Electronic address: d109001704@mail.nchu.edu.tw.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Complement Ther Clin Pract</MedlineTA><NlmUniqueID>101225531</NlmUniqueID><ISSNLinking>1744-3881</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="Y">Exercise</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064866" MajorTopicYN="N">Mindfulness</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015013" MajorTopicYN="Y">Yoga</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Gut-muscle-brain axis</Keyword><Keyword MajorTopicYN="N">IBS</Keyword><Keyword MajorTopicYN="N">Irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">Physical activity</Keyword><Keyword MajorTopicYN="N">Probiotics</Keyword><Keyword MajorTopicYN="N">Yoga</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>14</Day><Hour>3</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>11</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>10</Day><Hour>18</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39126817</ArticleId><ArticleId IdType="doi">10.1016/j.ctcp.2024.101892</ArticleId><ArticleId IdType="pii">S1744-3881(24)00065-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30845384</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2233-6869</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>2</Issue><PubDate><Year>2019</Year><Month>Feb</Month><Day>25</Day></PubDate></JournalIssue><Title>The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi</Title><ISOAbbreviation>Korean J Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>[Irritable Bowel Syndrome].</ArticleTitle><Pagination><StartPage>84</StartPage><EndPage>91</EndPage><MedlinePgn>84-91</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4166/kjg.2019.73.2.84</ELocationID><Abstract><AbstractText>Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder. Its diagnosis is based on symptoms, and the Rome IV criteria are recognized as the gold diagnostic standard. The Korean Society of Neurogastroenterology and Motility (KSNM) recently updated their clinical practice guidelines for the treatment of IBS, which were last issued in 2011. In this updated edition, the KSNM defines IBS as a chronic, recurrent symptom complex that includes abdominal pain or discomfort, changes in bowel habits, and bloating for at least 6 months, which is somewhat broader than the previous definition. Four major topics have been changed in the up-dated version in-line with the results of recent studies, that is, colonoscopy; a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols; probiotics; and rifaximin. Herein, we review the 2017 revised edition of the KSNM with respect to recommended clinical practice guidelines for IBS and compare these with other guidelines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jae Hak</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dongguk University College of Medicine, Goyang, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jee</LastName><ForeName>Sam Ryong</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Inje University College of Medicine, Busan, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>kor</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Korean J Gastroenterol</MedlineTA><NlmUniqueID>101189416</NlmUniqueID><ISSNLinking>1598-9992</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012702">Serotonin Antagonists</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004032" MajorTopicYN="N">Diet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055317" MajorTopicYN="N">Evidence-Based Practice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012702" MajorTopicYN="N">Serotonin Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Evidence-based practice</Keyword><Keyword MajorTopicYN="N">Irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">Practice guideline</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30845384</ArticleId><ArticleId IdType="doi">10.4166/kjg.2019.73.2.84</ArticleId><ArticleId IdType="pii">kjg.2019.73.2.84</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32277872</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2468-1253</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The lancet. Gastroenterology &amp; hepatology</Title><ISOAbbreviation>Lancet Gastroenterol Hepatol</ISOAbbreviation></Journal><ArticleTitle>Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial.</ArticleTitle><Pagination><StartPage>658</StartPage><EndPage>666</EndPage><MedlinePgn>658-666</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S2468-1253(20)30056-X</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2468-1253(20)30056-X</ELocationID><Abstract><AbstractText Label="BACKGROUND">Bifidobacterium bifidum MIMBb75 is one of a few probiotic strains that have been shown to be effective in the treatment of irritable bowel syndrome (IBS) and its symptoms. Non-viable strains might have advantages over viable bacteria for product stability and standardisation, as well as for tolerability because safety concerns have been raised for specific patient groups who are susceptible to infection. We aimed to assess the efficacy of non-viable, heat-inactivated (HI) B bifidum MIMBb75 (SYN-HI-001) in the treatment of IBS and its symptoms.</AbstractText><AbstractText Label="METHODS">We did a double-blind, placebo-controlled trial in which patients with IBS were recruited from 20 study sites in Germany and randomly assigned to receive either two placebo capsules or two capsules with a combined total of 1&#x2008;&#xd7;&#x2008;10<sup>9</sup> non-viable B bifidum HI-MIMBb75 cells to be taken orally once a day for 8 weeks. Eligible patients were diagnosed with IBS according to Rome III criteria and had abdominal pain (&#x2265;4 on an 11-point numerical rating scale) on at least 2 days during a 2-week run-in phase. Patients with chronic inflammatory bowel diseases, systemic diseases, cancer, autoimmune diseases, with an intake of antipsychotic medications 3 months before study start, or with an intake of systemic corticosteroids within 1 month before study start were excluded. Randomisation was in a 1:1 ratio according to a computer-generated blocked list. Patients, investigators, clinical monitors, project managers, and statisticians were masked to the randomisation. The primary composite endpoint was the combination of at least 30% improvement of abdominal pain and adequate relief of overall IBS symptoms being fulfilled in at least 4 of 8 weeks during treatment. Analysis of the primary endpoint included all randomly assigned patients receiving at least one dose of study medication and who had no severe protocol violation. Safety analysis included all patients who had taken at least one dose of the study medication and was based on frequency and severity of adverse events, laboratory evaluation, and global assessment of tolerability. This trial is registered with the ISRCTN registry, ISRCTN14066467, and is completed: the results shown here represent the final analysis.</AbstractText><AbstractText Label="FINDINGS">Patients were screened between April 15, 2016, and Feb 3, 2017, and 443 patients were allocated to the placebo group (n=222) or the B bifidum HI-MIMBb75 group (n=221). The composite primary endpoint was reached by 74 (34%) of 221 patients in the B bifidum HI-MIMBb75 group compared with 43 (19%) of 222 in the placebo group (risk ratio 1&#xb7;7, 95% CI 1&#xb7;3-2&#xb7;4; p=0&#xb7;0007). No serious adverse events occurred in the B bifidum HI-MIMBb75 group; seven adverse events suspected to be related to the study product were reported in the B bifidum HI-MIMBb75 group as were eight in the placebo group. No deaths were reported in this study. The most common reported adverse event with a suspected relationship to the study product was abdominal pain, which was reported in two (&lt;1%) patients in the B bifidum HI-MIMBb75 group and one (&lt;1%) in the placebo group. Tolerability was rated as very good or good by 200 (91%) patients in the B bifidum HI-MIMBb75 group compared with 191 (86%) in the placebo group.</AbstractText><AbstractText Label="INTERPRETATION">This study shows that B bifidum HI-MIMBb75 substantially alleviates IBS and its symptoms in a real-life setting. These results indicate that specific beneficial bacterial effects are mediated independently of cell viability.</AbstractText><AbstractText Label="FUNDING">Synformulas.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Andresen</LastName><ForeName>Viola</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Israelitic Hospital, University of Hamburg Teaching Hospital, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gschossmann</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Forchheim, Forchheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Layer</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Israelitic Hospital, University of Hamburg Teaching Hospital, Hamburg, Germany. Electronic address: p.layer@ik-h.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Lancet Gastroenterol Hepatol</MedlineTA><NlmUniqueID>101690683</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Gastroenterol Hepatol. 2020 Jul;5(7):627-629. doi: 10.1016/S2468-1253(20)30079-0.</RefSource><PMID Version="1">32277873</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Gastroenterol Hepatol. 2020 Sep;5(9):797. doi: 10.1016/S2468-1253(20)30243-0.</RefSource><PMID Version="1">32818454</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Gastroenterol Hepatol. 2020 Sep;5(9):797-798. doi: 10.1016/S2468-1253(20)30239-9.</RefSource><PMID Version="1">32818455</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015746" MajorTopicYN="N">Abdominal Pain</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069985" MajorTopicYN="N">Bifidobacterium bifidum</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007422" MajorTopicYN="N">Intestines</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010147" MajorTopicYN="N">Pain Measurement</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012449" MajorTopicYN="N">Safety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32277872</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(20)30056-X</ArticleId><ArticleId IdType="pii">S2468-1253(20)30056-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">23384803</PMID><DateCompleted><Year>2013</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1532-1916</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>5</Issue><PubDate><Year>2012</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Best practice &amp; research. Clinical gastroenterology</Title><ISOAbbreviation>Best Pract Res Clin Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Irritable bowel syndrome--diarrhoea.</ArticleTitle><Pagination><StartPage>573</StartPage><EndPage>580</EndPage><MedlinePgn>573-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bpg.2012.11.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1521-6918(12)00101-1</ELocationID><Abstract><AbstractText>IBS is a functional gastrointestinal disorder which has been subtyped according to bowel habits. This review presents recommendations for IBS-D which makes up about 1/3 of all patients and which is defined as IBS with loose or watery stools with &#x2265;25% of bowel movements. Because IBS is a complex biopsychosocial illness, treatment cannot and should not be directed only to altered bowel habits. Evidence will be presented for dietary manipulations, probiotics and pharmacotherapies including tricyclic agents, antibiotics, serotonin antagonists and anti-diarrhoeal agents in the management of patients with IBS-D.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wald</LastName><ForeName>Arnold</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health, 1685 Highland Avenue, Suite 4000, Madison, WI 53705, USA. axw@medicine.wisc.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Best Pract Res Clin Gastroenterol</MedlineTA><NlmUniqueID>101120605</NlmUniqueID><ISSNLinking>1521-6918</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000929">Antidepressive Agents, Tricyclic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000930">Antidiarrheals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004040">Dietary Carbohydrates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004043">Dietary Fiber</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012702">Serotonin Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>6X9OC3H4II</RegistryNumber><NameOfSubstance UI="D008139">Loperamide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000929" MajorTopicYN="N">Antidepressive Agents, Tricyclic</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000930" MajorTopicYN="N">Antidiarrheals</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003248" MajorTopicYN="N">Constipation</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003672" MajorTopicYN="N">Defecation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004040" MajorTopicYN="N">Dietary Carbohydrates</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004043" MajorTopicYN="N">Dietary Fiber</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008139" MajorTopicYN="N">Loperamide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012702" MajorTopicYN="N">Serotonin Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23384803</ArticleId><ArticleId IdType="doi">10.1016/j.bpg.2012.11.002</ArticleId><ArticleId IdType="pii">S1521-6918(12)00101-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26819502</PMID><DateCompleted><Year>2017</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2219-2840</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Jan</Month><Day>28</Day></PubDate></JournalIssue><Title>World journal of gastroenterology</Title><ISOAbbreviation>World J Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Is irritable bowel syndrome an infectious disease?</ArticleTitle><Pagination><StartPage>1331</StartPage><EndPage>1334</EndPage><MedlinePgn>1331-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3748/wjg.v22.i4.1331</ELocationID><Abstract><AbstractText>Irritable bowel syndrome (IBS) is the most common of all gastroenterological diseases. While many mechanisms have been postulated to explain its etiology, no single mechanism entirely explains the heterogeneity of symptoms seen with the various phenotypes of the disease. Recent data from both basic and clinical sciences suggest that underlying infectious disease may provide a unifying hypothesis that better explains the overall symptomatology. The presence of small intestinal bowel overgrowth (SIBO) has been documented in patients with IBS and reductions in SIBO as determined by breath testing correlate with IBS symptom improvement in clinical trials. The incidence of new onset IBS symptoms following acute infectious gastroenteritis also suggests an infectious cause. Alterations in microbiota-host interactions may compromise epithelial barrier integrity, immune function, and the development and function of both central and enteric nervous systems explaining alterations in the brain-gut axis. Clinical evidence from treatment trials with both probiotics and antibiotics also support this etiology. Probiotics appear to restore the imbalance in the microflora and improve IBS-specific quality of life. Antibiotic trials with both neomycin and rifaximin show improvement in global IBS symptoms that correlates with breath test normalization in diarrhea-predominant patients. The treatment response to two weeks of rifaximin is sustained for up to ten weeks and comparable results are seen in symptom reduction with retreatment in patients who develop recurrent symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>John Richard</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>John Richard Thompson, Department of Pharmacy Practice, Lipscomb University College of Pharmacy, One University Park Drive, Nashville, TN 37204, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>World J Gastroenterol</MedlineTA><NlmUniqueID>100883448</NlmUniqueID><ISSNLinking>1007-9327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001419" MajorTopicYN="N">Bacteria</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000254" MajorTopicYN="Y">growth &amp; development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064806" MajorTopicYN="N">Dysbiosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054884" MajorTopicYN="N">Host-Pathogen Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007422" MajorTopicYN="N">Intestines</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibiotics</Keyword><Keyword MajorTopicYN="N">Etiology</Keyword><Keyword MajorTopicYN="N">Infectious disease</Keyword><Keyword MajorTopicYN="N">Irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">Pathopohysiology</Keyword><Keyword MajorTopicYN="N">Probiotics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>1</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26819502</ArticleId><ArticleId IdType="pmc">PMC4721968</ArticleId><ArticleId IdType="doi">10.3748/wjg.v22.i4.1331</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313:949&#x2013;958.</Citation><ArticleIdList><ArticleId IdType="pubmed">25734736</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall BJ. The discovery that Helicobacter pylori, a spiral bacterium, caused peptic ulcer disease. In: Marshall BJ, editor. Helicobacter Pioneers: Firsthand Accounts from the Scientists who Discovered Helicobacters 1892-1982. Oxford: Blackwell. pp; 2002. pp. 165&#x2013;202.</Citation></Reference><Reference><Citation>Buckley MM, O&#x2019;Mahony SM, O&#x2019;Malley D. Convergence of neuro-endocrine-immune pathways in the pathophysiology of irritable bowel syndrome. World J Gastroenterol. 2014;20:8846&#x2013;8858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4112880</ArticleId><ArticleId IdType="pubmed">25083058</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal UC, Srivastava D. Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype. World J Gastroenterol. 2014;20:2482&#x2013;2491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3949258</ArticleId><ArticleId IdType="pubmed">24627585</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA. 2004;292:852&#x2013;858.</Citation><ArticleIdList><ArticleId IdType="pubmed">15316000</ArticleId></ArticleIdList></Reference><Reference><Citation>King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet. 1998;352:1187&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pubmed">9777836</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen S, Dear KL, King TS, Elia M, Hunter JO. Evaluation of hydrogen excretion after lactulose administration as a screening test for causes of irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2002;14:753&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">12169984</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal UC, Kumar S, Mehrotra M, Lakshmi C, Misra A. Frequency of small intestinal bacterial overgrowth in patients with irritable bowel syndrome and chronic non-specific diarrhea. J Neurogastroenterol Motil. 2010;16:40&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2879828</ArticleId><ArticleId IdType="pubmed">20535325</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee S, Park S, Low K, Kong Y, Pimentel M. The degree of breath methane production in IBS correlates with the severity of constipation. Am J Gastroenterol. 2007;102:837&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pubmed">17397408</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M, Lezcano S. Irritable Bowel Syndrome: Bacterial Overgrowth--What&#x2019;s Known and What to Do. Curr Treat Options Gastroenterol. 2007;10:328&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">17761126</ArticleId></ArticleIdList></Reference><Reference><Citation>Simr&#xe9;n M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013;62:159&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551212</ArticleId><ArticleId IdType="pubmed">22730468</ArticleId></ArticleIdList></Reference><Reference><Citation>Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26:535&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pubmed">17661757</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupp C, Robertson ML, Wickham ME, Sekirov I, Champion OL, Gaynor EC, Finlay BB. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe. 2007;2:204.</Citation><ArticleIdList><ArticleId IdType="pubmed">18030708</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyland NP, Quigley EM, Brint E. Microbiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactions. World J Gastroenterol. 2014;20:8859&#x2013;8866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4112904</ArticleId><ArticleId IdType="pubmed">25083059</ArticleId></ArticleIdList></Reference><Reference><Citation>Gareau MG, Jury J, MacQueen G, Sherman PM, Perdue MH. Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation. Gut. 2007;56:1522&#x2013;1528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2095679</ArticleId><ArticleId IdType="pubmed">17339238</ArticleId></ArticleIdList></Reference><Reference><Citation>Tojo R, Su&#xe1;rez A, Clemente MG, de los Reyes-Gavil&#xe1;n CG, Margolles A, Gueimonde M, Ruas-Madiedo P. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World J Gastroenterol. 2014;20:15163&#x2013;15176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4223251</ArticleId><ArticleId IdType="pubmed">25386066</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajander K, Myllyluoma E, Rajili&#x107;-Stojanovi&#x107; M, Kyr&#xf6;npalo S, Rasmussen M, J&#xe4;rvenp&#xe4;&#xe4; S, Zoetendal EG, de Vos WM, Vapaatalo H, Korpela R. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther. 2008;27:48&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">17919270</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, Mercier CH, Matuchansky C. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther. 2007;26:475&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">17635382</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzo-Z&#xfa;&#xf1;iga V, Llop E, Su&#xe1;rez C, Alvarez B, Abreu L, Espadaler J, Serra J. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J Gastroenterol. 2014;20:8709&#x2013;8716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4093724</ArticleId><ArticleId IdType="pubmed">25024629</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">12591062</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">21208106</ArticleId></ArticleIdList></Reference><Reference><Citation>Lembo A, Pimentel M, Rao SS. Efficacy and safety of repeat treatment with rifaximin for diarrhea-predominant irritable bowel syndrome (IBS-D): Results of the TARGET 3 study. Philadelphia, PA: Presented at the American College of Gastroenterology Annual Meeting; 2014. pp. 17&#x2013;22.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27161354</PMID><DateCompleted><Year>2016</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0065-2598</ISSN><JournalIssue CitedMedium="Print"><Volume>902</Volume><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>Advances in experimental medicine and biology</Title><ISOAbbreviation>Adv Exp Med Biol</ISOAbbreviation></Journal><ArticleTitle>Manipulation of the Microbiota Using Probiotics.</ArticleTitle><Pagination><StartPage>109</StartPage><EndPage>117</EndPage><MedlinePgn>109-17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/978-3-319-31248-4_8</ELocationID><Abstract><AbstractText>A number of diseases are associated with alterations in the composition of the microbiota of various niches of the human body. Although, in most cases, it is unclear if these alterations are the cause or the consequence of disease, they provide a rationale for therapeutic or prophylactic manipulation of a dysbiotic microbiota. Approaches to manipulate the microbiome include administration of either live bacteria, which are underrepresented in the diseased individual, substances that aim at increasing the populations of these bacteria, or a combination of the two. This chapter summarizes the available data in therapeutic manipulation of a various diseased states including irritable bowel syndrome, inflammatory bowel disease, necrotizing enterocolitis, atopic and allergic diseases, and antibiotic-associated and infectious diarrhoea.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grimm</LastName><ForeName>Verena</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute of Microbiology and Biotechnology, University of Ulm, Albert-Einstein-Allee 11, 89069, Ulm, Germany. verena.grimm@uni-ulm.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riedel</LastName><ForeName>Christian U</ForeName><Initials>CU</Initials><AffiliationInfo><Affiliation>Institute of Microbiology and Biotechnology, University of Ulm, Albert-Einstein-Allee 11, 89069, Ulm, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Adv Exp Med Biol</MedlineTA><NlmUniqueID>0121103</NlmUniqueID><ISSNLinking>0065-2598</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020345" MajorTopicYN="N">Enterocolitis, Necrotizing</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054884" MajorTopicYN="N">Host-Pathogen Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006967" MajorTopicYN="N">Hypersensitivity</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015212" MajorTopicYN="N">Inflammatory Bowel Diseases</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007422" MajorTopicYN="N">Intestines</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013559" MajorTopicYN="N">Symbiosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Allergy</Keyword><Keyword MajorTopicYN="N">Diarrhea</Keyword><Keyword MajorTopicYN="N">IBD</Keyword><Keyword MajorTopicYN="N">IBS</Keyword><Keyword MajorTopicYN="N">Necrotising enterocolitis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27161354</ArticleId><ArticleId IdType="doi">10.1007/978-3-319-31248-4_8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34904950</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1438-8871</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>14</Day></PubDate></JournalIssue><Title>Journal of medical Internet research</Title><ISOAbbreviation>J Med Internet Res</ISOAbbreviation></Journal><ArticleTitle>Long-Term Effects of a Web-Based Low-FODMAP Diet Versus Probiotic Treatment for Irritable Bowel Syndrome, Including Shotgun Analyses of Microbiota: Randomized, Double-Crossover Clinical Trial.</ArticleTitle><Pagination><StartPage>e30291</StartPage><MedlinePgn>e30291</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e30291</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/30291</ELocationID><Abstract><AbstractText Label="BACKGROUND">The long-term management of irritable bowel syndrome (IBS) poses many challenges. In short-term studies, eHealth interventions have been demonstrated to be safe and practical for at-home monitoring of the effects of probiotic treatments and a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs). IBS has been linked to alterations in the microbiota.</AbstractText><AbstractText Label="OBJECTIVE">The aim of this study was to determine whether a web-based low-FODMAP diet (LFD) intervention and probiotic treatment were equally good at reducing IBS symptoms, and whether the response to treatments could be explained by patients' microbiota.</AbstractText><AbstractText Label="METHODS">Adult IBS patients were enrolled in an open-label, randomized crossover trial (for nonresponders) with 1 year of follow-up using the web application IBS Constant Care (IBS CC). Patients were recruited from the outpatient clinic at the Department of Gastroenterology, North Zealand University Hospital, Denmark. Patients received either VSL#3 for 4 weeks (2 &#xd7; 450 billion colony-forming units per day) or were placed on an LFD for 4 weeks. Patients responding to the LFD were reintroduced to foods high in FODMAPs, and probiotic responders received treatments whenever they experienced a flare-up of symptoms. Treatment response and symptom flare-ups were defined as a reduction or increase, respectively, of at least 50 points on the IBS Severity Scoring System (IBS-SSS). Web-based ward rounds were performed daily by the study investigator. Fecal microbiota were analyzed by shotgun metagenomic sequencing (at least 10 million 2 &#xd7; 100 bp paired-end sequencing reads per sample).</AbstractText><AbstractText Label="RESULTS">A total of 34 IBS patients without comorbidities and 6 healthy controls were enrolled in the study. Taken from participating subjects, 180 fecal samples were analyzed for their microbiota composition. Out of 21 IBS patients, 12 (57%) responded to the LFD and 8 (38%) completed the reintroduction of FODMAPs. Out of 21 patients, 13 (62%) responded to their first treatment of VSL#3 and 7 (33%) responded to multiple VSL#3 treatments. A median of 3 (IQR 2.25-3.75) probiotic treatments were needed for sustained symptom control. LFD responders were reintroduced to a median of 14.50 (IQR 7.25-21.75) high-FODMAP items. No significant difference in the median reduction of IBS-SSS for LFD versus probiotic responders was observed, where for LFD it was -126.50 (IQR -196.75 to -76.75) and for VSL#3 it was -130.00 (IQR -211.00 to -70.50; P&gt;.99). Responses to either of the two treatments were not able to be predicted using patients' microbiota.</AbstractText><AbstractText Label="CONCLUSIONS">The web-based LFD intervention and probiotic treatment were equally efficacious in managing IBS symptoms. The response to treatments could not be explained by the composition of the microbiota. The IBS CC web application was shown to be practical, safe, and useful for clinical decision making in the long-term management of IBS. Although this study was underpowered, findings from this study warrant further research in a larger sample of patients with IBS to confirm these long-term outcomes.</AbstractText><AbstractText Label="TRIAL REGISTRATION">ClinicalTrials.gov NCT03586622; https://clinicaltrials.gov/ct2/show/NCT03586622.</AbstractText><CopyrightInformation>&#xa9;Dorit Vedel Ankersen, Petra Weimers, Mette Bennedsen, Anne Birgitte Haaber, Eva Lund Fjordside, Moritz Emanuel Beber, Christian Lieven, Sanaz Saboori, Nicolai Vad, Terje Rannem, Dorte Marker, Kristine Paridaens, Suzanne Frahm, Lisbeth Jensen, Malte Rosager Hansen, Johan Burisch, Pia Munkholm. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 14.12.2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ankersen</LastName><ForeName>Dorit Vedel</ForeName><Initials>DV</Initials><Identifier Source="ORCID">0000-0003-1098-3998</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, North Zealand University Hospital, Frederikssund, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weimers</LastName><ForeName>Petra</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-7646-3728</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, North Zealand University Hospital, Frederikssund, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennedsen</LastName><ForeName>Mette</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2635-4187</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, North Zealand University Hospital, Frederikssund, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haaber</LastName><ForeName>Anne Birgitte</ForeName><Initials>AB</Initials><Identifier Source="ORCID">0000-0001-5980-3367</Identifier></Author><Author ValidYN="Y"><LastName>Fjordside</LastName><ForeName>Eva Lund</ForeName><Initials>EL</Initials><Identifier Source="ORCID">0000-0002-9040-509X</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, North Zealand University Hospital, Frederikssund, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beber</LastName><ForeName>Moritz Emanuel</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0003-2406-1978</Identifier><AffiliationInfo><Affiliation>Unseen Bio Anpartsselskab, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lieven</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-5377-4091</Identifier><AffiliationInfo><Affiliation>Unseen Bio Anpartsselskab, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saboori</LastName><ForeName>Sanaz</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7677-668X</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, North Zealand University Hospital, Frederikssund, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vad</LastName><ForeName>Nicolai</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-3737-210X</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, North Zealand University Hospital, Frederikssund, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rannem</LastName><ForeName>Terje</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-3605-9162</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, North Zealand University Hospital, Frederikssund, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marker</LastName><ForeName>Dorte</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-5017-8339</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, North Zealand University Hospital, Frederikssund, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paridaens</LastName><ForeName>Kristine</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-6865-5415</Identifier><AffiliationInfo><Affiliation>Ferring International Center Soci&#xe9;t&#xe9; Anonyme, Saint-Prex, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frahm</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9602-2110</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, North Zealand University Hospital, Frederikssund, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Lisbeth</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-4326-7621</Identifier><AffiliationInfo><Affiliation>Department of Dietetics, Herlev University Hospital, Herlev, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosager Hansen</LastName><ForeName>Malte</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7891-787X</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, North Zealand University Hospital, Frederikssund, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burisch</LastName><ForeName>Johan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3312-5139</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, North Zealand University Hospital, Frederikssund, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munkholm</LastName><ForeName>Pia</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-7263-1122</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, North Zealand University Hospital, Frederikssund, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03586622</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>J Med Internet Res</MedlineTA><NlmUniqueID>100959882</NlmUniqueID><ISSNLinking>1438-8871</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004032" MajorTopicYN="N">Diet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020407" MajorTopicYN="N">Internet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064307" MajorTopicYN="Y">Microbiota</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IBS</Keyword><Keyword MajorTopicYN="N">eHealth</Keyword><Keyword MajorTopicYN="N">gastroenterology</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">mHealth</Keyword><Keyword MajorTopicYN="N">microbiome</Keyword><Keyword MajorTopicYN="N">microbiota</Keyword><Keyword MajorTopicYN="N">mobile app</Keyword><Keyword MajorTopicYN="N">outcomes</Keyword><Keyword MajorTopicYN="N">probiotics</Keyword><Keyword MajorTopicYN="N">randomized trial</Keyword><Keyword MajorTopicYN="N">symptom management</Keyword><Keyword MajorTopicYN="N">treatment</Keyword><Keyword MajorTopicYN="N">treatment outcomes</Keyword><Keyword MajorTopicYN="N">web-based</Keyword><Keyword MajorTopicYN="N">web-based low-FODMAP diet</Keyword></KeywordList><CoiStatement>Conflicts of Interest: MEB and CL are cofounders of Unseen Bio ApS, a company that offers microbiome profiling to consumers. The remaining authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>14</Day><Hour>12</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34904950</ArticleId><ArticleId IdType="pmc">PMC8715363</ArticleId><ArticleId IdType="doi">10.2196/30291</ArticleId><ArticleId IdType="pii">v23i12e30291</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014;6:71&#x2013;80. doi: 10.2147/CLEP.S40245. doi: 10.2147/CLEP.S40245.clep-6-071</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S40245</ArticleId><ArticleId IdType="doi">10.2147/CLEP.S40245</ArticleId><ArticleId IdType="pmc">PMC3921083</ArticleId><ArticleId IdType="pubmed">24523597</ArticleId></ArticleIdList></Reference><Reference><Citation>Corsetti M, Whorwell P. The global impact of IBS: Time to think about IBS-specific models of care? Therap Adv Gastroenterol. 2017 Sep;10(9):727&#x2013;736. doi: 10.1177/1756283X17718677. 
 
10.1177_1756283X17718677</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756283X17718677?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%3dpubmed</ArticleId><ArticleId IdType="doi">10.1177/1756283X17718677</ArticleId><ArticleId IdType="pmc">PMC5598808</ArticleId><ArticleId IdType="pubmed">28932273</ArticleId></ArticleIdList></Reference><Reference><Citation>Simr&#xe9;n M, Barbara G, Flint HJ, Spiegel BMR, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG, Rome Foundation Committee  Intestinal microbiota in functional bowel disorders: A Rome Foundation report. Gut. 2013 Jan;62(1):159&#x2013;176. doi: 10.1136/gutjnl-2012-302167. 
 
gutjnl-2012-302167</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2012-302167</ArticleId><ArticleId IdType="pmc">PMC3551212</ArticleId><ArticleId IdType="pubmed">22730468</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer EA. The role of gut-brain interactions in influencing symptoms of irritable bowel syndrome. Gastroenterol Hepatol (N Y) 2018 Jan;14(1):44&#x2013;46. 
 
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5824595</ArticleId><ArticleId IdType="pubmed">29491761</ArticleId></ArticleIdList></Reference><Reference><Citation>Thabane M, Marshall JK. Post-infectious irritable bowel syndrome. World J Gastroenterol. 2009 Aug 07;15(29):3591&#x2013;3596. doi: 10.3748/wjg.15.3591. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.15.3591</ArticleId><ArticleId IdType="pmc">PMC2721231</ArticleId><ArticleId IdType="pubmed">19653335</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones MP, Chey WD, Singh S, Gong H, Shringarpure R, Hoe N, Chuang E, Talley NJ. A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads. Aliment Pharmacol Ther. 2014 Feb;39(4):426&#x2013;437. doi: 10.1111/apt.12608. doi: 10.1111/apt.12608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.12608</ArticleId><ArticleId IdType="doi">10.1111/apt.12608</ArticleId><ArticleId IdType="pubmed">24387672</ArticleId></ArticleIdList></Reference><Reference><Citation>Ankersen DV, Weimers P, Burisch J. Whats 'app-ening': The help of new technologies in nutrition in digestive diseases. Curr Opin Clin Nutr Metab Care. 2017 Sep;20(5):426&#x2013;431. doi: 10.1097/MCO.0000000000000399.00075197-201709000-00020</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCO.0000000000000399</ArticleId><ArticleId IdType="pubmed">28768297</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen N. EHealth: Self-management in inflammatory bowel disease and in irritable bowel syndrome using novel constant-care web applications. EHealth by constant-care in IBD and IBS. Dan Med J. 2015 Dec;62(12):B5168. 
 
B5168</Citation><ArticleIdList><ArticleId IdType="pubmed">26621403</ArticleId></ArticleIdList></Reference><Reference><Citation>Whelan K, Martin LD, Staudacher HM, Lomer MCE. The low FODMAP diet in the management of irritable bowel syndrome: An evidence-based review of FODMAP restriction, reintroduction and personalisation in clinical practice. J Hum Nutr Diet. 2018 Apr;31(2):239&#x2013;255. doi: 10.1111/jhn.12530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jhn.12530</ArticleId><ArticleId IdType="pubmed">29336079</ArticleId></ArticleIdList></Reference><Reference><Citation>Altobelli E, Del Negro V, Angeletti P, Latella G. Low-FODMAP diet improves irritable bowel syndrome symptoms: A meta-analysis. Nutrients. 2017 Aug 26;9(9):940. doi: 10.3390/nu9090940. 
 
nu9090940</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu9090940</ArticleId><ArticleId IdType="pmc">PMC5622700</ArticleId><ArticleId IdType="pubmed">28846594</ArticleId></ArticleIdList></Reference><Reference><Citation>Maagaard L, Ankersen DV, V&#xe9;gh Z, Burisch J, Jensen L, Pedersen N, Munkholm P. Follow-up of patients with functional bowel symptoms treated with a low FODMAP diet. World J Gastroenterol. 2016 Apr 21;22(15):4009&#x2013;4019. doi: 10.3748/wjg.v22.i15.4009. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i15.4009</ArticleId><ArticleId IdType="pmc">PMC4823251</ArticleId><ArticleId IdType="pubmed">27099444</ArticleId></ArticleIdList></Reference><Reference><Citation>Weynants A, Goossens L, Genetello M, De Looze D, Van Winckel M. The long-term effect and adherence of a low fermentable oligosaccharides disaccharides monosaccharides and polyols (FODMAP) diet in patients with irritable bowel syndrome. J Hum Nutr Diet. 2020 Apr;33(2):159&#x2013;169. doi: 10.1111/jhn.12706.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jhn.12706</ArticleId><ArticleId IdType="pubmed">31637777</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen N, Andersen NN, V&#xe9;gh Z, Jensen L, Ankersen DV, Felding M, Simonsen MH, Burisch J, Munkholm P. Ehealth: Low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome. World J Gastroenterol. 2014 Nov 21;20(43):16215&#x2013;16226. doi: 10.3748/wjg.v20.i43.16215. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i43.16215</ArticleId><ArticleId IdType="pmc">PMC4239510</ArticleId><ArticleId IdType="pubmed">25473176</ArticleId></ArticleIdList></Reference><Reference><Citation>Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Gibson PR, Muir JG. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut. 2015 Jan;64(1):93&#x2013;100. doi: 10.1136/gutjnl-2014-307264.gutjnl-2014-307264</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2014-307264</ArticleId><ArticleId IdType="pubmed">25016597</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher HM, Irving PM, Lomer MCE, Whelan K. Mechanisms and efficacy of dietary FODMAP restriction in IBS. Nat Rev Gastroenterol Hepatol. 2014 Apr;11(4):256&#x2013;266. doi: 10.1038/nrgastro.2013.259.nrgastro.2013.259</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2013.259</ArticleId><ArticleId IdType="pubmed">24445613</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittayanon R, Lau JT, Yuan Y, Leontiadis GI, Tse F, Surette M, Moayyedi P. Gut microbiota in patients with irritable bowel syndrome-A systematic review. Gastroenterology. 2019 Jul;157(1):97&#x2013;108. doi: 10.1053/j.gastro.2019.03.049.S0016-5085(19)34649-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2019.03.049</ArticleId><ArticleId IdType="pubmed">30940523</ArticleId></ArticleIdList></Reference><Reference><Citation>Probiotics Market Size, Share &amp; Trends Analysis Report by Product (Food &amp; Beverages, Dietary Supplements), by Ingredient (Bacteria, Yeast), by End Use, by Distribution Channel, and Segment Forecasts, 2019 - 2025. San Francisco, CA: Grand View Research; 2019.  [2021-04-06].  
 https://www.grandviewresearch.com/industry-analysis/probiotics-market
.</Citation></Reference><Reference><Citation>Yang M, Yu Y, Lei P, Yuan J. Comparative efficacy and safety of probiotics for the treatment of irritable bowel syndrome: A systematic review and network meta-analysis protocol. BMJ Open. 2019 Dec 02;9(12):e027376. doi: 10.1136/bmjopen-2018-027376. 
 
bmjopen-2018-027376</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2018-027376</ArticleId><ArticleId IdType="pmc">PMC7003387</ArticleId><ArticleId IdType="pubmed">31796470</ArticleId></ArticleIdList></Reference><Reference><Citation>Hookway C, Buckner S, Crosland P, Longson D. Irritable bowel syndrome in adults in primary care: Summary of updated NICE guidance. BMJ. 2015 Feb 25;350:h701. doi: 10.1136/bmj.h701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.h701</ArticleId><ArticleId IdType="pubmed">25716701</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol. 2008 May 07;14(17):2650&#x2013;2661. doi: 10.3748/wjg.14.2650. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.14.2650</ArticleId><ArticleId IdType="pmc">PMC2709042</ArticleId><ArticleId IdType="pubmed">18461650</ArticleId></ArticleIdList></Reference><Reference><Citation>Didari T, Mozaffari S, Nikfar S, Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World J Gastroenterol. 2015 Mar 14;21(10):3072&#x2013;3084. doi: 10.3748/wjg.v21.i10.3072. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v21.i10.3072</ArticleId><ArticleId IdType="pmc">PMC4356930</ArticleId><ArticleId IdType="pubmed">25780308</ArticleId></ArticleIdList></Reference><Reference><Citation>Wie&#xeb;rs G, Belkhir L, Enaud R, Leclercq S, Philippart de Foy J, Dequenne I, de Timary P, Cani PD. How probiotics affect the microbiota. Front Cell Infect Microbiol. 2019;9:454. doi: 10.3389/fcimb.2019.00454. doi: 10.3389/fcimb.2019.00454.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2019.00454</ArticleId><ArticleId IdType="doi">10.3389/fcimb.2019.00454</ArticleId><ArticleId IdType="pmc">PMC6974441</ArticleId><ArticleId IdType="pubmed">32010640</ArticleId></ArticleIdList></Reference><Reference><Citation>IBS Constant Care.  [2021-11-29].  
 https://ibs.constant-care.com/
</Citation></Reference><Reference><Citation>Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997 Apr;11(2):395&#x2013;402. doi: 10.1046/j.1365-2036.1997.142318000.x. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.1997.142318000.x</ArticleId><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen N, Vegh Z, Burisch J, Jensen L, Ankersen DV, Felding M, Andersen NN, Munkholm P. Ehealth monitoring in irritable bowel syndrome patients treated with low fermentable oligo-, di-, mono-saccharides and polyols diet. World J Gastroenterol. 2014 Jun 07;20(21):6680&#x2013;6684. doi: 10.3748/wjg.v20.i21.6680. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i21.6680</ArticleId><ArticleId IdType="pmc">PMC4047359</ArticleId><ArticleId IdType="pubmed">24914395</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlsen K, Jakobsen C, Houen G, Kallemose T, Paerregaard A, Riis LB, Munkholm P, Wewer V. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: A randomized controlled trial. Inflamm Bowel Dis. 2017 Mar;23(3):357&#x2013;365. doi: 10.1097/MIB.0000000000001026.00054725-201703000-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MIB.0000000000001026</ArticleId><ArticleId IdType="pubmed">28221247</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen N, Thielsen P, Martinsen L, Bennedsen M, Haaber A, Langholz E, V&#xe9;gh Z, Duricova D, Jess T, Bell S, Burisch J, Munkholm P. eHealth: Individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2014 Dec;20(12):2276&#x2013;2285. doi: 10.1097/MIB.0000000000000199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MIB.0000000000000199</ArticleId><ArticleId IdType="pubmed">25248002</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick D, Drossman D, Frederick I, DiCesare J, Puder K. Quality of life in persons with irritable bowel syndrome: Development and validation of a new measure. Dig Dis Sci. 1998 Feb;43(2):400&#x2013;411. doi: 10.1023/a:1018831127942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/a:1018831127942</ArticleId><ArticleId IdType="pubmed">9512138</ArticleId></ArticleIdList></Reference><Reference><Citation>bcl2fastq2 Conversion Software v2.20. Illumina. 2017.  [2021-04-01].  
 https://support.illumina.com/downloads/bcl2fastq-conversion-software-v2-20.html
.</Citation></Reference><Reference><Citation>Jiang H, Lei R, Ding S, Zhu S. Skewer: A fast and accurate adapter trimmer for next-generation sequencing paired-end reads. BMC Bioinformatics. 2014 Jun 12;15:182. doi: 10.1186/1471-2105-15-182. 
 
1471-2105-15-182</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-15-182</ArticleId><ArticleId IdType="doi">10.1186/1471-2105-15-182</ArticleId><ArticleId IdType="pmc">PMC4074385</ArticleId><ArticleId IdType="pubmed">24925680</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Tommaso P, Chatzou M, Floden EW, Barja PP, Palumbo E, Notredame C. Nextflow enables reproducible computational workflows. Nat Biotechnol. 2017 Apr 11;35(4):316&#x2013;319. doi: 10.1038/nbt.3820.nbt.3820</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3820</ArticleId><ArticleId IdType="pubmed">28398311</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews S. FastQC. Babraham Bioinformatics.  [2021-04-01].  
 https://www.bioinformatics.babraham.ac.uk/projects/fastqc/
</Citation></Reference><Reference><Citation>Chen S, Zhou Y, Chen Y, Gu J. fastp: An ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018 Sep 01;34(17):i884&#x2013;i890. doi: 10.1093/bioinformatics/bty560. 
 
5093234</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bty560</ArticleId><ArticleId IdType="pmc">PMC6129281</ArticleId><ArticleId IdType="pubmed">30423086</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood DE, Lu J, Langmead B. Improved metagenomic analysis with Kraken 2. Genome Biol. 2019 Nov 28;20(1):257. doi: 10.1186/s13059-019-1891-0.10.1186/s13059-019-1891-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-019-1891-0</ArticleId><ArticleId IdType="pmc">PMC6883579</ArticleId><ArticleId IdType="pubmed">31779668</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewels P, Magnusson M, Lundin S, K&#xe4;ller M. MultiQC: Summarize analysis results for multiple tools and samples in a single report. Bioinformatics. 2016 Oct 01;32(19):3047&#x2013;3048. doi: 10.1093/bioinformatics/btw354. 
 
btw354</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btw354</ArticleId><ArticleId IdType="pmc">PMC5039924</ArticleId><ArticleId IdType="pubmed">27312411</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell A, Almeida A, Beracochea M, Boland M, Burgin J, Cochrane G, Crusoe MR, Kale V, Potter SC, Richardson LJ, Sakharova E, Scheremetjew M, Korobeynikov A, Shlemov A, Kunyavskaya O, Lapidus A, Finn RD. MGnify: The microbiome analysis resource in 2020. Nucleic Acids Res. 2020 Jan 08;48(D1):D570&#x2013;D578. doi: 10.1093/nar/gkz1035. 
 
5614179</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz1035</ArticleId><ArticleId IdType="pmc">PMC7145632</ArticleId><ArticleId IdType="pubmed">31696235</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J, Breitwieser F, Thielen P, Salzberg S. Bracken: Estimating species abundance in metagenomics data. PeerJ Comput Sci. 2017:e104. doi: 10.7717/peerj-cs.104. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj-cs.104</ArticleId></ArticleIdList></Reference><Reference><Citation>McMurdie PJ, Holmes S. phyloseq: An R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One. 2013;8(4):e61217. doi: 10.1371/journal.pone.0061217. 
 
PONE-D-12-31789</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0061217</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0061217</ArticleId><ArticleId IdType="pmc">PMC3632530</ArticleId><ArticleId IdType="pubmed">23630581</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith B, Wilson JB. A consumer's guide to evenness indices. Oikos. 1996 May;76(1):70&#x2013;82. doi: 10.2307/3545749.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/3545749</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon P. VEGAN, a package of R functions for community ecology. J Veg Sci. 2003 Apr 09;14(6):927&#x2013;930. doi: 10.1111/j.1654-1103.2003.tb02228.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1654-1103.2003.tb02228.x</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes L, Healy J, Saul N, Gro&#xdf;berger L. UMAP: Uniform Manifold Approximation and Projection. J Open Source Softw. 2018 Sep;3(29):861. doi: 10.21105/joss.00861.</Citation><ArticleIdList><ArticleId IdType="doi">10.21105/joss.00861</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin BD, Witten D, Willis AD. Modeling microbial abundances and dysbiosis with beta-binomial regression. Ann Appl Stat. 2020 Mar;14(1):94&#x2013;115. doi: 10.1214/19-aoas1283. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1214/19-aoas1283</ArticleId><ArticleId IdType="pmc">PMC7514055</ArticleId><ArticleId IdType="pubmed">32983313</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates D, M&#xe4;chler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67(1):1&#x2013;48. doi: 10.18637/jss.v067.i01.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v067.i01</ArticleId></ArticleIdList></Reference><Reference><Citation>Hvidberg MF, Johnsen SP, Davidsen M, Ehlers L. A nationwide study of prevalence rates and characteristics of 199 chronic conditions in Denmark. Pharmacoecon Open. 2020 Jun;4(2):361&#x2013;380. doi: 10.1007/s41669-019-0167-7. doi: 10.1007/s41669-019-0167-7.10.1007/s41669-019-0167-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s41669-019-0167-7</ArticleId><ArticleId IdType="doi">10.1007/s41669-019-0167-7</ArticleId><ArticleId IdType="pmc">PMC7248158</ArticleId><ArticleId IdType="pubmed">31342402</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, Liang L, Deng H, Guo J, Shu H, Zhang L. Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis. Front Pharmacol. 2020;11:332. doi: 10.3389/fphar.2020.00332. doi: 10.3389/fphar.2020.00332.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.00332</ArticleId><ArticleId IdType="doi">10.3389/fphar.2020.00332</ArticleId><ArticleId IdType="pmc">PMC7147251</ArticleId><ArticleId IdType="pubmed">32317962</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Liu W, Ran C, Hu J, Zhou Z. Abrupt suspension of probiotics administration may increase host pathogen susceptibility by inducing gut dysbiosis. Sci Rep. 2016 Mar 17;6:23214. doi: 10.1038/srep23214. doi: 10.1038/srep23214.srep23214</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep23214</ArticleId><ArticleId IdType="doi">10.1038/srep23214</ArticleId><ArticleId IdType="pmc">PMC4794715</ArticleId><ArticleId IdType="pubmed">26983596</ArticleId></ArticleIdList></Reference><Reference><Citation>Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014 Jan;146(1):67&#x2013;75.e5. doi: 10.1053/j.gastro.2013.09.046.S0016-5085(13)01407-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2013.09.046</ArticleId><ArticleId IdType="pubmed">24076059</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher H, Whelan K, Irving P, Lomer M. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J Hum Nutr Diet. 2011 Oct;24(5):487&#x2013;495. doi: 10.1111/j.1365-277X.2011.01162.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-277X.2011.01162.x</ArticleId><ArticleId IdType="pubmed">21615553</ArticleId></ArticleIdList></Reference><Reference><Citation>Gearry R, Skidmore P, O'Brien L, Wilkinson T, Nanayakkara W. Efficacy of the low FODMAP diet for treating irritable bowel syndrome: The evidence to date. Clin Exp Gastroenterol. 2016 Jun;:131&#x2013;142. doi: 10.2147/ceg.s86798. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/ceg.s86798</ArticleId><ArticleId IdType="pmc">PMC4918736</ArticleId><ArticleId IdType="pubmed">27382323</ArticleId></ArticleIdList></Reference><Reference><Citation>van Lanen A, de Bree A, Greyling A. Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: A systematic review and meta-analysis. Eur J Nutr. 2021 Sep;60(6):3505&#x2013;3522. doi: 10.1007/s00394-020-02473-0. 
 
10.1007/s00394-020-02473-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00394-020-02473-0</ArticleId><ArticleId IdType="pmc">PMC8354978</ArticleId><ArticleId IdType="pubmed">33585949</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher H, Lomer M, Anderson J, Barrett JS, Muir JG, Irving PM, Whelan K. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr. 2012 Aug;142(8):1510&#x2013;1518. doi: 10.3945/jn.112.159285.jn.112.159285</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/jn.112.159285</ArticleId><ArticleId IdType="pubmed">22739368</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher HM, Lomer MC, Farquharson FM, Louis P, Fava F, Franciosi E, Scholz M, Tuohy KM, Lindsay JO, Irving PM, Whelan K. A diet low in FODMAPs reduces symptoms in patients with irritable bowel syndrome and a probiotic restores Bifidobacterium species: A randomized controlled trial. Gastroenterology. 2017 Oct;153(4):936&#x2013;947. doi: 10.1053/j.gastro.2017.06.010.S0016-5085(17)35744-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2017.06.010</ArticleId><ArticleId IdType="pubmed">28625832</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher HM, Scholz M, Lomer MC, Ralph FS, Irving PM, Lindsay JO, Fava F, Tuohy K, Whelan K. Gut microbiota associations with diet in irritable bowel syndrome and the effect of low FODMAP diet and probiotics. Clin Nutr. 2021 Apr;40(4):1861&#x2013;1870. doi: 10.1016/j.clnu.2020.10.013.S0261-5614(20)30541-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2020.10.013</ArticleId><ArticleId IdType="pubmed">33183883</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson B, Rossi M, Kanno T, Parkes GC, Anderson S, Mason AJ, Irving PM, Lomer MC, Whelan K. &#x3b2;-Galactooligosaccharide in conjunction with low FODMAP diet improves irritable bowel syndrome symptoms but reduces fecal Bifidobacteria. Am J Gastroenterol. 2020 Jun;115(6):906&#x2013;915. doi: 10.14309/ajg.0000000000000641.00000434-202006000-00020</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000000641</ArticleId><ArticleId IdType="pubmed">32433273</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Siles M, Duncan SH, Garcia-Gil LJ, Martinez-Medina M. Faecalibacterium prausnitzii: From microbiology to diagnostics and prognostics. ISME J. 2017 Apr;11(4):841&#x2013;852. doi: 10.1038/ismej.2016.176. 
 
ismej2016176</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ismej.2016.176</ArticleId><ArticleId IdType="pmc">PMC5364359</ArticleId><ArticleId IdType="pubmed">28045459</ArticleId></ArticleIdList></Reference><Reference><Citation>Costea PI, Zeller G, Sunagawa S, Pelletier E, Alberti A, Levenez F, Tramontano M, Driessen M, Hercog R, Jung F, Kultima JR, Hayward MR, Coelho LP, Allen-Vercoe E, Bertrand L, Blaut M, Brown JRM, Carton T, Cools-Portier S, Daigneault M, Derrien M, Druesne A, de Vos WM, Finlay BB, Flint HJ, Guarner F, Hattori M, Heilig H, Luna RA, van Hylckama Vlieg J, Junick J, Klymiuk I, Langella P, Le Chatelier E, Mai V, Manichanh C, Martin JC, Mery C, Morita H, O'Toole PW, Orvain C, Patil KR, Penders J, Persson S, Pons N, Popova M, Salonen A, Saulnier D, Scott KP, Singh B, Slezak K, Veiga P, Versalovic J, Zhao L, Zoetendal EG, Ehrlich SD, Dore J, Bork P. Towards standards for human fecal sample processing in metagenomic studies. Nat Biotechnol. 2017 Nov;35(11):1069&#x2013;1076. doi: 10.1038/nbt.3960.nbt.3960</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3960</ArticleId><ArticleId IdType="pubmed">28967887</ArticleId></ArticleIdList></Reference><Reference><Citation>Rintala A, Pietil&#xe4; S, Munukka E, Eerola E, Pursiheimo J, Laiho A, Pekkala S, Huovinen P. Gut microbiota analysis results are highly dependent on the 16S rRNA gene target region, whereas the impact of DNA extraction is minor. J Biomol Tech. 2017 Apr;28(1):19&#x2013;30. doi: 10.7171/jbt.17-2801-003. 
 
JBT_2017-2801-003</Citation><ArticleIdList><ArticleId IdType="doi">10.7171/jbt.17-2801-003</ArticleId><ArticleId IdType="pmc">PMC5330390</ArticleId><ArticleId IdType="pubmed">28260999</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorzelak MA, Gill SK, Tasnim N, Ahmadi-Vand Z, Jay M, Gibson DL. Methods for improving human gut microbiome data by reducing variability through sample processing and storage of stool. PLoS One. 2015;10(8):e0134802. doi: 10.1371/journal.pone.0134802. 
 
PONE-D-15-14406</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0134802</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0134802</ArticleId><ArticleId IdType="pmc">PMC4529225</ArticleId><ArticleId IdType="pubmed">26252519</ArticleId></ArticleIdList></Reference><Reference><Citation>Sczyrba A, Hofmann P, Belmann P, Koslicki D, Janssen S, Dr&#xf6;ge J, Gregor I, Majda S, Fiedler J, Dahms E, Bremges A, Fritz A, Garrido-Oter R, J&#xf8;rgensen TS, Shapiro N, Blood PD, Gurevich A, Bai Y, Turaev D, DeMaere MZ, Chikhi R, Nagarajan N, Quince C, Meyer F, Balvo&#x10d;i&#x16b;t&#x117; M, Hansen LH, S&#xf8;rensen SJ, Chia BKH, Denis B, Froula JL, Wang Z, Egan R, Don Kang D, Cook JJ, Deltel C, Beckstette M, Lemaitre C, Peterlongo P, Rizk G, Lavenier D, Wu Y, Singer SW, Jain C, Strous M, Klingenberg H, Meinicke P, Barton MD, Lingner T, Lin H, Liao Y, Silva GGZ, Cuevas DA, Edwards RA, Saha S, Piro VC, Renard BY, Pop M, Klenk H, G&#xf6;ker M, Kyrpides NC, Woyke T, Vorholt JA, Schulze-Lefert P, Rubin EM, Darling AE, Rattei T, McHardy AC. Critical Assessment of Metagenome Interpretation-A benchmark of metagenomics software. Nat Methods. 2017 Nov;14(11):1063&#x2013;1071. doi: 10.1038/nmeth.4458. 
 
nmeth.4458</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4458</ArticleId><ArticleId IdType="pmc">PMC5903868</ArticleId><ArticleId IdType="pubmed">28967888</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravina AG, Dallio M, Romeo M, Di Somma A, Cotticelli G, Loguercio C, Federico A. Adherence and effects derived from FODMAP diet on irritable bowel syndrome: A real life evaluation of a large follow-up observation. Nutrients. 2020 Mar 27;12(4):928. doi: 10.3390/nu12040928. 
 
nu12040928</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12040928</ArticleId><ArticleId IdType="pmc">PMC7231245</ArticleId><ArticleId IdType="pubmed">32230832</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafferty AJ, Hall R, Johnston CS. A novel mobile app (Heali) for disease treatment in participants with irritable bowel syndrome: Randomized controlled pilot trial. J Med Internet Res. 2021 Mar 02;23(3):e24134. doi: 10.2196/24134. 
 
v23i3e24134</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/24134</ArticleId><ArticleId IdType="pmc">PMC7967221</ArticleId><ArticleId IdType="pubmed">33650977</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogsgaard L, Andersen L, Johannesen T, Engsbro AL, Stensvold CR, Nielsen HV, Bytzer P. Characteristics of the bacterial microbiome in association with common intestinal parasites in irritable bowel syndrome. Clin Transl Gastroenterol. 2018 Jun 19;9(6):161. doi: 10.1038/s41424-018-0027-2. 
 
10.1038/s41424-018-0027-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41424-018-0027-2</ArticleId><ArticleId IdType="pmc">PMC6006308</ArticleId><ArticleId IdType="pubmed">29915224</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi M, Aggio R, Staudacher HM, Lomer MC, Lindsay JO, Irving P, Probert C, Whelan K. Volatile organic compounds in feces associate with response to dietary intervention in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2018 Mar;16(3):385&#x2013;391.e1. doi: 10.1016/j.cgh.2017.09.055.S1542-3565(17)31201-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2017.09.055</ArticleId><ArticleId IdType="pubmed">28993261</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JH, Lin E, Pimentel M. Biomarkers of irritable bowel syndrome. J Neurogastroenterol Motil. 2017 Jan 30;23(1):20&#x2013;26. doi: 10.5056/jnm16135. 
 
jnm16135</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm16135</ArticleId><ArticleId IdType="pmc">PMC5216630</ArticleId><ArticleId IdType="pubmed">27817184</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmulson MJ, Drossman DA. What is new in Rome IV. J Neurogastroenterol Motil. 2017 Apr 30;23(2):151&#x2013;163. doi: 10.5056/jnm16214. 
 
jnm16214</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm16214</ArticleId><ArticleId IdType="pmc">PMC5383110</ArticleId><ArticleId IdType="pubmed">28274109</ArticleId></ArticleIdList></Reference><Reference><Citation>Browne P, Nielsen T, Kot W, Aggerholm A, Gilbert MTP, Puetz L, Rasmussen M, Zervas A, Hansen LH. GC bias affects genomic and metagenomic reconstructions, underrepresenting GC-poor organisms. Gigascience. 2020 Feb 01;9(2):giaa008. doi: 10.1093/gigascience/giaa008. 
 
5735313</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gigascience/giaa008</ArticleId><ArticleId IdType="doi">10.1093/gigascience/giaa008</ArticleId><ArticleId IdType="pmc">PMC7016772</ArticleId><ArticleId IdType="pubmed">32052832</ArticleId></ArticleIdList></Reference><Reference><Citation>Quince C, Walker AW, Simpson JT, Loman NJ, Segata N. Shotgun metagenomics, from sampling to analysis. Nat Biotechnol. 2017 Sep 12;35(9):833&#x2013;844. doi: 10.1038/nbt.3935.nbt.3935</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3935</ArticleId><ArticleId IdType="pubmed">28898207</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38658619</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Apr</Month><Day>25</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>A randomized, double-blinded, placebo-controlled clinical trial on Lactobacillus-containing cultured milk drink as adjuvant therapy for depression in irritable bowel syndrome.</ArticleTitle><Pagination><StartPage>9478</StartPage><MedlinePgn>9478</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">9478</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-60029-2</ELocationID><Abstract><AbstractText>Irritable bowel syndrome (IBS) is frequently linked with coexisting mental illnesses. Our previous study discovered that 32.1% of IBS patients had subthreshold depression (SD), placing them at higher risk of developing major depression. Gut microbiota modulation through psychobiotics was found to influence depression via the gut-brain axis. However, the efficacy of lessening depression among IBS patients remains ambiguous. The study's aim was to investigate the roles of cultured milk drinks containing 10<sup>9</sup>&#xa0;cfu Lactobacillus acidophilus LA-5 and Lactobacillus paracasei L. CASEI-01 on depression and related variables among IBS participants with SD. A total of 110 IBS participants with normal mood (NM) and SD, were randomly assigned to one of four intervention groups: IBS-NM with placebo, IBS-NM with probiotic, IBS-SD with placebo, and IBS-SD with probiotic. Each participant was required to consume two bottles of cultured milk every day for a duration of 12&#xa0;weeks. The following outcomes were assessed: depression risk, quality of life, the severity of IBS, and hormonal changes. The depression scores were significantly reduced in IBS-SD with probiotic and placebo from baseline (p&#x2009;&lt;&#x2009;0.001). Only IBS-SD with probiotic showed a significant rise in serotonin serum levels (p&#x2009;&lt;&#x2009;0.05). A significantly higher life quality measures were seen in IBS-SD with probiotic, IBS-SD with placebo, and IBS-NM with placebo (p&#x2009;&lt;&#x2009;0.05). All groups, both placebo and probiotic, reported significant improvement in IBS severity post-intervention with a higher prevalence of remission and mild IBS (p&#x2009;&lt;&#x2009;0.05). Dual strains lactobacillus-containing cultured milk drink via its regulation of relevant biomarkers, is a potential anti-depressive prophylactic agent for IBS patients at risk.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sarkawi</LastName><ForeName>Marlynna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, Bandar Tun Razak, Cheras, 56000, Kuala Lumpur, Malaysia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Basic Medical Sciences, Faculty of Medicine and Health Sciences, Universiti Malaysia Sarawak, 94300, Kota Samarahan, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raja Ali</LastName><ForeName>Raja Affendi</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>School of Medical and Life Sciences, Sunway University, Sunway City, 47500, Petaling Jaya, Malaysia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>GUT Research Group, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdul Wahab</LastName><ForeName>Norhazlina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, Bandar Tun Razak, Cheras, 56000, Kuala Lumpur, Malaysia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>GUT Research Group, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdul Rathi</LastName><ForeName>Norshafila Diana</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, Bandar Tun Razak, Cheras, 56000, Kuala Lumpur, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mokhtar</LastName><ForeName>Norfilza Mohd</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, Bandar Tun Razak, Cheras, 56000, Kuala Lumpur, Malaysia. norfilza@ppukm.ukm.edu.my.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>GUT Research Group, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia. norfilza@ppukm.ukm.edu.my.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>FF-2019-064</GrantID><Agency>Cotra Enterprise Sdn Bhd</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="Y">Depression</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043302" MajorTopicYN="N">Cultured Milk Products</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008892" MajorTopicYN="N">Milk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007779" MajorTopicYN="N">Lactobacillus acidophilus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007778" MajorTopicYN="N">Lactobacillus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069980" MajorTopicYN="N">Lacticaseibacillus paracasei</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Functional gastrointestinal diseases</Keyword><Keyword MajorTopicYN="N">Gut-brain axis</Keyword><Keyword MajorTopicYN="N">Irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">Lactobacillus</Keyword><Keyword MajorTopicYN="N">Probiotics</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>25</Day><Hour>0</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>25</Day><Hour>0</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>24</Day><Hour>23</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38658619</ArticleId><ArticleId IdType="pmc">PMC11043363</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-60029-2</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-60029-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Riddle MS, Welsh M, Porter CK, Nieh C, Boyko EJ, Gackstetter G, et al. The epidemiology of irritable bowel syndrome in the US military: Findings from the Millennium Cohort Study. Am. J. Gastroenterol. 2016;111(1):93. doi: 10.1038/ajg.2015.386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2015.386</ArticleId><ArticleId IdType="pmc">PMC4759150</ArticleId><ArticleId IdType="pubmed">26729548</ArticleId></ArticleIdList></Reference><Reference><Citation>Icenhour A, Witt ST, Elsenbruch S, Low&#xe9;n M, Engstr&#xf6;m M, Tillisch K, et al. Brain functional connectivity is associated with visceral sensitivity in women with irritable bowel syndrome. NeuroImage Clin. 2017;15:449&#x2013;457. doi: 10.1016/j.nicl.2017.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2017.06.001</ArticleId><ArticleId IdType="pmc">PMC5470568</ArticleId><ArticleId IdType="pubmed">28649489</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumpitazi BP, Self MM, Czyzewski DI, Cejka S, Swank PR, Shulman RJ. Bristol Stool Form Scale reliability and agreement decreases when determining Rome III stool form designations. Neurogastroenterol. Motil. 2016;28(3):443&#x2013;448. doi: 10.1111/nmo.12738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12738</ArticleId><ArticleId IdType="pmc">PMC4760857</ArticleId><ArticleId IdType="pubmed">26690980</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2020;5(10):908&#x2013;917. doi: 10.1016/S2468-1253(20)30217-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30217-X</ArticleId><ArticleId IdType="pubmed">32702295</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman MM, Mahadeva S, Ghoshal UC. Epidemiological and clinical perspectives on irritable bowel syndrome in India, Bangladesh and Malaysia: A review. World J. Gastroenterol. 2017;23(37):6788. doi: 10.3748/wjg.v23.i37.6788.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v23.i37.6788</ArticleId><ArticleId IdType="pmc">PMC5645613</ArticleId><ArticleId IdType="pubmed">29085223</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwee KA, Gonlachanvit S, Ghoshal UC, Chua AS, Miwa H, Wu J, et al. Second Asian consensus on irritable bowel syndrome. J. Neurogastroenterol. Motil. 2019;25(3):343. doi: 10.5056/jnm19041.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm19041</ArticleId><ArticleId IdType="pmc">PMC6657923</ArticleId><ArticleId IdType="pubmed">31327218</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Zhao D, Qi Q, Long X, Li Y, Wang P, et al. Nr2b-containing nmda receptors contribute to diarrhea-predominant irritable bowel syndrome. Oncotarget. 2018;11:5.</Citation></Reference><Reference><Citation>Lee C, Doo E, Choi JM, Jang SH, Ryu HS, Lee JY, et al. The increased level of depression and anxiety in irritable bowel syndrome patients compared with healthy controls: Systematic review and meta-analysis. J. Neurogastroenterol. Motil. 2017;23(3):349. doi: 10.5056/jnm16220.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm16220</ArticleId><ArticleId IdType="pmc">PMC5503284</ArticleId><ArticleId IdType="pubmed">28672433</ArticleId></ArticleIdList></Reference><Reference><Citation>Batabyal A, Bhattacharya A, Thaker M, Mukherjee S. A longitudinal study of perceived stress and cortisol responses in an undergraduate student population from India. PLoS ONE. 2021;16(6):e0252579. doi: 10.1371/journal.pone.0252579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0252579</ArticleId><ArticleId IdType="pmc">PMC8177861</ArticleId><ArticleId IdType="pubmed">34086754</ArticleId></ArticleIdList></Reference><Reference><Citation>Mokhtar NM, Bahrudin MF, Abd Ghani N, Abdul Rani R, Raja Ali RA. Prevalence of subthreshold depression among constipation-predominant irritable bowel syndrome patients. Front. Psychol. 2020;6(11):1936. doi: 10.3389/fpsyg.2020.01936.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2020.01936</ArticleId><ArticleId IdType="pmc">PMC7423989</ArticleId><ArticleId IdType="pubmed">32849137</ArticleId></ArticleIdList></Reference><Reference><Citation>Stasi C, Nisita C, Cortopassi S, Corretti G, Gambaccini D, De Bortoli N, et al. Subthreshold psychiatric psychopathology in functional gastrointestinal disorders: can it be the bridge between gastroenterology and psychiatry? Gastroenterol. Res. Pract. 2017;30:2017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5682902</ArticleId><ArticleId IdType="pubmed">29213280</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Peng X, Song X, Long J, Wang C, Zhang C, et al. The prevalence and risk of developing major depression among individuals with subthreshold depression in the general population. Psychol. Med. 2022;14:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10277767</ArticleId><ArticleId IdType="pubmed">35156595</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeuring HW, Comijs HC, Deeg DJ, Stek ML, Huisman M, Beekman AT. Secular trends in the prevalence of major and subthreshold depression among 55&#x2013;64-year olds over 20 years. Psychol. Med. 2018;48(11):1824&#x2013;1834. doi: 10.1017/S0033291717003324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291717003324</ArticleId><ArticleId IdType="pubmed">29198199</ArticleId></ArticleIdList></Reference><Reference><Citation>Padhi P, Worth C, Zenitsky G, Jin H, Sambamurti K, Anantharam V, et al. Mechanistic insights into gut microbiome dysbiosis-mediated neuroimmune dysregulation and protein misfolding and clearance in the pathogenesis of chronic neurodegenerative disorders. Front. Neurosci. 2022;16:1. doi: 10.3389/fnins.2022.836605.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2022.836605</ArticleId><ArticleId IdType="pmc">PMC8914070</ArticleId><ArticleId IdType="pubmed">35281490</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014;11(8):506&#x2013;514. doi: 10.1038/nrgastro.2014.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2014.66</ArticleId><ArticleId IdType="pubmed">24912386</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizawa E, Tsuji H, Asahara T, Takahashi T, Teraishi T, Yoshida S, et al. Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder. J. Affect. Disord. 2016;15(202):254&#x2013;257. doi: 10.1016/j.jad.2016.05.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2016.05.038</ArticleId><ArticleId IdType="pubmed">27288567</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennet SM, Palsson O, Whitehead WE, Barrow DA, T&#xf6;rnblom H, &#xd6;hman L, et al. Systemic cytokines are elevated in a subset of patients with irritable bowel syndrome but largely unrelated to symptom characteristics. Neurogastroenterol. Motil. 2018;30(10):e13378. doi: 10.1111/nmo.13378.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13378</ArticleId><ArticleId IdType="pubmed">29797382</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie R, Jiang P, Lin LI, Jiang J, Yu B, Rao J, et al. Oral treatment with Lactobacillus reuteri attenuates depressive-like behaviors and serotonin metabolism alterations induced by chronic social defeat stress. J. Psychiatr. Res. 2020;1(122):70&#x2013;78. doi: 10.1016/j.jpsychires.2019.12.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2019.12.013</ArticleId><ArticleId IdType="pubmed">31927268</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou W, Feng R, Yang Y. Changes in the serum levels of inflammatory cytokines in antidepressant drug-na&#xef;ve patients with major depression. PLoS ONE. 2018;13(6):e0197267. doi: 10.1371/journal.pone.0197267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0197267</ArticleId><ArticleId IdType="pmc">PMC5983476</ArticleId><ArticleId IdType="pubmed">29856741</ArticleId></ArticleIdList></Reference><Reference><Citation>Mokhtar N, Jaafar N, Alfian E, Rathi NM, Rani RA, Ali RR. Clinical assessment and cytokines level in constipation-predominant irritable bowel syndrome participants treated with Lactobacillus-containing cultured milk drink. Acta Gastro Enterol. Belg. 2021;1(84):585&#x2013;591. doi: 10.51821/84.4.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.51821/84.4.009</ArticleId><ArticleId IdType="pubmed">34965040</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Liu YX, Wang Z, Wang XQ, Zhang JJ, Jiang RH, et al. Clinical characteristic and fecal microbiota responses to probiotic or antidepressant in patients with diarrhea-predominant irritable bowel syndrome with depression comorbidity: A pilot study. Chin. Med. J. 2019;132(03):346&#x2013;351. doi: 10.1097/CM9.0000000000000071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000000071</ArticleId><ArticleId IdType="pmc">PMC6595810</ArticleId><ArticleId IdType="pubmed">30681503</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudzki L, Ostrowska L, Pawlak D, Ma&#x142;us A, Pawlak K, Waszkiewicz N, Szulc A. Probiotic Lactobacillus Plantarum 299v decreases kynurenine concentration and improves cognitive functions in patients with major depression: A double-blind, randomized, placebo controlled study. Psychoneuroendocrinology. 2019;1(100):213&#x2013;222. doi: 10.1016/j.psyneuen.2018.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2018.10.010</ArticleId><ArticleId IdType="pubmed">30388595</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishaque SM, Khosruzzaman SM, Ahmed DS, Sah MP. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult&#xae;) in the management of diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol. 2018;18(1):1&#x2013;2. doi: 10.1186/s12876-018-0788-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-018-0788-9</ArticleId><ArticleId IdType="pmc">PMC5970461</ArticleId><ArticleId IdType="pubmed">29801486</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalitsuradej, E., Sirilun, S., Chaiyasut, C., &amp; Sittiprapaporn, P. A preliminary study on effect of lactobacillus paracasei hii01 on cortisol in fatigue subjects. In 2019 16th International Conference on Electrical Engineering/Electronics, Computer, Telecommunications and Information Technology (ECTI-CON) 2019 Jul 10 (pp. 466&#x2013;469). IEEE.</Citation></Reference><Reference><Citation>Ma T, Jin H, Kwok LY, Sun Z, Liong MT, Zhang H. Probiotic consumption relieved human stress and anxiety symptoms possibly via modulating the neuroactive potential of the gut microbiota. Neurobiol. Stress. 2021;1(14):100294. doi: 10.1016/j.ynstr.2021.100294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ynstr.2021.100294</ArticleId><ArticleId IdType="pmc">PMC7816019</ArticleId><ArticleId IdType="pubmed">33511258</ArticleId></ArticleIdList></Reference><Reference><Citation>Majeed M, Nagabhushanam K, Arumugam S, Majeed S, Ali F. Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: A randomised, double-blind, placebo controlled, multi-centre, pilot clinical study. Food Nutr. Res. 2018;62:1. doi: 10.29219/fnr.v62.1218.</Citation><ArticleIdList><ArticleId IdType="doi">10.29219/fnr.v62.1218</ArticleId><ArticleId IdType="pmc">PMC6034030</ArticleId><ArticleId IdType="pubmed">29997457</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto-Sanchez MI, Hall GB, Ghajar K, Nardelli A, Bolino C, Lau JT, et al. Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: A pilot study in patients with irritable bowel syndrome. Gastroenterology. 2017;153(2):448&#x2013;459. doi: 10.1053/j.gastro.2017.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2017.05.003</ArticleId><ArticleId IdType="pubmed">28483500</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment. Pharmacol. Ther. 1997;11(2):395&#x2013;402. doi: 10.1046/j.1365-2036.1997.142318000.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.1997.142318000.x</ArticleId><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dam NT, Earleywine M. Validation of the Center for Epidemiologic Studies Depression Scale&#x2014;Revised (CESD-R): Pragmatic depression assessment in the general population. Psychiatry Res. 2011;186(1):128&#x2013;132. doi: 10.1016/j.psychres.2010.08.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2010.08.018</ArticleId><ArticleId IdType="pubmed">20843557</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick DL, Drossman DA, Frederick IO, Dicesare J, Puder KL. Quality of life in persons with irritable bowel syndrome (development and validation of a new measure) Digest. Dis. Sci. 1998;43:400&#x2013;411. doi: 10.1023/A:1018831127942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1018831127942</ArticleId><ArticleId IdType="pubmed">9512138</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman DA, Chang L, Bellamy N, Gallo-Torres HE, Lembo A, Mearin F, et al. Severity in irritable bowel syndrome: A Rome Foundation Working Team report. Off. J. Am. Coll. Gastroenterol. 2011;106(10):1749&#x2013;1759. doi: 10.1038/ajg.2011.201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2011.201</ArticleId><ArticleId IdType="pubmed">21747417</ArticleId></ArticleIdList></Reference><Reference><Citation>Depression WH. Other common mental disorders: global health estimates. World Health Organization; 2017. p. 24.</Citation></Reference><Reference><Citation>Laterza L, Napoli M, Petito V, Scaldaferri F, Gaetani E, Gasbarrini A. Evaluation of tolerability and major factors affecting the adherence to probiotic therapy in patients with irritable bowel syndrome: A prospective, observational, real-life study. Minerva Med. 2021;1:1.</Citation><ArticleIdList><ArticleId IdType="pubmed">34114438</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaub AC, Schneider E, Vazquez-Castellanos JF, Schweinfurth N, Kettelhack C, Doll JP, et al. Clinical, gut microbial and neural effects of a probiotic add-on therapy in depressed patients: A randomized controlled trial. Transl. Psychiatry. 2022;12(1):227. doi: 10.1038/s41398-022-01977-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-022-01977-z</ArticleId><ArticleId IdType="pmc">PMC9163095</ArticleId><ArticleId IdType="pubmed">35654766</ArticleId></ArticleIdList></Reference><Reference><Citation>Akkasheh G, Kashani-Poor Z, Tajabadi-Ebrahimi M, Jafari P, Akbari H, Taghizadeh M, et al. Clinical and metabolic response to probiotic administration in patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial. Nutrition. 2016;32(3):315&#x2013;320. doi: 10.1016/j.nut.2015.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nut.2015.09.003</ArticleId><ArticleId IdType="pubmed">26706022</ArticleId></ArticleIdList></Reference><Reference><Citation>Michalsen VL, Vandvik PO, Farup PG. Predictors of health-related quality of life in patients with irritable bowel syndrome: A cross-sectional study in Norway. Health Qual. Life Outcomes. 2015;13(1):1&#x2013;9. doi: 10.1186/s12955-015-0311-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-015-0311-8</ArticleId><ArticleId IdType="pmc">PMC4518561</ArticleId><ArticleId IdType="pubmed">26223784</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexandru BA, Rat LA, Moldovan AF, Mihancea P, Mari&#x219; L. An open-label trial study of quality-of-life assessment in irritable bowel syndrome and their treatment. Medicina. 2022;58(6):763. doi: 10.3390/medicina58060763.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina58060763</ArticleId><ArticleId IdType="pmc">PMC9230795</ArticleId><ArticleId IdType="pubmed">35744026</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Yu X, Yu L, Tian F, Zhao J, Zhang H, et al. Lactobacillus plantarum CCFM8610 alleviates irritable bowel syndrome and prevents gut microbiota dysbiosis: A randomized, double-blind, placebo-controlled, pilot clinical trial. Engineering. 2021;7(3):376&#x2013;385. doi: 10.1016/j.eng.2020.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eng.2020.06.026</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Chen S, Zhang M, Ren F, Ren Y, Li Y, et al. Effects of fermented milk containing Lacticaseibacillus paracasei strain Shirota on constipation in patients with depression: A randomized, double-blind, placebo-controlled trial. Nutrients. 2021;13(7):2238. doi: 10.3390/nu13072238.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13072238</ArticleId><ArticleId IdType="pmc">PMC8308326</ArticleId><ArticleId IdType="pubmed">34209804</ArticleId></ArticleIdList></Reference><Reference><Citation>Dapoigny M, Piche T, Ducrotte P, Lunaud B, Cardot JM, Bernalier-Donadille A. Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: A randomized, double-blind study. World J. Gastroenterol. WJG. 2012;18(17):2067. doi: 10.3748/wjg.v18.i17.2067.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v18.i17.2067</ArticleId><ArticleId IdType="pmc">PMC3342605</ArticleId><ArticleId IdType="pubmed">22563194</ArticleId></ArticleIdList></Reference><Reference><Citation>Maixent JM, Pons O, Sennoune SR, Sadrin S. Clinical effects of Lactobacillus strains as probiotics in the treatment of irritable bowel syndrome: Results from the LAPIBSS trial: Future objectives. Cell. Mol. Biol. 2020;66(3):211&#x2013;214. doi: 10.14715/cmb/2020.66.3.34.</Citation><ArticleIdList><ArticleId IdType="doi">10.14715/cmb/2020.66.3.34</ArticleId><ArticleId IdType="pubmed">32538776</ArticleId></ArticleIdList></Reference><Reference><Citation>Og&#x142;odek EA. Changes in the serum concentration levels of serotonin, tryptophan and cortisol among stress-resilient and stress-susceptible individuals after experiencing traumatic stress. Int. J. Environ. Res. Public Health. 2022;19(24):16517. doi: 10.3390/ijerph192416517.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph192416517</ArticleId><ArticleId IdType="pmc">PMC9779530</ArticleId><ArticleId IdType="pubmed">36554398</ArticleId></ArticleIdList></Reference><Reference><Citation>Rode J, Edebol Carlman HM, K&#xf6;nig J, Hutchinson AN, Thunberg P, Persson J, et al. Multi-strain probiotic mixture affects brain morphology and resting state brain function in healthy subjects: An RCT. Cells. 2022;11(18):2922. doi: 10.3390/cells11182922.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11182922</ArticleId><ArticleId IdType="pmc">PMC9496704</ArticleId><ArticleId IdType="pubmed">36139496</ArticleId></ArticleIdList></Reference><Reference><Citation>Messaoudi M, Lalonde R, Violle N, Javelot H, Desor D, Nejdi A, et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br. J. Nutr. 2011;105(5):755&#x2013;764. doi: 10.1017/S0007114510004319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0007114510004319</ArticleId><ArticleId IdType="pubmed">20974015</ArticleId></ArticleIdList></Reference><Reference><Citation>Norlin AK, Walter S, Theodorsson E, Tegelstrom V, Grodzinsky E, Jones MP, et al. Cortisol levels in hair are altered in irritable bowel syndrome-A case control study in primary care. J. Psychosom. Res. 2017;1(93):69&#x2013;75. doi: 10.1016/j.jpsychores.2016.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychores.2016.12.009</ArticleId><ArticleId IdType="pubmed">28107896</ArticleId></ArticleIdList></Reference><Reference><Citation>Herr N, Bode C, Duerschmied D. The effects of serotonin in immune cells. Front. Cardiovasc. Med. 2017;20(4):48. doi: 10.3389/fcvm.2017.00048.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2017.00048</ArticleId><ArticleId IdType="pmc">PMC5517399</ArticleId><ArticleId IdType="pubmed">28775986</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon YH, Wang H, Denou E, Ghia JE, Rossi L, Fontes ME, Bernier SP, Shajib MS, Banskota S, Collins SM, Surette MG. Modulation of gut microbiota composition by serotonin signaling influences intestinal immune response and susceptibility to colitis. Cell. Mol. Gastroenterol. Hepatol. 2019;7(4):709&#x2013;728. doi: 10.1016/j.jcmgh.2019.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmgh.2019.01.004</ArticleId><ArticleId IdType="pmc">PMC6462823</ArticleId><ArticleId IdType="pubmed">30716420</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahora IS, Tsouklidis N, Kumar R, Soni R, Khan S. How serotonin level fluctuation affects the effectiveness of treatment in irritable bowel syndrome. Cureus. 2020;12(8):1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7505258</ArticleId><ArticleId IdType="pubmed">32968548</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayob N, Muhammad Nawawi KN, Mohamad Nor MH, Raja Ali RA, Ahmad HF, Oon SF, et al. The effects of probiotics on small intestinal microbiota composition, inflammatory cytokines and intestinal permeability in patients with non-alcoholic fatty liver disease. Biomedicines. 2023;11(2):640. doi: 10.3390/biomedicines11020640.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11020640</ArticleId><ArticleId IdType="pmc">PMC9953317</ArticleId><ArticleId IdType="pubmed">36831176</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranadheera CS, Vidanarachchi JK, Rocha RS, Cruz AG, Ajlouni S. Probiotic delivery through fermentation: Dairy vs non-dairy beverages. Fermentation. 2017;3(4):67. doi: 10.3390/fermentation3040067.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/fermentation3040067</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee A, Hodori NA, Tung YZ, Ooi PL, Latif SA, Isa HM, et al. Depression level and coping responses toward the movement control order and its impact on quality of life in the Malaysian community during the COVID-19 pandemic: A web-based cross-sectional study. Ann. Gen. Psychiatry. 2021;20(1):31. doi: 10.1186/s12991-021-00352-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12991-021-00352-4</ArticleId><ArticleId IdType="pmc">PMC8142880</ArticleId><ArticleId IdType="pubmed">34030704</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan Mohd Yunus WM, Badri SK, Panatik SA, Mukhtar F. The unprecedented movement control order (lockdown) and factors associated with the negative emotional symptoms, happiness, and work-life balance of Malaysian University students during the coronavirus disease (COVID-19) pandemic. Front. Psychiatr. 2021;11:566221. doi: 10.3389/fpsyt.2020.566221.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2020.566221</ArticleId><ArticleId IdType="pmc">PMC7921154</ArticleId><ArticleId IdType="pubmed">33664679</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahrudin MF, Abdul Rani R, Tamil AM, Mokhtar NM, Raja Ali RA. Effectiveness of sterilized symbiotic drink containing Lactobacillus helveticus comparable to probiotic alone in patients with constipation-predominant irritable bowel syndrome. Digest. Dis. Sci. 2020;65:541&#x2013;549. doi: 10.1007/s10620-019-05695-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-019-05695-3</ArticleId><ArticleId IdType="pmc">PMC6995448</ArticleId><ArticleId IdType="pubmed">31209720</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafiee NH, Razalli NH, Mokhtar NM, Tan E, Ali RA. An evaluation of dietary adequacy among patients with constipation-predominant irritable bowel syndrome in Malaysia. Intest. Res. 2022;20(1):124. doi: 10.5217/ir.2020.00050.</Citation><ArticleIdList><ArticleId IdType="doi">10.5217/ir.2020.00050</ArticleId><ArticleId IdType="pmc">PMC8831767</ArticleId><ArticleId IdType="pubmed">33472341</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong Z, Mok CZ, Majid HA, Mahadeva S. Early experience with a low FODMAP diet in Asian patients with irritable bowel syndrome. JGH Open. 2018;2(5):178&#x2013;181. doi: 10.1002/jgh3.12069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jgh3.12069</ArticleId><ArticleId IdType="pmc">PMC6207042</ArticleId><ArticleId IdType="pubmed">30483586</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20890316</PMID><DateCompleted><Year>2011</Year><Month>01</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1759-5053</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>10</Issue><PubDate><Year>2010</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nature reviews. Gastroenterology &amp; hepatology</Title><ISOAbbreviation>Nat Rev Gastroenterol Hepatol</ISOAbbreviation></Journal><ArticleTitle>Diagnosis and management of IBS.</ArticleTitle><Pagination><StartPage>565</StartPage><EndPage>581</EndPage><MedlinePgn>565-81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nrgastro.2010.137</ELocationID><Abstract><AbstractText>IBS is a common gastrointestinal condition characterized by chronic or recurrent abdominal pain associated with altered bowel habits. IBS is considered a functional bowel disorder (that is, not defined by structural or biochemical abnormalities) and is diagnosed using symptom-based criteria. Limited and judicious use of diagnostic testing is recommended, particularly in patients with typical symptoms of IBS without alarm signs and symptoms. Management of IBS is based on a multifactorial approach and includes establishment of an effective patient-provider relationship, education, reassurance, dietary alterations, pharmacotherapy, behavioral and psychological treatment. Patient-centered care is recommended, in which management is focused on the patient's most bothersome and impactful symptoms, their preferences and previous experiences with treatment, and addressing factors associated with the onset and exacerbation of symptoms. Pharmacotherapy is typically targeted against the predominant symptom. This Review discusses the current evidence-based recommendations for the diagnosis and management of IBS. An improved understanding of the recommended diagnostic and therapeutic approaches for IBS will lead to greater patient satisfaction, as well as reduced health-care costs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Neurobiology of Stress, Division of Digestive Diseases, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, CHS 47-122, Los Angeles, CA 90095-7378, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Lin</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Gastroenterol Hepatol</MedlineTA><NlmUniqueID>101500079</NlmUniqueID><ISSNLinking>1759-5045</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000930">Antidiarrheals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054368">Laxatives</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000930" MajorTopicYN="N">Antidiarrheals</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001521" MajorTopicYN="N">Behavior Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054368" MajorTopicYN="N">Laxatives</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20890316</ArticleId><ArticleId IdType="doi">10.1038/nrgastro.2010.137</ArticleId><ArticleId IdType="pii">nrgastro.2010.137</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Gastroenterol. 2008 May;103(5):1217-25</Citation><ArticleIdList><ArticleId IdType="pubmed">18477346</ArticleId></ArticleIdList></Reference><Reference><Citation>Dig Dis Sci. 2010 Sep;55(9):2441-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20467896</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2009 Aug;104(8):1984-91</Citation><ArticleIdList><ArticleId IdType="pubmed">19491835</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2006 Jul;101(7):1581-90</Citation><ArticleIdList><ArticleId IdType="pubmed">16863564</ArticleId></ArticleIdList></Reference><Reference><Citation>Gut. 2007 Dec;56(12):1770-98</Citation><ArticleIdList><ArticleId IdType="pubmed">17488783</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 1995 Sep;109(3):671-80</Citation><ArticleIdList><ArticleId IdType="pubmed">7657095</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliment Pharmacol Ther. 2005 Nov 15;22(10):935-42</Citation><ArticleIdList><ArticleId IdType="pubmed">16268967</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 1992 Jun;102(6):1962-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1587415</ArticleId></ArticleIdList></Reference><Reference><Citation>Digestion. 2001;63(2):108-15</Citation><ArticleIdList><ArticleId IdType="pubmed">11244249</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2003 Mar;124(3):754-61</Citation><ArticleIdList><ArticleId IdType="pubmed">12612913</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2009 Jun;104(6):1489-97</Citation><ArticleIdList><ArticleId IdType="pubmed">19455132</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Gastroenterol. 2009 Jun 7;15(21):2628-31</Citation><ArticleIdList><ArticleId IdType="pubmed">19496193</ArticleId></ArticleIdList></Reference><Reference><Citation>Respir Med. 2003 Jan;97(1):75-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12556015</ArticleId></ArticleIdList></Reference><Reference><Citation>Dig Dis Sci. 1998 Feb;43(2):400-11</Citation><ArticleIdList><ArticleId IdType="pubmed">9512138</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 1992 Jan;87(1):55-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1728124</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2003 Feb;98(2):420-30</Citation><ArticleIdList><ArticleId IdType="pubmed">12591063</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Geriatr Med. 2000 Feb;16(1):25-36, vii-viii</Citation><ArticleIdList><ArticleId IdType="pubmed">10723615</ArticleId></ArticleIdList></Reference><Reference><Citation>Dig Dis Sci. 2010 Feb;55(2):375-83</Citation><ArticleIdList><ArticleId IdType="pubmed">19513835</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2002 Apr;97(4):954-61</Citation><ArticleIdList><ArticleId IdType="pubmed">12003432</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2001 May;96(5):1340-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11374666</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Ther. 2006 Oct;28(10):1726-35; discussion 1710-1</Citation><ArticleIdList><ArticleId IdType="pubmed">17157129</ArticleId></ArticleIdList></Reference><Reference><Citation>Gut. 2003 Apr;52(4):523-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12631663</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Health Syst Pharm. 2007 May 15;64(10):1020</Citation><ArticleIdList><ArticleId IdType="pubmed">17494895</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Gastroenterol Hepatol. 2010 Mar;8(3):254-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19932763</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliment Pharmacol Ther. 2009 Oct;30(7):695-706</Citation><ArticleIdList><ArticleId IdType="pubmed">19575763</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 2003 Feb 10;163(3):286-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12578508</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2000 Jan;95(1):157-65</Citation><ArticleIdList><ArticleId IdType="pubmed">10638576</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2006 Apr;130(5):1492-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16678562</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2001;62 Suppl 8:38-45; discussion 46-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12108820</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliment Pharmacol Ther. 2009 Feb 1;29(3):329-41</Citation><ArticleIdList><ArticleId IdType="pubmed">19006537</ArticleId></ArticleIdList></Reference><Reference><Citation>Pain. 1998 May;76(1-2):105-14</Citation><ArticleIdList><ArticleId IdType="pubmed">9696463</ArticleId></ArticleIdList></Reference><Reference><Citation>Womens Health (Lond). 2008 Nov;4(6):605-22; quiz 623</Citation><ArticleIdList><ArticleId IdType="pubmed">19072463</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2002 May;122(5):1500-11</Citation><ArticleIdList><ArticleId IdType="pubmed">11984534</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004116</Citation><ArticleIdList><ArticleId IdType="pubmed">16437473</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2006 May;101(5):1069-79</Citation><ArticleIdList><ArticleId IdType="pubmed">16606352</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Arch Allergy Immunol. 2000 Apr;121(4):270-83</Citation><ArticleIdList><ArticleId IdType="pubmed">10828717</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2005 Oct;100(10):2262-73</Citation><ArticleIdList><ArticleId IdType="pubmed">16181379</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 1999 Oct;94(10):2912-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10520844</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Pharmacol. 2008 Dec;8(6):715-23</Citation><ArticleIdList><ArticleId IdType="pubmed">18760380</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Gastroenterol. 2007 Feb 7;13(5):732-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17278196</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Gastroenterol. 2001 Nov;36(11):1155-61</Citation><ArticleIdList><ArticleId IdType="pubmed">11686214</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2007 Dec;133(6):1763-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18054546</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliment Pharmacol Ther. 2008 Aug 15;28(4):385-96</Citation><ArticleIdList><ArticleId IdType="pubmed">18532993</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2009 Aug 27;339:b3154</Citation><ArticleIdList><ArticleId IdType="pubmed">19713235</ArticleId></ArticleIdList></Reference><Reference><Citation>Gut. 2008 Nov;57(11):1545-53</Citation><ArticleIdList><ArticleId IdType="pubmed">18676420</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1992 Jan 11;304(6819):87-90</Citation><ArticleIdList><ArticleId IdType="pubmed">1737146</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2010 Apr;105(4):848-58</Citation><ArticleIdList><ArticleId IdType="pubmed">20197761</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Gastroenterol. 2010 Feb 7;16(5):547-53</Citation><ArticleIdList><ArticleId IdType="pubmed">20128021</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 1991 Jan;100(1):68-74</Citation><ArticleIdList><ArticleId IdType="pubmed">1983850</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Gastroenterol Hepatol. 2008 Aug;6(8):899-906</Citation><ArticleIdList><ArticleId IdType="pubmed">18524691</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Surg. 2000 Dec;87(12):1658-63</Citation><ArticleIdList><ArticleId IdType="pubmed">11122180</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Nutr. 2003 Sep;57(9):1150-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12947435</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2002 Aug;123(2):450-60</Citation><ArticleIdList><ArticleId IdType="pubmed">12145798</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Gastroenterol Suppl. 1987;130:77-80</Citation><ArticleIdList><ArticleId IdType="pubmed">3306903</ArticleId></ArticleIdList></Reference><Reference><Citation>Recenti Prog Med. 1989 May;80(5):241-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2762661</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Physiol (Oxf). 2011 Jan;201(1):151-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20518750</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliment Pharmacol Ther. 2006 Jan 1;23(1):191-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16393297</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2010 Apr;105(4):718-21</Citation><ArticleIdList><ArticleId IdType="pubmed">20372119</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1984 Dec 1;2(8414):1232-4</Citation><ArticleIdList><ArticleId IdType="pubmed">6150275</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychosom Res. 2010 Apr;68(4):385-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20307706</ArticleId></ArticleIdList></Reference><Reference><Citation>Br Med J. 1978 Sep 2;2(6138):653-4</Citation><ArticleIdList><ArticleId IdType="pubmed">698649</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Res Ther. 1992 Nov;30(6):647-50</Citation><ArticleIdList><ArticleId IdType="pubmed">1417691</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliment Pharmacol Ther. 2009 Apr 15;29(8):834-42</Citation><ArticleIdList><ArticleId IdType="pubmed">19226291</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Surg Suppl. 1998;(583):57-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10027674</ArticleId></ArticleIdList></Reference><Reference><Citation>Gut. 2007 Jun;56(6):802-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17148502</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2000 Sep;119(3):654-60</Citation><ArticleIdList><ArticleId IdType="pubmed">10982758</ArticleId></ArticleIdList></Reference><Reference><Citation>Gut. 1999 Mar;44(3):400-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10026328</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurogastroenterol Motil. 2005 Jun;17(3):317-24</Citation><ArticleIdList><ArticleId IdType="pubmed">15916618</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2008 Nov 13;337:a2313</Citation><ArticleIdList><ArticleId IdType="pubmed">19008265</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2009 Jul;104(7):1831-43; quiz 1844</Citation><ArticleIdList><ArticleId IdType="pubmed">19471254</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2008 Oct;103(10):2536-43</Citation><ArticleIdList><ArticleId IdType="pubmed">18637089</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2008 May 3;336(7651):999-1003</Citation><ArticleIdList><ArticleId IdType="pubmed">18390493</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2002 Aug;97(8):1910-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12190153</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2004 Jun;126(7):1721-32</Citation><ArticleIdList><ArticleId IdType="pubmed">15188167</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Int Suppl. 2009 Feb;(112):S42-3</Citation><ArticleIdList><ArticleId IdType="pubmed">19180133</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Res Ther. 2006 Mar;44(3):317-37</Citation><ArticleIdList><ArticleId IdType="pubmed">16413495</ArticleId></ArticleIdList></Reference><Reference><Citation>Gut. 2005 May;54(5):601-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15831901</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2008 Oct 15;300(15):1793-805</Citation><ArticleIdList><ArticleId IdType="pubmed">18854541</ArticleId></ArticleIdList></Reference><Reference><Citation>Colorectal Dis. 2010 Nov;12(11):1131-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19575740</ArticleId></ArticleIdList></Reference><Reference><Citation>Gut. 2004 May;53(5):666-72</Citation><ArticleIdList><ArticleId IdType="pubmed">15082584</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Gastroenterol. 2005 May 14;11(18):2773-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15884120</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2006 Apr;130(5):1480-91</Citation><ArticleIdList><ArticleId IdType="pubmed">16678561</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2003 Jul;125(1):19-31</Citation><ArticleIdList><ArticleId IdType="pubmed">12851867</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2006 Apr;130(5):1435-46</Citation><ArticleIdList><ArticleId IdType="pubmed">16678557</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Gastroenterol. 1996 May;31(5):463-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8734343</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2002 Apr;122(4):1140-56</Citation><ArticleIdList><ArticleId IdType="pubmed">11910364</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Gastroenterol Hepatol. 2010 May;8(5):426-32</Citation><ArticleIdList><ArticleId IdType="pubmed">20170751</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2009 Jan;104 Suppl 1:S1-35</Citation><ArticleIdList><ArticleId IdType="pubmed">19521341</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2008 Dec;135(6):1877-91</Citation><ArticleIdList><ArticleId IdType="pubmed">18848833</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Diet Assoc. 2006 Oct;106(10):1631-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17000196</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1986 Jan 25;1(8474):207-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2868223</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2009 Apr;104(4):1033-49; quiz 1050</Citation><ArticleIdList><ArticleId IdType="pubmed">19277023</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 1984 Jul;87(1):1-7</Citation><ArticleIdList><ArticleId IdType="pubmed">6724251</ArticleId></ArticleIdList></Reference><Reference><Citation>J Intern Med. 1994 Jul;236(1):23-30</Citation><ArticleIdList><ArticleId IdType="pubmed">8021568</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2010 Apr;105(4):866-75</Citation><ArticleIdList><ArticleId IdType="pubmed">20197759</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliment Pharmacol Ther. 2005 Jun 1;21(11):1365-75</Citation><ArticleIdList><ArticleId IdType="pubmed">15932367</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoeconomics. 2006;24(1):21-37</Citation><ArticleIdList><ArticleId IdType="pubmed">16445300</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliment Pharmacol Ther. 2002 Jun;16(6):1171-85</Citation><ArticleIdList><ArticleId IdType="pubmed">12030961</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2006 Feb;101(2):326-33</Citation><ArticleIdList><ArticleId IdType="pubmed">16454838</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2005 Jan;100(1):115-23</Citation><ArticleIdList><ArticleId IdType="pubmed">15654790</ArticleId></ArticleIdList></Reference><Reference><Citation>Gut. 2006 May;55(5):649-54</Citation><ArticleIdList><ArticleId IdType="pubmed">16150852</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2002 Aug 8;347(6):417-29</Citation><ArticleIdList><ArticleId IdType="pubmed">12167685</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Gastroenterol Suppl. 1987;130:81-4</Citation><ArticleIdList><ArticleId IdType="pubmed">3306904</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Manag Care. 2005 Apr;11(1 Suppl):S17-26</Citation><ArticleIdList><ArticleId IdType="pubmed">15926760</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med. 1999 Nov 8;107(5A):74S-80S</Citation><ArticleIdList><ArticleId IdType="pubmed">10588176</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2003 Mar;98(3):600-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12650794</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliment Pharmacol Ther. 2008 Apr;27(8):685-96</Citation><ArticleIdList><ArticleId IdType="pubmed">18248656</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1996 Jan 20;347(8995):150-3</Citation><ArticleIdList><ArticleId IdType="pubmed">8544549</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 1992 Jun 15;116(12 Pt 1):1009-16</Citation><ArticleIdList><ArticleId IdType="pubmed">1586090</ArticleId></ArticleIdList></Reference><Reference><Citation>Dig Dis Sci. 1990 Oct;35(10):1285-90</Citation><ArticleIdList><ArticleId IdType="pubmed">2145139</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2007 Sep;102(9):1972-82</Citation><ArticleIdList><ArticleId IdType="pubmed">17488254</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 2004 Sep 13;164(16):1773-80</Citation><ArticleIdList><ArticleId IdType="pubmed">15364671</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gastroenterol Hepatol. 2010 Feb;25(2):252-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20136989</ArticleId></ArticleIdList></Reference><Reference><Citation>Gut. 2000 Jan;46(1):78-82</Citation><ArticleIdList><ArticleId IdType="pubmed">10601059</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2010 Apr;105(4):859-65</Citation><ArticleIdList><ArticleId IdType="pubmed">20179696</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2005 Mar;128(3):541-51</Citation><ArticleIdList><ArticleId IdType="pubmed">15765388</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005111</Citation><ArticleIdList><ArticleId IdType="pubmed">17054239</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Gastroenterol Hepatol. 2007 Jul;5(7):844-50; quiz 769</Citation><ArticleIdList><ArticleId IdType="pubmed">17553753</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2004 Nov;99(11):2195-203</Citation><ArticleIdList><ArticleId IdType="pubmed">15555002</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2009 May;136(6):1979-88</Citation><ArticleIdList><ArticleId IdType="pubmed">19457422</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterol Clin Biol. 2004 Jan;28(1):11-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15041804</ArticleId></ArticleIdList></Reference><Reference><Citation>Gut. 2009 Mar;58(3):367-78</Citation><ArticleIdList><ArticleId IdType="pubmed">19001059</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2000 Apr;95(4):999-1007</Citation><ArticleIdList><ArticleId IdType="pubmed">10763950</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 2009 Apr 13;169(7):651-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19364994</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2004 Jun;126(7):1665-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15188159</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2003 Feb;124(2):544-60</Citation><ArticleIdList><ArticleId IdType="pubmed">12557158</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 1999 Dec;94(12):3541-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10606316</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2002 Dec;123(6):2108-31</Citation><ArticleIdList><ArticleId IdType="pubmed">12454866</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurogastroenterol Motil. 2006 Aug;18(8):595-607</Citation><ArticleIdList><ArticleId IdType="pubmed">16918724</ArticleId></ArticleIdList></Reference><Reference><Citation>Dig Dis Sci. 2009 Jul;54(7):1532-41</Citation><ArticleIdList><ArticleId IdType="pubmed">19337833</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005110</Citation><ArticleIdList><ArticleId IdType="pubmed">17943840</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gastroenterol Hepatol. 2010 Apr;25(4):691-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20074154</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Gastroenterol Rep. 2005 Aug;7(4):272-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16042910</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21872090</PMID><DateCompleted><Year>2011</Year><Month>12</Month><Day>27</Day></DateCompleted><DateRevised><Year>2011</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1558-299X</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Primary care</Title><ISOAbbreviation>Prim Care</ISOAbbreviation></Journal><ArticleTitle>Irritable bowel syndrome.</ArticleTitle><Pagination><StartPage>433</StartPage><EndPage>viii</EndPage><MedlinePgn>433-47; viii</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pop.2011.05.003</ELocationID><Abstract><AbstractText>Irritable bowel syndrome (IBS) is a common gastrointestinal disorder that leads to crampy pain, gassiness, bloating, and changes in bowel habits in the absence of any currently identifiable organic disorder. Patients with IBS may be classified by their predominant bowel habit: diarrhea-predominant, constipation-predominant, or IBS with alternating bowel movements. IBS is often associated with stress or anxiety. Although IBS can be frustrating and concerning to patients with this disorder, it does not cause permanent harm to the intestines and does not lead to a serious disease such as cancer. Although treatments exist for its symptoms, there is no known cure.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Malone</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Family Medicine, Penn State College of Medicine, 845 Fishburn Road, Hershey, PA 17033, USA. mmalone@hmc.psu.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Prim Care</MedlineTA><NlmUniqueID>0430463</NlmUniqueID><ISSNLinking>0095-4543</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005765">Gastrointestinal Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005765" MajorTopicYN="N">Gastrointestinal Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="N">Patient Education as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010808" MajorTopicYN="N">Physical Examination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21872090</ArticleId><ArticleId IdType="doi">10.1016/j.pop.2011.05.003</ArticleId><ArticleId IdType="pii">S0095-4543(11)00040-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33978391</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2724-5365</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Minerva gastroenterology</Title><ISOAbbreviation>Minerva Gastroenterol (Torino)</ISOAbbreviation></Journal><ArticleTitle>Probiotics and gut health.</ArticleTitle><Pagination><StartPage>314</StartPage><EndPage>325</EndPage><MedlinePgn>314-325</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.23736/S2724-5985.21.02910-7</ELocationID><Abstract><AbstractText>Gut microbiota is a complex ecosystem of bacteria, viruses, archea, protozoa and yeasts in our intestine. It has several functions which maintain human body equilibrium. Microbial "dysbiosis" can be responsible for several gastrointestinal diseases. To build a narrative review we performed a Pubmed, Medline, Embase search for English language papers, reviews, meta-analyses, case series, and randomized controlled trials (RCTs) by keywords and their associations. Gut microbiota is altered in several gastrointestinal diseases with very different pathophysiology. They range from multifactorial diseases such as irritable bowel syndrome (IBS), nonalcoholic fatty liver disease (NAFLD) and gastric and colorectal cancers, immune-mediated such as celiac disease, inflammatory bowel diseases (IBD), and antibiotic-related such as clostridium difficile infection (CDI). Microbial dysbiosis remodulation by probiotics is feasible and safe in some of them. Gut microbial dysbiosis is statistically associated with several gastrointestinal diseases, affecting their pathophysiology. Its reverse by probiotics has some promising evidence of efficacy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scarpellini</LastName><ForeName>Emidio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Unit of Clinical Nutrition and Internal Medicine, Madonna del Soccorso General Hospital, San Benedetto del Tronto, Ascoli Piceno, Italy - scarpidio@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>T.A.R.G.I.D., Gasthuisberg University Hospital, KU Leuven, Lueven, Belgium - scarpidio@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basilico</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unit of Clinical Nutrition and Internal Medicine, Madonna del Soccorso General Hospital, San Benedetto del Tronto, Ascoli Piceno, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rinninella</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Unit of Clinical Nutrition, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sacred Heart Catholic University, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carbone</LastName><ForeName>Florencia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>T.A.R.G.I.D., Gasthuisberg University Hospital, UZ Leuven, Lueven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schol</LastName><ForeName>Jolien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>T.A.R.G.I.D., Gasthuisberg University Hospital, KU Leuven, Lueven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasetti</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unit of Clinical Nutrition and Internal Medicine, Madonna del Soccorso General Hospital, San Benedetto del Tronto, Ascoli Piceno, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abenavoli</LastName><ForeName>Ludovico</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Health Sciences, The Magna Gr&#xe6;cia University, Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santori</LastName><ForeName>Pierangelo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Unit of Clinical Nutrition and Internal Medicine, Madonna del Soccorso General Hospital, San Benedetto del Tronto, Ascoli Piceno, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Minerva Gastroenterol (Torino)</MedlineTA><NlmUniqueID>101777280</NlmUniqueID><ISSNLinking>2724-5985</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003015" MajorTopicYN="Y">Clostridium Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064806" MajorTopicYN="N">Dysbiosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>12</Day><Hour>11</Hour><Minute>56</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33978391</ArticleId><ArticleId IdType="doi">10.23736/S2724-5985.21.02910-7</ArticleId><ArticleId IdType="pii">S2724-5985.21.02910-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>